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This book provides a comprehensive overview of  he basic mechanisms underlying 
areas of acute leukemia, current advances, and future directions in management of 
this disease. The first section discusses the classification of acute leukemia, taking 
into account diagnoses  dependent on techniques that are essential, and thankfully 
readily available, in the laboratory. The second section concerns recent advances in 
molecular biology, markers, receptors, and signaling molecules responsible for disease 
progression, diagnostics based on biochips and other molecular genetic analysis. These 
advances provide clinicians with important understanding and improved decision 
making towards the most suitable therapy for acute leukemia. Biochemical, structural, 
and genetic studies may bring a new era of epigenetic based drugs along with 
additional molecular targets that will form the basis for novel treatment strategies. 
Later in the book, pediatric acute leukemia is covered, emphasizing that children are 
not small adults when it comes to drug development. The last section is a collection 
of chapters about treatment, as chemotherapy-induced toxicity is still a significant 
clinical concern. The present challenge lies in reducing the frequency and seriousness 





e Scientist’s Perspective and C
hallenge
ACUTE LEUKEMIA  








ACUTE LEUKEMIA  








Acute Leukemia - The Scientist’s Perspective and Challenge
http://dx.doi.org/10.5772/841
Edited by Mariastefania Antica
Contributors
Michael Cosgrove, Venkat Dharmarajan, Mariastefania Antica, Abbas H. Hashim Abdulsalam, Ota Fuchs, Gamal Abdul 
Hamid, Josep-Maria Ribera, Michel Zwaan, Marry van den Heuvel, Seiji Fukuda, Chie Onishi, Louis Pelus, José Manuel 
Vagace, Guillermo Gervasini, xudong Ma, Yiqun Huang, Yong Zou, Ruiji Zheng, Liyun Xiao, Shaohong Jiang, Miranda 
Buitenhuis, Roel Polak, Frederic Amant, Takaaki Konuma, Satoshi Takahashi, Yoshiko Hashii, Tatyana Nasedkina, Julia 
Yatsenko, Olga Gra, Natalia Guseva, Elena Samochatova, Alexander Zasedatelev, Ofer Shpilberg, Ron Ram, Liat Vidal, 
Ronit Gurion, Pia Sophia Raanani, Cezar Martins-De-Sa, Lilian Barros Queiroz, Juliana Forte Mazzeu, Isis Quezado 
Magalhaes, Beatriz Dolabela De Lima<bdlima@unb.Br>, Iris Ferrari, Meir Wetzler, Donald Trump, Candace Johnson, 
Hun Lee
© The Editor(s) and the Author(s) 2011
The moral rights of the and the author(s) have been asserted.
All rights to the book as a whole are reserved by INTECH. The book as a whole (compilation) cannot be reproduced, 
distributed or used for commercial or non-commercial purposes without INTECH’s written permission.  
Enquiries concerning the use of the book should be directed to INTECH rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons Attribution 3.0 
Unported License which permits commercial use, distribution and reproduction of the individual chapters, provided 
the original author(s) and source publication are appropriately acknowledged. If so indicated, certain images may not 
be included under the Creative Commons license. In such cases users will need to obtain permission from the license 
holder to reproduce the material. More details and guidelines concerning content reuse and adaptation can be 
foundat http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those 
of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published 
chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the 
use of any materials, instructions, methods or ideas contained in the book.
First published in Croatia, 2011 by INTECH d.o.o.
eBook (PDF) Published by  IN TECH d.o.o.
Place and year of publication of eBook (PDF): Rijeka, 2019.
IntechOpen is the global imprint of IN TECH d.o.o.
Printed in Croatia
Legal deposit, Croatia: National and University Library in Zagreb
Additional hard and PDF copies can be obtained from orders@intechopen.com
Acute Leukemia - The Scientist’s Perspective and Challenge
Edited by Mariastefania Antica
p. cm.
ISBN 978-953-307-553-2
eBook (PDF) ISBN 978-953-51-6617-7
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,000+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




Mariastefania Antica graduated from the Faculty of 
Science, Zagreb University, Croatia in 1981. She obtained 
and her PhD in Immunology from Ludwig Maximilian’s 
University, Munich, Germany in 1987 prior to becoming a 
visiting scientist (WEHI, Melbourne, Australia, 1990-1994, 
Institute of Immunology, Munich, Germany, 1996, Mayo 
Clinic, Rochester, USA, 1998), and a principal investigator 
of national and international scientific projects. She is employed as Senior 
Scientist at the Rudjer Boskovic Institute, and a professor at the Faculty 
of Science in Zagreb, Croatia, teaching both undergraduate and graduate 
studies at the Faculty and Medical School, Zagreb University. In regard to 
her scientific achievements, she was awarded the National Science Award 
for young scientists (1984), the Award of the Academy of Sciences and Arts 
(1999), and the Award of Croatian Government (2000). She was the vice 
president of the Croatian Immunological Society from 1996 – 2001, editor of 
the Internet Journal of Hematology, and member of the Croatian Medical 
Journal Editorial Board. She is a life member of the UICC, and referee for 











Part 1 Introduction 1 
Chapter 1 Classification of Acute Leukemia 3 
Gamal Abdul-Hamid 
Chapter 2 Diagnosis of Acute Leukemia in 
Under-Resourced Laboratories 19 
Abbas H. Abdulsalam 
Part 2 Molecular Mechanisms and Markers 41 
Chapter 3 The PI3K/PKB Signaling Module in  
Normal and Malignant Hematopoiesis 43 
Roel Polak and Miranda Buitenhuis 
Chapter 4 Lymphocyte Commitment and  
Ikaros Transcription Factors 69 
Mariastefania Antica 
Chapter 5 Epigenetics and Targeted 
Therapy in Acute Leukemia 75 
Xudong Ma, Shaohong Jiang,  
Yiqun Huang, Yong Zou,  
Ruiji Zheng and Liyun Xiao 
Chapter 6 Molecular Markers for Risk  
Stratification in Adult Acute Myeloid  
Leukemia with Normal Cytogenetics 95 
Ota Fuchs 
Chapter 7 Trafficking of Acute Leukemia Cells –  
Chemokine Receptor Pathways that  
Modulate Leukemia Cell Dissemination 137 
Seiji Fukuda, Chie Onishi and Louis M. Pelus 
Contents 
Preface XI 
Part 1 Introduction 1 
Chapter 1 Classification of Acute Leukemia 3 
Gamal Abdul-Hamid 
Chapter 2 Diagnosis of Acute Leukemia in 
Under-Resourced Laboratories 19 
Abbas H. Abdulsalam 
Part 2 Molecular Mechanisms and Markers 41 
Chapter 3 The PI3K/PKB Signaling Module in 
Normal and Malignant Hematopoiesis 43 
Roel Polak and Miranda Buitenhuis 
Chapter 4 Lymphocyte Commitment and 
Ikaros Transcription Factors 69 
Mariastefania Antica 
Chapter 5 Epigenetics and Targeted 
Therapy in Acute Leukemia 75 
Xudong Ma, Shaohong Jiang,  
Yiqun Huang, Yong Zou,  
Ruiji Zheng and Liyun Xiao 
Chapter 6 Molecular Markers for Risk 
Stratification in Adult Acute Myeloid  
Leukemia with Normal Cytogenetics 95 
Ota Fuchs 
Chapter 7 Trafficking of Acute Leukemia Cells – 
Chemokine Receptor Pathways that  
Modulate Leukemia Cell Dissemination 137 
Seiji Fukuda, Chie Onishi and Louis M. Pelus 
X Contents
Chapter 8 Biochemistry of the Mixed Lineage 
Leukemia 1 (MLL1) Protein and Targeted  
Therapies for Associated Leukemia 157 
Venkatasubramanian Dharmarajan and Michael S. Cosgrove 
Part 3 Pediatric Acute Leukemia 205 
Chapter 9 Diagnostics of Molecular Markers in 
Childhood Acute Leukaemia Using Biochips 207 
Tatyana Nasedkina, Yuliya Yatsenko, Olga Gra, Natalia Guseva, 
Elena Samochatova and Alexander Zasedatelev 
Chapter 10 Pediatric Acute Myeloid Leukemia 235 
C. Michel Zwaan and Marry M. van den Heuvel-Eibrink 
Chapter 11 Pediatric Natural Killer Cell Malignancy 277 
Yoshiko Hashii 
Chapter 12 Leukemogenesis in Down Syndrome 295 
Lílian Barros Queiroz, Íris Ferrari,  
Cezar Martins de Sá, Juliana Forte Mazzeu, 
Isis Quezado Magalhães and Beatriz Dolabela de Lima 
Part 4 Treatment and Future Prospects 313 
Chapter 13 Cord Blood Transplantation in 
Adults with Acute Leukemia 315 
Takaaki Konuma and Satoshi Takahashi 
Chapter 14 Acute Lymphoblastic Leukemia in 
Adolescents and Young Adults 339 
Josep-Maria Ribera 
Chapter 15 Evidence-Based Guided 
Interventions in Acute Leukemia 349 
Ron Ram, Liat Vidal, Ronit Gurion,  
Pia Raanani and Ofer Shpilberg 
Chapter 16 Hematologic Malignancies in Pregnancy 371 
C. Vandenbriele, A. Vassou, G. Pentheroudakis, 
K. Van Calsteren and F. Amant 
Chapter 17 Chemotherapy Toxicity 
in Patients with Acute Leukemia 391 
Jose Manuel Vagace and Guillermo Gervasini 
Chapter 18 Vitamin D and Acute Myeloid Leukemia 415 









Remarkable advances have been made in the understanding and treatment of 
leukemia since its first description by Alfred Velpeau in 1827 and Alfred Donné in 
1844. John Hughes Bennett gave the first official diagnosis back in 1845, and in 1856, 
the pathologist Rudolf Virchow coined the term leukemia from the Greek words 
“leukos” and “heima,” also meaning “white blood”. In 1970, it was first confirmed that 
some patients could be cured of leukemia, and by 1990s, the cure rate for leukemia 
was around 70 percent. Recent advances in the diagnosis and treatment of childhood 
acute lymphoblastic leukemia have since achieved a success rate of some 80 percent. 
This book gives a comprehensive overview of basic mechanisms underlying acute 
leukemia, current advances, and future directions in the management of this disease. It 
presents a collection of articles on acute leukemia and the most important advances 
made in recent years. Employing the principles of molecular biology and 
understanding the basic mechanisms of cell proliferation and development are 
essential for dealing with leukemia. The book brings together the expert knowledge 
from more than 40 internationally renowned scientists, and conveys the basic 
information, from classification, analysis and treatment, to novel molecular 
mechanism and principles observed in acute leukemia. It combines and assembles 
scientific groups worldwide dealing with acute leukemia, from the molecular to the 
clinical point of view. After a thorough revision of more than 30 reviews submitted, 
only about 50 percent were selected for the first phase of this editorial process. 
The book is divided in four chapters: 1) Introduction to acute leukemia, 2) Molecular 
mechanisms and markers, 3) Pediatric acute leukemia, and 4) Treatment and future 
prospects. The articles synthesize an enormous amount of scientific and clinical data 
and give a comprehensive overview to create state-of-the-art descriptions of acute 
leukemia. 
Objective of the book Acute Leukemia – The Scientist's Perspective and Challenge 
represents an extremely aggressive, malignant transformation of an early 
hematopoieetic precursor into an immature blast form. It may be derived from 
myeloid cell lines, resulting in acute myeloid leukemia (AML), or from lymphoid cell 
lines resulting in acute lymphoblastic leukemia (ALL). This general division has 
implications for different management approaches. The undifferentiated malignant 
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clone proliferates abnormally, accumulates in bone marrow, and results in progressive 
hematopoietic failure with anemia, thrombocytopenia, and granulocytopenia. It may 
also infiltrate different organs, including liver, spleen, lymph nodes, CNS, kidneys, 
and gonads. Treatment options for patients with acute leukemia include 
chemotherapy, radiation therapy, targeted therapy, immunotherapy and stem cell or 
bone marrow transplantation. Finding a cure is a realistic goal for both ALL and AML, 
especially in younger patients. However, long-term survival is reachable in about one 
half of patients with acute lymphoblastic leukemia and in the minority of patients with 
acute myeloid leukemia. Current research, such as new genes whose protein products 
are suitable for targeted therapy and new strategies of immunotherapy, is focalized to 
improve therapy for this challenging disease. 
Acknowledgments 
Most important acknowledgements go to all the contributing authors for their 
assistance, eagerness, support, and their expert scientific reviews. I thank my 
colleagues, Lipa Cicin-Sain, Maja Matulic and Mladen Paradzik for the motivating and 
inspiring discussions. Thanks to my husband Darko for taking care of our children 
during the long days and weekends while I worked on this project, and for his 
understanding and encouragement. Last but not least, I am most grateful to the 
publishing process managers Petra Nenadic and Ana Pantar for their outstanding 
work, great support and indispensable help at every phase in the preparation of this 
book.  
 
Prof. Mariastefania Antica, PhD 






clone proliferates abnormally, accumulates in bone marrow, and results in progressive 
hematopoietic failure with anemia, thrombocytopenia, and granulocytopenia. It may 
also infiltrate different organs, including liver, spleen, lymph nodes, CNS, kidneys, 
and gonads. Treatment options for patients with acute leukemia include 
chemotherapy, radiation therapy, targeted therapy, immunotherapy and stem cell or 
bone marrow transplantation. Finding a cure is a realistic goal for both ALL and AML, 
especially in younger patients. However, long-term survival is reachable in about one 
half of patients with acute lymphoblastic leukemia and in the minority of patients with 
acute myeloid leukemia. Current research, such as new genes whose protein products 
are suitable for targeted therapy and new strategies of immunotherapy, is focalized to 
improve therapy for this challenging disease. 
Acknowledgments 
Most important acknowledgements go to all the contributing authors for their 
assistance, eagerness, support, and their expert scientific reviews. I thank my 
colleagues, Lipa Cicin-Sain, Maja Matulic and Mladen Paradzik for the motivating and 
inspiring discussions. Thanks to my husband Darko for taking care of our children 
during the long days and weekends while I worked on this project, and for his 
understanding and encouragement. Last but not least, I am most grateful to the 
publishing process managers Petra Nenadic and Ana Pantar for their outstanding 
work, great support and indispensable help at every phase in the preparation of this 
book.  
 
Prof. Mariastefania Antica, PhD 









Classification of Acute Leukemia 
Gamal Abdul-Hamid 
University of Aden/Hematology Unit 
Yemen 
1. Introduction 
Acute leukemia is a proliferation of immature bone marrow-derived cells (blasts) that may 
also involve peripheral blood or solid organs. The percentage of bone marrow blast cells 
required for a diagnosis of acute leukemia has traditionally been set arbitrarily at 30% or more. 
However, more recently proposed classification systems have lowered the blast cell count to 
20% for many leukemia types, and do not require any minimum blast cell percentage when 
certain morphologic and cytogenetic features are present. 
2. Acute leukemia can be classified in many ways 
(1) by morphology and cytochemistry supplemented by immunophenotyping, as proposed by 
French-American-British (FAB) group (Bennet et al 1976); (2) Proposed World Health 
Organization Classification of Acute Leukemia (Harris et al 1999); (3) by immunophenotyping 
alone, as proposed by the European Group for the  immunological classification of leukemias 
(EGIL) (Bene et al 1995 & Hayhoe FG 1988).  
The traditional classification of acute leukemia used criteria proposed by the French–
American–British Cooperative Group (FAB) , using the 30% bone marrow blast cell cutoff 
(Bennett et al, 1985). This classification system originally distinguished different leukemia 
types by morphologic features and cytochemical studies, particularly myeloperoxidase (or 
Sudan black B) and non-specific esterase staining. It was revised to include leukemia types 
that could only be accurately identified with the addition of immunophenotyping or 
electron microscopic studies (Bennett et al., 1991). Although the FAB classification failed to 
distinguish immunophenotypic groups of acute lymphoblastic leukemias, did not recognize 
the significance of myelodysplastic changes in acute myeloid leukemias or cytogenetic 
abnormalities in either leukemia type, and resulted in some subcategories of little clinical 
significance, this system provided very clear guidelines for classification. In addition, some 
distinct leukemia subtypes, particularly acute promyelocytic leukemia and acute myeloid 
leukemia with abnormal eosinophils, were found to correlate with specific cytogenetic 
aberrations and had unique clinical features, and those remain in recently proposed 
classification systems. 
Acute myelogenous leukemia (AML) was based on how leukemic blasts, the predominant 
cell in the disease process, recapitulate normal hematopoiesis. Are blasts in a given case 
myeloblasts, monoblasts, megakaryoblasts, etc., and are they un-, minimally, or moderately 
differentiated.  
 1 
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The original classification scheme proposed by the French-American-British (FAB) 
Cooperative Group  divides AML into 8 subtypes (M0 to M7) and ALL into 3 subtypes (L1 to 
L3). Although AML blasts evolve from common myeloid precursors, the 8 subtypes differ in 
degree of maturation (Table 1). As specified in the table, M0 designates AML with minimal 
morphologic or cytochemical differentiation, M1–2 AML with minimal or moderate 
granulocytic differentiation, M3 acute promyelocytic leukemia (APL), M4 AML with mixed 
myelomonocytic differentiation, M5a and M5b monoblastic leukemia with minimal or 
moderate differentiation, M6a myeloid leukemia with dysplastic background erythropoiesis, 
M6b acute erythroblastic leukemia, and M7 acute megakaryoblastic leukemia. The FAB 
classification of ALL includes 3 subtypes (L1 to L3), which are differentiated based on 
morphology, including cell size, prominence of nucleoli, and the amount and appearance of 
cytoplasm (Table 2). Approximately 75% of adult ALL cases have blasts with the B -cell 
phenotype, and 25% have blasts with the T-cell phenotype. The FAB classification of ALL and 
AML is based on morphology and cytochemical staining of blasts (Cheson et al 1990).  
 
M0 AML with no Romanowsky or cytochemical evidence of differentiation 
M1 Myeloblastic leukemia with little maturation 
M2 Myeloblastic leukemia with maturation 
M3 Acute promyelocytic leukemia (APL) 
M3h APL, hypergranular variant 
M3v APL, microgranular variant 
M4 Acute myelomonocytic leukemia (AMML) 
M4eo AMML with dysplastic marrow eosinophils 
M5 Acute monoblastic leukemia (AMoL) 
M5a AMoL, poorly differentiated 
M5b AMoL, differentiated 
M6 “Erythroleukemia” 
M6a AML with erythroid dysplasia 
M6b Erythroleukemia 
M7 Acute megakaryoblastic leukemia (AMkL) 
Table 1. French-American-British (FAB) Classification of Acute Myelogenous Leukemia 
2.1 M0 Acute myeloblastic leukemia with minimally differentiated 
AML-M0 is most common in adult patients. Accounts for approximately 5-10% of all AML 
patients. WBCs show Leukocytosis in 40% and > 50% with leukocytopenia. The diagnosis is 
made if less than 3% of the blasts are positive for peroxidase or the Sudan black B reaction 
and if the Blasts are positive for the myeloid-associated markers CD13, 14, CD15 or CD33, 
CD34 and negative for B or T lineage marker (CD3, CD10, CD19 and CD5). Bone marrow 
aspirated was hypercellular in all patients and contained a large number of leukemic blasts 
(Bennette JM 1991). Almost no mature myeloid cells were seen. The blasts were small to 
medium-sized round cells with an eccentric nucleus. The nucleus often had a flattened 
shape and was sometimes lobulated or cleaved and contained fine chromatin with several 
distinct nucleoli. The cytoplasm was lightly basophilic without granules. Auer rods are not 
found. 
 




Fig. 1. Acute myeloblastic leukemia AML –M0  
2.2 M1 Acute myeloblastic leukemia without maturation 
It is found in all aged groups with highest incidence seen in adult and in infants less than a 
year old. Leukocytes in about 50% of patients at the time of diagnosis was increased. The 
predominant cell in the peripheral blood is usually a poorly differentiated myeloblast with 
finely reticulated chromatin and prominent nucleoli. Auer rods are found in the blast of 50% 
of the M1. If no evidence of granules or Auer rods is present, the blasts may resemble L2 
lymphoblast. The myeloperoxidase or Sudan black B stains are positive in more than 3% of 
the blasts indicating granulocytes differentiation, the diagnosis is more likely AML-M1 than 
ALL (Bennett et al, 1976). PAS  and  alpha-naphthyl acetate esterase and naphthol AS-D-
esterase are negative. About 50% of the patients will have acquired clonal chromosome 
aberrations in the leukemic cells. CD13, 14, 15, 33 and CD34 myeloid antigens are frequently 
positive in M1 leukemia. The most common cytogenetic abnormalities are: t (9; 22) (q34; q11)  
 
 
Fig. 2. Acute myeloblastic leukemia AML-M1  
2.3 M2 Acute myeloblastic leukemia with maturation 
The presenting symptoms for M2 AML are similar to those of the M1 type. Leukocytes 
increased in 50% of patients. Myeloblast can usually be found in the blood smears and may 
be the predominant cell type. Pseudopelger–Huet and hypogranular neutrophils being most 
common cells are seen in M2. 
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The bone marrow is hypercellular and types I and II myeloblasts make up from 30-83% of 
the promyelocytes to mature segmented cells. The monocytic component is less than 20%, 
differentiating M2 from M4. Basophils in some patient (M2 baso) was increased. Eosinophils 
and their precursors may be abundant, and in some cases accounts for up to 15% of 
myelogram (Berger and Flandrin, 1984). The characteristic that distinguishes AML-M2 from 
AML-M1 is the presence of maturation at or beyond the promyelocyte stage.  Abnormal 
neutrophil maturation appears to be an integral part of AML-M2 with t(8;21) translocation. 
The neutrophils may show many abnormal nuclear segmentations and Auer rods. 
Cytochemistry; Myeloperoxidase (MPO) reaction in blast cells gives the same result as in 
AML-M1, but the reaction is often of little practical value because the granulocytic nature of 
AML-M2 is usually demonstrated clearly by the presence of maturing cells in the granulocytic 
series. Sodium fluoride does not inhibit esterase. PAS and nonspecific esterase are  negative. 
Positive reaction with CD13 and CD15 antigens are frequently seen in cases of M2. 
 
 
Fig. 3. Acute myeloblastic leukemia AML-M2 
2.4 M3 Acute promyelocytic leukemia (APL) 
The median age and survival average of APL is about 18 months and occurred in younger 
adult. M3 is of particular interest because it results in the fusion of a truncated retinoic acid 
receptor alpha (RAR-alpha) gene on chromosome 17 to a transcription unit called PML (for 
promyelocytic leukemia) on chromosome 15. It is interesting to note that high doses of the 
vitamin A derivative all-trans-retinoic acid are able to overcome thus block in differentiation 
both in vitro and in vivo and this agent has been successfully used to induce remission in 
patients.   
A "variant" form of M3 (Bennett et al, 1980) is characterized by paucity of granules within 
the promyelocytic blasts and should not be confused with monocytic leukemia.  The blasts 
are large with abundant cytoplasm, and the nucleus is usually irregular. The nucleus is often 
bilobed or markedly indented and a nucleolus can be seen in each lobe. The cytoplasm is 
completely occupied by closely packed  large granules, staining bright pink, red or purple. 
Cells containing bundles of Auer rods "faggots" randomly distributed in the cytoplasm are 
characteristic, but are not present in all cases.  
It is believed that the release of large numbers of promyelocytic granules containing a 
procoagulant initiate disseminated intravascular clotting (DIC). This is the most serious 
complication of M3 AML  occurs frequently in both AML-M3 as well as AML-M3 variant 
(McKenna et al, 1982) . Initial therapy with the differentiating agent all-trans-retinoic acid 
 
Classification of Acute Leukemia 
 
7 
(ATRA) has improved significantly the treatment of AML-M3 in this regard; early mortality 
as a result of DIC is substantially reduced.   
Cytochemistry: Peroxidase  (MPO) and Sudan black B are strong positive. The periodic acid 
Schiff (PAS) is negative and Nonspecific esterase is also weak positive . The MPO reaction is 
also strong positive in the AML-M3 variant.  
Immunological studies demonstrate positivity with CD13, CD15, CD1 and CD33 myeloid 
antigens. Cytogenetic studies have revealed a high prevalence (almost 50%) of the 
chromosomal translocation t(15; 17) associated with both AML M3 and M3 variant . M3 
AML with t(15;17) is usually characterized by the association of the lymphoid marker, CD2 
and CD19, with myeloid markers and the negativity of HLA-DR and CD34.  
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(monoblast, promoncytes, monocytes), are increased to 5000/L or more. Anemia and 
thrombocytopenia are present in almost all cases. The marrow differs from M1, M2 and M3 
in those monocytic cells exceed 20% of the nonerythroid nucleated cells. The sum of the 
myelocytic cells including myeloblasts, promyelocytes and later granulocytes is >20% and 
<80% of nonerythroid cells. This bone marrow picture together with a peripheral blood 
monocyte count of 5000/L or more is compatible with a diagnosis of M4. 
Confirmation of the monocytic component of this subgroup requires cytochemistry. The 
profile includes positive reactions for sudan black B or peroxidase and both specific and 
non-specific esterase. A few cases of M4 AML are characterized by increased marrow 
eosinophils and classified as M4e (Berger et al 1985) . Immunological studies demonstrate 
positivity with CD13, CD33, CD11b and CD14. Cytogenetic: inv(16) (p13; q22) and del 
(16)(q22) . 
2.6 M5 Acute monoblastic leukemia (AMoL)   
Common findings are weakness, bleeding and a diffuse erythematous skin rash. There is a 
high frequency of extramedulary infiltration of the lungs, colon, meninges, lymphnodes, 
bladder and larynx and gingival hyperplasia. Serum and urinary muramidase levels are 
often extremely high. The one criterion for a diagnosis of M5 is that 80% or more of all 
nonerythroid cells in the bone marrow are monocytic cells. There are two distinct forms 5a 
(maturation index <4%) and 5b   (maturation index > 4%).M5a: Granulocyte <20% and 
Monocyte >80%   >80% monoblast. M5b: Granulocyte <20% and Monocyte >80%   <80% 
monoblast (Characterized by the presence of all developmental stages of monocytes; 
monoblast, promonocyte, monocyte) 
Cytochemistry: Non-specific esterase stains and alpha-naphthyl esterase are positive and 
PAS is negative. Myeloperoxidase and Sudan black are weak diffuse activity in the 
monoblast. The use of alph-naphthyl butyrate esterase (ANBE) is advantageous because of 
its greater degree of specificity and stronger reaction, and also because sodium fluoride 
inhibition is not required (Shibata et al, 1985). Immunological studies demonstrate positivity 
with CD11b and CD14. There is a strong association between AML M5/M4 and deletion 
and translocations involving band 11q23.   
 
 
Fig. 6. M5 Acute monoblastic leukemia (AMoL) 
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2.7 M6 “Erythroleukemia"   
M6 is a rare form of leukemia that primarily affects the peripheral cells. It is nonsexist in 
children. The clinical manifestations are similar to other types of AML. The most frequent 
presentation is bleeding. The most dominant changes in the peripheral blood are anemia 
with sticking poikilocytosis and anisocytosis. Nucleated red cells demonstrate abnormal 
nuclear configuration. The leukocytes and platelets are usually decreased. The diagnosis of 
erythroleukemia can be made when more than 50% of all nucleated bone marrow cells are 
erythroid and 30% or more of all remaining nonerythroid cells are type I or type II blast cells 
(Bennett et al, 1985). The erythroblast is abnormal with bizarre morphologic features. Giant 
multilobular or multinucleated forms are common. Other features are; fragmentation, 
Howell-Jolly bodies, ring sideroblast, megaloblastic and dyserythropoiesis changes are 
common. The cytochemistry of erythroblasts are normally PAS negative but in AML-M6, 
erythroblasts especially pronormoblast demonstrates coarse positivity of PAS. Blast cells 
express a variety of myeloid associated antigens such as CD13, CD33, anti-MPO with or 
without expression of precursor-cell markers as CD34, HLA-Dr determinants as for blast 
cells from other AML subtypes. In M6-variant forms, the more differentiated cells can be 
detected by the expression of glycophorin A and the absence of myeloid markers. 
 
 
Fig. 7. M6 “Erythroleukemia” 
2.8 M7 Acute megakaryoblastic leukemia (AMkL) 
M7 is rare. It occurs as a leukemia transformation of chronic granulocytic leukemia (CGL) 
and myelodysplastic syndrome (MDS). Pancytopenia is characteristic at initial diagnosis. 
Peripheral blood shows micromegakaryocytes and undifferentiated blasts. Bone marrow 
dry tap is common. Bone marrow biopsy show increased fibroblasts and/or increased 
reticulin and presence of greater than 30% blast cells. The diagnosis of M7 should be 
suspected when the blast cells show cytoplasmic protrusion or budding. As bone marrow 
smears obtained by aspiration may not be adequate to make a diagnosis, the peripheral 
blood films must be examined carefully for the presence of micromegakaryoblasts. Bone 
marrow biopsy sections are usually necessary and show a prominent reticulin fibrosis and 
excessive numbers of small blasts.  
Cytochemistry: Peroxidase is negative, PAS +/-, Esterase +/- and positive acid phospatase. 
Cytochemical positivity for -naphthyl acetate esterase reaction and negative reaction with 
-naphthyl butyrate esterase is unique to megakaryoblast. (Monocytes react positively with 
both esterase substrates).  
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The monoclonal antibodies that reacts with platelet glycoprotein Ib, IIb/IIIa and IIIb, using 
immunologic technique as well as CD41, CD42 and CD61 positivity. 
There is no unique chromosomal abnormality associated with acute megakaryoblastic 
leukemia, with the exception of t(1;22)(p13;q13), which has been found almost exclusively in 
young children, less than 18 months old who do not have Downís syndrome. 
 
 
Fig. 8. M7 Acute megakaryoblastic leukemia (AMkL) 
 
Morphologic Classification 
FAB Type Features of Blasts 
L1 Small cells with scant cytoplasm; nucleoli indistinct and not visible 
L2 Large, heterogeneous cells with moderately abundant cytoplasm; 
clefting and indentation of nucleus; large and prominent nucleoli 
L3 Large cells with moderately abundant cytoplasm; regular, oval-to-round 
nucleus; prominent nucleoli; 
prominent cytoplasmic basophilia and cytoplasmic vacuoles 
Table 2. Morphologic Classification of Acute Lymphocytic Leukemia 
Acute lymphoblastic leukemia (ALL)  is divided in FAB L1 (children), L2 (older children 
and adult), and L3 (patients with leukemia secondary to Burkitt's lymphoma. These types 
are defined according to two criteria (1) the occurrence of individual cytologic features and 
(2) the degree of heterogeneity among the leukemic cells. These features considered are cell 
size, chromatin, nuclear shape, nucleoli, and degree of basophilia in the cytoplasm and the 
presence of cytoplasmic vacuolation (Bennett et al 1976). 
ALL-L1: Homogenous cells  (Small cell): One population of cells within the case. Small cells 
predominant, nuclear shape is regular with occasional cleft. Nuclear contents are rarely 
visible. Cytoplasm is moderately basophilic. L1 accounts 70% of patients. The L1 type is the 
acute leukemia that is common in childhood, with 74% of these cases occurring in children 
15 years of age or younger.  
ALL-L2: Heterogeneous cells: Large cells with an irregular nuclear shape, cleft in the 
nucleus are common. One or more large nucleoli are visible. Cytoplasm varies in colour and 
nuclear membrane irregularities. L2 accounts 27% of ALL patients. The FAB-L2 blast may be 
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confused with the blasts of acute myeloid leukemia. Approximately 66% of these cases of 
ALL in patients older than 15 years are of type 2. 
 
 
Fig. 9. Acute lymphoblastic leukemia L1 
 
 
Fig. 10. Acute lymphoblastic leukemia L2 
ALL-L3: Burkitt's lymphoma type: Cells are large and homogenous in size, nuclear shape is 
round or oval. One to three prominent nucleoli and sometimes to 5 nuleoli are visible. 
Cytoplasm is deeply basophilic with vacuoles often prominent. Intense cytoplasmic 
basophilia is present in every cell, with prominent vacuolation in most.  A high mitotic 
index is characteristic with presence of varying degrees of macrophage activity. Mature B-
lymphoid markers are expressed by most cases.  
 
 
Fig. 11. Acute lymphoblastic leukemia L3 
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Acute Myeloid Leukemia (AML) and Related Precursor Neoplasm 
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
Acute promyelocytic leukemia with t(15;17)(q22;q12); PML-RARA 
AML with t(9 ;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML with mutated NPM1 
AML with mutated CEBPA 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Myeloid sarcoma  
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis 
Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid denderitic cell neoplasm 
Table 3. World Health Organization Classification of Acute Myelogenous Leukemia (2008) 
AML defined as ≥20% blasts in blood or bone marrow; however, clonal, recurring 
cytogenetic abnormalities should be considered AML regardless of blast percentage. 
Ongoing clinical trials may continue to use French-American-British (FAB) criteria of ≥30% 
blasts until completion of trial. FAB classification identified as M0 through M7. 
The classification schemes by the World Health Organization (WHO) require the additional 
evaluation of the leukemic blasts by molecular analysis and flow cytometry (Harris NL 1997 
& Brunangelo Falini 2010, Sachdeva et al 2006). The results of these 4 methods of evaluation 
(i.e, morphology, staining, molecular analysis, flow cytometry) not only differentiate ALL 
from AML, but also categorize the subtypes of acute leukemia. Table 3 summarizes the new 
classification of AML as proposed by WHO, Knowing the subtype of a patient’s leukemia 
helps in predicting the clinical behavior of the disease and the prognosis, and in making 
treatment recommendations. This classification also improves the reproducibility of 
diagnoses and stresses the heterogeneity of the subtypes of AML and ALL (Vardiman 2009). 
Recent advances in molecular biology have shown that various subtypes of AML and ALL 
behave differently and should not be treated similarly. For example, the identification of M3 
AML (acute promyelocytic leukemia) is crucial because it is associated with disseminated 
intravascular coagulation (DIC), and retinoic acid, in addition to chemotherapy, is the 
treatment of choice.  
The two most significant differences between the FAB and the WHO classifications are: 
(a) A lower blast threshold for the diagnosis of AML: The WHO defines AML when the 
blast percentage reaches 20% in the bone marrow. 
(b) Patients with recurring clonal cytogenetic abnormalities should be considered to have 
AML regardless of the blast percentage (8;21)(q22;q22), t(16;16)(p13;q22), inv(16)(p13;q22), 
or t(15;17)(q22;q12) (Arber DA  et al 2008abc, Weinberg OK et al 2009). 
The world Health Organization (WHO) classification has changed the grouping of ALL to 
reflect increased understanding of the biology and molecular pathogenesis of the diseases. In 
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addition to discarding the L1-L3 terms, the new classification characterizes these heterogenous 
diseases based upon immunophenotype into 3 basic categories: precursor B-cell ALL, 
precursor T-cell ALL, and mature B-cell ALL (Burkitt lymphoma/leukemia) (Jaffe et al 2001) 
 
WHO classification 
Precursor B-cell ALL/LBL 
Cytogenetic subgroups 
  t(9;22)(q34,q11),BCR/ABL 
  t(v;11q23);MLL rearranged 
  t(1;19)(q23;p13);PBX1/E2A 
  t(12;21)(p13;q22);TEL/AML1 
  Hypodiploid 
  Hyperdiploid, >50 
 
Precursor T-cell ALL/LBL 
 
Mature B-cell leukemia/lymphoma 
ALL= acute lymphoblastic leukemia;  
LBL= lymphoblastic lymphoma;  
MLL= mixed lineage leukemia  
Table 4. World Health Organization classification of acute lymphoblastic leukemia 
Abnormalities in chromosome number as well as structural rearrangements (translocations) 
occur commonly in ALL. Important cytogenetic abnormalities in precursor B-cell ALL that 
are associated with a poor prognosis include t(9;22) or Philadelphia chromosome-positive 
(Ph+) ALL, which increases in frequency with age; t(4;11); hypodiploidy, especially if <45% 
chromosomes ; and trisomy 8 in adult ALL. The t(4;11) results from a balanced translocation 
involving a gene on the long arm of chromosome 11 at band q23 (11q23), known as the 
mixed lineage leukemia (MLL) gene. MLL gene translocations occur most commonly in 
infancy and are associated with both acute lymphoid and myeloid leukemias. 
3. European Group for the Immunological classification of Leukemias (EGIL) 
The European Group for the Immunological Classification of Leukemias (EGIL)(Bene MC et al 
1995 & Hoelzer et al 2002)) has proposed that acute leukaemia be classified on the basis of 
immunophenotype alone. This classification has the strength that it suggests standardized 
criteria for defining a leukaemia as myeloid, T lineage, B lineage, or biphenotypic. It also 
suggests criteria for distinguishing biphenotypic leukaemia from AML with aberrant 
expression of lymphoid antigens, and from ALL with aberrant expression of myeloid antigens. 
However, a purely immunological classification has the disadvantage that discrete entities 
may fall into one of two categories; for example some cases of AML of FAB M2 subtype 
associated with t(8;21)(q22;q22) would be classified as "AML of myelomonocytic lineage", 
while others would be classified as "AML with lymphoid antigen expression," depending on 
whether or not a case showed aberrant expression of CD19. In addition, rare cases of acute 
leukaemia have been described which were clearly myeloid when assessed by cytology and 
cytochemistry but which did not express any of the commonly investigated myeloid antigens. 
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addition to discarding the L1-L3 terms, the new classification characterizes these heterogenous 
diseases based upon immunophenotype into 3 basic categories: precursor B-cell ALL, 
precursor T-cell ALL, and mature B-cell ALL (Burkitt lymphoma/leukemia) (Jaffe et al 2001) 
 
WHO classification 
Precursor B-cell ALL/LBL 
Cytogenetic subgroups 
  t(9;22)(q34,q11),BCR/ABL 
  t(v;11q23);MLL rearranged 
  t(1;19)(q23;p13);PBX1/E2A 
  t(12;21)(p13;q22);TEL/AML1 
  Hypodiploid 
  Hyperdiploid, >50 
 
Precursor T-cell ALL/LBL 
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ALL= acute lymphoblastic leukemia;  
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MLL= mixed lineage leukemia  
Table 4. World Health Organization classification of acute lymphoblastic leukemia 
Abnormalities in chromosome number as well as structural rearrangements (translocations) 
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mixed lineage leukemia (MLL) gene. MLL gene translocations occur most commonly in 
infancy and are associated with both acute lymphoid and myeloid leukemias. 
3. European Group for the Immunological classification of Leukemias (EGIL) 
The European Group for the Immunological Classification of Leukemias (EGIL)(Bene MC et al 
1995 & Hoelzer et al 2002)) has proposed that acute leukaemia be classified on the basis of 
immunophenotype alone. This classification has the strength that it suggests standardized 
criteria for defining a leukaemia as myeloid, T lineage, B lineage, or biphenotypic. It also 
suggests criteria for distinguishing biphenotypic leukaemia from AML with aberrant 
expression of lymphoid antigens, and from ALL with aberrant expression of myeloid antigens. 
However, a purely immunological classification has the disadvantage that discrete entities 
may fall into one of two categories; for example some cases of AML of FAB M2 subtype 
associated with t(8;21)(q22;q22) would be classified as "AML of myelomonocytic lineage", 
while others would be classified as "AML with lymphoid antigen expression," depending on 
whether or not a case showed aberrant expression of CD19. In addition, rare cases of acute 
leukaemia have been described which were clearly myeloid when assessed by cytology and 
cytochemistry but which did not express any of the commonly investigated myeloid antigens. 
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Precursor B-lymphoblastic leukemia ( HLA-DR+, TdT+, CD19+, and/or CD79a+, 
and/or CD22+, and/or CD34+). This type of ALL accounts for around 75% of 
adult cases and is subdivided into the following groups: 
a.  Pro B-ALL expresses HLA-DR, TdT, and CD19. CD10-, cytoplasmic 
immunoglobulin negative; represents approximately 10% of adult ALL. 
b. Common ALL is characterized by the presence of CD10, cytoplasmic 
immunoglobulin negative; comprises greater than 50% of adult cases of ALL. 
c.  Pre B-ALL is characterised by the expression of cytoplasmic immunoglobulin 
and CD10; this subtype of ALL is identified in nearly 10% of adult cases. 
d. Mature B-ALL is found in approximately 4% of adult ALL patients. The blast 
cells express surface antigens of mature B cells, including surface membrane 
immunoglobulin (SmIg+). They are typically TdT and CD34 negative and have 
L3 morphology. This category overlaps with Burkitt lymphoma, which is 
included under the mature B-cell neoplasms. 
Precursor T-lymphoblastic leukemia 
Cells are TdT+ in addition to cytoplasmic CD3+ and CD34+. This type of ALL 
accounts for around 25% of adult cases and is subdivided into: 
a. Pro T-ALL CD2-, CD7+, CD4-, CD8- seen in around 7% of adult ALL. 
b. Pre T-ALL CD2+, CD7+, CD4-, CD8-. 
c. Cortical T-ALL or Thymic ALL (Thy ALL) is CD1a+ and accounts for 17% of 
adult ALL CD7+, CD2+, CD5+, CD4+, CD8+ 
d. Mature T-ALL are surface CD3+, CD2+, CD7+, CD4 or 8, and 
TdT/CD34/CD1a- and make up approximately 1% of adult ALL. 
Table 5. European Group for the Immunological Characterization of Leukemias (EGIL) 
classification of acute lymphocytic leukemia (Hoelzer  2002) 
The consensus considers a 20% minimum threshold to define a positive reaction of blast 
cells to a given monoclonal antibody. Roughly 75% of cases of adult ALL are of B-cell 
lineage. B-lineage markers are CD19, CD20, CD22, CD24, and CD79a (Huh 2000).  
The earliest B-lineage markers are CD19, CD22 (membrane and cytoplasm) and CD79a 
(Campana 1988). A positive reaction for any two of these three markers, without further 
differentiation markers, identifies pro-B ALL. The presence of CD10 antigen (CALLA) 
defines the "common" ALL subgroup. Cases with additional identification of cytoplasmatic 
IgM constitute the pre-B group, whereas the presence of surface immunglobulin light chains 
defines mature B-ALL. 
T-cell ALL constitutes approximately 25% of all adult cases of ALL. T-cell markers are CD1a, 
CD2, CD3 (membrane and cytoplasm), CD4, CD5, CD7 and CD8. CD2, CD5 and CD7 
antigens are the most immature T-cell markers, but none of them is absolutely lineage-
specific, so that the unequivocal diagnosis of T-ALL rests on the demonstration of 
surface/cytoplasmic CD3.  
ALL of B or T lineage can additionally express myeloid antigens or stem-cell antigen CD34. 
The latter has little diagnostic relevance but can be prognostically important (De Waele 2001) 
The scoring system recently proposed by the EGIL group addressed the characterization of the 
acute leukemia as B or T lineage ALL, or AML by including the most specific markers for the 
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lymphoid and myeloid lineages among those of earlier stages of cell differentiation, plus some 
non-specific but stem-cell markers. The system introduced a modified terminology specific to 
each 'maturation' step within the B- or T-cell lineage (EGIL 1995) and was confirmed as 
adequate for both diagnosis and subclassification of ALL (Thalhammer-Scherrer 2002). 
4. European Group for the Immunological characterization of Leukemias 
(EGIL) classification for biphenotypic acute leukemia 
Biphenotypic acute leukemia (BAL), or acute leukemia with a single population of blasts 
coexpressing markers of two different lineages, is a rare clinical entity.  
The scoring systems proposed by Catovsky et al. and by the EGIL (Bene 1995) allowed for a 
better definition of biphenotypic acute leukemia (BAL), clearly distinguishing them from 
classical AL expressing aberrantly one or two markers of another lineage. However, 
increasing evidence suggests that this system has limitations, as acknowledged by the 2008 
World Health Organization (WHO) Classification of Tumors of Hematopoietic and 
Lymphoid Tissues. Although substantially improved in relation to the EGIL, the new WHO 
Classification is still not optimal for guiding the clinical management of patients with BAL. 
Typical examples of such aberrations are the expression of CD15 on B-ALL(Maynadie et al 
1997),  or of CD2 on acute promyelocytic –AML( Albano 2006). In 1998, the EGIL further 
refined this scoring system by attributing one point for the expression of CD117, after 
showing the strong relationship of this marker with engagement in the myeloid lineage 
(Bene MC et al 1998) . To identify BAL, it is therefore necessary to consider aberrant co-
expression of markers usually associated to different lineages, with a score higher than 2 in 
more than one lineage (Zhao XF et al 2009) 
 
Myeloid lineage T-lineage B-lineage  
MPO CD3 CD79 2 point 
Lisozyme Anti TCR IgM 
  CD22 
CD13 CD2 CD19 1 point 
CD33 CD5 CD10 
CD65 CD8 CD20 
CD10 
CD14 TdT TdT 0.5 point 
CD15 CD17 CD24 
CD64, CD117 CD10 
Table 6. EGIL Scoring system for biphenotypic acute leukemia 
Biphenotypic acute leukemia is defined when scores are >2 for the myeloid lineage and >1 
for the lymphoid lineage. In some T-ALL cases, clonality of TCR alphabeta rearrangements 
can now be assessed cytoflourmetrically (Langerak 2001, Xu XQ et al 2009).  
The prognosis of biphenotypic acute leukemia patients is poor when compared with de 
novo acute myeloid leukemia or acute lymphoblastic leukemia. Biphenotypic acute 
leukemia patients showed a much higher incidence of CD34 antigen expression, complex 
abnormal karyotype, extramedullary infiltration, relapse, and resistance to therapy after 
relapse (Xu XQ et al 2009). 
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lymphoid and myeloid lineages among those of earlier stages of cell differentiation, plus some 
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coexpressing markers of two different lineages, is a rare clinical entity.  
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for the lymphoid lineage. In some T-ALL cases, clonality of TCR alphabeta rearrangements 
can now be assessed cytoflourmetrically (Langerak 2001, Xu XQ et al 2009).  
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leukemia patients showed a much higher incidence of CD34 antigen expression, complex 
abnormal karyotype, extramedullary infiltration, relapse, and resistance to therapy after 
relapse (Xu XQ et al 2009). 
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5. Conclusion  
Acute leukaemia can be classified in many ways. An ideal classification is one which 
recognizes real entities with fundamental biological differences. The FAB classification of 
ALL and AML is based on morphology and cytochemical staining of blasts. However, the 
recent classification schemes proposed by the World Health Organization (WHO) require 
the additional evaluation of the leukemic blasts by molecular analysis and flow cytometry. 
The results of these 4 methods of evaluation (ie, morphology, staining, molecular analysis, 
flow cytometry) not only differentiate ALL from AML, but also categorize the subtypes of 
acute leukemia . Recent advances in molecular biology have shown that various subtypes of 
AML and ALL behave differently and should not be treated similarly. For example, the 
identification of M3 AML (acute promyelocytic leukemia) is crucial because it is associated 
with disseminated intravascular coagulation (DIC), and retinoic acid, in addition to 
chemotherapy, is the treatment of choice.  
The European Group for the Immunological Classification of Leukemias (EGIL) has 
proposed that acute leukaemia be classified on the basis of immunophenotype alone. This 
classification has the strength that it suggests standardized criteria for defining a leukaemia 
as myeloid, T lineage, B lineage, or biphenotypic. It also suggests criteria for distinguishing 
biphenotypic leukaemia from AML with aberrant expression of lymphoid antigens, and 
from ALL with aberrant expression of myeloid antigens. 
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1. Introduction 
Laboratory diagnosis of acute leukemia in modern hematology practice is increasingly 
relying on guidelines that require the availability of relatively expensive machines with 
consistent need for continuous quality control, kits supply and maintenance. 
In under-resourced hematology laboratories there is usually a missing step in the battery of 
required investigations. Moreover, when some of the advanced diagnostic instruments can 
be found then the problem of chronic inadequate and irregular supply of kits and services 
would supervene. Therefore, the laboratory diagnosis would mostly depend on the more 
basic, but consistently available and well controlled, laboratory techniques that should at 
least include complete blood count (CBC) and peripheral blood morphology, after which a 
bone marrow study with aspirate and sometimes a trephine biopsy will follow. 
Moreover, in specialized hematology centers there may be a routine availability of few 
special stains, a very limited immunophenotyping CD markers panel, cytogenetics and PCR 
or FISH testing mostly for BCR-ABL1 oncogene. 
The aim of diagnosis, lineage assignment and sub-classification of acute leukemia in these 
laboratories should immediately serve a clear therapeutic goal. 
Sketching rational systematic schemes for optimum use of the locally available investigation 
options would usually permit the diagnosis of most varieties of acute leukemias with a very 
acceptable level of reliability. Also these schemes may provide invaluable information 
regarding the prospect of update and future plans for laboratory development as it can 
show clearly where the weak joints are (Abdulsalam, 2010). 
2. Basis of diagnosis of myelodysplastic syndrome (MDS) 
The WHO classification of this pre-AML disorder (Table 1) can be applied in most under-
resourced laboratories as it only entails the use of peripheral blood morphology and bone 
marrow aspirate morphology with Perl’s reaction (diagnosis of rare hypoplastic and 
myelofibrotic MDS would require also bone marrow trephine biopsy) with the sole addition 
of cytogenetics, preferably performed on marrow aspirate sample. 
Even when cytogenetic testing is not available, still the WHO classification can be reliably 
applied for the diagnosis of most of the MDS subcategories, with the exceptions of the 
otherwise provisional diagnosis of MDS-5q- syndrome (which is characteristically found in a 
middle age or an elderly female with  peripheral blood macrocytic anemia and upper 
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Type Peripheral blood Bone marrow aspirate 
Refractory cytopenia with 
unilineage dysplasia: 
- Refractory anemia (RA) 
- Refractory neutropenia 
- Refractory 
thrombocytopenia 
Uni- or bi-cytopenia 
and <1% blasts Unilineage dysplasia* with <5% blasts 
Refractory anemia with ring 
sideroblasts (RARS) 
Anemia and <1% 
blasts 
Erythroid dysplasia only with <5% 
blasts and >15% ring sideroblasts 
Refractory cytopenia with 
multilineage dysplasia 
Bi- or pan-cytopenia 
and <1% blasts 
Bi- or tri-dysplasia with <5% blasts 
and <15% ring sideroblasts 
Refractory cytopenia with 
multilineage dysplasia and 
ring sideroblasts 
Bi- or pan-cytopenia 
and <1% blasts 
Bi- or tri-dysplasia with <5% blasts 
and >15% ring sideroblasts 
Refractory anemia with excess 
blasts-1 (RAEB-1) 1-4% blasts 5-9% blasts and no Auer rods 
Refractory anemia with excess 
blasts-2 (RAEB-2) 5-19% blasts 
10-19% blasts, or <19% blasts plus 
Auer rods** 
MDS-Unclassified 
Uni-, bi- or pan-
cytopenia and <1% 
blasts 
Cytogenetic diagnosis of MDS with 
uni-, bi- or tri-lineage dysplasia in 
<10% of the cells and <5% blasts 
Isolated 5q- syndrome 
Anemia with upper 
normal or increase 
platelet count 
Isolated del(5q) on cytogenetic study, 
prominent large megakaryocytes with 
hypolobated nuclei and <5% blasts*** 
* Dysplasia is considered significant only if it is present in >10% of the cells. 
** If Auer rods or pseudo-Chediak Higashi inclusions are present then MDS RAEB-2 is diagnosed even 
when the peripheral blood and bone marrow blasts are <5% and <10% respectively. 
*** If blasts > 5% then it is classified as RAEB, although still lenalidomide treatment should be tried. 
Table 1. WHO classification of MDS, 2008 (Vardiman, et al, 2009) 
normal platelet count or even thrombocytosis, bone marrow megakaryocytes of normal 
overall size but with a relatively small mono- or bi-lobed nucleus and a very good response 
to a therapeutic trial of lenalidomide) (Kelaidi et al, 2008) and MDS-Unclassified (which can 
be diagnosed on follow up when the disease persists or even progress). This classification, 
unlike the late FAB classification, would keep with the newest 20% blasts cut-off point to 
diagnose acute leukemia, coping with the worldwide standards of MDS literatures and 
provide much more relevant prognostic groups. 
3. Diagnosis of acute leukemia in under-resourced laboratories 
FAB classification (Table 2) of acute leukemia should be applied in under-resourced 
laboratories where the only available routine techniques for diagnosis are morphology and 
special stains (Abdulsalam, 2010). The scheme in (Figure 1) may be used as a general 
guideline for the diagnosis of acute leukemia in under-resourced laboratories; however, it 
should be modified to optimally fit into the locally available techniques. 
The practical application of WHO classification for acute leukemia (Tables 3 and 4) requires 
both diagnosis and risk stratification. The diagnosis can be based on morphology, special 
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stains and immunophenotyping (preferably using flowcytometry, or if it is not available 
then one can rely on either immunocytochemistry with/without immunohistochemistry). 
Laboratory risk stratification relies on cytogenetics and multiplex conventional PCR. 
Later on, a follow up for minimal residual disease can be performed using the same genetic 
abnormality found at diagnosis, i.e., cytogenetic remission, or more accurately, real time 
quantitative (RQ) PCR for quantization of the characteristic translocation that was found 
positive (but without quantization using conventional “qualitative” PCR) at diagnosis. 
 
Acute 
leukemia Subtype Morphology Additional tests 
ALL 
L1 Small, homogeneous with high N:C ratio blasts 
TdT, CD3, CD79a, CD20, CD10 
L2 
Larger, heterogeneous, 





Large, homogeneous and 
nucleolated blasts with 
basophilic and vacuolated 
cytoplasm 
Cytogenetics, ISH or PCR 
AML 
M0 Undifferentiated blasts Anti-MPO, CD117, CD33, CD68 or Lysozyme 
M1 




M2 Myeloblasts with myeloid maturation 
M3 Characteristic morphology, Faggot cells 
M3 variant Characteristic morphology, bilobed nuclei 
M4 
Peripheral blood monocytes 
≥5.0 *109/l ± bone marrow 
monocytic lineage ≥20% 







Bone marrow monocytic 
lineage ≥80% 
M6 Trilineage dysplasia and >50% erythroblasts 
SBB, Glycophorin + anti-MPO, 
avoid CD34 as it would stain 
both myeloblasts and 
proerythroblasts 
M7 Blast with cytoplasmic blebs and bone marrow fibrosis CD41 
Table 2. Diagnosis of acute leukemia based on FAB groups 
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Follow up for minimal residual disease using a multi-color flowcytometry can be adequately 
performed (Thorn et al, 2011) but is usually more demanding than the genetic techniques, 
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AML 
Romanowsky stain: M2, 
M3, M4, M5b, M5c & M6 
SBB: M1, M3v 




ALL Romanowsky stain: 
L1, L2 and L3 
SBB: Negative 
PAS: cALL 
TdT: positive in L2 and 
negative in leukemic phase 
of lymphoma including L3, 
which is positive for sIg 











CD1a and sCD3 
CD10 and cIg 
L1: Start chemotherapy 
 
Fig. 1. Options for diagnosis of acute leukemia in resource-poor laboratories: FAB-based 
classification serving a clear therapeutic target. 
3.1 Basis of diagnosis of acute leukemia 
In the WHO classification of acute leukemia (Jaffe, et al, 2001) the diagnosis is based on an 
arbitrary cut-off point of 20% blasts as a percentage of bone marrow total or non-erythroid 
cells or as a percentage of peripheral blood cells. This exact percent is also applied 
nowadays in under-resourced laboratories were the FAB classification should be used (Bain, 
2010a). 
This 20% myeloblasts cut-off point seems to be universally accepted and for the time being it 
represents the best known tool for defining acute leukemia. However, the word “arbitrary” 
may still precede it and this may be attributed to (Abdulsalam, 2011): 
1. This precise percent does not represent some specific biological event in the continuum 
of increasing blast count, but it is merely, to the best to our current knowledge, a cut-off 
point that permits a relatively clear classification and therapeutic aim. However, the fact 
that some high risk MDS patients are being treated actively with only 10% bone 
marrow blasts should be remembered. 
 




--- Therapy- related myeloid neoplasms 
--- De novo myeloid neoplasms 
- AML with recurrent genetic abnormalities including 
t(8;21)(q22;q22); RUNX1–RUNX1T1 




inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1–EVI1 
t(1;22)(p13;q13); RBM15–MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
- AML with myelodysplasia-related changes 
- AML not otherwise categorized 
- Myeloid sarcoma 
- Myeloid proliferation related to Down syndrome 
- Transient abnormal myelopoiesis 
- Myeloid leukemia associated with Down syndrome 
- Blastic plasmacytoid dendritic cell neoplasm 
Table 3. WHO classification of AML, 2008 (Vardiman, et al, 2009) 
 
 
--- B lymphoblastic leukemia/lymphoma 
- B lymphoblastic leukemia/lymphoma, not otherwise specified 
- B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities including 
t(9;22)(q34;q11.2) and BCR–ABL1 
translocation involving 11q23 and MLL rearrangement 
t(12;21)(p13;q22) and ETV6–RUNX1 
hyperdiploidy (> 50 chromosomes) 
hypodiploidy (< 46 chromosomes) 
t(5;14)(q31;q32) and IL3–IGH 
t(1;19)(q23;p13.3) and TCF3–PBX1 
--- T lymphoblastic leukemia/lymphoma 
Table 4. WHO classification of ALL, 2008 (Vardiman, et al, 2009) 
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2. The significant difference in the cut-off point of blast percent between peripheral blood 
and bone marrow is well established in MDS as the two groups RAEB-1 (blast count 
less than 5% in peripheral blood and 5-9% in bone marrow) and RAEB-2 (blast count 5-
9% in peripheral blood and 10-19% in bone marrow). In acute leukemia no such 
discrimination is available. 
3. The morphological finding of pathological “clonal” blast, type II that contains Auer 
rods, Pseudo-Chédiak-Higashi (Abdulsalam & Sabeeh, 2011) (Image 1) or other specific 
inclusions that are not seen in reactive marrow, is referring to the diagnosis of RAEB-2 
or AML, here again the arbitrary cut-off point of 20% blasts will decide the specific 
diagnosis. 
4. The original FAB classification was based for many years on the arbitrary cut-off point of 
30% bone marrow blasts and previously some patients with 20-29% blasts remained stable 
over months without chemotherapy. However, this major percent change was driven by 
the survival studies which revealed that patients with 20-29% myeloblasts have a similar 
survival pattern as those with 30% and more in the bone marrow (Jaffe et al, 2001). 
5. Although myeloblasts recognition criteria as agranular and granular blasts achieved a 
reasonable consensus, there are minor discordances in their definitions and in practice it 
may be a matter of convention (subjective method) to discriminate it from the 
continuum of cells, as in deciding whether this cell is a blast type III or a promyelocyte. 
6. The “blasts” refer to myeloblasts, lymphoblasts, monoblasts, promonocytes and 
megakaryoblasts. 
7. Diagnosis of AML-M3 and its variant is not related to the blast percent. 
8. Cases with blast cells less than 20% may still be diagnosed as acute leukemia if they 
present with certain recurrent cytogenetic abnormalities as in AML M4 with inv(16) or 
t(16;16)(p13;q22) and AML M2 with t(8;21) (Jaffe et al, 2001). 
9. The utilization of 20% lower blast threshold is not really an issue in ALL because most 
patients at diagnosis already have more than 50% blasts. Moreover, a patient with 
normal or reduced peripheral blood count and bone marrow lymphoblasts about or 
slightly above 20% would usually be classified as lymphoblastic lymphoma rather than 
ALL. A 25% cut-off point has been suggested to arbitrarily differentiate between the 
two conditions. 
10.  In AML-M0 and M1 the 20% blasts cut-off point is also of no use in practice. 
Laboratory diagnosis of acute leukemia in modern hematology practice is increasingly 
relying on objective techniques to detect a specific ultrastructural or genetic abnormality. 
Therefore, the era of 20% blasts to diagnose acute leukemia may not stand the time any 
longer than that of the old FAB group 30% blasts lower threshold. However, at least in the 
present and the near future the morphology will remain the initial diagnostic test of acute 
leukemia and the abovementioned blast threshold will still be useful as a tool for 
classification (Abdulsalam, 2011). 
The presence or absence of myeloblasts has a central role in diagnosis of AML and suspicion 
of ALL respectively. The blasts are divided into agranular (type I) and granular (type II and 
III) blasts based on Romanowsky stain morphology. However, when using SBB stain many 
of the “apparently” agranular blasts turn to be granular. Pathognomonic signs of AML that 
can be seen with Romanowsky stain and more frequently with SBB stain include SBB-
positive granules, Auer rods, atypical “thick” Auer rods, pseudo-Chediak-Higashi 
inclusions (Abdulsalam et al, 2011a) (Image 1) and rectangular crystalline structures (Merino 
& Esteve, 2005) . 
 




Image 1. Pseudo-Chédiak-Higashi inclusions together with atypical “thick” Auer rods in 
AML. 
3.2 Clinical features 
At diagnosis, acute leukemia should, in most of the cases, be clinically manifested within the 
last month with non-specific features like lethargy and fatigue or more commonly with 
specific features related to organ infiltration including bone marrow which results in anemia-
related features, infections and bleeding. Other organ infiltration may refer not only to broad 
suspicion of acute leukemia but more likely to lineage assignment or even to a specific 
diagnosis, e.g., hepatosplenomegaly, lymphadenopathy, CNS symptoms and testicular 
involvement are in favor of ALL, severe bone pain in lower extremities would refer to B-ALL, 
thymic mediastinal mass and pleural effusion to T-ALL, bleeding tendency with overt 
coagulation tests defect can refer to AML-M3 and its variant and gum hypertrophy, skin 
involvement and hepatosplenomegaly in M4 and, more commonly, in M5. 
3.3 Complete blood count (CBC) 
Acute leukemia in most of the cases would present with one, or more often more abnormalities 
of the CBC, including anemia, leucocytosis (or less common leucopenia) and thrombocytopenia. 
Even when the WBC count is within normal limits the anemia, thrombocytopenia and WBC 
flags (in most automated cell counters) would raise fair enough suspicion. 
Clinical features combined with CBC should be very sensitive in directing acute leukemia 
cases to be studied by peripheral blood smear. 
3.4 Peripheral blood smear 
Should be the backbone for the diagnosis of acute leukemia when there is leucocytosis or 
when leucocyte count is within reference range, as in most of the cases it provides a specific 
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2. The significant difference in the cut-off point of blast percent between peripheral blood 
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over months without chemotherapy. However, this major percent change was driven by 
the survival studies which revealed that patients with 20-29% myeloblasts have a similar 
survival pattern as those with 30% and more in the bone marrow (Jaffe et al, 2001). 
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8. Cases with blast cells less than 20% may still be diagnosed as acute leukemia if they 
present with certain recurrent cytogenetic abnormalities as in AML M4 with inv(16) or 
t(16;16)(p13;q22) and AML M2 with t(8;21) (Jaffe et al, 2001). 
9. The utilization of 20% lower blast threshold is not really an issue in ALL because most 
patients at diagnosis already have more than 50% blasts. Moreover, a patient with 
normal or reduced peripheral blood count and bone marrow lymphoblasts about or 
slightly above 20% would usually be classified as lymphoblastic lymphoma rather than 
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inclusions (Abdulsalam et al, 2011a) (Image 1) and rectangular crystalline structures (Merino 
& Esteve, 2005) . 
 




Image 1. Pseudo-Chédiak-Higashi inclusions together with atypical “thick” Auer rods in 
AML. 
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Acute leukemia in most of the cases would present with one, or more often more abnormalities 
of the CBC, including anemia, leucocytosis (or less common leucopenia) and thrombocytopenia. 
Even when the WBC count is within normal limits the anemia, thrombocytopenia and WBC 
flags (in most automated cell counters) would raise fair enough suspicion. 
Clinical features combined with CBC should be very sensitive in directing acute leukemia 
cases to be studied by peripheral blood smear. 
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diagnosis (ALL-L3 and AML-M3), a provisional diagnosis (ALL-L1 and AML M2, M3 
variant, M4, M5b, M5c and M6) or at least a limited differential diagnosis (ALL-L2 and 
AML-M0, M1, M5a and M7). 
When blasts are numerous in peripheral blood then special stains like SBB can be applied 
directly to it, this can be very useful for emergency diagnosis of AML-M3 variant especially 
within short time like before the weekend (Abdulsalam & Sabeeh, 2010). In cases with 
leucopenia, although frank blast cells may not be easily found, still there should be at least a 
clue to the diagnosis (including anemia, thrombocytopenia and myeloid dysplasia). 
The presence of nucleated red cells and myeloid dysplasia mainly in the form of Pelger-
Huet neutrophils should be investigated as the former can refer to AML-M6 and the later 
can suggest an AML with myelodysplasia. A bone marrow study should follow including 
aspirate and biopsy (when there is peripheral blood pancytopenia, and dry tap, 
hypocellular, diluted or difficult aspirate). 
3.5 Bone marrow aspirate (BMA) 
The diagnosis of acute leukemia in many instances is evident from the peripheral blood 
film; however, the bone marrow aspirate examination is always essential for confirmation of 
diagnosis, classification and application of special techniques including cytochemical stains, 
genetic studies, Immunocytochemistry (ICC) and immunohistochemistry (IHC). 
IHC staining can be applied using the clotted marrow aspirate as a regular tissue sample 
after fixation and without decalcification (Bain, 2001a), to avoid bone marrow biopsy when 
there is no need for this procedure apart from the intention to apply immunophenotyping; 
however, it should be noted that the only use of clotted aspirate is for immunophenotyping, 
i.e., it should not be used as a regular morphology sample or any other application. 
Apart from AML-M3 and its variant, the provisional and final diagnosis of the subtype of 
acute leukemia should not be issued before a proper BMA is performed. The classification of 
AML FAB groups is based on the percentages of blasts, maturing myeloid series 
(promyelocytes to neutrophils), monocytic series and erythroblasts from the total nucleated 
marrow cells. Also in some occasions many vital signs may be seen only in marrow aspirate 
like few Faggot cells in AML-M3 variant and even Auer rods. This phenomenon is 
aggravated when there is a peripheral leucopenia. 
Diagnosis of acute leukemia is based on the presence of at least 20% blasts of total nucleated 
marrow cells, this condition may not be applicable especially in some AML cases, then 20% 
blasts limit should be obtained from the non-erythroid non-lymphoid marrow cells, 
otherwise the case would be labelled as MDS (Table 1). The reason for setting two lower 
thresholds is to simplify the morphology counts in practice, where in the first type of 
threshold the hematologist needs only to count the blast cells from all the nucleated cells in 
the field, this is much easier in practice but it would certainly require much higher blast 
threshold (which is available in almost all cases of ALL and many AML patients) than what 
would be required in the second form, which would be much more effort demanding and 
time consuming as one has to exclude erythroblasts, lymphocytes, plasma cells, 
macrophages and mast cells from the count. 
Diagnosis of AML with myelodysplasia can only be confirmed by studying the bone 
marrow aspirate morphology with trilineage dysplasia. Dyserythropoiesis alone can be seen 
in many malignancies and is multifactorial, dysmyelopoiesis is supportive to the diagnosis 
of AML; however in cases where neutrophils and maturing myeloid cells are few then 
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absence of dysmyelopoiesis does not affect the diagnosis. Dysmegakaryopoiesis, especially 
in the form of micromegakaryocytes is in favour of diagnosis of AML with a preceding 
myelodysplastic syndrome. 
3.6 Bone marrow biopsy 
Is indicated when failed to obtain an adequate marrow aspirate, which may result from 
improper aspiration technique, presence of fibrosis (especially in ALL and AML-M7; in both 
conditions there may be a leucoerythroblastic anemia and tear drop poikilocytes in peripheral 
blood), aleukemic or subleukemic peripheral blood and bone marrow aspirate smears due to 
heavily packed marrow (especially in ALL) or presence of hypoplastic acute leukemia 
(especially in AML). It is also indicated when there is an intention to apply routine 
immunophenotyping (although this can be adequately applied on clotted marrow sections, see 
paragraph 3.5). It can be stated that the bone marrow biopsy is not an essential investigation in 
acute leukemia diagnosis when obtaining an adequate marrow aspirate (Bain, 2001b). 
The presence of peripheral blood leucocyte count above or within the upper normal count 
can be used as an indicator that a bone marrow biopsy would not be essential; in contrast, 
leucopenia or pancytopenia suggest the need for bone marrow biopsy. 
3.7 Acute Myeloid Leukemia (AML) 
With Romanowsky stain morphology AML- M2, M3, M4, M5b, M5c and M6 can be 
recognized readily. 
By adding few special stains such as Sudan black B, and not myeloperoxidase (MPO) as SBB 
has a little more sensitivity in detecting myeloblasts which is crucial for diagnosis of AML, 
plus a non-specific esterase (NSE) stain as ANAE it becomes possible to recognize AML-M1 
and most cases of AML-M5a respectively (Bain, 2006). 
Rare types of AML like M5c require a higher degree of morphology experience, in which 
malignant cells appearance is reminiscent of tissue histiocytes (Image 2) (Abdulsalam & 
Sabeeh, 2009a). 
The AML cases that cannot be distinguished by Romanowsky and special stains 
morphology are M0 and M7, for which the presence of myeloid dysplasia (abnormal nuclear 
morphology and cytoplasm hypogranularity using a Romanowsky stain or absence of SBB 
stained granules from maturing myeloid cells and neutrophils) (Image 7) in the former and 
the blasts' cytoplasmic blebs and bone marrow fibrosis in the latter may give a hint for the 
probable diagnosis, however there is still the need for more positive diagnostic technique 
and as the flow cytometry immunophenotyping may not be available then the use of a 
limited number of CD markers study by ICC/IHC is the option, these include mainly anti-
myeloperoxidase for M0 and CD41 for M7. 
When resources are limited then it is for the best to concentrate on cytoplasmic ICC/IHC 
CD markers with the highest lineage sensitivity and specificity. 
There is a small proportion of cases that would be only certainly subclassified after the 
response to treatment as in rare forms of AML-M3v in spite that SBB stain is usually of help 
in this form (Images 5 and 6). 
Risk stratification of AML is based on genetic studies. 
3.8 Acute Lymphoblastic Leukemia (ALL) 
Consideration of clinical as well as hematological features permits a strong presumptive 
diagnosis of ALL (Bain, 2010). ALL-L3 diagnosis (which should be referred to as the 
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diagnosis (ALL-L3 and AML-M3), a provisional diagnosis (ALL-L1 and AML M2, M3 
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leucopenia, although frank blast cells may not be easily found, still there should be at least a 
clue to the diagnosis (including anemia, thrombocytopenia and myeloid dysplasia). 
The presence of nucleated red cells and myeloid dysplasia mainly in the form of Pelger-
Huet neutrophils should be investigated as the former can refer to AML-M6 and the later 
can suggest an AML with myelodysplasia. A bone marrow study should follow including 
aspirate and biopsy (when there is peripheral blood pancytopenia, and dry tap, 
hypocellular, diluted or difficult aspirate). 
3.5 Bone marrow aspirate (BMA) 
The diagnosis of acute leukemia in many instances is evident from the peripheral blood 
film; however, the bone marrow aspirate examination is always essential for confirmation of 
diagnosis, classification and application of special techniques including cytochemical stains, 
genetic studies, Immunocytochemistry (ICC) and immunohistochemistry (IHC). 
IHC staining can be applied using the clotted marrow aspirate as a regular tissue sample 
after fixation and without decalcification (Bain, 2001a), to avoid bone marrow biopsy when 
there is no need for this procedure apart from the intention to apply immunophenotyping; 
however, it should be noted that the only use of clotted aspirate is for immunophenotyping, 
i.e., it should not be used as a regular morphology sample or any other application. 
Apart from AML-M3 and its variant, the provisional and final diagnosis of the subtype of 
acute leukemia should not be issued before a proper BMA is performed. The classification of 
AML FAB groups is based on the percentages of blasts, maturing myeloid series 
(promyelocytes to neutrophils), monocytic series and erythroblasts from the total nucleated 
marrow cells. Also in some occasions many vital signs may be seen only in marrow aspirate 
like few Faggot cells in AML-M3 variant and even Auer rods. This phenomenon is 
aggravated when there is a peripheral leucopenia. 
Diagnosis of acute leukemia is based on the presence of at least 20% blasts of total nucleated 
marrow cells, this condition may not be applicable especially in some AML cases, then 20% 
blasts limit should be obtained from the non-erythroid non-lymphoid marrow cells, 
otherwise the case would be labelled as MDS (Table 1). The reason for setting two lower 
thresholds is to simplify the morphology counts in practice, where in the first type of 
threshold the hematologist needs only to count the blast cells from all the nucleated cells in 
the field, this is much easier in practice but it would certainly require much higher blast 
threshold (which is available in almost all cases of ALL and many AML patients) than what 
would be required in the second form, which would be much more effort demanding and 
time consuming as one has to exclude erythroblasts, lymphocytes, plasma cells, 
macrophages and mast cells from the count. 
Diagnosis of AML with myelodysplasia can only be confirmed by studying the bone 
marrow aspirate morphology with trilineage dysplasia. Dyserythropoiesis alone can be seen 
in many malignancies and is multifactorial, dysmyelopoiesis is supportive to the diagnosis 
of AML; however in cases where neutrophils and maturing myeloid cells are few then 
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absence of dysmyelopoiesis does not affect the diagnosis. Dysmegakaryopoiesis, especially 
in the form of micromegakaryocytes is in favour of diagnosis of AML with a preceding 
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Is indicated when failed to obtain an adequate marrow aspirate, which may result from 
improper aspiration technique, presence of fibrosis (especially in ALL and AML-M7; in both 
conditions there may be a leucoerythroblastic anemia and tear drop poikilocytes in peripheral 
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heavily packed marrow (especially in ALL) or presence of hypoplastic acute leukemia 
(especially in AML). It is also indicated when there is an intention to apply routine 
immunophenotyping (although this can be adequately applied on clotted marrow sections, see 
paragraph 3.5). It can be stated that the bone marrow biopsy is not an essential investigation in 
acute leukemia diagnosis when obtaining an adequate marrow aspirate (Bain, 2001b). 
The presence of peripheral blood leucocyte count above or within the upper normal count 
can be used as an indicator that a bone marrow biopsy would not be essential; in contrast, 
leucopenia or pancytopenia suggest the need for bone marrow biopsy. 
3.7 Acute Myeloid Leukemia (AML) 
With Romanowsky stain morphology AML- M2, M3, M4, M5b, M5c and M6 can be 
recognized readily. 
By adding few special stains such as Sudan black B, and not myeloperoxidase (MPO) as SBB 
has a little more sensitivity in detecting myeloblasts which is crucial for diagnosis of AML, 
plus a non-specific esterase (NSE) stain as ANAE it becomes possible to recognize AML-M1 
and most cases of AML-M5a respectively (Bain, 2006). 
Rare types of AML like M5c require a higher degree of morphology experience, in which 
malignant cells appearance is reminiscent of tissue histiocytes (Image 2) (Abdulsalam & 
Sabeeh, 2009a). 
The AML cases that cannot be distinguished by Romanowsky and special stains 
morphology are M0 and M7, for which the presence of myeloid dysplasia (abnormal nuclear 
morphology and cytoplasm hypogranularity using a Romanowsky stain or absence of SBB 
stained granules from maturing myeloid cells and neutrophils) (Image 7) in the former and 
the blasts' cytoplasmic blebs and bone marrow fibrosis in the latter may give a hint for the 
probable diagnosis, however there is still the need for more positive diagnostic technique 
and as the flow cytometry immunophenotyping may not be available then the use of a 
limited number of CD markers study by ICC/IHC is the option, these include mainly anti-
myeloperoxidase for M0 and CD41 for M7. 
When resources are limited then it is for the best to concentrate on cytoplasmic ICC/IHC 
CD markers with the highest lineage sensitivity and specificity. 
There is a small proportion of cases that would be only certainly subclassified after the 
response to treatment as in rare forms of AML-M3v in spite that SBB stain is usually of help 
in this form (Images 5 and 6). 
Risk stratification of AML is based on genetic studies. 
3.8 Acute Lymphoblastic Leukemia (ALL) 
Consideration of clinical as well as hematological features permits a strong presumptive 
diagnosis of ALL (Bain, 2010). ALL-L3 diagnosis (which should be referred to as the 
 




Image 2. Blast cells appearance in AML-M5c. 
leukemic phase of Burkitt’s lymphoma as it arises from mature B-cells) would be obvious 
by morphology alone and it is convenient to rely on morphological diagnosis of ALL-L1 
and start treatment. Also if a patient with an acute leukemia showing heterogeneous 
blasts that has no morphological markers of myeloid differentiation, negative staining 
with SBB with unavailability of further differentiating procedures then it may be treated 
initially as ALL-L2, as statistically speaking it would be much more possible than AML-
M0. The negative result in staining with SBB is very helpful, while the addition of the 
special stain PAS would improve the chances of the correct diagnosis of common ALL. 
However, a case with positive staining results for both SBB and PAS is an acute myeloid 
leukemia (Image 3). 
Clinical features as bone pain and radiological sign of mediastinal mass may presumptively 
aid in differentiating between B- and T-ALL, however, using ICC/IHC antibodies including 
CD79a for B lineage and CD3 for T lineage are necessary. After setting the diagnosis of B-
ALL in adults then ICC/IHC CD20 typing and PCR or FISH for BCR-ABL1 fusion gene 
would affect the treatment options. 
In children (neonate up to 15 years) there is some reluctance for BCR-ABL1 testing due to its 
low frequency, only about 3%. However, it may be prudent to test for this transcript in 
children who have some lymphoblasts with large azurophilic granules (represent 
approximately 10% of cases) (Jaffe, et al, 2001) as this, beside cutting short additional costs, 
can offer a safer limit. 
Rare cases of ALL-L2 that are confused with leukemic phase of large cell lymphoma can be 
differentiated through the use of TdT immunohistochemistry typing on bone marrow 
biopsy slide, which would be positive in ALL but not in lymphoma. 
Risk stratification of ALL is based on immunophenotypic and genetic studies. 
 




Image 3. Composite photograph of a patient with AML-M1 who had a 95% PAS-positive 
blasts (left image) and SBB positive blasts (right image). 
3.9 Biphenotypic acute leukemia 
The diagnosis of this acute leukemia requires a simultaneous application of several myeloid 
and lymphoid CD markers, or at least a request for the main lymphoid markers (CD3 and 
CD79a) after finding a SBB positive result (Matutes et al, 1997). 
In resource-poor laboratories a step-by-step algorithm is followed in order to use the least 
possible resources, therefore, the identification of a mixed acute leukemia can be missed, as 
when some clinical, morphological, cytochemical or immunological markers refer to one 
diagnosis then the other lines of investigations are usually skipped to save expenses. 
However, misdiagnosis of this rare type of acute leukemia to only one of its components 
may, in some cases, not adversely affect the patient. 
3.10 Rare types of acute leukemia 
In a resource-poor laboratory these types of acute leukemia can be identified only if it 
happened to show some characteristic features using one of the essential techniques 
including, e.g., AML-M5c characteristic peripheral blood and bone marrow morphology, 
while others like biphenotypic acute leukemia may be misdiagnosed to only one of its 
components as described in paragraph 3.9. Natural killer-cell leukemia can be confused 
initially with reactive lymphocytosis as it results in CD3 negative and its characteristic CD56 
marker is not usually tested for in an under-resourced laboratory. 
3.11 Special stains 
For diagnosis of AML, especially M1 and M5, the addition of Sudan black B (SBB) and a 
non-specific esterase stain as α-naphthyl acetate esterase is respectively essential. While for 
ALL a negative result (0-2%, these rare SBB positively stained blasts represent remnant 
normal myeloblasts) with SBB staining is crucial to support the diagnosis. The addition of 
PAS stain would not add a lot to support the diagnosis of ALL as it can, at least occasionally, 
be equally positive in AML; however, a positive PAS stained vacuolated blasts can be useful 
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to refer to cALL in 98% of cases (Bain, 2010a), here again CD10 ICC/IHC staining would be 
more meaningful. 
3.11.1 Sudan Black B (SBB) stain 
It is one of the few, but very useful, cytochemical stains to choose in a resource-poor 
laboratory. Care should always be paid for counting blasts with the right black color, 
intensely stained granules. The appealing characters that entail the use of SBB stain are: 
i. The reaction and non-reaction with SBB stain are both significant, as the former refer 
practically to AML and the latter supports the diagnosis of ALL or AML-M0. 
ii. The intensity of a positive reaction with SBB in general parallels myeloperoxidase 
activity. Generally local experience would decide which stain to choose. However, SBB 
gives a slightly more intense reaction and sensitivity than myeloperoxidase staining in 
the detection of myeloblasts and is safer than the older technique of MPO staining 
(using carcinogenic benzidine or its derivatives). 
iii. Better demonstration of Auer rods by using SBB stain than any of the usual 
Romanowsky stains. This would be of utmost benefit to identify all MDS cases with 
Auer rods, to differentiate some AML from ALL cases (Image 4) and also to follow up 
AML cases for morphological remission after induction chemotherapy.  
 
 
Image 4. Composite photograph of the peripheral blood film of a patient with AML-M2, the 
blasts showed unusual nuclear lobulation, these blasts contained  SBB positive granules and 
Auer rods (Abdulsalam et al, 2011b) 
In all AML subtypes, except for AML-M3, the presence of even one blast cell with Auer 
rod would refer to failure to achieve remission and indicate the need for a second 
induction chemotherapy course, while in AML-M3 finding an Auer rod after induction 
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is usually a part of response to treatment as it appears in more maturing myeloid cells 
(Wong, 2010) (Image 5). 
iv. The presence of 3% or more SBB stain positive blasts would characteristically refer to 
the diagnosis of AML-M1 rather than ALL. 
Although it is now about 30 years since first reporting that in very rare cases even ALL 
blasts may show SBB positivity (Tricota, et al, 1982); however characters like being of 
less intensity than the control (remnant normal cells of the myeloid series), non-
granular and diffuse reaction help to indicate that these are not myeloblasts. Also 
lymphoblasts would universally stain negative with MPO which can then be used to 
confirm the nature of the blasts. 
v. Increased SBB stain positivity at diagnosis is associated with better prognosis. 
vi. Speedy and firm enough diagnosis of AML-M3 variant cases (Image 6) to start ATRA 
treatment in the same day (Abdulsalam & Sabeeh, 2010). 
vii. Demonstration of myeloid series dysplasia (Image 7) (Bain, 2010b). 




Image 5. Peripheral blood film of a patient with AML-M3 on ATRA treatment showing a 
dysplastic neutrophil that contains an Auer rod (Abdulsalam and Sabeeh, 2009b) 
3.11.1.1 How to count the percentage of SBB positively stained blasts 
The literatures are always referring to directly counting the blasts from the SBB stain slide, 
which is the best technique if the blasts can be easily recognized, but in practice and 
especially with AML-M1 this is not always feasible due to the nature of the stain which 
renders many blasts indistinguishable from other less immature cells. Therefore, there 
should be a second best technique to count the percent of smear positive SBB blasts, because 
it is not always possible to differentiate all the blasts directly from the SBB slide. 
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laboratory. Care should always be paid for counting blasts with the right black color, 
intensely stained granules. The appealing characters that entail the use of SBB stain are: 
i. The reaction and non-reaction with SBB stain are both significant, as the former refer 
practically to AML and the latter supports the diagnosis of ALL or AML-M0. 
ii. The intensity of a positive reaction with SBB in general parallels myeloperoxidase 
activity. Generally local experience would decide which stain to choose. However, SBB 
gives a slightly more intense reaction and sensitivity than myeloperoxidase staining in 
the detection of myeloblasts and is safer than the older technique of MPO staining 
(using carcinogenic benzidine or its derivatives). 
iii. Better demonstration of Auer rods by using SBB stain than any of the usual 
Romanowsky stains. This would be of utmost benefit to identify all MDS cases with 
Auer rods, to differentiate some AML from ALL cases (Image 4) and also to follow up 
AML cases for morphological remission after induction chemotherapy.  
 
 
Image 4. Composite photograph of the peripheral blood film of a patient with AML-M2, the 
blasts showed unusual nuclear lobulation, these blasts contained  SBB positive granules and 
Auer rods (Abdulsalam et al, 2011b) 
In all AML subtypes, except for AML-M3, the presence of even one blast cell with Auer 
rod would refer to failure to achieve remission and indicate the need for a second 
induction chemotherapy course, while in AML-M3 finding an Auer rod after induction 
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is usually a part of response to treatment as it appears in more maturing myeloid cells 
(Wong, 2010) (Image 5). 
iv. The presence of 3% or more SBB stain positive blasts would characteristically refer to 
the diagnosis of AML-M1 rather than ALL. 
Although it is now about 30 years since first reporting that in very rare cases even ALL 
blasts may show SBB positivity (Tricota, et al, 1982); however characters like being of 
less intensity than the control (remnant normal cells of the myeloid series), non-
granular and diffuse reaction help to indicate that these are not myeloblasts. Also 
lymphoblasts would universally stain negative with MPO which can then be used to 
confirm the nature of the blasts. 
v. Increased SBB stain positivity at diagnosis is associated with better prognosis. 
vi. Speedy and firm enough diagnosis of AML-M3 variant cases (Image 6) to start ATRA 
treatment in the same day (Abdulsalam & Sabeeh, 2010). 
vii. Demonstration of myeloid series dysplasia (Image 7) (Bain, 2010b). 




Image 5. Peripheral blood film of a patient with AML-M3 on ATRA treatment showing a 
dysplastic neutrophil that contains an Auer rod (Abdulsalam and Sabeeh, 2009b) 
3.11.1.1 How to count the percentage of SBB positively stained blasts 
The literatures are always referring to directly counting the blasts from the SBB stain slide, 
which is the best technique if the blasts can be easily recognized, but in practice and 
especially with AML-M1 this is not always feasible due to the nature of the stain which 
renders many blasts indistinguishable from other less immature cells. Therefore, there 
should be a second best technique to count the percent of smear positive SBB blasts, because 
it is not always possible to differentiate all the blasts directly from the SBB slide. 
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In the author’s hematology laboratory practice the following procedure is applied by first 
utilizing the Leishman stain slide for counting cells into 3 categories as fractions from all the 
total marrow cells: 1st the blast cells; 2nd the maturing myeloid cells, which would be all 
assumed to stain positive, although some may actually be negative as a feature of 
myelodysplasia but nevertheless in calculations this would provide a higher safety 
threshold to avoid inappropriately classifying a case as AML and 3rd category for 
lymphocytes and nucleated red cells, which would be negatively stained. Then from the SBB 




Image 6. Composite photograph showing Leishman staining (left) and SBB,    
cytochemical, staining (right)  diagnosis of the variant form of AML-M3  (Abdulsalam & 
Sabeeh, 2010). 
3.11.2 NSE 
Including α-naphthyl acetate esterase (ANAE), or preferably, α-naphthyl butyrate esterase 
(ANBE) which is more specific than the acetate stain for the monocytic lineage, either stain 
is required to confirm the morphological diagnosis of AML-M4, M5a and M5b. 
In some occasions there might be a differential diagnosis between M3v and M5b, in which 
cases it is best to avoid discrimination between them based only on NSE as it may be 
positive in both leukemias, instead a strong reaction with SBB in M3v can be used. 
 




Image 7. Dysplastic metamyelocyte (bottom right) that is completely agranular with SBB 
staining. {Same patient in Image 4} 
3.11.3 Periodic Acid Schiff (PAS) 
It adds a minor support to diagnosis of ALL as a similar reaction can be seen, although less 
frequently in AML. Although the pattern of reaction was considered important in some 
literatures (Lewis et al, 2006) to differentiate between ALL (with clear cytoplasm between 
the positive granules) and AML (with cytoplasmic smudge positivity between the positive 
granules) but in practice relying on such a difference is very difficult, therefore, PAS use is 
considered non-essential and should be replaced by CD3 and CD79a ICC/IHC. 
The other late advantage of PAS was to refer to possible cases of c-ALL; again this use has 
been superseded by CD10. 
3.12 Immunophenotyping 
Refers to identification of antigens within or on the surface of cells for the purpose of 
lineage assignment. It is not a proof for clonality instead of the genetic study. 
In AML patients it is essential for proper diagnosis of M0 and M7. In ALL it is essential for 
diagnosis and risk stratification including T and B lineage assignment (as there is no reliable 
morphological features to differentiate between them), and subclassification into pro-, 
common (c), pre- and mature B-ALL and early, cortical and mature T-ALL. 
A suggested list of ICC and IHC CD markers that should be available for diagnosis of acute 
leukemia can include: CD3 for T-ALL (CD7 is more sensitive than CD3, it almost reach 100% 
sensitivity for T-ALL but is not specific as it is also positive in 20% of AML cases; however, 
CD7 is still an excellent substitute for T-lineage assignment in rare cases of CD3 negative T-
ALL where with the proper clinical and radiological features, Romanowsky and special 
stains morphology and other CD markers, as negative anti-MPO, then the diagnosis of ALL 
is evident) and CD79a for B-ALL. 
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When B-ALL diagnosis is confirmed then CD20 would help to decide for anti-CD20 
(Rituximab) treatment option. 
 TdT would help to differentiate ALL-L2 (where it is positive) from leukemic phase of 
lymphoma (where it is negative). 
For B-ALL CD10 is negative in pro-B-ALL and positive in common-ALL (c-ALL) which 
confers better prognosis. In pre-B-ALL cytoplasmic immunoglobulin (cIg) is positive while 
surface Ig (sIg) is positive only in mature B-ALL (ALL-L3 or leukemic phase of Burkitt’s 
lymphoma, in which case TdT is negative). 
Only cytoplasmic CD3 (cCD3) is positive in early T-ALL, cCD3 and CD1a are both positive 
in thymic or cortical T-ALL which confers better prognosis, while in mature T-ALL surface 
CD3 (sCD3) is positive and CD1a is negative. 
Anti-myeloperoxidase, CD117 or CD33 can be used for AML-M0 and CD41 for AML-M7. 
The availability of CD45 can be useful in rare occasions to ensure the hemopoietic nature of 
a poorly differentiated malignancy (Bain et al, 2002). 
3.12.1 Flowcytometry 
The newer multicolor (detecting many CD markers in/on the same single malignant cell) 
and multiparametric (a character comparative to that of automated blood counters studying 
characters like cell size and granularity) flowcytometer is one of the ultimate routine 
techniques in diagnosis of AML and ALL, primary risk stratification of ALL and follow up 
for MRD. When there is leucocytosis due to leukemic blasts then the flowcytometry study 
can be done on peripheral blood, otherwise, a bone marrow aspirate is the specimen of 
choice. However, the current price of the flowcytometer, cost of operating kits and 
maintenance make it unsuitable for laboratories with small budget. 
3.12.2 Immunocytochemistry (ICC) 
This technique should be consistently used in resource-poor laboratories for lineage and 
sub-lineage assignment of acute leukemia. It is applied on the bone marrow aspirate smear 
or, less conveniently on the peripheral blood after removal of plasma or on buffy coat (only 
if the blast percent is high). Sample spread can be done on a regular glass-slide (it is not 
essential to use a positively charged slide as in IHC) and after fixation in alcohol, ICC can be 
applied directly or after storage. 
In acute leukemia the results of ICC (Image 8) can be interpreted in much more logical sense 
than IHC as the remaining normal or reactive cells can express some diagnosis-unrelated 
but confusing CD marker that in the aspirate can be easily detected to appear only for non-
blast cells. 
3.12.3 Immunohistochemistry (IHC) 
Can be used as a substitute for ICC as the second best test for immunophenotyping of acute 
leukemia in the resource-poor laboratories if the blast percent is high, and if the results are 
unequivocally positive or negative or when the bone marrow aspirate is inadequate, 
otherwise when the blast percent is low or when the IHC positive result is in the borderline 
zone (20-30%) the judgment on the result of IHC can be difficult. For paraffin embedded 
IHC the designation between marker-positive blasts or reactive cells can be very difficult 
and in almost all conditions the total positivity per all marrow cells is expressed. 
 






Fig. 8. Composite photograph of the same AML-M1 patient in (Image 2) showing CD 3 
negative blasts (top image) with 28% “uncounted” positive small lymphocytes, and CD20 
negative blasts (bottom image) with 5% “uncounted” positive small lymphocytes. 
3.13 Genetic studies 
Including mainly cytogenetics, InSitu Hybridization (ISH) and PCR. All of these techniques 
have advantages and limitations and the choice in acute leukemia should be based on at 
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least two different techniques that would give complementary information especially for 
risk stratification and follow up for MRD. 
Older techniques, like Feulgen stain for quantization of DNA contents should be avoided 
even in under-resourced laboratories because these techniques are non-standard and 
confusing. 
3.13.1 Cytogenetics 
It should be routinely applied for every suspected case of acute leukemia. Cytogenetics 
would represent to genetic studies what a blood smear represents to hematology, i.e., study 
of morphology of chromosomes and blood cells respectively. However, it has major 
limitations as the procedure-inherent failure rate and inability to detect small size 
aberrations or cryptic translocations. 
Cytogenetics, beside a molecular study, is essential for the application of the WHO 
classification of acute leukemia and its risk stratification. 
3.13.2 InSitu Hybridization (ISH) 
Including Flourescent InSitu Hybridization (FISH) and Chromogenic InSitu Hybridization 
(CISH). Each technique has its advantages and limitations. FISH would represent a 
molecular genetic study plus demonstration of some chromosomal morphology. While 
CISH would represent a molecular genetic study plus demonstration of tissue morphology. 
In the author’s opinion both techniques are not ideal for diagnosis, risk stratification and 
follow up of acute leukemia in an under-resourced laboratory. 
3.13.3 Polymerase Chain Reaction (PCR) 
Using only one detection kit multiplex RT-PCR assay is an effective, sensitive, accurate and 
cost-effective one-step multiple molecular re-arrangements diagnostic and risk-stratification 
tool. It is a complementary technique to conventional cytogenetics for risk stratification of 
acute leukemia and it provides a platform for the later on possibility of RQ-PCR detection of 
minimal residual disease (MRD) as multiplex RT-PCR is a qualitative procedure and is not 
used by itself as a mean for detection of MRD. For ALL, ETV6-RUNX1 and TCF3-PBX1 
(both confer good prognosis), and MLL-MLLt2 and BCR-ABL1 (both confer poor prognosis) 
(Cerveira at al, 2000 and Shai, 2010); and for AML, FLT3 and MLL (both confer poor 
prognosis), and NPM1 and CEBPA (both confer good prognosis) (Strehl et al, 2001) paired 
primers are useful options (Salto-Tellez et al, 2003). 
3.14 Chemotherapeutic trial for acute leukemia 
A chemotherapeutic trial for those who cannot afford to seek a more precise diagnosis with 
genetic study and lineage specification abroad is a realistic option, as the response to 
treatment could be a very useful confirmation of the provisional diagnosis. The two 
examples already the author had faced are AML-M3v diagnosed provisionally only by 
morphology but with a dramatic response to ATRA trial, confirming the diagnosis (Image 9) 
and a few cases of morphologically undifferentiated acute leukemia in which the induction 
therapy for ALL is tried first (using vincristine and prednisolone only). If the patient 
responds, then a diagnosis of ALL can be deduced; if not, the regimen should be shifted to 
chemotherapy of AML (Abdulsalam, 2009). 
 







Image 9. Peripheral blood film showed 94% abnormal granulated promyelocytes. In the 
absence of any specialized tests, the diagnosis was made from cytological features. There 
was a dramatic response to ATRA, confirming the morphological diagnosis of AML-M3v 
(Abdulsalam & Nafila, 2009). 
3.15 Lumbar puncture 
Looking for cerebrospinal fluid (CSF) involvement with acute leukemia is advised in all 
patients with ALL, while for patients with AML it is only indicated for patients with 
neurological symptoms.  
3.16 Remission 
Durable remission in acute leukemia is based on clinical and morphological evidences. 
Clinical remission includes absence of symptoms and signs of leukemia. Complete blood 
count consistent with remission would include absence of severe anemia, neutrophil 
count more than 1 ×109/l and platelet count more than 100 ×109/l (Bain, 2010). 
Morphological remission of acute leukemia from peripheral blood involves absence of 
blasts, immature myeloid cells and nucleated red cells. Bone marrow aspirate consistent 
with morphological remission would include blast cells being less than 5% with absence 
of Auer rods. The presence of even one Auer rod on SBB stain would refer to failure to 
achieve remission. 
Flowcytometry, cytogenetics or molecular genetics may be used to validate a morphological 
remission if any of these techniques were already utilized at diagnosis. 
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3.17 Minimal residual disease (MRD) 
Detection of MRD entails the availability of either RQ-PCR or multi-color flowcytometry. 
Both techniques may not be routinely feasible for a laboratory with poor-resources. 
4. Minimal technical requirements for application of WHO classification of 
acute leukemia 
There should be at least a routine availability of CBC (manual or, preferably, automated), 
peripheral blood and bone marrow aspirate smears (and in some occasions bone marrow 
biopsy), SBB and a NSE stains, immunocytochemistry with/without immunohistochemistry 
(including at least CD3, CD79a, anti-MPO and CD41), cytogenetics and conventional PCR 
for the multiplex primers already mentioned in paragraph 3.13.3. 
5. Conclusion 
In hematology laboratories where the diagnostic resources are limited, it is essential to 
establish local guidelines that are practical in developing cost-effective diagnostic protocols 
for conditions for which the treatment is available, plus leaving the door wide open for 
future improvements, as to the introduction of newer techniques to the already available 
procedures once a newer therapeutic agent with certain lineage assignment demands has 
been introduced. 
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3.17 Minimal residual disease (MRD) 
Detection of MRD entails the availability of either RQ-PCR or multi-color flowcytometry. 
Both techniques may not be routinely feasible for a laboratory with poor-resources. 
4. Minimal technical requirements for application of WHO classification of 
acute leukemia 
There should be at least a routine availability of CBC (manual or, preferably, automated), 
peripheral blood and bone marrow aspirate smears (and in some occasions bone marrow 
biopsy), SBB and a NSE stains, immunocytochemistry with/without immunohistochemistry 
(including at least CD3, CD79a, anti-MPO and CD41), cytogenetics and conventional PCR 
for the multiplex primers already mentioned in paragraph 3.13.3. 
5. Conclusion 
In hematology laboratories where the diagnostic resources are limited, it is essential to 
establish local guidelines that are practical in developing cost-effective diagnostic protocols 
for conditions for which the treatment is available, plus leaving the door wide open for 
future improvements, as to the introduction of newer techniques to the already available 
procedures once a newer therapeutic agent with certain lineage assignment demands has 
been introduced. 
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1. Introduction 
Hematopoiesis is a complex series of events resulting in the formation of mature blood cells. 
This process is regulated by cytokines at various levels, including self-renewal, proliferation, 
and differentiation. Upon binding of cytokines to their cognate receptors, the activity of 
intracellular signal transduction pathways is regulated, leading to modulation of gene 
expression. Although our appreciation of the transcriptional regulators of hematopoiesis has 
developed considerably, until recently, the roles of specific intracellular signal transduction 
pathways were largely unknown. An important mediator of cytokine signaling implicated 
in regulation of hematopoiesis is the Phosphatidylinositol-3-Kinase (PI3K) / Protein Kinase 
B (PKB/c-Akt) signaling module (Figure 1).  
The PI3K family consists of three distinct subclasses of which, to date, only the class I 
isoforms have been implicated in regulation of hematopoiesis. Four distinct catalytic class I 
isoforms have been identified; p110, p110, p110and p110(reviewed by Vanhaesebroeck 
et al., 2001) These isoforms are predominantly activated by protein tyrosine kinases and 
form heterodimers with a group a regulatory adapter molecules, including p85, p85, p50 
p55, p55and p101(reviewed by Vanhaesebroeck et al., 2001). The most important 
substrate for these Class I PI3Ks is phosphatidylinositol 4,5 bisphosphate (PI(4,5)P2) which 
can be phosphorylated at the D3 position of the inositol ring upon extracellular stimulation, 
resulting in the formation of phosphatidylinositol 3,4,5 trisphosphate (PI(3,4,5)P3) (reviewed 
by Hawkins et al., 2006). PI(3,4,5)P3 subsequently serves as an anchor for pleckstrin 
homology (PH) domain-containing proteins, such as Protein Kinase B (PKB/ c-akt) 
(Burgering & Coffer, 1995). Activation of PKB requires phosphorylation on both Thr308, in 
the activation loop, by phosphoinositide-dependent kinase 1 (PDK1) and Ser473, within the 
carboxyl-terminal hydrophobic motif, by the MTORC2 complex that consists of multiple 
proteins, including Mammalian Target of Rapamycin (mTOR) and Rictor (Sarbassov et al., 
2005). 
PKB itself subsequently regulates the activity of multiple downstream effectors, including 
the serine/threonine kinase Glycogen Synthase Kinase-3 (GSK-3) (Cross et al., 1995), 
members of the FoxO subfamily of forkhead transcription factors FoxO1, FoxO3, and FoxO4 
(Brunet et al., 1999; Kops et al., 1999) and the serine/threonine kinase mammalian target of 
rapamycin (mTOR) as part of the MTORC1 complex, which also includes  the regulatory 
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associated protein of mTOR (Raptor). In contrast to GSK-3 and the FoxO transcription 
factors that are inhibitory phosphorylated by PKB, activation of mTOR is positively 
regulated (Nave et al., 1999; Inoki et al., 2002). It has been demonstrated that PKB can inhibit 
the GTPase activating protein Tuberous sclerosis protein 2 (TSC2)/TSC1 complex, resulting 
in accumulation of GTP-bound Rheb and subsequent activation of mTOR (Inoki et al., 2002).  
 
 
Fig. 1. Schematic representation of the PI3K/PKB signaling module. Activation of PI3K by 
receptor stimulation results in the production of PtdIns(3,4,5)P3 at the plasma membrane. 
PKB subsequently translocates to the plasma membrane where it is phopshorylated by 
PDK1 and the mTORC2 complex. Upon phosphorylation, PKB is released into the 
cytoplasm where it can both inhibitory phosphorylate multiple substrates, including FoxO 
transcription factors and GSK-3 and induce the activity of other substrates such as mTOR as 
part of the mTORC1 complex. Negative regulators of the PI3K/PKB signaling module 
include PTEN, SHIP1 and Ins(1,3,4,5)P4. 
While cytokines and growth factors positively induce PI3K activity, its activity can also be 
inhibited by SH2-containing inositol-5'-phosphatase 1 (SHIP1) (Damen et al., 1996), a protein 
predominantly expressed in hematopoietic cells (Liu et al., 1998), that hydrolyzes PIP3 to 
generate PI(3,4)P2 (Damen et al., 1996). Similarly, Phosphate and Tensin Homologue (PTEN) 
(Maehama & Dixon, 1998), a ubiquitously expressed tumor suppressor protein, can 
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dephosphorylate PIP3 resulting in the formation of PI(4,5)P2 (Maehama & Dixon, 1998). 
Although both PTEN and SHIP1 act on the main product of PI3K activity, PIP3, the products 
generated are distinct. PI(3,4)P2 and PI(4,5)P2 both act as discrete second messengers 
activating distinct downstream events (Dowler et al., 2000; Golub & Caroni, 2005) indicating 
that the activation of SHIP1 and PTEN not only inhibit PI3K activity, but also can re-route 
the signal transduction pathways activated by PI-lipid second messengers. 
2. PI3K/PKB signaling and normal hematopoiesis 
2.1 PI3K  
The role of PI3K class I isoforms was initially examined utilizing knockout mice deficient for 
one or multiple regulatory or catalytic subunits. Combined deletion of p85, p55 and p50 
resulted in a complete block in B cell development (Fruman et al., 2000). Similarly, 
introduction of a mutated, catalytically inactive p110 (p110D910A) in the normal p110 locus 
also resulted in a block in early B cell development while T cell development was unaffected 
(Jou et al., 2002; Okkenhaug et al., 2002). These results indicate that PI3K activity is essential 
for normal B lymphocyte development. Pharmacological inhibition of PI3K activity in 
human umbilical cord blood derived CD34+ hematopoietic stem and progenitor cells 
revealed that inhibition of the activity of PI3K is sufficient to completely abrogate both 
proliferation and differentiation during ex vivo eosinophil and neutrophil development 
eventually leading to cell death (Buitenhuis et al., 2008). Conditional deletion of either PTEN 
or SHIP1 in adult HSCs resulting in activation of the PI3K pathway not only reduced the 
level of B-lymphocytes but also enhanced the level of myeloid cells (Helgason et al., 1998; 
Liu et al., 1999; Zhang et al., 2006). In addition, these mice developed a myeloproliferative 
disorder that progressed to leukemia (Helgason et al., 1998; Liu et al., 1999; Zhang et al., 
2006). Furthermore, enhanced levels of megakaryocyte progenitors have been observed in 
SHIP1 deficient mice (Perez et al., 2008). In PTEN heterozygote (+/-) SHIP null (-/-)  mice, a 
more severe myeloproliferative phenotype, displayed by reduced erythrocyte and platelet 
numbers and enhanced white blood cell counts including elevated levels of neutrophils and 
monocytes in the peripheral blood, could be observed (Moody et al., 2004). Interestingly, 
PI3K appears not only to be involved in lineage development, but is also required for stem 
cell maintenance. In PTEN and SHIP1 deficient mice, an initial expansion of HSCs could be 
observed which was followed by a depletion of long-term repopulating HSCs (Damen et al., 
1996; Helgason et al., 2003). Recently, a shorter SHIP1 isoform (s-SHIP1), which is 
transcribed from an internal promoter in the SHIP1 gene, has also been implicated in 
positive regulation of lymphocyte development during hematopoiesis. (Nguyen et al., 2011). 
Its role in regulation of HSCs and long-term hematopoiesis remains to be investigated 
(Nguyen et al., 2011). A third negative regulator of the PI3K/PKB signaling module is 
Inositol 1,3,4,5-tetrakiphosphate (Ins(1,3,4,5)P4), which is generated from Inositol 1,4,5-
triphosphate (Ins(1,4,5)P3) by Inositol triphosphate 3-kinase B (InsP3KB). It has been shown 
that Ins(1,3,4,5)P4 can bind to the PIP3-specific PH domains and competes for binding to 
those PH domains with PIP3 (Jia et al., 2007). In the bone marrow of mice deficient for 
InsP3KB, an acceleration of proliferation of the granulocyte macrophage progenitor has been 
observed resulting in higher levels of GMPs and mature neutrophils (Jia et al., 2008). In 
addition, although B lymphocytes could still be observed in InsP3KB deficient mice, mature 
CD4+ and CD8+ T lymphocytes were almost completely absent (Pouillon et al., 2003). 
Although InsP3KB is also involved in regulation of other pathways, the enhanced PKB 
phosphorylation in these mice (Jia et al., 2008) suggest that the observed phenotype is at 
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least partially due to activation of the PI3K/PKB signaling module. Taken together, these 
studies suggest that correct temporal regulation of PI3K activity is critical for both HSC 
maintenance and regulation of lineage development. 
2.2 PKB 
PKB, an important effector of PI3K signaling, has been demonstrated to play an important 
role in regulation of cell survival and proliferation in a variety of systems (reviewed by 
Manning & Cantley, 2007). Three highly homologous PKB isoforms have been described to 
be expressed in mammalian cells; PKB, PKB, and PKB. Analysis of HSCs derived from 
PKB/PKB double-knockout mice revealed that PKB plays an important role in 
maintenance of long-term repopulating HSCs. These PKB/PKB double-deficient HSCs 
were found to persist in the G0 phase of the cell cycle, suggesting that the long-term 
functional defects observed in these mice were caused by enhanced quiescence (Juntilla et 
al., 2010). In contrast, loss of only one of the isoforms only minimally affected HSCs (Juntilla 
et al., 2010). In addition, analysis of mice deficient for both PKB and PKB revealed that the 
generation of marginal zone and B1 B cells and the survival of mature follicular B cells 
highly depend on the combined expression of PKB and PKB. Again no significant 
differences could be observed in mice deficient for the single isoforms (Calamito et al., 2010). 
In addition, ectopic expression of constitutively active PKB in mouse HSCs conversely 
resulted in transient expansion and increased cycling of HSCs, followed by apoptosis and 
expansion of immature progenitors in BM and spleen, which was also associated with 
impaired engraftment (Kharas et al., 2010), again demonstrating the importance of PKB in 
HSC maintenance. Utilizing an ex vivo human granulocyte differentiation system and a 
mouse transplantation model, it has recently been demonstrated that PKB not only plays a 
role in expansion of hematopoietic progenitors, but also has an important function in 
regulation of cell fate decisions during hematopoietic lineage commitment (Buitenhuis et al., 
2008). High PKB activity was found to promote neutrophil and monocyte development and 
to inhibit B lymphocyte development, while conversely reduction of PKB activity is required 
to induce optimal eosinophil differentiation (Buitenhuis et al., 2008). In addition, PKB plays 
an important role in regulation of proliferation and survival of dendritic cell (DC) 
progenitors, but not maturation (van de Laar et al., 2010). Transplantion of mouse bone 
marrow cells ectopically expressing constitutively active PKB was sufficient to induce a 
myeloproliferative disease in most mice, characterized by extramedullary hematopoiesis in 
liver and spleen. In the majority of those mice, lymphoblastic thymic T cell lymphoma could 
also be observed. In addition, an undifferentiated AML developed in those mice that did not 
develop a myeloproliferative disease (Kharas et al., 2010). 
2.3 Downstream effectors of PKB 
To understand the molecular mechanisms underlying PKB mediated regulation of 
hematopoiesis, the roles of its downstream effectors in hematopoiesis have been 
investigated. FoxO transcription factors are known to play an important role in regulation of 
proliferation and survival of various cell types (reviewed by Birkenkamp & Coffer, 2003). 
Although proliferation and differentiation of hematopoietic progenitors appears not to be 
affected in FoxO3 deficient mice, competitive repopulation experiments revealed that deletion 
of FoxO3 is sufficient to impair long-term reconstitution (Miyamoto et al., 2007). In addition, in 
aging mice, the frequency of HSCs was increased compared to wild type littermate controls 
 
The PI3K/PKB Signaling Module in Normal and Malignant Hematopoiesis 
 
47 
(Miyamoto et al., 2007) and neutrophilia developed upon myelosuppressive stress conditions 
(Miyamoto et al., 2007). In contrast to FoxO3 deficient mice in which neutrophilia only 
occurred after myelosuppression while aging, conditional deletion of FoxO1, 3, and 4 in the 
adult hematopoietic system, was sufficient to increase the levels of myeloid cells and decrease 
the number of peripheral blood lymphocytes under normal conditions. In time, these mice 
developed leukocytosis characterized by a relative neutrophilia and lymphopenia (Tothova et 
al., 2007). In addition, an initial expansion of HSCs has been observed in these mice which 
correlated with an HSC-specific up-regulation of Cyclin D2 and down-regulation of Cyclin G2, 
p130/Rb, p27, and p21 (Tothova et al., 2007). Furthermore, a defective long-term repopulating 
capacity of bone marrow cells was observed, which could be explained by the reduction in 
HSC numbers that followed the initial expansion (Tothova et al., 2007). Although deletion of 
FoxO3 alone was not sufficient to improve myeloid development, ectopic expression of a 
constitutively active, non-phosphorylatable, FoxO3 mutant in mouse hematopoietic 
progenitors did result in a decrease in the formation of both myeloid and erythroid colonies 
(Engstrom et al., 2003), suggesting that FoxO3 does plays an important role in lineage 
development.  
Modulation of the activity of the PI3K signaling pathway has been observed to alter the 
level of reactive oxygen species (ROS). While ROS levels are reduced in PKB/ deficient 
mice (Juntilla et al., 2010), increased levels have been observed in mice deficient for FoxO 
(Miyamoto et al., 2007). Increasing ROS levels in PKB/ deficient mice was sufficient to 
rescue differentiation defects, but not impaired long-term hematopoiesis (Juntilla et al., 
2010). Restoring the ROS levels in FoxO deficient mice by in vivo treatment with an 
antioxidative agent N-acetyl-L-cysteine was sufficient to abrogate the enhanced levels of 
proliferation and apoptosis in FoxO deficient HSCs and to restore the reduced colony 
forming ability of these cells (Tothova et al., 2007). These studies demonstrate that correct 
regulation of ROS by FoxO transcription factors is essential for normal hematopoiesis.  
Recent findings have demonstrated that correct regulation of the activity of GSK-3, another 
downstream effector of PKB, is also essential for maintenance of hematopoietic stem cell 
homeostasis. A reduction in long-term, but not short-term repopulating HSCs has, for 
example, been observed in GSK3 deficient mice (Huang et al., 2009). In addition, disruption 
of GSK-3 activity in mice with a pharmacological inhibitor or shRNAs has been shown to 
transiently induce expansion of both hematopoietic stem and progenitor cells followed by 
exhaustion of long-term repopulation HSCs (Trowbridge et al., 2006; Huang et al., 2009). In 
addition, since GSK-3 has been demonstrated to inhibit mTOR activity by phosphorylation 
and activation of TSC1/2 (Inoki et al., 2006) and the level of phosphorylated S6 was 
enhanced in cells with reduced GSK-3 levels, mice were treated with rapamycin. Rapamycin 
induced the number of LSK cells when GSK3 was depleted, but not in un-manipulated cells, 
suggesting that mTOR is an important effector of GSK-3 in regulation of HSC numbers 
(Huang et al., 2009) In addition to the observed expansion of HSCs in mice treated with a 
GSK-3 inhibitor, the recovery of neutrophil and megakaryocyte numbers after 
transplantation was accelerated in these mice, resulting in improved survival of the 
recipients (Trowbridge et al., 2006). In addition, ex vivo experiments revealed that GSK-3 can 
enhance eosinophil differentiation and inhibit neutrophil development (Buitenhuis et al., 
2008). C/EBP, a key regulator of hematopoiesis, has been demonstrated to be an important 
mediator of PKB/GSK-3 signaling in regulation of granulocyte development (Buitenhuis et 
al., 2008). 
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least partially due to activation of the PI3K/PKB signaling module. Taken together, these 
studies suggest that correct temporal regulation of PI3K activity is critical for both HSC 
maintenance and regulation of lineage development. 
2.2 PKB 
PKB, an important effector of PI3K signaling, has been demonstrated to play an important 
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PKB/PKB double-knockout mice revealed that PKB plays an important role in 
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mouse transplantation model, it has recently been demonstrated that PKB not only plays a 
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regulation of cell fate decisions during hematopoietic lineage commitment (Buitenhuis et al., 
2008). High PKB activity was found to promote neutrophil and monocyte development and 
to inhibit B lymphocyte development, while conversely reduction of PKB activity is required 
to induce optimal eosinophil differentiation (Buitenhuis et al., 2008). In addition, PKB plays 
an important role in regulation of proliferation and survival of dendritic cell (DC) 
progenitors, but not maturation (van de Laar et al., 2010). Transplantion of mouse bone 
marrow cells ectopically expressing constitutively active PKB was sufficient to induce a 
myeloproliferative disease in most mice, characterized by extramedullary hematopoiesis in 
liver and spleen. In the majority of those mice, lymphoblastic thymic T cell lymphoma could 
also be observed. In addition, an undifferentiated AML developed in those mice that did not 
develop a myeloproliferative disease (Kharas et al., 2010). 
2.3 Downstream effectors of PKB 
To understand the molecular mechanisms underlying PKB mediated regulation of 
hematopoiesis, the roles of its downstream effectors in hematopoiesis have been 
investigated. FoxO transcription factors are known to play an important role in regulation of 
proliferation and survival of various cell types (reviewed by Birkenkamp & Coffer, 2003). 
Although proliferation and differentiation of hematopoietic progenitors appears not to be 
affected in FoxO3 deficient mice, competitive repopulation experiments revealed that deletion 
of FoxO3 is sufficient to impair long-term reconstitution (Miyamoto et al., 2007). In addition, in 
aging mice, the frequency of HSCs was increased compared to wild type littermate controls 
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(Miyamoto et al., 2007) and neutrophilia developed upon myelosuppressive stress conditions 
(Miyamoto et al., 2007). In contrast to FoxO3 deficient mice in which neutrophilia only 
occurred after myelosuppression while aging, conditional deletion of FoxO1, 3, and 4 in the 
adult hematopoietic system, was sufficient to increase the levels of myeloid cells and decrease 
the number of peripheral blood lymphocytes under normal conditions. In time, these mice 
developed leukocytosis characterized by a relative neutrophilia and lymphopenia (Tothova et 
al., 2007). In addition, an initial expansion of HSCs has been observed in these mice which 
correlated with an HSC-specific up-regulation of Cyclin D2 and down-regulation of Cyclin G2, 
p130/Rb, p27, and p21 (Tothova et al., 2007). Furthermore, a defective long-term repopulating 
capacity of bone marrow cells was observed, which could be explained by the reduction in 
HSC numbers that followed the initial expansion (Tothova et al., 2007). Although deletion of 
FoxO3 alone was not sufficient to improve myeloid development, ectopic expression of a 
constitutively active, non-phosphorylatable, FoxO3 mutant in mouse hematopoietic 
progenitors did result in a decrease in the formation of both myeloid and erythroid colonies 
(Engstrom et al., 2003), suggesting that FoxO3 does plays an important role in lineage 
development.  
Modulation of the activity of the PI3K signaling pathway has been observed to alter the 
level of reactive oxygen species (ROS). While ROS levels are reduced in PKB/ deficient 
mice (Juntilla et al., 2010), increased levels have been observed in mice deficient for FoxO 
(Miyamoto et al., 2007). Increasing ROS levels in PKB/ deficient mice was sufficient to 
rescue differentiation defects, but not impaired long-term hematopoiesis (Juntilla et al., 
2010). Restoring the ROS levels in FoxO deficient mice by in vivo treatment with an 
antioxidative agent N-acetyl-L-cysteine was sufficient to abrogate the enhanced levels of 
proliferation and apoptosis in FoxO deficient HSCs and to restore the reduced colony 
forming ability of these cells (Tothova et al., 2007). These studies demonstrate that correct 
regulation of ROS by FoxO transcription factors is essential for normal hematopoiesis.  
Recent findings have demonstrated that correct regulation of the activity of GSK-3, another 
downstream effector of PKB, is also essential for maintenance of hematopoietic stem cell 
homeostasis. A reduction in long-term, but not short-term repopulating HSCs has, for 
example, been observed in GSK3 deficient mice (Huang et al., 2009). In addition, disruption 
of GSK-3 activity in mice with a pharmacological inhibitor or shRNAs has been shown to 
transiently induce expansion of both hematopoietic stem and progenitor cells followed by 
exhaustion of long-term repopulation HSCs (Trowbridge et al., 2006; Huang et al., 2009). In 
addition, since GSK-3 has been demonstrated to inhibit mTOR activity by phosphorylation 
and activation of TSC1/2 (Inoki et al., 2006) and the level of phosphorylated S6 was 
enhanced in cells with reduced GSK-3 levels, mice were treated with rapamycin. Rapamycin 
induced the number of LSK cells when GSK3 was depleted, but not in un-manipulated cells, 
suggesting that mTOR is an important effector of GSK-3 in regulation of HSC numbers 
(Huang et al., 2009) In addition to the observed expansion of HSCs in mice treated with a 
GSK-3 inhibitor, the recovery of neutrophil and megakaryocyte numbers after 
transplantation was accelerated in these mice, resulting in improved survival of the 
recipients (Trowbridge et al., 2006). In addition, ex vivo experiments revealed that GSK-3 can 
enhance eosinophil differentiation and inhibit neutrophil development (Buitenhuis et al., 
2008). C/EBP, a key regulator of hematopoiesis, has been demonstrated to be an important 
mediator of PKB/GSK-3 signaling in regulation of granulocyte development (Buitenhuis et 
al., 2008). 
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A third, important mediator of PI3K/PKB signaling is mTOR. Conditional deletion of TSC1 
in mice, resulting in activation of mTOR, has been demonstrated to enhance the percentage 
of cycling HSCs and to reduce the self-renewal capacity of HSCs in serial transplantation 
assays (Chen et al., 2008). In addition, a reduction in the number of granulocytes and 
lymphocytes has been observed in those mice (Chen et al., 2008). As described above, 
activation of the PI3K signaling pathway by conditional deletion of PTEN in adult murine 
HSCs resulted in an initial expansion followed by exhaustion of LT-HSCs. Inhibition of 
mTOR in murine HSCs deficient for PTEN with Rapamycin was sufficient to revert this 
phenotype, again suggesting that mTORC1 signaling plays an important role in 
proliferation of HSCs (Yilmaz et al., 2006). A role for mTOR in progenitor expansion has 
been demonstrated utilizing an ex vivo human granulocyte differentiation system (Geest et 
al., 2009). In contrast to inhibition of PKB activity which not only affects progenitor 
expansion but also alters lineage development (Buitenhuis et al., 2008), inhibition of mTOR 
activity with Rapamycin only reduced the expansion of hematopoietic progenitors, during 
both eosinophil and neutrophil differentiation, without altering levels of apoptosis or 
maturation (Geest et al., 2009). Similarly, inhibition of mTOR reduced the number of 
interstitial DCs and Langerhans cells in in vitro experiments (van de Laar et al., 2010). In 
contrast to granulocyte development, treatment with rapamycin appears not only to affect 
proliferation during megakaryocyte (MK) development, but also appears to delay the 
generation of pro-platelet MKs (Raslova et al., 2006). Similar to FOXO transcription factors, 
TSC1 also appears to be involved in regulation of ROS levels in HSCs. Elevated levels of 
ROS have been observed in TSC1 deficient mice. In vivo treatment of those mice with a ROS 
antagonist restored HSC numbers and function (Chen et al., 2008), suggesting that TSC1 
regulates HSC numbers at least in part via ROS. In addition to GSK3, the activity of C/EBP 
also appears to be regulated by mTOR, albeit in a different manner.  It has recently been 
shown that the ratio of wild type C/EBP (C/EBPp42) and truncated C/EBPp30, which 
is generated by alternative translation initiation, is decreased by mTOR, resulting in high 
levels of the smaller p30 C/EBP isoform (Fu et al., 2010) that inhibits trans-activation of 
C/EBP target genes in a dominant-negative manner (Pabst et al., 2001) and binds to the 
promoters of a unique set of target genes to suppress their transcription (Wang et al., 2007).  
3. PI3K/PKB signaling and malignant hematopoiesis 
3.1 Deregulated PI3K/PKB signaling in malignant hematopoiesis 
The above described studies clearly demonstrate that the PI3K/PKB signaling module plays 
a critical role in regulation of hematopoiesis. Since constitutive activation of PI3K and/or its 
downstream effectors has been observed in a high percentage of patients with hematological 
malignancies, it is likely that the development of leukemia may at least in part depend on 
aberrant regulation of this signaling module.  
3.1.1 PI3K  
Constitutive activation of class I PI3K isoforms has been observed in a high percentage of 
patients with acute leukemia (Kubota et al., 2004; Silva et al., 2008; Billottet et al., 2009; Zhao, 
2010). In contrast to the expression of p110, and which is only up-regulated in leukemic 
blasts of some patients, p110expression appears to be consistently up-regulated in cells 
from patients with either AML or APL (Sujobert et al., 2005; Billottet et al., 2009). Activating 
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mutations in p110, have been detected in a wide variety of human solid tumors (Ligresti et 
al., 2009). The most common mutations in p110 are located in the kinase domain (H1047R) 
and in the helical domain (E545A) (Lee et al., 2005). The E545A mutation has also been 
detected in acute, but not further specified, leukemia, albeit in a very low percentage (1/88) 
(Lee et al., 2005). In a series of 44 pediatric T-ALL patients,  activating mutations in the 
catalytic subunit of PI3K (PIK3CA) have been observed in 2 patients, while in frame 
insertions/deletions have been detected in the PI3K regulatory subunit PIK3R1 in two other 
patients (Gutierrez et al., 2009). Transplantation of mice with bone marrow cells ectopically 
expressing mutated p110 resulted in the development of a leukemia-like disease within 5 
weeks after transplantation (Horn et al., 2008), suggesting that mutations in p110 would be 
sufficient to induce leukemia. However, since mutations in PI3K appear to be very rare, it is 
unlikely that these mutations would be a major cause of leukemic development. 
Alternatively, the constitutive activation of PI3K observed in many patients with leukemia 
could also be caused by either aberrant expression or activation of modulators of PI3K 
activity, including PTEN and SHIP1. 
Reduced expression of PTEN has, for example, been observed in different types of leukemia 
(Xu et al., 2003; Nyakern et al., 2006). Both homozygous and heterozygous deletion of PTEN 
as well as non-synonymous sequence alterations in exon 7 have been detected in 
approximately 15% and 25% of T-ALL patients, respectively (Gutierrez et al., 2009). In 
contrast, analysis of both leukemic cell lines and primary AML blasts indicate that PTEN 
mutations are rare in AML (Aggerholm et al., 2000; Liu et al., 2000). In addition to mutations 
in PTEN itself, aberrant PTEN expression may also be caused by mutations in its upstream 
regulators. Both enhanced casein kinase 2 (CK2) expression/activity and enhanced ROS 
levels appear, for example, to correlate with decreased PTEN phosphatase activity in T-ALL 
cells (Silva et al., 2008). Both CK2 inhibitors and ROS scavengers were sufficient to restore 
PTEN activity and impaired PI3K/PKB signaling in those T-ALL cells, demonstrating that 
aberrant CK2 and ROS levels may affect PI3K signaling in leukemia (Silva et al., 2008). 
Another important, negative regulator of PI3K activity that has been demonstrated to play a 
critical role in hematopoiesis is SHIP1. Analysis of primary T-ALL cells revealed that full 
length SHIP1 expression is often low or undetectable. However, when using an antibody 
against the C terminal domain of SHIP1, low molecular weight proteins can frequently be 
observed. These low molecular weight proteins are thought to be the result of mutation 
induced alternative splicing (Lo et al., 2009). In addition, in leukemic cells from an AML 
patient, a mutation in the phosphatase domain of SHIP1 has also been detected which 
results in reduced catalytic activity and enhanced PKB phosphorylation (Luo et al., 2003). 
For an overview of all known mutations affecting PI3K/PKB signaling, see table 1. 
3.1.2 PKB 
Constitutive activation of PKB has been demonstrated in a significant fraction of AML 
patients (Min et al., 2003; Xu et al., 2003; Zhao et al., 2004; Grandage et al., 2005; Gallay et al., 
2009). Until recently, no PKB mutations were found in patients with leukemia. However, an 
activating mutation in the pleckstrin homology domain of PKB (E17K) has recently been 
detected in solid tumors (Carpten et al., 2007). Transplantation of mice with bone marrow 
cells ectopically expressing this E17K mutation was sufficient to induce leukemia, ten weeks 
after transplantation (Carpten et al., 2007). Although this particular mutation has been 
observed in different types of cancer, it appears to be rare in leukemic patients. Thus far, this 
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A third, important mediator of PI3K/PKB signaling is mTOR. Conditional deletion of TSC1 
in mice, resulting in activation of mTOR, has been demonstrated to enhance the percentage 
of cycling HSCs and to reduce the self-renewal capacity of HSCs in serial transplantation 
assays (Chen et al., 2008). In addition, a reduction in the number of granulocytes and 
lymphocytes has been observed in those mice (Chen et al., 2008). As described above, 
activation of the PI3K signaling pathway by conditional deletion of PTEN in adult murine 
HSCs resulted in an initial expansion followed by exhaustion of LT-HSCs. Inhibition of 
mTOR in murine HSCs deficient for PTEN with Rapamycin was sufficient to revert this 
phenotype, again suggesting that mTORC1 signaling plays an important role in 
proliferation of HSCs (Yilmaz et al., 2006). A role for mTOR in progenitor expansion has 
been demonstrated utilizing an ex vivo human granulocyte differentiation system (Geest et 
al., 2009). In contrast to inhibition of PKB activity which not only affects progenitor 
expansion but also alters lineage development (Buitenhuis et al., 2008), inhibition of mTOR 
activity with Rapamycin only reduced the expansion of hematopoietic progenitors, during 
both eosinophil and neutrophil differentiation, without altering levels of apoptosis or 
maturation (Geest et al., 2009). Similarly, inhibition of mTOR reduced the number of 
interstitial DCs and Langerhans cells in in vitro experiments (van de Laar et al., 2010). In 
contrast to granulocyte development, treatment with rapamycin appears not only to affect 
proliferation during megakaryocyte (MK) development, but also appears to delay the 
generation of pro-platelet MKs (Raslova et al., 2006). Similar to FOXO transcription factors, 
TSC1 also appears to be involved in regulation of ROS levels in HSCs. Elevated levels of 
ROS have been observed in TSC1 deficient mice. In vivo treatment of those mice with a ROS 
antagonist restored HSC numbers and function (Chen et al., 2008), suggesting that TSC1 
regulates HSC numbers at least in part via ROS. In addition to GSK3, the activity of C/EBP 
also appears to be regulated by mTOR, albeit in a different manner.  It has recently been 
shown that the ratio of wild type C/EBP (C/EBPp42) and truncated C/EBPp30, which 
is generated by alternative translation initiation, is decreased by mTOR, resulting in high 
levels of the smaller p30 C/EBP isoform (Fu et al., 2010) that inhibits trans-activation of 
C/EBP target genes in a dominant-negative manner (Pabst et al., 2001) and binds to the 
promoters of a unique set of target genes to suppress their transcription (Wang et al., 2007).  
3. PI3K/PKB signaling and malignant hematopoiesis 
3.1 Deregulated PI3K/PKB signaling in malignant hematopoiesis 
The above described studies clearly demonstrate that the PI3K/PKB signaling module plays 
a critical role in regulation of hematopoiesis. Since constitutive activation of PI3K and/or its 
downstream effectors has been observed in a high percentage of patients with hematological 
malignancies, it is likely that the development of leukemia may at least in part depend on 
aberrant regulation of this signaling module.  
3.1.1 PI3K  
Constitutive activation of class I PI3K isoforms has been observed in a high percentage of 
patients with acute leukemia (Kubota et al., 2004; Silva et al., 2008; Billottet et al., 2009; Zhao, 
2010). In contrast to the expression of p110, and which is only up-regulated in leukemic 
blasts of some patients, p110expression appears to be consistently up-regulated in cells 
from patients with either AML or APL (Sujobert et al., 2005; Billottet et al., 2009). Activating 
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mutations in p110, have been detected in a wide variety of human solid tumors (Ligresti et 
al., 2009). The most common mutations in p110 are located in the kinase domain (H1047R) 
and in the helical domain (E545A) (Lee et al., 2005). The E545A mutation has also been 
detected in acute, but not further specified, leukemia, albeit in a very low percentage (1/88) 
(Lee et al., 2005). In a series of 44 pediatric T-ALL patients,  activating mutations in the 
catalytic subunit of PI3K (PIK3CA) have been observed in 2 patients, while in frame 
insertions/deletions have been detected in the PI3K regulatory subunit PIK3R1 in two other 
patients (Gutierrez et al., 2009). Transplantation of mice with bone marrow cells ectopically 
expressing mutated p110 resulted in the development of a leukemia-like disease within 5 
weeks after transplantation (Horn et al., 2008), suggesting that mutations in p110 would be 
sufficient to induce leukemia. However, since mutations in PI3K appear to be very rare, it is 
unlikely that these mutations would be a major cause of leukemic development. 
Alternatively, the constitutive activation of PI3K observed in many patients with leukemia 
could also be caused by either aberrant expression or activation of modulators of PI3K 
activity, including PTEN and SHIP1. 
Reduced expression of PTEN has, for example, been observed in different types of leukemia 
(Xu et al., 2003; Nyakern et al., 2006). Both homozygous and heterozygous deletion of PTEN 
as well as non-synonymous sequence alterations in exon 7 have been detected in 
approximately 15% and 25% of T-ALL patients, respectively (Gutierrez et al., 2009). In 
contrast, analysis of both leukemic cell lines and primary AML blasts indicate that PTEN 
mutations are rare in AML (Aggerholm et al., 2000; Liu et al., 2000). In addition to mutations 
in PTEN itself, aberrant PTEN expression may also be caused by mutations in its upstream 
regulators. Both enhanced casein kinase 2 (CK2) expression/activity and enhanced ROS 
levels appear, for example, to correlate with decreased PTEN phosphatase activity in T-ALL 
cells (Silva et al., 2008). Both CK2 inhibitors and ROS scavengers were sufficient to restore 
PTEN activity and impaired PI3K/PKB signaling in those T-ALL cells, demonstrating that 
aberrant CK2 and ROS levels may affect PI3K signaling in leukemia (Silva et al., 2008). 
Another important, negative regulator of PI3K activity that has been demonstrated to play a 
critical role in hematopoiesis is SHIP1. Analysis of primary T-ALL cells revealed that full 
length SHIP1 expression is often low or undetectable. However, when using an antibody 
against the C terminal domain of SHIP1, low molecular weight proteins can frequently be 
observed. These low molecular weight proteins are thought to be the result of mutation 
induced alternative splicing (Lo et al., 2009). In addition, in leukemic cells from an AML 
patient, a mutation in the phosphatase domain of SHIP1 has also been detected which 
results in reduced catalytic activity and enhanced PKB phosphorylation (Luo et al., 2003). 
For an overview of all known mutations affecting PI3K/PKB signaling, see table 1. 
3.1.2 PKB 
Constitutive activation of PKB has been demonstrated in a significant fraction of AML 
patients (Min et al., 2003; Xu et al., 2003; Zhao et al., 2004; Grandage et al., 2005; Gallay et al., 
2009). Until recently, no PKB mutations were found in patients with leukemia. However, an 
activating mutation in the pleckstrin homology domain of PKB (E17K) has recently been 
detected in solid tumors (Carpten et al., 2007). Transplantation of mice with bone marrow 
cells ectopically expressing this E17K mutation was sufficient to induce leukemia, ten weeks 
after transplantation (Carpten et al., 2007). Although this particular mutation has been 
observed in different types of cancer, it appears to be rare in leukemic patients. Thus far, this 
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mutation has only been detected in one pediatric T-ALL patient (Gutierrez et al., 2009). To 
date, no other mutations in PKB have been described. 
 
 Mutation Activation/ loss 
Detected 
in: Location References 
Pathway      
PI3K E545A Activation AML & ALL Helical domain p110α 
Lee , 2005; Horn , 
2008 
 E542K Activation # Helical domain p110α Horn , 2008 
 H1047R Activation # Kinase domain p110α Horn , 2008 
 PIK3CA Activation T-ALL Catalytic subunit PI3K Gutierrez , 2009 
 PIK3R1 Deletion T-ALL Regulatory subunit PI3K Gutierrez , 2009 
PTEN PTEN Deletion T-ALL Homozygous and heterozygous Gutierrez , 2009 
  Dysruption T-ALL Sequence alterations in exon 7 Gutierrez , 2009 
  Deletion ALL cell line Exons 2 through 5 Sakai , 1998 
  Deletion AMl cell line Exons 2 through 5 Aggerholm , 2000 
SHIP1 SHIP1 Deactivation AML Phosphatase domain Luo , 2003 
PKB E17K Activation T-ALL Pleckstrin homology domain Carpten , 2007; Gutierrez , 2009 
PP2A Deletion Deletion/Loss AML  Cristobal , 2011 
Upstream      
Flt3 Flt3-ITD Activation AML & ALL Juxtamembrane (JM) domain  
 JM-point mutation
Less 
autoinhibition AML Juxtamembrane (JM) domain 
Reviewed by 
Parcells , 2006 
 AL-point mutation Activation 
AML & 
ALL 




 K663Q Activation AML First mutation outside JM and AL domain  
c-Kit EC-point mutation Activation AML 
Extracellular (EC) domain of 
the kinase Yuzawa, 2007 
 AL-point mutation Activation AML 
Activation loop (AL) of the 
kinase domain 
Reviewed by  Scholl 
, 2008 
Ras Mutations Activation AML & ALL  Gutierrez , 2009; 
     Dicker , 2010 
Bcr-Abl Translocation Activation ALL t(9;22) (q34;q11) Clark , 1988; 
     Varticovski , 1991 
# Mutation induces leukemia in mouse model. 
Table 1. Mutations in the PI3K/PKB pathway.  
3.1.3 Activating mutations upstream of PI3K/PKB signaling pathway 
The PI3K/PKB signaling module is an important mediator of cytokine signals. In 
hematological malignancies, mutations in cytokine receptors have been described to affect 
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PI3K signaling. Constitutive activation of FMS-like tyrosine kinase 3 (FLT3), by internal 
tandem duplication (Flt3-ITD) (Brandts et al., 2005) and mutation in c-Kit (Ning et al., 2001) 
have, for example, been demonstrated to induce PKB activity. This induction of PKB activity 
appears to be essential for the survival and proliferation of cells expressing FLT3-ITD 
(Brandts et al., 2005) or mutated c-Kit (Hashimoto et al., 2003; Cammenga et al., 2005; Horn 
et al., 2008). In addition to these tyrosine kinase receptors, the activity of the PI3K/PKB 
pathway can also be enhanced by several fusion proteins, including Bcr-Abl, which can be 
detected in virtually all patients with CML (Ben-Neriah et al., 1986) and in patients with 
ALL (Clark et al., 1988). It has been demonstrated that the PI3K/PKB signal transduction 
pathway plays an important role in Bcr-abl mediated leukemic transformation (Varticovski 
et al., 1991; Skorski et al., 1997; Hirano et al., 2009). Other potential regulators of PI3K often 
mutated in leukemia include Ras (Rodriguez-Viciana et al., 1994; reviewed by Schubbert et 
al., 2007; Gutierrez et al., 2009) Evi1 (Yoshimi et al., 2011) and PP2A. In AML patients, 
decreased PP2A activity has, for example, been reported to correlate with enhanced levels of 
PKB phosphorylation on Thr308 (Gallay et al., 2009). In addition, restoration of PP2A 
activity also resulted in a reduction of PKB phosphorylation (Cristobal et al., 2011). 
3.2 Prognosis of acute leukemia with activated PI3K/PKB signaling  
As described above, the PI3K/PKB signaling module appears to be aberrantly regulated in a 
large fraction of patients with leukemia. Recent evidence suggests that the level of 
PI3K/PKB activation in leukemic blasts could be used to predict the survival rate of 
patients. Comparison of pediatric T-ALL patients with either no mutations in PTEN, mono-
allelic mutations or bi-allelic mutations revealed that the survival rate of patients positively 
correlates with the level of PTEN (Jotta et al., 2010). Similar observations were made in a 
different cohort of pediatric T-ALL patients, in which PTEN deletions correlated with early 
treatment failure in T-ALL (Gutierrez et al., 2009). These studies suggest that constitutive 
activation of PI3K and its downstream effectors reduces the survival rate of ALL patients.  
To determine whether the level of mTOR activity similarly correlates with reduced survival 
of ALL patients, mice were transplanted with blasts from pediatric de novo B cell progenitor 
ALL patients. In those experiments, a rapid induction of leukemia correlated with enhanced 
mTOR activity in the leukemic blasts (Meyer et al., 2011). In addition to ALL, constitutive 
activation of PI3K, as measured by enhanced FoxO3 expression or phosphorylation, is also 
considered to be an independent adverse prognostic factor in AML patients  (Santamaria et 
al., 2009; Kornblau et al., 2010). In addition, a reduced survival rate has also been observed 
in AML patients displaying enhanced levels of phosphorylated, and therefore inactive, 
PTEN (Cheong et al., 2003) and phosphorylated PKB on Serine 473 (Kornblau et al., 2006) 
and Threonine 308 (Gallay et al., 2009). In contrast, Tamburini et al. suggest that PI3K 
activity, as was determined by analysis of the level of phosphorylation of PKB on Ser473, 
positively correlates with the survival of AML patients (Tamburini et al., 2007). Although 
the short-term survival rate (within 12 months) appeared to be slightly lower in the group 
displaying high PKB phosphorylation compared to the group with low levels of 
phosphorylated PKB, both the long-term survival and relapse free survival were 
significantly enhanced (Tamburini et al., 2007). Except for this last study, all other studies 
suggest that enhanced PI3K/PKB activity correlates with reduced survival rate in both ALL 
and AML patients. The molecular mechanisms underlying this reduced prognosis are, thus 
far, incompletely understood. However, it has been demonstrated that AML blasts 
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mutation has only been detected in one pediatric T-ALL patient (Gutierrez et al., 2009). To 
date, no other mutations in PKB have been described. 
 
 Mutation Activation/ loss 
Detected 
in: Location References 
Pathway      
PI3K E545A Activation AML & ALL Helical domain p110α 
Lee , 2005; Horn , 
2008 
 E542K Activation # Helical domain p110α Horn , 2008 
 H1047R Activation # Kinase domain p110α Horn , 2008 
 PIK3CA Activation T-ALL Catalytic subunit PI3K Gutierrez , 2009 
 PIK3R1 Deletion T-ALL Regulatory subunit PI3K Gutierrez , 2009 
PTEN PTEN Deletion T-ALL Homozygous and heterozygous Gutierrez , 2009 
  Dysruption T-ALL Sequence alterations in exon 7 Gutierrez , 2009 
  Deletion ALL cell line Exons 2 through 5 Sakai , 1998 
  Deletion AMl cell line Exons 2 through 5 Aggerholm , 2000 
SHIP1 SHIP1 Deactivation AML Phosphatase domain Luo , 2003 
PKB E17K Activation T-ALL Pleckstrin homology domain Carpten , 2007; Gutierrez , 2009 
PP2A Deletion Deletion/Loss AML  Cristobal , 2011 
Upstream      
Flt3 Flt3-ITD Activation AML & ALL Juxtamembrane (JM) domain  
 JM-point mutation
Less 
autoinhibition AML Juxtamembrane (JM) domain 
Reviewed by 
Parcells , 2006 
 AL-point mutation Activation 
AML & 
ALL 




 K663Q Activation AML First mutation outside JM and AL domain  
c-Kit EC-point mutation Activation AML 
Extracellular (EC) domain of 
the kinase Yuzawa, 2007 
 AL-point mutation Activation AML 
Activation loop (AL) of the 
kinase domain 
Reviewed by  Scholl 
, 2008 
Ras Mutations Activation AML & ALL  Gutierrez , 2009; 
     Dicker , 2010 
Bcr-Abl Translocation Activation ALL t(9;22) (q34;q11) Clark , 1988; 
     Varticovski , 1991 
# Mutation induces leukemia in mouse model. 
Table 1. Mutations in the PI3K/PKB pathway.  
3.1.3 Activating mutations upstream of PI3K/PKB signaling pathway 
The PI3K/PKB signaling module is an important mediator of cytokine signals. In 
hematological malignancies, mutations in cytokine receptors have been described to affect 
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PI3K signaling. Constitutive activation of FMS-like tyrosine kinase 3 (FLT3), by internal 
tandem duplication (Flt3-ITD) (Brandts et al., 2005) and mutation in c-Kit (Ning et al., 2001) 
have, for example, been demonstrated to induce PKB activity. This induction of PKB activity 
appears to be essential for the survival and proliferation of cells expressing FLT3-ITD 
(Brandts et al., 2005) or mutated c-Kit (Hashimoto et al., 2003; Cammenga et al., 2005; Horn 
et al., 2008). In addition to these tyrosine kinase receptors, the activity of the PI3K/PKB 
pathway can also be enhanced by several fusion proteins, including Bcr-Abl, which can be 
detected in virtually all patients with CML (Ben-Neriah et al., 1986) and in patients with 
ALL (Clark et al., 1988). It has been demonstrated that the PI3K/PKB signal transduction 
pathway plays an important role in Bcr-abl mediated leukemic transformation (Varticovski 
et al., 1991; Skorski et al., 1997; Hirano et al., 2009). Other potential regulators of PI3K often 
mutated in leukemia include Ras (Rodriguez-Viciana et al., 1994; reviewed by Schubbert et 
al., 2007; Gutierrez et al., 2009) Evi1 (Yoshimi et al., 2011) and PP2A. In AML patients, 
decreased PP2A activity has, for example, been reported to correlate with enhanced levels of 
PKB phosphorylation on Thr308 (Gallay et al., 2009). In addition, restoration of PP2A 
activity also resulted in a reduction of PKB phosphorylation (Cristobal et al., 2011). 
3.2 Prognosis of acute leukemia with activated PI3K/PKB signaling  
As described above, the PI3K/PKB signaling module appears to be aberrantly regulated in a 
large fraction of patients with leukemia. Recent evidence suggests that the level of 
PI3K/PKB activation in leukemic blasts could be used to predict the survival rate of 
patients. Comparison of pediatric T-ALL patients with either no mutations in PTEN, mono-
allelic mutations or bi-allelic mutations revealed that the survival rate of patients positively 
correlates with the level of PTEN (Jotta et al., 2010). Similar observations were made in a 
different cohort of pediatric T-ALL patients, in which PTEN deletions correlated with early 
treatment failure in T-ALL (Gutierrez et al., 2009). These studies suggest that constitutive 
activation of PI3K and its downstream effectors reduces the survival rate of ALL patients.  
To determine whether the level of mTOR activity similarly correlates with reduced survival 
of ALL patients, mice were transplanted with blasts from pediatric de novo B cell progenitor 
ALL patients. In those experiments, a rapid induction of leukemia correlated with enhanced 
mTOR activity in the leukemic blasts (Meyer et al., 2011). In addition to ALL, constitutive 
activation of PI3K, as measured by enhanced FoxO3 expression or phosphorylation, is also 
considered to be an independent adverse prognostic factor in AML patients  (Santamaria et 
al., 2009; Kornblau et al., 2010). In addition, a reduced survival rate has also been observed 
in AML patients displaying enhanced levels of phosphorylated, and therefore inactive, 
PTEN (Cheong et al., 2003) and phosphorylated PKB on Serine 473 (Kornblau et al., 2006) 
and Threonine 308 (Gallay et al., 2009). In contrast, Tamburini et al. suggest that PI3K 
activity, as was determined by analysis of the level of phosphorylation of PKB on Ser473, 
positively correlates with the survival of AML patients (Tamburini et al., 2007). Although 
the short-term survival rate (within 12 months) appeared to be slightly lower in the group 
displaying high PKB phosphorylation compared to the group with low levels of 
phosphorylated PKB, both the long-term survival and relapse free survival were 
significantly enhanced (Tamburini et al., 2007). Except for this last study, all other studies 
suggest that enhanced PI3K/PKB activity correlates with reduced survival rate in both ALL 
and AML patients. The molecular mechanisms underlying this reduced prognosis are, thus 
far, incompletely understood. However, it has been demonstrated that AML blasts 
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displaying enhanced PI3K/PKB activation exhibit a reduced apoptotic response (Rosen et 
al., 2010) which might be due to positive regulation of the anti-apoptotic NF-kB pathway 
and negative regulation of the P53 pathway (Grandage et al., 2005).  
In addition, since PI3K has been demonstrated to induce expression of the multidrug 
resistance-associated protein 1 (MRP1), a member of the ATP-binding cassette (ABC) 
membrane transporters that functions as a drug efflux pump (Tazzari, Cappellini et al. 
2007), it could also be hypothesized that constitutive activation of this signaling module 
results in drug-resistance. The observation that high levels of MRP1 correlates with 
enhanced drug resistance of AML cells and poor prognosis supports this hypothesis 
(Legrand et al., 1999; Mahadevan & List, 2004). 
3.3 PI3K/PKB signaling as therapeutic target in acute leukemia 
3.3.1 PI3K inhibitors 
Since aberrant regulation of PI3K and its downstream effectors has frequently been 
observed in leukemic cells and are known to play a critical role in normal hematopoiesis, 
these molecules are considered to be promising targets for therapy (Table 2). Wortmannin 
and LY294002 are two well characterized inhibitors of PI3K activity that prevent ATP to 
bind to and activate PI3K by association with its catalytic subunit (Vlahos et al., 1994; 
Wymann et al., 1996). Although pre-clinical experiments indicate that both LY294002 and 
Wortmannin are potent inhibitors of PI3K activity, induce apoptosis in leukemic cells (Xu et 
al., 2003; Zhao et al., 2004) and rescue drug sensitivity (Neri et al., 2003), it has been 
demonstrated that both inhibitors exhibit little specificity within the PI3K family and can 
also inhibit other kinases, including CK2 and smMLCK, respectively (Davies et al., 2000; 
Gharbi et al., 2007). Since both inhibitors are also insoluble in an aqueous solution (Garlich 
et al., 2008; Zask et al., 2008) and are detrimental for normal cells (Gunther et al., 1989; 
Buitenhuis et al., 2008), different PI3K inhibitors are currently developed. Recently, while 
screening for inhibitors of Cyclin D expression, a novel inhibitor of PI3K activity (S14161) 
has been discovered that appears to be able to delay tumor growth in mice transplanted 
with human leukemic cell lines (Mao et al., 2011). In addition, novel inhibitors have been 
developed that efficiently block the activity of individual p110 isoforms. The p110δ-selective 
inhibitor IC87114, for example, significantly reduced proliferation and survival of AML 
blasts (Sujobert et al., 2005) and APL cells (Billottet et al., 2009) without affecting the 
proliferation of normal hematopoietic progenitors (Sujobert et al., 2005). Similar results were 
obtained in APL cells treated with an inhibitor directed against p110TGX-115) (Billottet et 
al., 2009).  
3.3.2 PKB inhibitors 
In addition to PI3K inhibitors, research has also focused on the development of 
pharmacological compounds that inhibit its downstream effector PKB. Perifosine, a 
synthetic alkylphosphocholine with oral bioavailability inhibits PKB phosphorylation by 
competitive interaction with its PH doma1in (Kondapaka et al., 2003) and promotes 
degradation of PKB, mTOR, Raptor, Rictor, p70S6K and 4E-BP1 (Fu et al., 2009). In vitro 
experiments with multidrug-resistant human T-ALL cells  and primary AML cells revealed 
that treatment with Perisofine is sufficient to induce apoptosis (Chiarini et al., 2008; Papa et 
al., 2008). Moreover, Perifosine reduced the clonogenic activity of AML blasts, but not 
normal CD34+ hematopoietic progenitor cells (Papa et al., 2008). The efficacy of Perifosine in 
treatment of different types of leukemia is currently examined in several phase II clinical 
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trials (NCT00391560, NCT00873457). Phosphatidylinositol ether lipid analogues (PIA) 
inhibit PKB activity in a similar manner compared to Perifosine. Treatment of HL60 cells 
with PIA resulted in inhibition of proliferation and sensitization to chemotherapeutic agents 
in concentrations which did not affect proliferation of normal hematopoietic progenitors 
(Tabellini et al., 2004). Another specific PKB inhibitor (AKT-I-1/2 inhibitor) (Bain et al., 
2007), has been demonstrated to efficiently reduce colony formation in high-risk AML 
samples (Gallay et al., 2009). The PKB inhibitor Triciribine (API-2), a purine analog that has 
initially been identified as an inhibitor of DNA synthesis, inhibits PKB phosphorylation by 
interacting with the PH domain of PKB, thus preventing PKB membrane localization and 
phosphorylation (Berndt et al., 2010). Experiments in T-ALL cell lines revealed that API-2 
induces cell cycle arrest and caspase-dependent apoptosis (Evangelisti et al., 2011a). The 
safety of this inhibitor is currently under investigation in a phase I clinical trial in patients 
with advanced hematologic malignancies (NCT00363454). 
3.3.3 mTOR inhibitors 
Rapamycin and its analogues RAD001 (everolimus), CCI-779 (temsirolimus) and AP23573 
(deforolimus) inhibit the mTORC1 complex by association with FKBP-12 which prohibits 
association of Raptor with mTOR. (Choi et al., 1996; Oshiro et al., 2004).  The efficacy of 
these compounds as therapeutic drugs has been examined in various preclinical and clinical 
studies for a wide range of malignancies (reviewed by Yuan et al., 2009; reviewed by 
Chapuis et al., 2010a). The anti-tumor properties of Rapamycin have also been examined in 
both AML derived cell lines and primary AML blasts, revealing a strong anti-tumor effect of 
this agent in short-term cultures (Recher et al., 2005). Furthermore, Rapamycin and its 
analog CCI-779 showed promising effects in preclinical models of T-ALL (Teachey et al., 
2008; Meyer et al., 2011) and pre-B ALL (Teachey et al., 2006), respectively. Clinical trials 
initiated to examine the efficacy of Rapamycin (Recher et al., 2005) and its analog AP23573 
in hematological malignancies only resulted in a partial response (Rizzieri et al., 2008). The 
limited therapeutic effects of Rapamycin and AP23573 may be explained by the induction of 
PKB activity in AML blasts treated with these compounds (Easton & Houghton, 2006; 
Tamburini et al., 2008; Yap et al., 2008). Furthermore, experiments with PTEN deficient mice 
revealed that, due to failure to eliminate the leukemic stem cell population, withdrawal of 
rapamycin results in a rapid re-induction of leukemia and death in the majority of mice 
(Guo et al., 2011). This suggests that rapamycin primarily has cytostatic, but not cytotoxic, 
effects on hematopoietic stem cells. 
To circumvent the observed up-regulation of PKB phosphorylation by Rapamycin and its 
analogs, ATP-competitive mTOR inhibitors have been generated that inhibit both the 
activity of mTORC1 and mTORC2 (Garcia-Martinez et al., 2009; Bhagwat & Crew, 2010; 
Janes et al., 2010). Treatment of mice transplanted with primary ALL blasts or pre-leukemic 
thymocytes over-expressing PKB with the mTORC 1/2 inhibitor PP242, but not Rapamycin, 
significantly reduced the development of leukemia (Hsieh et al., 2010; Janes et al., 2010). 
Importantly, PP242 appears to induce less adverse effects on proliferation and function of 
normal lymphocytes in comparison to Rapamycin (Janes et al., 2010; Evangelisti et al., 
2011b). In addition to PP-242, another mTORC1/2 inhibitor, OSI-027, has recently been 
described. (Evangelisti et al., 2011). It has been demonstrated that this inhibitor exhibits anti-
leukemic effects in both Ph+ ALL and CML cells (Carayol et al., 2010). Furthermore, 
proliferation experiments indicate that, in comparison to Rapamycin, OSI-027 is a more 
efficient suppressor of proliferation of AML cell lines (Altman et al., 2011). 
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displaying enhanced PI3K/PKB activation exhibit a reduced apoptotic response (Rosen et 
al., 2010) which might be due to positive regulation of the anti-apoptotic NF-kB pathway 
and negative regulation of the P53 pathway (Grandage et al., 2005).  
In addition, since PI3K has been demonstrated to induce expression of the multidrug 
resistance-associated protein 1 (MRP1), a member of the ATP-binding cassette (ABC) 
membrane transporters that functions as a drug efflux pump (Tazzari, Cappellini et al. 
2007), it could also be hypothesized that constitutive activation of this signaling module 
results in drug-resistance. The observation that high levels of MRP1 correlates with 
enhanced drug resistance of AML cells and poor prognosis supports this hypothesis 
(Legrand et al., 1999; Mahadevan & List, 2004). 
3.3 PI3K/PKB signaling as therapeutic target in acute leukemia 
3.3.1 PI3K inhibitors 
Since aberrant regulation of PI3K and its downstream effectors has frequently been 
observed in leukemic cells and are known to play a critical role in normal hematopoiesis, 
these molecules are considered to be promising targets for therapy (Table 2). Wortmannin 
and LY294002 are two well characterized inhibitors of PI3K activity that prevent ATP to 
bind to and activate PI3K by association with its catalytic subunit (Vlahos et al., 1994; 
Wymann et al., 1996). Although pre-clinical experiments indicate that both LY294002 and 
Wortmannin are potent inhibitors of PI3K activity, induce apoptosis in leukemic cells (Xu et 
al., 2003; Zhao et al., 2004) and rescue drug sensitivity (Neri et al., 2003), it has been 
demonstrated that both inhibitors exhibit little specificity within the PI3K family and can 
also inhibit other kinases, including CK2 and smMLCK, respectively (Davies et al., 2000; 
Gharbi et al., 2007). Since both inhibitors are also insoluble in an aqueous solution (Garlich 
et al., 2008; Zask et al., 2008) and are detrimental for normal cells (Gunther et al., 1989; 
Buitenhuis et al., 2008), different PI3K inhibitors are currently developed. Recently, while 
screening for inhibitors of Cyclin D expression, a novel inhibitor of PI3K activity (S14161) 
has been discovered that appears to be able to delay tumor growth in mice transplanted 
with human leukemic cell lines (Mao et al., 2011). In addition, novel inhibitors have been 
developed that efficiently block the activity of individual p110 isoforms. The p110δ-selective 
inhibitor IC87114, for example, significantly reduced proliferation and survival of AML 
blasts (Sujobert et al., 2005) and APL cells (Billottet et al., 2009) without affecting the 
proliferation of normal hematopoietic progenitors (Sujobert et al., 2005). Similar results were 
obtained in APL cells treated with an inhibitor directed against p110TGX-115) (Billottet et 
al., 2009).  
3.3.2 PKB inhibitors 
In addition to PI3K inhibitors, research has also focused on the development of 
pharmacological compounds that inhibit its downstream effector PKB. Perifosine, a 
synthetic alkylphosphocholine with oral bioavailability inhibits PKB phosphorylation by 
competitive interaction with its PH doma1in (Kondapaka et al., 2003) and promotes 
degradation of PKB, mTOR, Raptor, Rictor, p70S6K and 4E-BP1 (Fu et al., 2009). In vitro 
experiments with multidrug-resistant human T-ALL cells  and primary AML cells revealed 
that treatment with Perisofine is sufficient to induce apoptosis (Chiarini et al., 2008; Papa et 
al., 2008). Moreover, Perifosine reduced the clonogenic activity of AML blasts, but not 
normal CD34+ hematopoietic progenitor cells (Papa et al., 2008). The efficacy of Perifosine in 
treatment of different types of leukemia is currently examined in several phase II clinical 
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trials (NCT00391560, NCT00873457). Phosphatidylinositol ether lipid analogues (PIA) 
inhibit PKB activity in a similar manner compared to Perifosine. Treatment of HL60 cells 
with PIA resulted in inhibition of proliferation and sensitization to chemotherapeutic agents 
in concentrations which did not affect proliferation of normal hematopoietic progenitors 
(Tabellini et al., 2004). Another specific PKB inhibitor (AKT-I-1/2 inhibitor) (Bain et al., 
2007), has been demonstrated to efficiently reduce colony formation in high-risk AML 
samples (Gallay et al., 2009). The PKB inhibitor Triciribine (API-2), a purine analog that has 
initially been identified as an inhibitor of DNA synthesis, inhibits PKB phosphorylation by 
interacting with the PH domain of PKB, thus preventing PKB membrane localization and 
phosphorylation (Berndt et al., 2010). Experiments in T-ALL cell lines revealed that API-2 
induces cell cycle arrest and caspase-dependent apoptosis (Evangelisti et al., 2011a). The 
safety of this inhibitor is currently under investigation in a phase I clinical trial in patients 
with advanced hematologic malignancies (NCT00363454). 
3.3.3 mTOR inhibitors 
Rapamycin and its analogues RAD001 (everolimus), CCI-779 (temsirolimus) and AP23573 
(deforolimus) inhibit the mTORC1 complex by association with FKBP-12 which prohibits 
association of Raptor with mTOR. (Choi et al., 1996; Oshiro et al., 2004).  The efficacy of 
these compounds as therapeutic drugs has been examined in various preclinical and clinical 
studies for a wide range of malignancies (reviewed by Yuan et al., 2009; reviewed by 
Chapuis et al., 2010a). The anti-tumor properties of Rapamycin have also been examined in 
both AML derived cell lines and primary AML blasts, revealing a strong anti-tumor effect of 
this agent in short-term cultures (Recher et al., 2005). Furthermore, Rapamycin and its 
analog CCI-779 showed promising effects in preclinical models of T-ALL (Teachey et al., 
2008; Meyer et al., 2011) and pre-B ALL (Teachey et al., 2006), respectively. Clinical trials 
initiated to examine the efficacy of Rapamycin (Recher et al., 2005) and its analog AP23573 
in hematological malignancies only resulted in a partial response (Rizzieri et al., 2008). The 
limited therapeutic effects of Rapamycin and AP23573 may be explained by the induction of 
PKB activity in AML blasts treated with these compounds (Easton & Houghton, 2006; 
Tamburini et al., 2008; Yap et al., 2008). Furthermore, experiments with PTEN deficient mice 
revealed that, due to failure to eliminate the leukemic stem cell population, withdrawal of 
rapamycin results in a rapid re-induction of leukemia and death in the majority of mice 
(Guo et al., 2011). This suggests that rapamycin primarily has cytostatic, but not cytotoxic, 
effects on hematopoietic stem cells. 
To circumvent the observed up-regulation of PKB phosphorylation by Rapamycin and its 
analogs, ATP-competitive mTOR inhibitors have been generated that inhibit both the 
activity of mTORC1 and mTORC2 (Garcia-Martinez et al., 2009; Bhagwat & Crew, 2010; 
Janes et al., 2010). Treatment of mice transplanted with primary ALL blasts or pre-leukemic 
thymocytes over-expressing PKB with the mTORC 1/2 inhibitor PP242, but not Rapamycin, 
significantly reduced the development of leukemia (Hsieh et al., 2010; Janes et al., 2010). 
Importantly, PP242 appears to induce less adverse effects on proliferation and function of 
normal lymphocytes in comparison to Rapamycin (Janes et al., 2010; Evangelisti et al., 
2011b). In addition to PP-242, another mTORC1/2 inhibitor, OSI-027, has recently been 
described. (Evangelisti et al., 2011). It has been demonstrated that this inhibitor exhibits anti-
leukemic effects in both Ph+ ALL and CML cells (Carayol et al., 2010). Furthermore, 
proliferation experiments indicate that, in comparison to Rapamycin, OSI-027 is a more 
efficient suppressor of proliferation of AML cell lines (Altman et al., 2011). 
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3.3.4 Dual inhibition of the PI3K/PKB pathway 
In addition to the recently developed mTORC1/2 inhibitors, dual specificity inhibitors have 
been generated to further optimize inhibition of the PI3K signaling module. PI-103, a 
synthetic small molecule of the pyridofuropyrimidine class is, for example, a potent 
inhibitor for both class I PI3K isoforms and mTORC1 (Raynaud et al., 2007). PI-103 has been 
demonstrated to reduce proliferation and survival of cells from T-ALL (Chiarini et al., 2009) 
and AML patients  (Kojima et al., 2008; Park et al., 2008) and appears to exhibit a stronger 
anti-leukemic activity compared to both Rapamycin (Chiarini et al., 2009) and the 
combination of RAD001 and IC87114 (Park et al., 2008). Importantly, although PI-103 
reduces proliferation of normal hematopoietic progenitors, survival is not affected (Park et 
al., 2008). Recently, NVP-BEZ235, another dual PI3K/mTOR inhibitor has been identified. 
This orally bioavailable imidazoquinoline derivative, has been demonstrated to inhibit the 
activity of both PI3K and mTOR by binding to their ATP-binding pocket (Maira et al., 2008). 
In both primary T-ALL (Chiarini et al., 2010) and AML cells (Chapuis, Tamburini et al. 
2010b) as well as leukemic cell lines, NVP-BEZ235 significantly reduced proliferation and 
survival (Chapuis et al., 2010b; Chiarini et al., 2010). Furthermore, this compound did not 
affect the clonogenic capacity of normal hematopoietic progenitors (Chapuis et al., 2010b). A 
dual PI3K/PDK1 inhibitor called BAG956 has also recently been described to inhibit 
proliferation of BCR-ABL and FLT3-ITD expressing cells. However, in contrast to RAD001 
which efficiently reduced the tumor load in mice transplanted with BCR-ABL expressing 
cells, treatment with BAG956 alone was not sufficient to reduce the tumor load (Weisberg et 
al., 2008). In addition to these dual inhibitors, KP372-1, a multiple kinase inhibitor capable of 
inhibiting PKB, PDK1, and FLT3 has been described (Zeng et al., 2006). It has been 
demonstrated that KP372-1 can induce apoptosis in primary AML cells and leukemic cell 
lines, as was visualized by mitochondrial depolarization and phosphatidylserine 
externalization (Zeng et al., 2006). Although the survival of normal hematopoietic 
progenitors was not impaired by this compound, their clonogenic capacity was, albeit with a 
low efficiency (Zeng et al., 2006). 
In addition to the above described dual inhibitors, the efficacy of combination therapy 
utilizing multiple inhibitors, which are directed against different intermediates of the PI3K 
signaling module, is also under investigation. To abrogate the RAD001 mediated up-
regulation of PKB phosphorylation, the p110 inhibitor IC87114 has, for example, been 
added to leukemic cells simultaneously with RAD001. Combined inhibition of mTOR and 
p110 not only resulted in a block in PKB phosphorylation in primary AML blasts, but a 
synergistic reduction in proliferation could also be observed (Tamburini et al., 2008). 
Similarly, combining the PI3K/PDK1 inhibitor BAG956 with RAD001 also resulted in a 
synergistic reduction in tumor volume in a mouse model transplanted with BCR-ABL 
expressing cells (Weisberg et al., 2008). Recently, a phase I trial focusing on development of 
a combination regimen including both perifosine and UCN-01 (NCT00301938), a PDK1 
inhibitor which is known to induce apoptosis in AML cells in vitro (Hahn et al., 2005), has 
been initiated. 
3.3.5 Combination of PI3K/PKB pathway inhibitors with other pathway inhibitors 
Leukemogenesis involves aberrant regulation of various signal transduction pathways, 
including, but not limited to, the PI3K signaling module. Simultaneous targeting of multiple  
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Target Compound Effect Clinical Trials (phase) Leukemia References 
  In vitro In vivo    
PI3K Wortmannin + - -  Wymann , 1996 
 LY294002 + - -  Xu , 2003; Zhao , 2004 
 S14161 + + -  Mao , 2011 
p110β TGX-115 + - -  Billottet , 2009 
p110δ IC87114 + - -  Sujobert , 2005; Billottet , 2006, 2009 
 AMG 319 - - NCT01300026 (I) ALL  
PDK1 UCN-01 + - -  Hahn , 2005 
PKB Perifosine + - NCT00391560 (II) AML&ALL Chiarini , 2008; Fu , 2009; Papa , 2008 
    NCT00873457 (II) CLL  
 PIA + - -  Tabellini , 2004 
 AKT-I-1/2 + - -  Gallay , 2009 
 Triciribine 
(API-2) 
+ - NCT00363454 (I) - Evangelisti , 2011a 
      
 GSK690693 + - NCT00666081 (I) AML&ALL Levy , 2009 
 MK2206 - - NCT01231919 (I) AML&ALL  
    NCT01253447 (II) AML  
 SR13668 - - NCT00896207 (I) -  
 GSK2141795 - - NCT00920257 (I) -  
 GSK21110183 - - NCT00881946 (I/II) AML&ALL  
mTOR Rapamycin + + NCT00795886 (I) ALL Recher  2005; Meyer , 2011; 
      Teachey , 2008; Gu , 2010; Guo , 2011 
 RAD001 + + Yee, 2006 (I/II) AML Yee  , 2006 
 CCI-779 + + Recher, 2005 (II) AML Teachey , 2006; Recher, 2005 
 AP23573 - - Rizzieri, 2008 (II) AML Rizzieri, 2008 
    NCT00086125 (II) AML&ALL  
 PP242 + + -  Hsieh , 2010; Janes , 2010; Evangelisti , 2011b 
 OSI-027 + - -  Evangelisti, 2011b ; Carayol, 2010; Altman, 2011 
 AZD-8050 + - - - Evangelisti , 2011b 
PI3K/mTOR PI-103 + + - - Chiarini , 2009; Kojima , 2008; Park , 2008 
PI3K/mTOR NVP-BEZ235 + + - - 
Maira , 2008; Chiarini , 2010; 
Chapuis , 2010b 
PI3K/PDK1 BAG956 + + - - Weisberg , 2008 
PKB/PDK1/Flt3 KP372-1 + - - - Zeng , 2006 
Table 2. Inhibitors of PI3K/PKB signaling pathway 
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3.3.4 Dual inhibition of the PI3K/PKB pathway 
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lines, as was visualized by mitochondrial depolarization and phosphatidylserine 
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low efficiency (Zeng et al., 2006). 
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a combination regimen including both perifosine and UCN-01 (NCT00301938), a PDK1 
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3.3.5 Combination of PI3K/PKB pathway inhibitors with other pathway inhibitors 
Leukemogenesis involves aberrant regulation of various signal transduction pathways, 
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Target Compound Effect Clinical Trials (phase) Leukemia References 
  In vitro In vivo    
PI3K Wortmannin + - -  Wymann , 1996 
 LY294002 + - -  Xu , 2003; Zhao , 2004 
 S14161 + + -  Mao , 2011 
p110β TGX-115 + - -  Billottet , 2009 
p110δ IC87114 + - -  Sujobert , 2005; Billottet , 2006, 2009 
 AMG 319 - - NCT01300026 (I) ALL  
PDK1 UCN-01 + - -  Hahn , 2005 
PKB Perifosine + - NCT00391560 (II) AML&ALL Chiarini , 2008; Fu , 2009; Papa , 2008 
    NCT00873457 (II) CLL  
 PIA + - -  Tabellini , 2004 
 AKT-I-1/2 + - -  Gallay , 2009 
 Triciribine 
(API-2) 
+ - NCT00363454 (I) - Evangelisti , 2011a 
      
 GSK690693 + - NCT00666081 (I) AML&ALL Levy , 2009 
 MK2206 - - NCT01231919 (I) AML&ALL  
    NCT01253447 (II) AML  
 SR13668 - - NCT00896207 (I) -  
 GSK2141795 - - NCT00920257 (I) -  
 GSK21110183 - - NCT00881946 (I/II) AML&ALL  
mTOR Rapamycin + + NCT00795886 (I) ALL Recher  2005; Meyer , 2011; 
      Teachey , 2008; Gu , 2010; Guo , 2011 
 RAD001 + + Yee, 2006 (I/II) AML Yee  , 2006 
 CCI-779 + + Recher, 2005 (II) AML Teachey , 2006; Recher, 2005 
 AP23573 - - Rizzieri, 2008 (II) AML Rizzieri, 2008 
    NCT00086125 (II) AML&ALL  
 PP242 + + -  Hsieh , 2010; Janes , 2010; Evangelisti , 2011b 
 OSI-027 + - -  Evangelisti, 2011b ; Carayol, 2010; Altman, 2011 
 AZD-8050 + - - - Evangelisti , 2011b 
PI3K/mTOR PI-103 + + - - Chiarini , 2009; Kojima , 2008; Park , 2008 
PI3K/mTOR NVP-BEZ235 + + - - 
Maira , 2008; Chiarini , 2010; 
Chapuis , 2010b 
PI3K/PDK1 BAG956 + + - - Weisberg , 2008 
PKB/PDK1/Flt3 KP372-1 + - - - Zeng , 2006 
Table 2. Inhibitors of PI3K/PKB signaling pathway 
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aberrantly regulated signal transduction pathways is considered to be a promising 
therapeutic strategy (Table 3). Proteosome inhibitors are considered to be a new class of 
therapeutic agents. However, treatment of both pediatric and adult B-ALL patients with 
such an inhibitor (Bortezomib) alone was not sufficient to induce a robust anti-tumor 
response (Cortes et al., 2004; Horton et al., 2007). Experiments in leukemic cell lines and 
primary cells from B-ALL patients revealed that while MG132, a proteosome inhibitor, 
and RAD001 alone only modestly reduce cell viability, combined inhibition of 
proteosomes and mTOR significantly enhanced cell death (Saunders et al., 2011), 
suggesting a synergistic effect of both inhibitors. In addition to proteosome inhibitors, 
HDAC inhibitors have also emerged as a promising class of anti-tumor agents (reviewed 
by Minucci & Pelicci, 2006). Although the HDAC inhibitor MS-275 appears to induce 
growth arrest, apoptosis and differentiation of leukemic cell lines, in mouse models only a 
partial reduction in tumor volume could be observed (Nishioka et al., 2008). Combined 
administration of MS-275 and RAD001, however, potentiated the effect of both inhibitors 
individually both in vitro and in vivo (Nishioka et al., 2008). Synergistic effects on 
proliferation and survival of leukemic cell lines have also been observed after co-
administration of HDAC inhibitors and the PKB inhibitor Perisofine (Rahmani et al., 
2005). Additionally, the efficacy of specific inhibitors targeting constitutively activated 
tyrosine kinases in leukemia, including inhibitors of Flt3, Abl, and c-Kit, has been 
investigated in preclinical and clinical models. Although anti-leukemia effects were 
observed in vivo and in vitro, combined inhibition of tyrosine kinases and the PI3K/PKB 
pathway resulted in a synergistically enhanced anti-leukemia effect in ALL (Kharas et al., 
2008; Weisberg et al., 2008) and AML (Weisberg et al., 2008) compared to the individual 
inhibitors. Phase I/II clinical trials have already been initiated to investigate the 
synergistic effects of combined inhibition of PI3K/PKB and Flt3 (NCT00819546) or c-Kit 
(NCT00762632). 
3.3.6 Combination of PI3K/PKB pathway inhibitors with chemotherapeutical agents 
Despite the effectiveness of chemotherapy in a subset of patients, incomplete remission and 
the development of a refractory disease have been observed in many patients with acute 
leukemia (Thomas, 2009; Burnett et al., 2011). To optimize treatment of those patients, 
chemotherapy could potentially be combined with leukemia-specific inhibitors or 
chemosensitizing drugs (Table 3). Co-administration of mTOR inhibitors with different 
types of chemotherapeutic drugs, including Etoposide, Ara-C, Cytarabine and 
Dexamethason has, for example, been demonstrated to induce synergistic anti-leukemia 
effects in cells from AML patients (Xu et al., 2003; Xu et al., 2005) and ALL patients (Avellino 
et al., 2005; Teachey et al., 2008; Bonapace et al., 2010; Gu et al., 2010; Saunders et al., 2011). 
Several phase I/II clinical trials have been initiated to investigate and optimize the 
synergistic effect of mTOR inhibitors and chemotherapeutic drugs in patients with acute 
leukemia (NCT00544999, NCT01184898, NCT00780104, NCT01162551 and NCT00776373). In 
addition, co-administration of chemotherapeutic agents with IC87114 (Billottet et al., 2006), 
UCN-01 (Sampath et al., 2006) or Triciribine (Evangelisti et al., 2011a) showed similar 
synergistic effects in AML cells. Strong synergistic, cytotoxic, activity was also observed in 
T-ALL cells when combining the dual specificity inhibitors PI-103 and NVP-BEZ235 with 
chemotherapy (Chiarini et al., 2009; Chiarini et al., 2010).  
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Clinical trials (phase) Leukemia References 
PI3K Wortmannin ATRA (DA) + - -  Neri , 2003 
 LY294002 Apigenin (CK2 I) + - -  Cheong , 2010 
  ATRA (DA) + - -  Neri , 2003 
p110δ IC87114 VP16 (CT) + - -  Billottet , 2006 
PDK1 UCN-01 Ara-c (CT) + - Sampath, 2006 (II) AML Sampath , 2006 
  Cytarabine (CT) - - NCT00004263 (I) AML  
  Fludarabine (CT) - - NCT00019838 (I) AML&ALL  
PP2A Forskolin Idarubicine/Ara-C + - -  Cristobal , 2011 
PKB Perifosine UCN-01 - - NCT00301938 (I) AML&ALL  
  HDAC I + - -  Rahmani , 2005 
  TRAIL (AI) + - -  Tazzari , 2008 
  Etoposide (CT + - -  Papa , 2008 
 PIA CT + - -  Tabellini , 2004 
 Triciribine Cytarabine (CT) + - -  Evangelisti , 2011a 
mTOR Rapamycin UCN-01 + - -  Hahn , 2005 
  3-BrOP (glycolysis I) + - -  Akers , 2011 
  Notch I + - -  Chan , 2007 
  Dexamethason + - -  Gu, 2010; Bonapace , 2010 
  Etoposide (CT) + + -  Xu , 2005 
  Methotrexate (CT) + + NCT01162551 (II) ALL Teachey , 2008 
  Anthracyclin (CT) + - -  Avellino , 2005 
  CT + - NCT00776373 (I/II) ALL  
   + - NCT01184898 (I/II) AML  
     NCT00780104 ( I/II) AML  
 RAD001 IC87114 + - -  Tamburini , 2008 
  BAG956 + + -  Weisberg , 2008 
  Bortezomib (PI) + - -  Saunders , 2011 
  MS-275 (HDAC I) + + -  Nishioka , 2008 
  PKC412 (Flt3 TKI) - - NCT00819546 (I) AML  
  Nilotinib (c-Kit-TKI) - - NCT00762632 (I/II) AML  
  ATRA (DA) + + -  Nishioko , 2009 
  Ara-c (CT) + - -  Xu , 2003; Saunders , 2011 
  Vincristine (CT) + - - ALL Crazzolara, 2009 
  CT + - NCT00544999 (I) AML&ALL  
 CCI-779 Methotrexate (CT) + + -  Teachey , 2008 
 PP242 Vincristine (CT) + -   Evangelisti , 2011b 
PI3K/mTOR PI-103 Nutlin-3 (MDM2-I) + -   Kojima , 2008 
  Vincristine (CT) + -   Chiarini , 2009 
  Imatinib (Bcr-Abl-TKI) + -   Kharas , 2008 
PI3K/mTOR NVP-BEZ235 CT + -   Chiarini , 2010 
PI3K/PDK1 BAG956 Imatinib (Bcr-Abl-TKI) + +   Weisberg , 2008 
  PKC412 (Flt3 TKI) + +   Weisberg , 2008 
DA: Differentiating agents; I: Inhibitor; CT: Chemotherapy; AI: Apoptosis inducer; PI: Proteasome 
inhibitor; TKI: Tyrosine kinase inhibitor. 
Table 3. Combination regimens.  
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During the last two decades, it has become clear that intracellular signal transduction 
pathways play an important role in both normal and malignant hematopoiesis. One such 
module implicated in playing a critical role in regulation of various hematopoietic processes 
includes PI3K and PKB. Aberrant regulation of these molecules appears to be sufficient to 
induce hematological malignancies.  As discussed in this chapter, constitutive activation of 
this signaling module has been observed in a large group of acute leukemia’s. Although 
activating mutations in PI3K and PKB have been detected in cells from patients with 
leukemia, these mutations appear to be very rare. In patients, mutations have also been 
observed in PTEN and SHIP1 resulting in activation of PI3K and its downstream effectors. 
These mutations, however, cannot account for the large incidence of constitutive activation 
of PI3K in patients with leukemia. Alternatively, constitutive activation of PI3K and PKB 
can also be induced by mutations in, for example, tyrosine kinase receptors and by 
translocation induced formation of fusion proteins. Since PI3K is frequently activated in 
leukemia and activation of this molecule is thought to correlate with poor prognosis and 
drug resistance, it is considered to be a promising target for therapy. A high number of 
pharmacological inhibitors directed against both individual and multiple components of 
this pathway has already been developed in order to improve therapy. Especially the dual 
specificity inhibitors seem to possess promising anti-leukemic activities. In addition, 
research currently focuses on combining inhibitors of the PI3K signaling module with either 
inhibitors directed against other signal transduction molecules or classic chemotherapy. 
Mouse models and in vitro experiments indicate that both strategies could be used to 
improve current therapeutic regimes in specific patient groups. To confirm the pre-clinical 
data and to examine the safety and efficacy of the individual inhibitors and combination 
regimes in patients with leukemia, several phase I and II clinical trials have already been 
initiated.  
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inhibitors directed against other signal transduction molecules or classic chemotherapy. 
Mouse models and in vitro experiments indicate that both strategies could be used to 
improve current therapeutic regimes in specific patient groups. To confirm the pre-clinical 
data and to examine the safety and efficacy of the individual inhibitors and combination 
regimes in patients with leukemia, several phase I and II clinical trials have already been 
initiated.  
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1. Introduction 
T lymphocytes like all blood cells are progenies of a single multipotent hematopoietic stem 
cell (HSC). The existence of HSCs was proven by Till and McCulloch in 1961 when bone 
marrow cells injected into irradiated mice formed multilineage colonies in their spleens. 
These cells were called colony forming units (CFU-S) and they have potential for self-
renewal and differentiation into all types of blood cells(Till and McCulloch 1961; Wu et al. 
1968). For lymphocyte development HSCs migrate from the bone marrow, differentiate in 
the thymus into immunocompetent cells and seed the peripheral lymphatic organs.  This 
process occurs during fetal development (for review see (Godin and Cumano 2002), but also 
during the adult life of an individual since T lymphocytes have to be continuously 
replenished. Transplantation experiments proved that thirty hematopoietic stem cells are 
sufficient to save 50 percent of lethally irradiated mice, and to reconstitute all blood cell 
types in vivo (Spangrude et al. 1988). Because it is extremely important to produce 
immunocompetent T cells the process of their maturation and development is strictly 
regulated and is succumb to very strict check points at several stages of differentiation. In 
this context we’ll discuss Ikaros family transcription factors as major regulators of T 
lymphocyte development. 
2. Committed lymphocyte precursor 
For a long time it has been postulated analogously to committed myeloid precursors that 
there is a committed lymphocyte precursor. However the first experiments that showed the 
existence of a committed lymphocyte precursor was described in the early 90tis when a new 
population of cells in the thymus was found and its features described (Wu 1991; Wu et al. 
1991). These cells expressed most markers of the multipotent hematopoietic stem cells like 
Thy-1lowCD44+H2k+Sca-1+ but they expressed Sca-2 and low levels of CD4. These cells were 
negative for all mature blood cells markers lymphocytes (CD8-CD3-Ig-), macrophages (Mac-
1-), granulocytes (Gr-1-) and erhytrocytes (TER119-), lineage negative, (Lin- cells). Their Ig 
and TCR receptor genes were in germline configuration. The described precursors represent 
0.05% of the cells in an adult mouse thymus. If the cells were sorted and transferred by 
intrathymic injections (i.t.) into lethally irradiated congenic mice they developed into all 
thymic subpopulations, first CD4-CD8- (double negatives, DN) thymocytes, than into 
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CD4+CD8+ double positives which give rise to mature CD4+ and CD8+ lymphocytes. Mature 
cells derived from the CD4low precursors seeded the spleen, lymph nodes and bone marrow. 
The reconstitution potential of the described precursors was lower and the time for 
development was shorter when compared to the multipotent hematopoietic stem cells from 
the bone marrow. These experiments proved that the CD4low precursors in the thymus can 
develop into T lymphocytes. Because of their resemblance to the multipotent progenitors 
from the bone marrow it was important to answer the question whether their potential was 
restricted only to develop into T lymphocytes. Therefore we transplanted these cells into the 
periphery by injecting them intravenously (i.v.) into lethally irradiated congenic animals. 
Their progenies were found to develop into T lymphocytes similarly to the results obtained 
by direct i.t. transplantation experiments. When injected intravenously they also developed 
into B lymphocytes but there were no myeloid progenies. During fetal development these 
cells were detected from day 14 in the fetal thymus but only after birth their function was 
comparable to the adult ones(Antica et al. 1993). In the bone marrow the CD4low precursor 
cells were described, but their function was not lymphocyte restricted (Antica et al. 1994a). 
Further studies showed that in the bone marrow the marker that could differentiate the 
lymphoid precursor cells from the multipotent precursors was IL7Rα (Kondo et al. 1997). 
This population, called common lymphoid precursor (CLP) is characterized by Lin− Thy-
1−Sca-1loc-Kitlo IL-7R+ and possess rapid and prominent short-term lymphoid-restricted (T, 
B, and NK cells) reconstitution activity. However, this progenitor population clonally 
produces both B and T lymphocytes, but have little myeloid potential in vivo. A recently 
developed bioinformatics method, called Mining Developmentally Regulated Genes, which 
mines the publically available microarray data to identify genes that are up- or down-
regulated within a developmental pathway was applied to identify surface proteins that 
distinguish functional CLPs from other progenitors (Inlay et al. 2009; Sahoo et al. 2010). A 
surface marker Ly6d dissects the CLP population in two and shows that it consists of a 
mixture of all lymphoid progenitor cells (ALP) which retain B and T lymphoid potential, 
and BLP (B cell biased lymphoid progenitors). This manuscript offers strong support for the 
validity of our earlier conclusions. However, ALPs still keep low myeloid potential 
indicating that ALPs are either a mixture of the CD4low precursor cells and myeloid 
progenitors or is a single population but at an earlier developmental stage and still 
multipotent(Wu et al. 1991; Antica et al. 1993; Antica et al. 1994b; Inlay et al. 2009). Here we 
also stress the necessity and importance of in vivo assays for the determination of 
physiologic lineage potentials since it has been recently shown that in vitro assays can 
misrepresent in vivo lineage potentials of murine lymphoid progenitors(Richie Ehrlich et al. 
2011). 
From the clinical point of view defining the earliest lymphoid precursor is important for a 
rapid engraftment and protection from infections after hematopoietic stem cell 
transplantation in chemotherapy or irradiation compromised patients (Arber et al. 2003; 
Holländer et al. 2010).  
3. Ikaros transcription factors 
Mechanisms and factors that regulate lymphocyte development from stem cells have to be 
very accurate since any alteration of this process may lead to serious diseases like leukemia.  
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Transcription factors from the Ikaros family play an essential role in the commitment of 
hematopoietic progenitors into the lymphoid lineage as well as in the choice of effector 
functions at later stages of development(Georgopoulos 1994; Sun et al. 1996; Wang et al. 
1998; Cortes et al. 1999). Their role has been addressed by gene targeting and such gene 
inactivation studies have identified Ikaros, Aiolos and Helios as transcription factors 
required for the maturation of lymphocytes(Morgan 1997; Hahm 1998; Kelley 1998). It has 
been shown that mice homozygous for a deletion in these genes undergo remarkable 
changes in their lymphocyte populations and also those ageing animals with the same 
mutation develop lymphoproliferative disorders. A number of studies show that Ikaros 
genes in both mice and human malignancies might be deregulated (Winandy et al. 1995; 
Nichogiannopoulou et al. 1999; Nakase et al. 2000; Nakayama et al. 2000; Nakase et al. 
2002; Rebollo and Schmitt 2003; Dovat et al. 2005; Mullighan et al. 2008; Matulic et al. 
2009; Billot et al. 2010). Therefore we addressed the question whether a combination of 
transcription factor failures may contribute to the development of human lymphoma. We 
amplified human mRNA from formalin fixed paraffin embedded tissues from lymphoma 
patients in order to have consistent and well defined groups of patients. Hence, we were 
able to analyze Ikaros, Aiolos and Helios mRNA from archive tissue specimens from 
patients with Hodgkin’s and non- Hodgkin’s lymphoma and follicular hyperplasia 
(Antica et al. 2008; Antica et al. 2010). Further we and others show a deregulation in 
human leukemia. Acute lymphoblastic leukemia (ALL) is characterized by the 
Philadelphia chromosome (Ph) which encodes the BCR-ABL1 tyrosine kinase, the most 
frequent cytogenetic abnormality (∼25–30% of cases)(Mancini et al. 2005). Deletion of the 
IKAROS gene (IKZF1) was found in 83.7% cases of BCR-ABL1 ALL, but not in chronic-
phase CML(Mullighan et al. 2008). Posttranscriptional regulation of alternative splicing of 
Ikaros was associated with resistance to tyrosine kinase inhibitors (TKIs) in Ph/positive 
acute lymphoblastic leukemia (ALL) patients (Iacobucci et al. 2008). Further, IKZF1 
deletions are likely to be a genomic alteration that significantly affects the prognosis of 
Ph-positive ALL in adults (Martinelli et al. 2009). Further, when Ikaros expression was 
analyzed by real time RT-PCR the quantitative distribution of mRNA level in 
hematopoietic cells of patients with lymphocytic leukemia was similar but a clear 
difference among groups was due to Aiolos lower expression in all types of acute 
leukemia(Antica et al. 2007). The mechanisms involved have been tested in the mouse 
model. It has been found that pre-BCR induces Ikaros to inhibit the proliferation of 
Philadelphia chromosome-positive B-ALL cells (Trageser et al. 2009). Pre–B cell 
receptor/IKAROS-induced cell cycle arrest can be reversed by dominant-negative Ikaros 
splicing variant IK6(Trageser et al. 2009). A possible mechanism of Ikaros suppression has 
been described by Ma et al. Their experiments on mice show that Ikaros inhibits c-Myc as 
a direct target, resulting in inhibition of pre B-lymphocyte proliferation (Ma et al 2010).  
In the last ten years a new system, besides fetal thymic organ cultures (FTOC) or 
reaggregation cultures, for T cell growth in vitro has been developed. It has been shown 
that OP9 stromal cells transfected with the Notch ligand delta like 1 DL1 (OP9-DL1) can 
support T lymphocyte differentiation in vitro ( Schmitt and Zúńiga-Pflücker 2002). This 
new technology provided a powerful tool for analyzing developmental phases from 
multipotent stem cells to mature T lymphocytes at single cell level in vitro and allowed a 
better understanding of the processes underlying development. However, there are still a 
lot of unanswered and exciting questions to be solved. Who is regulating Ikaros and 
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Notch? How transcription factors regulate development with their partners and DNA 
where and how do they interfere with their partners, and DNA, how can we identify 
targets for new drugs and finally how can we produce T cells in vitro for practical 
applications and regenerative medicine? 
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1. Introduction 
Chromatin is a highly ordered structure consisting of repeats of nucleosomes connected by 
linker DNA. It consists of DNA, histone, and nonhistone proteins condensed into 
nucleoprotein complexes and it functions as the physiological template of all eukaryotic 
genetic information. Histones are small basic proteins containing a globular domain and a 
flexible charged NH2 terminus known as the histone tail, which protrudes from the 
nucleosome. Epigenetic codes are set up by modifications on the DNA (methylation) or on the 
histones (acetylation, methylation, phosphorylation, ubiquitination, and ADP ribosylation, 
etc.), by different classes of enzymes in a precise and targeted manner. Posttranslational 
modification to histones affects chromatin structure and function resulting in altered gene 
expression and changes in cell behavior. These modifications do not alter the primary 
sequence of DNA but have an impact on gene expression regulation, most frequently gene 
suppression. They lead to pathological states in hematopoietic system resulting in acute 
leukemia.  
DNA methylation is catalyzed by DNA methyltransferases (DNMTs), of which three active 
enzymes have been identified in mammals, namely DNMT1, DNMT3A and DNMT3B. 
DNMT1 is responsible for maintaining pre-existing methylation patterns during DNA 
replication, while DNMT3A and DNMT3B are required for initiation of de novo methylation. 
Acetylation is a reversible process. The balance between acetylation (transcriptional activation) 
and deacetylation (transcriptional repression) is regulated by histone acetyltransferase (HATs) 
and histone deacetylases (HDACs) in specific lysine residues in the N-termini of histone tails 
and/or in transcription factors (eg, p53, E2F1, GATA1, RelA, YY1, and Mad/Max) without 
directly binding to the DNA (Minucci et al., 2006, Gallinare et al., 2007), and is critical in 
regulating gene expression. Mammalian HDACs are classified into three classes based on their 
homology to yeast HDACs. Class I HDACs (HDAC1, 2, 3, 8, and 11) are homologues of 
Sacharomyces cerevisiae histone deacetylase Rpd 3 (reduced potassium dependency 3) and those 
with greater similarity to yeast Hda1, are class II HDACs (Gray & Ekstrom, 2001; Gao et al., 
2002; Kao et al., 2002). Class III HDACs are called Sirtuins, which are homologoues of yeast 
sir2 (silence information regulator). Histones can be mono-, di-, or tri-methylated at lysine and 
arginine residues by HMTs, and the recent identification of histone lysine demethylases such 
as KDM1/LSD1 and the Jumonji-domain (JMJD)-containing protein family shows that histone 
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methylation is an enzymatically dynamic process (Lan et al., 2008). In general, methylation 
at H3K4, H3K36, and H3K79 is associated with transcriptional activation, whereas H3K9, 
H3K27, and H3K20 methylation is associated with transcriptional repression (Kouzarides et 
al., 2007). The involvement of HMTases, more so of DNMTs (DNA methyltransferase) is 
observed in cancer (Zhang et al., 2005). Several chromosomal translocations in acute 
myeloid leukemia (AML) that produce chimerical fusion oncoproteins have been shown to 
repress genes involved in cell-cycle growth inhibition, differentiation, and apoptosis (Bhalla 
et al., 2005; Hormaeche, 2007) . The reversal of aberrant epigenetic changes has therefore 
emerged as a potential strategy for the treatment of cancer. DNA methylation and histone 
deacetylation inhibitors and a number of compounds targeting enzymes that regulate DNA 
methylation, histone acetylation and histone methylation have been developed as epigenetic 
therapies, with some demonstrating efficacy in hematological malignancies and solid 
tumors. The aberrance of DNA methylation, histone acetylation and methylation has been 
found in acute leukemia. We found that PHI (Phenylhexyl isothiocyanate), synthetic 
phenylhexyl  isothiocyanates，could correct the aberrance ( Ma et al., 2006; Xiao et al., 2010 ; 
Jiang et al., 2010) . 
2. Epigenetic event in acute leukemia 
Epigenetic mechanisms controlling transcription of genes involved in cell differentiation, 
proliferation, and survival are often targets for deregulation in malignant development. 
Misregulation of epigenetic modification may be as significant as genetic mutation in 
driving cancer development and growth. There are some acute leukemias with cytogenetic 
translocations in WHO classification, which involved in epigenetic modification change. 
DNA methylation is established during early embryogenesis and continues through 
different generations of cell cycle and development. Abnormal patterns in DNA methylation 
are one of epigenetic deregulation to be characterized in human cancers, either as a result of 
DNMT over expression or aberrant recruitment. Acetylation and methylation are the two 
histone modification that has been clinically associated with pathological epigenetic 
disruption in cancer cells. Specific recurring chromosomal abnormalities are commonly 
associated with acute myeloid leukemia. These chromosomal anomalies influence the 
molecular and cellular phenotype of the leukemia blasts and may be responsible for their 
malignant potential (Caligiuri et al., 1997; Thandla et al., 1997). The aberrations often lead to 
the formation of one or more fusion genes resulting in the over expression or untimely 
expression of a normal gene, eg, the MYC/Ig gene enhancer fusion produced by the t (8;14) 
in Burkitt’s lymphoma (Crosce et al., 1986; Thandla et al., 1997) , or the creation of a new 
gene product by fusing genes as in the PML-RAR fusion produced by the t(15;17) 
characteristic of acute promyelocytic leukemia (Zelent et al., 2001). Some regions are 
common partners in fusion events, and 11q23 is involved in at least 40 different 
translocations in acute leukemia.  
2.1 DNA methylation and acute leukemia 
The maintenance of appropriate DNA methylation within CpG nucleotide islands plays a 
significant role in regulation of a wide variety of molecular processes including stability of 
chromosomal structure and control of gene expression (Das, 2004). DNA methylation can 
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also result in the recruitment of proteins that bind methylated CpG sequences (methyl-CpG-
binding domain [MBD] proteins) complexes with histone deacetylases (HDACs) and histone 
methyltransferase (HMTase) prompting coordinated epigenetic modifications of the 
surrounding chromatin (Esteller, 2005). Tumor cell-specific promoter hypermethylation in 
genes that play important roles in regulating cell cycle, apoptosis, DNA repair, 
differentiation, and cell adhesion is often a hallmark of disease ( Esteller, 2008). In addition, 
hypomethylation of repetitive sequences may result in chromosomal and genetic instability, 
leading to further oncogenic events.  Transcriptional silencing via DNA hypermethylation 
can often be associated with poor clinical outcome in several malignancies (Bhalla et al., 
2005; Das, 2004; Herranz, 2007). Abnormal gain in DNA methylation with aberrant silencing 
of transcription may occur at specific gene promoter regions and represents a mechanism 
for inactivation of tumor-suppressor genes. In a clinical experiment, the methylation profiles 
of 344 patients with acute myeloid leukemia (AML) were examined. A common aberrant 
DNA methylation signature consisting of 45 genes in most of them hypermethylated was 
identified, that was consistently detected in at least 10 of the 16 clusters’ methylation 
signatures and affecting at least 70% of the cases studied. Genes in this signature are likely 
to be part of a common epigenetic pathway involved in leukemic transformation of 
hematopoietic cells. They are the tumor suppressor PDZD2, transcriptional regulators 
(ZNF667, ZNF582, PIAS2, CDK8), nuclear import receptors (TNPO3, IPO8), and CSDA, a 
repressor of GM-CSF. They could predict the clinical outcome (Maria et al., 2010). Silencing 
of CDKN2A and CDKN1A has been associated with poor clinical outcome in acute 
leukemias (Herman, 2003; Bernstein et al., 2007). Aberrant p15CDKN2B has been widely 
reported in leukemias and other myeloid neoplasms (Cameron et al., 1999; Christiansen et 
al., 2003; Shimamoto et al., 2005; Toyota et al., 2001). Roman-Gomez et al. reported an 
incidence of p21CIP1 methylation of 41% in 124 patients with acute lymphocytic leukemia 
(ALL). Most importantly, they observed that p21CIP1 methylation was an independent 
predictor of poor prognosis both in adults and children with this disease (Roman-Gomez et 
al., 2002). Zheng et al. reported that there are 35.29%, 48.65% hypermethylation of the p15 
INK4，p16 INK4 gene exon 1 in acute leukemia respectively, 25%, 37.5% hypermethylation 
of the p15 INK4，p16 INK4 gene exon 1  in acute myeloid leukemia respectively, 60%, 
69.23% hypermethylation of the p15 INK4，p16 INK4 gene exon 1 in acute lymphoid 
leukemia respectively (Zheng et al., 2004a, 2004b).  
2.2 Histone acetylation and acute leukemia 
Histone acetylation is associated with transcriptionally active chromatin, which has been 
established over 40 years ago (Littau et al., 1964). The acetylation of the histone tails was 
surmised to result in a decreased affinity of the histone for the DNA, on account of the 
decreasing positive charge, establishing an ‘open’ chromatin state. The transcriptionally 
active state may be mediated via the transient formation of (H3-H4) 2 tetrameric particle that 
could adopt an open structure only when H3 and H4 tails are acetylated (Morales et al., 
2000). Mistargeting and mutations in HATs and HDACs are major factors leading to 
diseases and disorders. A classic example of one such disorder is the Rubinstein-Taybi 
syndrome (RSTS), which is a consequence of a single mutation in the gene encoding the 
HAT CREB binding protein (CBP) located on chromosome 16p13.3. In addition to 
functioning as a bridge between transcription factors and the basal transcription machinery, 
CBP has histone acetyltransferase activity (Bannister et al., 1996; Ogryzko et al., 1996). CBP 
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causes an acetylation of core histone proteins, such as H2A, H2B, H3 and H4, and interacts 
with histone acetyltransferases, such as PCAF (P300/CBP associated factor), SRC-1 (steroid 
receptor coactivator-1) and ACTR (coactivator for nuclear hormone receptors). It is generally 
accepted that CBP is involved in the remodeling of nucleosomes via these factors. Altered 
HAT (histone acetylase) activity has been reported in both hematological and solid cancers, 
by inactivation of HAT activity through gene mutation or through deregulation of HAT 
activity by viral oncoproteins. Chromosomal translocations involving HATs and their 
consequent fusion proteins have been implicated in the onset and progression of acute 
leukemia. Such translocations have been identified in acute myeloid leukemia (AML) and 
acute lymphoblastic leukemia (ALL) cases in which the translocation t (11;16) (q23;p13) 
results in a fusion protein (MLL-CBP) consisting of the CBP and the mixed lineage leukemia 
(MLL) protein. The underlying mechanisms of effects of this fusion protein in the formation 
of AML may involve deregulation of MLL target genes by CBP-mediated chromatin 
remodeling and increased chromatin accessibility (Ayton et al., 2001). The fusion protein has 
A/T hooks and cysteine-rich DNA recognition domain of MLL fused to intact CBP and fails 
to recruit SWI/SNF to its target as it lacks the SET domain, which is important for 
interacting with hSNF5 (Taki et al., 1997). MLL can also be aberrantly fused to p300 in AML 
via the t (11;22)(q23;p13) translocation (Ida et al., 1997). In addition to p300 and CBP fusion 
proteins involving the HATs, TIF2, MOZ (monocytic zinc finger protein) and MORF that 
arise as a result of chromosomal translocations have also been identified in hematological 
malignancies (Cairns, 2001; Cairns et al., 2001; Panagopoulos et al., 2001; Liang J et al., 1998). 
The MOZ-CBP fusion proteins is expressed due to a translocation t (8;16)(p11;p13), 
associated with a subtype of acute monocytic leukemia (AML M5). The resulting fusion 
protein has been recently shown to increase expression of genes regulated by NF-κB (Chan 
et al., 2007). MORF gene fusions are expressed in t (10;16) (q22;p13) in childhood AML and 
myelodysplastic syndrome, in which the MORF gene is fused with the CBP gene 
(Champagne et al., 1999). The MOZ-TIF2 fusion is one of a new family of chromosomal 
rearrangements that associate HAT activity, transcriptional coactivation, and acute leukemia 
(Jian et al., 1998). The CBP gene has been shown to fuse with MOZ in AML patients with t 
(8;16)(p11;p13) (Borrow et al., 1996; Giles et al., 1997), and in MLL patients with therapy-
related acute leukemia with t(11;16)(q23;p13) (Rowley et al., 1997; Satake et al., 1997; Sobulo 
et al., 1997; Taki et al., 1997).  
Deregulation of HDAC activity by chromosomal translocations has been strongly implicated 
in aberrant gene silencing and the promotion of tumorigenesis, especially in leukemia. A 
well-understood link between tumorigenesis and aberrant HDAC activity occurs in acute 
promyelocytic leukemia (APL). In APL, the chromosomal translocations t (15;17) and t 
(11;17) results in fusion proteins RARα-PML (promyelocytic leukemia protein) and RARα-
PLZF (promyelocytic zinc finger), respectively. These aberrant proteins retain the ability to 
bind RAREs and HDACs with high affinity and are no responsive to retinoids, resulting in 
the deregulated transcriptional silencing of RAR-targeted genes and prevention of cell 
differentiation  (Zelent et al., 2001). The retinoic acid receptor (RAR) is important for 
myeloid differentiation and acts as a transcriptional regulator by binding its 
heterodimerization partner RXR, which in turn bind to retinoic acid response elements 
(RAREs) within the promoters of target genes (Bolden et al., 2006). Both PML-RARalpha and 
PLZF-RARalpha fusion proteins recruit the nuclear co-repressor (N-CoR)-histone 
deacetylase complex through the RARalpha CoR box (Iris & Luciano, 2011). AML1-ETO is a 
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fusion protein that results from t (8;21) and CBFβ-MYH11 caused by the chromatin 
inversion 16(p13;q22) in cases of AML. It is of translocations in leukemogenesis that is 
capable of altering protein acetylation. Fusion proteins from these translocations result in 
the recruitment of HDACs to target gene promoters and consequent gene silencing  (Wang 
et al., 2007; Bhalla et al., 2005). 
We have studied on the state of histone acetylation in acute leukemia. The levels of 
acetylated H3 and H4 were examined in patients with or without complete remission 
response. The deficient histone acetylation existed in all 15 cases of acute leukemias, 
including both myeloid and lymphoid lineages. The results showed that both levels of 
histone H3 and H4 acetylation in 15 AL patients were significantly lower, as compared with 
4 individuals without leukemia(H3 0.128±0.013 vs 0.386±0.104，H4 0.096± 0.008 vs 
0.341±0.096 respectively, both p<0.01)．This deficiency was revealed in all the acute 
leukemia cases investigated in all age groups from 2.5 to 69 years, including both myeloid 
and lymphoid lineages (Xiao et al., 2010). 
2.3 Histone methylation and acute leukemia 
Histone methylation is brought about by histone methyltransferases (HMTases), which 
catalyze the transfer of methyl group from the donor SAM (S-adenosyl methionine) 
predominantly to the lysine or arginine residues on the N-terminal histone tails. Based on 
the basis of amino acids that get modified, they are classified into the lysine 
methyltransferases (Martin & Zhang, 2005) and arginine methyltransferases (Bedford et al., 
2005). The residues can be mono-, di- or tri-methylated, which further increase the scope 
and range of methylation-mediated regulation. Arginine methyltransferase have an 
additional level of regulation in catalyzing the formation of asymmetricdimethylarginine 
(aDMA) or symmetricdimethylarginine (sDMA). HMTases are versatile enzymes with their 
modifications being involved in both activation and repression. The exact residue on the 
histone tails that gets modification determines transcriptional activation or repression. The 
lysineme methyltransferases are involved in transcriptional activation (methylation on 
H3K4, H3K36 and H3K79) as well as transcription repression (methylation of H3K9, H3K27 
and H4K20), while the arginine methyltransferases so far have been shown to be involved in 
transcriptional activation (Kourzarides et al., 2007). There are a form of chromosomal 
translocations involving HMTs (e.g., MLL1, NSD1, NSD3), gene over expression or 
amplification (e.g., EZH2, MLL2, NSD3, BMI1, GASC1), gene silencing (e.g., RIZ1), and gene 
deletion (e.g., MLL3). 
Chromosomal rearrangements, affecting chromosome 11q23 and involving the human MLL 
gene, is a histone methyltransferase. It recurrently associated with the disease phenotype of 
acute leukemias (Pui et al., 2002, 2003). There are a total of 87 different MLL rearrangements 
of which 51 TPGs are now characterized at the molecular level. The four most frequently 
found TPGs (AF4, AF9, ENL and AF10) encode nuclear proteins that are part of a protein 
network involved in histone H3K79 methylation (Meyer et al., 2006). Because H3K79 
methylation is important for transcriptional elongation (Krogan et al., 2003), global 
hypomethylation could also lead to a reduced expression of a great number of genes (Dik et 
al., 2005).  
The key transcriptional pathways that are subordinate to both wild-type and oncogenic 
MLL proteins include Hox genes, which are master regulators of cell fate, proliferation, and 
morphogenesis (Owens & Hawley, 2002). Hematopoietic cells transformed by MLL 
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causes an acetylation of core histone proteins, such as H2A, H2B, H3 and H4, and interacts 
with histone acetyltransferases, such as PCAF (P300/CBP associated factor), SRC-1 (steroid 
receptor coactivator-1) and ACTR (coactivator for nuclear hormone receptors). It is generally 
accepted that CBP is involved in the remodeling of nucleosomes via these factors. Altered 
HAT (histone acetylase) activity has been reported in both hematological and solid cancers, 
by inactivation of HAT activity through gene mutation or through deregulation of HAT 
activity by viral oncoproteins. Chromosomal translocations involving HATs and their 
consequent fusion proteins have been implicated in the onset and progression of acute 
leukemia. Such translocations have been identified in acute myeloid leukemia (AML) and 
acute lymphoblastic leukemia (ALL) cases in which the translocation t (11;16) (q23;p13) 
results in a fusion protein (MLL-CBP) consisting of the CBP and the mixed lineage leukemia 
(MLL) protein. The underlying mechanisms of effects of this fusion protein in the formation 
of AML may involve deregulation of MLL target genes by CBP-mediated chromatin 
remodeling and increased chromatin accessibility (Ayton et al., 2001). The fusion protein has 
A/T hooks and cysteine-rich DNA recognition domain of MLL fused to intact CBP and fails 
to recruit SWI/SNF to its target as it lacks the SET domain, which is important for 
interacting with hSNF5 (Taki et al., 1997). MLL can also be aberrantly fused to p300 in AML 
via the t (11;22)(q23;p13) translocation (Ida et al., 1997). In addition to p300 and CBP fusion 
proteins involving the HATs, TIF2, MOZ (monocytic zinc finger protein) and MORF that 
arise as a result of chromosomal translocations have also been identified in hematological 
malignancies (Cairns, 2001; Cairns et al., 2001; Panagopoulos et al., 2001; Liang J et al., 1998). 
The MOZ-CBP fusion proteins is expressed due to a translocation t (8;16)(p11;p13), 
associated with a subtype of acute monocytic leukemia (AML M5). The resulting fusion 
protein has been recently shown to increase expression of genes regulated by NF-κB (Chan 
et al., 2007). MORF gene fusions are expressed in t (10;16) (q22;p13) in childhood AML and 
myelodysplastic syndrome, in which the MORF gene is fused with the CBP gene 
(Champagne et al., 1999). The MOZ-TIF2 fusion is one of a new family of chromosomal 
rearrangements that associate HAT activity, transcriptional coactivation, and acute leukemia 
(Jian et al., 1998). The CBP gene has been shown to fuse with MOZ in AML patients with t 
(8;16)(p11;p13) (Borrow et al., 1996; Giles et al., 1997), and in MLL patients with therapy-
related acute leukemia with t(11;16)(q23;p13) (Rowley et al., 1997; Satake et al., 1997; Sobulo 
et al., 1997; Taki et al., 1997).  
Deregulation of HDAC activity by chromosomal translocations has been strongly implicated 
in aberrant gene silencing and the promotion of tumorigenesis, especially in leukemia. A 
well-understood link between tumorigenesis and aberrant HDAC activity occurs in acute 
promyelocytic leukemia (APL). In APL, the chromosomal translocations t (15;17) and t 
(11;17) results in fusion proteins RARα-PML (promyelocytic leukemia protein) and RARα-
PLZF (promyelocytic zinc finger), respectively. These aberrant proteins retain the ability to 
bind RAREs and HDACs with high affinity and are no responsive to retinoids, resulting in 
the deregulated transcriptional silencing of RAR-targeted genes and prevention of cell 
differentiation  (Zelent et al., 2001). The retinoic acid receptor (RAR) is important for 
myeloid differentiation and acts as a transcriptional regulator by binding its 
heterodimerization partner RXR, which in turn bind to retinoic acid response elements 
(RAREs) within the promoters of target genes (Bolden et al., 2006). Both PML-RARalpha and 
PLZF-RARalpha fusion proteins recruit the nuclear co-repressor (N-CoR)-histone 
deacetylase complex through the RARalpha CoR box (Iris & Luciano, 2011). AML1-ETO is a 
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fusion protein that results from t (8;21) and CBFβ-MYH11 caused by the chromatin 
inversion 16(p13;q22) in cases of AML. It is of translocations in leukemogenesis that is 
capable of altering protein acetylation. Fusion proteins from these translocations result in 
the recruitment of HDACs to target gene promoters and consequent gene silencing  (Wang 
et al., 2007; Bhalla et al., 2005). 
We have studied on the state of histone acetylation in acute leukemia. The levels of 
acetylated H3 and H4 were examined in patients with or without complete remission 
response. The deficient histone acetylation existed in all 15 cases of acute leukemias, 
including both myeloid and lymphoid lineages. The results showed that both levels of 
histone H3 and H4 acetylation in 15 AL patients were significantly lower, as compared with 
4 individuals without leukemia(H3 0.128±0.013 vs 0.386±0.104，H4 0.096± 0.008 vs 
0.341±0.096 respectively, both p<0.01)．This deficiency was revealed in all the acute 
leukemia cases investigated in all age groups from 2.5 to 69 years, including both myeloid 
and lymphoid lineages (Xiao et al., 2010). 
2.3 Histone methylation and acute leukemia 
Histone methylation is brought about by histone methyltransferases (HMTases), which 
catalyze the transfer of methyl group from the donor SAM (S-adenosyl methionine) 
predominantly to the lysine or arginine residues on the N-terminal histone tails. Based on 
the basis of amino acids that get modified, they are classified into the lysine 
methyltransferases (Martin & Zhang, 2005) and arginine methyltransferases (Bedford et al., 
2005). The residues can be mono-, di- or tri-methylated, which further increase the scope 
and range of methylation-mediated regulation. Arginine methyltransferase have an 
additional level of regulation in catalyzing the formation of asymmetricdimethylarginine 
(aDMA) or symmetricdimethylarginine (sDMA). HMTases are versatile enzymes with their 
modifications being involved in both activation and repression. The exact residue on the 
histone tails that gets modification determines transcriptional activation or repression. The 
lysineme methyltransferases are involved in transcriptional activation (methylation on 
H3K4, H3K36 and H3K79) as well as transcription repression (methylation of H3K9, H3K27 
and H4K20), while the arginine methyltransferases so far have been shown to be involved in 
transcriptional activation (Kourzarides et al., 2007). There are a form of chromosomal 
translocations involving HMTs (e.g., MLL1, NSD1, NSD3), gene over expression or 
amplification (e.g., EZH2, MLL2, NSD3, BMI1, GASC1), gene silencing (e.g., RIZ1), and gene 
deletion (e.g., MLL3). 
Chromosomal rearrangements, affecting chromosome 11q23 and involving the human MLL 
gene, is a histone methyltransferase. It recurrently associated with the disease phenotype of 
acute leukemias (Pui et al., 2002, 2003). There are a total of 87 different MLL rearrangements 
of which 51 TPGs are now characterized at the molecular level. The four most frequently 
found TPGs (AF4, AF9, ENL and AF10) encode nuclear proteins that are part of a protein 
network involved in histone H3K79 methylation (Meyer et al., 2006). Because H3K79 
methylation is important for transcriptional elongation (Krogan et al., 2003), global 
hypomethylation could also lead to a reduced expression of a great number of genes (Dik et 
al., 2005).  
The key transcriptional pathways that are subordinate to both wild-type and oncogenic 
MLL proteins include Hox genes, which are master regulators of cell fate, proliferation, and 
morphogenesis (Owens & Hawley, 2002). Hematopoietic cells transformed by MLL 
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oncoproteins consistently hyperexpress several Hoxa cluster genes, some of which have 
been shown to be direct targets of MLL and key contributors to the pathologic features of 
MLL associated leukemia (Ayton & Cleary, 2003; Kumar et al., 2004; Wang et al., 2005). This 
subtype of acute leukemia has a particularly aggressive with a very dismal prognosis. Thus, 
an interesting scenario about the contribution of CALM-AF10 in leukemogenesis can be 
envisioned whereby the CALM-AF10 fusion, in addition to up-regulating specific oncogenes 
(eg, HOXA5 genes) via local hypermethylation, might promote leukemogenesis by 
interfering with multiple cellular pathways through global hypomethylation of H3K79. 
Lin et al. suggested that the increased chromosomal instability associated with H3K79 
hypomethylation caused by the CALM-AF10 fusion might accelerate the acquisition of 
additional genetic abnormalities required for leukemogenesis. AF10 fusion proteins seem to 
use at least 2 mechanisms that promote leukemogenesis: (1) deregulation of target genes 
resulting from local epigenetic changes, and (2) increasing genomic instability due to global 
epigenetic changes (Lin et al., 2009). 
ALL-1 is a member of the human trithorax/Polycomb gene family and is also involved in 
acute leukemia. ALL-1 is associated in a stable complex with at least 27 proteins (Tatsuya et 
al., 2002), most ALL-1-associated proteins can be classified into well-known complexes 
involved in transcription. The ALL-1 protein was found to be posttranslationally processed 
into two polypeptides, p300 and p180. The two ALL-1 polypeptides are present within a 
single supercomplex, which is physical association between segments spanning residues 
1979–2130 and 3613–3876. p180 contains the SET domain which methylates H3-K4, as well 
as a domain (TAD) with transcriptional activation capacity. p300 comprises the HAT hooks 
which bind DNA, a bromodomain which binds acetylated lysines within histone H4 
(Dhalluin et al., 1999; Jacobson et al., 2000), the PHD zinc fingers domain, and a region with 
homology to DNA methyltransferase. The cleavage might enable the formation of a spatial 
configuration accommodating the many interactions of ALL-1 with proteins and DNA. 
ALL-1-associated leukemias show some unusual and intriguing features (DiMartino et al., 
1999). A study showed 16/22 (68%) infant’s acute leukemia with ALL-1 gene 
rearrangements. It demonstrated that ALL-1, a highly intricate chromatin modifier, in acute 
leukemia is abnormal in its function (Cimino et al., 1997). 
The t (8;21) is found in 10–15% of myeloid  leukemia and gives rise to a fusion protein that 
contains the N-terminal portion of RUNX1 fused to nearly all of myeloid translocation gene 
on chromosome 8 (MTG8, also known as eight-twenty-one (ETO)) (Miyoshi et al., 1991, 
1993; Erickson et al., 1994). The fusion protein appears to function as a transcriptional 
repressor of RUNX1-regulated genes (Peterson et al., 2004). The t (12;21) is found in up to 
25% of pediatric B-cell acute leukemia and creates a chimerical gene encoding the TEL–
RUNX1 fusion protein (Golub et al., 1995; Nucifora et al., 1995). RUNX1 function is also 
impaired by the inv (16), which fuses the RUNX1 associating factor, core binding factor b 
(CBFb or polyoma enhancer binding protein 2 betas) to the smooth muscle myosin heavy-
chain gene MYH11, in approximately 8% of acute myeloid leukemia (Liu et al., 1993). Two 
SUV39H1 contact points within repression domain 2 of RUNX1, with one of these RUNX1 
domains also contacting HDAC1 and HDAC3, begins to provide a mechanistic basis for 
gene silencing mediated by RUNX1. Both Runt and RUNX1 are required for gene silencing 
during development and a central domain of RUNX1, termed repression domain 2 (RD2). 
RD2 contacts SUV39H1, a histone methyltransferase, via two motifs and that endogenous 
SUV39H1 associates with a Runx1-regulated repression element in murine erythroleukemia 
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cells. In addition, one of these SUV39H1-binding motifs is also sufficient forbidding to 
histone deacetylases 1 and 3, and both of these domains are required for full RUNX1-
mediated transcriptional repression. The association between RUNX1, histone deacetylases 
and SUV39H1 provides a molecular mechanism for repressor (E et al., 2006). 
The state of histone methylation in acute leukemia has been studied. Aberrant histone 
methylations showed downregulation of H3K4 methylation and upregulation of H3K9 
methylation in all acute leukemia. The methylation status of histone H3 at lysines 4 and 9 of 
mononuclear cells from 19 patients with acute leukemia, aged from 6 to 78, including AML 
and ALL and that from 9 individuals without leukemia were compared. The results showed 
that the level of H3K4 methylation was significantly lower in 19 AL patients than that in non 
leukemia (0.220±0.096 vs 0.447±0.186, P<0．01), while the level of H3K9 methylation was 
significantly higher (0.409 4±0.106 vs  0.168±0.015，P<0.01). These results clearly 
demonstrated that the patients with acute leukemias are hypomethylated at H3K4, and 
hypermethylated at H3K9. (Ma et al., 2010).  
3. Epigenetic therapy in acute leukemia 
The cause of most epigenetic diseases can be traced to the enzymes that establish them. A 
great deal of research has gone into the discovery of the modulators of these enzymes, 
which not only leads to a better understanding of the mechanism, but also to therapeutic 
possibilities. Fusion protein, such as MLL-MOZ, PML-RARA results mutations in HATs, 
HDACs and HMTas, and misregulating gene expression. Inactivation of tumor suppressor 
genes is central to the development of cancer. Silencing of these genes occurs by epigenetic 
means and inhibition of these factors lead to reversal of tumor suppressor gene silencing 
and inhibition of tumorigenesis (Gibbons et al., 2005). 
Chemical compound acting on epigenetic control of gene expression mainly fall into two 
broad categories: inhibitors of DNA methyltransferases and inhibitors of histone deacetylase 
(HDACi). Recently, compounds regulating histone methylations have been studied. These 
drugs have been used in phase I and II trials in patients with hematological and solid tumor. 
Some of them have been approved by FDA (U.S. Food and Drug Administration) to treat 
hematological disorders and solid tumor.  
Pharmacologic inhibition of DNA methylation causes the trapping of DNMTs and their 
targeted degradation results in re-expression of genes that have been aberrantly silenced by 
hypermethylation, concomitant with inhibition of clonal expansion and tumor cell growth, 
induction of cell differentiation, and cancer cell death (Issa, 2007). A number of DNA 
methylation inhibitors are currently under investigation, including the pyrimidine 
nucleoside analogs Decitabine (Dacogen, SuperGen, Inc., Dublin, CA) and Azacitidine 
(Vidaza, Celgene, Summit, NJ), and the nonucleoside inhibitor Hydralazine. Azacitidine and 
Decitabine are both approved by FDA for the treatment of a number of myelodysplastic 
syndrome subtypes, including refractory anemia and chronic myelogenous leukemia (CML) 
(Gal-Yam et al., 2008; Issa. 2007; Wong et al., 2007).  
Most current DNA-demethylating agents block the action of DNA methyltransferases 
(DNMTs), whose expression levels are usually moderately elevated in human tumors. The 
genetic inactivation of two DNMTs, DNMT1 and DNMT3B, induces demethylation of all 
known hypermethylated tumor-suppressor genes and remarkably slow growth. DNMTs 
have two binding sites: one for the cytosine residue and another for S-adenosyl- methionine. 
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oncoproteins consistently hyperexpress several Hoxa cluster genes, some of which have 
been shown to be direct targets of MLL and key contributors to the pathologic features of 
MLL associated leukemia (Ayton & Cleary, 2003; Kumar et al., 2004; Wang et al., 2005). This 
subtype of acute leukemia has a particularly aggressive with a very dismal prognosis. Thus, 
an interesting scenario about the contribution of CALM-AF10 in leukemogenesis can be 
envisioned whereby the CALM-AF10 fusion, in addition to up-regulating specific oncogenes 
(eg, HOXA5 genes) via local hypermethylation, might promote leukemogenesis by 
interfering with multiple cellular pathways through global hypomethylation of H3K79. 
Lin et al. suggested that the increased chromosomal instability associated with H3K79 
hypomethylation caused by the CALM-AF10 fusion might accelerate the acquisition of 
additional genetic abnormalities required for leukemogenesis. AF10 fusion proteins seem to 
use at least 2 mechanisms that promote leukemogenesis: (1) deregulation of target genes 
resulting from local epigenetic changes, and (2) increasing genomic instability due to global 
epigenetic changes (Lin et al., 2009). 
ALL-1 is a member of the human trithorax/Polycomb gene family and is also involved in 
acute leukemia. ALL-1 is associated in a stable complex with at least 27 proteins (Tatsuya et 
al., 2002), most ALL-1-associated proteins can be classified into well-known complexes 
involved in transcription. The ALL-1 protein was found to be posttranslationally processed 
into two polypeptides, p300 and p180. The two ALL-1 polypeptides are present within a 
single supercomplex, which is physical association between segments spanning residues 
1979–2130 and 3613–3876. p180 contains the SET domain which methylates H3-K4, as well 
as a domain (TAD) with transcriptional activation capacity. p300 comprises the HAT hooks 
which bind DNA, a bromodomain which binds acetylated lysines within histone H4 
(Dhalluin et al., 1999; Jacobson et al., 2000), the PHD zinc fingers domain, and a region with 
homology to DNA methyltransferase. The cleavage might enable the formation of a spatial 
configuration accommodating the many interactions of ALL-1 with proteins and DNA. 
ALL-1-associated leukemias show some unusual and intriguing features (DiMartino et al., 
1999). A study showed 16/22 (68%) infant’s acute leukemia with ALL-1 gene 
rearrangements. It demonstrated that ALL-1, a highly intricate chromatin modifier, in acute 
leukemia is abnormal in its function (Cimino et al., 1997). 
The t (8;21) is found in 10–15% of myeloid  leukemia and gives rise to a fusion protein that 
contains the N-terminal portion of RUNX1 fused to nearly all of myeloid translocation gene 
on chromosome 8 (MTG8, also known as eight-twenty-one (ETO)) (Miyoshi et al., 1991, 
1993; Erickson et al., 1994). The fusion protein appears to function as a transcriptional 
repressor of RUNX1-regulated genes (Peterson et al., 2004). The t (12;21) is found in up to 
25% of pediatric B-cell acute leukemia and creates a chimerical gene encoding the TEL–
RUNX1 fusion protein (Golub et al., 1995; Nucifora et al., 1995). RUNX1 function is also 
impaired by the inv (16), which fuses the RUNX1 associating factor, core binding factor b 
(CBFb or polyoma enhancer binding protein 2 betas) to the smooth muscle myosin heavy-
chain gene MYH11, in approximately 8% of acute myeloid leukemia (Liu et al., 1993). Two 
SUV39H1 contact points within repression domain 2 of RUNX1, with one of these RUNX1 
domains also contacting HDAC1 and HDAC3, begins to provide a mechanistic basis for 
gene silencing mediated by RUNX1. Both Runt and RUNX1 are required for gene silencing 
during development and a central domain of RUNX1, termed repression domain 2 (RD2). 
RD2 contacts SUV39H1, a histone methyltransferase, via two motifs and that endogenous 
SUV39H1 associates with a Runx1-regulated repression element in murine erythroleukemia 
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cells. In addition, one of these SUV39H1-binding motifs is also sufficient forbidding to 
histone deacetylases 1 and 3, and both of these domains are required for full RUNX1-
mediated transcriptional repression. The association between RUNX1, histone deacetylases 
and SUV39H1 provides a molecular mechanism for repressor (E et al., 2006). 
The state of histone methylation in acute leukemia has been studied. Aberrant histone 
methylations showed downregulation of H3K4 methylation and upregulation of H3K9 
methylation in all acute leukemia. The methylation status of histone H3 at lysines 4 and 9 of 
mononuclear cells from 19 patients with acute leukemia, aged from 6 to 78, including AML 
and ALL and that from 9 individuals without leukemia were compared. The results showed 
that the level of H3K4 methylation was significantly lower in 19 AL patients than that in non 
leukemia (0.220±0.096 vs 0.447±0.186, P<0．01), while the level of H3K9 methylation was 
significantly higher (0.409 4±0.106 vs  0.168±0.015，P<0.01). These results clearly 
demonstrated that the patients with acute leukemias are hypomethylated at H3K4, and 
hypermethylated at H3K9. (Ma et al., 2010).  
3. Epigenetic therapy in acute leukemia 
The cause of most epigenetic diseases can be traced to the enzymes that establish them. A 
great deal of research has gone into the discovery of the modulators of these enzymes, 
which not only leads to a better understanding of the mechanism, but also to therapeutic 
possibilities. Fusion protein, such as MLL-MOZ, PML-RARA results mutations in HATs, 
HDACs and HMTas, and misregulating gene expression. Inactivation of tumor suppressor 
genes is central to the development of cancer. Silencing of these genes occurs by epigenetic 
means and inhibition of these factors lead to reversal of tumor suppressor gene silencing 
and inhibition of tumorigenesis (Gibbons et al., 2005). 
Chemical compound acting on epigenetic control of gene expression mainly fall into two 
broad categories: inhibitors of DNA methyltransferases and inhibitors of histone deacetylase 
(HDACi). Recently, compounds regulating histone methylations have been studied. These 
drugs have been used in phase I and II trials in patients with hematological and solid tumor. 
Some of them have been approved by FDA (U.S. Food and Drug Administration) to treat 
hematological disorders and solid tumor.  
Pharmacologic inhibition of DNA methylation causes the trapping of DNMTs and their 
targeted degradation results in re-expression of genes that have been aberrantly silenced by 
hypermethylation, concomitant with inhibition of clonal expansion and tumor cell growth, 
induction of cell differentiation, and cancer cell death (Issa, 2007). A number of DNA 
methylation inhibitors are currently under investigation, including the pyrimidine 
nucleoside analogs Decitabine (Dacogen, SuperGen, Inc., Dublin, CA) and Azacitidine 
(Vidaza, Celgene, Summit, NJ), and the nonucleoside inhibitor Hydralazine. Azacitidine and 
Decitabine are both approved by FDA for the treatment of a number of myelodysplastic 
syndrome subtypes, including refractory anemia and chronic myelogenous leukemia (CML) 
(Gal-Yam et al., 2008; Issa. 2007; Wong et al., 2007).  
Most current DNA-demethylating agents block the action of DNA methyltransferases 
(DNMTs), whose expression levels are usually moderately elevated in human tumors. The 
genetic inactivation of two DNMTs, DNMT1 and DNMT3B, induces demethylation of all 
known hypermethylated tumor-suppressor genes and remarkably slow growth. DNMTs 
have two binding sites: one for the cytosine residue and another for S-adenosyl- methionine. 
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It is expected that chemicals tightly binding any of these pockets will reduce the methylation 
rate because of competitive inhibition. The cytidine and 2-deoxycytidine analogs are the 
most extensively studied members of this class. The first analog tested to determine whether 
it was an inhibitor of DNA methylation was 5-azacytidine (5-aza-CR), which was first 
synthesized almost 50 years ago. 5-azacytidine could incorporate into DNA forming 
covalent adducts with cellular DNMT1, thereby depleting cells from enzyme activity and 
causing demethylation of genomic DNA as a secondary consequence. Schneider-Stock 
reported that 5-aza-CR caused a marked down-regulation of DNMT1 and DNMT3A mRNA 
levels, in contrast to a null effect on DNMT3B (Schneider-Stock, et al., 2005). In various in 
vitro experiments, 5-aza-CR treatment leads to re-expression of former silenced genes. The 
resulting DNA hypomethylation has been linked to the induction of cellular differentiation 
and altered expression of genes involved in tumor suppression. It was demonstrated to have 
a wide range of anti-metabolic activities when tested against cultured cancer cells and to be 
an effective chemotherapeutic agent for acute myelogenous leukemia. Their clinical efficacy 
in hematological malignancies has been demonstrated in vitro and in a series of phase I and 
II trials. Azacitidine was first approved by FDA in 2004 for the treatment of myelodyspalstic 
syndrome (MDS). The phase II trials recorded complete remission (CR), partial remission 
(PR) and hematological improvement (HI) rates of 15%, 2% and 27%, and of 17%, 0% and 
23% in the CALGB 8421 and CALGB 8921, respectively. A subsequent phase III randomized 
trial in 191 MDS patients reported an overall response rate of 60% on the Azacitidine arm 
(CR, 7%) compared with 5% of patients receiving supportive care (Silverman et al., 1993). A 
recent re-analysis of three CALGB trials by applying WHO classification and International 
Working Group (IWG) responds criteria confirmed those response figures, with 90% of 
patients achieving a response by six cycles; however, whereas quality of life significantly 
ameliorated, there was no improvement in overall survival in the whole patient population 
or in the separate classes of risk (Silverman et al,. 2006). Because of 5-azacytidine's general 
toxicity, other nucleoside analogs were favored as therapeutics. There is now a revived 
interest in the use of Decitabine (5-aza-2 -deoxycytidine) as a therapeutic agent for cancers in 
which epigenetic silencing of critical regulatory genes has occurred (Christman, 2006).  
Decitabine was approved by FDA in 2006 for the treatment of MDS. It is an analog of 
deoxycytidine that incorporates into DNA and forms irreversible covalent bonding with 
DNA-methyltransferases (Mtase) at cytosine sites targeted for methylation. That leads to 
DNA synthesis stalling and eventual degradation of DNA-Mtase. Resumption of DNA 
replication in the absence of Mtase results in gene hypomethylation and reactivation of gene 
expression, as has been demonstrated for multiple epigenetically inactivated loci (Karpf et 
al., 2002; Li et al., 1999; Toyota et al., 2002). At high doses, treated cells die via apoptosis 
triggered by the DNA adducts and DNA synthesis arrest. By contrast, at low doses, cells 
survive but change their gene expression profile to favor differentiation, reduced 
proliferation, and/or increased apoptosis. Thus, Decitabine has potentially dual effects on 
treated cells. Clinical development of Decitabine was initiated more than 2 decades ago, 
with classical phase I studies that defined 1500 to 2250 mg/m2 per course as the maximum 
tolerated dose (MTD), and demonstrated a short half-life for the drug ( Santini et al., 2001). 
In a multicenter, phase II study,  patients older than 60 years who had AML (i.e., ＞20% 
bone marrow blasts) and no prior therapy for AML were treated with Decitabine 20 mg/m2 
intravenously for 5 consecutive days of a 4-week cycle. Response was assessed by weekly 
CBC and bone marrow biopsy after cycle 2nd and after each subsequent cycle. Patients 
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continued to receive Decitabine until disease progression or an unacceptable adverse event 
occurred. Fifty-five patients (mean age, 74 years) were enrolled and were treated with a 
median of three cycles (range, 1 to 25 cycles) of Decitabine. The expert-reviewed overall 
response rate was 25% (complete response rate, 24%). The response rate was consistent 
across subgroups, including in patients with poor-risk cytogenetics and in those with a 
history of myelodysplastic syndrome. The overall median survival was 7.7 months, and the 
30-day mortality rate was 7%. The most common toxicities were myelosuppression, febrile 
neutropenia, and fatigue (Amanda et al., 2010). Decitabine has been used also in Imatinib-
resistant CML (Issa, et al., 2005) or in combination with Imatinib in patients with accelerated 
or leukaemic-phase CML (Oki et al., 2007).  
Several classes of HDACIs have been identified, including: (a) short-chain fatty acids  (e.g., 
butyrates); (b) organic hydroxamic acids (e.g., TSA and hybrid polar compounds [HPCs]); 
(c) cyclic tetrapeptides containing a 2-amino-8-oxo 9,10-epoxy-decanoyl (AOE) moiety (e.g., 
trapoxin); and (d) cyclic peptides not containing the AOE moiety (e.g., FR901228, apicidin). 
HDAC inhibitors (HDACIs) also impact epigenetic expression. They display ability to affect 
several cellular processes which are dysregulated in neoplastic cells. One of the mechanism 
is that HDACIs could upregulate acetylation of histones, activate tumor suppressor genes 
and repress oncogenes. They are potent inducers of differentiation with arrest of  cells in the 
G1 but sometimes also in the G2 phase. They activate transcription of the cyclin-dependent 
kinase (CDK) inhibitor WAF1 which are responsible for cell cycle arrest and subsequent cell 
differentiation (Rocchi et al., 2005). Another mechanism is that they can induce apoptosis in 
vitro and in vivo by activating both the death-receptor and intrinsic apoptotic pathway 
(Nebbioso et al., 2005; Peart et al., 2005) and increase p53 acetylation diminishes Mdm2-
mediated ubiquitination and the subsequent proteasome-facilitated degradation (Luo et al., 
2000). In addition, HDAC inhibitors might lead to activation of the host immune response 
and inhibition of tumor angiogenesis by multifactorial processes.  
Drugs belonging to several classes of HDACIs are in clinical trials. TSA is a fermentation 
product of Streptomycin with anti-fungal properties and was found to be a reversible 
inhibitor of HDACs in vitro, as well as in vivo. It is a highly potent HDAC inhibitor. Because 
of its known pharmacology, it has come to be a “reference” substance in research aimed at 
changing the acetylation-deacetylation state of proteins for clinical as well as research 
applications. Januchowski R et al. found that TSA down-regulate DNMT1 mRNA and 
protein expression in Jurkat T leukemia cells clone E6-1. They also observed that TSA 
decreased DNMT1 mRNA stability and reduced this transcript half-life from approximately 
7 to 2 h. The finding suggests that TSA not only alters histone acetylation, but also may 
affect DNA methylation (Januchowski et al, 2007). 
Vorinostat, suberoylanilide hydroxamic acid (SAHA), is an inhibitor of class I and II HDAC 
enzymes, promoting cell-cycle arrest and apoptosis of cancer cells (Marks et al., 2007). 
Relevant target genes have been characterized through gene expression analysis (Peart et al., 
2005). SAHA has been shown to have clinical activity in a transgenic animal model of 
therapy resistant acute promyelocytic leukemia, restoring sensitivity to retinoic acid, and to 
induce differentiation of human breast cancer cells (He et al., 2001). It has been approved by 
FDA for the treatment of CTCL in 2006. In phase I clinical trials, it was demonstrated that 
the maximum tolerated dose was 400 mg qd and 200 mg bid for continuous daily dosing 
and 300 mg bid for 3 consecutive days per week dosing. Histones isolated from peripheral-
blood mononuclear cells showed consistent accumulation of acetylated histones post-
therapy, and enzyme-linked immunosorbent assay demonstrated a trend towards a dose-
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It is expected that chemicals tightly binding any of these pockets will reduce the methylation 
rate because of competitive inhibition. The cytidine and 2-deoxycytidine analogs are the 
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levels, in contrast to a null effect on DNMT3B (Schneider-Stock, et al., 2005). In various in 
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replication in the absence of Mtase results in gene hypomethylation and reactivation of gene 
expression, as has been demonstrated for multiple epigenetically inactivated loci (Karpf et 
al., 2002; Li et al., 1999; Toyota et al., 2002). At high doses, treated cells die via apoptosis 
triggered by the DNA adducts and DNA synthesis arrest. By contrast, at low doses, cells 
survive but change their gene expression profile to favor differentiation, reduced 
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continued to receive Decitabine until disease progression or an unacceptable adverse event 
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mediated ubiquitination and the subsequent proteasome-facilitated degradation (Luo et al., 
2000). In addition, HDAC inhibitors might lead to activation of the host immune response 
and inhibition of tumor angiogenesis by multifactorial processes.  
Drugs belonging to several classes of HDACIs are in clinical trials. TSA is a fermentation 
product of Streptomycin with anti-fungal properties and was found to be a reversible 
inhibitor of HDACs in vitro, as well as in vivo. It is a highly potent HDAC inhibitor. Because 
of its known pharmacology, it has come to be a “reference” substance in research aimed at 
changing the acetylation-deacetylation state of proteins for clinical as well as research 
applications. Januchowski R et al. found that TSA down-regulate DNMT1 mRNA and 
protein expression in Jurkat T leukemia cells clone E6-1. They also observed that TSA 
decreased DNMT1 mRNA stability and reduced this transcript half-life from approximately 
7 to 2 h. The finding suggests that TSA not only alters histone acetylation, but also may 
affect DNA methylation (Januchowski et al, 2007). 
Vorinostat, suberoylanilide hydroxamic acid (SAHA), is an inhibitor of class I and II HDAC 
enzymes, promoting cell-cycle arrest and apoptosis of cancer cells (Marks et al., 2007). 
Relevant target genes have been characterized through gene expression analysis (Peart et al., 
2005). SAHA has been shown to have clinical activity in a transgenic animal model of 
therapy resistant acute promyelocytic leukemia, restoring sensitivity to retinoic acid, and to 
induce differentiation of human breast cancer cells (He et al., 2001). It has been approved by 
FDA for the treatment of CTCL in 2006. In phase I clinical trials, it was demonstrated that 
the maximum tolerated dose was 400 mg qd and 200 mg bid for continuous daily dosing 
and 300 mg bid for 3 consecutive days per week dosing. Histones isolated from peripheral-
blood mononuclear cells showed consistent accumulation of acetylated histones post-
therapy, and enzyme-linked immunosorbent assay demonstrated a trend towards a dose-
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dependent accumulation of acetylated histones from 200 to 600 mg of oral SAHA. There was 
one complete response, three partial responses, two unconfirmed partial responses, and 22 
(30%) patients remained on study for 4 to 37+ months (William et al., 2005). Phase I studies 
with vorinostat (SAHA) have also resulted in complete and partial responses (CRs and PRs, 
respectively) in both refractory solid and hematological malignancies. The major adverse 
events (AEs) observed with vorinostat differ by route of administration, i.v. or oral, possibly 
due to differences in pharmacokinetics. Oral vorinostat produced fatigue, diarrhea, anorexia 
and dehydration as major AEs, whereas i.v. vorinostat produced myelosuppression and 
thrombocytopenia as major AEs (O’Connor et al., 2006). In another phase I/II study, 
vorinostat was used to treat 41 patients with leukaemia or MDS who were relapsed or 
refractory to previous therapy or who were not candidate to chemotherapy. Hematological 
improvement was observed in 17% of cases including two complete responses in AML. 
Evidence of histone H3 acetylation was found in peripheral blood and bone marrow cells, 
and down-regulation of proliferation-associated genes was associated with hematological 
improvement (Garcia-Manero et al., 2008).  
Phenylbutyrate is a fatty acid with HDACi activity that has been studied extensively in 
patients with solid tumors, leukemia, and myelodysplastic syndromes (MDS). Depsipetide 
(FK-228) is a cyclic tetrapeptide with potent HDACi activity especially of Class I HDACs. 
Depsipeptide also has been studied in several clinical trials.  
Valproic Acid is a short chain fatty acid that is clinically used as an anticonvulsant. It has 
excellent bioavailability and can be given orally. Its elimination half-life is 6–17 hours. And 
overall, it has a good toxicity profile (Garcia-Manero G &Issa, 2005). Clinical activity has 
been demonstrated in studies in MDS patients who received VPA orally on a continuous 
schedule to maintain a serum concentration of 50–100 mg/ml. The first pilot study reported 
a 44% overall response rate in MDS with a median response duration of 4 months 
(Kuendgen et al., 2004). In a follow-up study on 122 patients with MSD and AML, an overall 
response rate of 20% was reported, including one CR. A higher percentage of response was 
observed in low-risk MDS, according to morphological subtype (Kuendgen et al., 2007). 
VPA has been used in combination with all-trans retinoic acid in patients with acute 
leukaemia, eventually in association with cytotoxic therapy, without appreciable or with 
only minor improvements (Raffoux et al.,2005; Pilatrino et al., 2005; Bug et al., 2005).  
The field of HMTase is relatively unexplored with just a few examples of which majority are 
substrate analogues. The only specific inhibitor is Chaetocin, a SU(VAR)3–9 inhibitor 
(Greiner et al., 2005) and the documented analogue inhibitors are AMI-1, analogue inhibitor 
of PRMT (Cheng et al., 2004). Chaetocin killed human tumor cell lines and primary 
myeloma cells in vitro whereas normal human B cells were insensitive to the compound 
(Isham et al., 2007). We have designed siRNA segments targeting JARID1B and SU (VAR) 3–
9 gene and transfected them into tumor cells. The result showed that JARID1B siRNA 
upregulated histone methylated H3K4 remarkbly and histone acetylation of H3 slightly. SU 
(VAR) 3–9 siRNA downregulated H3K9, upregulated histone acetyaltion H3. JARID1B and 
SU (VAR) 3–9 siRNA upregulated P27 and suppressed the proliferation in tumor cells. The 
expression of BCL-2, procaspase-9, procaspase-3, and C-myc decreased and cells apoptosis 
induced. (Cai, et al., unpublished; Ma et al., unpublished).  
Sinefungin is another analogue inhibitor of Arginine methyltransferase (Amur et al., 1986). 
Since the role of HMTases in cancer manifestations is well established, these inhibitors will 
be of great use for cancer treatment. The small molecule inhibitor BIX-01294 inhibited 
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methylation at H3K9 at several G9a-targeting genes. 3-Deazaneplanocin (DZNep) is a 
compound capable of depleting levels of the polycomb-recessive complex 2 (PRC2) 
components EZH2, SUZ12, and EED. Treatment of tumor cell lines with DZNep inhibited 
methylation at H3K27 but not H3K9 reactivated a series of genes that are transcriptionally 
repressed by PRC2 and induced potent tumor cell-selective apoptosis (Tan et al., 2007). An 
alternative way to reactivate epigenetically silencing genes is to inhibit the activity of 
histone demethylases. Recently, polyamine-based inhibitors of LSD1 have been developed 
that induce mono- and di-methylation at H3K4 and concomitant reactivation of previously 
silenced genes in treated tumor cell lines (Huang et al., 2007). The biological effects of these 
agents have not yet been evaluated but they represent an important step forward in the 
development of new agents to target the epigenetics. 
Both HDAC inhibitors and DNA demethylating agents have shown clinical efficacy as 
single agents; yet combination of the two therapies has been shown to have strong 
synergistic effects on the reactivation of silenced genes and antiproliferative and cytotoxic 
effects on cancer cells (Bhalla et al., 2005; Glaser et al., 2007). 
Combination therapies employing DNMT inhibitors and HDACIs together or with other 
agents are being pursued clinically. The combination of azacitidine with histone deacetylase 
inhibitors, such as sodium phenylbutyrate (Maslak et al., 2006), valproic acid and all-trans 
retinoic acid (Soriano et al., 2007), has been explored with little evidence of improvement in 
patients with leukaemia or high-risk MDS. 
A phase I/II trial of vorinostat in combination with azacitidine (NCT00392353) are currently 
underway; preliminary results from phase I of the combination trial indicated that the 
therapy is safe and well tolerated and appears superior to azacitidine alone for time to 
response, overall response and CR rate (Silverman et al., 2008). 
Isothiocyanates has been found potential anti-tumor agents. Natural isothiocyanates occur 
as thioglucoside conjugates, i.e. glucosinolate, in a wide variety of cruciferous vegetables 
including broccoli, cabbages, watercress, and Brussel's sprouts. The isothiocyanates (ITS) are 
released when the vegetables are cut or masticated. The research currently demonstrated 
that natural and synthetic isothiocyanates are potent cancer chemopreventive agents in a 
number of carcinogen-induced cancer models in rodents. The primary mechanism is the 
blocking of initiation of carcinogenesis via inhibiting cytochrome P450s, and inducing 
detoxifying enzymes to remove carcinogens (Chiao et al, 2002). We have demonstrated that 
Phenylhexyl isothiocyanate (PHI), one of ITC, a man-made isothiocyanate, may induce cell 
cycle blocking and apoptosis via altering epigenetic modification. PHI inhibited cell cycle 
CDK activity and up-regulated p21WAF1 (p21) in cancer cells. Exposure of HL-60 and Molt-
4 leukemia cells to PHI induced G1 arrest and apoptosis. Additionally, PHI reduced the 
expression of HDAC and increased the level of acetyl transferase p300, in favor of 
accumulation of acetylated histones. Within hours, global acetylation of histones was 
enhanced. PHI further mediated selective alterations of histone methylation, with 
upregulated H3K4 and downregulated H3K9, a pattern consistent to the marks of 
transcription competent chromatins. ChIP assay showed that chromatins from cells exposed 
to PHI contained more p21 DNA in the precipitates of hyperacetylated histones, indicating 
more accessibility of transcription machinery to the p21 promoter after chromatin unfolding 
(Ma XD et al., 2006; Xiao et al., 2010). On the other hand, PHI could induce DNA 
demethylation in Molt-4 cells. Hypermethylation of gene p15 was reversed and activation 
transcription could be de novo by PHI. Hypermethylation of gene p15 was attenuated and 
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dependent accumulation of acetylated histones from 200 to 600 mg of oral SAHA. There was 
one complete response, three partial responses, two unconfirmed partial responses, and 22 
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and dehydration as major AEs, whereas i.v. vorinostat produced myelosuppression and 
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vorinostat was used to treat 41 patients with leukaemia or MDS who were relapsed or 
refractory to previous therapy or who were not candidate to chemotherapy. Hematological 
improvement was observed in 17% of cases including two complete responses in AML. 
Evidence of histone H3 acetylation was found in peripheral blood and bone marrow cells, 
and down-regulation of proliferation-associated genes was associated with hematological 
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methylation at H3K9 at several G9a-targeting genes. 3-Deazaneplanocin (DZNep) is a 
compound capable of depleting levels of the polycomb-recessive complex 2 (PRC2) 
components EZH2, SUZ12, and EED. Treatment of tumor cell lines with DZNep inhibited 
methylation at H3K27 but not H3K9 reactivated a series of genes that are transcriptionally 
repressed by PRC2 and induced potent tumor cell-selective apoptosis (Tan et al., 2007). An 
alternative way to reactivate epigenetically silencing genes is to inhibit the activity of 
histone demethylases. Recently, polyamine-based inhibitors of LSD1 have been developed 
that induce mono- and di-methylation at H3K4 and concomitant reactivation of previously 
silenced genes in treated tumor cell lines (Huang et al., 2007). The biological effects of these 
agents have not yet been evaluated but they represent an important step forward in the 
development of new agents to target the epigenetics. 
Both HDAC inhibitors and DNA demethylating agents have shown clinical efficacy as 
single agents; yet combination of the two therapies has been shown to have strong 
synergistic effects on the reactivation of silenced genes and antiproliferative and cytotoxic 
effects on cancer cells (Bhalla et al., 2005; Glaser et al., 2007). 
Combination therapies employing DNMT inhibitors and HDACIs together or with other 
agents are being pursued clinically. The combination of azacitidine with histone deacetylase 
inhibitors, such as sodium phenylbutyrate (Maslak et al., 2006), valproic acid and all-trans 
retinoic acid (Soriano et al., 2007), has been explored with little evidence of improvement in 
patients with leukaemia or high-risk MDS. 
A phase I/II trial of vorinostat in combination with azacitidine (NCT00392353) are currently 
underway; preliminary results from phase I of the combination trial indicated that the 
therapy is safe and well tolerated and appears superior to azacitidine alone for time to 
response, overall response and CR rate (Silverman et al., 2008). 
Isothiocyanates has been found potential anti-tumor agents. Natural isothiocyanates occur 
as thioglucoside conjugates, i.e. glucosinolate, in a wide variety of cruciferous vegetables 
including broccoli, cabbages, watercress, and Brussel's sprouts. The isothiocyanates (ITS) are 
released when the vegetables are cut or masticated. The research currently demonstrated 
that natural and synthetic isothiocyanates are potent cancer chemopreventive agents in a 
number of carcinogen-induced cancer models in rodents. The primary mechanism is the 
blocking of initiation of carcinogenesis via inhibiting cytochrome P450s, and inducing 
detoxifying enzymes to remove carcinogens (Chiao et al, 2002). We have demonstrated that 
Phenylhexyl isothiocyanate (PHI), one of ITC, a man-made isothiocyanate, may induce cell 
cycle blocking and apoptosis via altering epigenetic modification. PHI inhibited cell cycle 
CDK activity and up-regulated p21WAF1 (p21) in cancer cells. Exposure of HL-60 and Molt-
4 leukemia cells to PHI induced G1 arrest and apoptosis. Additionally, PHI reduced the 
expression of HDAC and increased the level of acetyl transferase p300, in favor of 
accumulation of acetylated histones. Within hours, global acetylation of histones was 
enhanced. PHI further mediated selective alterations of histone methylation, with 
upregulated H3K4 and downregulated H3K9, a pattern consistent to the marks of 
transcription competent chromatins. ChIP assay showed that chromatins from cells exposed 
to PHI contained more p21 DNA in the precipitates of hyperacetylated histones, indicating 
more accessibility of transcription machinery to the p21 promoter after chromatin unfolding 
(Ma XD et al., 2006; Xiao et al., 2010). On the other hand, PHI could induce DNA 
demethylation in Molt-4 cells. Hypermethylation of gene p15 was reversed and activation 
transcription could be de novo by PHI. Hypermethylation of gene p15 was attenuated and 
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p15 gene was activated de novo after 5 days exposure to PHI in a concentration-dependent 
manner(0-40μM). DNMT1 and DNMT3B were inhibited by PHI (P<0.05). Alteration of 
DNMT3A was not significant at those concentrations (Jiang et al., 2010). PHI has multi-
target in epigenetic, it might represent a combination target for correcting aberrant histone 
acetylation, histone methylation and DNA methylation, and a promising potential 
epigenetic regulators for preventing the progression of leukemia.  
4. Conclusion 
Epigenetic disorder may be the mechanism in acute leukemia. It is now understood that 
deregulated epigenetic mechanisms can cause, as well as compound, the effects of oncogenic 
mutations to promote tumor development and growth. Epigenetic therapy is a promising 
approach for the prevention and treatment of malignancies. The discovery of modulators of 
HATs and HMTases which are highly specific may bring a new era of epigenetics based 
drugs. 
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approach for the prevention and treatment of malignancies. The discovery of modulators of 
HATs and HMTases which are highly specific may bring a new era of epigenetics based 
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1. Introduction 
Acute myeloid leukemia (AML) is a broad range of disorders that are all characterized by a 
block in the differentiation and by uncontrolled proliferation of hematopoietic progenitor 
cells. AML is the most frequent hematological malignancy in adults, with an annual 
incidence of three to four cases per 100 000 individuals. Specific recurrent chromosomal 
abnormalities can be identified in approximately 55% of cases by cytogenetic analysis. These 
detected chromosomal aberrations are the most important tool to classify patients at their 
initial diagnosis and to divide them into favorable, intermediate and unfavorable 
subgroups. The age of the patient is also an important prognostic factor (Juliusson et al., 
2009; Szotkowski et al., 2010). However, approximately 45% of adult patients with AML 
have normal karyotype (cytogenetically normal /CN/-AML patients) and are usually 
classified as an intermediate risk group (Mrozek et al., 2007; Smith et al., 2011). These 
patients have a 5-year overall survival rate between 24% and 42%, but clinical outcome may 
vary greatly.  
The prognosis of AML with normal cytogenetics may be further subdivided based on 
genetic lesions. Even though a growing number of genetic lesions have been identified in 
CN-AML, about 25% CN-AML patients do not carry any of the currently known mutations. 
Therefore, many research groups conducted retrospective studies to find some candidate 
molecular markers that could identify good and poor risk AML patients with normal 
karyotype. In recent years, a number of gene mutations (NPM1 /nucleophosmin/, FLT3 
/Fms-like tyrosine kinase 3/, MLL-PTD /mixed lineage leukemia-partial tandem 
duplications/, C/EBPα /CCAAT/enhancer-binding protein alpha/CEBPA/, WT1 /Wilms 
tumor 1/, DNMT3A /DNA methyltransferase 3A/, IDH1 and IDH2 /isocitrate 
dehydrogenase/, CBL /Casitas B-lineage lymphoma/and others), as well as deregulated 
expression of genes (BAALC /brain and acute leukemia cytoplasmic/, ERG /ETS-related 
gene/, MN1 /meningioma 1/, EVI1 /ecotropic virus integration 1/, AF1q /ALL1-fused 
gene chromosome 1q/, PRAME /preferentially expressed antigen in melanoma/, WT1) 
have been found and further molecular markers (gene expression profiles and microRNA 
expression signatures) are studied and incorporated into clinical practice (Baldus & 
Bullinger, 2008; Bullinger & Valk, 2005; Bullinger 2006;  Kohlmann et al, 2010; Marcucci et 
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al., 2009, 2011a,b; Motyckova & Stone, 2010; Ramsingh et al., 2010; Schlenk et al., 2008; 
Wouters et al., 2009). It is necessary to improve current classification systems in order to 
reflect better the molecular heterogeneity of CN-AML (Döhner et al., 2010; Vardiman et al., 
2009).  
In addition, some of the genetic abnormalities have also been found to be useful for minimal 
residual disease (MRD) monitoring and as potential therapeutic targets in the development 
of new agents for AML therapy. The aim of monitoring of MRD is the identification of cases 
with a very high risk of relapse who then can be treated much earlier and more effectively 
(Jaeger & Kainz, 2003; Schnittger et al., 2009; Shook et al., 2009).   
Knowing the status of FLT-3 and other molecular markers (mutations and gene expression 
described above together with gene expression profiling) in CN-AML patients has not only 
prognostic significance but is important in the treatment based on these molecular markers. 
For example, patients with FLT3-ITD (an internal tandem duplication of the FLT3 receptor 
tyrosine kinase gene), who are not candidates for induction therapy and allogeneic stem cell 
transplantation may respond to an FLT3 inhibitor used in combination with chemotherapy 
or without chemotherapy. Deregulation of microRNA (miR) in CN-AML patients may act as 
complementary hit in the multisteps mechanism of leukemogenesis and has been not only 
used to identify subsets of  CN-AML patients  with diversified outcome but  will certainly 
play a role in the future of treatment in  new therapeutic strategies.  Thus, miR expression 
profiling has diagnostic and prognostic significance.  
2. Methods for the detection of gene mutations and expression 
2.1 Sample material 
After informed consent patient- or healthy individual-derived mononuclear cells were 
isolated from bone marrow (BM) or peripheral blood cells by a ficoll  (for example Ficoll-
Paque PLUS, GE Healthcare Bio-Sciences AB, Uppsala, Sweden) density gradient 
centrifugation. Total RNA and genomic DNA were isolated. Yield and quality of the RNA 
were measured by spectrophotometric analysis. Each sample was assessed for the integrity 
of RNA by discrimination of 18S and 28 S ribosomal RNA on 1% agarose gels using 
ethidium bromide for visualization. Complementary DNA was synthetised from total RNA 
using  reverse transcriptase (for example SuperScript II reverse transcriptase (Invitrogen 
Corporation, Carlsbad, CA, USA). 
2.2 Detection of gene mutations 
Most mutation detection methods use PCR (polymerase chain reaction) to amplify the 
region of DNA of interest. Mutant DNA has a different secondary structure (conformation) 
compared with that of the normal DNA. Frequently, this difference in conformation results 
in altered gel electrophoresis mobility of the mutant DNA species. Single-strand 
conformation polymorphism (SSCP) method (Orita et al., 1989; Perry, 1999) based on this 
conformation change is a fast and efficient method for detecting many types of aberrations, 
including point mutations, insertions, deletions and rearrangements (Frayling, 2002; Kutach 
et al., 1999). SSCP has the sensitivity to identify single nucleotide changes in the DNA 
sequence. Thermally denaturated DNA is electrophoresed and mutation is detected as 
aberrantly migrating bands on the electrophoresis gel. Analyzed PCR products must be less 
than 300 bp and preferably less than 200 bp in size because the method is increasingly 
inefficient with increasing size of the PCR product. Another technique, related to SSCP is 
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DNA heteroduplex analysis (Frayling, 2002). Both SSCP and heteroduplex analysis can be 
carried on fluorescent DNA analysers at a controlled temperature. The related techniques 
DGGE (denaturing gradient gel electrophoresis) and TGGE (thermal gradient gel 
electrophoresis) arevery efficient, but they require specially designed PCR primers of 
increased length (Frayling, 2002). Sequencing of the mutated PCR product is almost 
universally carried out using dideoxy terminator chemistry .   
High resolution melting  (HRM) analysis is rapidly becoming the most important initial 
screen procedure for potential mutations (Razga et al., 2009; Tan et al., 2008; Vaughn & 
Elenitoba-Johnson, 2004; Wittwer, 2009).  PCR amplification and subsequent HRM analysis 
are sequentially performed in the one tube.  HRM is more simple than denaturing high – 
performance liquid chromatography (DHPLC), which can be also used after PCR 
amplification for mutation detection (Bianchini et al., 2003; Kosaki et al., 2005; Roti et al., 
2006). Real-time PCR machine with HRM capability, for example LightCycler 480 High – 
Resolution Melting Master (Roche Diagnostics) has been successfully used for PCR 
amplification and HRM analysis. PCR reactions must be designed in the maner to avoid 
primer dimers and non-specific amplification. DNA has to be prepared in a uniform fashion 
to avoid variation in salt concentration with effect on the melting. HRM significantly 
reduces the quantity of samples that is necessary for sequencing with consequent reduction 
of cost and labour and enables rapid detection of mutations.  The melting curves are 
normalized and temperature shifted to allow samples to be directly compared. Difference 
plots are generated by selecting a negative (nonmutated) control as the base-line and the 
fluorescence of all other samples is plotted relative  to this negative control. Significant  
differences in fluorescence are indicative of mutations which must be detected by 
sequencing. Noordermer et al. (2010) used HRM curve analysis for rapid identification of 
IDH1 and IDH2 mutations in AML.  
Currently, identification of mutations by PCR and direct nucleotide sequencing is used as 
the gold standard.  The great progress  was achieved in DNA sequencing technology in last 
ten years after the end of Human Genome Project (Mardis, 2011).  The Roche/454, Life 
Technologies SOliD and Illumina instruments have been used to sequence the complete 
tumor and normal genomes in order to identify mutations that alter the protein-coding 
genes. Whole genome sequencing is now possible at a reasonable cost  per tumor and 
normal genome of around $ 30,000 and can be completed in about 8 days. A pilot study of 
high-throughput, sequence-based mutational profiling of primary AML cell genomes was 
done eight years ago (Ley et al., 2003). Whole genomic DNA sequencing of  a cytogenetically 
normal FAB M1 AML patient was done three years ago and discovered ten genes with 
acquired mutations (Ley et al., 2008).  Eight novel somatic mutations were described in 
genes not previously implicated in AML pathogenesis. Two well-known AML-associated 
mutations, including FLT3-ITD, which constitutively activates kinase signaling and a four 
base insertion in exon 12 of the NPM1 gene were also detected. Mardis et al. (2009) 
identified twelve somatic mutations within the coding sequences of genes and 52 somatic 
point mutations in conserved or regulatory portions of the AML genome. Two known 
mutations in NRAS and NPM1 and ten novel mutations were detected. One of these 
mutations (missense R132C mutation in IDH1 gene) is today included in many mutational 
screening of AML patients. The more efficient, faster and cheaper approach will be 
sequencing of coding regions (the cDNA transcriptome) but the abundance of transripts can 
vary and some mutations can be missed (Greif et al., 2011). The size of the transcriptome is 
about  ten times shorter than a diploid human genome  
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Mutations in molecular markers can be present in low abundance within a high background 
of wild type sequence that may only differ from mutant at a single nucleotide. Several 
methods exist for detection of somatic mutations by real-time PCR. These methods include 
use of allele-specific competitive blocker PCR (Orou et al., 1995),  blocker-PCR (Seyama et 
al., 1992), real-time genotyping with locked nucleic acids (Ugozzoli et al., 2004), the 
amplification refractory mutation system (Newton et al., 1989), and fluorescent amplicon 
generation as a novel real-time PCR technology (Amicarelli et al., 2007). 
Mutated NPM1 is localised in the cytoplasm and not in the nucleus (Bolli et al., 2007; Falini 
et al., 2006; Liso et al., 2008; Oelschlaegel et al., 2010). Immunohistochemical detection of 
cytoplasmic nucleophosmin is performed with monoclonal antibody or by Western blotting  
(Falini et al., 2006, 2009, 2010a; Martelli et al. 2008). 
2.3 Technique of real-time PCR (RQ-PCR) for marker gene expression evaluation 
RQ-PCR permits accurate quantification of PCR products during the exponential phase of 
the PCR amplification process. Three main types of this analysis are used: (1) RQ-PCR using 
the hydrolysis probe format (“TaqMan probe“);  (2)  RQ-PCR using the hybridization probe 
format;  and (3)  RQ-PCR using SYBR Green Dye (Kern et al., 2005).  Analysis with TaqMan 
probe uses 5´-3´ exonuclease activity of the Thermus aquaticus (Taq) polymerase to detect and 
quantify the PCR product. The hydrolysis probe  is positioned within the target sequence 
and is conjugated with a reporter fluorochrome at the 5´ end and a quencher fluorochrome 
at the 3´ end. The quencher avoids the reporter from emission of a fluorescence signal as 
long as the probe is intact and both fluorochromes are in the close proximity. Upon 
amplification of the target sequence, the hydrolysis probe is displaced from the DNA strand 
by the Taq polymerase and subsequently hydrolysed by the 5´-3´ exonuclease activity of the 
Taq polymerase. This results in displacement of of the reporter from the quencher and the 
fluorescence of the reporter becomes detectable. 
Generally two quantification types (relative or absolute) in RQ-PCR are possible.  A relative 
quantification based on relative expression of a target gene versus a reference gene is 
adequate for the most purposes. For absolute quantification, based either on an internal or 
an external calibration curve (Bustin et al., 2005; Ptaffl, 2001, Ptaffl et al. 2002), the 
methodology must be highly validated and the identical LightCycler PCR amplification 
efficiencies for standard material and target cDNA must be confirmed. 
2.4 Genes and microRNAs microarrays 
RNA was extracted using Trizol reagent  and processed for Affymetrix U133 plus 2.0 
GeneChip (Affymetrix, Santa Clara, CA) hybridizations. Briefly, from 5 µg total RNA, 
double-stranded cDNA was prepared with the use of the T7-Oligo(dT) primer (Affymetrix). 
In vitro transcription for amplification and biotinylation of the RNA transcript was 
performed with the BioArray HighYield RNA Transcript Labeling Kit (T7; Enzo Life Science, 
Farmingdale, NY). Biotin-cRNA (10 µg) was fragmented and hybridized onto the U133 plus 
2.0 GeneChip for 16 hours at 45°C and labelled with Cy-3-streptavidin conjugate according 
to manufacturer protocols. Scanned images were converted to CEL files using GCOS 
software (Affymetrix). For the miRNA microarray chips, biotinylated first-strand cDNA was 
synthesized in reverse transcription from 2.5 to 5.0 µg total RNA using biotin-labeled 
random octamer oligo primer from pretreatment BM and blood mononuclear cell samples 
and hybridized to miRNA microarray chip KCC/TJU containing 368 probes in triplicate, 
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corresponding to 245 human miRNA genes. After hybridization for 18 hours at 25°C and 
washing, direct detection of the biotin-containing transcripts by streptavidin-Alexa647 
conjugate was done and processed slides were scanned. Expression profiles were analyzed 
in GENESPRING software(Silicon Genetics, Redwood City, CA). 
3. Mutations in the molecular markers 
3.1 Mutations in the NPM1 gene 
Nucleophosmin (NPM1, also called nucleolar protein B23, numatrin or NO38) is a 
multifunctional phosphoprotein which contains 294 amino acids (Okuwaki et al., 2006). 
NPM1 is one of the three nucleophosmin isoforms which are generated through alternative 
splicing. NPM1 resides predominantly in the nucleoli, but also continuously shuttles 
between nucleus and cytoplasm (Frehlick et al., 2006).  The NPM1 gene is located on 
chromosome 5q35 in humans and is composed of 12 exons (Chan et al., 1989).  NPM1 is 
essential for processing and transportation of ribosomal RNA and proteins, molecular 
chaperoning, and regulation of the stability  of tumor suppressors, such as p53 and ARF 
(Borer et al., 1989; Colombo et al., 2002; Enomoto et al., 2006; Herrera et al., 1995; Li & Hann, 
2009; Maggi et al., 2008; Savkur & Olson, 1998; Yu et al., 2006). The ARF tumor suppressor is 
a protein that is transcribed from an alternate reading frame of the  inhibitor of cyclin-
dependent kinase CDK4. NPM1 can affect DNA replication, repair and transcription by 
interacting with the components of chromatin such as histones and chromatin remodeling 
proteins  (Amin et al., 2008a,b; Angelov et al., 2006; Koike et al., 2010). NPM1 plays 
important roles in cell cycle (Ugrinova et al., 2007; Xiao et al., 2009). NPM1 may 
preferentially promote ribosome biogenesis in G1, facilitate DNA replication during S-phase 
while supporting chromosome segregation in mitosis (Hisaoka et al., 2010). 
Almost 40% of  CN-AML patients have mutations in exon 12 of the NPM1 gene which result 
in loss of tryptophan residues normally required for NPM1 binding to the nucleoli and in 
the generation of an additional nuclear export signal motif at the C-terminus of NPM1 
which causes its abnormal cytoplasmic localization (Bolli et al., 2007; Falini et al., 2006; Liso 
et al., 2008; Oelschlaegel et al., 2010). These mutations are the most common genetic 
alterations in adult CN-AML patients and are associated with female sex, higher white 
blood count, increased blast percentage, and low or absent CD34 expression. Cytoplasmic 
nucleophosmin leukemic mutant is also rarely generated by a exon-11 NPM1 mutation 
(Albiero et al., 2007). Acute myeloid leukemias with mutated NPM1 (NPM1c+)  have 
distinct characteristics, including a significant association with a normal karyotype, 
involvement of different hematopoietic lineages, a specific gene-expression profile and 
clinically, a better response to induction therapy and a favorable prognosis (Meani & 
Alcalay, 2009; Rau & Brown, 2009, Falini et al., 2010). NPM1c+ maintains the capacity of 
wild-type NPM to interact with a variety of cellular proteins, and impairs their activity by 
delocalizing them to the cytoplasm. NPM1c+  specifically inhibits the activities of the cell-
death proteases, caspase-6 and -8, through direct interaction with their cleaved, active 
forms, but not the immature procaspases. NPM1c+ not only affords protection from death 
ligand-induced cell death but also suppresses caspase-6/-8-mediated myeloid 
differentiation (Leong et al., 2010). 
After the discovery of NPM1-mutated AML in 2005 and its subsequent inclusion as a 
provisional entity in the 2008 World Health Organization classification of myeloid 
neoplasms, several controversial issues remained to be clarified (Falini, 2011). It was unclear 
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amplification refractory mutation system (Newton et al., 1989), and fluorescent amplicon 
generation as a novel real-time PCR technology (Amicarelli et al., 2007). 
Mutated NPM1 is localised in the cytoplasm and not in the nucleus (Bolli et al., 2007; Falini 
et al., 2006; Liso et al., 2008; Oelschlaegel et al., 2010). Immunohistochemical detection of 
cytoplasmic nucleophosmin is performed with monoclonal antibody or by Western blotting  
(Falini et al., 2006, 2009, 2010a; Martelli et al. 2008). 
2.3 Technique of real-time PCR (RQ-PCR) for marker gene expression evaluation 
RQ-PCR permits accurate quantification of PCR products during the exponential phase of 
the PCR amplification process. Three main types of this analysis are used: (1) RQ-PCR using 
the hydrolysis probe format (“TaqMan probe“);  (2)  RQ-PCR using the hybridization probe 
format;  and (3)  RQ-PCR using SYBR Green Dye (Kern et al., 2005).  Analysis with TaqMan 
probe uses 5´-3´ exonuclease activity of the Thermus aquaticus (Taq) polymerase to detect and 
quantify the PCR product. The hydrolysis probe  is positioned within the target sequence 
and is conjugated with a reporter fluorochrome at the 5´ end and a quencher fluorochrome 
at the 3´ end. The quencher avoids the reporter from emission of a fluorescence signal as 
long as the probe is intact and both fluorochromes are in the close proximity. Upon 
amplification of the target sequence, the hydrolysis probe is displaced from the DNA strand 
by the Taq polymerase and subsequently hydrolysed by the 5´-3´ exonuclease activity of the 
Taq polymerase. This results in displacement of of the reporter from the quencher and the 
fluorescence of the reporter becomes detectable. 
Generally two quantification types (relative or absolute) in RQ-PCR are possible.  A relative 
quantification based on relative expression of a target gene versus a reference gene is 
adequate for the most purposes. For absolute quantification, based either on an internal or 
an external calibration curve (Bustin et al., 2005; Ptaffl, 2001, Ptaffl et al. 2002), the 
methodology must be highly validated and the identical LightCycler PCR amplification 
efficiencies for standard material and target cDNA must be confirmed. 
2.4 Genes and microRNAs microarrays 
RNA was extracted using Trizol reagent  and processed for Affymetrix U133 plus 2.0 
GeneChip (Affymetrix, Santa Clara, CA) hybridizations. Briefly, from 5 µg total RNA, 
double-stranded cDNA was prepared with the use of the T7-Oligo(dT) primer (Affymetrix). 
In vitro transcription for amplification and biotinylation of the RNA transcript was 
performed with the BioArray HighYield RNA Transcript Labeling Kit (T7; Enzo Life Science, 
Farmingdale, NY). Biotin-cRNA (10 µg) was fragmented and hybridized onto the U133 plus 
2.0 GeneChip for 16 hours at 45°C and labelled with Cy-3-streptavidin conjugate according 
to manufacturer protocols. Scanned images were converted to CEL files using GCOS 
software (Affymetrix). For the miRNA microarray chips, biotinylated first-strand cDNA was 
synthesized in reverse transcription from 2.5 to 5.0 µg total RNA using biotin-labeled 
random octamer oligo primer from pretreatment BM and blood mononuclear cell samples 
and hybridized to miRNA microarray chip KCC/TJU containing 368 probes in triplicate, 
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corresponding to 245 human miRNA genes. After hybridization for 18 hours at 25°C and 
washing, direct detection of the biotin-containing transcripts by streptavidin-Alexa647 
conjugate was done and processed slides were scanned. Expression profiles were analyzed 
in GENESPRING software(Silicon Genetics, Redwood City, CA). 
3. Mutations in the molecular markers 
3.1 Mutations in the NPM1 gene 
Nucleophosmin (NPM1, also called nucleolar protein B23, numatrin or NO38) is a 
multifunctional phosphoprotein which contains 294 amino acids (Okuwaki et al., 2006). 
NPM1 is one of the three nucleophosmin isoforms which are generated through alternative 
splicing. NPM1 resides predominantly in the nucleoli, but also continuously shuttles 
between nucleus and cytoplasm (Frehlick et al., 2006).  The NPM1 gene is located on 
chromosome 5q35 in humans and is composed of 12 exons (Chan et al., 1989).  NPM1 is 
essential for processing and transportation of ribosomal RNA and proteins, molecular 
chaperoning, and regulation of the stability  of tumor suppressors, such as p53 and ARF 
(Borer et al., 1989; Colombo et al., 2002; Enomoto et al., 2006; Herrera et al., 1995; Li & Hann, 
2009; Maggi et al., 2008; Savkur & Olson, 1998; Yu et al., 2006). The ARF tumor suppressor is 
a protein that is transcribed from an alternate reading frame of the  inhibitor of cyclin-
dependent kinase CDK4. NPM1 can affect DNA replication, repair and transcription by 
interacting with the components of chromatin such as histones and chromatin remodeling 
proteins  (Amin et al., 2008a,b; Angelov et al., 2006; Koike et al., 2010). NPM1 plays 
important roles in cell cycle (Ugrinova et al., 2007; Xiao et al., 2009). NPM1 may 
preferentially promote ribosome biogenesis in G1, facilitate DNA replication during S-phase 
while supporting chromosome segregation in mitosis (Hisaoka et al., 2010). 
Almost 40% of  CN-AML patients have mutations in exon 12 of the NPM1 gene which result 
in loss of tryptophan residues normally required for NPM1 binding to the nucleoli and in 
the generation of an additional nuclear export signal motif at the C-terminus of NPM1 
which causes its abnormal cytoplasmic localization (Bolli et al., 2007; Falini et al., 2006; Liso 
et al., 2008; Oelschlaegel et al., 2010). These mutations are the most common genetic 
alterations in adult CN-AML patients and are associated with female sex, higher white 
blood count, increased blast percentage, and low or absent CD34 expression. Cytoplasmic 
nucleophosmin leukemic mutant is also rarely generated by a exon-11 NPM1 mutation 
(Albiero et al., 2007). Acute myeloid leukemias with mutated NPM1 (NPM1c+)  have 
distinct characteristics, including a significant association with a normal karyotype, 
involvement of different hematopoietic lineages, a specific gene-expression profile and 
clinically, a better response to induction therapy and a favorable prognosis (Meani & 
Alcalay, 2009; Rau & Brown, 2009, Falini et al., 2010). NPM1c+ maintains the capacity of 
wild-type NPM to interact with a variety of cellular proteins, and impairs their activity by 
delocalizing them to the cytoplasm. NPM1c+  specifically inhibits the activities of the cell-
death proteases, caspase-6 and -8, through direct interaction with their cleaved, active 
forms, but not the immature procaspases. NPM1c+ not only affords protection from death 
ligand-induced cell death but also suppresses caspase-6/-8-mediated myeloid 
differentiation (Leong et al., 2010). 
After the discovery of NPM1-mutated AML in 2005 and its subsequent inclusion as a 
provisional entity in the 2008 World Health Organization classification of myeloid 
neoplasms, several controversial issues remained to be clarified (Falini, 2011). It was unclear 
 
Acute Leukemia – The Scientist's Perspective and Challenge 
 
100 
whether the NPM1 mutation was a primary genetic lesion and whether additional 
chromosomal aberrations and multilineage dysplasia (MLD) had any impact on the biologic 
and prognostic features of NPM1-mutated AML. Moreover, it was uncertain how to classify 
AML patients who were double-mutated for NPM1 and CEBPA. Recent studies have shown 
that: (1) the NPM1 mutant perturbs hemopoiesis in experimental models; (2) leukemic stem 
cells from NPM1-mutated AML patients carry the mutation; and (3) the NPM1 mutation is 
usually mutually exclusive of biallelic CEPBA mutations. Moreover, the biologic and clinical 
features of NPM1-mutated AML do not seem to be significantly influenced by concomitant 
chromosomal aberrations or multilineage dysplasia. NPM1-mutated AML with and without 
MLD showed overlapping immunophenotype (CD34 negativity) and gene expression 
profile (CD34 down-regulation, homeobox (HOX) genes up-regulation). Altogether, these 
pieces of evidence point to NPM1-mutated AML as a founder genetic event that defines a 
distinct leukemia entity accounting for approximately one-third of all AML. Distinctive gene 
expression and microRNA signatures were found associated with AML bearing cytoplasmic 
mutated NPM1 (Becker et al., 2010; Garzon et al., 2008, Verhaak et al., 2005). 
Approximately 40% of patients with NPM1 mutations also carry FLT3 internal tandem 
duplications (FLT3-ITD). Patients with NPM1 mutations, who did not also have FLT3 
mutation have generally more favorable prognosis (Gale et al., 2008; Scholl et al., 2008; Luo 
et al., 2009).  The favourable prognosis of NPM1-mutated/FLT3-ITD negative patients might 
be explained by a higher bax/bcl-2 ratio (Del Poeta et al., 2010). These patients respond to 
induction therapy and stay in remission more likely. These patients may be exempted from 
allogenic hematopoietic stem cell transplantation during the first complete remission 
because their outcome after conventional consolidation chemotherapy is the same as after 
allogenic transplantation. However, patients with NPM1 mutations who also carry FLT3 
mutation have bad prognosis. 
Moreower, NPM1 mutations due to their frequency and stability, may be used for minimal 
residual disease monitoring in AML patients with a normal karyotype (Bacher et al., 2009; 
Schnittger et al., 2009; Dvorakova et al., 2010).  
3.2 FLT3 mutations 
The feline c-fms proto-oncogene product is a 170 kd glycoprotein with associated tyrosine 
kinase activity. Fms-like tyrosine kinase 3 (FLT3)  and its ligand (FL) are important in 
hematopoietic progenitor cell proliferation and differentiation (Gilliland & Griffin, 2002).  As 
a result of ligand binding, FLT3 receptor on the cell surface of hematopoietic progenitors 
dimerizes, resulting in activation of its tyrosine kinase domain, receptor 
autophosphorylation, and recruitment of downstream signaling molecules such as signal 
transducer and activator of transcription 5a (STAT5a), and the MAPK (mitogen activated  
protein kinases) pathways leading to proliferative and pro-survival effects.   
Internal tandem duplication (ITD) of base pairs within the juxtamembrane coding portion or 
point mutations in the second kinase domain occur in approximately 30% of patients with 
newly diagnosed AML and  result in constitutive activation of the  FLT3 gene on 
chromosome 13q12 ( Nakao et al., 1996; Naoe & Kiyoi, 2004; Yamamoto et al., 2001). FLT3 
mutations in the case of ITDs are associated with chemoresistance in the leukemic stem cells, 
shorter disease-free survival and overall survival and higher rate of relapse (Frohling et al., 
2002; Ravandi et al., 2010; Whitman et al., 2010). Specific gene expression signature 
associated with FLT3-ITD was described (Bullinger et al., 2008; Whitman et al., 2010). 
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Overexpression  of FLT3, homeobox genes  and immunotherapeutics targets and decreased 
expression of erythropoiesis-associated genes is connected with FLT3-ITD. The prognostic 
significance of FLT3 point mutations is less clear with conflicting results (Mead et al., 2008). 
In clinical practice, a frequent approach to patients with poor prognostic AML is to offer 
allogenic stem cell transplantation (SCT). Gale et al. (2005) found no benefit from any form 
of transplantation consolidation for patients with FLT3-ITD. Several inhibitors of FLT3 have 
entered clinical trials and are studied alone or mainly in combination with chemotherapy 
(Kindler et al., 2010; Small, 2008; Weisberg et al., 2009; Wiernik, 2010). 
3.3 CCAAT/enhancer binding protein alpha (CEBPA) mutations 
The CCAAT/enhancer binding protein alpha (C/EBPα) is the founding member of a family 
of related leucine zipper transcription factors that play important roles in myeloid 
differentiation (Friedman et al., 2007; Keeshan et al., 2003; Pabst & Mueller, 2007; Suh et al, 
2006; Tenen et al. 1997). Members of this family consist of N-terminal transactivation 




Fig. 1. The location of functional domains within the C/EBPα protein. Numbers directly 
above the schema indicate the amino acids of the human C/EBPα. Numbers directly under 
the schema indicate nucleotides (GenBank Accession No. NM_004364.2). The full-length 42 
kDa form of C/EBPα protein and the shorter, dominant negative 30 kDa form of this protein 
are also shown. 
The dimerization domain, known as  ”leucine zipper“, contains leucine repeats that 
intercalate with leucine repeats of the dimer partner forming a coiled coil of α helices in 
parallel orientation. C/EBPα mRNA is translated into two major proteins, C/EBPα p42 (42 
 
Acute Leukemia – The Scientist's Perspective and Challenge 
 
100 
whether the NPM1 mutation was a primary genetic lesion and whether additional 
chromosomal aberrations and multilineage dysplasia (MLD) had any impact on the biologic 
and prognostic features of NPM1-mutated AML. Moreover, it was uncertain how to classify 
AML patients who were double-mutated for NPM1 and CEBPA. Recent studies have shown 
that: (1) the NPM1 mutant perturbs hemopoiesis in experimental models; (2) leukemic stem 
cells from NPM1-mutated AML patients carry the mutation; and (3) the NPM1 mutation is 
usually mutually exclusive of biallelic CEPBA mutations. Moreover, the biologic and clinical 
features of NPM1-mutated AML do not seem to be significantly influenced by concomitant 
chromosomal aberrations or multilineage dysplasia. NPM1-mutated AML with and without 
MLD showed overlapping immunophenotype (CD34 negativity) and gene expression 
profile (CD34 down-regulation, homeobox (HOX) genes up-regulation). Altogether, these 
pieces of evidence point to NPM1-mutated AML as a founder genetic event that defines a 
distinct leukemia entity accounting for approximately one-third of all AML. Distinctive gene 
expression and microRNA signatures were found associated with AML bearing cytoplasmic 
mutated NPM1 (Becker et al., 2010; Garzon et al., 2008, Verhaak et al., 2005). 
Approximately 40% of patients with NPM1 mutations also carry FLT3 internal tandem 
duplications (FLT3-ITD). Patients with NPM1 mutations, who did not also have FLT3 
mutation have generally more favorable prognosis (Gale et al., 2008; Scholl et al., 2008; Luo 
et al., 2009).  The favourable prognosis of NPM1-mutated/FLT3-ITD negative patients might 
be explained by a higher bax/bcl-2 ratio (Del Poeta et al., 2010). These patients respond to 
induction therapy and stay in remission more likely. These patients may be exempted from 
allogenic hematopoietic stem cell transplantation during the first complete remission 
because their outcome after conventional consolidation chemotherapy is the same as after 
allogenic transplantation. However, patients with NPM1 mutations who also carry FLT3 
mutation have bad prognosis. 
Moreower, NPM1 mutations due to their frequency and stability, may be used for minimal 
residual disease monitoring in AML patients with a normal karyotype (Bacher et al., 2009; 
Schnittger et al., 2009; Dvorakova et al., 2010).  
3.2 FLT3 mutations 
The feline c-fms proto-oncogene product is a 170 kd glycoprotein with associated tyrosine 
kinase activity. Fms-like tyrosine kinase 3 (FLT3)  and its ligand (FL) are important in 
hematopoietic progenitor cell proliferation and differentiation (Gilliland & Griffin, 2002).  As 
a result of ligand binding, FLT3 receptor on the cell surface of hematopoietic progenitors 
dimerizes, resulting in activation of its tyrosine kinase domain, receptor 
autophosphorylation, and recruitment of downstream signaling molecules such as signal 
transducer and activator of transcription 5a (STAT5a), and the MAPK (mitogen activated  
protein kinases) pathways leading to proliferative and pro-survival effects.   
Internal tandem duplication (ITD) of base pairs within the juxtamembrane coding portion or 
point mutations in the second kinase domain occur in approximately 30% of patients with 
newly diagnosed AML and  result in constitutive activation of the  FLT3 gene on 
chromosome 13q12 ( Nakao et al., 1996; Naoe & Kiyoi, 2004; Yamamoto et al., 2001). FLT3 
mutations in the case of ITDs are associated with chemoresistance in the leukemic stem cells, 
shorter disease-free survival and overall survival and higher rate of relapse (Frohling et al., 
2002; Ravandi et al., 2010; Whitman et al., 2010). Specific gene expression signature 
associated with FLT3-ITD was described (Bullinger et al., 2008; Whitman et al., 2010). 
Molecular Markers for Risk Stratification in 
Adult Acute Myeloid Leukemia with Normal Cytogenetics 
 
101 
Overexpression  of FLT3, homeobox genes  and immunotherapeutics targets and decreased 
expression of erythropoiesis-associated genes is connected with FLT3-ITD. The prognostic 
significance of FLT3 point mutations is less clear with conflicting results (Mead et al., 2008). 
In clinical practice, a frequent approach to patients with poor prognostic AML is to offer 
allogenic stem cell transplantation (SCT). Gale et al. (2005) found no benefit from any form 
of transplantation consolidation for patients with FLT3-ITD. Several inhibitors of FLT3 have 
entered clinical trials and are studied alone or mainly in combination with chemotherapy 
(Kindler et al., 2010; Small, 2008; Weisberg et al., 2009; Wiernik, 2010). 
3.3 CCAAT/enhancer binding protein alpha (CEBPA) mutations 
The CCAAT/enhancer binding protein alpha (C/EBPα) is the founding member of a family 
of related leucine zipper transcription factors that play important roles in myeloid 
differentiation (Friedman et al., 2007; Keeshan et al., 2003; Pabst & Mueller, 2007; Suh et al, 
2006; Tenen et al. 1997). Members of this family consist of N-terminal transactivation 




Fig. 1. The location of functional domains within the C/EBPα protein. Numbers directly 
above the schema indicate the amino acids of the human C/EBPα. Numbers directly under 
the schema indicate nucleotides (GenBank Accession No. NM_004364.2). The full-length 42 
kDa form of C/EBPα protein and the shorter, dominant negative 30 kDa form of this protein 
are also shown. 
The dimerization domain, known as  ”leucine zipper“, contains leucine repeats that 
intercalate with leucine repeats of the dimer partner forming a coiled coil of α helices in 
parallel orientation. C/EBPα mRNA is translated into two major proteins, C/EBPα p42 (42 
 
Acute Leukemia – The Scientist's Perspective and Challenge 
 
102 
kDa) and C/EBPα p30 (30 kDa) by ribosomal scanning mechanism in which a fraction of 
ribosomes ignore the first two AUG codons and initiate translation at the third AUG codon 
located 357 nucleotides downstream of the first one (Fig. 1). The 30 kDa protein lacks the 
transactivating domain TAD1 (Fig. 1) and was shown to inhibit DNA binding and 
transactivation by C/EBPα p42 (Pabst et al., 2001). C/EBPα p30 fails to induce myeloid 
differentiation (D'Alo' et al., 2003; Friedman et al., 2007). Targeted inactivation of C/EBPα in 
mice demonstrates its importance in the proper development and function of liver, adipose 
tissue, lung and hematopoietic tissues (Flodby et al., 2006; Wang et al., 1995; Zhang et al., 
1997). C/EBPα is highly expressed in these differentiated tissues where it controls 
differentiation-dependent gene expression and inhibits cell proliferation (Fuchs 2007).  
Learning more about the precise molecular functions of the C/EBPα protein and how these 
are affected by leukemogenic mutations should lead to an improved understanding of the 
cellular functions that are disrupted in patients with AML.  
CEBPA mutations were found in 10-19% of  CN-AML patients (Gombart et al., 2002; 
Fröhling et al., 2004; Fuchs et al., 2008, 2009; Lin et al., 2005; Pabst et al., 2001; Preudhomme 
et al., 2002). Two kinds of mutations were mainly described: 1) truncating, frameshift 
mutations occuring near the N-terminus in one of the two transcription activations domais 
(TAD1 and TAD2) on one allele and 2) in-frame insertions or deletions clustering within the 
C-terminal basic domain- leucine zipper (DBD and ZIP) on the other allele. Often, CN-AML 
patients with CEBPA mutations belong to FAB (French –American –British) subtypes M1 or 
M2 and have one mutation towards N-end  and one  towards C-end but other cases of 
mutations were also detected. Kato et al. (2011) showed that a mutation of CEBPA in one 
allele was observed in AML after MDS while the two alleles are mutated in de novo AML. 
Favourable impact of CEBPA mutations was mainly observed in patients with biallelic 
mutation and with lack of FLT3-ITD (Dufour et al., 2010; Hou et al., 2009; Pabst et al., 2009; 
Radomska et al. 2006; Taskesen et al., 2011; Wouters et al., 2009).  
3.4 Partial tandem duplications of the MLL gene 
The mixed lineage leukemia gene (MLL, also known as ALL-1 or HRX), located on 
chromosome 11q23,  encodes a histone methyltransferase and is frequently rearranged in 
AML. Wild-type MLL is schematicly presented in Fig. 2. To date, MLL has been found in 
more than sixty different translocations with different fusion partners (Basecke et al., 2006; 
De Braekeleer et al., 2005). Partial tandem duplications of the MLL gene were first observed 
in CN-AML by Caligury et al., 1994. These duplications consist of an in-frame repetition of 
MLL exons in a 5´-3´ direction and lead to the change of the resulting transcript and protein. 
MLL-PTD are named according to the fused exons (mainly e9/e3, e10/e3, e11/e3).  
MLL-PTD are detectable in 5%-11% of patients with CN-AML (Döhner et al., 2002; Döhner & 
Döhner 2008; Schnittger  et al., 2000; Steudel et al., 2003). MLL-PTD have been found also in 
peripheral blood and bone marrow samples of healthy adults. However in contrast to the 
MLL-PTD in AML, MLL-PTD in healthy adults had often unusual exon fusions and showed 
an ladder on gel electrophoresis after the nested RT-PCR (Basecke et al., 2006; Marcucci et 
al., 1998; Schnittger  et al., 1998). MLL-PTD cooperate with silencing of the MLL wild-type 
allele by epigenetic mechanisms. MLL-PTD contribute to leukemogenesis through 
hypermethylation of DNA and epigenetic silencing of tumor suppressor genes (Dorrance et 
al., 2006; Whitman et al., 2008a). Inhibitors of  DNA methyltransferase and histone acetylase 
inhibitors and their combination can re-activate the wild-type allele in MLL-PTD-positive 
blasts (Whitman et al., 2005). 
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Fig. 2. Exon-intron structure of the wild-type MLL gene involved in tandem and nontandem 
duplications. The nomenclature is different in various studies (Nilson et al., 1996; Strout et 
al., 1998, Šárová et al., 2009). The MLL gene as a whole contains 36 or 37 exons according to 
the different nomenclatures and the resulting product of its expression contains 3969 amino 
acids. In the case of  MLL-PTD e9/e3 are exons and introns between exons 3 and 9 inserted 
between exons  9 and 10 of the wild-type MLL and are duplicated by this way (the fusion of 
introns 2 and 9). 
MLL-PTD are associated with shorter duration of the complete remission, shorter relapse-
free survival and event-free survival, but  MLL-PTD have no effect on overall survival 
Döhner & Döhner. 
3.5 Wilms´ tumor 1 (WT1) mutations 
The Wilms tumor  1 (WT1) gene is located on chromosome 11p13 and encodes a zinc-finger  
transcriptional regulator that can function as tumor suppressor in patients with the WAGR 
(Wilms´ tumor predisposition, aniridia, genitourinary abnormalities, and mental 
retardation) tumor predisposition syndrome (Haber et al., 1990) and as an oncogene in 
various leukemias, as well as other cancers (Ariyaratana & Loeb, 2007; King-Underwood et 
al., 1996; Miwa et al., 1992; Yang et al., 2007). Mutations in WT1 gene were found in 
approximately 10% of AML patients (Hou et al., 2010; Gaidzik et al., 2009; Owen et al., 2010; 
Paschka et al., 2008; Virappane et al. 2008). Mutations are mainly localized in zinc-finger 
domains in exons 7 and 9 but can be also found in exons 1,2,3, and 8. The truncated WT1 
protein is the result of frameshift mutations in exon 7. Truncated WT1 is without nuclear 
localization signal and does not bind to other interacting proteins as p53 and its homologue 
p73. Frameshift mutations in exon 9 are less frequent but there are also missense mutations. 
WT1 mutations have been reported as an adverse prognostic factor in adult CN-AML and 
independently predict for poor outcome  (Hou et al., 2010; Gaidzik et al., 2009; Owen et al., 
2010; Paschka et al., 2008; Renneville et al., 2009; Virappane et al. 2008). WT1 mutations lead 
to inferior rate of complete remission, higher incidence of relapse abd to shorter relapse-free 
survival and overall survival. A recent study demonstrated  that a single nucleotide 
polymorphism SNP rs16754 in the WT1 mutational hotspot predicted favorable outcome in 
CN-AML (Damm et al. 2010). 
3.6 Isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) gene mutations 
Mardis et al. (2009) found recurring mutations in codon 132 of the IDH1 gene by sequencing 
a whole AML genome as described in paragraph 2.2. The protein encoded by this gene is the 
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acids. In the case of  MLL-PTD e9/e3 are exons and introns between exons 3 and 9 inserted 
between exons  9 and 10 of the wild-type MLL and are duplicated by this way (the fusion of 
introns 2 and 9). 
MLL-PTD are associated with shorter duration of the complete remission, shorter relapse-
free survival and event-free survival, but  MLL-PTD have no effect on overall survival 
Döhner & Döhner. 
3.5 Wilms´ tumor 1 (WT1) mutations 
The Wilms tumor  1 (WT1) gene is located on chromosome 11p13 and encodes a zinc-finger  
transcriptional regulator that can function as tumor suppressor in patients with the WAGR 
(Wilms´ tumor predisposition, aniridia, genitourinary abnormalities, and mental 
retardation) tumor predisposition syndrome (Haber et al., 1990) and as an oncogene in 
various leukemias, as well as other cancers (Ariyaratana & Loeb, 2007; King-Underwood et 
al., 1996; Miwa et al., 1992; Yang et al., 2007). Mutations in WT1 gene were found in 
approximately 10% of AML patients (Hou et al., 2010; Gaidzik et al., 2009; Owen et al., 2010; 
Paschka et al., 2008; Virappane et al. 2008). Mutations are mainly localized in zinc-finger 
domains in exons 7 and 9 but can be also found in exons 1,2,3, and 8. The truncated WT1 
protein is the result of frameshift mutations in exon 7. Truncated WT1 is without nuclear 
localization signal and does not bind to other interacting proteins as p53 and its homologue 
p73. Frameshift mutations in exon 9 are less frequent but there are also missense mutations. 
WT1 mutations have been reported as an adverse prognostic factor in adult CN-AML and 
independently predict for poor outcome  (Hou et al., 2010; Gaidzik et al., 2009; Owen et al., 
2010; Paschka et al., 2008; Renneville et al., 2009; Virappane et al. 2008). WT1 mutations lead 
to inferior rate of complete remission, higher incidence of relapse abd to shorter relapse-free 
survival and overall survival. A recent study demonstrated  that a single nucleotide 
polymorphism SNP rs16754 in the WT1 mutational hotspot predicted favorable outcome in 
CN-AML (Damm et al. 2010). 
3.6 Isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) gene mutations 
Mardis et al. (2009) found recurring mutations in codon 132 of the IDH1 gene by sequencing 
a whole AML genome as described in paragraph 2.2. The protein encoded by this gene is the 
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enzyme that catalyzes the oxidative carboxylation of isocitrate to α-ketoglutarate leading to 
nicotinamide adenine dinucleotide phosphate production in Krebs cycle and was found in 
the cytoplasm and peroxisomes (Geisbrecht & Gould, 1999). Three classes of IDH 
isoenzymes exist in mammalian cells (two forms of mitochondrial IDH and cytosolic IDH). 
IDH1 gene is localized to chromosome band 2q33.3 and IDH2 gene to chromosome band 
15q26.1 (Narahara et al.,1985; Oh et al.,1996). IDH2 encodes the mitochondrial isoform that 
uses nicotinamide adenine dinucleotide phosphate as a cofactor. The same cofactor is also 
used by IDH1. 
Most cancer-associated enzyme mutations result in constitutive activation or inactivation of 
the mutated enzyme. IDH1 and IDH2 mutations result in the new enzyme activity, 
production of 2-hydroxyglutarate, not shared by wild type enzymes (Ward et al., 2010). This 
accumulation of  2-hydroxyglutarate induces global DNA hypermethylation, disrupts TET2 
function because this enzyme is α-ketoglutarate-dependent, and impairs hematopoietic 
differentiation (Figueroa et al., 2010). TET2  is a homolog of the gene originally discovered at 
the chromosome ten-eleven translocation (TET) site in a subset of patients with AML. TET2 
catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine, suggesting a 
potential role for TET proteins in epigenetic regulation. Blocking the accumulation of  2-
hydroxyglutarate  through the inhibition of mutant IDH enzymes could represent a 
therapeutic target (Dang et al. , 2010; Cazola 2010). 
IDH1 mutations at codon R132 occur in CN-AML patients with a frequency of 5.5% to 11% 
(Boissel et al., 2010; Gross et al., 2010; Patel et al., 2011; Schnittger et al., 2010; Wagner et al., 
2010). A strong association between IDH1 mutations and the NPM1 mutation and M1 FAB 
subtype was observed. On the other hand, IDH1 mutations are inversely associated with the 
M4 FAB subtype and expression of HLA-DR, CD13 and CD14 antigens. The prognostic 
impact of  IDH1 mutations in CN-AML is associated with a higher risk of relapse and a 
shorter overall survival (Abbas et al., 2010; Boissel et al., 2010; Marcucci et al., 2010; Paschka 
et al., 2010; Schnittger et al., 2010). Others (Chou et al., 2010a; Patel et al., 2011; Wagner et al., 
2010), however, found no significant impact of IDH1 mutations on CN-AML patients 
outcome. IDH2 mutations in exon 4, including mainly codon R140 and in rare cases codon 
R172, had no prognostic impact (Thol et al., 2010). Recent study of Chou et al. (2011) showed 
high stability of  IDH2 mutations during disease evolution and their connection with 
favorable prognosis. Contrary to this observation, Boissel et al. (2010) found IDH2 mutations 
independently associated with a higher risk of relapse and shorter overall survival. The 
prognostic impact of  IDH1 mutations and IDH2 mutations needs further study as very 
controversial results were obtained. Green et al. (2010) observed no difference in outcome 
between IDH1 mutated and nonmutated patients when the results were stratified by an 
NPM1 mutation status but an adverse outcome for IDH1 mutated  patients when the results 
were correlated with FLT3-ITD mutation. 
3.7 Mutations in gene for DNA methyltransferase 3A (DNMT3A) 
About 22% of CN-AML patients have DNMT3A mutations. The most common DNMT3A 
mutation affects amino acid R882 but other parts of DNMT3A gene are also affected by 
mutations  in CN-AML patients (Ley et al., 2010). Aberrant DNA methylation contributes to 
the pathogenesis of cancer (Rodríguez-Paredes & Esteller 2011; Taberlay & Jones, 2011; 
Watanabe & Maekawa, 2010). Clusters of CpG dinucleotides in promoters of tumor-
supppressor genes are hypermethylated in cancer genomes and this hypermethylation 
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results in reduced expression of the downstream gene. However, inhibition of DNA 
methyltransferases is only one potential mechanism of function of demethylating agents (5-
azacytidine and decitabine). DNMT3A mutations do not change 5-methylcytosine content in 
AML genomes but are associated with poor survival. DNMT3A mutations are in many cases 
found together with FLT3 mutations, NPM1 mutations and IDH1 mutations. All these 
combinations of mutations have a significantly worse outcome.    
3.8 RAS mutations in CN-AML 
Ras-signaling cascade contributes to the molecular pathogenesis of myeloproliferative 
disorders (Chan et al., 2004). Ras oncogenes (small GTPases) regulate mechanism of 
proliferation, differentiation, and apoptosis. NRAS (neuroblastoma RAS) mutations  were 
detected in 9% of adult CN-AML patients and 14% of CN-AML patients younger than 56 or 
60 years (Bacher et al., 2006; Bowen et al., 2005). There was no prognostic impact of these 
mutations in most studies (Gaidzik & Döhner, 2008; Ritter et al., 2004; Schlenk & Döhner, 
2009). Mutations in other members of  Ras family are rare in CN-AML and there was also no 
consistent effect on prognosis but the presence of  Ras mutations appears to sentisize AML 
blasts  to high dose cytarabine in vivo (Motyckova & Stone 2010). 
3.9 Other gene mutations in CN-AML 
Mutations in RUNX1 have been shown in approximately 10%-13% of CN-AML (Döhner & 
Döhner, 2008, Tang et al., 2009). These mutations were positively associated with MLL-PTD 
and negatively associated with NPM1 and CEBPA mutations. They predict ed a lower 
complete remission rate and shorter disease-free and overall survival .   
TET2 (ten-eleven-translocation)  first described in 2008, include frameshift, nonsense and 
missense mutations lying across several of its 12 exons located on chromosome 4q24 (Abdel-
Wahab et al., 2009; Bacher et al., 2010; Mohr et al., 2011; Nibourel et al., 2010). The direct 
influence of  mutations in TET2 on patient survival in CN-AML  remains a disputable issue. 
TET2 mutations were revealed in 10%-25% of CN-AML patients. Abdel-Wahab et al. (2009) 
showed a decreased survival rate in mutated TET2 in comparison with wild-type TET2 
group of CN-AML. However, Nibourel et al. (2010) did not find significant impact of TET2 
mutation on clinical outcome of CN-AML patients but they observed mutated TET2 
strongly associated with mutated NPM1. Recently, Metzeler et al. (2011) have found TET2 
mutations in 23%of CN-AML patients and these mutations were associated with older age. 
In favorable–risk group of CN-AML patients with CEBPA mutation and/or  mutated NPM1 
without FLT3-ITD, TET2-mutated patients had shorter event-free survival, lower complete 
remission rate and shorter disease-free and overal survival. In CN-AML patients with 
intermediate risk with wild-type CEBPA and wild-type NPM1 without FLT3-ITD, TET2 
mutations were not associated with outcomes. 
CBL (Casitas B-cell lymphoma) mutations were identified in rare cases of CN-AML (Bacher 
et al., 2010; Makishima et al., 2009; Reindl et al., 2009). Cbl is E3 ubiquitin ligase involved in 
degradation of activated receptor tyrosine kinases, including Src kinases (Makishima et al., 
2009). Presence of these mutations was suggested  to be involved in aberrant FLT3 
expression. FLT3 ligand–dependent hyperproliferation of CBL mutant cells could be 
abrogated by treatment with the specific inhibitor, midostaurin (PKC412). 
Mutations in the additional sex comb-like 1 (ASXL1) gene were analyzed in exon 12 in CN-
AML patients and 8.9% mutations were detected (Chou et al., 2010b).  This mutation was 
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enzyme that catalyzes the oxidative carboxylation of isocitrate to α-ketoglutarate leading to 
nicotinamide adenine dinucleotide phosphate production in Krebs cycle and was found in 
the cytoplasm and peroxisomes (Geisbrecht & Gould, 1999). Three classes of IDH 
isoenzymes exist in mammalian cells (two forms of mitochondrial IDH and cytosolic IDH). 
IDH1 gene is localized to chromosome band 2q33.3 and IDH2 gene to chromosome band 
15q26.1 (Narahara et al.,1985; Oh et al.,1996). IDH2 encodes the mitochondrial isoform that 
uses nicotinamide adenine dinucleotide phosphate as a cofactor. The same cofactor is also 
used by IDH1. 
Most cancer-associated enzyme mutations result in constitutive activation or inactivation of 
the mutated enzyme. IDH1 and IDH2 mutations result in the new enzyme activity, 
production of 2-hydroxyglutarate, not shared by wild type enzymes (Ward et al., 2010). This 
accumulation of  2-hydroxyglutarate induces global DNA hypermethylation, disrupts TET2 
function because this enzyme is α-ketoglutarate-dependent, and impairs hematopoietic 
differentiation (Figueroa et al., 2010). TET2  is a homolog of the gene originally discovered at 
the chromosome ten-eleven translocation (TET) site in a subset of patients with AML. TET2 
catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine, suggesting a 
potential role for TET proteins in epigenetic regulation. Blocking the accumulation of  2-
hydroxyglutarate  through the inhibition of mutant IDH enzymes could represent a 
therapeutic target (Dang et al. , 2010; Cazola 2010). 
IDH1 mutations at codon R132 occur in CN-AML patients with a frequency of 5.5% to 11% 
(Boissel et al., 2010; Gross et al., 2010; Patel et al., 2011; Schnittger et al., 2010; Wagner et al., 
2010). A strong association between IDH1 mutations and the NPM1 mutation and M1 FAB 
subtype was observed. On the other hand, IDH1 mutations are inversely associated with the 
M4 FAB subtype and expression of HLA-DR, CD13 and CD14 antigens. The prognostic 
impact of  IDH1 mutations in CN-AML is associated with a higher risk of relapse and a 
shorter overall survival (Abbas et al., 2010; Boissel et al., 2010; Marcucci et al., 2010; Paschka 
et al., 2010; Schnittger et al., 2010). Others (Chou et al., 2010a; Patel et al., 2011; Wagner et al., 
2010), however, found no significant impact of IDH1 mutations on CN-AML patients 
outcome. IDH2 mutations in exon 4, including mainly codon R140 and in rare cases codon 
R172, had no prognostic impact (Thol et al., 2010). Recent study of Chou et al. (2011) showed 
high stability of  IDH2 mutations during disease evolution and their connection with 
favorable prognosis. Contrary to this observation, Boissel et al. (2010) found IDH2 mutations 
independently associated with a higher risk of relapse and shorter overall survival. The 
prognostic impact of  IDH1 mutations and IDH2 mutations needs further study as very 
controversial results were obtained. Green et al. (2010) observed no difference in outcome 
between IDH1 mutated and nonmutated patients when the results were stratified by an 
NPM1 mutation status but an adverse outcome for IDH1 mutated  patients when the results 
were correlated with FLT3-ITD mutation. 
3.7 Mutations in gene for DNA methyltransferase 3A (DNMT3A) 
About 22% of CN-AML patients have DNMT3A mutations. The most common DNMT3A 
mutation affects amino acid R882 but other parts of DNMT3A gene are also affected by 
mutations  in CN-AML patients (Ley et al., 2010). Aberrant DNA methylation contributes to 
the pathogenesis of cancer (Rodríguez-Paredes & Esteller 2011; Taberlay & Jones, 2011; 
Watanabe & Maekawa, 2010). Clusters of CpG dinucleotides in promoters of tumor-
supppressor genes are hypermethylated in cancer genomes and this hypermethylation 
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results in reduced expression of the downstream gene. However, inhibition of DNA 
methyltransferases is only one potential mechanism of function of demethylating agents (5-
azacytidine and decitabine). DNMT3A mutations do not change 5-methylcytosine content in 
AML genomes but are associated with poor survival. DNMT3A mutations are in many cases 
found together with FLT3 mutations, NPM1 mutations and IDH1 mutations. All these 
combinations of mutations have a significantly worse outcome.    
3.8 RAS mutations in CN-AML 
Ras-signaling cascade contributes to the molecular pathogenesis of myeloproliferative 
disorders (Chan et al., 2004). Ras oncogenes (small GTPases) regulate mechanism of 
proliferation, differentiation, and apoptosis. NRAS (neuroblastoma RAS) mutations  were 
detected in 9% of adult CN-AML patients and 14% of CN-AML patients younger than 56 or 
60 years (Bacher et al., 2006; Bowen et al., 2005). There was no prognostic impact of these 
mutations in most studies (Gaidzik & Döhner, 2008; Ritter et al., 2004; Schlenk & Döhner, 
2009). Mutations in other members of  Ras family are rare in CN-AML and there was also no 
consistent effect on prognosis but the presence of  Ras mutations appears to sentisize AML 
blasts  to high dose cytarabine in vivo (Motyckova & Stone 2010). 
3.9 Other gene mutations in CN-AML 
Mutations in RUNX1 have been shown in approximately 10%-13% of CN-AML (Döhner & 
Döhner, 2008, Tang et al., 2009). These mutations were positively associated with MLL-PTD 
and negatively associated with NPM1 and CEBPA mutations. They predict ed a lower 
complete remission rate and shorter disease-free and overall survival .   
TET2 (ten-eleven-translocation)  first described in 2008, include frameshift, nonsense and 
missense mutations lying across several of its 12 exons located on chromosome 4q24 (Abdel-
Wahab et al., 2009; Bacher et al., 2010; Mohr et al., 2011; Nibourel et al., 2010). The direct 
influence of  mutations in TET2 on patient survival in CN-AML  remains a disputable issue. 
TET2 mutations were revealed in 10%-25% of CN-AML patients. Abdel-Wahab et al. (2009) 
showed a decreased survival rate in mutated TET2 in comparison with wild-type TET2 
group of CN-AML. However, Nibourel et al. (2010) did not find significant impact of TET2 
mutation on clinical outcome of CN-AML patients but they observed mutated TET2 
strongly associated with mutated NPM1. Recently, Metzeler et al. (2011) have found TET2 
mutations in 23%of CN-AML patients and these mutations were associated with older age. 
In favorable–risk group of CN-AML patients with CEBPA mutation and/or  mutated NPM1 
without FLT3-ITD, TET2-mutated patients had shorter event-free survival, lower complete 
remission rate and shorter disease-free and overal survival. In CN-AML patients with 
intermediate risk with wild-type CEBPA and wild-type NPM1 without FLT3-ITD, TET2 
mutations were not associated with outcomes. 
CBL (Casitas B-cell lymphoma) mutations were identified in rare cases of CN-AML (Bacher 
et al., 2010; Makishima et al., 2009; Reindl et al., 2009). Cbl is E3 ubiquitin ligase involved in 
degradation of activated receptor tyrosine kinases, including Src kinases (Makishima et al., 
2009). Presence of these mutations was suggested  to be involved in aberrant FLT3 
expression. FLT3 ligand–dependent hyperproliferation of CBL mutant cells could be 
abrogated by treatment with the specific inhibitor, midostaurin (PKC412). 
Mutations in the additional sex comb-like 1 (ASXL1) gene were analyzed in exon 12 in CN-
AML patients and 8.9% mutations were detected (Chou et al., 2010b).  This mutation was 
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closely associated with older age, male sex, RUNX1 mutation and expression of human 
leukocyte-antigen-DR and CD34 (Chou et al., 2010b; Rocquain et al., 2010).  Association with 
FLT3-ITD, NPM1 mutation, WT1 mutation, and expression of CD33 and CD15 was not 
detected. ASXL1 mutated patients had a shorter overall survival than patients without this 
mutation, but  the mutation was not an independent adverse prognostic factor in 
multivariete analysis. 
Phosphoinositide phospholipase Cβ1 (PI-PLCβ1) gene mutations are very rare in CN-AML  
(Damm et al., 2010). Follo et al. (2009) described greater representation of these mutations 
(monoallelic deletions) in AML and their association with a worse clinical outcome. 
4. Overexpression of marker genes with prognostic relevance 
Alterations in the expression of genes belonging to signal transduction pathways as well as 
transcription factors are known to play a  functional role in the pathogenesis of AML.  
Therefore, these marker genes are implicated in the process of leukemogenesis and their 
overexpression may be useful to predict outcome in CN-AML patients. 
4.1 WT1 gene expression 
The WT1 gene overexpression was found in several leukemias, including AML (Cilloni et 
al., 2009). WT1 mRNA levels in the peripheral blood can predict relapse after achieving 
complete remission, and its levels after consolidation therapy are closely correlated with 
disease-free and overall survival, and with early relapse (Cilloni et al., 2009; Gianfaldoni et 
al., 2010; Miyawaki et al., 2010). Monitoring of WT1 expression is significant predictor of 
relapse in AML patients after hematopoietic cell transplantation (Lange et al., 2011). 
4.2 BAALC (brain and acute leukemia, cytoplasmic) expression 
The BAALC gene, located on chromosome 8q22.3, is primarily expressed in neuroectoderm-
derived tissues and in hematopoietic precursors and encodes a protein with unknown 
function (Baldus et al., 2003, 2006; Langer et al., 2008; Santamaria et al., 2010). High level of 
BAALC expression showed a higher refractoriness to induction treatment , lower complete 
remission rate after salvage therapy and lower overall survival and relapse – free survival in 
intermediate-risk AML (Santamaria et al., 2010).  The BAALC expression is considered an 
independent prognostic factor in CN-AML. High BAALC expression was associated with 
FLT3-ITD, and high ERG expression in multivariable analysis (Baldus et al., 2006). High 
BAALC expression is also connected with overexpression of genes involved in drug 
resistance (MDR1)  and stem cell markers (CD133, CD34, KIT). In low BAALC expressers, 
genes associated with undifferentiated hematopoietic precursors and unfavorable outcome 
predictors were downregulated, while HOX–genes and HOX–gene-embedded-miR were 
upregulated (Schwind et al., 2010).  Global miR expression analysis did not reveal significant 
differences between different rate BAALC expression groups (Langer et al., 2008).  Inverse 
association between the expression of miR148a and BAALC was revealed. 
4.3 ERG (v-ets erythroblastosis virus E26 oncogene homolog) expression 
ETS-related gene (ERG), located at chromosome band 21q22, is downstream effector of 
signaling transduction pathways involved in the regulation of cell proliferation, 
differentiation, and apoptosis (Marcucci et al., 2005,2007; Mrózek et  al., 2007; Metzeler et al. 
2009, Schwind et al., 2010). CN-AML patients with overexpression of ERG have been 
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reported to have a poor clinical outcome. When combined with other known prognostic 
markers, ERG expression can improve the molecular risk-based stratification of patients 
with CN-AML. Low ERG expression is associated with downregulation of genes involved in 
the DNA-methylation machinery, upregulation of miR148a, which targets DNA 
methyltransferase 3B (DNMT3B) and with better outcome (Schwind et al., 2010).   
4.4 MN1 (meningioma 1) expression 
MN1 is located at 22q11 and its overexpression is associated with lower response rate after 
first course of induction therapy and poor clinical outcome for CN-AML patients. Moreover, 
high MN1 expression was connected with a higher relapse rate and worse relapse-free and 
overall survival (Grosveld, 2007; Heuser et al., 2006; Langer et al., 2009). MN1 expression 
levels were directly correlated with BAALC expression levels and with the expression of 
genes reported as associated with a BAALC expression signature, specifically with 
expression of CD34 and ABCB1 (MDR1) and several other genes (Langer et al., 2008, 2009). 
MN1 expression levels were negatively connected with expression of HOX genes and with 
NPM1 mutated CN-AML (Langer et al., 2009). MN1-associated miR-expression signature 
comprises 15 miR, expression of 8 miR (hsa-miR-126 family) was positively correlated and 
expression of 7 miR (hsa-miR-16, hsa-miR-19a and hsa-miR-20a, all members of miR-17-92 
polycistron) negatively correlated with MN1 expression (Langer et al., 2009). MN1 
overexpression confered resistance to the differentiation activity of all-trans-retinoic acid 
(ATRA) in AML (Heuser et al., 2007).   
4.5 EVI1 (ecotropic viral integration site 1) expression 
Human EVI1 is localized to chromosome 3 band q26, spans 60kb, and contains 16 exons 
(Goyama &Kurokawa, 2009). High EVI1 expression occurs in approximately 8% of patients 
with de novo AML (Barjesteh van Waalwijk van Doom-Khosrovani et al., 2003). High EVI1 
expression was observed not only in AML carrying the chromosome 3 abnormalities, but 
also in CN-AML (Gröschel et al., 2010; Lugthart et al., 2008; Santamaria et al., 2009) and is in 
both groups connected with poor treatment response.  
4.6 Other molecular marker genes expression 
The PRAME (preferentially expressed antigen of melanoma) gene was shown to be 
expressed in high levels in AML. PRAME mRNA was observed in about one-third of AML 
cases and there was a good correlation between PRAME mRNA level and hematological 
remission and relapse. It may be also useful marker to detect minimal residual disease after 
allogenic transplantation (Paydas et al., 2005; Qin et al. ., 2009). Epping et al. (2005) showed 
that PRAME is a repressor of retinoic acid signaling but Steinbach et al. (2007) did not 
confirm this mechanism in the pathogenesis of AML. Specific immunotherapies for patients 
with AML using leukemia-associated antigens (LAA) as target structures might be a 
therapeutic option. Expression of genes for these antigens have prognostic importance 
(Greiner et al., 2008). 
AF1q (ALL1 fused gene from chromosome 1q) gene overexpression in CN-AML patients is 
associated with a significantly greater incidence of concurrent FLT3-ITD and with a poor 
outcome (Strunk et al., 2009). NC-AML patients with low AF1q expression had better overall 
survival and complete remission rate than patients with high AF1q mRNA level.  
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closely associated with older age, male sex, RUNX1 mutation and expression of human 
leukocyte-antigen-DR and CD34 (Chou et al., 2010b; Rocquain et al., 2010).  Association with 
FLT3-ITD, NPM1 mutation, WT1 mutation, and expression of CD33 and CD15 was not 
detected. ASXL1 mutated patients had a shorter overall survival than patients without this 
mutation, but  the mutation was not an independent adverse prognostic factor in 
multivariete analysis. 
Phosphoinositide phospholipase Cβ1 (PI-PLCβ1) gene mutations are very rare in CN-AML  
(Damm et al., 2010). Follo et al. (2009) described greater representation of these mutations 
(monoallelic deletions) in AML and their association with a worse clinical outcome. 
4. Overexpression of marker genes with prognostic relevance 
Alterations in the expression of genes belonging to signal transduction pathways as well as 
transcription factors are known to play a  functional role in the pathogenesis of AML.  
Therefore, these marker genes are implicated in the process of leukemogenesis and their 
overexpression may be useful to predict outcome in CN-AML patients. 
4.1 WT1 gene expression 
The WT1 gene overexpression was found in several leukemias, including AML (Cilloni et 
al., 2009). WT1 mRNA levels in the peripheral blood can predict relapse after achieving 
complete remission, and its levels after consolidation therapy are closely correlated with 
disease-free and overall survival, and with early relapse (Cilloni et al., 2009; Gianfaldoni et 
al., 2010; Miyawaki et al., 2010). Monitoring of WT1 expression is significant predictor of 
relapse in AML patients after hematopoietic cell transplantation (Lange et al., 2011). 
4.2 BAALC (brain and acute leukemia, cytoplasmic) expression 
The BAALC gene, located on chromosome 8q22.3, is primarily expressed in neuroectoderm-
derived tissues and in hematopoietic precursors and encodes a protein with unknown 
function (Baldus et al., 2003, 2006; Langer et al., 2008; Santamaria et al., 2010). High level of 
BAALC expression showed a higher refractoriness to induction treatment , lower complete 
remission rate after salvage therapy and lower overall survival and relapse – free survival in 
intermediate-risk AML (Santamaria et al., 2010).  The BAALC expression is considered an 
independent prognostic factor in CN-AML. High BAALC expression was associated with 
FLT3-ITD, and high ERG expression in multivariable analysis (Baldus et al., 2006). High 
BAALC expression is also connected with overexpression of genes involved in drug 
resistance (MDR1)  and stem cell markers (CD133, CD34, KIT). In low BAALC expressers, 
genes associated with undifferentiated hematopoietic precursors and unfavorable outcome 
predictors were downregulated, while HOX–genes and HOX–gene-embedded-miR were 
upregulated (Schwind et al., 2010).  Global miR expression analysis did not reveal significant 
differences between different rate BAALC expression groups (Langer et al., 2008).  Inverse 
association between the expression of miR148a and BAALC was revealed. 
4.3 ERG (v-ets erythroblastosis virus E26 oncogene homolog) expression 
ETS-related gene (ERG), located at chromosome band 21q22, is downstream effector of 
signaling transduction pathways involved in the regulation of cell proliferation, 
differentiation, and apoptosis (Marcucci et al., 2005,2007; Mrózek et  al., 2007; Metzeler et al. 
2009, Schwind et al., 2010). CN-AML patients with overexpression of ERG have been 
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reported to have a poor clinical outcome. When combined with other known prognostic 
markers, ERG expression can improve the molecular risk-based stratification of patients 
with CN-AML. Low ERG expression is associated with downregulation of genes involved in 
the DNA-methylation machinery, upregulation of miR148a, which targets DNA 
methyltransferase 3B (DNMT3B) and with better outcome (Schwind et al., 2010).   
4.4 MN1 (meningioma 1) expression 
MN1 is located at 22q11 and its overexpression is associated with lower response rate after 
first course of induction therapy and poor clinical outcome for CN-AML patients. Moreover, 
high MN1 expression was connected with a higher relapse rate and worse relapse-free and 
overall survival (Grosveld, 2007; Heuser et al., 2006; Langer et al., 2009). MN1 expression 
levels were directly correlated with BAALC expression levels and with the expression of 
genes reported as associated with a BAALC expression signature, specifically with 
expression of CD34 and ABCB1 (MDR1) and several other genes (Langer et al., 2008, 2009). 
MN1 expression levels were negatively connected with expression of HOX genes and with 
NPM1 mutated CN-AML (Langer et al., 2009). MN1-associated miR-expression signature 
comprises 15 miR, expression of 8 miR (hsa-miR-126 family) was positively correlated and 
expression of 7 miR (hsa-miR-16, hsa-miR-19a and hsa-miR-20a, all members of miR-17-92 
polycistron) negatively correlated with MN1 expression (Langer et al., 2009). MN1 
overexpression confered resistance to the differentiation activity of all-trans-retinoic acid 
(ATRA) in AML (Heuser et al., 2007).   
4.5 EVI1 (ecotropic viral integration site 1) expression 
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High MLL5 (mixed lineage leukemia 5) expression is associated with a favorable outcome of 
CN-AML patients and enables identification of a significant proportion of patients with 
favorable prognosis that are not identified by other markers analyses (Damm et al., 2011). 
Increased expression of the phosphoinositide phospholipase Cβ1 (PI-PLC β1) gene is an 
independent prognostic factor in CN-AML and is associated with a significantly shorter 
overall survival but with no difference for relapse-free survival (Damm et al., 2010).  
The Rho family of small GTPases, including Rho, Rac and Cdc42, functions as critical 
mediators of signaling pathways from plasma membrane regulating actin assembly, 
migration, proliferation and survival in hematopoietic cells. RhoH gene, also known as 
Translocation Three Four (TTF), encodes a 191-amino acid protein belonging to the Rho 
family (Gu et al., 2005; Iwasaki et al., 2008). Rho H functions as a negative regulator for 
interleukin 3 (IL3) – induced signals through modulation of the JAK-STAT (Janus Kinase-
Signal Transducer and Activator of Transcription)- signaling pathway (Gűndogdu et al., 
2010). Low RhoH levels are connected with an upregulation of IL3- dependent cell growth, 
STAT5 activity and an increase of CD123 surface expression that has been described in AML 
patients (Gűndogdu et al., 2010). Multivariate analysis demonstrated that low expression of 
RhoH was an independent unfavorable prognostic factor for both overall and disease-free 
survival of AML in the intermediate risk group (Iwasaki et al., 2008).  
Activation of Notch signal pathway (expression of Notch1, Jagged1 and Delta1 as members of 
this pathway) is associated with a poorer prognosis for AML patients with intermediate risk 
(Xu et al., 2010). 
The Forkhead transcription factors (FOXO) are direct target of the PI3K/AKT (protein 
kinase B) signaling and they integrate the signals of several other transduction pathways at 
the transcriptional level. The PI3K/AKT/FOXO signaling pathway is up-regulated in AML.  
High FOXO3a expression is associated with a poorer prognosis in CN-AML (Santamaria et 
al., 2009) and the increased levels of both total and of highly phosphorylated FOXO3a 
correlate with higher proliferation and blood blasts  and  these high levels of FOXO3a are an 
adverse prognostic factor in AML (Kornblau et al., 2010).  
Bone marrow neoangiogenesis plays an important pathogenetic and possible prognostic role 
in AML (Hou et al., 2008; Lee et al., 2007; Loges et al., 2005; Mourah et al. 2009). 
Multivariable analysis showed that the levels of vascular endothelial growth factor (VEGF) 
transcript isoform 121 (VEGF121) remained an independent prognostic factor for either 
event-free survivasl or overall survival (Mourah et al., 2009). High levels of VEGF121 were 
significantly related to a worse prognosis. Angiopoietin-2  (Ang2) gene expression 
represents also an independent prognostic factor in AML with intermediate risk and high 
Ang2 expression is associated with an unfavorable prognosis (Hou et al., 2008; Lee et al., 
2007; Loges et al., 2005). High VEGFC expression appeared strongly associated with reduced 
complete remission rate, reduced overall and event-free survival in adult AML independent 
of cytogenetic risk and white blood cell count (de Jonge et al., 2010). High VEGFC 
expression was related to enhanced chemoresistance and predicted adverse long-term 
prognosis. 
TGFβ (transforming growth factor beta) superfamily receptors ALK-1 (activin receptor like 
kinase) and ALK-5 have an important role in endothelial cells behavior and might be 
involved in the pathogenesis of AML. ALK-1 and ALK-5 are both expressed by the majority 
of AML patients. ALK-5 expression has a significant negative impact on complete remission 
achievment and overall survival of AML patients (Otten et al., 2011). 
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Dysregulation of the Wnt/β-catenin pathway has been observed in various malignancies, 
including AML. Overexpression of β-catenin is an independent adverse prognostic factor in 
AML (Chen et al., 2009; Ysebaert et al., 2006). 
Chemokine  (C-X-C motif) receptor 4 (CXCR4) retains hematopoietic progenitors and 
leukemia cells within the marrow microenvironment. Multivariate analysis revealed CXCR4 
expression as an independent prognostic factor for disease relapse and survival (Konoplev 
et al., 2007; Spoo et al., 2007; Tavernier-Tardy et al., 2009). Low CXCR4 expression correlated 
with a better prognosis, resulting in a longer relapse-free and overall survival. 
Many studies of AML have linked the overexpression of ABCB1 (also named permeability 
glycoprotein, Pgp), a member of ATP-binding proteins coded by the multi-drug resistance 
gene (MDR1), to poor prognosis (Leith et al., 1997; Steinbach & Legrand, 2007; Trnkova et 
al., 2007).  Other drug-resistance proteins BCRP (breast cancer resistance protein, also 
named ABCG2) and LRP (lung resistance protein) have also an adverse impact  (Dimiani et 
al., 2010; Huh et al., 2006).  
5. Gene expression profiling in CN-AML 
Gene expression profiling (GEP) was described twelve years ago by Golub et al. (1999). GEP 
analyses on the basis of microarrays allow the simultaneous characterization of thousands of 
genes. GEP is useful for the classification of leukemias. In CN-AML, microarray GEP has 
been applied to identify expression signatures in order  to predict clinical outcome within 
this very heterogeneous group of patients.  
Bullinger et al. (2004) and Radmacher et al. (2006) defined by GEP two novel molecular 
subclasses of CN-AML with significant differences in survival times with respect to the 
presence or absence of FLT3 mutations and the FAB subtypes.  
NPM1 gene mutations are connected with specific gene expression pattern in CN-AML 
(Alcalay et al., 2005; Becker et al., 2010; Garzon et al., 2008; Verhaak et al., 2005; Wilson et al., 
2006). This specific gene expression signature was characterised by the activation of homeobox 
(HOX) genes including a particular subset of homeobox TALE (three amino acid loop 
extension) genes distinguish themselves from typical homeodomains containing genes. 
Downregulated in the NPM1 mutations group were genes whose low expression is associated 
with better prognosis in CN-AML as BAALC, MN1, ERG, and multidrug resistance genes. 
Comparison of gene expression between biallelic CEBPA mutation and monoallelic CEBPA 
mutation AML was described by Dufour et al. (2010). Expression of multiple members of the 
homeobox gene family (HOXA5, HOXA9, HOXA10, HOXB2, and HOXB6), CD34, and 
lymphoid markers CD6, CD52, and TSPO (gene for translocator protein, benzodiazepine 
receptor) is downregulated in CN-AML patients with biallelic CEBPA mutation. 
Specific gene expression signatures associated with FLT3-ITD and FLT3-TKD (mutations in 
the tyrosine kinase domain)  were described (Bullinger et al., 2008; Neben et al., 2005; 
Whitman et al., 2008b, 2010). Overexpression of FLT3, homeobox genes (HOXB3, HOXB5, 
PBX3, MEIS1), and immunotherapeutic targets (WT1, CD33) and underexpression of 
leukemia associated (MLLT3, TAL1) and erythropoiesis-associated genes (GATA3, EPOR, 
ANK1, HEMGN) is typical for  FLT3-ITD, whereas overexpression of gene for transcription 
factor FOXA1 containing forkhead box was observed in FLT3-TKD (Neben et al., 2005, 
Whitman et al., 2010). Whereas the predictive value for FLT3-ITD was relatively high (77%), 
the high number of false predictions eliminates GEP as an investigational tool for research 
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studies  waiting on an entrance to clinical practice and decision making (Marcucci et al., 
2011a; Verhaak et al., 2009; Wouters et al., 2009). GEP technique seems not to be in future a 
primary diagnostic tool but will be used in many cases as a confirmative method. 
6. MicroRNA expression profiling 
MicroRNAs (miRs) are small noncoding RNAs of 19 to 25 nucleotides which function as 
negative regulators of gene expression by causing target mRNA cleavage or by interfering 
with target mRNA translation. Dysregulation of miRs plays an important role in the 
pathogenesis of many cancers based on their involvement in basic cellular functions (Nana-
Sinkam & Croce, 2010). In addition, miRs have the capacity to target tens to hundreds of 
genes simultaneously. Thus, they are attractive candidates as prognostic biomarkers and 
therapeutic targets in cancer. 
MiR expression signatures have been correlated with recurrent molecular aberrations in AML. 
NPM1 mutations associate with upregulation of miR10a, miR10b, and miR196a, all lying in the 
genomic cluster of HOX genes that are overexpressed (Becker et al., 2010, Garzon et al., 2008). 
Upregulation of miR181a and miR181b  expression is associated with  CEBPA mutations in CN-
AML (Marcucci et al., 2008; 2009; 2011b). FLT3-ITD was observed to be associated with miR155 
upregulation and miR144 and miR451 downregulation (Whitman et al., 2010). Genome-wide 
profiling identified aberrantly expressed miR associated with R172 IDH2 mutated CN-AML 
patients (Marcucci et al., 2010). The most upregulated miR genes were genes of miR125 family 
(miR125a and miR125b), miR1 and miR133. The most downregulated miR genes were miR194-1, 
miR526, miR520a-3p, and miR548b.  
Recent studies have also shown that clinical outcome in CN-AML is affected by changes in 
miR expression. Overexpression of miR20a, miR25, miR191, miR199a and miR199b adversely 
affected overall survival (Garzon et al., 2008).  
7. DNA methylation arrays 
DNA cytosine methylation in CpG islands regulates gene expression. Aberrant methylation 
of specific genes was observed in cancer including leukemia, although little is known about 
the mechanisms of this specific gene sets methylation. Genome-wide promoter DNA 
methylation profiling revealed unique AML subgroups and methylation patterns that are 
associated with clinical outcome (Bullinger & Armstrong, 2010; Figueroa et al., 2010). DNA 
methylation profiles segregates patients with CEBPA mutations from other subtypes of 
leukemia and defined four epigenetically distinct forms of AML with NPM1 mutations. 
Epigenetic modification of the CEBPA promoter regions was also described and CEBPA 
hypermethylation appeared to be favorable prognostic marker in addition to NPM1  
mutation with lack of FLT3-ITD and CEBPA bi-allelic, double mutations (Hackanson et al., 
2008; Lin et al., 2010; Szankasi et al., 2011). Lugthart et al. (2011) found that the promoter 
DNA methylation signature of EVI1 AML blast cells differed from normal bone marrow 
cells and other AMLs and contained many hypermethylated genes. EVI1 was observed to 
physically interact with DNA methyltransferases 3A and 3B and colocalize with them in 
nuclei and complex is involved in EVI1-mediated transcriptional repression.  Cases with the 
significantly higher levels of EVI1 are associated with many more methylated genes 
(Lugthart et al., 2011).  
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8. Conclusion and future directions 
CN-AML is very heterogeneous on the molecular level and harbours many genetic 
alterations that define new molecular subgroups. This molecular heterogeneity of CN-AML 
is not fully reflected in current classification systems (Vardiman et al. 2008, Döhner et al., 
2010). Molecular markers with prognostic significance are very important  for future 
therapies. Decision over whether to allograft a patient in first complete remission depends 
on the evaluation in a risk/benefit analysis in prognostic scoring system (Smith et al., 2011). 
The favorable cytogenetic risk group is now supplemented by CN-AML with mutant NPM1 
or  biallelic CEBPA mutations in the absence of FLT3-ITD (Döhner et al., 2010). These CN-
AML patients may not need to be referred for allogenic stem cell transplantation in first 
complete remission (Burnett et al., 2011). Low expression of BAALC is also associated with 
favorable outcome in CN-AML (Santamaria et al., 2010), but not  in association with FLT3, 
NPM1, and CEBPA mutations and may not be prognostic in older patients (Langer et al., 
2008). Low BAALC expression is an important factor for complete remission achievment and 
longer disease-free survival. Even better overall survival is reached in CN-AML patients 
who had low ERG expression in addition to low BAALC expression (Burnett et al., 2011). 
The similarity of BAALC  and ERG expression signatures  between younger and older CN-
AML patients and the fact that these molecular markers affect similarly outcomes in the 
group of younger and older than 60 years CN-AML patients sugest that older patients with 
favorable molecular risk factors, such as low BAALC  and ERG expression , if treated more 
intensively, might have outcomes comparable with  those of younger CN-AML patients 
with the same molecular markers (Schwind et al., 2010). Patients with low ERG, low EVI1, 
and high PRAME expression levels were also shown to have a good prognosis (Santamaria 
et al., 2009). Recently, Damm et al. (2011) proposed an integrative prognostic risk score 
(IPRS) for CN-AML patients based on clinical and molecular markers. Nine clinical, 
hematological and molecular factors including age, white blood cell count, mutation status 
of NPM1, FLT3-ITD, CEBPA, WT1 single nucleotide polymorphism SNP rs16754, and 
expression levels of BAALC, ERG, MN1, and WT1 (Damm et al., 2011). Other molecular 
markers like NRAS, MLL-PTD, WT1, IDH1, or IDH2 mutations were not significant and thus 
not included in the IPRS. 
Genomewide search and new technologies will help to subcategorize CN-AML. Gene and 
microRNA signatures and DNA methylation signatures obtained in these studies may 
detect potential targets for new therapies.  
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1. Introduction  
Recent advances in therapeutic regimens targeting aberrant proliferation of leukemia cells 
have led to a decline in the mortality of patients with acute leukemia. Nevertheless, a 
number of patients still suffer from refractory disease or relapse, indicating that more 
innovative and effective therapeutic strategies are required to achieve superior outcomes. 
One of the major indicators of poor prognosis in leukemia patients is extramedullary 
infiltration or dissemination of leukemia cells. In particular, leukemia cell infiltration into 
the central nervous system is one of the major complications negatively influencing 
prognosis. However, little is known about the mechanisms responsible for extramedullary 
dissemination of leukemia cells compared to those responsible for solid tumor metastasis.  
The chemokine SDF1 (stromal derived factor-1) and its receptor CXCR4 regulate trafficking 
of normal hematopoietic stem cells (HSC) as well as metastasis of solid tumor cells. 
Similarly, the majority of acute myeloid leukemia (AML) cells express CXCR4 and migrate 
in response to SDF1, suggesting that the SDF1/CXCR4 axis may be involved in the 
dissemination of AML cells to various organs. A recent study also suggests that 
chemokine/chemokine receptor interactions orchestrate extramedullary dissemination in 
childhood AML. Moreover, signaling through the chemokine receptor CCR7 is crucial for 
infiltration of T-ALL cells in the central nervous system. Our recent studies indicate that 
internal tandem duplication mutations of the Flt3 gene (ITD-Flt3), found in patients with 
AML, significantly augments migration of hematopoietic cells by deregulating CXCR4 
signaling that are qualitatively distinct from cells lacking ITD-Flt3 and facilitate their 
infiltration to visceral organs while decreasing their homing to the bone marrow. ITD-Flt3 
regulates overlapping as well as functionally distinct signaling pathways down-stream of 
SDF1/CXCR4 compared to cells that do not harbor ITD-Flt3 mutations. The data suggest 
that ITD-Flt3 may facilitate dissemination of leukemia cells by modulating SDF1/CXCR4 
signaling and that blocking this functional cross-talk between ITD-Flt3 and CXCR4 
pathways may have therapeutic benefit. Therefore, genes differentially regulated by SDF1 
specifically in ITD-Flt3 cells may represent key targets regulating aberrant migration by 
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ITD-Flt3 in response to SDF1 to prevent unnecessary dissemination and invasiveness of 
ITD-Flt3+ acute leukemia cells without affecting normal hematopoiesis. This chapter will 
describe gene and receptor signaling pathways responsible for aberrant trafficking of acute 
leukemia cells and discuss therapeutic implications of antagonizing chemokine receptor 
signaling to selectively block extramedullary dissemination of leukemia cells. 
2. Dissemination of acute leukemia and the role of chemokines and 
chemokine receptors 
Despite significant advances in treatments for patients with acute leukemia during the past 
decade, the prognosis of patients with minimal residual disease is generally poor and 
recurrence of the disease is common. One of the major complications that leads to poor 
outcomes of both adults and pediatric patients with acute leukemia is central nervous 
system (CNS) infiltration of leukemia cells. Intensified intrathecal chemotherapy and cranial 
irradiation for prophylaxis of CNS relapse can lead to serious adverse side effects, 
particularly secondary tumors, bone marrow suppression, growth impairment and 
endocrine complications (Pui CH & Howard SC, 2008). In order to minimize the treatment 
associated mortality, blocking leukemia cell invasion and migration may represent a rational 
alternative strategy. However, despite the clinical importance of CNS infiltration of 
leukemia cells, little is known about the underlying mechanism. In addition to CNS, 
leukemia cells are often found in other extramedullary sites, including skin and visceral 
organs, which is also an adverse prognostic factor (Byrd JC et al., 1995, Kaneider NC et al., 
2002). It is conceivable that leukemia stem cells are derived from a single transformed clone 
in the bone marrow that subsequently peripheralize into the peripheral blood circulation 
and home to other organs or different sites within the marrow where they occupy normal 
hematopoietic niches and impair production of functionally normal blood cells. Similar 
processes can take place in simultaneously or successive manner, which in turn causes 
serious hematological complications. Dissemination of AML cells to other marrow sites 
increases the frequency for AML cells to interact with normal marrow niches and 
extracellular matrix (ECM), such as stromal fibronectin, via surface integrins, which is one of 
the mechanisms responsible for minimal residual disease in AML (Matsunaga T et al., 2003). 
Therefore, dissemination of acute leukemia cells must be considered a crucial step in 
leukemic progression (Figure 1). The current chemotherapies and molecular targeting drugs 
were designed to kill leukemia cells but none of them are able to antagonize their movement 
and trafficking. Understanding molecular mechanisms regulating aberrant leukemia cell 
trafficking will aid in developing innovative therapeutic modalities to block leukemic 
infiltration to secondary organs, and will lead to superior outcomes of leukemia treatment. 
One of the major causative molecules associated with AML and poor prognosis is internal 
tandem duplication mutation of the Flt3 kinase gene (ITD-Flt3). Several Flt3 kinase 
inhibitors have been developed and evaluated in early clinical trials with varied degrees of 
success, achieving >50% blast reduction in 12.5 to 81.3% of patients, with the duration of 
response ranging from two weeks to five months (Fiedler W et al., 2003, Smith BD et al., 
2004, Stirewalt DL & Radich JP, 2003), indicating that targeting cell autonomous mechanism 
alone by these therapies was not sufficient to produce a complete cure. In this regard, the 
discovery of the leukemia cell niche identifies a new concept and suggests potential 
therapeutic approaches to antagonize interaction between the leukemia cell and their niche 
in addition to those targeting cell autonomous mechanisms. The leukemia cells destroy the 
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normal hematopoietic niche and create their own niche by down-regulating SDF1 in the 
lesion where leukemia cells invade in the bone marrow (Colmone et al., 2008). 
Extramedullary infiltration of AML to distant organs likely accompanies creation of new 
niches in secondary organs by the leukemia cells, which in turn protects them from various 







Fig. 1. Dissemination of leukemia cells is a crucial step for disease progression 
Chemokines and their receptors play an important role in trafficking of hematopoietic stem 
cells (HSC) (Lapidot T & Petit I, 2000) and metastasis of tumor cells to distant organs (Muller 
A et al., 2001). The major chemokine regulating homing and mobilization of HSC is stromal 
cell-derived factor-1 alpha (SDF1), a ligand for the cell surface CXCR4 receptor (Lapidot T & 
Petit I, 2000). SDF1 is expressed by osteoblasts, stromal cells and vascular endothelial cells in 
the bone marrow and attracts and retains HSC in the marrow niche (Lane SW, Scadden DT, 
& Gilliland DG, 2009). Within the niche, leukemia cells receive survival cues from 
osteoblasts and endothelial cells in the form of various cytokines and adhesion molecules 
provided by niche cells, which in turn increase their resistance to cytoreductive therapies 
(Lane SW, Scadden DT, & Gilliland DG, 2009). However, in skin, brain and visceral organs, 
extramedullary involvement is occasionally observed in patients with AML and ALL (Byrd 
JC, Edenfield WJ, Shields DJ, & Dawson NA, 1995, Pui CH & Howard SC, 2008). Leukemia 
cells need to leave their original bone marrow niche and find their home in the distant 
secondary niche for initiation of extramedullary dissemination. The mechanism for 
extramedullary infiltration of leukemia cells remains unexplored. Leukemia cells in the 
marrow express higher CXCR4 compared to their circulating counterparts, suggesting that 
interaction between SDF1 and CXCR4 facilitates retention of leukemia cells in the marrow 
niche (Spoo AC et al., 2006). The majority of leukemia cells express CXCR4 and migrate in 
response to SDF1. Antagonizing CXCR4 inhibits engraftment and development of AML in a 
human xenograft human AML model, suggesting that CXCR4 is required for human AML 
to home to marrow niches (Tavor S et al., 2004). Higher CXCR4 expression predicts 
extramedullary infiltration in pediatric patients with ALL (Crazzolara R et al., 2001) and 
functional CXCR4 microparticles and SDF1 correlate with circulating AML (Kalinkovich et 
al., 2006). These data suggest that chemokine signaling pathways are likely to play crucial 
roles in the dissemination of leukemia cells to secondary organs. Recent studies suggest that 
releasing leukemia cells from the marrow niche by blocking SDF1/CXCR4 interaction is 
effective in increasing their sensitivity to cytoreductive treatment (Nervi B et al., 2009). 
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Instead of this strategy that principally targets aberrant leukemia cell proliferation, 
modulating functions of CXCR4 or other chemokine signaling in leukemia cells themselves 
may represent an alternative strategy to reduce their dissemination to secondary organs.  
2.1 Physiological role of SDF1 and CXCR4 
SDF1 is expressed in spleen, liver, lung, kidney, thymus, brain (Nervi B et al., 2009), stromal 
cells (Nagasawa T et al., 1994) and osteoblasts (Jung Y et al., 2006, Semerad CL et al., 2005) in 
bone marrow and regulates development of hematopoietic cells, immune cells, blood 
vessels, heart and brain (Tachibana K et al., 1998, Zou YR et al., 1998). Targeted disruption of 
CXCR4 gene results in impaired bone marrow myelopoiesis and B-lymphopoiesis (Zou YR 
et al., 1998), which is a similar phenotype with SDF -/- mice (Nagasawa T et al., 1996). One 
of the major physiological roles of the SDF1/CXCR4 axis is to regulate homing, retention, 
and survival of primitive hematopoietic stem and progenitor cells (HSPC) (Christopherson 
KW 2nd et al., 2003, Kim CH & Broxmeyer HE, 1998, Levesque JP et al., 2003, Liles WC et al., 
2003, Peled A et al., 1999). Interaction between SDF1 and its receptor CXCR4 is believed to 
play an important role in these processes. SDF1 can attract HSPC that express CXCR4 to the 
marrow microenvironment (Kim CH & Broxmeyer HE, 1998, Peled A et al., 1999), while 
disruption of SDF1/CXCR4 interaction within marrow can under appropriate circumstances 















Fig. 2. SDF1 and CXCR4 regulate homing and mobilization of hematopoietic stem cells 
HSCs can be found in contact with the cells expressing high amounts of SDF1 (Sugiyama T 
et al., 2006). SDF1/CXCR4 signaling plays an essential role in maintaining the quiescent HSC 
pool (Sugiyama T et al., 2006). SDF1 can activate adhesion molecules, particularly very late 
antigen-4 (VLA-4) and lymphocyte function associated antigen-1 (LFA-1) on HSPC, which 
also regulate the homing process (Peled A et al., 2000). SDF1 enhances survival or 
proliferation of normal hematopoietic progenitor cells (Broxmeyer HE et al., 2003) and 
regulates development of B-cells (Ma Q et al., 1999). Expression of CXCR4 is up-regulated by 
various cytokines, including stem cell factor (Peled A et al., 1999), VEGF, bFGF, EGF, IL2, 
IL4, IL6, IL7, IL10 and IL15 (Busillo JM & Benovic JL, 2007). In contrast, Flt3 ligand (Fukuda 
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S et al., 2005), TNF and INF down-regulate CXCR4 expression (Busillo JM & Benovic JL, 
2007). Adrenergic inputs down-regulate SDF1 in the marrow environment during daytime 
(Mendez-Ferrer et al., 2008), but up-regulate CXCR4 on HSC at night (Lucas D et al., 2008). 
Although it was believed that CXCR4 was the only receptor for SDF1, a recent study 
identified CXCR7 as a secondary receptor for SDF1 (Balabanian K et al., 2005). However, 
unlike CXCR4, CXCR7 mediates only cell survival, clustering and proliferation and lacks the 
ability to mediate chemotaxis (Burns JM et al., 2006).  
2.2 SDF1/CXCR4 in hematological malignancies  
CXCR4 is expressed in most hematological malignancies including chronic lymphocytic 
leukemia (CLL), chronic myeloid leukemia (CML) (Burger JA et al., 1999), acute 
lymphoblastic leukemia (ALL) (Bradstock KF et al., 2000, Mohle R et al., 2000), acute myeloid 
leukemia (AML) (Kalinkovich A et al., 2006, Rombouts EJ et al., 2004) (Voermans C et al., 
2002), B-cell lymphoma (Burger JA et al., 1999, Trentin L et al., 2004), T-cell non Hodgkin 
lymphoma (NHL) (Weng AP et al., 2003) and multiple myeloma (Weng AP et al., 2003). High 
expression of CXCR4 predicts extramedullary organ infiltration in childhood ALL 
(Crazzolara R et al., 2001) and elevated CXCR4 expression is associated with poor prognosis 
of patients with AML (Rombouts EJ et al., 2004, Spoo AC et al., 2006). Extramedullary 
infiltration of M5 AML is associated with high CXCR4 expression (Mohle R et al., 2000), 
suggesting that the SDF1/CXCR4 axis may be involved in the extramedullary disease of 
AML. In contrast, a recent report suggests that involvement of CXCR4 in skin infiltration of 
AML is unlikely (Faaij CMJM et al., 2010). The extramedullary dissemination of AML may 
be associated with differentiation of AML that appears to affect CXCR4 expression, namely 
lower CXCR4 in undifferentiated M0, M1 and M2 compared to more differentiated M3, M4 
and M5. Another study described that extramedullary dissemination of AML depends on 
single nucleotide polymorphism (SNP) of SDF1 (Dommange F et al., 2006). Furthermore, 
SDF1 can recruit endothelial progenitor cells to the tumor microenvironment to facilitate 
neo-vascularization (Orimo A et al., 2005), which may be required for continued growth of 
leukemia cells in the extramedullary niche. It has been suggested that targeting CXCR4 
signaling pathways may be an important therapeutic strategy for ALL (Juarez J et al., 2003), 
CLL (Burger M et al., 2005a) and NHL (Bertolini F et al., 2002). Recent data indicates that 
SDF1 plays an important role in protecting AML cells in the marrow niche, especially 
during intensive chemotherapy (Zeng ZH et al., 2009). Blocking SDF1/CXCR4 signaling 
releases leukemia cells from marrow niches into blood circulation, dissociating them from 
the protective signal in the niche, and increases their sensitivity to chemotherapy (Nervi B et 
al., 2009). Physiological circadian oscillation of SDF1 in the marrow niche and CXCR4 
expression on HSC allows HSC to peripheralize into the blood circulation (Lucas D et al., 
2008, Mendez-Ferrer S et al., 2008). It is likely that similar fluctuation in SDF1 and CXCR4 on 
leukemia stem cells that can affect their mobilization and homing may exist.  
Similarly, recent evidence suggests that SDF1/CXCR4 signaling plays a central role in 
metastasis of solid tumors to the bone marrow or other tissues where SDF1 is expressed 
(Geminder H et al., 2001, Muller A et al., 2001) and serves as a survival factor for various 
solid tumor or leukemia cells (Burger JA et al., 2000, Orimo A et al., 2005, Zhou Y et al., 2002). 
A growing body of evidence indicates that SDF1/CXCR4 signaling and oncogenic proteins, 
such as BCR/ABL in CML (Geay JF et al., 2005, Mishra S et al., 2006, Ptasznik A et al., 2002, 
Salgia R et al., 1999), HER2 in breast cancer (Cabioglu N et al., 2006, Li YM et al., 2004) and 
Internal Tandem Duplication (ITD)-Flt3 in AML (Fukuda S et al., 2005, Fukuda S & Pelus 
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Instead of this strategy that principally targets aberrant leukemia cell proliferation, 
modulating functions of CXCR4 or other chemokine signaling in leukemia cells themselves 
may represent an alternative strategy to reduce their dissemination to secondary organs.  
2.1 Physiological role of SDF1 and CXCR4 
SDF1 is expressed in spleen, liver, lung, kidney, thymus, brain (Nervi B et al., 2009), stromal 
cells (Nagasawa T et al., 1994) and osteoblasts (Jung Y et al., 2006, Semerad CL et al., 2005) in 
bone marrow and regulates development of hematopoietic cells, immune cells, blood 
vessels, heart and brain (Tachibana K et al., 1998, Zou YR et al., 1998). Targeted disruption of 
CXCR4 gene results in impaired bone marrow myelopoiesis and B-lymphopoiesis (Zou YR 
et al., 1998), which is a similar phenotype with SDF -/- mice (Nagasawa T et al., 1996). One 
of the major physiological roles of the SDF1/CXCR4 axis is to regulate homing, retention, 
and survival of primitive hematopoietic stem and progenitor cells (HSPC) (Christopherson 
KW 2nd et al., 2003, Kim CH & Broxmeyer HE, 1998, Levesque JP et al., 2003, Liles WC et al., 
2003, Peled A et al., 1999). Interaction between SDF1 and its receptor CXCR4 is believed to 
play an important role in these processes. SDF1 can attract HSPC that express CXCR4 to the 
marrow microenvironment (Kim CH & Broxmeyer HE, 1998, Peled A et al., 1999), while 
disruption of SDF1/CXCR4 interaction within marrow can under appropriate circumstances 















Fig. 2. SDF1 and CXCR4 regulate homing and mobilization of hematopoietic stem cells 
HSCs can be found in contact with the cells expressing high amounts of SDF1 (Sugiyama T 
et al., 2006). SDF1/CXCR4 signaling plays an essential role in maintaining the quiescent HSC 
pool (Sugiyama T et al., 2006). SDF1 can activate adhesion molecules, particularly very late 
antigen-4 (VLA-4) and lymphocyte function associated antigen-1 (LFA-1) on HSPC, which 
also regulate the homing process (Peled A et al., 2000). SDF1 enhances survival or 
proliferation of normal hematopoietic progenitor cells (Broxmeyer HE et al., 2003) and 
regulates development of B-cells (Ma Q et al., 1999). Expression of CXCR4 is up-regulated by 
various cytokines, including stem cell factor (Peled A et al., 1999), VEGF, bFGF, EGF, IL2, 
IL4, IL6, IL7, IL10 and IL15 (Busillo JM & Benovic JL, 2007). In contrast, Flt3 ligand (Fukuda 
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S et al., 2005), TNF and INF down-regulate CXCR4 expression (Busillo JM & Benovic JL, 
2007). Adrenergic inputs down-regulate SDF1 in the marrow environment during daytime 
(Mendez-Ferrer et al., 2008), but up-regulate CXCR4 on HSC at night (Lucas D et al., 2008). 
Although it was believed that CXCR4 was the only receptor for SDF1, a recent study 
identified CXCR7 as a secondary receptor for SDF1 (Balabanian K et al., 2005). However, 
unlike CXCR4, CXCR7 mediates only cell survival, clustering and proliferation and lacks the 
ability to mediate chemotaxis (Burns JM et al., 2006).  
2.2 SDF1/CXCR4 in hematological malignancies  
CXCR4 is expressed in most hematological malignancies including chronic lymphocytic 
leukemia (CLL), chronic myeloid leukemia (CML) (Burger JA et al., 1999), acute 
lymphoblastic leukemia (ALL) (Bradstock KF et al., 2000, Mohle R et al., 2000), acute myeloid 
leukemia (AML) (Kalinkovich A et al., 2006, Rombouts EJ et al., 2004) (Voermans C et al., 
2002), B-cell lymphoma (Burger JA et al., 1999, Trentin L et al., 2004), T-cell non Hodgkin 
lymphoma (NHL) (Weng AP et al., 2003) and multiple myeloma (Weng AP et al., 2003). High 
expression of CXCR4 predicts extramedullary organ infiltration in childhood ALL 
(Crazzolara R et al., 2001) and elevated CXCR4 expression is associated with poor prognosis 
of patients with AML (Rombouts EJ et al., 2004, Spoo AC et al., 2006). Extramedullary 
infiltration of M5 AML is associated with high CXCR4 expression (Mohle R et al., 2000), 
suggesting that the SDF1/CXCR4 axis may be involved in the extramedullary disease of 
AML. In contrast, a recent report suggests that involvement of CXCR4 in skin infiltration of 
AML is unlikely (Faaij CMJM et al., 2010). The extramedullary dissemination of AML may 
be associated with differentiation of AML that appears to affect CXCR4 expression, namely 
lower CXCR4 in undifferentiated M0, M1 and M2 compared to more differentiated M3, M4 
and M5. Another study described that extramedullary dissemination of AML depends on 
single nucleotide polymorphism (SNP) of SDF1 (Dommange F et al., 2006). Furthermore, 
SDF1 can recruit endothelial progenitor cells to the tumor microenvironment to facilitate 
neo-vascularization (Orimo A et al., 2005), which may be required for continued growth of 
leukemia cells in the extramedullary niche. It has been suggested that targeting CXCR4 
signaling pathways may be an important therapeutic strategy for ALL (Juarez J et al., 2003), 
CLL (Burger M et al., 2005a) and NHL (Bertolini F et al., 2002). Recent data indicates that 
SDF1 plays an important role in protecting AML cells in the marrow niche, especially 
during intensive chemotherapy (Zeng ZH et al., 2009). Blocking SDF1/CXCR4 signaling 
releases leukemia cells from marrow niches into blood circulation, dissociating them from 
the protective signal in the niche, and increases their sensitivity to chemotherapy (Nervi B et 
al., 2009). Physiological circadian oscillation of SDF1 in the marrow niche and CXCR4 
expression on HSC allows HSC to peripheralize into the blood circulation (Lucas D et al., 
2008, Mendez-Ferrer S et al., 2008). It is likely that similar fluctuation in SDF1 and CXCR4 on 
leukemia stem cells that can affect their mobilization and homing may exist.  
Similarly, recent evidence suggests that SDF1/CXCR4 signaling plays a central role in 
metastasis of solid tumors to the bone marrow or other tissues where SDF1 is expressed 
(Geminder H et al., 2001, Muller A et al., 2001) and serves as a survival factor for various 
solid tumor or leukemia cells (Burger JA et al., 2000, Orimo A et al., 2005, Zhou Y et al., 2002). 
A growing body of evidence indicates that SDF1/CXCR4 signaling and oncogenic proteins, 
such as BCR/ABL in CML (Geay JF et al., 2005, Mishra S et al., 2006, Ptasznik A et al., 2002, 
Salgia R et al., 1999), HER2 in breast cancer (Cabioglu N et al., 2006, Li YM et al., 2004) and 
Internal Tandem Duplication (ITD)-Flt3 in AML (Fukuda S et al., 2005, Fukuda S & Pelus 
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LM, 2006), functionally interact to modulate migration of malignant cells. Their concomitant 
expression with CXCR4 is often associated with poor patient prognosis (Li YM et al., 2004, 
Mishra S et al., 2006).  
2.3 Hematopoietic growth factors that affect SDF1/CXCR4 signaling and migration of 
leukemia cells 
While hematopoietic growth factors normally stimulate proliferation and survival of HSPC, 
some of them can stimulate migration. Stem cell factor (SCF) and Flt3 ligand (FL) are the 
respective ligands for the receptor tyrosine kinases c-kit and Flt3 that are expressed on 
HSPC. Although they have similar but distinct roles in HSPC proliferation and survival 
(Lyman SD & Jacobsen SEW, 1998), they both stimulate migration of human cord blood 
(UCB) CD34+ cells (Fukuda S et al., 2005, Kim CH & Broxmeyer HE, 1998). In contrast to the 
chemotactic activity of SDF1 that stimulates directional cell migration towards the 
chemokine (chemotaxis), SCF and FL stimulate random cell migration (chemokinesis). SCF 
increases SDF1-induced chemotaxis of the AML line MO7e cells when combined with SDF1 
(Kim CH & Broxmeyer HE, 1998). Similarly, FL enhances migration of the RS4;11 bi-
phenotypic acute leukemia cell lines to SDF1 (Fukuda S et al., 2005). These data suggest that 
hematopoietic growth factors regulate migration of acute leukemia cells by modulating the 
SDF1/CXCR4 axis.  
Although both SCF as well as FL enhance migration of human UCB CD34+ cells induced by 
SDF1 in a similar manner, prolonged exposure the cells to SDF1 result in differential 
migratory responses. Prolonged incubation of UCB CD34+ cells with SCF up-regulates 
CXCR4 expression and enhances subsequent migration to SDF1 (Peled A et al., 1999). In 
contrast, incubation of UCB CD34+ cells with FL over 24 hrs down-regulates CXCR4 
expression coincident with a decrease in subsequent migration to SDF1 (Fukuda S et al., 
2005). Down-regulation of CXCR4 by incubation with FL is consistent with reduction of 
CXCR4 in CD34+ cells transfected with ITD-Flt3 that activate Flt3 without ligand binding 
(Jacobi A et al., 2010). Similar to human CD34+ cells, the differential migration to SDF1 
modulated by FL was also observed in Ba/F3 cells expressing human wild-type Flt3 
receptor. The synergistic cell migration in response to the combination of SDF1 and FL was 
associated with synergistic phosphorylation of ERK, Akt and CREB. These results suggest 
that ERK, Akt and CREB are involved in the synergistic increase in migration by the 
combination of SDF1 plus FL. On the other hand, pre-incubation of Ba/F3 cells expressing 
Flt3 with FL for 24 hours down-regulates CXCR4 and significantly diminishes their 
subsequent migration to SDF1 compared to control cells pre-incubated without FL. In 
contrast to synergistic response, phosphorylation of ERK, Akt and CREB in response to 
SDF1 was reduced in the cells pretreated with FL compared to untreated control cells, 
further validating the differential modulation of SDF1/CXCR4 signaling by FL/Flt3 
(Fukuda S et al., 2005). Down-regulation of CXCR4 by FL may explain one of the 
mechanisms of HPC mobilization by FL administration (Brasel K et al., 1997). A similar 
effect by SCF is not known. These data indicate overlapping but distinct roles of c-kit and 
Flt3 signaling on CD34+ cell migration induced by SDF1. 
2.4 Bcr/abl alters signaling and chemotactic response mediated by SDF1/CXCR4 
Chronic myeloid leukemia (CML) is caused by the Bcr/Abl oncogene with constitutive 
kinase activity, a result of a reciprocal translocation between chromosmes 9 and 22 
(Kurzrock R et al., 1988, Sawyers CL, 1999). Bcr/abl is occasionally observed in acute 
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lymphoblastic leukemia cells (ALL) as well (Mishra S et al., 2006). One of the characteristics 
of CML is an early release of myeloid cells from the marrow and their accumulation in the 
blood and spleen, suggesting that cell retention in the marrow or migration may be 
impaired. CML cells show reduced adhesion to stromal cells and extracellular matrix 
(Gordon MY et al., 1987, Verfaillie CM et al., 1992) that may concomitantly contribute to 
impaired retention. Ectopic Bcr/Abl increases spontaneous motility of hematopoietic cell 
lines; however, it significantly reduces chemotactic response to SDF1 (Salgia R et al.,1999). 
Homing of mouse hematopoietic Ba/F3 cells expressing Bcr/Abl to spleens in the mice that 
have been ectopically injected with SDF1 was significantly reduced compared to control 
cells, although their homing to the bone marrow, lung or blood was not affected. The 
migratory response of primary CML cells to SDF1 at blast crisis was profoundly reduced, 
which was associated with reduced CXCR4 expression, while CD34+ cells at chronic phase 
migrate normally in response to SDF1 (Geay JF et al., 2005). In addition, higher Bcr/abl 
expression induces a marked down regulation of CXCR4, while treatment with STI-571 
(Imatinib), the Bcr/abl antagonist, that blocks Bcr/abl activity restores CXCR4 expression in 
CD34+ cells from patients in blast crisis (Geay JF et al.,2005). The reduction in CXCR4 
expression and loss of response to SDF1 mediated by Bcr/abl may allow CML cells to exit 
bone marrow, resulting in infiltration to secondary organs, including blood and spleen. 
These data suggest that Bcr/abl regulates trafficking of hematopoietic cells by modulating 
SDF1/CXCR4 function, which is associated with disease progression and extramedullary 
dissemination. Conversely, SDF1 can increase resistance of acute lymphoblastic leukemia 
cells expressing Bcr/abl to STI-571, suggesting that SDF1/CXCR4 signaling may augment 
Bcr/abl signaling that enhances resistance to the therapy (Mishra S et al., 2006).  
2.5 ITD-Flt3 alters chemotaxis induced by SDF1/CXCR4 signaling 
Genetic mutations (Internal tandem duplication: ITD) of the Flt3 gene that pathologically 
auto-activate Flt3 tyrosine kinase activity have been found in ~25-30% of patients with AML 
and elevated CXCR4 receptor expression is associated with poor outcome in patients with 
acute myeloid leukemia (AML) (Levis M & Small D, 2003, Spoo AC et al., 2006), suggesting 
a role for ITD-Flt3 and CXCR4 in disease progression. Fifteen percent of patients with 
extramedullary AML were positive for ITD-Flt3 (Ansari-Lari et al., 2004), suggesting that 
ITD-Flt3 may affect migration and trafficking of leukemia cells. ITD-Flt3 mutations cause 
extramedullary infiltration of hematopoietic cells with splenomegaly in a myeloproliferative 
disease model in mice (Kelly LM et al., 2002). Consistent with this finding, ITD-Flt3 
significantly increases accumulation of Ba/F3 cells in the spleen shortly after transplantation 
compared to wild-type Flt3 (Fukuda S & Pelus LM, 2006). Stable expression of ITD-Flt3 in 
mouse Ba/F3 and 32D cells significantly increases migration to SDF1 in addition to 
enhancing spontaneous motility (Figure 3) (Fukuda S et al., 2005). This is in contrast to 
Bcr/abl that increases spontaneous motility while reducing migration in response to SDF1 
(Geay JF et al., 2005, Salgia R et al., 1999). Importantly, CXCR4 expression on Ba/F3 cells 
harboring ITD-Flt3 mutations was significantly reduced, indicating that enhanced migration 
is not explained by CXCR4 expression (Fukuda S et al., 2005) (Figure 3). This is consistent 
with down-regulation of CXCR4 in Ba/F3 cells expressing wild–type Flt3 or UCB CD34+ 
cells incubated with FL for over 24 hours. However, longer exposure to FL reduces 
migration to SDF1 (Fukuda S et al., 2005). In contrast to synergistic phosphorylation of ERK, 
Akt or CREB coincident with enhanced migration to SDF1 and FL in Ba/F3 cells harboring 
wild-type Flt3, accentuated migration to SDF1 by ITD-Flt3 was not associated with an 
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LM, 2006), functionally interact to modulate migration of malignant cells. Their concomitant 
expression with CXCR4 is often associated with poor patient prognosis (Li YM et al., 2004, 
Mishra S et al., 2006).  
2.3 Hematopoietic growth factors that affect SDF1/CXCR4 signaling and migration of 
leukemia cells 
While hematopoietic growth factors normally stimulate proliferation and survival of HSPC, 
some of them can stimulate migration. Stem cell factor (SCF) and Flt3 ligand (FL) are the 
respective ligands for the receptor tyrosine kinases c-kit and Flt3 that are expressed on 
HSPC. Although they have similar but distinct roles in HSPC proliferation and survival 
(Lyman SD & Jacobsen SEW, 1998), they both stimulate migration of human cord blood 
(UCB) CD34+ cells (Fukuda S et al., 2005, Kim CH & Broxmeyer HE, 1998). In contrast to the 
chemotactic activity of SDF1 that stimulates directional cell migration towards the 
chemokine (chemotaxis), SCF and FL stimulate random cell migration (chemokinesis). SCF 
increases SDF1-induced chemotaxis of the AML line MO7e cells when combined with SDF1 
(Kim CH & Broxmeyer HE, 1998). Similarly, FL enhances migration of the RS4;11 bi-
phenotypic acute leukemia cell lines to SDF1 (Fukuda S et al., 2005). These data suggest that 
hematopoietic growth factors regulate migration of acute leukemia cells by modulating the 
SDF1/CXCR4 axis.  
Although both SCF as well as FL enhance migration of human UCB CD34+ cells induced by 
SDF1 in a similar manner, prolonged exposure the cells to SDF1 result in differential 
migratory responses. Prolonged incubation of UCB CD34+ cells with SCF up-regulates 
CXCR4 expression and enhances subsequent migration to SDF1 (Peled A et al., 1999). In 
contrast, incubation of UCB CD34+ cells with FL over 24 hrs down-regulates CXCR4 
expression coincident with a decrease in subsequent migration to SDF1 (Fukuda S et al., 
2005). Down-regulation of CXCR4 by incubation with FL is consistent with reduction of 
CXCR4 in CD34+ cells transfected with ITD-Flt3 that activate Flt3 without ligand binding 
(Jacobi A et al., 2010). Similar to human CD34+ cells, the differential migration to SDF1 
modulated by FL was also observed in Ba/F3 cells expressing human wild-type Flt3 
receptor. The synergistic cell migration in response to the combination of SDF1 and FL was 
associated with synergistic phosphorylation of ERK, Akt and CREB. These results suggest 
that ERK, Akt and CREB are involved in the synergistic increase in migration by the 
combination of SDF1 plus FL. On the other hand, pre-incubation of Ba/F3 cells expressing 
Flt3 with FL for 24 hours down-regulates CXCR4 and significantly diminishes their 
subsequent migration to SDF1 compared to control cells pre-incubated without FL. In 
contrast to synergistic response, phosphorylation of ERK, Akt and CREB in response to 
SDF1 was reduced in the cells pretreated with FL compared to untreated control cells, 
further validating the differential modulation of SDF1/CXCR4 signaling by FL/Flt3 
(Fukuda S et al., 2005). Down-regulation of CXCR4 by FL may explain one of the 
mechanisms of HPC mobilization by FL administration (Brasel K et al., 1997). A similar 
effect by SCF is not known. These data indicate overlapping but distinct roles of c-kit and 
Flt3 signaling on CD34+ cell migration induced by SDF1. 
2.4 Bcr/abl alters signaling and chemotactic response mediated by SDF1/CXCR4 
Chronic myeloid leukemia (CML) is caused by the Bcr/Abl oncogene with constitutive 
kinase activity, a result of a reciprocal translocation between chromosmes 9 and 22 
(Kurzrock R et al., 1988, Sawyers CL, 1999). Bcr/abl is occasionally observed in acute 
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lymphoblastic leukemia cells (ALL) as well (Mishra S et al., 2006). One of the characteristics 
of CML is an early release of myeloid cells from the marrow and their accumulation in the 
blood and spleen, suggesting that cell retention in the marrow or migration may be 
impaired. CML cells show reduced adhesion to stromal cells and extracellular matrix 
(Gordon MY et al., 1987, Verfaillie CM et al., 1992) that may concomitantly contribute to 
impaired retention. Ectopic Bcr/Abl increases spontaneous motility of hematopoietic cell 
lines; however, it significantly reduces chemotactic response to SDF1 (Salgia R et al.,1999). 
Homing of mouse hematopoietic Ba/F3 cells expressing Bcr/Abl to spleens in the mice that 
have been ectopically injected with SDF1 was significantly reduced compared to control 
cells, although their homing to the bone marrow, lung or blood was not affected. The 
migratory response of primary CML cells to SDF1 at blast crisis was profoundly reduced, 
which was associated with reduced CXCR4 expression, while CD34+ cells at chronic phase 
migrate normally in response to SDF1 (Geay JF et al., 2005). In addition, higher Bcr/abl 
expression induces a marked down regulation of CXCR4, while treatment with STI-571 
(Imatinib), the Bcr/abl antagonist, that blocks Bcr/abl activity restores CXCR4 expression in 
CD34+ cells from patients in blast crisis (Geay JF et al.,2005). The reduction in CXCR4 
expression and loss of response to SDF1 mediated by Bcr/abl may allow CML cells to exit 
bone marrow, resulting in infiltration to secondary organs, including blood and spleen. 
These data suggest that Bcr/abl regulates trafficking of hematopoietic cells by modulating 
SDF1/CXCR4 function, which is associated with disease progression and extramedullary 
dissemination. Conversely, SDF1 can increase resistance of acute lymphoblastic leukemia 
cells expressing Bcr/abl to STI-571, suggesting that SDF1/CXCR4 signaling may augment 
Bcr/abl signaling that enhances resistance to the therapy (Mishra S et al., 2006).  
2.5 ITD-Flt3 alters chemotaxis induced by SDF1/CXCR4 signaling 
Genetic mutations (Internal tandem duplication: ITD) of the Flt3 gene that pathologically 
auto-activate Flt3 tyrosine kinase activity have been found in ~25-30% of patients with AML 
and elevated CXCR4 receptor expression is associated with poor outcome in patients with 
acute myeloid leukemia (AML) (Levis M & Small D, 2003, Spoo AC et al., 2006), suggesting 
a role for ITD-Flt3 and CXCR4 in disease progression. Fifteen percent of patients with 
extramedullary AML were positive for ITD-Flt3 (Ansari-Lari et al., 2004), suggesting that 
ITD-Flt3 may affect migration and trafficking of leukemia cells. ITD-Flt3 mutations cause 
extramedullary infiltration of hematopoietic cells with splenomegaly in a myeloproliferative 
disease model in mice (Kelly LM et al., 2002). Consistent with this finding, ITD-Flt3 
significantly increases accumulation of Ba/F3 cells in the spleen shortly after transplantation 
compared to wild-type Flt3 (Fukuda S & Pelus LM, 2006). Stable expression of ITD-Flt3 in 
mouse Ba/F3 and 32D cells significantly increases migration to SDF1 in addition to 
enhancing spontaneous motility (Figure 3) (Fukuda S et al., 2005). This is in contrast to 
Bcr/abl that increases spontaneous motility while reducing migration in response to SDF1 
(Geay JF et al., 2005, Salgia R et al., 1999). Importantly, CXCR4 expression on Ba/F3 cells 
harboring ITD-Flt3 mutations was significantly reduced, indicating that enhanced migration 
is not explained by CXCR4 expression (Fukuda S et al., 2005) (Figure 3). This is consistent 
with down-regulation of CXCR4 in Ba/F3 cells expressing wild–type Flt3 or UCB CD34+ 
cells incubated with FL for over 24 hours. However, longer exposure to FL reduces 
migration to SDF1 (Fukuda S et al., 2005). In contrast to synergistic phosphorylation of ERK, 
Akt or CREB coincident with enhanced migration to SDF1 and FL in Ba/F3 cells harboring 
wild-type Flt3, accentuated migration to SDF1 by ITD-Flt3 was not associated with an 
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increase in phosphorylation of these molecules (Table 1). These findings suggest qualitative 
differences between ITD-Flt3 signaling and FL /wild type Flt3 signaling, even if both stimuli 
result in similar enhancement in migration to SDF1.  
 
FL prolonged stimulation with FL ITD-Flt3
CXCR4 no change → decrease ↓ decrease ↓
Migration to SDF1 increase ↑ decrease ↓ increase ↑
Phospho ERK, Akt, CREB increase ↑ decrease ↓ no change →  
Table 1. Differential regulation on CXCR4 expression and migration to SDF1 by FL/wild-

















Fig. 3. Migration and CXCR4 expression of ITD-Flt3 + or ITD-Flt3 - Ba/F3 cells. Migration of 
ITD-Flt3+ cells towards SDF1 was significantly elevated compared to ITD-Flt3 – cells  
(* P<0.05: left panel). However, CXCR4 expression was significantly reduced in 
ITD-Flt3 + cells compared to ITD-Flt3 – cells (right panel), suggesting that the enhanced 
migration is not a quantitative increase of CXCR4 signaling but more likely to be a 
qualitative alteration of CXCR4 signaling by ITD-Flt3. 
Enhanced chemotactic response to SDF1 is partially mediated through Ras signaling, since 
dominant negative H-Ras dramatically inhibits spontaneous and SDF-mediated migration 
of Ba/F3 cells, while constitutively active H-Ras expression in Ba/F3 cells harboring wild-
type Flt3 increases chemotactic response to SDF1 to a similar extent as ITD-Flt3 (Fukuda S & 
Pelus LM, 2006). Accentuated migration of Ba/F3 cells to SDF1 induced by ITD-Flt3 was 
barely inhibited by the Flt3 inhibitor AG1296 or the CXCR4 antagonist AMD3100 alone, 
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whereas it was partially inhibited by the combination of both compounds (Figure 4). 
Surprisingly, ITD-Flt3 mutations also increase cell migration away from an SDF1 gradient 
compared to control cells (Fukuda S et al., 2005). This result implies that ITD-Flt3 may 
facilitate peripheralization of leukemia cells out of the bone marrow niche where SDF1 is 
present, in addition to the effects of enhancing cell homing towards SDF1 in the niche. 
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Fig. 4. Migration of Ba/F3 cells expressing ITD-Flt3 pretreated with AMD3100 and/or 
AG1296 
In contrast to the mouse cell system where human ITD-Flt3 mutations were retrovirally 
transduced into Ba/F3 cells and 32D cells (Fukuda S et al., 2005), a recent report has shown 
that transient expression of ITD-Flt3 in human CD34+ cells inhibited migration to SDF1 
concomitant with reduction in cell surface CXCR4 expression (Jacobi A et al., 2010). While 
reduction in CXCR4 in CD34+ cells by ITD-Flt3 is consistent with Ba/F3 cells transduced 
with ITD-Flt3, the differential effects on migration to SDF1 by these cells may reflect the 
timeframe of exposure to SDF1 following introduction of ITD-Flt3 into the cells. Shortly 
after introduction of ITD-Flt3, expression of CXCR4 is down-regulated, thereby inhibited 
migration to SDF1. In contrast, prolonged expression of ITD-Flt3 leads to functional 
activation of CXCR4 signaling pathways and increases cell migration, while maintaining 
lower CXCR4 expression, suggesting that ITD-Flt3 may differentially regulate chemotactic 
response to SDF1. These findings suggest that migration of leukemia cells to SDF1 may be 
diminished shortly after emergence of ITD-Flt3 in the patients due to reduction of CXCR4 
level and concomitant quantitative decline in CXCR4 signaling. This does not accompany 
qualitative changes in CXCR4 signaling. In contrast, their migration to SDF1 is enhanced at a 
later stage of the disease long after ITD-Flt3 appearance, most likely due to subsequent 
functional alteration of CXCR4 signaling by ITD-Flt3 that is not coupled with CXCR4 
expression level. Reduced migration to SDF1 by ITD-Flt3 can facilitate their 
peripheralization into blood at an early stage of the disease whereas enhanced migration 
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increase in phosphorylation of these molecules (Table 1). These findings suggest qualitative 
differences between ITD-Flt3 signaling and FL /wild type Flt3 signaling, even if both stimuli 
result in similar enhancement in migration to SDF1.  
 
FL prolonged stimulation with FL ITD-Flt3
CXCR4 no change → decrease ↓ decrease ↓
Migration to SDF1 increase ↑ decrease ↓ increase ↑
Phospho ERK, Akt, CREB increase ↑ decrease ↓ no change →  
Table 1. Differential regulation on CXCR4 expression and migration to SDF1 by FL/wild-

















Fig. 3. Migration and CXCR4 expression of ITD-Flt3 + or ITD-Flt3 - Ba/F3 cells. Migration of 
ITD-Flt3+ cells towards SDF1 was significantly elevated compared to ITD-Flt3 – cells  
(* P<0.05: left panel). However, CXCR4 expression was significantly reduced in 
ITD-Flt3 + cells compared to ITD-Flt3 – cells (right panel), suggesting that the enhanced 
migration is not a quantitative increase of CXCR4 signaling but more likely to be a 
qualitative alteration of CXCR4 signaling by ITD-Flt3. 
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Pelus LM, 2006). Accentuated migration of Ba/F3 cells to SDF1 induced by ITD-Flt3 was 
barely inhibited by the Flt3 inhibitor AG1296 or the CXCR4 antagonist AMD3100 alone, 
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whereas it was partially inhibited by the combination of both compounds (Figure 4). 
Surprisingly, ITD-Flt3 mutations also increase cell migration away from an SDF1 gradient 
compared to control cells (Fukuda S et al., 2005). This result implies that ITD-Flt3 may 
facilitate peripheralization of leukemia cells out of the bone marrow niche where SDF1 is 
present, in addition to the effects of enhancing cell homing towards SDF1 in the niche. 
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Fig. 4. Migration of Ba/F3 cells expressing ITD-Flt3 pretreated with AMD3100 and/or 
AG1296 
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after introduction of ITD-Flt3, expression of CXCR4 is down-regulated, thereby inhibited 
migration to SDF1. In contrast, prolonged expression of ITD-Flt3 leads to functional 
activation of CXCR4 signaling pathways and increases cell migration, while maintaining 
lower CXCR4 expression, suggesting that ITD-Flt3 may differentially regulate chemotactic 
response to SDF1. These findings suggest that migration of leukemia cells to SDF1 may be 
diminished shortly after emergence of ITD-Flt3 in the patients due to reduction of CXCR4 
level and concomitant quantitative decline in CXCR4 signaling. This does not accompany 
qualitative changes in CXCR4 signaling. In contrast, their migration to SDF1 is enhanced at a 
later stage of the disease long after ITD-Flt3 appearance, most likely due to subsequent 
functional alteration of CXCR4 signaling by ITD-Flt3 that is not coupled with CXCR4 
expression level. Reduced migration to SDF1 by ITD-Flt3 can facilitate their 
peripheralization into blood at an early stage of the disease whereas enhanced migration 
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to SDF1 may aid to increase homing of the leukemia cells to the organs where SDF1 is 
expressed at a later stage of the disease.  
2.6 Identification of CXCR4 pathways that are selectively regulated by ITD-Flt3 
CXCR4 is expressed in the majority of hematopoietic cells, including HSC, T-cells, B-cells 
and myeloid cells. While antagonizing CXCR4 has been shown to be a safe way to collect 
HSC from the healthy donors (Liles WC et al., 2003), it is known that SDF1/CXCR4 signaling 
provides survival effects to the primitive hematopoietic cell compartment (Broxmeyer HE et 
al., 2003), therefore the long term effect of CXCR4 antagonist on normal hematopoietic cell 
function should be monitored with caution. In this regard, concomitant use of a CXCR4 
antagonist with chemotherapeutic drugs may enhance toxicity, not just to leukemia cells, 
but also to normal HSC. In order to minimize toxicity on HSC by CXCR4 antagonist, it 
would be necessary to identify selective signaling molecules downstream of CXCR4 that are 
specifically regulated in leukemia stem cells but not in normal HSC. Similarly, identification 
of selective CXCR4 related molecular pathways regulating homing of leukemia cells distinct 
from normal hematopoietic cells will aid to antagonize aberrant trafficking of leukemia cells 


















Fig. 5. Functional classification of genes downstream of SDF1/CXCR4 in ITD-Flt3 + versus 
ITD-Flt3 - mouse Ba/F3 cells. 
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As we previously described, ITD-Flt3 mutations enhance migration of hematopoietic cells to 
the chemokine SDF1 (Figure 3) (Fukuda S et al., 2005), suggesting that ITD-Flt3 may facilitate 
dissemination of leukemia cells by modulating the SDF1/CXCR4 signaling pathway. The 
enhanced migration to SDF1 by ITD-Flt3 positive cells was associated with down regulation 
of CXCR4 compared to control cells lacking ITD-Flt3. This suggests that the enhanced 
migration to SDF1 by ITD-Flt3 is not a consequence of a quantitative increase in 
SDF1/CXCR4 signaling, which led us to investigate qualitative alteration of CXCR4 
signaling by ITD-Flt3. Analysis of gene expression in ITD-Flt3- and ITD-Flt3+ Ba/F3 cells 
migrating to SDF1 indicated that SDF1 modulates 4.0% of 40,000 genes analyzed in ITD-
Flt3+ cells, of which 2.5% were regulated by SDF1 exclusively in ITD- Flt3+ cells. Figure 4 
indicates comparison of changes in gene expression before and after migration to SDF1 
(SDF1 responsive genes) between ITD-Flt3- and ITD-Flt3+ Ba/F3 cells. Genes modulated in 
ITD-Flt3- cells or ITD-Flt3+ cells following migration to SDF1 compared to these cells 
analyzed before migration were functionally classified based on Gene Ontology Term using 
DAVID software (Huang DW et al., 2009)(Figure 5). X-axis represents functional categories 
of the individual genes analyzed in the Y-axis. Functional classification indicated that 
several functional signaling pathways were significantly enriched exclusively in ITD-Flt3 
but not in control cells. These data indicate that enhanced cell migration to SDF1 induced by 
ITD-Flt3 is likely mediated through activation of selective CXCR4 signaling pathways that 
are functionally distinct from ITD-Flt3- cells and that are not coupled with CXCR4 
expression. Importantly, several of these CXCR4 downstream molecules selectively 
regulated by ITD-Flt3 are products of genes known to be deregulated in AML stem cells 
(Majeti R et al., 2009). Leukemia stem cells (LSC) are likely responsible for dissemination to 
secondary organs in addition to disease initiation and recurrence. Genes deregulated by LSC 
and regulated by SDF1 specifically in ITD-Flt3+ cells may represent key targets to prevent 
unnecessary dissemination and invasion of ITD-Flt3+ acute leukemia cells without affecting 
normal hematopoiesis. In addition to the genes selectively regulated by SDF1 in ITD-Flt3+ 
cells, approximately 30 mRNAs that are known to be functionally associated with cell 
motility or migration were deregulated in ITD-Flt3+ cells compared to ITD-Flt3- cells. This 
data suggests that ITD-Flt3 itself may affect cell migration. This is consistent with enhanced 
spontaneous migration by ITD-Flt3 in Ba/F3 cells (Fukuda S et al., 2005). 
Our working hypothesis on ITD-Flt3+ AML cell trafficking regulated by interaction between 
ITD-Flt3 and SDF1/CXCR4 pathway is shown in Figure 6. The presence of ITD-Flt3 
mutations decrease CXCR4 expression, thereby reducing interaction between SDF1 and 
AML cells and allowing their release from bone marrow. In addition, ITD-Flt3+ cells can 
migrate away from SDF1 more efficiently compared to ITD-Flt3- cells, which can also 
contribute to their peripheralization/egress. Alternatively, migration to SDF1 may not be 
enhanced shortly after ITD-Flt3 emergence or at an early stage of the disease owing to the 
reduction of CXCR4 that without activation of CXCR4 signaling. Prolonged exposure to 
aberrant signaling generated by ITD-Flt3 functionally activates SDF1/CXCR4 signaling in 
the ITD-Flt3+ cells that is different from ITD-Flt3- cells (Figure 5) while maintaining lower 
levels of CXCR4 expression (Figure 3). This suggests that enhanced migration to SDF1 is a 
consequence of functional alteration of CXCR4 signaling rather than CXCR4 up-regulation. 
This will help AML cells to home to the distant organs or secondary bone marrow where 
SDF1 is present. Circadian oscillation of SDF1 in the marrow niche and CXCR4 expression 
on HSC (Lucas D et al., et al 2008, Mendez-Ferrer S et al., 2008) may also exist in the 
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to SDF1 may aid to increase homing of the leukemia cells to the organs where SDF1 is 
expressed at a later stage of the disease.  
2.6 Identification of CXCR4 pathways that are selectively regulated by ITD-Flt3 
CXCR4 is expressed in the majority of hematopoietic cells, including HSC, T-cells, B-cells 
and myeloid cells. While antagonizing CXCR4 has been shown to be a safe way to collect 
HSC from the healthy donors (Liles WC et al., 2003), it is known that SDF1/CXCR4 signaling 
provides survival effects to the primitive hematopoietic cell compartment (Broxmeyer HE et 
al., 2003), therefore the long term effect of CXCR4 antagonist on normal hematopoietic cell 
function should be monitored with caution. In this regard, concomitant use of a CXCR4 
antagonist with chemotherapeutic drugs may enhance toxicity, not just to leukemia cells, 
but also to normal HSC. In order to minimize toxicity on HSC by CXCR4 antagonist, it 
would be necessary to identify selective signaling molecules downstream of CXCR4 that are 
specifically regulated in leukemia stem cells but not in normal HSC. Similarly, identification 
of selective CXCR4 related molecular pathways regulating homing of leukemia cells distinct 
from normal hematopoietic cells will aid to antagonize aberrant trafficking of leukemia cells 


















Fig. 5. Functional classification of genes downstream of SDF1/CXCR4 in ITD-Flt3 + versus 
ITD-Flt3 - mouse Ba/F3 cells. 
Trafficking of Acute Leukemia Cells 
– Chemokine Receptor Pathways that Modulate Leukemia Cell Dissemination 
 
147 
As we previously described, ITD-Flt3 mutations enhance migration of hematopoietic cells to 
the chemokine SDF1 (Figure 3) (Fukuda S et al., 2005), suggesting that ITD-Flt3 may facilitate 
dissemination of leukemia cells by modulating the SDF1/CXCR4 signaling pathway. The 
enhanced migration to SDF1 by ITD-Flt3 positive cells was associated with down regulation 
of CXCR4 compared to control cells lacking ITD-Flt3. This suggests that the enhanced 
migration to SDF1 by ITD-Flt3 is not a consequence of a quantitative increase in 
SDF1/CXCR4 signaling, which led us to investigate qualitative alteration of CXCR4 
signaling by ITD-Flt3. Analysis of gene expression in ITD-Flt3- and ITD-Flt3+ Ba/F3 cells 
migrating to SDF1 indicated that SDF1 modulates 4.0% of 40,000 genes analyzed in ITD-
Flt3+ cells, of which 2.5% were regulated by SDF1 exclusively in ITD- Flt3+ cells. Figure 4 
indicates comparison of changes in gene expression before and after migration to SDF1 
(SDF1 responsive genes) between ITD-Flt3- and ITD-Flt3+ Ba/F3 cells. Genes modulated in 
ITD-Flt3- cells or ITD-Flt3+ cells following migration to SDF1 compared to these cells 
analyzed before migration were functionally classified based on Gene Ontology Term using 
DAVID software (Huang DW et al., 2009)(Figure 5). X-axis represents functional categories 
of the individual genes analyzed in the Y-axis. Functional classification indicated that 
several functional signaling pathways were significantly enriched exclusively in ITD-Flt3 
but not in control cells. These data indicate that enhanced cell migration to SDF1 induced by 
ITD-Flt3 is likely mediated through activation of selective CXCR4 signaling pathways that 
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mutations decrease CXCR4 expression, thereby reducing interaction between SDF1 and 
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migrate away from SDF1 more efficiently compared to ITD-Flt3- cells, which can also 
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leukemia niche and leukemia stem cells expressing ITD-Flt3. This fluctuation of SDF1 and 
CXCR4 can also affect their mobilization and homing. De-sensitization of CXCR4 signaling 
following exposure to SDF1 may also be distinct in leukemia cells versus normal HSC, 
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Fig. 6. Suggested model for ITD-Flt3+ AML cell trafficking regulated by interaction between 
ITD-Flt3 and SDF1/CXCR4 pathway 
2.7 Role of other chemokines and their receptors for leukemia cell dissemination 
Childhood T-ALL often relapses in the CNS (Pui CH & Howard SC, 2008). Oncogenic 
Notch1 signaling that is frequently activated in T-ALL regulates CCR7 expression. CCL19 
expressed in central nervous system serves as a chemo-attractant for T-ALL cells with 
elevated expression of CCR7. Antagonizing CCR7 and its chemokine ligand CCL19 inhibit 
CNS infiltration of T-ALL in an animal model (Buonamici S et al., 2009). On the other hand, 
overexpression of CCR7 was sufficient to recruit T-ALL cells into the CNS. The data 
indicates that CCL19/CCR7 signaling activated by oncogenic Notch1 regulates CNS 
infiltration of T-ALL and that targeting the CCR7 pathway may represent a novel 
therapeutic strategy for treatment of CNS prophylaxis of T-ALL (Buonamici S et al., 2009) 
(Figure 7). 
While antagonizing CCR7 signaling is a promising strategy to block invasion of T-ALL cells, 
it may impair immune surveillance by normal T-cells, since CCR7 is one of the chemokine 
receptors required for T-cell trafficking (Burger M et al., 2005b). Unnecessary immune 
impairment that can cause serious life threatening infection by pathogens needs to be 
avoided during the intensified treatment for leukemia. In this regard, identification of 
selective signaling molecules in the CCR7 pathway in T-ALL that are functionally distinct 
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from normal T-cells is important in order to develop selective strategy with minimal toxicity 














Fig. 7. Migration and invasion of T-ALL cells into central nervous system mediated through 
CCL19/CCR7 pathway 
Mixed lineage leukemia (MLL) frequently found in infant ALL is caused by a chromosomal 
translocation that involves 11q23 (Pieters R, 2009). This is associated with poor outcome 
with relatively high frequency of central nervous involvement compared to older children, 
suggesting that MLL gene rearrangement modulates leukemia cell dissemination. A recent 
report indicates that MEF2C regulates homing and invasiveness of MLL/ENL leukemia 
cells without affecting establishment and maintenance of leukemia stem cells (Schwieger M 
et al., 2009). MEF2 regulates expression of the chemokine receptors CXCR4, CCR2 and CCR5 
and chemokines, such as CCL2, CCL3, CCL4 and CCL6 (Schwieger M et al., 2009). This 
suggests that MLL gene rearrangement regulates homing and invasion of leukemia cells 
through MEF2C by affecting expression of chemokines and their receptors.  
Chemokine receptor expression is differentially regulated in AML patients with skin 
involvement. Skin residing AML cells displayed a different set of chemokine receptors in 
situ, for instance: CCR5, CXCR4, CXCR7 and CX3CR1. However, a recent report indicates a 
high percentage of circulating CCR2 pos AML cells were only detected in patients with 
extramedullary disease (Faaij CMJM et al., 2010). High expression of CCR2 was not observed 
in bone marrow blasts. This study showed that there was no difference in the expression of 
CXCR4, suggesting that CCR2 may be a dominant regulator for skin dissemination of AML.  
3. Conclusion 
Given that various oncogenic molecules responsible for hematological malignancies such as 
ITD-Flt3, Bcr-abl and Ras, modulate response to SDF1, these oncogenes likely modulate 
trafficking of leukemia cells. Although there is no definitive evidence that CXCR4 is indeed 
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leukemia niche and leukemia stem cells expressing ITD-Flt3. This fluctuation of SDF1 and 
CXCR4 can also affect their mobilization and homing. De-sensitization of CXCR4 signaling 
following exposure to SDF1 may also be distinct in leukemia cells versus normal HSC, 
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from normal T-cells is important in order to develop selective strategy with minimal toxicity 
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3. Conclusion 
Given that various oncogenic molecules responsible for hematological malignancies such as 
ITD-Flt3, Bcr-abl and Ras, modulate response to SDF1, these oncogenes likely modulate 
trafficking of leukemia cells. Although there is no definitive evidence that CXCR4 is indeed 
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involved in the dissemination of acute leukemia, multiple data support that this is most 
likely the case. Blocking CXCR4 appears to be a promising strategy to sensitize leukemia 
cells to chemotherapy by releasing/mobilizing them into the peripheral blood circulation. 
Targeting CXCR4 signaling pathways may also be useful to minimize leukemia cell 
dissemination in addition to sensitizing them to chemotherapy by releasing them from 
marrow niches. This idea is consistent with targeting the CCR7 receptor in T-ALL that 
blocks their CNS dissemination (Buonamici S et al., 2009). Although promising, precautions 
need to be taken since antagonizing CXCR4 initiates mobilization of leukemia cells into 
circulation, which may facilitate secondary organ infiltration. 
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involved in the dissemination of acute leukemia, multiple data support that this is most 
likely the case. Blocking CXCR4 appears to be a promising strategy to sensitize leukemia 
cells to chemotherapy by releasing/mobilizing them into the peripheral blood circulation. 
Targeting CXCR4 signaling pathways may also be useful to minimize leukemia cell 
dissemination in addition to sensitizing them to chemotherapy by releasing them from 
marrow niches. This idea is consistent with targeting the CCR7 receptor in T-ALL that 
blocks their CNS dissemination (Buonamici S et al., 2009). Although promising, precautions 
need to be taken since antagonizing CXCR4 initiates mobilization of leukemia cells into 
circulation, which may facilitate secondary organ infiltration. 
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1. Introduction 
Mixed Lineage Leukemia constitutes a heterogeneous category of rare acute leukemias that 
are characterized by a mixed population of poorly differentiated lymphoid and myeloid 
progenitor cells. The mixed lineage leukemia (MLL1) gene, also known as HRX or ALL-1, is 
a frequent site of genetic rearrangements in infant acute leukemias and therapy-related 
malignancies (Daser and Rabbitts, 2005) and since its discovery (Djabali et al., 1992; Tkachuk 
et al., 1992; Ziemin-van der Poel et al., 1991), significant progress has been made in 
understanding its role in human biology and leukemogenesis (Liu et al., 2009; Slany, 2009). 
Chromosomal abnormalities involving the MLL1 gene include reciprocal chromosomal 
translocations, internal partial tandem duplications (PTD), and amplifications of un-
rearranged MLL1 (Dou and Hess, 2008). These chromosomal aberrations are associated with 
mechanistically distinct gain-of-function phenotypes that may be amenable to targeted 
therapeutic approaches. However, progress in this area has been impeded by a lack of 
understanding of the molecular details by which MLL1 translocations, amplifications and 
PTDs contribute to leukemogenesis. To date, more than 60 MLL1 fusion partners have been 
described (Krivtsov and Armstrong, 2007), and detailed genetic/biochemical studies have 
identified several functional domains within chimeric MLL1-fusion proteins that are 
essential for leukemic transformation (Daser and Rabbitts, 2005; Debernardi et al., 2002; 
Eguchi et al., 2004; Ernst et al., 2002; Krivtsov and Armstrong, 2007; Lavau et al., 2000; Liu et 
al., 2009; Luo et al., 2001; Mitterbauer-Hohendanner and Mannhalter, 2004; Mueller et al., 
2009; Prasad et al., 1995). Although our understanding of the molecular pathology of MLL1-
associated leukemias remains incomplete, recent biochemical and structural information is 
contributing to an evolution of potential treatment strategies from a broadly-based 
chemotherapeutics approach towards therapies targeted to the underlying molecular 
pathogenesis of leukemia (Liedtke and Cleary, 2009). This chapter reviews recent advances 
in our efforts to develop novel MLL1-targeted therapies.   
2. MLL1- a master epigenetic regulator with multiple roles in transcription 
2.1 MLL1 in embryonic development and hematopoiesis 
The MLL1 protein is a histone H3 lysine 4 (H3K4) methyltransferase that functions to maintain 
gene expression during development and hematopoiesis (Hess et al., 1997; Milne et al., 2002; 
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Yagi et al., 1998).  The best studied target genes of MLL1 include the homeobox transcription 
factors or HOX genes, which are important for segment identity and cell fate during metazoan 
development (Abramovich and Humphries, 2005; Ernst et al., 2004b). Genetic studies in mice 
have demonstrated that the homozygous knock out of MLL1 is embryonic lethal and is 
associated with multiple developmental defects including neural crest patterning and 
hematopoietic abnormalities (Ernst et al., 2004a; Hess et al., 1997; Yagi et al., 1998; Yu et al., 
1995). Notably, the expression levels of several HOX genes including HOXa4, HOXa7, HOXa9, 
and HOXa10 are decreased in MLL1-/- mice and are associated with defects in fetal liver 
hematopoiesis (Hanson et al., 1999; Yagi et al., 1998). MLL1+/- mice are not embryonic lethal 
but are anemic and exhibit homeotic developmental defects that are related to posterior shifts 
in HOX gene expression patterns (Yagi et al., 1998; Yu et al., 1995). Likewise, MLL1 is also 
required for adult hematopoiesis and stem cell self-renewal. In MLL1 conditional knockout 
mice fetal hematopoiesis is unaltered; however, adult mice exhibit anemia, a significant 
reduction in the number of bone marrow hematopoietic stem cell progenitors, and poor 
survival rates (Gan et al., 2010). In addition, it has been demonstrated that MLL1 plays a 
crucial role in self-renewal in cultured fetal liver and adult bone marrow stem cells (Jude et al., 
2007; McMahon et al., 2007). These studies suggest that MLL1 orchestrates its biological 
functions at least in part through the regulation of HOX genes. Indeed, HOX dysregulation is a 
common phenotype that underlies the pathogenesis of acute leukemias associated with 
alterations in the MLL1 gene (Armstrong et al., 2002; Ayton and Cleary, 2003; Dorrance et al., 
2006; Ferrando et al., 2003; Liu et al., 2009). However, MLL1 is also required for the regulation 
of cell cycle dependent genes such as: cyclins A, B, and E (Takeda et al., 2006) and CDK 
inhibitors p16Ink4a, p18, p27 (Milne et al., 2005; Takeda et al., 2006); E2F family of transcription 
factors (E2F2, E2F4 and E2F6) (Takeda et al., 2006) as well as the transcription factor GATA3, 
which plays an essential role in specifying lymphoid subtype (Yamashita et al., 2006). In 
addition, MLL1 regulates expression of several genes involved in organogenesis and 
differentiation (Ansari and Mandal, 2010; Scharf et al., 2007) . Therefore, MLL1 is a master 
regulator that is critical for many gene expression programs required for normal development, 
hematopoiesis and the cell cycle.  
2.2 MLL1 regulates the degree of H3K4 methylation and transcription 
In eukaryotes, DNA is condensed into highly ordered structures known as chromatin- the 
structure of which is dynamically altered according to the needs of the cell. The basic 
repeating unit of chromatin is the nucleosome, which is composed of ~146 base pairs of 
DNA wrapped around an octameric disc of histone proteins containing two copies each of 
histones H2A, H2B, H3 and H4 (Luger and Hansen, 2005). Cellular processes that require 
access to DNA often use enzymes that dynamically regulate the structure of chromatin 
either through recruitment of adaptor proteins or additional enzymatic machineries that 
alter the positioning of nucleosomes on DNA (Cosgrove and Wolberger, 2005). One such 
enzymatic activity is the methylation of lysine 4 of histone H3 (H3K4), an evolutionarily 
conserved epigenetic mark predominantly associated with transcriptional activation in 
eukaryotes (Bernstein et al., 2002; Boggs et al., 2002; Litt et al., 2001; Noma and Grewal, 2002; 
Strahl et al., 1999). The epsilon amino group of lysine 4 can be mono-, di-, or trimethylated, 
with each modification correlating with distinct transcriptional outcomes (Bernstein et al., 
2005; Ng et al., 2003; Pokholok et al., 2005; Santos-Rosa et al., 2002; Schneider et al., 2004; 
Schubeler et al., 2004). For example, genome-wide chromatin immunoprecipitation studies 
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have demonstrated that high levels of H3K4 trimethylation are present within the 5’ regions 
of actively transcribed genes (Pokholok et al., 2005; Santos-Rosa et al., 2002; Schneider et al., 
2004; Schubeler et al., 2004). It has been demonstrated that H3K4 trimethylation functions to 
recruit ATP dependent nucleosome remodeling enzymes that increase promoter DNA 
accessibility by sliding or displacing nucleosomes (Pray-Grant et al., 2005; Santos-Rosa et al., 
2003; Wysocka et al., 2006). H3K4 dimethylation is spread more evenly across the coding 
regions of genes and is thought to be associated with a transcriptionally “poised” state of 
chromatin (Bernstein et al., 2002; Schneider et al., 2004; Schubeler et al., 2004). In contrast, 
H3K4 monomethylation is enriched at the 3’ ends of the genes and distal enhancer 
sequences, and is associated with ribosomal DNA (rDNA) and telomeric silencing 
(Bernstein et al., 2002; Heintzman et al., 2007; Pokholok et al., 2005; Santos-Rosa et al., 2002; 
Schneider et al., 2004; Schubeler et al., 2004)(Nislow, Ray et al. 1997; Briggs, Bryk et al. 2001; 
Schneider, Wood et al. 2005; van Dijk, Marley et al. 2005). These studies suggest that the 
degree of H3K4 methylation is a highly regulated process. Indeed eukaryotes have evolved 
a number of highly conserved enzymes whose function appears to precisely regulate the 
degree of H3K4 methylation.  
H3K4 methylation is mainly deposited by a group of enzymes that share an evolutionarily 
conserved  SET (SuVar, E(z), Trithorax) domain  (Dillon et al., 2005) , although a new H3K4 
methyltransferase lacking a SET domain has recently been reported (Patel et al., 2009; Patel 
et al., 2011). While there are several SET domains enzymes that differ with regard to their 
substrate specificity (Dillon et al., 2005; Qian and Zhou, 2006), members of the SET1 family 
share the properties that they all methylate H3K4, and all interact with an evolutionarily 
conserved core group of proteins that function to regulate the degree of H3K4 methylation. 
MLL1 belongs to the SET1 family of histone methyltransferases and evidence suggests that 
its transcriptional co-activator function is mediated in part by the enzymatic activity of its 
SET domain (Dillon et al., 2005; Milne et al., 2002). For example, homozygous deletion of the 
MLL1 SET domain in mice, while not embryonic lethal, exhibits skeletal defects and altered 
expression of several HOX genes that partially phenocopy the heterozygous knockout of the 
whole MLL1 gene (Terranova et al., 2006). These changes are correlated with decreased 
levels of mono- and dimethylation of H3K4 and deregulated DNA methylation patterns at 
several HOX gene promoters (Terranova et al., 2006).  
MLL1 functions within a large macromolecular complex with more than 30 subunits that 
regulate the degree of H3K4 methylation and MLL1’s target gene specificity (Cosgrove and 
Patel, 2010). While subunit composition of different SET1 family members varies to some 
degree, each SET1 family member interacts with a conserved core group of proteins that 
include WD-40 repeat protein-5 (WDR5), Retinoblastoma binding protein-5 (RbBP5), Absent 
small homeotic 2-like protein (Ash2L) and Dumpy30 (Dpy-30) (Cho et al., 2007; Dou et al., 
2006; Lee et al., 2007). WRD5, RbBP5, Ash2L and DPY-30 form an indepedent complex 
called WRAD that possesses an intrisic histone methyltransferase activity on its own (Patel 
et al., 2009; Patel et al., 2011). When WRAD interacts with MLL1, it forms what is known as 
the MLL1 core complex, which is required for mono- and dimethylation of H3K4 (Dou et al., 
2006; Patel et al., 2009). These studies have led to a model in which H3K4 methylation is 
sequentially catalyzed by a complex that contains multiple distinct active sites for the 
addition of each methyl group (Patel et al., 2009).  
2.3 Mechanism of multiple lysine methylation catalyzed by MLL1 core complex 
Previously it was thought that mono-, di-, and trimethylation of H3K4 could be attributed to 
the SET domain dependent methyltransferase activity of MLL1 alone and that the WRAD 
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2005; Ng et al., 2003; Pokholok et al., 2005; Santos-Rosa et al., 2002; Schneider et al., 2004; 
Schubeler et al., 2004). For example, genome-wide chromatin immunoprecipitation studies 
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have demonstrated that high levels of H3K4 trimethylation are present within the 5’ regions 
of actively transcribed genes (Pokholok et al., 2005; Santos-Rosa et al., 2002; Schneider et al., 
2004; Schubeler et al., 2004). It has been demonstrated that H3K4 trimethylation functions to 
recruit ATP dependent nucleosome remodeling enzymes that increase promoter DNA 
accessibility by sliding or displacing nucleosomes (Pray-Grant et al., 2005; Santos-Rosa et al., 
2003; Wysocka et al., 2006). H3K4 dimethylation is spread more evenly across the coding 
regions of genes and is thought to be associated with a transcriptionally “poised” state of 
chromatin (Bernstein et al., 2002; Schneider et al., 2004; Schubeler et al., 2004). In contrast, 
H3K4 monomethylation is enriched at the 3’ ends of the genes and distal enhancer 
sequences, and is associated with ribosomal DNA (rDNA) and telomeric silencing 
(Bernstein et al., 2002; Heintzman et al., 2007; Pokholok et al., 2005; Santos-Rosa et al., 2002; 
Schneider et al., 2004; Schubeler et al., 2004)(Nislow, Ray et al. 1997; Briggs, Bryk et al. 2001; 
Schneider, Wood et al. 2005; van Dijk, Marley et al. 2005). These studies suggest that the 
degree of H3K4 methylation is a highly regulated process. Indeed eukaryotes have evolved 
a number of highly conserved enzymes whose function appears to precisely regulate the 
degree of H3K4 methylation.  
H3K4 methylation is mainly deposited by a group of enzymes that share an evolutionarily 
conserved  SET (SuVar, E(z), Trithorax) domain  (Dillon et al., 2005) , although a new H3K4 
methyltransferase lacking a SET domain has recently been reported (Patel et al., 2009; Patel 
et al., 2011). While there are several SET domains enzymes that differ with regard to their 
substrate specificity (Dillon et al., 2005; Qian and Zhou, 2006), members of the SET1 family 
share the properties that they all methylate H3K4, and all interact with an evolutionarily 
conserved core group of proteins that function to regulate the degree of H3K4 methylation. 
MLL1 belongs to the SET1 family of histone methyltransferases and evidence suggests that 
its transcriptional co-activator function is mediated in part by the enzymatic activity of its 
SET domain (Dillon et al., 2005; Milne et al., 2002). For example, homozygous deletion of the 
MLL1 SET domain in mice, while not embryonic lethal, exhibits skeletal defects and altered 
expression of several HOX genes that partially phenocopy the heterozygous knockout of the 
whole MLL1 gene (Terranova et al., 2006). These changes are correlated with decreased 
levels of mono- and dimethylation of H3K4 and deregulated DNA methylation patterns at 
several HOX gene promoters (Terranova et al., 2006).  
MLL1 functions within a large macromolecular complex with more than 30 subunits that 
regulate the degree of H3K4 methylation and MLL1’s target gene specificity (Cosgrove and 
Patel, 2010). While subunit composition of different SET1 family members varies to some 
degree, each SET1 family member interacts with a conserved core group of proteins that 
include WD-40 repeat protein-5 (WDR5), Retinoblastoma binding protein-5 (RbBP5), Absent 
small homeotic 2-like protein (Ash2L) and Dumpy30 (Dpy-30) (Cho et al., 2007; Dou et al., 
2006; Lee et al., 2007). WRD5, RbBP5, Ash2L and DPY-30 form an indepedent complex 
called WRAD that possesses an intrisic histone methyltransferase activity on its own (Patel 
et al., 2009; Patel et al., 2011). When WRAD interacts with MLL1, it forms what is known as 
the MLL1 core complex, which is required for mono- and dimethylation of H3K4 (Dou et al., 
2006; Patel et al., 2009). These studies have led to a model in which H3K4 methylation is 
sequentially catalyzed by a complex that contains multiple distinct active sites for the 
addition of each methyl group (Patel et al., 2009).  
2.3 Mechanism of multiple lysine methylation catalyzed by MLL1 core complex 
Previously it was thought that mono-, di-, and trimethylation of H3K4 could be attributed to 
the SET domain dependent methyltransferase activity of MLL1 alone and that the WRAD 
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complex functions merely as an allosteric regulator of MLL1 (Cheng et al., 2005; Collins et al., 
2005; Dou et al., 2006; Han et al., 2006; Ruthenburg et al., 2006; Southall et al., 2009; Steward et 
al., 2006; Takahashi et al., 2009). However, since it has more recently been demonstrated that 
the WRAD complex dimethylates H3K4 in a manner that is independent of the enzymatic 
activity of the MLL1 SET domain (Patel et al., 2009), the allosteric model needs to be revised. 
Indeed, in vitro methylation assays demonstrate that the isolated MLL1 SET domain is 
predominantly a monomethyltranferse, which can be attributed to the presence of a conserved 
tyrosine residue in the SET domain active site (Patel et al., 2009). Furthermore, loss of the 
WDR5, RbBP5 or Ash2L subunits of WRAD results in the loss of di- and trimethylation of 
H3K4 both in vivo and in vitro without significant changes in H3K4 monomethylation (Dou et 
al., 2006; Patel et al., 2009; Patel et al., 2008b; Wysocka et al., 2005). These results are consistent 
with a sequential mechanism whereby the MLL1 SET domain catalyzes H3K4 
monomethylation and the WRAD enzyme catalyzes H3K4 dimethylation within the MLL1 
core complex. However, WRAD lacks the ability to dimethylate H3K4 without MLL1, 
suggesting that MLL1 amino acid sequences,  distinct from the MLL1 SET domain active site,  
contributes to the WRAD active site within the MLL1 core complex. That a complex between 
WRAD and MLL1 is required for H3K4 dimethylation is supported by the demonstration that 
amino acid substitutions that disrupt the interaction between MLL1 and WRAD also disrupt 
the H3K4 dimethylation activity of the MLL1 core complex (Patel et al., 2008b). Therefore, the 
completely assembled MLL1 core complex is required for efficient H3K4 dimethylation and 
for nucleosome methylation (Patel et al., 2011). The existence of a sequential mechanism 
utilizing several active sites for multiple lysine methylation suggests that the degree of H3K4 
methylation is more highly regulated than previously appreciated.  
2.4 WRAD components are associated with development and oncogenesis 
One of the common features of the greater than 60-MLL fusion proteins associated with 
leukemias is that in most cases they lose the amino acid sequences required for interaction 
with WRAD. This raises questions about WRAD’s role in MLL1 associated oncogenesis. 
WRAD subunits are conserved within SET1 family complexes ranging from yeast to humans 
(Cho et al., 2007; Dou et al., 2006; Lee and Skalnik, 2005; Lee et al., 2007; Steward et al., 2006) 
and have been shown to play essential roles in cellular differentiation (Gori and Demay, 
2005; Gori et al., 2005; Zhu et al., 2008), development (Adamson and Shearn, 1996; Wysocka 
et al., 2005), dosage compensation (Hsu et al., 1995; Hsu and Meyer, 1994), embryogenesis 
(Stoller et al.), and transcription (Tan et al., 2008). However, the WRAD enzyme lacks 
sequence homology to known methyltransferase folds and as a result relatively little is 
understood about its methyltransferase activity and the role it might play in oncogenesis. 
WRAD’s potential role in oncogenesis is supported by the observation that the Ash2L 
component of WRAD is overexpressed at the protein level in many human tumors, and that 
knockdown of Ash2L inhibits tumor cell proliferation (Luscher-Firzlaff et al., 2008). In 
addition, the RbBP5 component of WRAD has been shown to be amplified in several 
glioblastomas, suggesting that it may be a novel oncogene (Bralten et al., 2010). Further 
studies will be required to better understand WRAD’s role in MLL1 associated 
leukemogenesis and other cancers.  
In contrast, the MLL1 component of the MLL1 core complex is more extensively 
characterized and several functional domains implicated in transcriptional regulation have 
been identified (for recent reviews refer to Ansari and Mandal, 2010; Cosgrove and Patel, 
2010). Furthermore, MLL1 is a frequent site of chromosomal alterations that sometimes 
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disrupt the functions of these domains. The next subsection summarizes recent genetic, 
biochemical and structural studies of the functional domains that regulate MLL1’s gene 
targeting and H3K4 methyltransferase activity.   
2.5 MLL1 functional domains implicated in transcriptional regulation 
The MLL1 gene encodes a large protein of 3,969 amino acid residues and contains several 
functional domains including: menin binding motif (MBM), Lens epithelium derived 
growth factor (LEDGF) binding domain (LBD), DNA-binding AT hooks, a cysteine-rich 
CXXC DNA binding motif, plant homeodomain (PHD) fingers, a bromo domain (BD), a 
transactivation domain (TAD), a WDR5 interaction (Win) motif, and a C-terminal histone 
methyltransferase SET domain (Figure 1) (Cosgrove and Patel, 2010). The full-length MLL1 
protein, synthesized as a single transcript, is cleaved by taspase I into MLL1-N (320 kDa) 
and MLL1-C (180 kDa) fragments, which then re-associate through the FYRN and FYRC 
motifs to form the functional MLL1 complex in vivo (Figure 1) (Hsieh et al., 2003a; Hsieh et 
al., 2003b; Yokoyama et al., 2002). The mature MLL1 protein assembles into macromolecular 
complexes with several regulatory proteins that are essential for MLL1’s transcriptional co- 




Schematic representation showing the functional domains present in the MLL1 protein. Menin binding 
motif MBM (purple), LEDGF binding domain or LBD (light red), DNA binding AT-hooks (black), zinc 
finger containing CXXC motifs (pink), plant homeodomain (PHD) fingers (blue), bromodomain (BD) 
(yellow), phenylalanine-tyrosine rich regions (FYR) (brown), WDR5 interaction (Win) motif (light 
green), and the histone methyltransferase SET domain (red) are highlighted. a) The full-length MLL1 
protein (3969 amino acids) is cleaved by Taspase 1 into MLL-N (300 kDa) and MLL-C (180 kDa) 
fragments that then re-associate through FYRN and FYRC motifs to form a stable complex. This mature 
MLL1 protein then assembles into a macromolecular complex with a number of proteins including- 
menin (green); lens epithelium derived growth factor or LEDGF (dark grey); nuclear cyclophilin 
(Cyp33) (light grey); host cell factor (HCF) (light pink); CREB binding protein (CBP) (dark green); 
histone acetyltransferase MOF (orange); WD-40 repeat containing protein-5 (WDR5) (dark blue); 
retinoblastoma binding protein-5 (RbBP5) (cyan); absent, small, homeotic disc-2 like (Ash2L) (olive 
green); and DPY-30 (light purple).   
Fig. 1. Domain architecture of human MLL1. 
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complex functions merely as an allosteric regulator of MLL1 (Cheng et al., 2005; Collins et al., 
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activity of the MLL1 SET domain (Patel et al., 2009), the allosteric model needs to be revised. 
Indeed, in vitro methylation assays demonstrate that the isolated MLL1 SET domain is 
predominantly a monomethyltranferse, which can be attributed to the presence of a conserved 
tyrosine residue in the SET domain active site (Patel et al., 2009). Furthermore, loss of the 
WDR5, RbBP5 or Ash2L subunits of WRAD results in the loss of di- and trimethylation of 
H3K4 both in vivo and in vitro without significant changes in H3K4 monomethylation (Dou et 
al., 2006; Patel et al., 2009; Patel et al., 2008b; Wysocka et al., 2005). These results are consistent 
with a sequential mechanism whereby the MLL1 SET domain catalyzes H3K4 
monomethylation and the WRAD enzyme catalyzes H3K4 dimethylation within the MLL1 
core complex. However, WRAD lacks the ability to dimethylate H3K4 without MLL1, 
suggesting that MLL1 amino acid sequences,  distinct from the MLL1 SET domain active site,  
contributes to the WRAD active site within the MLL1 core complex. That a complex between 
WRAD and MLL1 is required for H3K4 dimethylation is supported by the demonstration that 
amino acid substitutions that disrupt the interaction between MLL1 and WRAD also disrupt 
the H3K4 dimethylation activity of the MLL1 core complex (Patel et al., 2008b). Therefore, the 
completely assembled MLL1 core complex is required for efficient H3K4 dimethylation and 
for nucleosome methylation (Patel et al., 2011). The existence of a sequential mechanism 
utilizing several active sites for multiple lysine methylation suggests that the degree of H3K4 
methylation is more highly regulated than previously appreciated.  
2.4 WRAD components are associated with development and oncogenesis 
One of the common features of the greater than 60-MLL fusion proteins associated with 
leukemias is that in most cases they lose the amino acid sequences required for interaction 
with WRAD. This raises questions about WRAD’s role in MLL1 associated oncogenesis. 
WRAD subunits are conserved within SET1 family complexes ranging from yeast to humans 
(Cho et al., 2007; Dou et al., 2006; Lee and Skalnik, 2005; Lee et al., 2007; Steward et al., 2006) 
and have been shown to play essential roles in cellular differentiation (Gori and Demay, 
2005; Gori et al., 2005; Zhu et al., 2008), development (Adamson and Shearn, 1996; Wysocka 
et al., 2005), dosage compensation (Hsu et al., 1995; Hsu and Meyer, 1994), embryogenesis 
(Stoller et al.), and transcription (Tan et al., 2008). However, the WRAD enzyme lacks 
sequence homology to known methyltransferase folds and as a result relatively little is 
understood about its methyltransferase activity and the role it might play in oncogenesis. 
WRAD’s potential role in oncogenesis is supported by the observation that the Ash2L 
component of WRAD is overexpressed at the protein level in many human tumors, and that 
knockdown of Ash2L inhibits tumor cell proliferation (Luscher-Firzlaff et al., 2008). In 
addition, the RbBP5 component of WRAD has been shown to be amplified in several 
glioblastomas, suggesting that it may be a novel oncogene (Bralten et al., 2010). Further 
studies will be required to better understand WRAD’s role in MLL1 associated 
leukemogenesis and other cancers.  
In contrast, the MLL1 component of the MLL1 core complex is more extensively 
characterized and several functional domains implicated in transcriptional regulation have 
been identified (for recent reviews refer to Ansari and Mandal, 2010; Cosgrove and Patel, 
2010). Furthermore, MLL1 is a frequent site of chromosomal alterations that sometimes 
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disrupt the functions of these domains. The next subsection summarizes recent genetic, 
biochemical and structural studies of the functional domains that regulate MLL1’s gene 
targeting and H3K4 methyltransferase activity.   
2.5 MLL1 functional domains implicated in transcriptional regulation 
The MLL1 gene encodes a large protein of 3,969 amino acid residues and contains several 
functional domains including: menin binding motif (MBM), Lens epithelium derived 
growth factor (LEDGF) binding domain (LBD), DNA-binding AT hooks, a cysteine-rich 
CXXC DNA binding motif, plant homeodomain (PHD) fingers, a bromo domain (BD), a 
transactivation domain (TAD), a WDR5 interaction (Win) motif, and a C-terminal histone 
methyltransferase SET domain (Figure 1) (Cosgrove and Patel, 2010). The full-length MLL1 
protein, synthesized as a single transcript, is cleaved by taspase I into MLL1-N (320 kDa) 
and MLL1-C (180 kDa) fragments, which then re-associate through the FYRN and FYRC 
motifs to form the functional MLL1 complex in vivo (Figure 1) (Hsieh et al., 2003a; Hsieh et 
al., 2003b; Yokoyama et al., 2002). The mature MLL1 protein assembles into macromolecular 
complexes with several regulatory proteins that are essential for MLL1’s transcriptional co- 




Schematic representation showing the functional domains present in the MLL1 protein. Menin binding 
motif MBM (purple), LEDGF binding domain or LBD (light red), DNA binding AT-hooks (black), zinc 
finger containing CXXC motifs (pink), plant homeodomain (PHD) fingers (blue), bromodomain (BD) 
(yellow), phenylalanine-tyrosine rich regions (FYR) (brown), WDR5 interaction (Win) motif (light 
green), and the histone methyltransferase SET domain (red) are highlighted. a) The full-length MLL1 
protein (3969 amino acids) is cleaved by Taspase 1 into MLL-N (300 kDa) and MLL-C (180 kDa) 
fragments that then re-associate through FYRN and FYRC motifs to form a stable complex. This mature 
MLL1 protein then assembles into a macromolecular complex with a number of proteins including- 
menin (green); lens epithelium derived growth factor or LEDGF (dark grey); nuclear cyclophilin 
(Cyp33) (light grey); host cell factor (HCF) (light pink); CREB binding protein (CBP) (dark green); 
histone acetyltransferase MOF (orange); WD-40 repeat containing protein-5 (WDR5) (dark blue); 
retinoblastoma binding protein-5 (RbBP5) (cyan); absent, small, homeotic disc-2 like (Ash2L) (olive 
green); and DPY-30 (light purple).   
Fig. 1. Domain architecture of human MLL1. 
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indirect interaction partners for MLL1 that include; the menin tumor suppressor protein 
(Hughes et al., 2004; Yokoyama et al., 2004); cell cycle regulators such as E2Fs and HCF-1 
(Tyagi et al., 2007; Yokoyama et al., 2004);   polycomb group proteins, BMI-1 and HPC-2 (Xia 
et al., 2003); histone deacetylases (Nakamura et al., 2002; Xia et al., 2003); nuclear 
cyclophilin, Cyp33 (Xia et al., 2003); acetyltransferases such as p300, CBP and MOF (Dou et 
al., 2005; Ernst et al., 2001); chromatin remodeling factors, INI1/SNF5 (Rozenblatt-Rosen et 
al., 1998); and WDR5/RbBP5/Ash2L and DPY30, which are core components of SET1 family 
methyltransferases (Dou et al., 2006). In addition, a recent paper describes the identification 
of a gene internal promoter that transcribes the C-terminal half of MLL1 (Scharf et al., 2007), 
the function of which is not known. Interestingly, the gene internal promoter coincides with 
an MLL1 breakpoint region, suggesting that the pathogenesis of MLL1 translocation 
induced leukemia could be due in part to the loss of this N-terminally truncated form of 
MLL1 when the breakpoint is 5’ to the gene internal promoter. However, in cases where the 
MLL1 breakpoint is 3’ to the gene internal promoter, it could result in aberrant expression of 
the fusion protein (Scharf et al., 2007). Indeed, it has been noted that the common MLL1 
translocation partners AF4, AF6, and ENL have potential AUG start codons in positions 
where they could be transcribed within the context of the translocated MLL1 gene (Scharf et 
al., 2007). 
These studies suggest that the transcriptional activator properties of MLL1 are mediated 
through multiple functional domains through protein-protein and protein-DNA 
interactions. Many of these interactions are retained in leukemogenic MLL1s, some 
participating in gain-of function phenotypes, making them candidates for molecular 
targeted therapy. We review progress in this area in sections 3-5.  In section 2, we describe in 
more detail our current understanding of the role of MLL1 alterations in hematopoietic 
malignancies.  
3. MLL1-A key player in hematologic malignancies 
3.1 Acute myeloid and lymphoblastic leukemia with 11q23 abnormalities  
3.1.1 Incidence and clinical significance of 11q23 chromosomal translocations 
The MLL1 gene located at chromosome 11, band q23, is frequently involved in reciprocal 
translocations found in several cases of acute myeloid (AML) and acute lymphoblastic 
leukemia (ALL) (Djabali et al., 1992; Gu et al., 1992; Ziemin-van der Poel et al., 1991) and 
identify a patient sub-population with a poor prognosis (Daser and Rabbitts, 2005). 
Recurrent MLL1 translocations account for >70% of infant acute leukemias (both ALL and 
AML) and are also observed in approximately 10% of de novo AML in adults (Krivtsov and 
Armstrong, 2007), and in therapy-related leukemias that develop in patients treated with 
topoisomerase II inhibitors (Bigoni et al., 1999; Felix et al., 1995; Krivtsov and Armstrong, 
2007). Chromosomal translocations fuse the N-terminal part (~1400 amino acids) of the MLL1 
protein in-frame to one of more than 60 partner proteins that range from nuclear factors to 
cytoplasmic proteins (Daser and Rabbitts, 2005; Huret et al., 2001; Schoch et al., 2003). 
The five most common MLL1 translocations include: MLL1-AF4 or t(4;11)(q21;q23); 
MLL1-ENL or t(11;19)(q23;p13.3); MLL1-AF9 or t(9;11)(p23;q23), MLL1-AF10 or 
t(10;11)(p12;q23), and MLL1-AF6 or t(6;11)(q27;q23) and account for greater than 80% of 
MLL1-rearranged leukemias (Burmeister et al., 2009; Meyer et al., 2009; Meyer et al., 2006; 
Slany, 2009). In addition, chimeric MLL1-fusions involving ELL, EEN, GAS7, AF1p, AFx, 
Septins, and histone acetyltransferases CBP/p300 have also been reported (Bernard et al., 
1994; Dobson et al., 2000; Hall and Russell, 2004; Ida et al., 1997; Krivtsov and Armstrong, 
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2007; Meyer et al., 2009; Schichman et al., 1995; So et al., 2003; Taki et al., 1997; Tkachuk et 
al., 1992; Wang et al., 2005). The translocation partners identified to date are diverse and 
do not share any biochemical function or structural motifs. However, all known MLL1 
fusion proteins share the property that the N-terminal portion containing the AT hooks 
and CxxC domains of MLL1 are retained, suggesting the preservation of DNA binding 
activity (Ayton et al., 2004; Macrini et al., 2003). In contrast, the taspase cleavage site, gene 
internal promoter, TAD domain, PHD fingers, Win motif and the SET domain are lost 
(Figure 2) (Liu et al., 2009).  
 
 
The putative protein products generated by the two most common chromosomal alterations associated 
with the MLL1 gene are indicated along with wild-type MLL1: a) wild-type MLL1, b) reciprocal 
chromosomal translocations involving MLL1, and c) partial tandem duplications (PTDs) in MLL1. The 
various functional domains are color coded as in Figure 1.  Chromosomal translocations fuse the N-
terminal ~1400 amino acids of MLL1 in-frame to one of over 60 different fusion partners (indicated in 
orange in b). PTDs have a duplicated N-terminus (AT-hooks and CXXC motifs) in addition to all the 
functional domains present in wild-type MLL1.  
Fig. 2. Schematic representation of the most common genetic alterations associated with the 
MLL1 gene. 
3.1.2 Pathogenesis of acute leukemias with MLL1-translocations 
While it is expected that the loss of SET domain in MLL1 translocations would result in 
decreased H3K4 methylation and Hox gene expression, genetic studies have revealed that 
the individual fusion partners possess transcriptional activator properties and are 
indispensable for leukemogenesis (Chen et al., 2006a; Dobson et al., 1999; Dobson et al., 
2000; Wang et al., 2005). Given the complexity of different translocation partners, MLL1-
fusions may activate a common leukemia-associated gene expression program through 
multiple mechanisms. Indeed, AF4, AF5, AF9, ENL, ELL and AF10 proteins are all 
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indirect interaction partners for MLL1 that include; the menin tumor suppressor protein 
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participating in gain-of function phenotypes, making them candidates for molecular 
targeted therapy. We review progress in this area in sections 3-5.  In section 2, we describe in 
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Armstrong, 2007), and in therapy-related leukemias that develop in patients treated with 
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2007; Meyer et al., 2009; Schichman et al., 1995; So et al., 2003; Taki et al., 1997; Tkachuk et 
al., 1992; Wang et al., 2005). The translocation partners identified to date are diverse and 
do not share any biochemical function or structural motifs. However, all known MLL1 
fusion proteins share the property that the N-terminal portion containing the AT hooks 
and CxxC domains of MLL1 are retained, suggesting the preservation of DNA binding 
activity (Ayton et al., 2004; Macrini et al., 2003). In contrast, the taspase cleavage site, gene 
internal promoter, TAD domain, PHD fingers, Win motif and the SET domain are lost 
(Figure 2) (Liu et al., 2009).  
 
 
The putative protein products generated by the two most common chromosomal alterations associated 
with the MLL1 gene are indicated along with wild-type MLL1: a) wild-type MLL1, b) reciprocal 
chromosomal translocations involving MLL1, and c) partial tandem duplications (PTDs) in MLL1. The 
various functional domains are color coded as in Figure 1.  Chromosomal translocations fuse the N-
terminal ~1400 amino acids of MLL1 in-frame to one of over 60 different fusion partners (indicated in 
orange in b). PTDs have a duplicated N-terminus (AT-hooks and CXXC motifs) in addition to all the 
functional domains present in wild-type MLL1.  
Fig. 2. Schematic representation of the most common genetic alterations associated with the 
MLL1 gene. 
3.1.2 Pathogenesis of acute leukemias with MLL1-translocations 
While it is expected that the loss of SET domain in MLL1 translocations would result in 
decreased H3K4 methylation and Hox gene expression, genetic studies have revealed that 
the individual fusion partners possess transcriptional activator properties and are 
indispensable for leukemogenesis (Chen et al., 2006a; Dobson et al., 1999; Dobson et al., 
2000; Wang et al., 2005). Given the complexity of different translocation partners, MLL1-
fusions may activate a common leukemia-associated gene expression program through 
multiple mechanisms. Indeed, AF4, AF5, AF9, ENL, ELL and AF10 proteins are all 
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implicated in transcriptional elongation via association with the EAF complex, pTEFb 
kinase, and hDOT1 mediated methylation of H3K79 (Bitoun et al., 2007; Luo et al., 2001; 
Mueller et al., 2007; Mueller et al., 2009; Okada et al., 2005; Simone et al., 2001). Another 
mechanism could involve transcriptional activation via increased or aberrant histone 
acetylation (MLL-CBP/p300) (Lavau et al., 2000; Sobulo et al., 1997), protein arginine 
methyltransferase-1 (PRMT1) association (MLL-EEN) (Cheung et al., 2007), SWI-SNF 
chromatin-remodeling complex recruitment (MLL-ENL, -AF9, -AF10) (Debernardi et al., 
2002; Nie et al., 2003; Schreiner et al., 1999), and  self-association or dimerization of the N-
terminal part of MLL1 (MLL-GAS7, -AF1p, -beta-galactosidase, -gephyrin, -SEPT6) (Dobson 
et al., 2000; Eguchi et al., 2004; Martin et al., 2003; So et al., 2003).  
Regardless of the mechanism, aberrant expression of MLL1 target genes are a common 
feature of MLL1-rearrangements examined to date. For example, HOXa7, HOXa9, and the 
HOX cofactor MEIS1 are consistently over expressed in human leukemias with MLL1-
translocations (Armstrong et al., 2002; Ayton and Cleary, 2003; Rozovskaia et al., 2001; Yeoh 
et al., 2002; Zeisig et al., 2004) and act, at least partially, through the activation of the proto-
oncogene c-Myb (Hess et al., 2006). Furthermore, retroviral co-transduction studies in mice 
have demonstrated that HOXa9 and MEIS1 expression immortalizes hematopoietic 
progenitors in vitro and rapidly accelerates leukemia development (Kroon et al., 1998). In 
addition, MLL1-fusion proteins fail to transform bone marrow cells in which HOXa7 and 
HOXa9 expression are genetically ablated (Ayton and Cleary, 2003). Similarly, it has been 
demonstrated that expression of HOXa9 and MEIS1 can replace the leukemogenic activity of 
MLL1-ENL (Zeisig et al., 2004). Collectively, these results suggest that HOXa9 dysregulation 
is an important factor in some MLL1-fusion induced leukemias (Ayton and Cleary, 2003). 
However, not all leukemogenic fusions result in HOXa9 dysregulation. For example, MLL1-
GAS7 and MLL1-AF9 fusions were shown to transform bone marrow cells or mice that do 
not express HOXa9 (Kumar et al., 2004; So et al., 2004).  
However, in addition to disregulation of HOX genes, other signaling pathways are 
perturbed by MLL-translocations and may contribute to leukemogeneis. For example, 
transcriptional deregulation of FMS-like tyrosine kinase 3(FLT3), glycogen synthase kinase 3 
(GSK3), heat shock protein-90 (HSP-90), myeloid cell leukemia sequence-1 (MCL-1), and 
components of the RAS pathway have been implicated in MLL1-induced leukemogenesis 
(Armstrong et al., 2003; Brown et al., 2005; Carnicer et al., 2004; Liang et al., 2006; Stubbs et 
al., 2008; Wang et al., 2008; Yao et al., 2005; Yasui et al., 2005; Yocum et al., 2006). MLL1’s 
role as a master regulator of gene expression significantly complicates understanding its role 
in MLL1 associated leukemogenesis.  
The master regulatory role of MLL1 in transcriptional control has implications that affect 
our normal understanding of malignancy. For example, it has been suggested that second-
hit mutations are required to initiate the full leukemia phenotype (Dobson et al., 2000). 
Indeed, recent studies have identified mutations in p53, ATM, Ras, and FLT3 genes in MLL1 
leukemia patients (Felix et al., 1998; Mahgoub et al., 1998; Oguchi et al., 2003; Taketani et al., 
2004).  However, because of MLL1’s role in epigenetic gene control, second hit mutations 
could also arise in the form of epigenetic mutations that result in silencing of tumor 
suppressors genes without changes in their DNA sequence. For example, it has been 
demonstrated that the FHIT tumor suppressor gene is epigenetically silenced in human 
primary tumor cells and tumor cell lines with MLL1-translocations (Stam et al., 2006).   
These data suggest that epigenetic alterations may be just as important as genetic mutations 
in sources of so called “2nd hit” mutations that underlie the pathogenesis of leukemia. 
Recent advances in deep sequencing technologies such as RNA-SEQ and CHIP-SEq will 
likely allow us to better distinguish genetic versus epigenetic aberrations in future studies.  
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3.2 Partial tandem duplications: A cytogenetically normal rearrangement in MLL1 
3.2.1 Clinical significance of MLL1 partial tandem duplications (MLL1-PTDs) 
The second common MLL1-rearrangement, internal partial tandem duplication (MLL1- 
PTD) was first observed in de novo AML patients with a normal karyotype or trisomy 11 
(Caligiuri et al., 1994). MLL1-PTDs are found in 4-7% of the cases of AML and present a 
cytogenetically normal rearrangement that is associated with poor prognosis (Caligiuri et 
al., 1998; Dohner et al., 2002; Schichman et al., 1994; Schichman et al., 1995). MLL1-PTDs 
result from an in frame fusion of exons 11-5 or 12-5 upstream of exon 5, partially duplicating 
sequences in the 5’ end of MLL1 (Caligiuri et al., 1994; Quentmeier et al., 2003; Schichman et 
al., 1994). The protein product of MLL1-PTDs has a duplicated N-terminus that contains an 
additional AT-hook and CXXC domain while essentially retaining all the conserved 
domains in wild-type MLL1 (Quentmeier et al., 2003; Schichman et al., 1994). In contrast to 
the variety of MLL1-fusions that delete the MLL1 C-terminus, MLL1-PTDs retain the 3’-
portion of the gene that encodes the SET domain methyltransferase motif (Figure 2).  Recent 
data suggests that the enzymatic activity of the MLL-PTD SET domain participates in a gain-
of function phenotype in AML. 
3.2.2 Mechanism of leukemic transformation by MLL1-PTDs 
The molecular mechanisms that underlie MLL1-PTD transformation in AML are currently 
unknown. The crucial alteration is the duplication of AT hooks and CXXC DNA binding 
motifs, which may alter target gene specificity. It has been suggested that duplication of 
these segments may also mimic dimerization observed in several MLL1 chimeric fusion 
proteins (Martin et al., 2003). Indeed, it has been demonstrated that a synthetic MLL1 N-
terminal construct containing duplicated AT-hook and CXXC domains possesses potent 
transactivation activity in luciferase reporter assays (Martin et al., 2003). However, 
comparison of genome-wide gene expression data shows that MLL1-PTD primary cells 
have gene expression patterns that are distinct from that of cells bearing MLL1 chimeric 
fusions suggesting that the mechanism underlying transformation is distinct (Ross et al., 
2004). Alternatively, it has been suggested that the additional amino acid sequences in 
MLL1-PTD might adopt a conformation that potentially interferes with the normal 
function of MLL1 by distancing the regulatory domains from its target site (Dou and 
Hess, 2008).  
There is a growing body of evidence that suggests that epigenetic alterations underlie the 
pathogenesis of MLL1-PTDs. For example, it has been demonstrated that knock-in mice 
bearing MLL1PTD/WT exhibit increased expression of HOXa7, HOXa9, and HOXa10 that is 
associated with increased H3K4 methylation and H3/H4 acetylation within these promoters 
(Dorrance et al., 2006). Similar gene expression and H3K4 dimethylation changes were seen 
in the presence and absence of the wild type MLL1 allele in primary MLL1-PTD mouse fetal 
liver cells, suggesting that MLL1-PTD behaves as a dominant gain-of-function mutation 
(Dorrance et al., 2008). This phenotype may also be due to other epigenetic alterations. For 
example, Whitman and colleagues (2005) have demonstrated that the wild type MLL1 allele 
in MLL1PTD/WT AML cells is silenced in a manner that is associated with hypoacetylation of 
histones H3 and H4 (Whitman et al., 2005). Treatment of MLL1-PTD cells with histone 
deacetylase inhibitors partially reactivates wild type MLL1 expression and reduces AML 
blast colony forming units (Whitman et al., 2008). In addition, it has been demonstrated that 
the SLC5A8 tumor suppressor gene is silenced in MLL-PTD cells in a manner that is 
associated with increased DNA methylation in its promoter, a phenotype that is partially 
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implicated in transcriptional elongation via association with the EAF complex, pTEFb 
kinase, and hDOT1 mediated methylation of H3K79 (Bitoun et al., 2007; Luo et al., 2001; 
Mueller et al., 2007; Mueller et al., 2009; Okada et al., 2005; Simone et al., 2001). Another 
mechanism could involve transcriptional activation via increased or aberrant histone 
acetylation (MLL-CBP/p300) (Lavau et al., 2000; Sobulo et al., 1997), protein arginine 
methyltransferase-1 (PRMT1) association (MLL-EEN) (Cheung et al., 2007), SWI-SNF 
chromatin-remodeling complex recruitment (MLL-ENL, -AF9, -AF10) (Debernardi et al., 
2002; Nie et al., 2003; Schreiner et al., 1999), and  self-association or dimerization of the N-
terminal part of MLL1 (MLL-GAS7, -AF1p, -beta-galactosidase, -gephyrin, -SEPT6) (Dobson 
et al., 2000; Eguchi et al., 2004; Martin et al., 2003; So et al., 2003).  
Regardless of the mechanism, aberrant expression of MLL1 target genes are a common 
feature of MLL1-rearrangements examined to date. For example, HOXa7, HOXa9, and the 
HOX cofactor MEIS1 are consistently over expressed in human leukemias with MLL1-
translocations (Armstrong et al., 2002; Ayton and Cleary, 2003; Rozovskaia et al., 2001; Yeoh 
et al., 2002; Zeisig et al., 2004) and act, at least partially, through the activation of the proto-
oncogene c-Myb (Hess et al., 2006). Furthermore, retroviral co-transduction studies in mice 
have demonstrated that HOXa9 and MEIS1 expression immortalizes hematopoietic 
progenitors in vitro and rapidly accelerates leukemia development (Kroon et al., 1998). In 
addition, MLL1-fusion proteins fail to transform bone marrow cells in which HOXa7 and 
HOXa9 expression are genetically ablated (Ayton and Cleary, 2003). Similarly, it has been 
demonstrated that expression of HOXa9 and MEIS1 can replace the leukemogenic activity of 
MLL1-ENL (Zeisig et al., 2004). Collectively, these results suggest that HOXa9 dysregulation 
is an important factor in some MLL1-fusion induced leukemias (Ayton and Cleary, 2003). 
However, not all leukemogenic fusions result in HOXa9 dysregulation. For example, MLL1-
GAS7 and MLL1-AF9 fusions were shown to transform bone marrow cells or mice that do 
not express HOXa9 (Kumar et al., 2004; So et al., 2004).  
However, in addition to disregulation of HOX genes, other signaling pathways are 
perturbed by MLL-translocations and may contribute to leukemogeneis. For example, 
transcriptional deregulation of FMS-like tyrosine kinase 3(FLT3), glycogen synthase kinase 3 
(GSK3), heat shock protein-90 (HSP-90), myeloid cell leukemia sequence-1 (MCL-1), and 
components of the RAS pathway have been implicated in MLL1-induced leukemogenesis 
(Armstrong et al., 2003; Brown et al., 2005; Carnicer et al., 2004; Liang et al., 2006; Stubbs et 
al., 2008; Wang et al., 2008; Yao et al., 2005; Yasui et al., 2005; Yocum et al., 2006). MLL1’s 
role as a master regulator of gene expression significantly complicates understanding its role 
in MLL1 associated leukemogenesis.  
The master regulatory role of MLL1 in transcriptional control has implications that affect 
our normal understanding of malignancy. For example, it has been suggested that second-
hit mutations are required to initiate the full leukemia phenotype (Dobson et al., 2000). 
Indeed, recent studies have identified mutations in p53, ATM, Ras, and FLT3 genes in MLL1 
leukemia patients (Felix et al., 1998; Mahgoub et al., 1998; Oguchi et al., 2003; Taketani et al., 
2004).  However, because of MLL1’s role in epigenetic gene control, second hit mutations 
could also arise in the form of epigenetic mutations that result in silencing of tumor 
suppressors genes without changes in their DNA sequence. For example, it has been 
demonstrated that the FHIT tumor suppressor gene is epigenetically silenced in human 
primary tumor cells and tumor cell lines with MLL1-translocations (Stam et al., 2006).   
These data suggest that epigenetic alterations may be just as important as genetic mutations 
in sources of so called “2nd hit” mutations that underlie the pathogenesis of leukemia. 
Recent advances in deep sequencing technologies such as RNA-SEQ and CHIP-SEq will 
likely allow us to better distinguish genetic versus epigenetic aberrations in future studies.  
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3.2 Partial tandem duplications: A cytogenetically normal rearrangement in MLL1 
3.2.1 Clinical significance of MLL1 partial tandem duplications (MLL1-PTDs) 
The second common MLL1-rearrangement, internal partial tandem duplication (MLL1- 
PTD) was first observed in de novo AML patients with a normal karyotype or trisomy 11 
(Caligiuri et al., 1994). MLL1-PTDs are found in 4-7% of the cases of AML and present a 
cytogenetically normal rearrangement that is associated with poor prognosis (Caligiuri et 
al., 1998; Dohner et al., 2002; Schichman et al., 1994; Schichman et al., 1995). MLL1-PTDs 
result from an in frame fusion of exons 11-5 or 12-5 upstream of exon 5, partially duplicating 
sequences in the 5’ end of MLL1 (Caligiuri et al., 1994; Quentmeier et al., 2003; Schichman et 
al., 1994). The protein product of MLL1-PTDs has a duplicated N-terminus that contains an 
additional AT-hook and CXXC domain while essentially retaining all the conserved 
domains in wild-type MLL1 (Quentmeier et al., 2003; Schichman et al., 1994). In contrast to 
the variety of MLL1-fusions that delete the MLL1 C-terminus, MLL1-PTDs retain the 3’-
portion of the gene that encodes the SET domain methyltransferase motif (Figure 2).  Recent 
data suggests that the enzymatic activity of the MLL-PTD SET domain participates in a gain-
of function phenotype in AML. 
3.2.2 Mechanism of leukemic transformation by MLL1-PTDs 
The molecular mechanisms that underlie MLL1-PTD transformation in AML are currently 
unknown. The crucial alteration is the duplication of AT hooks and CXXC DNA binding 
motifs, which may alter target gene specificity. It has been suggested that duplication of 
these segments may also mimic dimerization observed in several MLL1 chimeric fusion 
proteins (Martin et al., 2003). Indeed, it has been demonstrated that a synthetic MLL1 N-
terminal construct containing duplicated AT-hook and CXXC domains possesses potent 
transactivation activity in luciferase reporter assays (Martin et al., 2003). However, 
comparison of genome-wide gene expression data shows that MLL1-PTD primary cells 
have gene expression patterns that are distinct from that of cells bearing MLL1 chimeric 
fusions suggesting that the mechanism underlying transformation is distinct (Ross et al., 
2004). Alternatively, it has been suggested that the additional amino acid sequences in 
MLL1-PTD might adopt a conformation that potentially interferes with the normal 
function of MLL1 by distancing the regulatory domains from its target site (Dou and 
Hess, 2008).  
There is a growing body of evidence that suggests that epigenetic alterations underlie the 
pathogenesis of MLL1-PTDs. For example, it has been demonstrated that knock-in mice 
bearing MLL1PTD/WT exhibit increased expression of HOXa7, HOXa9, and HOXa10 that is 
associated with increased H3K4 methylation and H3/H4 acetylation within these promoters 
(Dorrance et al., 2006). Similar gene expression and H3K4 dimethylation changes were seen 
in the presence and absence of the wild type MLL1 allele in primary MLL1-PTD mouse fetal 
liver cells, suggesting that MLL1-PTD behaves as a dominant gain-of-function mutation 
(Dorrance et al., 2008). This phenotype may also be due to other epigenetic alterations. For 
example, Whitman and colleagues (2005) have demonstrated that the wild type MLL1 allele 
in MLL1PTD/WT AML cells is silenced in a manner that is associated with hypoacetylation of 
histones H3 and H4 (Whitman et al., 2005). Treatment of MLL1-PTD cells with histone 
deacetylase inhibitors partially reactivates wild type MLL1 expression and reduces AML 
blast colony forming units (Whitman et al., 2008). In addition, it has been demonstrated that 
the SLC5A8 tumor suppressor gene is silenced in MLL-PTD cells in a manner that is 
associated with increased DNA methylation in its promoter, a phenotype that is partially 
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reversed with DNA methyltransferase inhibitors (Whitman et al., 2008). SLC5A8 encodes a 
membrane monocarboxylate transporter that regulates intracellular concentrations of 
histone deacetylase inhibitors, such as butyrate and pyruvate (Ganapathy et al., 2005; Gupta 
et al., 2006). Together, these observations suggest that targeting MLL1-PTD may have 
therapeutic value in the treatment of AML (Whitman et al., 2005). Indeed, it has been 
demonstrated that down regulation of MLL1-PTD using antisense oligodeoxynucleotides 
(aODNs) in primary human MLL-PTD AMLs results in reactivation of the wild type MLL1 
gene, reduced AML blast-derived colony forming units, and increased sensitivity to cell 
death (Whitman et al., 2008).   
3.3 Acute myeloid leukemia with amplifications in MLL1 
Amplifications of the MLL1 gene, including trisomy 11 and intrachromosomal 
amplifications, are found with less frequency in AML and other myelodysplastic syndromes 
and are associated with a complex karyotype and poor prognosis (Allen et al., 1998; 
Ariyama et al., 1998; Avet-Loiseau et al., 1999; Cuthbert et al., 1999; Herry et al., 2006; Poppe 
et al., 2004; Streubel et al., 2000). Amplifications involving MLL1 result in up-regulation of 
several HOX genes including, HOXa7, HOXa9, and MEIS1 (Herry et al., 2006; Poppe et al., 
2004). These studies suggest that MLL1-amplifications contribute to leukemogenesis 
through mechanisms that share some features with that of MLL1-fusions and MLL1-PTDs. 
In addition, gene expression analyses have identified other proteins that are up-regulated in 
AML with 11q23 amplifications including cell surface receptors PROML1, ADAM10, and 
NKG2D, and the inosine triphosphatase (ITPA) (Poppe et al., 2004). These data suggest that 
MLL1 amplifications are associated with a gain-of-function phenotype that may be 
responsive to targeted therapy (Poppe et al., 2004).  
In spite of these advances in our understanding of the pathogenesis of MLL1-linked 
leukemias, identification of inhibitors that specifically target MLL1 or MLL1-chimeric 
fusion proteins has so far proven elusive. Although in recent years the introduction of 
broadly based chemotherapeutic interventions such as all-trans retinoic acid, cytosine 
arabinoside, histone deacetylase and DNA methyltransferase inhibitors has increased the 
survival rates in some leukemia patients (Altucci et al., 2005; Downing, 2008; Liedtke and 
Cleary, 2009), molecular therapies that target MLL1 are still lacking. Recent advances in 
our understanding of the protein-protein interactions involving MLL1 suggest several 
novel therapeutic strategies for targeted inhibition of MLL1 or MLL1 chimeric fusion 
activity in leukemic cells. These advances are reviewed in sections 3-6 (and are 
summarized in Figure 8).  
4. Targeting MLL1-Menin interaction as a therapeutic strategy to treat Mixed 
Lineage Leukemia 
4.1 Menin is a common component of wild-type and mutant MLL1 complexes 
Despite the growing evidence demonstrating a role for HOX genes in hematopoiesis, it is 
unclear how the array of mutations involving the MLL1 gene all contribute to altered HOX 
gene expression in acute leukemias. While there is little that is common among the different 
types of MLL1 aberrations, all types of MLL1 gene mutations including: chromosomal 
translocations, internal partial tandem duplications, and gene amplifications, retain the N-
terminus of MLL1 (Daser and Rabbitts, 2005; Hess, 2004; Mitterbauer-Hohendanner and 
Mannhalter, 2004). These ~1400 N-terminal amino acids contain the DNA binding AT-hooks 
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and CXXC domains as well as the binding site for nuclear proteins menin (called the Menin 
Binding Motif or MBM) and the LEDGF binding domain (LBD) (Figures 1 and 2). Menin, 
which directly binds wild-type MLL1 and MLL1-oncogenic fusion proteins, is an essential 
co-factor for the maintenance of normal hematopoiesis and the leukemogenic activity of 
MLL1-associated translocations (Chen et al., 2006b; Hughes et al., 2004; Yokoyama et al., 
2005; Yokoyama et al., 2004). The importance of menin in the pathogenesis of MLL1-related 
leukemia and progress on the development of inhibitors that target the MLL1-menin 
interaction is reviewed in this section.  
4.2 MEN1 tumorigenesis 
Menin is the product of MEN1 gene located at chromosome band 11q13.  Menin functions as 
a tumor suppressor protein that is mutated in patients with an inherited syndrome called 
Multiple Endocrine Neoplasia 1 (MEN1) (Chandrasekharappa et al., 1997; 
Chandrasekharappa and Teh, 2001; Larsson et al., 1988). To date, more than 400 nonsense 
and frame-shift mutations have been reported in MEN1 patients often developing 
parathyroid, pancreatic or pituitary tumors after the loss of the wild-type MEN1 allele 
(Dong et al., 1997; Larsson et al., 1988; Lemmens et al., 1997; Thakker, 2001). Homozygous 
knockout of MEN1 (-/-) is embryonic lethal in mice, which die at the mid-gestation period 
with profound defects in liver, heart and the neural tube (Bertolino et al., 2003a; Crabtree et 
al., 2001; Stewart et al., 1998). Heterozygous knockout mice are viable until the adult stages, 
but develop tumors similar to human MEN1 syndrome in pancreatic islets, parathyroid, 
anterior pituitary, adrenal cortex and adrenal medulla (Bertolino et al., 2003b; Crabtree et al., 
2001). Although the loss of menin results in tumors of the endocrine lineage, the MEN1 gene 
is ubiquitously expressed in most adult tissues and at all developmental stages 
(Chandrasekharappa and Teh, 2001, 2003). In spite of the increasing evidence that highlights 
a role for menin in MEN1 tumors, the basic biology of menin dependent tumor suppression 
is unclear.  
4.3 Menin homology and conserved domain architecture 
Menin is highly conserved among vertebrates including, humans, mouse, rat, and 
zebrafish. However, menin orthologs have not been identified in budding yeast 
Saccharomyces cerevisiae or in the nematode Caenorhabditis elegans (Stewart et al., 1998) 
(Guru et al., 1999; Guru et al., 2001; Khodaei et al., 1999; Manickam et al., 2000). Strikingly, 
several of the disease-associated MEN1 mutations occur at conserved amino acid 
positions, highlighting a crucial role for menin in regulating cell proliferation in higher 
eukaryotes (Chandrasekharappa and Teh, 2003; Poisson et al., 2003). Menin is a novel 
nuclear protein of ~610 amino acids and does not share significant sequence homology to 
any other known proteins (Chandrasekharappa et al., 1997; Guru et al., 1998; Poisson et 
al., 2003). However, extensive analysis of sequence alignments among menin homologues 
has revealed several domains with putative roles in nuclear targeting and transcriptional 
regulation. Conserved domain search using the human menin amino acid sequence 
identified putative domains such as: consensus GTPase-like motifs (G1-G5), two leucine-
zipper motifs, a proline-rich region and two nuclear localization signals (NLS) (Balogh et 
al., 2006; Chandrasekharappa and Teh, 2003; Poisson et al., 2003) (Figure 3). However, it is 
unclear as to how these conserved motifs contribute to the tumor suppressor function of 
menin.  
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reversed with DNA methyltransferase inhibitors (Whitman et al., 2008). SLC5A8 encodes a 
membrane monocarboxylate transporter that regulates intracellular concentrations of 
histone deacetylase inhibitors, such as butyrate and pyruvate (Ganapathy et al., 2005; Gupta 
et al., 2006). Together, these observations suggest that targeting MLL1-PTD may have 
therapeutic value in the treatment of AML (Whitman et al., 2005). Indeed, it has been 
demonstrated that down regulation of MLL1-PTD using antisense oligodeoxynucleotides 
(aODNs) in primary human MLL-PTD AMLs results in reactivation of the wild type MLL1 
gene, reduced AML blast-derived colony forming units, and increased sensitivity to cell 
death (Whitman et al., 2008).   
3.3 Acute myeloid leukemia with amplifications in MLL1 
Amplifications of the MLL1 gene, including trisomy 11 and intrachromosomal 
amplifications, are found with less frequency in AML and other myelodysplastic syndromes 
and are associated with a complex karyotype and poor prognosis (Allen et al., 1998; 
Ariyama et al., 1998; Avet-Loiseau et al., 1999; Cuthbert et al., 1999; Herry et al., 2006; Poppe 
et al., 2004; Streubel et al., 2000). Amplifications involving MLL1 result in up-regulation of 
several HOX genes including, HOXa7, HOXa9, and MEIS1 (Herry et al., 2006; Poppe et al., 
2004). These studies suggest that MLL1-amplifications contribute to leukemogenesis 
through mechanisms that share some features with that of MLL1-fusions and MLL1-PTDs. 
In addition, gene expression analyses have identified other proteins that are up-regulated in 
AML with 11q23 amplifications including cell surface receptors PROML1, ADAM10, and 
NKG2D, and the inosine triphosphatase (ITPA) (Poppe et al., 2004). These data suggest that 
MLL1 amplifications are associated with a gain-of-function phenotype that may be 
responsive to targeted therapy (Poppe et al., 2004).  
In spite of these advances in our understanding of the pathogenesis of MLL1-linked 
leukemias, identification of inhibitors that specifically target MLL1 or MLL1-chimeric 
fusion proteins has so far proven elusive. Although in recent years the introduction of 
broadly based chemotherapeutic interventions such as all-trans retinoic acid, cytosine 
arabinoside, histone deacetylase and DNA methyltransferase inhibitors has increased the 
survival rates in some leukemia patients (Altucci et al., 2005; Downing, 2008; Liedtke and 
Cleary, 2009), molecular therapies that target MLL1 are still lacking. Recent advances in 
our understanding of the protein-protein interactions involving MLL1 suggest several 
novel therapeutic strategies for targeted inhibition of MLL1 or MLL1 chimeric fusion 
activity in leukemic cells. These advances are reviewed in sections 3-6 (and are 
summarized in Figure 8).  
4. Targeting MLL1-Menin interaction as a therapeutic strategy to treat Mixed 
Lineage Leukemia 
4.1 Menin is a common component of wild-type and mutant MLL1 complexes 
Despite the growing evidence demonstrating a role for HOX genes in hematopoiesis, it is 
unclear how the array of mutations involving the MLL1 gene all contribute to altered HOX 
gene expression in acute leukemias. While there is little that is common among the different 
types of MLL1 aberrations, all types of MLL1 gene mutations including: chromosomal 
translocations, internal partial tandem duplications, and gene amplifications, retain the N-
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and CXXC domains as well as the binding site for nuclear proteins menin (called the Menin 
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al., 2006; Chandrasekharappa and Teh, 2003; Poisson et al., 2003) (Figure 3). However, it is 
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Schematic representation of the conserved regions in human menin with the various functional 
domains indicated in different colors:  GTPase consensus-motifs G1-G5 (black), leucine-zipper-like 
motifs (purple), proline-rich sequence (blue), and nuclear localization signal (NLS) (orange). Naturally 
occurring MEN1 mutations that disrupt its interaction with MLL1 (green) and LEDGF (red) are 
indicated below.  
Fig. 3. Domain architecture of human menin showing conserved domains  
4.4 Menin molecular interaction network 
The precise biochemical function of menin has so far proven elusive due to the lack of any 
known functional domains in menin. However,  it has been suggested that the 
transcriptional regulatory properties of menin are regulated by protein-protein 
interactions (Balogh et al., 2006; Jin et al.; Poisson et al., 2003; Yokoyama and Cleary, 2008; 
Yokoyama et al., 2004). Recent biochemical efforts have been undertaken to elucidate the 
molecular pathways that underlie menin-dependent transcriptional regulation (Balogh et 
al., 2006). Using yeast two-hybrid, GST pull-down and co-immunoprecipitation assays, 
menin was shown to interact with a cohort of proteins that are involved in cell cycle 
regulation, DNA replication and repair, genome stability, endocrine metabolism, bone 
morphogenesis and hematopoiesis (Balogh et al., 2006; Chandrasekharappa and Teh, 
2003; Hughes et al., 2004; Wu and Hua, 2008). These studies uncovered a wide variety of 
proteins that may or may not interact directly with menin. These proteins (menin 
interacting proteins or MIPs) can be grouped into four major functional classes: Class I, 
which includes transcription factors like JunD (Agarwal et al., 1999; Gobl et al., 1999; 
Heppner et al., 2001), NFkB (p50, p52 and p65) (Heppner et al., 2001), Smad3 (Kaji et al., 
2001), BMP2 (bone morphogenic protein 2) (Sowa et al., 2004), IGFBP-2 (Insulin-like 
growth factor binding protein 2) (La et al., 2004), FANCD2 (fanconi anemia 
complementation group D2 protein) (Jin et al., 2003), Pem (a homeobox containing 
transcription factor) (Lemmens et al., 2001), cMyb (Jin et al.); Class II, which includes 
DNA damage and replication proteins such as RPA (replication protein A 1 and 2) 
(Sukhodolets et al., 2003); Class III, which includes cell cycle regulatory proteins such as 
CDK inhibitors (p18 and p27) (Milne et al., 2005),  ASK (activator s-phase kinase) 
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(Schnepp et al., 2004), type III intermediate filaments (glial fibrillary acidic protein or 
GFAP and Vimentin) (Lopez-Egido et al., 2002); and Class IV, which includes 
transcriptional activators such as MLL1/2 (mixed lineage leukemia proteins) (Hughes et 
al., 2004; Yokoyama et al., 2004), RNA polymerase II phosphorylated carboxy terminal 
domain (Hughes et al., 2004), LEDGF (Yokoyama and Cleary, 2008), and CHD1 (chromo 
domain helicase I) (Chen et al., 2006b). Based on these studies it has been suggested that 
MIPs modulate the transcriptional activator/repressor functions of menin (Agarwal et al., 
1999; Agarwal et al., 2003; Heppner et al., 2001; Kaji et al., 2001). While a direct role for the 
interaction of menin with all MIPs has yet to be validated in vivo, it is possible that MIPs 
regulate transcription by binding directly or indirectly to menin (Balogh et al., 2006; 
Chandrasekharappa and Teh, 2003; Wu and Hua, 2008). In addition, menin also binds to a 
putative tumor metastasis suppressor/nucleoside diphosphate kinase (Nm23), which 
stimulates the GTP hydrolyzing activity of menin (Ohkura et al., 2001). Moreover, menin 
also functions as a transcriptional co-activator of the nuclear receptor pathway by binding 
with estrogen receptor-alpha (ERalpha) in a hormone-dependent manner (Dreijerink et 
al., 2006). A non-specific DNA binding activity through the C-terminal NLS has also been 
reported for menin (La et al., 2004). Of the multitude of interactions reported for menin, it 
is the association with the SET1 family methyltransferases MLL1/2 that has generated a 
lot of interest due to their roles in hematopoiesis and leukemia.  
4.5 Role of menin in Hematopoiesis 
Menin is an essential component of MLL1/2 family complexes with specific roles in the 
maintenance of HOX gene expression patterns during hematopoiesis (Hughes et al., 2004; 
Yokoyama et al., 2004).  Conditional knockouts of the MEN1 gene in mice decreases 
peripheral white blood cell counts as well as colony forming potential of bone marrow 
hematopoietic progenitors (Chen et al., 2006b). Recent work by Maillard et al., (2009a), 
suggests that while conditional menin knockouts have modest effects on hematopoiesis 
under steady-state conditions, more severe defects are observed in competitive 
transplantation assays and during drug-mediated chemoablation (Maillard et al., 2009). 
These studies suggest that menin functions as an essential regulator of hematopoietic stem 
cell (HSC) homeostasis specifically in situations of hematopoietic stress (Maillard and Hess, 
2009). These phenotypes may be due, at least in part, to menin’s role in regulating HOX gene 
expression. For example, small-interfering RNA (siRNA) mediated knockdown of menin or 
conditional MEN1 (-/-) knockout embryos show significant decreases in the expression 
levels of several HOX genes including HOXa9, HOXc6, and HOXc8 (Chen et al., 2006b; 
Hughes et al., 2004; Wu and Hua, 2008; Yokoyama et al., 2004). Interestingly, these 
hematopoietic defects are rescued by the ectopic expression of menin or its downstream 
targets HOXa9/MEIS1 (Chen et al., 2006b; Hughes et al., 2004). Evidence indicates that 
menin’s interaction with MLL1/2 complexes is required for its role in transcription. For 
example, chromatin immunoprecipitation studies using antibodies specific to menin, MLL1, 
trimethylated H3K4 or CHD1 (which binds trimethylated H3K4) (Flanagan et al., 2005; 
Pray-Grant et al., 2005; Sims et al., 2005) have further established that menin co-localizes 
with these components at HOXa9 promoters and is required for transcriptional activation 
(Chen et al., 2006b; Wu and Hua, 2008). Furthermore, it has been shown that a subset of 
naturally occurring mutations in menin (H139D, A242V, and T344R) disrupts its association 
with MLL1 and fails to associate with MLL1-dependent H3K4 methyltransferase activity 
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putative tumor metastasis suppressor/nucleoside diphosphate kinase (Nm23), which 
stimulates the GTP hydrolyzing activity of menin (Ohkura et al., 2001). Moreover, menin 
also functions as a transcriptional co-activator of the nuclear receptor pathway by binding 
with estrogen receptor-alpha (ERalpha) in a hormone-dependent manner (Dreijerink et 
al., 2006). A non-specific DNA binding activity through the C-terminal NLS has also been 
reported for menin (La et al., 2004). Of the multitude of interactions reported for menin, it 
is the association with the SET1 family methyltransferases MLL1/2 that has generated a 
lot of interest due to their roles in hematopoiesis and leukemia.  
4.5 Role of menin in Hematopoiesis 
Menin is an essential component of MLL1/2 family complexes with specific roles in the 
maintenance of HOX gene expression patterns during hematopoiesis (Hughes et al., 2004; 
Yokoyama et al., 2004).  Conditional knockouts of the MEN1 gene in mice decreases 
peripheral white blood cell counts as well as colony forming potential of bone marrow 
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suggests that while conditional menin knockouts have modest effects on hematopoiesis 
under steady-state conditions, more severe defects are observed in competitive 
transplantation assays and during drug-mediated chemoablation (Maillard et al., 2009). 
These studies suggest that menin functions as an essential regulator of hematopoietic stem 
cell (HSC) homeostasis specifically in situations of hematopoietic stress (Maillard and Hess, 
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(Hughes et al., 2004) (Refer to figure 3 for MEN1 mutations). These findings underscore the 
importance of the menin-MLL1 interaction in regulating HOX gene expression in 
hematopoiesis.  
4.6 Role of menin in leukemogenesis 
The first evidence for the involvement of menin in MLL1-associated leukemogenesis came 
from the initial biochemical studies carried out by Yokoyama et al., (2005) who identified a 
menin binding motif (MBM) located within the first 330 amino acids of MLL1, a region that 
is also retained in all types of MLL1 aberrations (Figures 1 and 2) (Yokoyama et al., 2005). 
Using leukemia cells that carry specific MLL1-translocations (MLL1-AF6, MLL1-ENL, 
MLL1-AF9, MLL1-AF10, and MLL1-GAS7) it was demonstrated that menin specifically 
associates with these MLL1-fusion proteins at the promoter of HOX genes such as: HOXa7, 
HOXa9 and HOXa10, which are constitutively expressed in several cases of acute leukemia 
(Chen et al., 2006b; Yokoyama et al., 2005; Yokoyama et al., 2004). Acute loss of menin 
reduces the aberrant HOX gene expression and abrogates the differentiation arrest 
associated with these MLL1-fusions (Yokoyama et al., 2005). Furthermore, conditional 
knockouts of the MEN1 gene suggests that menin is essential for the initiation and 
maintenance of MLL1-associated, but not other oncogene induced, myeloid transformations 
(Caslini et al., 2007; Chen et al., 2006b; Yokoyama et al., 2005). Together, these results 
demonstrate that MLL1-fusion proteins are dependent on menin for their oncogenic 
properties and raise the possibility that molecular therapies that target the menin-MLL1 
interaction might be an effective strategy to treat leukemias.  
While it is unclear how menin modulates the activities of wild-type and MLL1-fusion 
proteins, recent studies suggest that menin functions to recruit other proteins that are 
required for targeting MLL1 to downstream genes. For example, a recent study by 
Yokoyama and Cleary (2008) suggests that menin promotes LEDGF binding to MLL1. 
LEDGF contains a highly conserved PWWP motif that is required for MLL1’s association 
with downstream target genes (Yokoyama and Cleary, 2008). In addition, menin amino acid 
substitutions that disrupt its interaction with LEDGF without affecting menin’s interaction 
with MLL1 also display decreased Hoxa9 gene expression (Roudaia and Speck, 2008; 
Yokoyama and Cleary, 2008).  These data indicate that part of menin’s function is to stabilize 
the interaction between MLL1 and LEDGF. More recently, it has been shown that menin 
recruits the transcription factor cMyb to the MLL1 complex, which is required for 
recruitment of MLL1 to the Hoxa9 promoter (Jin et al., 2010). It has been shown that 
depletion of cMyb decreases the transforming potential of the MLL1-ENL fusion protein (Jin 
et al., 2010), suggesting that molecules that inhibit the menin-cMyb interaction may also be 
useful therapeutic agents.  
4.7 Menin interacts with the N-terminus of MLL1 through an evolutionarily conserved 
Menin Binding Motif (MBM)  
The interaction of menin with N-terminal sequences of wild-type MLL1 and MLL1-chimeric 
fusion proteins have been demonstrated by three independent reports (Caslini et al., 2007; 
Grembecka et al., 2010; Yokoyama et al., 2005). While the conclusions of these studies differ 
with respect to the exact length of the MLL1 fragment predicted to be involved in the 
interaction with menin, they have collectively identified a highly conserved “menin binding 
motif” (MBM) localized within the first 46 residues of MLL1. For example, Yokoyama et al., 
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(2005) demonstrated that a consensus sequence (RXRFP), called the high-affinity MBM, is 
present between MLL1 amino acids 6-10. Sequence analysis reveals that the MBM is highly 
conserved among MLL1 orthologs and in MLL2 (residues 17-21) (Figure 3). Deletions of the 
MBM in the MLL1-ENL and MLL1-GAS7 fusion proteins abrogates the interaction with 
menin in 293T cells (Yokoyama et al., 2005). Furthermore, MLL1-ENL fusions that lack the 
MBM fails to induce acute myeloid leukemia in syngeneic recipient mice (Yokoyama et al., 
2005). This failure is associated with impaired expression of HOXa7 and HOXa9 genes in the 
MBM-deleted MLL1-ENL transduced murine myeloid progenitors (Yokoyama et al., 2005). 
Moreover, MBM deletion mutants of MLL1-ENL lose their clonogenic potential and induce 
differentiation in leukemia blasts, a phenotype similar to the conditional knock out of menin 
or MLL1-ENL itself (Ayton and Cleary, 2003; Yokoyama et al., 2005; Zeisig et al., 2004). 
These studies demonstrate the importance of menin-MLL1 interaction in the pathogenesis of 
MLL1-associated leukemias.  
 
 
The different functional domains in MLL1 are indicated and color coded as in Figure 1. The menin 
binding motif  encompassing residues 5-44 (purple) along with LEDGF binding domain (LBD)(light 
red), AT-hooks (black), and the CXXC motif (pink) are retained by both MLL1-translocations and PTD 
mutations. The blow up region shows a ClustalW multiple sequence alignment of the high affinity 
menin binding motifs, MBM1 and MBM2, present in human (Q03164), mouse (NP_001074518), 
zebrafish (ACN88688), and pufferfish (AAC41377) MLL1s; and human MLL2 (O14686), and MLL1-AF4 
(AAC37520) fusions (indicated in purple). MBM1 and 2 were identified based on three independent 
studies (Yokoyama et al., 2005; Caslini et al., 2007; Grembecka et al., 2010).  
Fig. 4. Menin Binding Motifs (MBMs) are present in the wild-type MLL1, MLL1 chimeric 
fusions and partial tandem duplications  
In an attempt to further characterize the physiological significance of the MLL1-menin 
interaction in acute leukemias, Caslini et al., (Caslini et al., 2007) demonstrated that MLL1 
residues 5-44 are required for high affinity binding with menin. This MBM region spans the 
RWRFP motif (residues 6-10) and also includes a second region between MLL1 residues 35 
and 44 that is necessary, but not sufficient, for high-affinity interaction with menin (Caslini 
et al., 2007). Internal deletions in the MLL1-AF9 fusion protein that lacked amino acids 5-15 
(high affinity MBM) or 35-44 (low affinity MBM) failed to co-immunoprecipitate with menin 
from 293T cells (Caslini et al., 2007). Furthermore, Caslini et al., (2007) also demonstrated 
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In an attempt to further characterize the physiological significance of the MLL1-menin 
interaction in acute leukemias, Caslini et al., (Caslini et al., 2007) demonstrated that MLL1 
residues 5-44 are required for high affinity binding with menin. This MBM region spans the 
RWRFP motif (residues 6-10) and also includes a second region between MLL1 residues 35 
and 44 that is necessary, but not sufficient, for high-affinity interaction with menin (Caslini 
et al., 2007). Internal deletions in the MLL1-AF9 fusion protein that lacked amino acids 5-15 
(high affinity MBM) or 35-44 (low affinity MBM) failed to co-immunoprecipitate with menin 
from 293T cells (Caslini et al., 2007). Furthermore, Caslini et al., (2007) also demonstrated 
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that MLL1-AF9 MBM sequences were essential for the transformation of hematopoietic 
progenitors by the MLL1-AF9 fusion protein. Interestingly, the MLL1 constructs MLL1(2-
167), MLL1(2-62), and MLL1(2-44) function as dominant negative inhibitors of the MLL1-
menin interaction by titrating menin from the endogenous MLL1-AF9 protein resulting in 
reduced HOXa9 and MEIS1 expression and inhibition of the growth of transformed bone 
marrow progenitors (Caslini et al., 2007). Together, these results suggest that expression of 
dominant negative MLL1 constructs or peptide inhibitors that mimic the MLL1-menin 
interaction can inhibit the transforming potential of MLL1-fusion proteins by specifically 
down regulating the expression of target HOX genes. Unexpectedly, dominant negative 
constructs of MLL1 also inhibited the colony-forming ability of wild-type hematopoietic 
progenitors since these constructs also mimic the interaction surface between wild-type 
MLL1 and menin (Caslini et al., 2007). Collectively, these findings suggest that small 
molecule inhibitors that target menin-MLL1 interaction have a therapeutic potential to treat 
MLL1-associated leukemias, but with the caveat that normal hematopoiesis might also be 
impaired (Caslini et al., 2007). 
4.8 MBM based peptides as novel therapeutic agents for acute leukemias with MLL1-
rearrangements 
Structural and biochemical studies that characterize the menin-MLL1 interaction in detail is 
an important step in the development of MBM-based small molecule inhibitors that can 
specifically help treat MLL1-mediated cancers. Grembecka et al., (2010) carried out a 
detailed biophysical characterization of the interaction between menin and MLL1 using a 
combination of NMR, Isothermal Titration Calorimetry (ITC) and Fluorescence Anisotropy 
(FP). They found that MLL1 binds menin with high affinity (Kd=~10nM) utilizing two 
menin binding motifs (MBM1 and 2) located within the first 43 amino acids of MLL1 as 
previously suggested (Caslini et al., 2007; Yokoyama et al., 2005). Furthermore, peptides 
derived from the MBM1 (amino acids 5-14) and MBM2 (23-40) in MLL1 bind menin with 
interaction affinities of 53nM and 1400nM, respectively (Grembecka et al., 2010). Using a 
series of peptide competition experiments, MBM1 and MBM2 peptides were shown to 
displace a construct of MLL1 (amino acids 2-43) from bound menin in vitro with IC50 values 
of 0.5 µM and 37 µM, respectively (Grembecka et al., 2010). Moreover, based on transfer-
nuclear overhauser effects (Tr-NOEs) based NMR experiments, it was further suggested that 
MBM1 interacts with menin in an extended conformation and that the binding is facilitated 
by hydrophobic residues Phe9, Pro10 and Pro13 (Grembecka et al., 2010). Substitution to 
alanine of these amino acid residues significantly impaired the binding of MLL1 constructs 
to menin (Grembecka et al., 2010). Together, these studies have identified MBM1 (which 
encompasses the consensus RWRFP) as a potential drug target for leukemias with MLL1 
translocations.   
5. Molecular targeting of MLL1-rearranged leukemias - Peptide inhibitors that 
target the activity of MLL1-AF4 and MLL1-AF9 fusion proteins 
5.1 Clinical significance of t(4;11) and t(9;11) translocations 
MLL1 translocations do not share a common structural motif or biochemical function.  
However, based on sequence similarities, the most commonly occurring MLL1 fusions can 
be grouped into three major gene families: AF10/AF17, ENL/AF9, and the largest family, 
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AF4/LAF4/AF5q31/FMR2 (Nilson et al., 1997). The most common translocation is 
t(4;11)(q21;q23) and is associated with more than 50% of acute leukemia cases in infants, and 
for 3-6% of cases in older children (Behm et al., 1996; Faderl et al., 1998; Heerema et al., 
1999). The t(4;11) translocations results in leukemic blasts expressing phenotypic markers for 
ALL in 95% of the cases (Chen et al., 1993; Pui et al., 2003)). t4:11 translocations result in 
cancers that often spread beyond the hematopoietic lineage and have a poor prognosis 
(Armstrong et al., 2002; Chen et al., 1993; Rubnitz et al., 1994a). The t(4:11) translocation 
retains the 5’ portion of MLL1 gene containing the menin binding motif (MBM), AT hooks 
and the CXXC DNA binding motifs, which are fused in-frame to the 3’ portion of the gene at 
the 4q21 locus called AF4 (Gu et al., 1992). The high occurrence rates of t(4;11) translocation 
in infants along with the poor prognosis and absence of chemotherapeutics to treat these 
leukemias highlight an urgent need for the development of inhibitors that specifically target 
the gain-of-function phenotypes associated with the MLL1-AF4 fusion. In this regard, 
inhibitors that target the interaction between AF4 and its partner protein AF9 have been 
developed recently and show promising results in inhibiting the transforming potential of 
leukemia cell lines bearing MLL1-AF4 or MLL1-AF9 translocations (Bennett et al., 2009; 
Palermo et al., 2008; Srinivasan et al., 2004). The biochemical studies that form the basis for 
these conclusions are summarized in this section.  
5.2 Domain architecture and the functional roles of AF4 family 
AF4, also known as AFF1/FEL, is a serine/proline-rich nuclear protein with crucial roles in 
B and T lymphocyte development. AF4 has several putative functional domains including 
the ALF (AF4/LAF4/FMR2 homology) domain, which  mediates the interaction with a 
family of ubiquitin ligases called SIAH (seven in absentia homolog), a serine/proline-rich 
transcriptional activation domain (TAD), nuclear localization signals (NLS), a guanosine 
triphosphate (GTP) binding motif (GBM), and  a C-terminal homology domain involved in 
intra-nuclear localization and binding to pre-mRNA splicing factors (Bensaid et al., 2009; 
Chen et al., 1993; Isnard et al., 2000; Melko et al.; Morrissey et al., 1993; Oliver et al., 2004) 
(Figure 5). AF4 is located at a fragile break-point region on chromosome 4 and is associated 
with a wide variety of chromosomal translocations. AF4 is a member of 
AF4/LAF4/AF5q31/FMR2 family of nuclear transcription factors (Gu et al., 1996; von 
Bergh et al., 2001; von Bergh et al., 2002) and also shows significant homology to the 
Drosophila melanogaster pair-rule gene Lilliputian  (Su et al., 2001). Surprisingly, three of 
these family members (AF4/LAF4/AF5q31) are associated with infant leukemias involving 
reciprocal translocations with the MLL1 gene (Domer et al., 1993; Ma and Staudt, 1996; Taki 
et al., 1999). The second family member LAF4, isolated from Burkitt’s lymphoma, is a 
lymphoid-specific transcription factor and has transcriptional activation domains and 
nuclear localization signals that are highly similar to AF4 (Ma and Staudt, 1996). Indeed, the 
MLL1-LAF4 fusion proteins also retain the TAD in LAF4, which can functionally substitute 
for the activation domain in MLL1, thereby the contributing to the leukemogenic potential 
of these chimeric fusion proteins (Ma and Staudt, 1996). The third AF4 homologue AF5q31 
was originally identified from infant acute leukemias with a (5;11)(q31;q13q23) translocation 
(Taki et al., 1999). Strikingly, each of these MLL1-AF4 gene family fusions manifest very 
similar clinical characteristics- that is, early onset, poor prognosis, and a mixed 
immunophenotype. However, the fourth AF4 family member, FMR2, is associated with 
mental retardation and is located in the folate-sensitive break-point region at chromosome X 
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that MLL1-AF9 MBM sequences were essential for the transformation of hematopoietic 
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alanine of these amino acid residues significantly impaired the binding of MLL1 constructs 
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AF4/LAF4/AF5q31/FMR2 (Nilson et al., 1997). The most common translocation is 
t(4;11)(q21;q23) and is associated with more than 50% of acute leukemia cases in infants, and 
for 3-6% of cases in older children (Behm et al., 1996; Faderl et al., 1998; Heerema et al., 
1999). The t(4;11) translocations results in leukemic blasts expressing phenotypic markers for 
ALL in 95% of the cases (Chen et al., 1993; Pui et al., 2003)). t4:11 translocations result in 
cancers that often spread beyond the hematopoietic lineage and have a poor prognosis 
(Armstrong et al., 2002; Chen et al., 1993; Rubnitz et al., 1994a). The t(4:11) translocation 
retains the 5’ portion of MLL1 gene containing the menin binding motif (MBM), AT hooks 
and the CXXC DNA binding motifs, which are fused in-frame to the 3’ portion of the gene at 
the 4q21 locus called AF4 (Gu et al., 1992). The high occurrence rates of t(4;11) translocation 
in infants along with the poor prognosis and absence of chemotherapeutics to treat these 
leukemias highlight an urgent need for the development of inhibitors that specifically target 
the gain-of-function phenotypes associated with the MLL1-AF4 fusion. In this regard, 
inhibitors that target the interaction between AF4 and its partner protein AF9 have been 
developed recently and show promising results in inhibiting the transforming potential of 
leukemia cell lines bearing MLL1-AF4 or MLL1-AF9 translocations (Bennett et al., 2009; 
Palermo et al., 2008; Srinivasan et al., 2004). The biochemical studies that form the basis for 
these conclusions are summarized in this section.  
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AF4, also known as AFF1/FEL, is a serine/proline-rich nuclear protein with crucial roles in 
B and T lymphocyte development. AF4 has several putative functional domains including 
the ALF (AF4/LAF4/FMR2 homology) domain, which  mediates the interaction with a 
family of ubiquitin ligases called SIAH (seven in absentia homolog), a serine/proline-rich 
transcriptional activation domain (TAD), nuclear localization signals (NLS), a guanosine 
triphosphate (GTP) binding motif (GBM), and  a C-terminal homology domain involved in 
intra-nuclear localization and binding to pre-mRNA splicing factors (Bensaid et al., 2009; 
Chen et al., 1993; Isnard et al., 2000; Melko et al.; Morrissey et al., 1993; Oliver et al., 2004) 
(Figure 5). AF4 is located at a fragile break-point region on chromosome 4 and is associated 
with a wide variety of chromosomal translocations. AF4 is a member of 
AF4/LAF4/AF5q31/FMR2 family of nuclear transcription factors (Gu et al., 1996; von 
Bergh et al., 2001; von Bergh et al., 2002) and also shows significant homology to the 
Drosophila melanogaster pair-rule gene Lilliputian  (Su et al., 2001). Surprisingly, three of 
these family members (AF4/LAF4/AF5q31) are associated with infant leukemias involving 
reciprocal translocations with the MLL1 gene (Domer et al., 1993; Ma and Staudt, 1996; Taki 
et al., 1999). The second family member LAF4, isolated from Burkitt’s lymphoma, is a 
lymphoid-specific transcription factor and has transcriptional activation domains and 
nuclear localization signals that are highly similar to AF4 (Ma and Staudt, 1996). Indeed, the 
MLL1-LAF4 fusion proteins also retain the TAD in LAF4, which can functionally substitute 
for the activation domain in MLL1, thereby the contributing to the leukemogenic potential 
of these chimeric fusion proteins (Ma and Staudt, 1996). The third AF4 homologue AF5q31 
was originally identified from infant acute leukemias with a (5;11)(q31;q13q23) translocation 
(Taki et al., 1999). Strikingly, each of these MLL1-AF4 gene family fusions manifest very 
similar clinical characteristics- that is, early onset, poor prognosis, and a mixed 
immunophenotype. However, the fourth AF4 family member, FMR2, is associated with 
mental retardation and is located in the folate-sensitive break-point region at chromosome X 
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band q28 (Gecz, Gedeon et al. 1996; Gu, Shen et al. 1996). FMR2 has not been reported to be 
a part of any MLL1 fusions.  
 
 
Overview of the protein domain structure of human AF4 adapted from (Li et al., 1998; Srinivasan et al., 
2004 and Melko et al., 2011). The different domains are highlighted: N-homology region with an 
unknown function (green), ALF (AF4/LAF4/FMR2 homology) region which includes the transcription 
activation domain (dark red), AF9 interaction region (orange), nuclear localization signals (dark blue), a 
putative consensus guanosine triphosphate (GTP) binding motif (purple), and C-terminal homology 
domain (light blue). The domains are not drawn to scale. The ClustalW multiple protein sequence 
alignment of the AF9 binding regions of AF4 family members: human AF4 (hAF4, Pubmed ID: P51825), 
mouse AF4 (mAF4, Pubmed: AAU93698), human LAF4 (hLAF4, PubMed ID: NP002276), human AF5 
(hAF5, PubMed ID: Q9UHB7), human FMR2 (hFMR2, PubMed ID: BAC81113) and mouse FMR2 
(mFMR2, PubMed ID: CAA04821) are shown with the AF9 interaction region boxed. Chromosomal 
break points are also indicated for cell lines carrying t(4;11) translocations. 
Fig. 5. Domain representation of human AF4 highlighting the AF9 interaction region. 
Despite the growing amount of clinical evidence suggesting the involvement of MLL1-AF4 
family translocations in human acute leukemias, the molecular mechanisms by which the 
MLL1-AF4 fusion proteins induce neoplasia are not fully understood. One possibility is that 
the resulting MLL1-AF4 fusion protein has a gain-of function phenotype wherein the 
transcriptional activation domain of AF4 is fused to the DNA binding domains of MLL1 and 
alters the regulation of MLL1 dependent genes  (Prasad et al., 1995). However, genetic 
studies using mouse knock-in models suggest that the two fusion proteins MLL1-AF4 and 
AF4-MLL1 resulting from the balanced reciprocal translocation between MLL1 and AF4 
could independently contribute to the pathogenesis of t(4;11) mediated acute leukemias 
(Bursen et al.; Chen et al., 2006a; Isnard et al., 2000). Importantly, the AF4-MLL1 fusion 
protein retains the C-terminal portion of MLL1 including its SET domain, and is sufficient to 
induce leukemia in the absence of MLL1-AF4 (Bursen et al., 2010).  
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5.3 Molecular interaction network for AF4 fusion proteins 
These studies raise the possibility that MLL1-AF4 and AF4-MLL1 participate in different 
sets of interaction networks as compared to the native full-length proteins (MLL1 and AF4) 
and result in gene expression signatures that are a representative of the physiological 
function of the fusion partners. This hypothesis is supported by the studies of Benedikt et 
al., (2011), who used affinity purified AF4 and AF4-MLL1 complexes from 293T cells to 
elucidate the subunit composition of the two complexes (Benedikt et al., 2011). Wild-type 
AF4 was purified in a complex containing the CDK9/Cyclin T heterodimer, which 
resembles the positive transcription elongation factor b (p-TEFb) (Benedikt et al., 2011; 
Estable et al., 2002) and also co-purifies with the wild type versions of two other known 
MLL1 fusion partners, AF9 and ENL, both of which bind to the C-terminus of AF4 family 
members (Benedikt et al., 2011; Erfurth et al., 2004; Mueller et al., 2009). Furthermore, ENL 
binding to AF4 creates a binding site for AF10, DOT1 methyltransferase and histone H3 
(Benedikt et al., 2011; Mueller et al., 2007). Both the DOT1 mediated H3K79 methylation and 
the p-TEFb mediated phosphorylation of RNA Pol II C-terminal domain could lead to 
transcriptional elongation and is facilitated by the interaction of wild-type AF4 with these 
proteins (Benedikt et al., 2011; Bitoun et al., 2007). In contrast, the subunit composition of the 
AF4-MLL1 complex is different from the wild-type AF4 protein alone due to additional 
proteins that interact with the fused MLL1 C-terminal fragment. These proteins likely 
modulate the transcriptional activating properties of AF4-MLL1 fusion protein (Benedikt et 
al., 2011). MLL1-AF4 chimeric fusions on the other hand have an intact C-terminus of AF4 
and therefore retain the transcriptional activation domains and its ability to interact with 
AF9 and ENL. 
5.4 Functional significance of AF9/ENL family 
Reciprocal translocations involving the AF9 (t(9;11)(p22;q23)) and ENL (t(11;19)(q23;p13)) 
genes are also associated with several cases of ALL and AML (Mitelman and Heim, 1992). 
Similar to AF4, AF9 also belongs to a family of serine/proline-rich transcription factors 
(Hemenway et al., 2001; Nakamura et al., 1993; Prasad et al., 1995) and shares significant 
similarity to ENL and the yeast protein ANC1 (Rubnitz et al., 1994b; Welch and Drubin, 
1994). Interestingly, ANC1 has been demonstrated to be a part of the yeast RNA polymerase 
II complex, as well as the SWI/SNF nucleosome-remodeling complex, a macromolecular 
complex which functions as ATP-dependent chromatin remodeler (Cairns et al., 1996; 
Carlson and Laurent, 1994; Cote et al., 1994). The high degree of sequence similarity 
between human AF9/ENL and the yeast ANC1 protein has led to the hypothesis that AF9 
and ENL may also interact with a human SWI/SNF remodeling complex similar to yeast 
ANC1, and the MLL1-AF9/ENL fusion proteins may retain these features.  The biological 
functions of AF4, AF9 and ENL are not clearly understood, however, gene deletion studies 
in mice have demonstrated important roles for these proteins during development (Collins 
et al., 2002; Doty et al., 2002; Isnard et al., 2000). Furthermore, the endogenous ENL protein 
was purified as a part of a macromolecular complex (ENL associated protein complex or 
EAP) that also contains p-TEFb, DOT1 and AF4 and plays a putative role in transcriptional 
elongation (Bitoun et al., 2007; Mueller et al., 2007). Despite the fact that MLL1-AF4 
translocations and MLL1-AF9/ENL fusions account for more than 50% of MLL1 11q23 
associated leukemias (Burmeister et al., 2009; Meyer et al., 2009; Meyer et al., 2006), there 
exists no functional similarity between these MLL1 fusion partners. It is tempting to 
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hypothesize that MLL1 fusion proteins might hijack the p-TEFb/DOT1 mediated 
transcriptional elongation activity or the SWI/SNF dependent nucleosome remodeling 
activity through the fusion partner and result in constitutive target gene expression leading 
to leukemia. These studies suggest that pTEFb, DOT1 and the MLL1 fusion partners 
AF4/AF9/ENL are all molecular targets in the development of therapeutics that target 
MLL1-fusion mediated leukemias.  
5.5 Domain mapping of the interaction region between AF4 and AF9 
Co-localization studies carried out by (Erfurth et al., 2004) have established that the two 
most common MLL1 fusion partners AF4 and AF9 form a stable complex within the nucleus 
and are restricted to discrete nuclear foci called “AF4 bodies”. AF4 bodies are nuclear 
speckle-like in appearance and are distinct from the nucleolus, cajal bodies, PML body or 
regions associated with DNA replication and repair (Erfurth et al., 2004). Using yeast two-
hybrid screens it was demonstrated that the minimum motif in human AF4 required for 
binding AF9 encompasses 14 residues (761-774) that are proximal to the bipartite nuclear 
localization signal (NLS) in AF4 (refer to figure 5 for domain representation). Deletion of 
these residues completely abolishes the interaction between AF4 and AF9 and also results in 
diffuse AF4 bodies (Erfurth et al., 2004; Srinivasan et al., 2004). Site-directed mutagenesis 
studies reveals that bulky hydrophobic residues within the conserved AF9 binding region in 
mouse AF4 ( mAF4 ) dictate its binding affinity to AF9 (Srinivasan et al., 2004). Using 
fluorescent tagged AF4 and AF9 constructs it was further demonstrated that both the 14 
residue AF9 binding motif and the bipartite NLS was required for the punctate nuclear 
speckle distribution of AF4-AF9 complexes (Erfurth et al., 2004).  Likewise, the terminal 93 
residues in AF9 (and the terminal 84 in the case of ENL) were identified as the minimal 
region required for binding AF4 (Erfurth et al., 2004). Interestingly, the mutual interaction 
domains between AF4 and AF9 are highly conserved in the AF4 and AF9 homologues (refer 
to figure 5 for sequence alignment) (Erfurth et al., 2004; Srinivasan et al., 2004) and the AF4-
AF9 interaction region is retained by the MLL1 fusion proteins (MLL1-AF4 and MLL1-AF9) 
(Dobson et al., 1999; Domer et al., 1993; Erfurth et al., 2004), suggesting that AF4-AF9 
interaction might be an important step in the pathogenesis associated with these MLL1 
fusions. The functional significance of the interaction between AF4 and AF9 is unclear; 
however, the co-localization of these two proteins to specific sub-nuclear foci suggests that 
AF4-AF9 interaction might be required for normal cellular functions as well as in the 
pathogenesis of MLL1-AF4 or MLL1-AF9 associated leukemias (Erfurth et al., 2004). 
Furthermore, the presence of this interaction region in MLL1-AF4 and MLL1-AF9 fusion 
proteins, and the ability of MLL1-AF4 fusions to alter the localization of endogenous AF9 
also suggest that AF4-AF9 protein complex is a pharmacological target for leukemia therapy 
(Erfurth et al., 2004; Srinivasan et al., 2004).  
5.6 A synthetic peptide PFWT disrupts the interaction between AF4 and AF9  
Based on the initial mapping studies of the AF9 binding region in AF4, a synthetic peptide, 
designated “PFWT” that mimics the interaction region was developed and tested for its 
ability to disrupt the AF4-AF9 interaction both in vitro and in vivo (Erfurth et al., 2004; 
Srinivasan et al., 2004). The initial PFWT peptide developed in this study was based on the 
highly conserved AF4-AF9 interaction sequence in the mouse FMR2 protein and 
encompasses residues (759-771) (see Figure 5 for the sequence alignment of the AF9 
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interaction region in AF4 family members). To enable nuclear uptake, the PFWT peptide 
was conjugated to a penetratin transporter sequence at its N-terminus (Srinivasan et al., 
2004). Using pull-down assays with GST-tagged AF4 and biotinylated AF9, it was shown 
that this PFWT peptide disrupts the interaction between human AF4 and AF9 in a 
concentration dependent manner (Srinivasan et al., 2004). However, a control peptide 
(containing amino acid substitutions at V763E and I765S) did not interfere with the binding 
of AF4-AF9 complex (Srinivasan et al., 2004). The specificity of PFWT peptide against AF4-
AF9 complexes was further demonstrated by its inability to disrupt the interaction between 
AF9 and two other proteins, the Polycomb protein (MPC3) and the mouse homolog of BCL-
6 co-repressor (mBCoR), both of which interact through the C-terminus of AF9 (Hemenway 
et al., 2001; Srinivasan et al., 2003; Srinivasan et al., 2004). Furthermore, the PFWT peptide 
was shown to be readily taken up by NIH3T3 cells and disrupts the co-localization of AF4-
AF9 in vivo (Srinivasan et al., 2004). These results corroborated the in vitro findings that the 
PFWT peptide has the ability to specifically disrupt the interaction between AF4 and AF9 
protein complexes.  
5.7 PFWT peptide inhibits the cell proliferation of leukemia cell lines with t(4;11) and 
t(9;11) translocations 
Based on these observations it was further predicted that the PFWT peptide will have the 
ability to inhibit the proliferation of leukemia cell lines that carry a t(4;11)(q21;q23) or 
t(9;11)(p22;q23) translocations (Bennett et al., 2009; Palermo et al., 2008; Srinivasan et al., 
2004). As expected, PFWT peptide specifically inhibits the proliferation of leukemia cell lines 
B1, MV4-11 and RS4;11 (Cohen et al., 1991; Lange et al., 1987; Stong et al., 1985) that harbor 
the MLL1-AF4 translocation (Bennett et al., 2009; Palermo et al., 2008; Srinivasan et al., 2004). 
Interestingly, the PFWT peptide also inhibits the survival capacity of KP-L-RY cell lines 
(Cohen et al., 1991) that are characterized by a t(5;11) translocation associated with MLL1-
AF5q31 fusions (Srinivasan et al., 2004). In contrast to cell lines that carry either the MLL1-
AF4 or MLL1-AF5q31 translocations, the PFWT peptide shows mixed effects in the 
inhibition of the proliferative capacity of leukemia cell lines that carry MLL1-AF9 
translocations (Palermo et al., 2008; Srinivasan et al., 2004).). For instance, based on the study 
by (Srinivasan et al., 2004), the PFWT peptide failed to inhibit the growth of THP-1 cells 
(Tsuchiya et al., 1980) that are associated with MLL1-AF9 translocations. However, a more 
recent study demonstrated that Molm13 leukemia cells that are also associated with MLL1-
AF9 translocations are sensitive to treatments with PFWT peptide in a dose dependent 
manner (Palermo et al., 2008). While these findings suggest that there are differences in the 
inhibitory properties of the PFWT peptide towards cell lines that carry a similar 
translocation, it highlights the fact that these leukemias might operate through additional 
pathways that lead to misregulated gene expression profiles (Palermo et al., 2008; Srinivasan 
et al., 2004). Furthermore, the specificity of PFWT peptide in inhibiting leukemia cells with 
MLL1-AF4 and MLL1-AF9 mutations is corroborated by the findings that the MOLT-4 (T-
ALL) cell line (Minowada et al., 1972) that does not contain a MLL1-AF4 translocation is not 
affected by the PFWT peptide even at higher doses (Srinivasan et al., 2004). However, the 
Reh (B-precursor) cell lines (Koziner et al., 1985) that do not carry a MLL1-AF4 chimeric 
fusion are susceptible to the PFWT peptide (Srinivasan et al., 2004). These results suggest 
that some cell lines might require the function of normal AF4-AF9 complexes for its 
carcinogenesis and these native complexes are also targeted by the PFWT peptides 
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(Srinivasan et al., 2004). Nevertheless, these findings demonstrate the wide range of 
specificity for the PFWT peptide and suggest that PFWT-like peptides are promising lead 
compounds in the development of treatment regimens for the most frequent 11q23 
translocations. The pharmacological importance of PFWT based peptides is further 
enhanced by the fact that these peptides have little effect on the number and colony forming 
potential of hematopoietic progenitor cells (Srinivasan et al., 2004), suggesting that PFWT-
like peptides may have fewer side effects .  
5.8 PFWT peptide as a lead compound in the treatment of MLL1-rearranged leukemias 
While initial studies suggest that the growth inhibitory properties of the PFWT peptide is 
mediated through apoptosis (Srinivasan et al., 2004), recent work by (Palermo et al., 2008) 
demonstrates that PFWT peptide induces cell death by necrosis in MV4-11 and Molm13 cell 
lines. Necrotic cell death was further demonstrated by the changes in plasma membrane 
integrity in the absence of traditional apoptotic markers: nuclear disintegration, caspase 
activation, DNA fragmentation or mitochondrial membrane depolarization (Palermo et al., 
2008). Given the resistance of t(4;11) translocations to conventional pro-apoptotic 
chemotherapeutic drugs, PFWT mediated necrotic cell death is an attractive alternative 
strategy to treat these acute leukemias. More recently, Bennett et al., (Bennett et al., 2009) 
demonstrated that the PFWT peptide in combination with standard chemotherapeutic 
agents such as etoposide, 17AAG (17-(allylamino)-17-demthoxygeldamycin), cytarabine, 
and Flt-3 kinase inhibitor results in synergistic cytotoxicity in MV4-11 cells that harbor 
t(4;11) translocations.  Furthermore, cell death was mediated through both apoptotic and 
necrotic pathways suggesting that PFWT peptides could be useful in combinatorial therapy 
to treat leukemia cell lines that are relatively resistant to current apoptotic drugs (Bennett et 
al., 2009; Campo Dell'Orto et al., 2007; Nakanishi et al., 2007; Wiederschain et al., 2005). 
Together, these findings emphasize that PFWT peptides inhibit the proliferation of t(4;11), 
t(5;11) and t(9;11) leukemia cell lines by specifically disrupting the association of AF4 or 
AF5q31 with AF9 and serves as a starting point for the development of more effective 
therapeutic strategies. In the absence of a crystal structure that clearly demonstrates the 
interaction mode between AF4 and AF9 proteins, systematic site-directed mutagenesis 
experiments can help identify amino acid positions that are more important for the overall 
binding affinity. Such an approach has the potential to help identify additional PFWT-based 
peptido-mimetic compounds that have better inhibitory properties than the initial PFWT 
peptide and prevent the potential toxic side effects that could occur at high doses of the 
PFWT peptide.  
6. Win motif-based inhibitors that target the assembly and enzymatic activity 
of the MLL1 core complex 
6.1 Novel strategies that target the histone methyltransferase activity of MLL1 
amplifications and MLL1-PTDs 
Growing evidence suggests that increased HOXa gene expression associated with MLL1 
amplifications and MLL1-PTDs underlie the pathogenesis of these leukemias (Basecke et al., 
2006; Dorrance et al., 2006). HOXa gene expression is dependent on the histone 
methyltransferase activity of MLL1 ((Milne et al., 2002), and given the increased H3K4 
methylation observed in MLL1-PTDs (Dorrance et al., 2008; Dorrance et al., 2006), inhibitors 
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that down-regulate the histone methyltransferase activity of MLL1-PTD have the potential 
to reverse this aberrant epigenetic program. Until recently, inhibitors that specifically target 
MLL1’s H3K4 methyltransferase activity have been difficult to develop due to lack of a clear 
understanding of MLL1’s structure and function. However, recent findings have established 
that H3K4 methylation levels are precisely regulated by the function of two independent 
methyltransferases: the MLL1 SET domain and a novel multi-subunit enzyme, WDR5-
RbBP5-Ash2L-DPY30 (WRAD), that lacks sequence homology to known methyltransferases 
(Patel et al., 2009; Patel et al., 2011). Because multiple methylation on H3K4 is catalyzed by 
two different enzymes, it is interesting to speculate that inhibitors that prevent the 
association of two methyltransferases will have clinical significance in the treatment of acute 
leukemias that are characterized by aberrant H3K4 methylation (Dorrance et al., 2008; 
Dorrance et al., 2006).  
6.2 WDR5 is central for the assembly and H3K4 methylation activity of MLL1 core 
complex 
The WD-40 repeat protein WDR5 is a conserved component of MLL1 family complexes 
ranging from yeast to humans and has been shown to be crucial for the assembly and H3K4 
dimethylation activity of MLL1 core complex HOX (Dou et al., 2006; Patel et al., 2008a; Patel 
et al., 2008b). Consistent with the role of WDR5 in the regulation of degree of H3K4 
methylation, siRNA mediated knock-down of WDR5 in mammalian cells results in a global 
decrease in the levels of H3K4 di- and trimethylation, down-regulation of HOXa9 and 
HOXc8 genes, and defects in hematopoiesis and development (Dou et al., 2006; Wysocka et 
al., 2005). WDR5 knock down and MLL1ΔSET mice show similar phenotypes suggesting 
that MLL1 and WDR5 function together to regulate H3K4 di/trimethylation and HOX gene 
expression in vivo (Terranova et al., 2006; Wysocka et al., 2005). Furthermore, growing 
evidence suggest that WDR5 interacts directly with MLL1 or other SET1 family members 
and functions as a scaffold to bridge the interactions between MLL1 and rest of the 
components of MLL1 core complex (Dou et al., 2006; Patel et al., 2008b; Trievel and 
Shilatifard, 2009; Wysocka et al., 2005). Indeed, MLL1 and WRAD enzymatic complexes fail 
to associate in the absence of WDR5 (Dou et al., 2006; Patel et al., 2008b), suggesting a crucial 
role for WDR5 in the assembly and H3K4 methylation activity of MLL1 core complex. 
6.3 WDR5 recognizes a conserved arginine containing sequence in the N-SET region 
of MLL1 
Previous studies have suggested that WDR5 functions within the MLL1 core complex as a 
histone “effector” or “presenter” domain, a domain that specifically recognizes methylated 
histones (Couture et al., 2006; Han et al., 2006; Ruthenburg et al., 2006; Schuetz et al., 2006; 
Trievel and Shilatifard, 2009; Wysocka et al., 2005). However, recent studies by Patel et al., 
(2008a and b) and Song and Kingston., (2008) demonstrate that WDR5 recognizes a conserved 
arginine containing motif in the N-SET region of MLL1 called the WDR5 interaction (Win) 
motif (Patel et al., 2008b), thereby promoting the assembly and the H3K4 dimethylation 
activity of the MLL1 core complex (Patel et al., 2008a; Patel et al., 2008b; Song and Kingston, 
2008) (Figure 6). Based on sedimentation velocity analytical ultracentrifugation experiments, 
Patel et al., (2008b) demonstrated that an MLL1 construct (encompassing residues 3745-3969) 
containing the highly conserved Win motif binds to WDR5 as a 1:1 complex with a dissociation 
constant of 120nM. Whereas, a shorter construct in MLL1 (encompassing residues 3811-3969) 
that lacks the Win motif sequence fails to associate with WDR5 (Patel et al., 2008b). In their 
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constant of 120nM. Whereas, a shorter construct in MLL1 (encompassing residues 3811-3969) 
that lacks the Win motif sequence fails to associate with WDR5 (Patel et al., 2008b). In their 
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efforts to further map the interaction region between MLL1 and WDR5, the two groups 
showed that the conserved Win motif closely resembles the sequence surrounding arginine 2 
of histone H3 and is highly conserved among metazoan MLL1 orthologs and other SET1 
family members (Patel et al., 2008b; Song and Kingston, 2008) (Figure 6). Using a combination 
of analytical ultracentrifugation and MALDI-TOF mass spectrometry, it was demonstrated 
that the conserved arginine (R3765) of the MLL1 Win motif is crucial for the interaction with 
WDR5 and that substitution of R3765 with alanine in MLL1 abolishes the interaction between 
MLL1 and the WRAD sub-complex, which also results in the loss of the H3K4 dimethylation 
activity of the MLL1 core complex (Patel et al., 2008b). However, replacement of other residues 
such as serine 3763 and glutamate 3767 in the conserved Win motif sequence only modestly 
weakens MLL1’s interaction with the WRAD sub-complex (Patel et al., 2008b). Furthermore, 
the MLL1 R3765A mutant fails to co-immunoprecipitate the rest of the core complex 
components RbBP5 and Ash2L from HeLa cells, consistent with a central role for the MLL1 
Win motif in the assembly of MLL1 core complex in vivo (unpublished results from Lee and 
Skalnik).  These results have led to a model in which the conserved Win motif of MLL1 and 
other metazoan SET1 family members functions to bind the WDR5 component of the WDR5-
RbBP5-Ash2L sub-complex, which is required for the assembly and H3K4 dimethylation 
activity of the MLL1 core complex (Cosgrove and Patel, 2010; Trievel and Shilatifard, 2009). 
These observations suggest that targeting MLL1-WDR5 interaction might be an effective 
strategy to down-regulate H3K4 dimethylation and HOX gene expression mediated by the 
MLL1 core complex.   
 
 
Schematic representation of the Win motif present in SET1 family members. At the top the domain 
architecture of wild-type MLL1 is shown and color coded as in Figure 1. The six-residue Win motif is 
present within the N-SET region of MLL1 (amino acid residues 3762-3767). The lower inset (green) 
shows the ClustalW multiple sequence alignment of the Win motif present in human SET1 family 
members: MLL1 (Q03164), MLL2 (O14686), MLL3 (AAK00583), MLL4 (Q9UMN6), SET1a (O15047), and 
SET1b (Q9UPS6). The conserved arginine of the Win motif is highlighted in red.  
Fig. 6. WDR5 Interaction (Win) motif is highly conserved among human SET1 family 
members 
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6.4 Peptides derived from the MLL1 Win motif specifically inhibit the H3K4 
dimethylation activity of MLL1 core complex 
Based on mapping studies of the WDR5 binding region in MLL1, Patel et al., (2008b) 
developed a peptide, designated the MLL1 Win motif peptide (3762-3773) that can bind 
WDR5 with high affinity (Kd=1700nM) and disrupt the assembly of the MLL1 core complex 
in vitro (Patel et al., 2008a; Patel et al., 2008b). Consequently, this 12-residue MLL1 Win 
motif peptide inhibits the in vitro H3K4 dimethylation activity of the MLL1 core complex in 
a dose dependent manner by competing with wild-type MLL1 for the arginine binding 
pocket in WDR5 (Patel et al., 2008b). However, a control p53 peptide that has an arginine in 
a different sequence context failed to inhibit the H3K4 dimethylation activity even with a 60-
fold excess,  suggesting that Win motif peptides are highly specific inhibitors of MLL1 
family complexes (Patel et al., 2008b). Furthermore, recent unpublished results from our lab 
demonstrate that peptides derived from other human SET1 family members bind WDR5 
with dissociation constants ranging from 50nM-1700nM (in preparation). In accordance with 
the binding studies, MALDI-TOF mass spectrometry based methylation assays further 
demonstrate that other human SET1 family Win motif peptides are significantly more potent 
inhibitors of the H3K4 dimethylation activity of the MLL1 core complex as compared to the 
MLL1 Win motif peptide (Dharmarajan and Cosgrove, unpublished results). These studies 
suggest that the MLL1 Win motif based peptide represents an excellent starting point for the 
design of lead compounds that would specifically disrupt the interaction between MLL1 
and WDR5 and inhibit the H3K4 dimethylation activity of MLL1 core complex in vivo. 
6.5 MLL1 Win motif peptide binds to WDR5 by adopting a 310 –helical conformation 
Design of Win motif based inhibitors with better efficiency could be greatly enhanced by 
determining the protein structural features within the Win motif that are required for the 
high affinity binding to WDR5. To facilitate the process of structure-based drug design and 
to understand the molecular basis for MLL1-WDR5 interaction, two independent groups 
determined the three-dimensional structure of WDR5 bound to a peptide derived from the 
MLL1 Win motif (Patel et al., 2008a; Song and Kingston, 2008). The structures reveal that 
MLL1 Win motif peptide binds WDR5 by adopting a partial 310 -helical conformation (Figure 
7) (Patel et al., 2008a; Song and Kingston, 2008). The conserved Win motif residues (3762-
3767) all participate in the formation of 310–helix with two-intramolecular i->i+3 main-chain 
hydrogen bonds stabilizing this conformation (Figure 7). MLL1 Win peptide binding is 
further stabilized by the insertion of conserved R3765 of MLL1 into a central water filled 
tunnel of WDR5 (Patel et al., 2008a; Song and Kingston, 2008). The structures also 
demonstrate that the side chain guanidinium of R3765 is sandwiched between two aromatic 
rings from WDR5- residues Phe-133 and Phe-263. R3765 is also stabilized by an extensive 
network of hydrogen bond, pi-pi and cation-pi, and hydrophobic interactions (Patel et al., 
2008a; Song and Kingston, 2008) (Figure 7). These structural studies further corroborate the 
role of R3765 in mediating the interaction with WDR5 and explain the high sequence 
conservation of this arginine within SET1 family Win motifs. Accordingly, structures of 
WDR5 bound to Win motif peptides derived from other human SET1 family members reveal 
that WDR5 recognizes the different SET1 family Win motifs using the same arginine binding 
pocket as previously described for MLL1 (Dharmarajan and Cosgrove, unpublished results). 
However, the different Win motif peptides also participate in additional sets of interactions 
that might contribute to their differential inhibitory properties and suggest a framework for 
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efforts to further map the interaction region between MLL1 and WDR5, the two groups 
showed that the conserved Win motif closely resembles the sequence surrounding arginine 2 
of histone H3 and is highly conserved among metazoan MLL1 orthologs and other SET1 
family members (Patel et al., 2008b; Song and Kingston, 2008) (Figure 6). Using a combination 
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MLL1 and the WRAD sub-complex, which also results in the loss of the H3K4 dimethylation 
activity of the MLL1 core complex (Patel et al., 2008b). However, replacement of other residues 
such as serine 3763 and glutamate 3767 in the conserved Win motif sequence only modestly 
weakens MLL1’s interaction with the WRAD sub-complex (Patel et al., 2008b). Furthermore, 
the MLL1 R3765A mutant fails to co-immunoprecipitate the rest of the core complex 
components RbBP5 and Ash2L from HeLa cells, consistent with a central role for the MLL1 
Win motif in the assembly of MLL1 core complex in vivo (unpublished results from Lee and 
Skalnik).  These results have led to a model in which the conserved Win motif of MLL1 and 
other metazoan SET1 family members functions to bind the WDR5 component of the WDR5-
RbBP5-Ash2L sub-complex, which is required for the assembly and H3K4 dimethylation 
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6.4 Peptides derived from the MLL1 Win motif specifically inhibit the H3K4 
dimethylation activity of MLL1 core complex 
Based on mapping studies of the WDR5 binding region in MLL1, Patel et al., (2008b) 
developed a peptide, designated the MLL1 Win motif peptide (3762-3773) that can bind 
WDR5 with high affinity (Kd=1700nM) and disrupt the assembly of the MLL1 core complex 
in vitro (Patel et al., 2008a; Patel et al., 2008b). Consequently, this 12-residue MLL1 Win 
motif peptide inhibits the in vitro H3K4 dimethylation activity of the MLL1 core complex in 
a dose dependent manner by competing with wild-type MLL1 for the arginine binding 
pocket in WDR5 (Patel et al., 2008b). However, a control p53 peptide that has an arginine in 
a different sequence context failed to inhibit the H3K4 dimethylation activity even with a 60-
fold excess,  suggesting that Win motif peptides are highly specific inhibitors of MLL1 
family complexes (Patel et al., 2008b). Furthermore, recent unpublished results from our lab 
demonstrate that peptides derived from other human SET1 family members bind WDR5 
with dissociation constants ranging from 50nM-1700nM (in preparation). In accordance with 
the binding studies, MALDI-TOF mass spectrometry based methylation assays further 
demonstrate that other human SET1 family Win motif peptides are significantly more potent 
inhibitors of the H3K4 dimethylation activity of the MLL1 core complex as compared to the 
MLL1 Win motif peptide (Dharmarajan and Cosgrove, unpublished results). These studies 
suggest that the MLL1 Win motif based peptide represents an excellent starting point for the 
design of lead compounds that would specifically disrupt the interaction between MLL1 
and WDR5 and inhibit the H3K4 dimethylation activity of MLL1 core complex in vivo. 
6.5 MLL1 Win motif peptide binds to WDR5 by adopting a 310 –helical conformation 
Design of Win motif based inhibitors with better efficiency could be greatly enhanced by 
determining the protein structural features within the Win motif that are required for the 
high affinity binding to WDR5. To facilitate the process of structure-based drug design and 
to understand the molecular basis for MLL1-WDR5 interaction, two independent groups 
determined the three-dimensional structure of WDR5 bound to a peptide derived from the 
MLL1 Win motif (Patel et al., 2008a; Song and Kingston, 2008). The structures reveal that 
MLL1 Win motif peptide binds WDR5 by adopting a partial 310 -helical conformation (Figure 
7) (Patel et al., 2008a; Song and Kingston, 2008). The conserved Win motif residues (3762-
3767) all participate in the formation of 310–helix with two-intramolecular i->i+3 main-chain 
hydrogen bonds stabilizing this conformation (Figure 7). MLL1 Win peptide binding is 
further stabilized by the insertion of conserved R3765 of MLL1 into a central water filled 
tunnel of WDR5 (Patel et al., 2008a; Song and Kingston, 2008). The structures also 
demonstrate that the side chain guanidinium of R3765 is sandwiched between two aromatic 
rings from WDR5- residues Phe-133 and Phe-263. R3765 is also stabilized by an extensive 
network of hydrogen bond, pi-pi and cation-pi, and hydrophobic interactions (Patel et al., 
2008a; Song and Kingston, 2008) (Figure 7). These structural studies further corroborate the 
role of R3765 in mediating the interaction with WDR5 and explain the high sequence 
conservation of this arginine within SET1 family Win motifs. Accordingly, structures of 
WDR5 bound to Win motif peptides derived from other human SET1 family members reveal 
that WDR5 recognizes the different SET1 family Win motifs using the same arginine binding 
pocket as previously described for MLL1 (Dharmarajan and Cosgrove, unpublished results). 
However, the different Win motif peptides also participate in additional sets of interactions 
that might contribute to their differential inhibitory properties and suggest a framework for 
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the use of Win motif peptides as lead compounds for drug development (Dharmarajan and 
Cosgrove, unpublished results). While the Win peptide binding mode is similar to the 
previously determined structures of WDR5 bound to histone peptides, which bind by 
inserting R2 of histone H3 into the central tunnel in WDR5 (Couture et al., 2006; Han et al., 
2006; Schuetz et al., 2006), the SET1 family Win motif peptides participate in more favorable 
interactions with WDR5 (Patel et al., 2008a; Song and Kingston, 2008). These findings 
suggest that peptidomimetics based on the Win motif sequence can specifically bind WDR5 
and down-regulate the activity of MLL1 core complex.  
 
 
Three-dimensional structure of WDR5 (PDB code 3EG6) in complex with MLL1 Win motif peptide 
(3762-3773). a) On the left, the MLL1 Win motif peptide (cyan) is shown bound to the central tunnel in 
WDR5 (white). MLL1 Win motif peptide binds WDR5 by adopting a 310-helical conformation. On the 
right, blow up of the peptide binding site with MLL1 residues indicated in red and WDR5 residues 
indicated in black. Atom coloring: oxygen (red), nitrogen (blue), carbon (cyan for Win motif residues 
and grey for WDR5 residues).  
Fig. 7. Crystal structure of MLL1 Win motif peptide bound to WDR5 
6.6 Analysis of the binding of MLL1 Win motif and histone H3 peptides to WDR5: 
identification of key structural elements required for binding WDR5 
To facilitate the design of small-molecule inhibitors of MLL1-WDR5 interaction, Karatas et al 
(2010) performed a systematic deletion analysis on the original 12-residue MLL1 Win motif 
peptide (3762-3773) and showed that a three residue sequence composed of  Acetyl-ARA- NH2 is 
the minimal motif that is required for its interaction with WDR5 (Karatas et al., 2010). The 
acetyl group on the N-terminus is essential as its removal results in the loss of binding. 
The Acetyl-ARA-NH2 peptide binds WDR5 in peptide competition experiments with similar 
affinity to that of the original 12 residue MLL1 Win motif peptide (~120 nM) (Karatas et al., 
2010; Patel et al., 2008b). Moreover, systematic mutagenesis and molecular dynamics 
Biochemistry of the Mixed Lineage 
Leukemia 1 (MLL1) Protein and Targeted Therapies for Associated Leukemia 
 
183 
simulations further suggest that Acetyl-ARA- NH2 peptide could recapitulate the two 
intramolecular i-> i+3 main chain hydrogen bonds that are present in the original 12-residue 
MLL1 Win motif peptide. Absence of one or both of these hydrogen bonds significantly 
weakens the interaction affinity between the 3-residue peptide and WDR5 (Karatas et al., 
2010). These results suggest that Acetyl-ARA-NH2 peptide binds WDR5 by adopting a partial 310 -
helical conformation similar to that of the 12-residue MLL1 Win motif peptide and participates 
in similar sets of interactions (Karatas et al., 2010; Patel et al., 2008b). However, the most potent 
inhibitor derived from the MLL1 Win motif peptide sequence is the acetyl-10mer (acetyl-
ARAEVHLRKS-NH2) encompassing residues 3764-3773, which binds WDR5 with a Ki = 3nM 
(Karatas et al., 2010). These results suggest that sequences outside of the ARA sequence 
contribute to the affinity and would likely increase specificity. In addition, replacement of 
alanine at the +1 position (1 residue C-terminal to R3765) with a threonine in the acetyl-10mer 
(acetyl-ARTEVHLRKS-NH2) or 3-mer (Acetyl-ART-NH2) results in a 3-to-6-fold increase in binding 
affinity to WDR5, respectively (Karatas et al., 2010). In summary, these experiments suggest 
that the Acetyl-ARA-NH2   motif anchors the peptide to the arginine binding pocket of WDR5 and 
that the 310 –helical conformation is crucial for interaction. In addition, sequences N- and C-
terminal to the ARA motif are important for increasing binding specificity. It remains to be 
determined if the Acetyl-ARA-NH2  peptide actually inhibits the WDR5-MLL1 interaction within 
the context of the assembled MLL1 core complex.  
6.7 Win motif based inhibitors - a novel class of compounds with potential to treat 
Acute Myeloid Leukemia 
The extensive biochemical characterization of the peptide derived from the MLL1 Win motif 
have demonstrated that these peptidomimetic compounds have the potential to inhibit the 
H3K4 methyltransferase activity of the MLL1 core complex by specifically disrupting the 
association of MLL1 with the WRAD sub-complex (Patel et al., 2008b). Furthermore, the 
crystal structures of WDR5 bound to human SET1 family Win motif  peptides provides a 
rationale for the design of new peptides and non-peptide mimetics with better inhibitory 
properties. The structures also reveal that conserved residues from the MLL1 Win motif 
(GSARAE) form a cyclical shaped 310 –helix that fits snugly into the outer opening in WDR5 
and raises the possibility that other cyclic peptidomimetic compounds might also bind 
WDR5 with similar or better inhibitory properties. The efficacy of Win motif based inhibitors 
in down regulating the H3K4 methylation activity of MLL1 core complex in vitro has yet to 
be demonstrated in vivo. However, based on the in vitro studies it is expected that the Win 
motif based peptides will have the ability to down regulate the increased H3K4 
dimethylation, and aberrant HOX gene expression associated with MLL1-PTDs and gene 
amplification mutations in MLL1. Hence, the MLL1 Win motif peptide is a novel “first in 
class” inhibitor that is expected to have the ability to specifically regulate H3K4 
dimethylation levels in cells without perturbing K3K4 monomethylation, or the methylation 
activities of other H3K4 methyltransferases.  
7. Conclusions and future perspectives - are there other molecular targets for 
leukemia therapy? 
Over the past decade, we have witnessed remarkable strides towards understanding the 
fundamental mechanisms of MLL1-mediated transcription and leukemogenesis, and many 
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the use of Win motif peptides as lead compounds for drug development (Dharmarajan and 
Cosgrove, unpublished results). While the Win peptide binding mode is similar to the 
previously determined structures of WDR5 bound to histone peptides, which bind by 
inserting R2 of histone H3 into the central tunnel in WDR5 (Couture et al., 2006; Han et al., 
2006; Schuetz et al., 2006), the SET1 family Win motif peptides participate in more favorable 
interactions with WDR5 (Patel et al., 2008a; Song and Kingston, 2008). These findings 
suggest that peptidomimetics based on the Win motif sequence can specifically bind WDR5 
and down-regulate the activity of MLL1 core complex.  
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acetyl group on the N-terminus is essential as its removal results in the loss of binding. 
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simulations further suggest that Acetyl-ARA- NH2 peptide could recapitulate the two 
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inhibitor derived from the MLL1 Win motif peptide sequence is the acetyl-10mer (acetyl-
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Acute Myeloid Leukemia 
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have demonstrated that these peptidomimetic compounds have the potential to inhibit the 
H3K4 methyltransferase activity of the MLL1 core complex by specifically disrupting the 
association of MLL1 with the WRAD sub-complex (Patel et al., 2008b). Furthermore, the 
crystal structures of WDR5 bound to human SET1 family Win motif  peptides provides a 
rationale for the design of new peptides and non-peptide mimetics with better inhibitory 
properties. The structures also reveal that conserved residues from the MLL1 Win motif 
(GSARAE) form a cyclical shaped 310 –helix that fits snugly into the outer opening in WDR5 
and raises the possibility that other cyclic peptidomimetic compounds might also bind 
WDR5 with similar or better inhibitory properties. The efficacy of Win motif based inhibitors 
in down regulating the H3K4 methylation activity of MLL1 core complex in vitro has yet to 
be demonstrated in vivo. However, based on the in vitro studies it is expected that the Win 
motif based peptides will have the ability to down regulate the increased H3K4 
dimethylation, and aberrant HOX gene expression associated with MLL1-PTDs and gene 
amplification mutations in MLL1. Hence, the MLL1 Win motif peptide is a novel “first in 
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Over the past decade, we have witnessed remarkable strides towards understanding the 
fundamental mechanisms of MLL1-mediated transcription and leukemogenesis, and many 
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targets that are likely to be biomedically important are beginning to be characterized (Dou 
and Hess, 2008; Liedtke and Cleary, 2009; Marschalek, 2010). Genetic, biochemical and 
structural studies have demonstrated that several MLL1 partner proteins (AF4, AF9, AF10, 
ENL, and EEN) are either directly or indirectly associated with macromolecular complexes 
involved in transcriptional initiation and elongation (Bitoun et al., 2007; Cheung et al., 2007; 
Marschalek; Mueller et al., 2007; Mueller et al., 2009; Okada et al., 2005; Okada et al., 2006). 
Based on these studies, it was also suggested that leukemogenic properties of these MLL1- 
fusions are mediated in part through their association with the histone methyltransferases: 
 
 
Cartoon representation of the different forms of MLL1 (a. wild-type, b. PTDs, and c. chromosomal 
translocations) and a summary of emerging potential molecular targeted therapies for mixed lineage 
leukemia. Key molecular targets include: i) inhibitors that disrupt the association of MLL1 with its 
target genes (MBM-based or CXXC motif-based inhibitors), ii) inhibitors that target the assembly of 
MLL1 core complex (Win motif-based inhibitors), iii) inhibitors that target the functions of fusion 
proteins (PFWT-like peptides, hDOT1L inhibitors, pTEFb kinase inhibitors), iv) WRAD sub-complex 
inhibitors and v) Inhibitors that target other co-operating pathways in leukemia (GSK-3, FLT3, MCL-1, 
and Ras). MLL-N (blue) and MLL-C (yellow) fragments are shown as localized to a hypothetical MLL1 
target gene. In a). menin (green), LEDGF (dark grey) and WRAD sub-complex associate with wild-type 
MLL1 to regulate the normal expression (indicated by a single arrow) of MLL1 target genes. Target gene 
expression is dysregulated in MLL1-PTDs and MLL1-fusions (b and c) as indicated by multiple arrows. 
b) MLL1-PTDs retain all the functional interactions as seen in wild-type MLL1 and c) MLL1-fusions do 
not retain the MLL-C fragment and many interacting proteins.. Figure 8 was adapted from Liedtke and 
Cleary (2009). 
Fig. 8. Potential protein:protein interaction targets for the development of novel therapies 
for MLL1-associated leukemias 
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hDOT1 (Bitoun et al., 2007; Okada et al., 2005; Okada et al., 2006) and protein arginine 
methyltransferase-1 or PRMT1 (Cheung et al., 2007). These studies have led to the proposal  
of the “MLL1 web hypothesis”, which states that MLL1 fusion partners are components of 
larger macromolecular complexes that are involved in transcriptional activation and/or 
elongation (Erfurth et al., 2004). Molecular therapies directed at the interactions of these 
proteins within the “MLL1 web hypothesis” or inhibiting the activity of associated histone 
modifying enzymes are emerging as promising targets (Dou and Hess, 2008; Liedtke and 
Cleary, 2009; Marschalek, 2010). In addition to targeting the function of MLL1-fusion 
proteins, inhibitors that target the association of MLL1-fusion proteins to target DNA might 
also have potential therapeutic implications. In this regard, inhibitors that disrupt the 
interaction between MLL1’s CXXC motif and unmethylated CpG containing target DNA are 
being investigated as molecular drug targets in MLL1-related leukemias (Allen et al., 2006; 
Cierpicki et al., 2010). In addition to these molecular targets, recent studies have also 
identified other cooperating pathways such as positive transcription elongation factor-b 
(pTEFb) recruitment (Marschalek, 2010; Mueller et al., 2007; Mueller et al., 2009; Shapiro, 
2006), activation of FMS-like tyrosine kinase 3 (FLT3) (Armstrong et al., 2003; Brown et al., 
2005; Stubbs et al., 2008; Yao et al., 2005), glycogen synthase kinase 3 (GSK3) (Wang et al., 
2008), heat shock protein-90 (HSP-90) (Yao et al., 2005; Yocum et al., 2006), myeloid cell 
leukemia sequence-1 (MCL-1) expression (Chen et al., 2009), and RAS pathways (Liang et 
al., 2006) that are implicated in MLL1-induced leukemogenesis. The therapeutic significance 
of these molecular targets in MLL1-therapy were reviewed recently (Dou and Hess, 2008; 
Liedtke and Cleary, 2009; Marschalek, 2010) and since then, additional potential 
pharmacological targets such as the multi-subunit complex WRAD, which regulates the 
degree of H3K4 methylation by the MLL1 core complex, have emerged (Patel et al., 2009; 
Patel et al., 2011) (Figure 8).   
In conclusion, this chapter summarizes recent biochemical studies that have contributed 
significantly to our understanding of how MLL1 works and have led to the identification of 
promising therapeutic targets for MLL1-related leukemias. In particular, inhibitors that 
target molecular interactions between menin and MLL1, AF4 and AF9, and MLL1 and 
WRAD have emerged as novel candidate small molecule targets. These MLL1-targeted 
therapies have enhanced pharmacological potential as compared to the existing broadly-
based chemotherapeutics for MLL1-associated leukemias and will hopefully result in better 
treatment outcomes. In the future, similar biochemical, structural and genetic studies will be 
instrumental in identifying additional molecular targets that will form the basis for novel 
treatment strategies.  
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targets that are likely to be biomedically important are beginning to be characterized (Dou 
and Hess, 2008; Liedtke and Cleary, 2009; Marschalek, 2010). Genetic, biochemical and 
structural studies have demonstrated that several MLL1 partner proteins (AF4, AF9, AF10, 
ENL, and EEN) are either directly or indirectly associated with macromolecular complexes 
involved in transcriptional initiation and elongation (Bitoun et al., 2007; Cheung et al., 2007; 
Marschalek; Mueller et al., 2007; Mueller et al., 2009; Okada et al., 2005; Okada et al., 2006). 
Based on these studies, it was also suggested that leukemogenic properties of these MLL1- 
fusions are mediated in part through their association with the histone methyltransferases: 
 
 
Cartoon representation of the different forms of MLL1 (a. wild-type, b. PTDs, and c. chromosomal 
translocations) and a summary of emerging potential molecular targeted therapies for mixed lineage 
leukemia. Key molecular targets include: i) inhibitors that disrupt the association of MLL1 with its 
target genes (MBM-based or CXXC motif-based inhibitors), ii) inhibitors that target the assembly of 
MLL1 core complex (Win motif-based inhibitors), iii) inhibitors that target the functions of fusion 
proteins (PFWT-like peptides, hDOT1L inhibitors, pTEFb kinase inhibitors), iv) WRAD sub-complex 
inhibitors and v) Inhibitors that target other co-operating pathways in leukemia (GSK-3, FLT3, MCL-1, 
and Ras). MLL-N (blue) and MLL-C (yellow) fragments are shown as localized to a hypothetical MLL1 
target gene. In a). menin (green), LEDGF (dark grey) and WRAD sub-complex associate with wild-type 
MLL1 to regulate the normal expression (indicated by a single arrow) of MLL1 target genes. Target gene 
expression is dysregulated in MLL1-PTDs and MLL1-fusions (b and c) as indicated by multiple arrows. 
b) MLL1-PTDs retain all the functional interactions as seen in wild-type MLL1 and c) MLL1-fusions do 
not retain the MLL-C fragment and many interacting proteins.. Figure 8 was adapted from Liedtke and 
Cleary (2009). 
Fig. 8. Potential protein:protein interaction targets for the development of novel therapies 
for MLL1-associated leukemias 
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hDOT1 (Bitoun et al., 2007; Okada et al., 2005; Okada et al., 2006) and protein arginine 
methyltransferase-1 or PRMT1 (Cheung et al., 2007). These studies have led to the proposal  
of the “MLL1 web hypothesis”, which states that MLL1 fusion partners are components of 
larger macromolecular complexes that are involved in transcriptional activation and/or 
elongation (Erfurth et al., 2004). Molecular therapies directed at the interactions of these 
proteins within the “MLL1 web hypothesis” or inhibiting the activity of associated histone 
modifying enzymes are emerging as promising targets (Dou and Hess, 2008; Liedtke and 
Cleary, 2009; Marschalek, 2010). In addition to targeting the function of MLL1-fusion 
proteins, inhibitors that target the association of MLL1-fusion proteins to target DNA might 
also have potential therapeutic implications. In this regard, inhibitors that disrupt the 
interaction between MLL1’s CXXC motif and unmethylated CpG containing target DNA are 
being investigated as molecular drug targets in MLL1-related leukemias (Allen et al., 2006; 
Cierpicki et al., 2010). In addition to these molecular targets, recent studies have also 
identified other cooperating pathways such as positive transcription elongation factor-b 
(pTEFb) recruitment (Marschalek, 2010; Mueller et al., 2007; Mueller et al., 2009; Shapiro, 
2006), activation of FMS-like tyrosine kinase 3 (FLT3) (Armstrong et al., 2003; Brown et al., 
2005; Stubbs et al., 2008; Yao et al., 2005), glycogen synthase kinase 3 (GSK3) (Wang et al., 
2008), heat shock protein-90 (HSP-90) (Yao et al., 2005; Yocum et al., 2006), myeloid cell 
leukemia sequence-1 (MCL-1) expression (Chen et al., 2009), and RAS pathways (Liang et 
al., 2006) that are implicated in MLL1-induced leukemogenesis. The therapeutic significance 
of these molecular targets in MLL1-therapy were reviewed recently (Dou and Hess, 2008; 
Liedtke and Cleary, 2009; Marschalek, 2010) and since then, additional potential 
pharmacological targets such as the multi-subunit complex WRAD, which regulates the 
degree of H3K4 methylation by the MLL1 core complex, have emerged (Patel et al., 2009; 
Patel et al., 2011) (Figure 8).   
In conclusion, this chapter summarizes recent biochemical studies that have contributed 
significantly to our understanding of how MLL1 works and have led to the identification of 
promising therapeutic targets for MLL1-related leukemias. In particular, inhibitors that 
target molecular interactions between menin and MLL1, AF4 and AF9, and MLL1 and 
WRAD have emerged as novel candidate small molecule targets. These MLL1-targeted 
therapies have enhanced pharmacological potential as compared to the existing broadly-
based chemotherapeutics for MLL1-associated leukemias and will hopefully result in better 
treatment outcomes. In the future, similar biochemical, structural and genetic studies will be 
instrumental in identifying additional molecular targets that will form the basis for novel 
treatment strategies.  
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1. Introduction 
Acute leukemia is a very heterogeneous disease that can be divided in two major groups 
according to lymphoblastic or myeloblastic origin of leukemic blast cells: acute 
lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML). ALL and AML, in 
their turn, are both subdivided into many subgroups with different clinical features.  
ALL is more frequent in children and represents about 80% of all pediatric leukemia cases. 
Prognosis of newly diagnosed children with ALL has improved significantly mainly due to 
treatment with high-doses of chemotherapeutic drugs, but also a risk-stratification strategy 
and optimization of therapy.  5-year event-free survival (EFS) rates in different clinics range 
between 76% and 86%. Overall remission rates usually are 98% or higher (Pui et al., 2011). 
Age and white cell count at diagnosis have been used to predict a prognosis in ALL for 
many years, having been identified in early epidemiologic studies as predictors of an 
outcome (Smith et al., 1996). Children aged from 1 to 9 years have the best outcomes; 
children and adolescents aged from 10 to 20 years have slightly worse outcomes, which is 
associated in part with higher incidence of T-cell leukemia and lower incidence of favorable 
genetic abnormalities such as TEL/AML1 and hyperdiploidy. Also, ALL blasts from older 
patients become more resistant to multiple antileukemic drugs than the blasts from younger 
children in the first decade of life (Pieters et al., 1998; Nachman et al., 2009). Infants 
diagnosed at age of less than 1 year have relatively poor outcomes, which is associated with 
high incidence of immature pro-B-ALL phenotype and presence of MLL gene 
rearrangements (Hilden et al., 2006). Another biologic factor of prognostic value besides 
immunophenotype is a rapidity of response to the induction therapy with glucocorticoides, 
for instance decrease in peripheral blood blast count after a week of treatment. It has been 
shown by flow cytometry and molecular techniques, that a level of minimal residual disease 
(MRD) in bone marrow during first months of therapy may have high prognostic value and 
is used for stratification in many protocols (Szczepanski et al., 2001). Further risk 
stratification has been achieved using cytogenetic and molecular genetic characteristics of 
leukemia. The TEL-AML1 translocation and hyperdiploidy were found to predict a good 
prognosis; therefore they allow relative therapy reduction in carriers (Pui et al., 2000). 
Philadelphia-chromosome-positive ALL (Ph+-ALL) is associated with a poorer prognosis 
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their turn, are both subdivided into many subgroups with different clinical features.  
ALL is more frequent in children and represents about 80% of all pediatric leukemia cases. 
Prognosis of newly diagnosed children with ALL has improved significantly mainly due to 
treatment with high-doses of chemotherapeutic drugs, but also a risk-stratification strategy 
and optimization of therapy.  5-year event-free survival (EFS) rates in different clinics range 
between 76% and 86%. Overall remission rates usually are 98% or higher (Pui et al., 2011). 
Age and white cell count at diagnosis have been used to predict a prognosis in ALL for 
many years, having been identified in early epidemiologic studies as predictors of an 
outcome (Smith et al., 1996). Children aged from 1 to 9 years have the best outcomes; 
children and adolescents aged from 10 to 20 years have slightly worse outcomes, which is 
associated in part with higher incidence of T-cell leukemia and lower incidence of favorable 
genetic abnormalities such as TEL/AML1 and hyperdiploidy. Also, ALL blasts from older 
patients become more resistant to multiple antileukemic drugs than the blasts from younger 
children in the first decade of life (Pieters et al., 1998; Nachman et al., 2009). Infants 
diagnosed at age of less than 1 year have relatively poor outcomes, which is associated with 
high incidence of immature pro-B-ALL phenotype and presence of MLL gene 
rearrangements (Hilden et al., 2006). Another biologic factor of prognostic value besides 
immunophenotype is a rapidity of response to the induction therapy with glucocorticoides, 
for instance decrease in peripheral blood blast count after a week of treatment. It has been 
shown by flow cytometry and molecular techniques, that a level of minimal residual disease 
(MRD) in bone marrow during first months of therapy may have high prognostic value and 
is used for stratification in many protocols (Szczepanski et al., 2001). Further risk 
stratification has been achieved using cytogenetic and molecular genetic characteristics of 
leukemia. The TEL-AML1 translocation and hyperdiploidy were found to predict a good 
prognosis; therefore they allow relative therapy reduction in carriers (Pui et al., 2000). 
Philadelphia-chromosome-positive ALL (Ph+-ALL) is associated with a poorer prognosis 
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and application of novel therapies may significantly improve clinical outcome (Arico et al., 
2000). Introduction of tyrosine kinase inhibitors  has completely changed therapy strategy 
for chronic myeloid leukemia (CML), potentially it may be a treatment of choice for 
Philadelphia positive ALL. Historically, the children with Ph+- ALL have been transplanted 
in their first complete remission (Davies & Mehta, 2010).  
Acute myeloid leukemia (AML) is defined as a hematologic malignancy in which more than 
20% of nucleated cells represent myeloid blasts by morphology and immunophenotype. 
Despite apparent phenotypic uniformity, it has become increasingly clear that AML is a 
heterogeneous group of neoplastic diseases (Watt & Bagg, 2010). To great extent, the 
heterogeneity is based upon its genetic complexity. The traditional parameters such as 
clinical features, blood counts, morphology, cytochemistry, immunophenotype are keeping 
their position in clinical evaluation, but genetic approaches are now firmly established as the 
central component in diagnostics and classification of AML. There are different, but 
recurrent, structural and numeric cytogenetic abnormalities, translocations, inversions and 
derivative chromosomes (Mitelman et al., 2011).  Three broad prognostic groups in AML 
with either favorable, intermediate, or adverse prognosis are identified by specific 
cytogenetic abnormalities (Grimwade & Hills, 2009). Also there is a growing number of 
acquired gene mutations which are essential to pathogenesis of AML (Gaidzik & Dohner, 
2008). In addition, aberrant gene expression and copy number variations have recently been 
recognized as a common phenomena that underlie malignant transformation (Eklund, 2010). 
The average EFS rate in AML is significantly lower comparing with ALL and usually ranges 
from 40% to 63% in most successful clinical trials, thus stimulating the search and 
implementation of new approaches to the treatment based on molecular genetic markers.  
Molecular technologies continue to evolve and provide more profound comprehension of 
leukemia pathology. Many of them have rapidly moved into clinical laboratories, while 
others remain as important discovery tools. Eventually, molecular genetic approaches will 
play the leading role in future leukemia practice. 
1.1 Clinically relevant genetic lesions in ALL 
The World Health Organization (WHO) provides current diagnostic criteria for ALL as a 
precursor B-cell acute lymphoblastic leukemia (B-ALL) or as a precursor T-cell acute 
lymphoblastic leukemia (T-ALL) (Brunning et al., 2001). Of the annually diagnosed ALL 
cases in different countries, approximately 80–85% have the B-ALL phenotype, and 
remainder displays the T-ALL phenotype. This classification scheme does not subdivide 
ALL into molecular subtypes, but most often, ALL is subtyped and studied on the basis of 
particular underlying genetic abnormality. The genetic defects in ALL include chromosomal 
translocations that deregulate gene expression or create novel fusion genes, numerical 
chromosome copy number aberrations (especially hyperdiploidy), and gene-specific 
mutations (Teitell & Pandolfi, 2009). 
Hyperdiploidy (more than 50 chromosomes per leukemia cell) is found in approximately 
25% of children who have B-lineage ALL. This genome abnormality is associated with a 
favorable outcome, especially when extra copies of chromosome 4, 10 or 17 are presented 
(Heerema et al., 2000). The hyperdiploid ALL cells are highly sensitive to cytostatics and L-
asparaginase, and accumulate high amounts of methotrexate derivates, so they are easily 
subjected to apoptosis (Kaspers et al., 1995).  
The TEL/AML1 (ETV6/RUNX1) fusion accounts for approximately 20-25% of cases and also 
is associated with a favorable outcome. It is formed by fusion of TEL gene on the 
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chromosome 12 encoding a member of the ETS family of transcription factors and AML1 
gene on the chromosome 21, a transcription factor gene encoding a part of core-binding 
factor (CBF). The TEL/ AML1 fusion probably inhibits transcription activity of normal AML1 
gene involved in proliferation and differentiation of hematopoietic cells. The t(12;21) is 
cryptic and cannot be identified by conventional cytogenetics. It is associated with high 
sensitivity to chemotherapeutic drugs, especially to L-asparaginase, though the mechanism 
of the sensitivity is unclear (Ramakers-van Woerden et al., 2000). Also the sensitivity to 
other drugs especially anthracyclines and etoposide has been reported (Frost et al., 2004). 
Both hyperdiploidy and TEL/AML1 translocation occur mainly in children younger than 10 
years with common or pre-B-ALL. 
Abnormalities of a mixed lineage leukemia (MLL) gene on the chromosome 11q23 occur in 
approximately 80% of infants with ALL, but only in 2% of children above age of 1 year. All 
types of MLL gene rearrangements, such as MLL/AF4 derived from t(4;11), 
MLL/MLLT1(ENL) derived from t(11;19), and MLL/MLLT3 derived from t(9;11), are 
associated with a poor outcome in infants (Pieters et al., 2007);  but in older children the 
poor outcome likely remains only for MLL/ AF4  fusion gene (Pui et al., 2002).  The fusion 
products involving MLL are associated with an aberrant expression of HOX genes, which 
are involved in early embryogenesis and may influence normal development of 
hematopoietic stem cells (Armsrong et al., 2002). The blast cells with MLL rearrangements 
are highly resistant to glucocorticoids and L-asparaginase (Dordelmann et al., 1999; 
Ramakers-van Woerden et al., 2004). These cells however, show a noticeable sensitivity to 
nucleoside analogue cytarabine, that is probably related to high expression of a membrane 
nucleoside transporter ENT1 (Stam et al., 2003).  
The translocation t(9;22) results in a fusion between BCR gene on the chromosome 22 and 
ABL gene on the chromosome 9 leading to over expression of the abnormal ABL tyrosine 
kinase, thus increasing proliferation and decreasing apoptosis (Kharas & Fruman, 2005). The 
BCR/ABL fusion is found mainly in common and pre-B ALL. Incidence of the BCR/ABL 
increases with age from approximately 3% of children with ALL up to approximately 25% in 
adult ALL cases. Presence of BCR/ABL predicts a poor outcome; more often it is associated 
with a poor response to prednisone and high levels of residual blasts carrying the BCR/ABL 
fusion after induction therapy (Schrappe et al., 1998). 
The prognostic value of genetic abnormalities in T-ALL is not so evident. The translocation 
t(1;14)  resulted in SIL/TAL1 fusion gene is found in approximately 25% of all T-ALL cases. 
The translocations t(10;14) and t(7;10) occur in approximately 10% of T-ALL cases leading to 
activation of HOX11 gene (Graux et al., 2006). Two recently described abnormalities occur 
exclusively in T-ALL: an abnormal expression of HOX11L2 caused mainly by translocation 
t(5;14) in approximately 25% of T-ALL cases, and activating mutations in NOTCH1 gene in 
50% of T-ALL cases. The mutations in NOTCH1 gene may be associated with a favorable 
outcome (Breit et al., 2006). Other recurrent genetic lesions occur in small subgroups of 
childhood ALL.  The translocation t(1;19) leading to E2A-PBX1 fusion occurs in less than 5% 
of precursor B-ALL, mainly pre-B-ALL cases and is associated with a more aggressive 
clinical course (Aspland et al., 2001). Hypodiploidy (<45 chromosomes) is detected in only 
1% of children who have ALL and is associated with a poor outcome (Nachman,et al., 2007).   
1.2 Clinically relevant genetic lesions an AML 
The WHO classification of AML is based on genetically defined entities of this complex 
disease (Swerdlow, 2008). In 2008 seven groups based on recurrent translocations (AML 
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and application of novel therapies may significantly improve clinical outcome (Arico et al., 
2000). Introduction of tyrosine kinase inhibitors  has completely changed therapy strategy 
for chronic myeloid leukemia (CML), potentially it may be a treatment of choice for 
Philadelphia positive ALL. Historically, the children with Ph+- ALL have been transplanted 
in their first complete remission (Davies & Mehta, 2010).  
Acute myeloid leukemia (AML) is defined as a hematologic malignancy in which more than 
20% of nucleated cells represent myeloid blasts by morphology and immunophenotype. 
Despite apparent phenotypic uniformity, it has become increasingly clear that AML is a 
heterogeneous group of neoplastic diseases (Watt & Bagg, 2010). To great extent, the 
heterogeneity is based upon its genetic complexity. The traditional parameters such as 
clinical features, blood counts, morphology, cytochemistry, immunophenotype are keeping 
their position in clinical evaluation, but genetic approaches are now firmly established as the 
central component in diagnostics and classification of AML. There are different, but 
recurrent, structural and numeric cytogenetic abnormalities, translocations, inversions and 
derivative chromosomes (Mitelman et al., 2011).  Three broad prognostic groups in AML 
with either favorable, intermediate, or adverse prognosis are identified by specific 
cytogenetic abnormalities (Grimwade & Hills, 2009). Also there is a growing number of 
acquired gene mutations which are essential to pathogenesis of AML (Gaidzik & Dohner, 
2008). In addition, aberrant gene expression and copy number variations have recently been 
recognized as a common phenomena that underlie malignant transformation (Eklund, 2010). 
The average EFS rate in AML is significantly lower comparing with ALL and usually ranges 
from 40% to 63% in most successful clinical trials, thus stimulating the search and 
implementation of new approaches to the treatment based on molecular genetic markers.  
Molecular technologies continue to evolve and provide more profound comprehension of 
leukemia pathology. Many of them have rapidly moved into clinical laboratories, while 
others remain as important discovery tools. Eventually, molecular genetic approaches will 
play the leading role in future leukemia practice. 
1.1 Clinically relevant genetic lesions in ALL 
The World Health Organization (WHO) provides current diagnostic criteria for ALL as a 
precursor B-cell acute lymphoblastic leukemia (B-ALL) or as a precursor T-cell acute 
lymphoblastic leukemia (T-ALL) (Brunning et al., 2001). Of the annually diagnosed ALL 
cases in different countries, approximately 80–85% have the B-ALL phenotype, and 
remainder displays the T-ALL phenotype. This classification scheme does not subdivide 
ALL into molecular subtypes, but most often, ALL is subtyped and studied on the basis of 
particular underlying genetic abnormality. The genetic defects in ALL include chromosomal 
translocations that deregulate gene expression or create novel fusion genes, numerical 
chromosome copy number aberrations (especially hyperdiploidy), and gene-specific 
mutations (Teitell & Pandolfi, 2009). 
Hyperdiploidy (more than 50 chromosomes per leukemia cell) is found in approximately 
25% of children who have B-lineage ALL. This genome abnormality is associated with a 
favorable outcome, especially when extra copies of chromosome 4, 10 or 17 are presented 
(Heerema et al., 2000). The hyperdiploid ALL cells are highly sensitive to cytostatics and L-
asparaginase, and accumulate high amounts of methotrexate derivates, so they are easily 
subjected to apoptosis (Kaspers et al., 1995).  
The TEL/AML1 (ETV6/RUNX1) fusion accounts for approximately 20-25% of cases and also 
is associated with a favorable outcome. It is formed by fusion of TEL gene on the 
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chromosome 12 encoding a member of the ETS family of transcription factors and AML1 
gene on the chromosome 21, a transcription factor gene encoding a part of core-binding 
factor (CBF). The TEL/ AML1 fusion probably inhibits transcription activity of normal AML1 
gene involved in proliferation and differentiation of hematopoietic cells. The t(12;21) is 
cryptic and cannot be identified by conventional cytogenetics. It is associated with high 
sensitivity to chemotherapeutic drugs, especially to L-asparaginase, though the mechanism 
of the sensitivity is unclear (Ramakers-van Woerden et al., 2000). Also the sensitivity to 
other drugs especially anthracyclines and etoposide has been reported (Frost et al., 2004). 
Both hyperdiploidy and TEL/AML1 translocation occur mainly in children younger than 10 
years with common or pre-B-ALL. 
Abnormalities of a mixed lineage leukemia (MLL) gene on the chromosome 11q23 occur in 
approximately 80% of infants with ALL, but only in 2% of children above age of 1 year. All 
types of MLL gene rearrangements, such as MLL/AF4 derived from t(4;11), 
MLL/MLLT1(ENL) derived from t(11;19), and MLL/MLLT3 derived from t(9;11), are 
associated with a poor outcome in infants (Pieters et al., 2007);  but in older children the 
poor outcome likely remains only for MLL/ AF4  fusion gene (Pui et al., 2002).  The fusion 
products involving MLL are associated with an aberrant expression of HOX genes, which 
are involved in early embryogenesis and may influence normal development of 
hematopoietic stem cells (Armsrong et al., 2002). The blast cells with MLL rearrangements 
are highly resistant to glucocorticoids and L-asparaginase (Dordelmann et al., 1999; 
Ramakers-van Woerden et al., 2004). These cells however, show a noticeable sensitivity to 
nucleoside analogue cytarabine, that is probably related to high expression of a membrane 
nucleoside transporter ENT1 (Stam et al., 2003).  
The translocation t(9;22) results in a fusion between BCR gene on the chromosome 22 and 
ABL gene on the chromosome 9 leading to over expression of the abnormal ABL tyrosine 
kinase, thus increasing proliferation and decreasing apoptosis (Kharas & Fruman, 2005). The 
BCR/ABL fusion is found mainly in common and pre-B ALL. Incidence of the BCR/ABL 
increases with age from approximately 3% of children with ALL up to approximately 25% in 
adult ALL cases. Presence of BCR/ABL predicts a poor outcome; more often it is associated 
with a poor response to prednisone and high levels of residual blasts carrying the BCR/ABL 
fusion after induction therapy (Schrappe et al., 1998). 
The prognostic value of genetic abnormalities in T-ALL is not so evident. The translocation 
t(1;14)  resulted in SIL/TAL1 fusion gene is found in approximately 25% of all T-ALL cases. 
The translocations t(10;14) and t(7;10) occur in approximately 10% of T-ALL cases leading to 
activation of HOX11 gene (Graux et al., 2006). Two recently described abnormalities occur 
exclusively in T-ALL: an abnormal expression of HOX11L2 caused mainly by translocation 
t(5;14) in approximately 25% of T-ALL cases, and activating mutations in NOTCH1 gene in 
50% of T-ALL cases. The mutations in NOTCH1 gene may be associated with a favorable 
outcome (Breit et al., 2006). Other recurrent genetic lesions occur in small subgroups of 
childhood ALL.  The translocation t(1;19) leading to E2A-PBX1 fusion occurs in less than 5% 
of precursor B-ALL, mainly pre-B-ALL cases and is associated with a more aggressive 
clinical course (Aspland et al., 2001). Hypodiploidy (<45 chromosomes) is detected in only 
1% of children who have ALL and is associated with a poor outcome (Nachman,et al., 2007).   
1.2 Clinically relevant genetic lesions an AML 
The WHO classification of AML is based on genetically defined entities of this complex 
disease (Swerdlow, 2008). In 2008 seven groups based on recurrent translocations (AML 
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with t(8;21) (q22;q22) RUNX1/RUNX1T1; AML with inv(16) (p13q22) or t(16;16) (p13;q22) 
CBFB/MYH11; AML with t(15;17) (q22;q12) PML/RARA; AML with t(9;11) (p22;q23) 
MLLT3/MLL; AML with t(6;9) (p23q34) DEK/NUP214; AML with inv(3) (q21q26.2) or t(3;3) 
(q21q26.2) RPN1/EVI1 and AML with t(1;22) (p13;q130RBM15/MKL1) and two provisional 
groups characterized by gene mutations (AML with mutated NPM1 and AML with mutated 
CEBPA) were included into the classification system. These nine diagnostic entities cover 
about two thirds of all AML cases, while additional subtypes of AML, in which genetic 
factors play the central role, include myelodysplastic syndrome and therapy-related 
myeloid neoplasms. The latter two subtypes typically represent cases with complex 
karyotype, which is defined as the coexistence of three and more clonal cytogenetic 
aberrations (Watt & Bagg, 2010).  
1.2.1 Reccurent chromosomal aberrations 
The t(8;21)(q22;q22) RUNX1/RUNX1T1 is a specific genetic lesion. It occurs in approximately 
8-10% of all cases of AML and usually is associated with the previously FAB-designated 
subtype AML-M2  (Peterson & Zhang, 2004; Swerdlow, 2008). RUNX1 and CBFB encode 
two components of a heterodimeric transcription complex known as core binding factor 
(CBF). The CBF plays an important role in regulation of normal hematopoiesis, thus the 
disruption of these two genes becomes obviously pathogenic. One of two major recurrent 
translocations involving CBF is the t(8;21), another is the inv(16). A part of RUNX1(AML1) 
gene on 21q22 is fused with a part of the RUNX1T1(ETO) gene on 8q22. The subsequently 
derived fusion protein, RUNX1–RUNX1T1 (AML1/ETO), represents a protein with 
inhibitory function which represses transcription of a number of important hematopoietic 
genes. Clinically, the t(8;21) translocation is associated with a favorable prognosis (Heerema-
McKenney & Arber, 2009). 
The inv(16)(p13q22) or t(16;16)(p13;q22) CBFB/MYH11 is a pericentric inversion or 
molecularly identical t(16;16) translocation. It represents approximately 5–10% of all cases of 
AML and is associated with the FAB entity of acute myelomonoblastic leukemia with 
eosinophilia (AML-M4Eo) (Heerema-McKenney & Arber, 2009). A part of CBFB gene is 
fused with a part of one of myosin heavy chain genes, MYH11 and the fusion prevents the 
formation of a functional CBF transcription factor. The CBFB–MYH11 can act also as a 
transcriptional repressor in the nucleus (Shigesada et al., 2004). Although this genetic fusion 
is most often seen in M4Eo, it may also be found in other subtypes of AML, including those 
designated by FAB as M2 and M5. The inv(16) can sometimes be missed by cytogenetics as 
cryptic, so molecular methods have a particularly important role in the detection of this 
aberration. The breakpoints in CBFB gene occur in intron 5, while in MYH11 gene 
breakpoints are involved seven different exons (7 through 13), yielding at least ten different 
fusion transcripts. The most common form, type A, accounts for approximately 90% of 
CBFB/MYH11 cases, while two other transcripts (types D and E) account for an additional 
5%.  The aberration is associated with a favorable outcome. 
The t(15;17)(q22;q12) PML/RARA is observed in approximately 5–8% of all cases of AML 
defining an unique entity acute promyelocytic  leukemia (APL) (Swerdlow, 2008). Among 
all acute leukemias, APL represents one with the most stable genotype–phenotype 
correlation, in that the presence of specific translocation can frequently be  expected based 
upon the characteristic morphology: the classic hypergranular form (FAB AML-M3) or the 
microgranular variant (FAB AML-M3v). The part of PML gene on 15q22 is fused with RARA 
gene on 17q12 resulting in a PML/RARA gene. In the absence of retinoic acid the wild-type 
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RARA protein is a component of a heterodimeric transcriptional repressor complex, while 
binding with retinoic acid converts the RARA complex into a transcriptional activator. The 
chimeric protein PML/RARA becomes a potential transcriptional repressor with altered 
DNA-binding properties and the capacity to block myeloid differentiation. The treatment of 
PML/RARA carriers with pharmacologic doses of retinoic acid in the form of ATRA 
destroys the co-repressor complex and leads to differentiation of the malignant 
promyelocytes (Guidez et al., 1998). At least four rare variant translocations associated with 
APL phenotype have been described: t(11;17) (q23;q12) ZBTB16/RARA, t(11;17)(q13;q12) 
NUMA1/RARA, t(5;17)(q35;q12) NPM1/RARA and t(17;17)(q11.2;q12) STAT5B/RARA. Some 
of these variants, the t(11;17) ZBTB16/RARA and  t(17;17) STAT5B/RARA, are not sensitive to 
ATRA, so the molecular characterization of APL is necessary.The breakpoints in RARA gene 
are restricted to intron 2, while in PML gene there are two major breakpoints leading to long 
(L-form, bcr 1) or short (S-form, bcr3) transcript variant.  
MLL gene on the chromosome 11q23 is an exceptional target in AML; as it is involved in at 
least 73 different translocations with more than 50 different partner genes (Huret, 2011) 
including different leukemia subtypes, such as de novo AML, therapy-related AML, 
myelodysplastic syndromes and acute lymphoblastic leukemia. The protein MLL is a histone 
methyltransferase that modulates gene expression, especially the expression of HOX genes, via 
chromatin remodeling (Dou & Hess, 2008), while most fused partners are supposed to be 
transcription factors. An exact mechanism of leukemogenesis involved different MLL 
translocations has not been completely understood.  The t(9;11) (p22;q23) MLL/MLLT3 
(MLL/AF9) is the most common, typically associated with subtype FAB-M5 having monocytic 
features. In contrast to most other MLL rearrangements that are associated with a poor 
prognosis, this translocation is associated with an intermediate prognosis. The breakpoints in 
MLL are clustered in a breakpoint cluster region, spanning exons 5–11. An extreme 
heterogeneity of translocations associated with MLL makes analysis using PCR diagnostic 
assay laborious.  FISH is applicable for detection of MLL translocations in clinical practice 
(Keefe et al., 2010). Other significant MLL translocations in AML are t(6;11) MLL/MLLT4 
(MLL/AF6), t(11;19) MLL/ELL, t(10;11) MLL/MLLT4 (MLL/AF10). 
One of the rarer recurrent translocations the t(6;9)(p23;q34) occurs in approximately 1% of 
AML cases. The inv(3) and related t(3;3) translocation are found in approximately 1–2% of 
AML cases and associated with a poor clinical outcome (Swerdlow, 2008). AML with the 
t(1;22) translocation occurs primarily in infants representing less than 1% of all cases of 
AML. It is particularly associated with acute megakaryoblastic leukemia (FAB M7) and a 
good prognosis, if treated with intensive chemotherapy (Duchayne et al., 2003). 
1.2.2 Gene mutations 
Approximately 45% of AML cases have a normal karyotype but carry submicroscopic and 
cryptic genetic lesions that cannot be detected by conventional cytogenetics. Several 
acquired gene mutations have been described and characterized in AML. Two lesions 
(NPM1 and CEBPA mutations) have obtained provisional status in the 2008 WHO 
classification (Swerdlow, 2008). 
NPM1 encodes a 37 kDa protein with versatile biologic activity that shuttles between the 
nucleolus, nucleoplasm and the cytoplasm (Grisendi et al., 2006; Meani & Alcalay, 2009). 
Mutations in NPM1 are common in AML, occurring with an overall frequency of 25–30% in 
adults and are associated with normal karyotype (Schnittger et al., 2005; Thiede et al., 2006). 
Most mutations in NPM1 are small insertions (4–11bp) in the terminal coding region (exon 
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with t(8;21) (q22;q22) RUNX1/RUNX1T1; AML with inv(16) (p13q22) or t(16;16) (p13;q22) 
CBFB/MYH11; AML with t(15;17) (q22;q12) PML/RARA; AML with t(9;11) (p22;q23) 
MLLT3/MLL; AML with t(6;9) (p23q34) DEK/NUP214; AML with inv(3) (q21q26.2) or t(3;3) 
(q21q26.2) RPN1/EVI1 and AML with t(1;22) (p13;q130RBM15/MKL1) and two provisional 
groups characterized by gene mutations (AML with mutated NPM1 and AML with mutated 
CEBPA) were included into the classification system. These nine diagnostic entities cover 
about two thirds of all AML cases, while additional subtypes of AML, in which genetic 
factors play the central role, include myelodysplastic syndrome and therapy-related 
myeloid neoplasms. The latter two subtypes typically represent cases with complex 
karyotype, which is defined as the coexistence of three and more clonal cytogenetic 
aberrations (Watt & Bagg, 2010).  
1.2.1 Reccurent chromosomal aberrations 
The t(8;21)(q22;q22) RUNX1/RUNX1T1 is a specific genetic lesion. It occurs in approximately 
8-10% of all cases of AML and usually is associated with the previously FAB-designated 
subtype AML-M2  (Peterson & Zhang, 2004; Swerdlow, 2008). RUNX1 and CBFB encode 
two components of a heterodimeric transcription complex known as core binding factor 
(CBF). The CBF plays an important role in regulation of normal hematopoiesis, thus the 
disruption of these two genes becomes obviously pathogenic. One of two major recurrent 
translocations involving CBF is the t(8;21), another is the inv(16). A part of RUNX1(AML1) 
gene on 21q22 is fused with a part of the RUNX1T1(ETO) gene on 8q22. The subsequently 
derived fusion protein, RUNX1–RUNX1T1 (AML1/ETO), represents a protein with 
inhibitory function which represses transcription of a number of important hematopoietic 
genes. Clinically, the t(8;21) translocation is associated with a favorable prognosis (Heerema-
McKenney & Arber, 2009). 
The inv(16)(p13q22) or t(16;16)(p13;q22) CBFB/MYH11 is a pericentric inversion or 
molecularly identical t(16;16) translocation. It represents approximately 5–10% of all cases of 
AML and is associated with the FAB entity of acute myelomonoblastic leukemia with 
eosinophilia (AML-M4Eo) (Heerema-McKenney & Arber, 2009). A part of CBFB gene is 
fused with a part of one of myosin heavy chain genes, MYH11 and the fusion prevents the 
formation of a functional CBF transcription factor. The CBFB–MYH11 can act also as a 
transcriptional repressor in the nucleus (Shigesada et al., 2004). Although this genetic fusion 
is most often seen in M4Eo, it may also be found in other subtypes of AML, including those 
designated by FAB as M2 and M5. The inv(16) can sometimes be missed by cytogenetics as 
cryptic, so molecular methods have a particularly important role in the detection of this 
aberration. The breakpoints in CBFB gene occur in intron 5, while in MYH11 gene 
breakpoints are involved seven different exons (7 through 13), yielding at least ten different 
fusion transcripts. The most common form, type A, accounts for approximately 90% of 
CBFB/MYH11 cases, while two other transcripts (types D and E) account for an additional 
5%.  The aberration is associated with a favorable outcome. 
The t(15;17)(q22;q12) PML/RARA is observed in approximately 5–8% of all cases of AML 
defining an unique entity acute promyelocytic  leukemia (APL) (Swerdlow, 2008). Among 
all acute leukemias, APL represents one with the most stable genotype–phenotype 
correlation, in that the presence of specific translocation can frequently be  expected based 
upon the characteristic morphology: the classic hypergranular form (FAB AML-M3) or the 
microgranular variant (FAB AML-M3v). The part of PML gene on 15q22 is fused with RARA 
gene on 17q12 resulting in a PML/RARA gene. In the absence of retinoic acid the wild-type 
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RARA protein is a component of a heterodimeric transcriptional repressor complex, while 
binding with retinoic acid converts the RARA complex into a transcriptional activator. The 
chimeric protein PML/RARA becomes a potential transcriptional repressor with altered 
DNA-binding properties and the capacity to block myeloid differentiation. The treatment of 
PML/RARA carriers with pharmacologic doses of retinoic acid in the form of ATRA 
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translocations has not been completely understood.  The t(9;11) (p22;q23) MLL/MLLT3 
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(MLL/AF6), t(11;19) MLL/ELL, t(10;11) MLL/MLLT4 (MLL/AF10). 
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AML cases and associated with a poor clinical outcome (Swerdlow, 2008). AML with the 
t(1;22) translocation occurs primarily in infants representing less than 1% of all cases of 
AML. It is particularly associated with acute megakaryoblastic leukemia (FAB M7) and a 
good prognosis, if treated with intensive chemotherapy (Duchayne et al., 2003). 
1.2.2 Gene mutations 
Approximately 45% of AML cases have a normal karyotype but carry submicroscopic and 
cryptic genetic lesions that cannot be detected by conventional cytogenetics. Several 
acquired gene mutations have been described and characterized in AML. Two lesions 
(NPM1 and CEBPA mutations) have obtained provisional status in the 2008 WHO 
classification (Swerdlow, 2008). 
NPM1 encodes a 37 kDa protein with versatile biologic activity that shuttles between the 
nucleolus, nucleoplasm and the cytoplasm (Grisendi et al., 2006; Meani & Alcalay, 2009). 
Mutations in NPM1 are common in AML, occurring with an overall frequency of 25–30% in 
adults and are associated with normal karyotype (Schnittger et al., 2005; Thiede et al., 2006). 
Most mutations in NPM1 are small insertions (4–11bp) in the terminal coding region (exon 
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12). Although over 50 mutations have been described, three specific mutations (A, B and D) 
account for the majority of the changes observed in AML (Falini et al., 2009). As a general 
rule, the presence of an NPM1 mutation is associated with a more favorable clinical 
outcome. However, the NPM1 mutations are often found together with an internal tandem 
duplication FLT3–ITD, in this case the negative prognostic impact of a FLT3–ITD mutation 
may override the positive value of an NPM1 mutation. 
FLT3 is a class III receptor tyrosine kinase and a member of immunoglobulin receptor 
superfamily. It is expressed mostly in progenitor cells; the level of expression is lowered 
during differentiation. The ligand binding with FLT3 protein results in a phosphorylation of 
a juxtamembranous (JM) domain leading to the proliferation and inhibition of apoptosis.  
Two major types of lesions in FLT3 gene have been described: an internal tandem 
duplication (ITD) of the JM domain and a missense mutation D835mut in the activation loop 
(PM). Functionally, these lesions result in the constitutive activation of the tyrosine kinase 
domains via autophosphorylation and, consequently, to permanent signaling through 
downstream effectors. FLT3-ITD is an independent predictor of poor clinical outcome 
(Meshinchi & Appelbaum, 2009). The prognostic value of the FLT3-PM is controversial 
(Yamamoto et al., 2001). Another important diagnostic target is c-KIT gene which encodes a 
type III tyrosine kinase involved in a signal transduction. The activating mutations, 
occurring in approximately 2–8% of all AML, lead to ligand independent signal 
transduction (Cairoli et al., 2006). In adults, the c-KIT mutations typically predict worse 
prognosis, but it may be different in children (Pollard et al., 2010).  
Due to significant progress in our understanding of acute leukemia pathogenesis, risk 
stratification of patients more and more relies on molecular genetic markers. New molecular 
targets will be found to enrich a clinician’s repertoire for making well-founded decisions 
regarding diagnosis, prognosis and therapy. This requires the establishment of appropriate 
and practical testing algorithms and development of standardized assays in order to obtain 
reliable and reproducible results. 
1.3 Methods for detection of genetic lesions 
Molecular diagnostics, first being a subsidiary tool in the clinical evaluation of acute 
leukemia, nowadays has been integrated rapidly into clinical laboratory practice. Genetic 
abnormalities associated with different leukemia subtypes can be detected by a variety of 
supplemental clinical methods, including conventional G-banded cytogenetics, FISH, PCR 
and DNA sequencing. The innovated technologies, such as gene-expression analysis, 
comparative genetic hybridization (CGH) and SNP arrays, still remaining at the 
experimental level, have a potential to hold a place in routine clinical evaluation and 
management of the disease. A brief overview of different methods allowing detection of 
different genetic lesions is presented in Table 1. Among them gel-based diagnostic biochips 
are considered, which are discussed further in more details.  
A traditional karyotyping, based on Giemsa-stained metaphase chromosome spreads, 
continues to provide valuable information about translocations, as well as numerical 
changes in chromosome number and structure. Diagnostics of clonal process in a clinical 
sample is typically defined by the presence of at least two cells with the same structural 
abnormality, and at least three cells with the same abnormality in the case of a chromosomal 
loss. Despite limitations in analytic sensitivity and availability of dividing cells in a clinical 
sample, traditional karyotyping remains one of the most robust tools in molecular 
hematopathology.  
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Fluorescence in situ hybridization (FISH) involves fluorescently labeled probe binding to 
specific chromosome sequences that is visualized under fluorescent microscope. The 
structural microscopic or submicroscopic cryptic lesions, as well as different numeric 
chromosomal changes can be identified depending on a probe design (Wolff et al., 2007). 
FISH is more direct method to evaluate chromosomal lesions comparing with karyotyping, 
also it is more sensitive and can be applied to non-dividing interphase cells.  
PCR is a popular and versatile tool in evaluation of acute leukemias. The technique is based on 
the exponential amplification of a target nucleic acid sequence; specific applications depend 
upon the type of initial nucleic acid and the detection method. The DNA-based allele-specific 
PCR is used for the detection of gene mutations. The RNA-based PCR assay, reverse-
transcription PCR or RT-PCR, is extremely useful in the analysis of fusion genes which express 
chimeric transcripts. Also the measurement of gene expression is possible. The resulting 
amplicons are evaluated either quantitatively by a real-time PCR approach or qualitatively by 
gel electrophoresis after 30-35 cycles of amplification. Because of the exponential amplification 
of target, sensitivity of the method is very high allowing detection of 1 blast with specific 
lesion among 10-4-10-5 normal cells (Rennert et al., 1999). Because of its increased analytical 
sensitivity regarding to karyotyping and FISH, RT-PCR is widely used for monitoring minimal 
residual disease in leukemia cases with recurrent translocations.  
 





















Time Clinical usage 
Karyotyping Mitotic
cells Yes
1 Yes No No No 5-10 2-3 days Yes 
FISH Any cells Yes Yes No No No 1-5 1-2 days Yes 
PCR DNA Yes No Yes No No 0.0001 3-4 h Yes 
RT-PCR RNA Yes No Yes Yes No 0.0001 5-6 h Yes 
Sequencing DNA No No Yes No No 10-20 1 day No 
CGH array DNA No Yes No No Yes 10-30 2 days No 
Expression 
array RNA No No No Yes No 10-30 2 days No 




NA Yes No Yes No No 
0.001-
52 16-20 h Yes 
Table 1. Characteristics of different molecular genetic methods in the analysis of acute 
leukemias 
The variability and complexity of mutations in some genes, like NPM1 or CEBPA, make 
them ineligible for standard PCR assays, in such cases direct DNA sequencing can be used 
to search for the presence of a genetic lesion (Ahn et al., 2009). The traditional sequencing is 
a robust and flexible methodology that reliably detects the presence of mutations when 
approximately 20% of cells carry the genetic lesion. While not available clinically, next-
generation DNA sequencing methods become more and more applicable regarding to time, 
money and data analysis. In 2010, it is feasible to sequence a human genome in 
                                                                 
1 ( -except cryptic aberrations;  
2  - the MRD level is 0.001% for translocations and  5 % per gene mutations) 
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occurring in approximately 2–8% of all AML, lead to ligand independent signal 
transduction (Cairoli et al., 2006). In adults, the c-KIT mutations typically predict worse 
prognosis, but it may be different in children (Pollard et al., 2010).  
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stratification of patients more and more relies on molecular genetic markers. New molecular 
targets will be found to enrich a clinician’s repertoire for making well-founded decisions 
regarding diagnosis, prognosis and therapy. This requires the establishment of appropriate 
and practical testing algorithms and development of standardized assays in order to obtain 
reliable and reproducible results. 
1.3 Methods for detection of genetic lesions 
Molecular diagnostics, first being a subsidiary tool in the clinical evaluation of acute 
leukemia, nowadays has been integrated rapidly into clinical laboratory practice. Genetic 
abnormalities associated with different leukemia subtypes can be detected by a variety of 
supplemental clinical methods, including conventional G-banded cytogenetics, FISH, PCR 
and DNA sequencing. The innovated technologies, such as gene-expression analysis, 
comparative genetic hybridization (CGH) and SNP arrays, still remaining at the 
experimental level, have a potential to hold a place in routine clinical evaluation and 
management of the disease. A brief overview of different methods allowing detection of 
different genetic lesions is presented in Table 1. Among them gel-based diagnostic biochips 
are considered, which are discussed further in more details.  
A traditional karyotyping, based on Giemsa-stained metaphase chromosome spreads, 
continues to provide valuable information about translocations, as well as numerical 
changes in chromosome number and structure. Diagnostics of clonal process in a clinical 
sample is typically defined by the presence of at least two cells with the same structural 
abnormality, and at least three cells with the same abnormality in the case of a chromosomal 
loss. Despite limitations in analytic sensitivity and availability of dividing cells in a clinical 
sample, traditional karyotyping remains one of the most robust tools in molecular 
hematopathology.  
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chimeric transcripts. Also the measurement of gene expression is possible. The resulting 
amplicons are evaluated either quantitatively by a real-time PCR approach or qualitatively by 
gel electrophoresis after 30-35 cycles of amplification. Because of the exponential amplification 
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approximately 1 week for approximately US$15,000 (Aparicio & Huntsman, 2010).  Different 
microarray-based methodologies are applied to profiling gene expression and measuring 
copy number variations (CNV) (Bacher al., 2010; Nasedkina et al., 2009). It has been shown 
that the gene expression measurement is independently capable of classifying many of the 
clinically relevant ALL and AML categories based on their distinct expression profiles 
(Bullinger et al., 2004; Radmacher et al., 2006).  At the same time, expression arrays can not 
predict the mutation status of several prognostically relevant genes, such as FLT3 
(Kohlmann et al., 2010). Further standardization of these complex techniques is needed for 
successful introduction into clinical laboratories (Haferlach et al., 2010). 
2. Diagnostics of molecular markers in childhood leukemia using biochips 
The translation of research to practice has been stimulated the development of novel 
approaches to clinical diagnostics potentially capable to overcome the limitations of settled 
technologies, like karyotyping, FISH and RT-PCR. Complicated assays using high-density 
arrays hardly are used in daily routine diagnostics, especially in small clinical laboratories. 
To overlap this gap different low-density array-based techniques have been developed, 
which are less complex, less expensive and more reproducible systems with a few molecular 
markers comparing to high-density microarrays. Gel-based biochips are a good example of 
such a technology. 
2.1 Gel-based biochip technology 
Overviews of low-density gel-based biochip or hydrogel biochip technology and 
applications in different fields exemplifying diagnostics from infectious diseases to protein 
oncological markers have been published recently (Mikhailovich et al., 2008; Nasedkina et 
al., 2009; Rubina et al., 2008). Principal difference of gel-based biochip technology 
comparing with other matrix microarrays is an immobilization of identifying probes in 
semi-spherical three-dimensional (3-D) gel elements instead of the flat supporting surface. 
The solution containing oligonucleotide probes mixed with gel-forming monomer is placed 
on a activated plastic or glace surface by a standard robotic device. Oligonucleotide probes 
are modified and carry NH2 -groups at their 3′ ends. Copolymerization of molecular probes 
and main gel components is processed under UV-light. As a result the immobilized 
molecules become covalently bound to monomers of a growing polymer chain and 
distribute evenly throughout each gel element, as shown by confocal microscopy (Rubina et 
al., 2004). The diameters of gel elements are ranged from 50 up to 300 µm with a distance 
between them from 100 up to 500 µm depending on experimental tasks. A number of gel 
elements vary from several tens up to several thousands depending on the complexity of 
target analyzed. The quality control of gel element disposition is performed using specialized 
optical device and computerized image analysis. Such quality control allows minimizing intra- 
and inter-array variation of a drop size on ready-to-use biochips and substantially increases 
the reproducibility of hybridization results with different series of biochips.  
Fluorescent dyes are used as labels to register hybridization pattern. Different analogs of 
cyanine fluorescent dyes Cy3 and Cy5 have been synthesized to increase the sensitivity and 
efficacy of hybridization analysis (Kuznetsova et al., 2008).  In the case of DNA sequence 
analysis the hybridization target represents a fragment of genome and the amplification of 
DNA is usually needed using PCR with simultaneous incorporation of fluorescent label. The 
size of amplified fragments is in range of 100-1000 b.p.  For proteome analysis gel elements 
contain antigen or antibody and the fluorescent label is conjugated directly with target 
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analyzed or with molecules of developing antibodies like in the sandwich immunoassay. A 
biochip photograph and view under light microscope are presented in Fig.1, A and B. 
 
 
A – General view of biochip with hybridization chamber; 
B – gel elements with a diameter of 100 µm under light microscope; 
C – portable biochip analyzer (on the right). Scale bar = 200 µm. 
Fig. 1. Gel-based biochips.  
The higher probe concentration in gel drops compared with spots of 2-dimensional 
microarrays allows the use of a simple detection system consisting of a laser source 
equipped with lenses and charge-coupled device camera (Fig. 1, C). The portable biochip 
analyzer is certified for clinical use by a national regulatory agency, the Ministry of Public 
Health of the Russian Federation (Registration Certificate of Federal Service for Supervision 
in Public Health Sphere No. FS 022а2006/3777-06). Image analysis is performed using 
automated user-friendly software «Imageware»® , which measures the fluorescence 
intensities in gel elements after allele-specific hybridization and determines the gel elements 
where the formation of perfect duplexes is performed between complementary probe and 
target. Then the system presents a report about the presence of mutation, polymorphism or 
chromosome translocation in a sample under analysis.   
The main features of the gel-based biochip analysis are its simplicity, and the low cost of 
equipment and biochips themselves (approximately 8 $US per chip in 2011), enabling their 
use by small diagnostic laboratories. One of the first clinical biochip applications was the 
analysis of chromosomal translocations occurring in leukemia. 
2.2 Analysis of chromosomal translocations in leukemia 
The recurrent chromosomal aberrations represent important diagnostic and prognostic 
markers of different types of disease requiring appropriate therapy and are taken into 
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equipment and biochips themselves (approximately 8 $US per chip in 2011), enabling their 
use by small diagnostic laboratories. One of the first clinical biochip applications was the 
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2.2 Analysis of chromosomal translocations in leukemia 
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account in the risk-stratification of patients in different clinical trials (Look, 1997; Möricke et 
al., 2008; Rubnitz et al., 2008; Rabbits, 1994; Shrappe, 2004). When an aberration is found, it 
also serves as a reliable target for monitoring of minimal residual disease. 
Traditionally, chromosomal translocations have been identified using cytogenetics and FISH. 
However, the analysis of chromosomal translocations with cytogenetic methods is not always 
accurate and representative, because of submicroscopic lesions and cryptic translocations. The 
FISH technique is comprehensive, reliable and available for clinics approach, but it requires 
expensive basic equipment, does not allow the detection of all targets of interest 
simultaneously and is not sensitive enough for effective monitoring of MRD. The reverse-
transcription (RT)-PCR is another widely used method able to detect chimeric transcripts, 
which derive from fusion genes and represent an excellent molecular target expressed in 
leukemic blasts (Braziel et al., 2003;  Haferlach et al., 2005). As far as the identification of each 
transcript requires an individual PCR reaction with specific primers, a scale of the study 
increases markedly when each patient is analyzed for several transcripts simultaneously. Thus, 
multiplex protocols have been developed to diminish time- and labor-intensity of the 
procedure (Pallisgaard et al., 1998; Scurto et al., 1998). The multiplex RT-PCR assay is usually 
multi-stage: the multiplex reaction is followed by series of identifying PCR reactions with 
primers specific for individual translocations. To facilitate the identification of recurrent 
translocations an oligonucleotide biochip has been developed and combined with multiplex 
RT-PCR assay. The hybridization step increases specificity of the assay while reduces 
associated costs and amount of patient material required. Taking into consideration the results 
of clinical trials, thirteen chromosomal aberrations considered the most important for 
diagnosis and prognosis, were chosen as targets (Mitiaeva et al., 2004; Nasedkina et al., 2003). 
The following translocations were included into the assay: t(9;22)p190 and p210, t(12;21), 
t(1;19), t(8;21), inv(16), t(15;17), t(4;11), t(6;11), t(9;11); t(10;11), t(11;19)ELL, t(11,19)ENL. 
Oligonucleotide probes of 20–25 bp in length were spotted in duplicates in order to increase 
reproducibility of hybridization results. The biochip contains probes for the detection of 
wild type ABL gene, which is expressed in all cells. The detection of ABL transcript is used 
to control the quantity and quality of isolated RNA and to estimate the effectiveness of 
labeled target preparation. For each translocation, a set of probes was designed including a 
so-called common probe from one of the genes involved in the translocation, and also 
specific probes to identify the breakpoint variants. The procedure includes the isolation of 
RNA from bone marrow or peripheral blood cells, multiplex RT-PCR using primers specific 
for different translocations, labeling of single strand PCR product via incorporation of 
modified Cy5-dUTP in the course of asymmetric PCR, hybridization on the biochip, and 
registration of fluorescence intensities in gel elements of biochip using a biochip analyzer. 
Computer-based processing of fluorescent signals using a specially developed algorithm 
allows an automated image analysis. Examples of different hybridization patterns are 
presented in Fig. 2, A and B.  The limit of sensitivity is one blast cell with a chromosomal 
translocation among 103–104 normal cells. 
The MLL translocations represent a difficult subject for analysis by conventional 
cytogenetics or standard RT-PCR due to high diversity of gene partners involved in 
translocations with MLL gene. In MLL translocations the fusion results in a gene and 
transcript with the 5′ end belonging to MLL gene originally located in 11q23 region and the 
3′ end belonging to one of more than 50 partner genes (Eguchi et al., 2005). In biochip-based 
assay a set of probes specific for different MLL exons and probes specific to different exons  
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Fig. 2. Identification of chromosomal translocations by Leukogen-biochip.  Two lower spots 
represent fluorescent marker, two upper spots correspond to ABL-gene specific signals. A – 
a sample of patient carrying no translocations; B- a sample of patient carrying translocation 
t(15;17), fusion gene PML/RARA, bcr3 breakpoint variant. 
of partner gene is used. The analysis was done as described previously (Mitiaeva et al., 
2004). The biochip-based approach can indicate which MLL exon is involved in formation of 
a chimeric transcript, as well as identifies the partner gene. Most frequent translocations in 
ALL and AML are included into assay, namely t(4;11), t(6;11), t(9;11); t(10;11), t(11;19)ELL, 
t(11,19)ENL.  They are included in the last version of Leukogen-biochip for the analysis of 13 
translocations. Another diagnostic biochip has been described which allowed the analysis of 
about thirty different gene partners, but the sensitivity limit of the assay is significantly 
lower: 1 blast cell per 10 normal (Maroc et al., 2004). 
During 2006-2009 the bone marrow samples of patients with leukemia of age 0 to 18 treated 
in hematological clinics were received and tested using the biochip-based approach for the 
presence of translocations. The hematologic malignancies ALL and AML were diagnosed 
according to standard criteria by cytomorphologic, cytochemical,  and immunophenotypic 
studies of bone marrow cells.  Totally, 1200 children with leukemia from different parts of 
Russia were included into assay: 912 patients were diagnosed with ALL and 282 with AML. 
In ALL patients the chromosomal aberrations analyzed were found in 24,4% of all cases. In 
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account in the risk-stratification of patients in different clinical trials (Look, 1997; Möricke et 
al., 2008; Rubnitz et al., 2008; Rabbits, 1994; Shrappe, 2004). When an aberration is found, it 
also serves as a reliable target for monitoring of minimal residual disease. 
Traditionally, chromosomal translocations have been identified using cytogenetics and FISH. 
However, the analysis of chromosomal translocations with cytogenetic methods is not always 
accurate and representative, because of submicroscopic lesions and cryptic translocations. The 
FISH technique is comprehensive, reliable and available for clinics approach, but it requires 
expensive basic equipment, does not allow the detection of all targets of interest 
simultaneously and is not sensitive enough for effective monitoring of MRD. The reverse-
transcription (RT)-PCR is another widely used method able to detect chimeric transcripts, 
which derive from fusion genes and represent an excellent molecular target expressed in 
leukemic blasts (Braziel et al., 2003;  Haferlach et al., 2005). As far as the identification of each 
transcript requires an individual PCR reaction with specific primers, a scale of the study 
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procedure (Pallisgaard et al., 1998; Scurto et al., 1998). The multiplex RT-PCR assay is usually 
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assay a set of probes specific for different MLL exons and probes specific to different exons  
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Fig. 2. Identification of chromosomal translocations by Leukogen-biochip.  Two lower spots 
represent fluorescent marker, two upper spots correspond to ABL-gene specific signals. A – 
a sample of patient carrying no translocations; B- a sample of patient carrying translocation 
t(15;17), fusion gene PML/RARA, bcr3 breakpoint variant. 
of partner gene is used. The analysis was done as described previously (Mitiaeva et al., 
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ALL and AML are included into assay, namely t(4;11), t(6;11), t(9;11); t(10;11), t(11;19)ELL, 
t(11,19)ENL.  They are included in the last version of Leukogen-biochip for the analysis of 13 
translocations. Another diagnostic biochip has been described which allowed the analysis of 
about thirty different gene partners, but the sensitivity limit of the assay is significantly 
lower: 1 blast cell per 10 normal (Maroc et al., 2004). 
During 2006-2009 the bone marrow samples of patients with leukemia of age 0 to 18 treated 
in hematological clinics were received and tested using the biochip-based approach for the 
presence of translocations. The hematologic malignancies ALL and AML were diagnosed 
according to standard criteria by cytomorphologic, cytochemical,  and immunophenotypic 
studies of bone marrow cells.  Totally, 1200 children with leukemia from different parts of 
Russia were included into assay: 912 patients were diagnosed with ALL and 282 with AML. 
In ALL patients the chromosomal aberrations analyzed were found in 24,4% of all cases. In 
 
Acute Leukemia – The Scientist's Perspective and Challenge 218 
AML the portion of patients carrying specific translocations was 36,4% of all cases. The most 
frequent translocation in ALL was cryptic translocation t(12;21) (12,8%), fusion transcript 
TEL/AML1 or ETV6/RUNX1. In AML most frequent translocations are t(8;21) (9,5%) with 
fusion gene AML/ETO or RUNX1/RUNX1T1; t(15;17) (8,0%) with fusion gene PML/RARA 
and t(9;11) (10,5 %) with  MLL/MLLT3. The frequency of t(12;21) obtained in Russia is lower 
than the frequencies of 18-20% found in other countries (Hilden et al., 2006; Rubnitz et al., 
2008; Vilmer et al., 2000).  
Validation of the method was done using individual RT-PCR protocols for each 
translocation (Pallisgaard et al., 1998), in others words, for 325 patients the standard RT-PCR 
assay was performed parallel to biochip-based analysis. The concordance between the two 
methods was about 98%. The main source of false-positive signals on biochip may be 
contamination by amplified DNA fragments; the problem can be overcome by more 
accurate PCR handling. To avoid false-negative results, biochips were tested periodically 
with control samples carrying translocations. The results of the biochip analysis were also 
compared with clinical data and a morphologically determined leukemia variant. The 
patients carrying translocations were further monitored for minimal residual disease to 
follow efficacy of therapy and to predict a relapse. The Leukogen-biochip was certified by a 
national regulatory agency, the Ministry of Public Health of the Russian Federation, for 
clinical application (Registration Certificate of Federal Service for Supervision in Public 
Health Sphere No. FS 012b2006/4756-06). 
2.3 Analysis of gene mutations using biochip 
Gene mutation analysis using gel-based biochips included following steps: DNA isolation 
from biological sample, two-round multiplex PCR of gene fragments containing the 
mutations analyzed, labeling of PCR products with Cy-5-dUTP during an asymmetric PCR 
of the second round, hybridization  on biochip, registration of fluorescent signals and image 
analysis of hybridization patterns. The hybridization with allele-specific probes allows 
distinguishing between wild-type and mutant alleles with high fidelity (Nasedkina et al., 
2006). Mutations in NPM1 gene are considered as genetic markers defining patient’s 
subgroups with different clinical characteristics. The genetic lesions in NPM1 gene are 
mostly presented by tetra nucleotide insertions in exon 12.  A biochip has been developed 
for the analysis of about 20 different insertion types in NPM1 gene. The biochip for the 
analysis of NPM1 gene mutations and hybridization patterns is presented in Fig. 3.  
A clinical screening was performed to identify the NPM1 mutations in 188 de novo 
diagnosed pediatric AML cases previously investigated for the presence of aberrations with 
Leukogen-biochip. The NPM1 mutations appeared only in patients without chromosomal 
aberrations and this association with normal karyotype was statistically significant (p<0.05). 
Frequency of mutations was 4.8% (9/186) of total AML patients group and 8.0% (9/112) of 
patients without aberrations. The mutations in NPM1 gene were represented by 4 b.p. 
insertions: TCTG (type A), CATG (type B), CCTG (type D), TCGG (type Qm). The 
nomenclature of mutation types is given as described previously (Rau & Brown, 2009). All 
patients with mutations were heterozygote carrying one mutant and one wild-type alleles. 
In adults, the mutations in NPM1 gene are considered most frequent events in AML, 
especially in AML with normal karyotype. The mutation frequency is ranged between 12%-
18% (Falini et al., 2005; Thiede et al., 2006; Rau & Brown, 2009).  In childhood AML it seems 
to be relatively rare occurring in 2-7% of all cases (Brown et al., 2007; Cazzaniga et al., 2005;  
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Fig. 3. Analysis of the mutations in NPM1 gene. A - scheme of biochip, B – hybridization 
pattern for patient homozygous for  wild-type NPM1 allele; C – hybridization pattern for 
patient carrying mutation type B, wild-type allele is also presented (WT – wildtype, A-Qm – 
mutation types). 
Renneville et al., 2008). In our study the NPM1 mutations were found in 4.8% of all patients 
and in 8.0% of patients without chromosomal aberrations, thus the data corresponded to 
those previously described.  As far as NPM1 mutations occur only in patients with normal 
karyotype it is possible to use them as potential diagnostic markers for MRD monitoring.  
The high diversity and complex nature of the NPM1 mutations make difficult the analysis 
using PCR methods, more often direct sequencing is applied. In this case the biochip-based 
hybridization analysis may be a method of choice allowing detection of a wide spectrum of 
NPM1 insertions. The usefulness of biochip-based approach becomes apparent in analysis of 
many mutations in different genes simultaneously. Further development of NPM1-biochip 
is suggested to include most important mutations in FLT3 and c-KIT genes. The parallel 
usage of two kinds of diagnostic biochips, one for translocations and another for mutations 
may significantly improve molecular diagnostics of leukemia.  
2.4 Pharmacogenetic testing and personalized treatment 
Germline polymorphisms in genes, which hypothetically can mediate differential responses 
to drugs in leukemic patients, are perspective targets for investigation. Such genes are 
involved in drug absorption and excretion, metabolism, cellular transport and the drug 
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AML the portion of patients carrying specific translocations was 36,4% of all cases. The most 
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contamination by amplified DNA fragments; the problem can be overcome by more 
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with control samples carrying translocations. The results of the biochip analysis were also 
compared with clinical data and a morphologically determined leukemia variant. The 
patients carrying translocations were further monitored for minimal residual disease to 
follow efficacy of therapy and to predict a relapse. The Leukogen-biochip was certified by a 
national regulatory agency, the Ministry of Public Health of the Russian Federation, for 
clinical application (Registration Certificate of Federal Service for Supervision in Public 
Health Sphere No. FS 012b2006/4756-06). 
2.3 Analysis of gene mutations using biochip 
Gene mutation analysis using gel-based biochips included following steps: DNA isolation 
from biological sample, two-round multiplex PCR of gene fragments containing the 
mutations analyzed, labeling of PCR products with Cy-5-dUTP during an asymmetric PCR 
of the second round, hybridization  on biochip, registration of fluorescent signals and image 
analysis of hybridization patterns. The hybridization with allele-specific probes allows 
distinguishing between wild-type and mutant alleles with high fidelity (Nasedkina et al., 
2006). Mutations in NPM1 gene are considered as genetic markers defining patient’s 
subgroups with different clinical characteristics. The genetic lesions in NPM1 gene are 
mostly presented by tetra nucleotide insertions in exon 12.  A biochip has been developed 
for the analysis of about 20 different insertion types in NPM1 gene. The biochip for the 
analysis of NPM1 gene mutations and hybridization patterns is presented in Fig. 3.  
A clinical screening was performed to identify the NPM1 mutations in 188 de novo 
diagnosed pediatric AML cases previously investigated for the presence of aberrations with 
Leukogen-biochip. The NPM1 mutations appeared only in patients without chromosomal 
aberrations and this association with normal karyotype was statistically significant (p<0.05). 
Frequency of mutations was 4.8% (9/186) of total AML patients group and 8.0% (9/112) of 
patients without aberrations. The mutations in NPM1 gene were represented by 4 b.p. 
insertions: TCTG (type A), CATG (type B), CCTG (type D), TCGG (type Qm). The 
nomenclature of mutation types is given as described previously (Rau & Brown, 2009). All 
patients with mutations were heterozygote carrying one mutant and one wild-type alleles. 
In adults, the mutations in NPM1 gene are considered most frequent events in AML, 
especially in AML with normal karyotype. The mutation frequency is ranged between 12%-
18% (Falini et al., 2005; Thiede et al., 2006; Rau & Brown, 2009).  In childhood AML it seems 
to be relatively rare occurring in 2-7% of all cases (Brown et al., 2007; Cazzaniga et al., 2005;  
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Fig. 3. Analysis of the mutations in NPM1 gene. A - scheme of biochip, B – hybridization 
pattern for patient homozygous for  wild-type NPM1 allele; C – hybridization pattern for 
patient carrying mutation type B, wild-type allele is also presented (WT – wildtype, A-Qm – 
mutation types). 
Renneville et al., 2008). In our study the NPM1 mutations were found in 4.8% of all patients 
and in 8.0% of patients without chromosomal aberrations, thus the data corresponded to 
those previously described.  As far as NPM1 mutations occur only in patients with normal 
karyotype it is possible to use them as potential diagnostic markers for MRD monitoring.  
The high diversity and complex nature of the NPM1 mutations make difficult the analysis 
using PCR methods, more often direct sequencing is applied. In this case the biochip-based 
hybridization analysis may be a method of choice allowing detection of a wide spectrum of 
NPM1 insertions. The usefulness of biochip-based approach becomes apparent in analysis of 
many mutations in different genes simultaneously. Further development of NPM1-biochip 
is suggested to include most important mutations in FLT3 and c-KIT genes. The parallel 
usage of two kinds of diagnostic biochips, one for translocations and another for mutations 
may significantly improve molecular diagnostics of leukemia.  
2.4 Pharmacogenetic testing and personalized treatment 
Germline polymorphisms in genes, which hypothetically can mediate differential responses 
to drugs in leukemic patients, are perspective targets for investigation. Such genes are 
involved in drug absorption and excretion, metabolism, cellular transport and the drug 
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targets and pathways of standard chemotherapeutics. Polymorphisms in these genes can 
potentially lead to higher or lower levels of chemotherapeutic drug response and 
consequently might affect toxicity or efficacy. Numerous studies have investigated an 
association of polymorphisms in different genes coding drug-metabolizing enzymes with 
patient responses to chemotherapy. The cytochrome P450 enzymes are involved in the 
Phase I metabolism of many antileukemic agents including cyclophosphamide, etoposide, 
doxorubicin and vincristine, and might influence on ALL therapy outcomes (Fleury et al., 
2004; Rocha et al., 2005).  A number of Phase II metabolism enzymes are involved in 
inactivation of antileukemic agents. Through glutathione conjugation, glutathione S-
transferases (GSTs) generally inactivate glucocorticoids, vincristine, anthracyclines, 
cyclophosphamide and epipodophyllotoxins. Polymorphisms in various GST genes (GSTT1, 
GSTM1, GSTP1) have been extensively studied in prognosis of childhood ALL (Anderer et 
al., 2000; Davies et al., 2002; Kishi et al., 2004; Stanulla et al., 2000). 
2.4.1 Biochip for the analysis of drug-metabolizing genes  
To investigate association between polymorphisms in drug-metabolizing genes and 
response to therapy and clinical outcome a Pharmagen-biochip has been designed. The 
following targets were included into assay:  genes CYP1A1, CYP2D6, CYP2C9, CYP2C19, 
coding cytochromes, enzymes of Phase I of biotransformation; genes GSTT1 and GSTM1, 
coding glutathione S-transferases (GST), gene NAT2, coding N-arylamine acetyl transferase, 
gene TPMT, coding thiopurine-S-methyl transferase, which products are involved in 
different Phase II reactions; and also MTHFR gene, which product participates in folate 
metabolism. An example of sample analysis using Pharmagen-biochip is given on Fig. 4.  
Finally, the Pharmagen-biochip allows analyzing 16 SNP’s and 2 deletions in 10 genes 
CYP1A1 (4887С>А, 4889A>G, 6235T>C), CYP2D6 (1934G>A, 2637delA), NAT2 (481С>Т, 
590G>A, 857G>A), MTHFR (677C>T), CYP2C9 (430С>T, 1075C>T), CYP2C19 (681G>A), , 
TPMT (238G>C, 460G>A, 719 A>G), GSTT1 (deletion) and GSTM1 (deletion).  Accuracy of 
the analysis was found to be no less than 98% in experiments with control samples of known 
genotype. The Pharmagen-biochip was approved by the Ministry of Public Health of the 
Russian Federation for clinical testing of drug-metabolizing enzyme polymorphisms 
(Registration Certificate No. FS 012b2006/5317-06).  
2.4.2 Polymorphism of thiopurine-S-methyltransferase 6-MP toxicity 
One of the well known antileukemic drugs is 6-mercaptopurine (6-MP), which is used for 
supportive therapy in ALL. Within the cell thiopurines are metabolized into active 
thioguanine nucleotides (TGNs) which incorporate into DNA or RNA and result in cell cycle 
arrest and apoptosis. Like other thiopurine drugs, 6-MP is metabolized mainly by a highly 
polymorphic enzyme thiopurine-S-methyltransferase (TPMT) (Evans & McLeod, 2003). The 
relationship between TPMT polymorphisms and thiopurines efficacy and toxicity in 
children with ALL is a paradigm of the clinical application of pharmacogenetics (Evans & 
McLeod, 2003; Stanulla et al., 2005; Relling et al., 1999). The TPMT activity is inherited in an 
autosomal dominant manner and demonstrates genetic polymorphism: about 91% of people 
have polymorphic variants with high activity, an intermediate TPMT activity occurs in 
about 9% of the population and 0.3% have low or undetectable TPMT enzyme activity 
(Yates et al., 1997). The wild-type allele, TPMT*1, encodes an active TPMT enzyme. While 
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Fig. 4. Image analysis of hybridization pattern. For correct genotype assignment the average 
signals from two upper and two lower drops in each column are divided on the strongest 
signal and normalized signals are compared (see diagram on the right). Two threshold lines 
are used to distinguish between homozygotes and heterozygotes. For homozygotes one 
signal from wild-type or mutant allele is maximal and another should not exceed the lower 
threshold. The discrimination between positive and negative signals is more than 5 fold. For 
heterozygotes both signals from wild-type and mutant alleles should not descend below the 
upper threshold.  
many variant alleles of TPMT have been identified, three account for more than 95% of 
inherited TPMT deficiency: TPMT*2 (238G>C), TPMT*3A (460G>A, 719A>G) and TPMT*3C 
(719A>G) (Krynetski & Evans, 2003). It was demonstrated that specific TPMT variants have 
low activity due to aggregation of variant proteins, providing a structural explanation for 
the observed differences in TPMT activity (Wang et al., 2005). The patients with very low or 
undetectable TPMT activity are at high risk of severe, potentially fatal hematopoietic toxicity 
when they are treated with standard doses of thiopurines (Evans et al., 1991).  At the same 
time they also have relatively lower levels of residual leukemic blasts and may be at lower 
risk of relapse (Lennard et al., 1990). The TPMT heterozygotes display a phenotype 
intermediate between the two homozygous states (Evans et al., 2001). Because of these data, 
the prospective testing of TPMT gene status in ALL patients is recommended to allow 
preventive dosage reductions in those with low enzyme activity to minimize the treatment 
toxicity. In some trials patients heterozygous for TPMT-deficient alleles received reduced 
6MP dose, but the risk of relapse is not higher than for those with wild type TPMT, who 
were treated with full dose (Relling et al., 2006; Evans et al., 1998).   
The most frequent TPMT gene mutations leading to enzyme deficiency in Russian 
population were analyzed using biochips (Nasedkina et al., 2006). The genotyping of 
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targets and pathways of standard chemotherapeutics. Polymorphisms in these genes can 
potentially lead to higher or lower levels of chemotherapeutic drug response and 
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patient responses to chemotherapy. The cytochrome P450 enzymes are involved in the 
Phase I metabolism of many antileukemic agents including cyclophosphamide, etoposide, 
doxorubicin and vincristine, and might influence on ALL therapy outcomes (Fleury et al., 
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transferases (GSTs) generally inactivate glucocorticoids, vincristine, anthracyclines, 
cyclophosphamide and epipodophyllotoxins. Polymorphisms in various GST genes (GSTT1, 
GSTM1, GSTP1) have been extensively studied in prognosis of childhood ALL (Anderer et 
al., 2000; Davies et al., 2002; Kishi et al., 2004; Stanulla et al., 2000). 
2.4.1 Biochip for the analysis of drug-metabolizing genes  
To investigate association between polymorphisms in drug-metabolizing genes and 
response to therapy and clinical outcome a Pharmagen-biochip has been designed. The 
following targets were included into assay:  genes CYP1A1, CYP2D6, CYP2C9, CYP2C19, 
coding cytochromes, enzymes of Phase I of biotransformation; genes GSTT1 and GSTM1, 
coding glutathione S-transferases (GST), gene NAT2, coding N-arylamine acetyl transferase, 
gene TPMT, coding thiopurine-S-methyl transferase, which products are involved in 
different Phase II reactions; and also MTHFR gene, which product participates in folate 
metabolism. An example of sample analysis using Pharmagen-biochip is given on Fig. 4.  
Finally, the Pharmagen-biochip allows analyzing 16 SNP’s and 2 deletions in 10 genes 
CYP1A1 (4887С>А, 4889A>G, 6235T>C), CYP2D6 (1934G>A, 2637delA), NAT2 (481С>Т, 
590G>A, 857G>A), MTHFR (677C>T), CYP2C9 (430С>T, 1075C>T), CYP2C19 (681G>A), , 
TPMT (238G>C, 460G>A, 719 A>G), GSTT1 (deletion) and GSTM1 (deletion).  Accuracy of 
the analysis was found to be no less than 98% in experiments with control samples of known 
genotype. The Pharmagen-biochip was approved by the Ministry of Public Health of the 
Russian Federation for clinical testing of drug-metabolizing enzyme polymorphisms 
(Registration Certificate No. FS 012b2006/5317-06).  
2.4.2 Polymorphism of thiopurine-S-methyltransferase 6-MP toxicity 
One of the well known antileukemic drugs is 6-mercaptopurine (6-MP), which is used for 
supportive therapy in ALL. Within the cell thiopurines are metabolized into active 
thioguanine nucleotides (TGNs) which incorporate into DNA or RNA and result in cell cycle 
arrest and apoptosis. Like other thiopurine drugs, 6-MP is metabolized mainly by a highly 
polymorphic enzyme thiopurine-S-methyltransferase (TPMT) (Evans & McLeod, 2003). The 
relationship between TPMT polymorphisms and thiopurines efficacy and toxicity in 
children with ALL is a paradigm of the clinical application of pharmacogenetics (Evans & 
McLeod, 2003; Stanulla et al., 2005; Relling et al., 1999). The TPMT activity is inherited in an 
autosomal dominant manner and demonstrates genetic polymorphism: about 91% of people 
have polymorphic variants with high activity, an intermediate TPMT activity occurs in 
about 9% of the population and 0.3% have low or undetectable TPMT enzyme activity 
(Yates et al., 1997). The wild-type allele, TPMT*1, encodes an active TPMT enzyme. While 
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Fig. 4. Image analysis of hybridization pattern. For correct genotype assignment the average 
signals from two upper and two lower drops in each column are divided on the strongest 
signal and normalized signals are compared (see diagram on the right). Two threshold lines 
are used to distinguish between homozygotes and heterozygotes. For homozygotes one 
signal from wild-type or mutant allele is maximal and another should not exceed the lower 
threshold. The discrimination between positive and negative signals is more than 5 fold. For 
heterozygotes both signals from wild-type and mutant alleles should not descend below the 
upper threshold.  
many variant alleles of TPMT have been identified, three account for more than 95% of 
inherited TPMT deficiency: TPMT*2 (238G>C), TPMT*3A (460G>A, 719A>G) and TPMT*3C 
(719A>G) (Krynetski & Evans, 2003). It was demonstrated that specific TPMT variants have 
low activity due to aggregation of variant proteins, providing a structural explanation for 
the observed differences in TPMT activity (Wang et al., 2005). The patients with very low or 
undetectable TPMT activity are at high risk of severe, potentially fatal hematopoietic toxicity 
when they are treated with standard doses of thiopurines (Evans et al., 1991).  At the same 
time they also have relatively lower levels of residual leukemic blasts and may be at lower 
risk of relapse (Lennard et al., 1990). The TPMT heterozygotes display a phenotype 
intermediate between the two homozygous states (Evans et al., 2001). Because of these data, 
the prospective testing of TPMT gene status in ALL patients is recommended to allow 
preventive dosage reductions in those with low enzyme activity to minimize the treatment 
toxicity. In some trials patients heterozygous for TPMT-deficient alleles received reduced 
6MP dose, but the risk of relapse is not higher than for those with wild type TPMT, who 
were treated with full dose (Relling et al., 2006; Evans et al., 1998).   
The most frequent TPMT gene mutations leading to enzyme deficiency in Russian 
population were analyzed using biochips (Nasedkina et al., 2006). The genotyping of 
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patients included DNA isolation from peripheral blood leukocytes, multiplex PCR, 
hybridization with the biochip, and image analysis.  A total of 446 children with 
hematologic malignancies were genotyped using the TPMT-biochip (Samochatova et al., 
2009). Of 241 patients with ALL for whom molecular analysis has been performed, 18 
patients (7.5%) were heterozygous carriers of polymorphic alleles with deficient enzyme 
activity. The most frequent deficient allele was ТPМТ*3A (2.3%), while more rare alleles 
were ТPМТ*3C (0.4%) and ТPМТ*2 (0.1%); the wild-type allele TPМТ*1 accounted for 
97.2%. Thus, spectrum of TPMT deficient alleles and their frequencies in Russian children 
with leukemia was close to those in European populations and in white population of USA. 
A retrospective analysis of the 6-MP therapy intolerance stratified by TPMT genotype was 
carried out using the TPMT-biochip. Dosages were adjusted to keep the WBC count 
between 2 and 3x109/Lm, but not on the basis of TPMT genotype. Eighteen ALL patients 
heterozygous for TPMT deficient allele were characterized by decreased ability to tolerate 
the 6-MP therapy, and as a result they received significantly lower doses of this drug 
compared with patients with a homozygous wild-type genotype (average weekly dose of 6-
MP was 264 vs 312 mg/m2 respectively; p = 0,04). Also they received more erythrocyte and 
thrombocyte transfusions and had more infectious episodes. Despite all deviations from 
protocol, the results of treatment did not differ significantly between patients who did and 
did not have the TPMT gene variations.  An EFS estimate was 90% for patients with 
variations and 83% for patients with wild-type genotype at a median follow-up of 31.3 
months (p= 0,562). It may be explained by a fact that the treatment levels of intracellular 
TGN (the active metabolite of 6MP) were achieved in both cases, regardless TPMT 
genotype. Thus, TPMT genotyping can be highly recommended to those patients treated 
with 6MP, who is found to have repeated episodes of prolonged cytopenia, to adjust an 
individual drug dosage (Samochatova et al., 2009). 
2.4.3 Polymorphism of drug-metabolizing enzyme genes and risk of relapse in ALL 
Other different polymorphic enzyme variants that have decreased or increased activity can 
potentially modulate clinical response to anticancer therapy. This may lead to increased 
toxicity of the treatment, but also to the development of drug resistance or increased risk of 
relapse or secondary tumor development (Balta et al., 2003; Krajinovic et al., 2002; Rocha et 
al., 2005). The most important enzymes of phase I biotransformation enzymes, cytochromes 
of the P450 family (CYP1A1, CYP2D6, CYP2C9, and CYP2C19), which activate xenobiotics to 
yield genotoxic intermediates, and phase II enzymes, such as glutathione S-transferases 
(GSTs) and arylamine N-acetyltransferases (NATs), which convert genotoxic compounds to 
nontoxic compounds, were chosen for the analysis. 
Using Pharmagen-biochip the frequencies of the polymorphic variants of CYP1A1, CYP2D6, 
GSTT1, GSTM1, MTHFR, CYP2C9, CYP2C19, and NAT2 in 332 children with acute 
lymphoblastic leukemia (ALL) were determined. Among them, 258 patients with primary 
leukemia, having no relapse within 1 year of therapy, and 74 with relapse were included in 
the study. Our results demonstrated that some allelic variants of the drug-metabolizing 
genes were associated with a higher risk of relapse in childhood acute leukemia (Fig. 5). The 
association of polymorphic variant CYP1A1*2A with poor therapeutic prognosis has been 
shown in children with ALL (OR = 2.3, 95% CI = 1.09 – 4.8, p = 0.03) (Gra et al., 2009). Also it 
was found that the GSTT1 null genotype occurred rarely in children with relapse as 
compared with those with one or two functional alleles (OR = 0.48, 95% CI = 0.26 – 0.90, p = 
0.02), thus being protective. The presence of both risk genotypes has an additive effect: the 
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frequency of relapse was higher among carriers of the combined CYP1A1 *1/*2A and GSTT1 
non-null genotype (OR = 2.36, CI = 1.02 – 5.46, p = 0.048). 
 
 
Fig. 5. The genotype frequencies in primary leukemia and relapsed patients with pediatric 
ALL (statistically significant difference is marked by asterisk).  
The observed regularities corresponded to published data (Anderer et al., 2000; Stanulla et 
al., 2000; Voso et al., 2005). An increase in frequency of the CYP1A1 genotype *1/*2A in 
children with ALL relapse may be explained by the impact of synthetic glucocorticoids 
(such as dexametasone and prednisolone) being an important component of the ALL 
treatment protocol and induction therapy. They cause lymphopenia and involution of 
lymphoid tissue that lead to immunosuppression. The increased enzymatic activity of the 
CYP1A1 *1/*2A leads to the increased concentration of intermediate genotoxic metabolites 
and of total mutagenic activity (Voso et al., 2005). Since the formation of additional 
mutations may cause resistance of cancer cells towards therapy, it is likely that the CYP1A1 
*1/*2A genotype may decrease the efficacy of therapy and promote the development of 
relapse. GSTs are involved in metabolism of many antitumor drugs, catalyzing conjugation 
of intermediate metabolites with reduced glutathione. The ALL children carrying GSTT1 
null genotype have been observed to respond well to induction therapy with prednisone, 
while carriers of at least one functional GSTT1 allele displayed glucocorticoid resistance, a 
poor response to therapy, and a higher relapse rate (Anderer et al., 2000).  It is likely, that in 
carriers of the GSTT1 and/or GSTM1 null genotype, lack of GSTT1 and/or GSTM1 enzymes 
leads to an accumulation of cytotoxic drugs that may enhance their efficacy and longer 
relapse-free survival.  
3. Conclusion 
The modern diagnostics of leukemia is multifaceted, including clinical characterization, 
histochemistry, cell morphology, immunophenotyping and also molecular genetic analysis. 
Molecular markers, recurrent chromosome aberrations and gene mutations, allow 
subdividing leukemia patients into biological groups with unique clinical features.  The risk-
stratification of patients based on genetics of leukemia blasts contributes not only to 
classification of leukemia subtypes, but can predict prognosis and clinical outcome. The 
molecular genetic analysis provides clinicians with an important knowledge for a decision 
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making and a choice of appropriate therapy. Further progress in therapy of oncologic 
diseases is inseparable from individualization of the treatment based on the molecular 
characteristics of malignant cells and genetic features of a patient. An introduction of new 
technologies in routine clinical practice can significantly increase the power of modern 
diagnostics. Low-density gel-based biochips are a good example of such a technology.  The 
diagnostic biochips may provide easily, rapid genotyping in clinics and be a useful tool in 
large screening programs. The properties of gel-based biochips are defined by 
immobilization in 3D-volume of hydrogel: high concentration of probe due to 
immobilization capacity of gel and high level of fluorescent signal enabling usage of a 
simple detecting device, like a portable biochip analyzer. Although hybridization on 2D-
microarrays is slightly faster, gel-based biochips provide better discrimination between 
perfect and imperfect duplexes (5- to 20-fold difference). Thus, unambiguous interpretation 
of results is attained that can be crucial for clinical diagnostics. Different genetic 
abnormalities may be identified successfully with diagnostic biochips: from balanced 
translocations forming fusion genes to gene mutations or polymorphic variants. 
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1. Introduction 
Acute leukemias are clonal diseases characterized by a maturation arrest and by enhanced 
proliferation of hematopoietic precursor cells, which normally would differentiate into 
mature blood cells. The leukemic cells are released from the bone marrow into the 
peripheral blood and may accumulate in vital organs such as the spleen, liver, skin, central 
nervous system and lymph nodes. Chronic leukemias arise form hyperproliferation without 
a clear maturation arrest. In children, chronic leukemias are rare, and most cases are 
classified as acute leukemias. (Pui, et al 2011) Acute leukemias can be further subdivided in 
acute lymphoblastic leukemias (ALL, either from precursor T- or B-cells), and in acute 
myeloid leukemias (AML, either from red blood cell precursors, platelet precursors, or 
granulocytic or monocytic precursors). In children, approximately 80% of cases are ALL, 
and 15-20% AML. There is a peak in the incidence of AML in infants under one year of age, 
after which the incidence is low throughout childhood. (Creutzig, et al 2010a, Kaspers and 
Zwaan 2007) AML may even be present in newborn babies. (Bresters, et al 2002) In 
adolescents the incidence of AML starts to rise and rises further throughout adult life (1-3 
per 105 each year in childhood, rising to 15 per 105 in early adulthood to 35 per 105 at the age 
of 90 years). (Ries, et al 1999)  
AML may either arise de novo or occur following underlying diseases such as 
myelodysplastic syndrome, which is much more frequent in elderly patients with AML than 
in children. Other underlying diseases may be chromosomal-breakage syndromes such as 
Fanconi anemia. (Tonnies, et al 2003) Moreover, AML may be secondary to previous 
exposure to irradiation or to chemotherapy, including both alkylating chemotherapy and 
epipodopyllotoxins. (Sandler, et al 1997, Weiss, et al 2003) A specific type of AML arises in 
children with Down syndrome. (Zwaan, et al 2008) Exposure to environmental factors has 
also been described as a potential cause of AML. (Smith, et al 2011) Infrequently, families 
with an unexplained high risk of AML have been described which suggests that germ-line 
mutations such as RUNX1 and CEBPA may play a role in leukemogenesis. (Owen, et al 2008)  
1.1 Clinical presentation  
AML has a variable clinical presentation. The history of a child with AML is often relatively 
short and at most a few weeks. Children with AML usually present with signs of inadequate 
production of normal blood cells, such as pallor and tiredness or feeding problems due to 
anemia, spontaneous bleeding due to al low platelet count, and fever/infections due to low 
white blood cells. High white counts can give rise to hyperviscosity and sludging and hence 
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to pulmonary complaints (dyspnea) or central nervous system related symptoms (lowered 
consciousness, coma, convulsions). Bone pain due to high intra-osseous pressure often 
occurs. Extramedullary disease due to infiltration of leukemic cells has been reported in 4-10 
percent of all cases, and may either present as skin infiltrates (referred to as ‘blue-berry 
muffin’ skin lesions) or solid leukemic masses, also referred to as chloromas. Organs prone 
for accumulation of leukemic cells and subsequent organomegaly are the spleen, liver, 
gingiva and lymph nodes. Leukemia in the central nervous system may occur either as 
liquor pleiocytosis or as solid tumors in the central nervous system. A specific type of AML, 
acute promyelocytic leukemia (APL), often presents with serious life threatening bleeding 
disorders, which is due to abnormal coagulation factors, and not just to thrombocytopenia. 
(Creutzig, et al 2010c)  
2. Diagnostics 
2.1 Morphology and immunophenotyping 
The first step to diagnose leukemia is to study the morphology of the peripheral blood and 
the bone marrow aspirate using light microscopy. A classical morphological feature 
distinguishing AML from ALL are the so-called Auer rods (see Figure 1), which are mainly 
seen in leukemias derived from granulocytic precursors. However, differentiation between 
AML and ALL is nowadays usually done with flow cytometry. Typically, AML blasts are 
positive for CD13 or CD33, and negative for lymphocyte markers such as CD3/CD7 (T-cells) 
or CD19/CD20/CD2 (B-cell precursors). Myeloperoxidase (MPO) staining can be used to 
differentiate AML from ALL, although MPO-positivity is mainly confined to granuclocytic 
leukemias. Esterase staining is helpful to identify monocytic types of leukemia.  
 
 
Fig. 1. Auer rods present in the 2 AML blasts visible in a peripheral blood smear. 
The morphological classification of AML is referred to as the French-American-British or 
FAB-classification (see table 1), and is based on the cell-line of origin. (Bennett, et al 1985a, 
Bennett, et al 1985b, Bennett, et al 1991)  Certain morphological subtypes need confirmation 
with flowcytometry, such as minimally differentiated AML (FAB M0) and acute 
megakaryoblastic leukemia (FAB M7). (Bennett, et al 1985a, Bennett, et al 1991) 
Morphological assessment should also focus on the occurrence of myelodysplasia, and 
differentiation between AML and advanced myelodysplastic syndromes (MDS) may be 
difficult. In adults, a blast threshold of 20% is used to differentiate between these 2 diseases, 
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but in children we still use the 30% cut-off. (Hasle, et al 2003) Other characteristics may also 
be helpful: AML-specific translocations, organomegaly, rapid progression and CNS-
localization are indicative or AML rather than MDS.  
 
FAB type Name Relationship with specific 
cytogenetic abnormalities 
M0 minimally differentiated acute 
myeloblastic leukemia 
 
M1 acute myeloblastic leukemia, without 
maturation 
 
M2 acute myeloblastic leukemia, with 
granulocytic maturation 
t(8;21)(q22;q22), t(6;9)(p23;q34) 
M3 promyelocytic, or acute promyelocytic 
leukemia (APL) 
t(15;17)(q22;q12) 
M4 acute myelomonocytic leukemia  




M5 acute monoblastic leukemia  MLL-gene rearrangements 
M6 acute erythroid leukemias  
M7 acute megakaryoblastic leukemia t(1;22)(p13;q13) 
Table 1. FAB-classification of AML, and relationship between FAB-types and specific 
cytogenetic abnormalities. (Bennett, et al 1985a, Bennett, et al 1985b, Bennett, et al 1991). 
MLL=mixed-lineage leukemia 
2.2 Cytogenetics and molecular genetic screening 
AML is a genetically very heterogeneous disease. Genetic aberrations in AML can be 
subdivided in type 1 and type 2 aberrations, based on the Gilliland hypothesis that at least two 
different collaborative types of abnormalities are needed in the pathogenesis of AML. Kelly, 
L.M. & Gilliland, D.G. (2002a) Genetics of myeloid leukemias. Annu.Rev.Genomics Hum.Genet., 
3, 179-198. Type 1 abnormalities mainly induce proliferation, and consist for instance of 
mutations in tyrosine kinase receptors such as the FLT3-gene(Zwaan, et al 2003a) or KIT-
mutations(Goemans, et al 2005, Pollard, et al 2010), and type 2 abnormalities induce maturation 
arrest and mainly result from genetic aberrations in hematopoietic transcription factors, either 
resulting from translocations, or from mutations in genes such as NPM1, GATA1 and CEBPA. 
(Ahmed, et al 2004, Hollink, et al 2011, Hollink, et al 2009c) Evidence for this model is 
supported by several factors: 1) AML-specific translocations can already be demonstrated in 
cord-blood (Wiemels, et al 2002), and may only cause AML several years later, 2) fusion 
transcripts may be demonstrated using sensitive techniques in patients in long-term clinical 
remission of AML (Leroy, et al 2005), 3) FLT3 mutations induce a myeloproliferative disorder 
in mice but lack the maturation arrest typical of full-blown AML (Kelly, et al 2002b), and 4) 
certain type I and II genetic aberrations cluster together in a non-random fashion.  
Conventional karyotyping may identify AML-specific abnormalities, which are not only 
of use in diagnosis and the correct classification of the leukemia, but may also provide 
prognostic information used for risk-group stratification of pediatric AML. (Harrison, et al 
2010, von Neuhoff, et al 2010) One of the recurrent aberrations in pediatric AML is the 
group of ‘core binding factor (CBF)’ leukemias, including t(8;21)(q22;q22) and 
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Major categories Subdivided in the following categories: 
Acute myeloid leukemia with recurrent 
genetic abnormalities 
 
 t(8;21)(q22;q22); RUNX1-RUNX1T1 





 inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-
EVI1 
 t(1;22)(p13;q13); RBM15-MKL1
 Provisional entity: AML with mutated NPM1 
 Provisional entity: AML with mutated CEBPA 
Acute myeloid leukemia with 
myelodysplasia-related changes 
 
Therapy-related myeloid neoplasms  
Acute myeloid leukemia, not otherwise 
specified 
 
 AML with minimal differentiation 
 AML without maturation
 AML with maturation
 Acute myelomonocytic leukemia 
 Acute monoblastic/monocytic leukemia 
 Acute erythroid leukemia
 Pure erythroid leukemia
 Erythroleukemia, erythroid/myeloid 
 Acute megakaryoblastic leukemia 
 Acute basophilic leukemia
 Acute panmyelosis with myelofibrosis 
Myeloid sarcoma  
Myeloid proliferations related to Down 
syndrome 
 
Table 2. The new WHO-classification of AML (Vardiman, et al 2009) 
inv16/t(16;16)(p13/p13;q22), which are considered as good-risk abnormalities by most 
collaborative groups. (Creutzig, et al 1993a, Grimwade, et al 1998) CBF-AML is present in 
approximately 20-25% of pediatric AML cases, which is a higher frequency than found in 
adults.  Rearrangements of the Mixed Lineage Leukemia (MLL)-gene, localized at chromosome 
11q23, are associated with >50 different fusion partners, and are considered as intermediate 
or poor risk. MLL-gene rearrangements are usually screened for with fluorescent in-situ 
hybridization (FISH), which does not identify the translocation partner. However, prognosis 
may depend on the translocation partner, and therefore certain translocation partners need 
to be specifically searched for with reverse-transcriptase polymerase chain reaction (RT-
PCR), such as the t(1;11)(q21;q23), t(6;11)(q27;q23) and t(10;11)(p12;p23). (Balgobind, et al 
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2009) Other abnormalities involve deletion of chromosome 7q or monosomy 7, which are 
generally considered as poor risk abnormalities. (Hasle, et al 2007) Some abnormalities are 
only found in pediatric AML, such as t(7;12)(q36;p13) and t(1;22)(p13;q13), which both occur 
in infants with AML. (Bernard, et al 2009, von Bergh, et al 2006) On the other hand, certain 
abnormalities such as inv(3)(q21q26.2), which is associated with poor clinical outcome, are 
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Fig. 2. Genetic abnormalities in pediatric AML, subdivided as type 1 and type 2 
abnormalities. WT1 mutations were included in this graph as type I aberrations, please see 
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In the revised WHO-2008 classification of myeloid neoplasms (Table 2), the category of 
AML with recurrent genetic abnormalities was further expanded and NPM1 and CEBPA 
mutated AML were added as provisional categories. (Vardiman, et al 2009) 
Apart from cytogenetic aberrations, AML is characterized by various gene mutations. Some 
of these mutations cluster in cytogenetically-normal AML, which is found in 20-25% of 
pediatric AML cases, which is a lower frequency than in adults, where approximately 50% 
of cases do not have cytogenetic abnormalities. (Balgobind, et al 2011a, Marcucci, et al 2011) 
NPM1 and CEBPA gene mutations confer good clinical outcome, whereas mutations in the 
FLT3 and WT1-genes confer poor clinical outcome. (Ho, et al 2009, Ho, et al 2010b, Hollink, 
et al 2011, Hollink, et al 2009a, Hollink, et al 2009c, Meshinchi, et al 2006, Zwaan, et al 2003a) 
Figure 2 shows the distribution of type 1 and 2 abnormalities, as identified in >400 cases of 
pediatric AML. We have arbitrarily included the WT1 mutations as type I aberrations, 
however, their role in AML still has to be elucidated. (Hollink, et al 2009a, Yang, et al 2007) 
Moreover, they are not mutually exclusive with some other typical type I aberrations, as 
shown in the graph.  
2.3 Gene expression profiling as a diagnostic tool 
Recently, in pediatric AML, several gene expression profiling studies have been performed 
with the aim to study their diagnostic potential, and whether they could replace the current 
diagnostics mentioned above. In a seminal study of 130 de novo pediatric AML patients, Ross 
and colleagues discriminated successfully between acute lymphoblastic leukemia (ALL) and 
AML by gene expression signatures. (Ross, et al 2004) Likewise, the major prognostic AML 
subclasses, i.e. t(15;17), t(8;21), inv(16), and t(11q23)/MLL, as well as cases classified as acute 
megakaryoblastic leukemia were correctly predicted with an overall classification accuracy 
greater than 93% using supervised learning algorithms. (Ross, et al 2004) This was confirmed 
by Balgobind et al. in an independent study of 237 children with pediatric AML (specificity 
and sensitivity for discovery of the indicated cytogenetic subclasses was 92% and 99%, 
respectively). (Balgobind, et al 2011b) However, in the latter study no general predictive 
gene expression signatures were found for the molecular genetic aberrations NPM1, CEBPA, 
FLT3-ITD, or KIT. This may have been caused either by a low frequency of certain 
mutations, but also by underlying cytogenetics or cell line of origin. For instance, distinct 
gene expression signatures were discovered for FLT3-ITD in patients with normal 
cytogenetics and in those with t(15;17)(q21;q22)-positive AML. (Balgobind, et al 2011b) 
Therefore, the value of gene expression profiling for use in routine diagnostics is limited to 
the 40% of cases with clearly discriminative profiles. 
3. Current treatment of pediatric AML 
3.1 Chemotherapy 
Chemotherapy treatment for pediatric AML can be subdivided in several treatment phases: 
a) induction chemotherapy – which typically consists of 2 courses of intensive 
chemotherapy; b) consolidation chemotherapy, which may again consist of 2 or 3 courses of 
chemotherapy; and c) maintenance therapy, which is currently only applied by some 
groups; and d) hematopoietic stem cell transplantation, which is subject to debate, and is 
discussed in more detail in paragraph 5.2. Almost all modern protocols include risk-group 
stratification based on a combination of cytogenetics (defining a good-risk group consisting 
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of CBF-AML and acute promyelocytic leukemia or FAB M3) and early response to therapy 
(either day 15 bone marrow results, or CR after course 1, or minimal-residual disease status 
after course 1, which is discussed further in paragraph 6 below). 
The former protocols of the Children’s Cancer Group (CCG-2891) were based on ’timed 
sequential induction chemotherapy’, which involved a 4-day cycle of five different 
chemotherapeutic agents, with the second cycle administered either 10 days after the first 
cycle, despite low or dropping blood counts (intensive timing), or 14 days or later from the 
beginning of the first cycle, depending on bone marrow status (standard timing). (Woods, et 
al 1996) This concept, however, was inferior to results obtained with other regimens in that 
era from the MRC and BFM-AML groups(Gibson, et al 2005, Stevens, et al 1998), and hence 
this was abandoned. One explanation for the differences in outcome between the CCG 2891 
study and the MRC and BFM protocols may have been differences in ethnicity between the 
populations enrolled on these studies, as Hispanic and black children have poorer outcome 
compared to white children on CCG 2891, and are over represented in the CCG compared to 
the Northern-European protocols. (Aplenc, et al 2006)  
Most protocols nowadays use a typical ‘3+10 day induction course’ (3 days of anthracyclines 
+ 10 days of cytarabine ± a third drug) followed by a second ‘3+7 or 3+8 course’ (3 days of 
anthracyclines plus 7 or 8 days of cytarabine ± a third drug). The NOPHO group uses a 
different format which resembles the aforementioned CCG-approach, but is response based. 
(Abrahamsson, et al 2011) The first induction course in their protocols lasts 6 days and 
contains only 4 days of cytarabine. The timing of the 2nd course then depends on the bone 
marrow response at day 15. All patients with <5% blast are allowed hematological recovery, 
all others start with the 2nd course at day 15. The total CR rate was 92% after 2 courses, 
which is very similar to the CR rates with MRC or BFM approaches. (Creutzig, et al 2010b, 
Gibson, et al 2005) Most protocols nowadays consist of a total of 4-5 courses of intensive 
chemotherapy, although the optimal number of cycles has not been established. (Creutzig, et 
al 2005b, Gibson, et al 2005, Kaspers and Creutzig 2005, Kaspers and Zwaan 2007) In 
protocol MRC AML 12 this question was addressed (see Table 4). Maintenance therapy in 
AML is subject to debate, but there are several studies showing that if any effect it leads to 
worse retrieval at relapse, and is therefore probably not índicated. (Perel, et al 2002, Wells, et 
al 1994) 
Chemotherapy for AML is intensive and consists of a cytarabine/anthracycline backbone to 
which other drugs may be added, for instance epipodophyllotoxins (i.e. etoposide) or anti-
metabolites (i.e. 6-thioguanine). In some protocols asparaginase is applied, which seems 
mainly effective against monoblastic leukemias (Zwaan, et al 2002a), and is usually given in 
combination with cytarabine (also referred to as the Capizzi regimen). (Capizzi, et al 1988, 
Zwaan, et al 2002b) Some protocols use 2-chlorodeoxyadenosine as nucleoside analog instead 
of cytarabine. Other protocols aim at potentiating cytarabine by combining it with fludarabine 
(often combined with GCSF and then referred to as a FLAG course) or 2-
chlorodeoxyadenosine, which leads to increased Ara-CTP levels (the active metabolite). 
(Burnett, et al 2011, Creutzig, et al 2010b, Rubnitz, et al 2009) In more recent studies 
gemtuzumab ozogamicin has been evaluated together with standard chemotherapy in 
induction and consolidation, but results for children have not been reported as yet. (Burnett, et 
al 2011) In older protocols, steroids were sometimes included, but steroids may (at least in-
vitro) induce proliferation of AML cells, and hence are no longer applied. (Zwaan, et al 2002b)  
Prevention of CNS-relapse is mainly based on intrathecal chemotherapy, which is given on 
top of intensive IV cytarabine courses. There is no evidence that low numbers of blasts in the 
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p=0.3 
6-TG 48% vs 
Etoposide 
45%, p=0.3 




et al 2005) 
CR=complete remission, EFS=event free survival, OS=overall survival, Ref=reference, 
DNR=daunorubicn, Ida=idarubicin, Mitox=mitoxantrone, 6-TG=6-thioguanine, NA=not available, 
BMA=bone-marrow aspirate, MRD=minimal residual disease. 
Table 3. Randomized induction questions in pediatric AML studies. 
cerebrospinal fluid (CNS-2 status) are clinically relevant in AML, and hence additional 
intrathecal therapy is not needed in case of CNS-2. (Abbott, et al 2003) Most groups do not 
apply prophylactic CNS-irradiation in pediatric AML patients, apart from the BFM-group. 
In their AML-BFM 87 study, which was initially set-up as a randomized study but failed 
due to non-compliance with this randomization, it was found that irradiated patients had 
fewer bone marrow relapses, and hence prophylactic irradiation was continued. (Creutzig, 
et al 1993b) Patients with clear CNS-involvement (CNS-3) are given irradiation in most 
treatment protocols, although this may be replaced by frequent intrathecal injections in 
younger children, with the aim to avoid late effects or cranial irradiation on neurocognitive 
development.  
Several randomized studies have been performed addressing either induction or 
consolidation chemotherapy questions over the past few years. Table 3 summarizes the 
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induction randomizations that were performed. As can be seen most randomizations were 
negative, although it remains difficult to interpret the results for the anthracyclines, as it is 
not known whether the randomized dosages are in fact dose-equivalent. Considering 
consolidation, the randomized questions are summarized in Table 4, and again most of 
these do not provide statistically significant results.  
 








2-CDA 51% vs. no 2-
CDA 51%, p=0.98 
2-CDA: 75% vs. 









6-week consolidation vs. 2 
short cycles 
6-week 51% vs 2 
cycles 50%, p=0.66 
 (Creutzig, 





Early HAM course in 
consolidation versus late 
Early: 49% vs. Late 
41% (p=non-
significant) 









Ciclosporin A (CsA) 
added to consolidation 
chemotherapy  
DFS: CsA 40.6% vs. 
no CsA 33.9%, p=0.24 






4 versus 5 courses 
(MIDAC vs. MIDAC plus 
CLASP) 
NA 4 courses 81% 
vs. 
5 courses 78%, 
p=0.5 
(Gibson, 
et al 2005) 
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Table 4. Chemotherapy-based consolidation randomizations in pediatric AML (excluding 
stem-cell transplant related questions). 
3.2 Stem-cell transplantation 
The principle of stem-cell transplantation is to eradicate minimal residual disease using 
high-dose chemotherapy and/or total body irradiation. (Bleakley, et al 2002, Niewerth, et al 
2010) Allogeneic SCT also has an immunological effect, as the graft may induce a ‘graft-
versus-leukemia effect (GVL)’, and hence may be able to prevent leukemia relapse. 
Autologous SCT has also been used in pediatric AML, but there is basically no evidence that 
this is superior to intensive chemotherapy consolidation. (Aplenc, et al 2006, Pession, et al 
2005) Two reviews have addressed the issue of allo-SCT versus chemotherapy in pediatric 
AML, and both conclude that although allo-SCT reduces relapse risk this is counterbalanced 
by increased procedure-related mortality and by poorer retrieval at relapse. (Bleakley, et al 
2002, Niewerth, et al 2010) Hence, in most studies overall survival does not improve. It 
should also be emphasized that ‘older’ studies may show more benefit from SCT than more 
recent studies, given that the beneficial effect of SCT is likely to be greater with less 
intensive induction chemotherapy. (Creutzig and Reinhardt 2002, Woods, et al 2001) In most 
current protocols SCT in 1st complete remission is therefore only recommended for selected 
high-risk cases, although there is little evidence that this in fact improves outcome in these 
cases. (Creutzig and Reinhardt 2002, Reinhardt, et al 2006) In first relapse, most patients are 
transplanted after achieving a 2nd CR. (Kaspers, et al 2009) There is limited evidence that 
pre-emptive therapy post-SCT may be effective in reducing the frequency of overt relapse. 
(Bader, et al 2004)  
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3.3 Supportive care 
The current intensity of pediatric AML treatment is only possible with rigorous supportive 
care, including (but not limited to) blood transfusions, antibiotic and antifungal prophylaxis, 
viral surveillance, early diagnostics of fungal infections with high-resolution CT-scans, 
prevention of nephropathy using rasburicase in hyperleucocytosis, GCSF use in life-
threatening infections, tube feeding and total parenteral nutrition. (Goldman, et al 2001, 
Inaba, et al 2011, Lehrnbecher, et al 2009, Lehrnbecher, et al 2004, van de Wetering, et al 2005) 
In fact, a substantial part of the progress in pediatric AML over the last decades is due to 
improvements in supportive care. Despite this progress, a a significant number of patients 
still do not survive as a result of early death or due to treatment related mortality, as 
summarized in Table 5. Therefore, further intensification of AML studies is currently not 
considered feasible. This was also demonstrated in a French study from the LAME group, 
who tried to further intensify induction therapy by a timed-sequential approach, but this 
pilot was stopped given the time needed for hematological recovery until consolidation, 
which was median 98 days in the timed-sequential approach versus 76 days using their 
regular 2 induction courses. (Perel, et al 2005) 
 
 Early death Treatment related 
mortality 
Cumulative 
incidence of death 
References 
DCOG 83, 87 and 
92/94 studies 
13.1% 4.4% NA (Slats, et al 
2005) 
BFM 93- and 98 
studies 
3.5% 8% NA (Creutzig, et 
al 2004) 
St Jude NA NA 7.6% (Rubnitz, et 
al 2004) 
NOPHO 84, 88 and 
93 studies 
3% 10% NA (Molgaard-
Hansen, et al 
2010b) 
NA=not available 
Table 5. Summary of early death and treatment related deaths in pediatric AML studies. 
4. Outcome of pediatric AML 
4.1 Newly diagnosed pediatric AML 
The outcome of newly diagnosed pediatric AML has increased significantly over the past 
decades. Contemporary studies show survival rates in the range of at least 65-75%, as 
detailed in Table 6. 
4.2 Relapsed AML 
The cumulative incidence of relapse is around 30% with modern intensive chemotherapy 
protocols used in newly diagnosed disease. (Creutzig, et al 2005b, Gibson, et al 2005, Sander, 
et al 2010) Relapsed AML is usually treated with similar chemotherapy as given upfront, 
hence intensive cytarabine/anthracyline based chemotherapy. Following a second remission 
induction patients are usually transplanted. A summary of studies in relapsed pediatric 
AML is provided in table 7. As can be seen, outcome is poor, and the largest and most recent 
study of the International BFM-Study Group reported 35% overall survival. (Kaspers, et al 
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2009) Outcome for patients with late relapse and/or good risk cytogenetics is better, as well 
as for patients who have not been transplanted in CR1 and for those achieving CR2 with re-
induction chemotherapy. (Sander, et al 2010, Webb 1999) Patients with refractory first 
relapse or with second relapse are considered candidates for experimental therapy. (Zwaan, 
et al 2010b)  
 
 
Study Group Years No of 
patients 
EFS (5yrs) OS (5yrs) References 
LAME 91 1991-1998 262 47% 61% (Perel, et al 2005) 
AIEOP LAM 92 1992-2001 160 54% 60% (Pession, et al 2005) 
GATLA AML 90 1993-2000 179 31% 41% (Armendariz, et al 
2005) 
EORTC 58921 1993-2000 177 49% 62% (Entz-Werle, et al 
2005) 
MRC AML 12 1994-2002 455 56% 66% (Gibson, et al 2005) 




(Becton, et al 2006) 
AML PPLLSG 98 1998-2002 147 47% 50% (Dluzniewska, et al 
2005) 
BMF 98 1998-2003 473 49% 62% (Creutzig, et al 2006) 
AML 99 Japan 2000-2002 240 62% 76% (Tsukimoto, et al 2009) 
SJCRH AML  2002-2008 230 63% 71% (Rubnitz, et al 2010) 




(Abrahamsson, et al 
2011) 
AML-BFM 2004 2004-2010 566 54% 72% (Creutzig, et al 2010b) 
Table 6. Overall outcome data for pediatric AML studies started from 1990 onwards. 
 
 
Study Group Years No of 
patients 
DFS (5yrs) EFS (5yrs) OS(5yrs) Ref 
TACL 
institutions 
1995-2004 99 43% 24% 29% (Gorman, et al 
2010) 
LAME group Relapse 
following 
LAME 89/91 
106 45% NA 33% (Aladjidi, et al 
2003) 
MRC group Relapse 
following 
MRC AML-10 
125 44% NA 24%  
(3 yrs) 





93 and 98 
379 NA NA 23% (Sander, et al 
2010) 
I-BFM 2002-2009 360 NA NA 35%  
(3-year OS) 
(Kaspers, et al 
2009) 
Table 7. Studies in relapsed pediatric AML. 
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as for patients who have not been transplanted in CR1 and for those achieving CR2 with re-
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4.3 Late effects of treatment 
The major long-term toxicity in AML patients treated without stem cell transplantation is 
long-term cardiac toxicity. (Creutzig, et al 2007, Temming, et al 2011)  This is associated with 
higher cumulative dosages of anthracyclines. (Nysom, et al 1998) The use of liposomal 
formulations may be an option to reduce cardiac toxicity, as discussed below in paragraph 
7.2. Stem cell transplantation is associated with many late effects, mainly depending on the 
type of conditioning regimen (type of chemotherapy and/or total body irradiation), and the 
occurrence of graft-versus-host disease. Toxicities include growth arrest, infertility, other 
endocrine abnormalities, secondary cancers and cataracts. (Leung, et al 2000, Leung, et al 
2001) Neurocognitive sequelae may be anticipated in patients receiving cranial irradiation, 
depending on dose and age of radiotherapy administration. (Reinhardt, et al 2002b, 
Temming and Jenney 2010) A quality-of-life study form the NOPHO group showed that 
self-reported health was considered excellent or very good in 77% of ex-patients, and 
comparable to that of siblings, with a median follow-up of 11 years. (Molgaard-Hansen, et al 
2010a)  
5. Specific subgroups in pediatric AML 
5.1 Children with Down syndrome 
Children with Down syndrome have an  increased risk (approximately 150-fold) of 
developing myeloid leukemia, which is often preceded by a so-called ‘transient leukemia 
(TL)’ in neonatal life. (Hasle, et al 2000, Zwaan, et al 2008) This Down syndrome associated 
myeloid-leukemia (ML-DS) is a unique disease entity characterized by occurrence at young 
age (before the age of 4 years), a smoldering disease course, megakaryocytic features, and 
mutations in the GATA1 transcription factor gene localized on the X-chromosome. (Ahmed, 
et al 2004, Creutzig, et al 2005a, Hitzler, et al 2003, Lange, et al 1998, Zwaan, et al 2008) 
Interestingly, ML-DS is a highly curable disease, when reduced-intensity treatment 
protocols are used, avoiding excessive treatment-related mortality. (Creutzig, et al 2005a, 
Gamis, et al 2006) This is probably due to enhanced sensitivity to chemotherapy, as was 
determined with in-vitro cell-kill assays. (Ge, et al 2004, Zwaan, et al 2002b) This also 
implicates that these patients should not be transplanted in CR1, and that longer intervals 
between courses are necessary and acceptable if the patient needs to recover from a prior 
course of chemotherapy. TL occurs in approximately 10% of children with DS, and is 
probably derived from trisomy 21 induced expansion of fetal liver megakarocyte precursors, 
which become ‘leukemic’ once a GATA1 mutation occurs. (Chou, et al 2008, Klusmann, et al 
2008, Tunstall-Pedoe, et al 2008) In most cases (~80%) TL resolves spontaneously without 
development of ML-DS later in life, however, in 20% of children TL is followed by ML-DS 
between 1-4 years of age (Figure 3). (Hasle, et al 2008) It is currently unknown whether ML-
DS may also occur without preceding TL, although it is perhaps unlikely. Moreover, it is 
unknown which factors exactly drive clonal evolution to ML-DS in these 20% of children, 
although research is ongoing to unravel this. (Chen, et al 2010, Klusmann, et al 2010a, 
Klusmann, et al 2010b) Of interest, a recent paper shows that lower protein expression of 
GATA1s predicts a higher chance of ML-DS development after TL. (Kanezaki, et al 2010) 
Current efforts in TL are focused on 2 aspects: 1) Treatment of children with symptomatic 
TL to avoid TL-related deaths, which may occur from either fluid overload, organomegaly 
and high WBC, or from liver failure which is believed to result from cytokines produced by 
the leukemic blasts infiltrating the liver. (Klusmann, et al 2008) Treatment can consist of 
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(repetitive) courses of low dose cytarabine (Al Ahmari, et al 2006), and 2) the potential to 
avoid clonal evolution to ML-DS by treating children with low clearance of TL as assessed 
by MRD measurements at pre-defined time-points. Results from the latter studies are not 
yet available, and hence this cannot be considered standard of care as yet. 
5.2 Infants with AML 
There is a peak in the incidence of AML in children below the age of 1 year. These leukemias 
have a different genetic profile compared to older children with AML, as approximately 
50% of these cases are characterized by MLL-rearrangements. (Creutzig, et al 2010a, 
Vormoor, et al 1992) Moreover, certain specific chromosomal aberrations are only found in 
children below one year of age, such as the OTT-MAL fusion gene found in young children 
with megakaryoblastic leukemia and t(1;22)(p13;q13)(Reinhardt, et al 2005), and the 
t(7;12)(q36,p13), which is characterized by very poor clinical outcome. (von Bergh, et al 2006) 
Clinically, children below the age of one year more often present with high WBC, 
organomegaly and CNS-involvement. (Pui, et al 2000, Vormoor, et al 1992) In ALL, outcome 
of infants is worse compared to older children, which led to the introduction of specific 
treatment protocols, but there is no evidence that this is the case in AML. (Creutzig, et al 
2010a, Pieters, et al 2007) Most protocols advise dose-reduction in infants with AML, and 
chemotherapy is usually calculated on a mg/kg basis rather than using body surface area. 
 
 
Fig. 3. Development of ML-DS from transient leukemia. 
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5.3 Adolescents and young adults with AML 
In ALL, it appeared that adolescents and younger adults fared much better on pediatric 
treatment protocols than on adult treatment regimens. (Boissel, et al 2003, de Bont, et al 2004) 
Subsequently, this was also investigated for AML. Creuztig et al. could not find differences 
in outcome between patients treated on a pediatric and an adult treatment protocol. 
(Creutzig, et al 2008) In an Australian study, for cases diagnosed between 2000 and 2004, 
there was no difference in outcome for children, adolescents and young adults (20-29 years). 
(Pinkerton, et al 2010) This is probably due to a greater similarity between pediatric and 
adult AML protocols, whereas there are major differences between pediatric and adult ALL 
protocols. Prognosis however declines with age, as a consequences of a reduction of good-
risk cytogenetic abnormalities, and reduced host-tolerance to chemotherapy. 
5.4 Cytogenetically normal AML 
In children, approximately 15-20% of AML cases present without karyotypic abnormalities, 
which is a much lower frequency than in adults. (Balgobind, et al 2011a, Harrison, et al 2010, 
von Neuhoff, et al 2010) Over the past few years many gene mutations or overexpression of 
specific genes have been identified in CN-AML, with clear prognostic impact. (Hollink, et al 
2009b) This includes typical type II aberrations such as NPM1 mutations in ~20%, CEPBA 
double mutations in ~15-20% of cases. (Balgobind, et al 2011a) The NPM1 and CEBPA 
double mutations confer good clinical outcome, allowing risk-stratification with the “good 
risk” cytogenetic subgroups. (Brown, et al 2007, Ho, et al 2009, Hollink, et al 2011, Hollink, et 
al 2009c) In addition, the following type-1 mutations were identified: FLT3-internal tandem 
duplications (FLT3-ITD), found in ~30-40% of cases, FLT3-tyrosine kinase domain mutations 
(FLT3-TKD) in ~2% and N- or K-RAS mutations in ~15-20% of CN-AML cases. (Balgobind, et 
al 2011a, Goemans, et al 2005, Meshinchi, et al 2006) WT1 mutations were found in 20-25% of 
pediatric CN-AML cases, in approximately half of the cases together with a FLT3-ITD, and 
in a quarter together with a RAS-mutation. (Balgobind, et al 2011a, Ho, et al 2010b, Hollink, 
et al 2009a) In 20-25% of cases no type-I aberration can be detected so far. The Children’s 
Oncology Group published similar data, although they could not confirm the poor outcome 
of patients with WT1 mutations. In adults, specific prognostic paradigms are being 
developed for CN-AML, which is not yet the case in children, in part because numbers are 
small. (Damm, et al 2011, Mrozek, et al 2007) 
5.5 MLL-rearranged AML 
MLL-rearrangements are typically found in younger children with AML. The true incidence 
of MLL-rearrangements in pediatric AML is considered to be in the range of 15-25% 
according to the latest trials, since cryptic MLL-rearrangements were not always identified 
in the past with conventional karyotyping only. (Harrison, et al 2010, von Neuhoff, et al 
2010) In the past, MLL-rearranged AML has been related to poor outcome despite intensive 
chemotherapy. However recent studies showed that outcome in MLL-rearranged AML is 
dependent on different factors, e.g. translocation partner, age, WBC and additional 
cytogenetic aberrations. (Balgobind, et al 2009) Cases with a t(1;11)(q21;q23) have an 
excellent outcome and may benefit from less intensive treatment, whereas cases with a 
t(6;11)(q27;q23) or t(10;11)(p21;q23) have a poor outcome and do need adjusted and 
alternative treatment strategies to improve outcome. This means that these abnormalities 
need to be specifically screened for, as suggested in Figure 4. Although cooperating events 
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are a hallmark of developing AML, additional genetic aberrations in MLL-rearranged AML 
are hardly identified. Roughly 50% of the MLL-rearranged AML cases harbor a known type-
I mutation, and most of these mutations were identified in genes involved in the RAS-
pathway, including mutations in NRAS, KRAS, PTPN11 and NF1. (Balgobind, et al 2008) 
Recently, novel aberrantly expressed genes have been identified that are involved in MLL-
gene rearranged AML leukemogenesis, such as IGSF4, BRE and EVI1. (Balgobind, et al 
2010a, Balgobind, et al 2010b, Kuipers, et al 2011) Upregulation of HOX genes is one of the 
most important hallmarks of MLL-rearranged leukemias, and may be a target for epigenetic 
therapy. (Krivtsov, et al 2008)  
 
 
Fig. 4. Screening for MLL-rearrangements in pediatric AML. 
5.6 Acute promyelocytic leukemia 
Acute promyelocytic leukemia (APL) is a distinct pathological entity that occurs in only 4-
8% of all AML cases in children. The disease is characterized by a specific morphological 
subtype (FAB M3), although in a small percentage morphology is different, referred to as 
‘microgranular variant morphology (M3V)’. (Tallman, et al 2010) Furthermore, APL is 
characterized by the presence of the chromosomal translocation t(15;17)(1q22;q21), which 
results in the PML-RARα fusion transcript, and its reciprocal product RARα-PML. (Sanz, et al 
2009) In a minority of cases (<5%), RARα is fused to an alternative partner, most commonly 
NPM1 resulting from a t(5;17)(q35;q21) or NuMA in t(11;17)(q13;q21). (Grimwade, et al 2000) 
The diagnostic white blood cell count is the most important prognostic factor in APL. The 
hallmarks of the disease is the sensitivity for all-trans-retinoic acid (ATRA), which is now 
considered standard of care for APL in induction and in maintenance in combination with 
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5.3 Adolescents and young adults with AML 
In ALL, it appeared that adolescents and younger adults fared much better on pediatric 
treatment protocols than on adult treatment regimens. (Boissel, et al 2003, de Bont, et al 2004) 
Subsequently, this was also investigated for AML. Creuztig et al. could not find differences 
in outcome between patients treated on a pediatric and an adult treatment protocol. 
(Creutzig, et al 2008) In an Australian study, for cases diagnosed between 2000 and 2004, 
there was no difference in outcome for children, adolescents and young adults (20-29 years). 
(Pinkerton, et al 2010) This is probably due to a greater similarity between pediatric and 
adult AML protocols, whereas there are major differences between pediatric and adult ALL 
protocols. Prognosis however declines with age, as a consequences of a reduction of good-
risk cytogenetic abnormalities, and reduced host-tolerance to chemotherapy. 
5.4 Cytogenetically normal AML 
In children, approximately 15-20% of AML cases present without karyotypic abnormalities, 
which is a much lower frequency than in adults. (Balgobind, et al 2011a, Harrison, et al 2010, 
von Neuhoff, et al 2010) Over the past few years many gene mutations or overexpression of 
specific genes have been identified in CN-AML, with clear prognostic impact. (Hollink, et al 
2009b) This includes typical type II aberrations such as NPM1 mutations in ~20%, CEPBA 
double mutations in ~15-20% of cases. (Balgobind, et al 2011a) The NPM1 and CEBPA 
double mutations confer good clinical outcome, allowing risk-stratification with the “good 
risk” cytogenetic subgroups. (Brown, et al 2007, Ho, et al 2009, Hollink, et al 2011, Hollink, et 
al 2009c) In addition, the following type-1 mutations were identified: FLT3-internal tandem 
duplications (FLT3-ITD), found in ~30-40% of cases, FLT3-tyrosine kinase domain mutations 
(FLT3-TKD) in ~2% and N- or K-RAS mutations in ~15-20% of CN-AML cases. (Balgobind, et 
al 2011a, Goemans, et al 2005, Meshinchi, et al 2006) WT1 mutations were found in 20-25% of 
pediatric CN-AML cases, in approximately half of the cases together with a FLT3-ITD, and 
in a quarter together with a RAS-mutation. (Balgobind, et al 2011a, Ho, et al 2010b, Hollink, 
et al 2009a) In 20-25% of cases no type-I aberration can be detected so far. The Children’s 
Oncology Group published similar data, although they could not confirm the poor outcome 
of patients with WT1 mutations. In adults, specific prognostic paradigms are being 
developed for CN-AML, which is not yet the case in children, in part because numbers are 
small. (Damm, et al 2011, Mrozek, et al 2007) 
5.5 MLL-rearranged AML 
MLL-rearrangements are typically found in younger children with AML. The true incidence 
of MLL-rearrangements in pediatric AML is considered to be in the range of 15-25% 
according to the latest trials, since cryptic MLL-rearrangements were not always identified 
in the past with conventional karyotyping only. (Harrison, et al 2010, von Neuhoff, et al 
2010) In the past, MLL-rearranged AML has been related to poor outcome despite intensive 
chemotherapy. However recent studies showed that outcome in MLL-rearranged AML is 
dependent on different factors, e.g. translocation partner, age, WBC and additional 
cytogenetic aberrations. (Balgobind, et al 2009) Cases with a t(1;11)(q21;q23) have an 
excellent outcome and may benefit from less intensive treatment, whereas cases with a 
t(6;11)(q27;q23) or t(10;11)(p21;q23) have a poor outcome and do need adjusted and 
alternative treatment strategies to improve outcome. This means that these abnormalities 
need to be specifically screened for, as suggested in Figure 4. Although cooperating events 
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are a hallmark of developing AML, additional genetic aberrations in MLL-rearranged AML 
are hardly identified. Roughly 50% of the MLL-rearranged AML cases harbor a known type-
I mutation, and most of these mutations were identified in genes involved in the RAS-
pathway, including mutations in NRAS, KRAS, PTPN11 and NF1. (Balgobind, et al 2008) 
Recently, novel aberrantly expressed genes have been identified that are involved in MLL-
gene rearranged AML leukemogenesis, such as IGSF4, BRE and EVI1. (Balgobind, et al 
2010a, Balgobind, et al 2010b, Kuipers, et al 2011) Upregulation of HOX genes is one of the 
most important hallmarks of MLL-rearranged leukemias, and may be a target for epigenetic 
therapy. (Krivtsov, et al 2008)  
 
 
Fig. 4. Screening for MLL-rearrangements in pediatric AML. 
5.6 Acute promyelocytic leukemia 
Acute promyelocytic leukemia (APL) is a distinct pathological entity that occurs in only 4-
8% of all AML cases in children. The disease is characterized by a specific morphological 
subtype (FAB M3), although in a small percentage morphology is different, referred to as 
‘microgranular variant morphology (M3V)’. (Tallman, et al 2010) Furthermore, APL is 
characterized by the presence of the chromosomal translocation t(15;17)(1q22;q21), which 
results in the PML-RARα fusion transcript, and its reciprocal product RARα-PML. (Sanz, et al 
2009) In a minority of cases (<5%), RARα is fused to an alternative partner, most commonly 
NPM1 resulting from a t(5;17)(q35;q21) or NuMA in t(11;17)(q13;q21). (Grimwade, et al 2000) 
The diagnostic white blood cell count is the most important prognostic factor in APL. The 
hallmarks of the disease is the sensitivity for all-trans-retinoic acid (ATRA), which is now 
considered standard of care for APL in induction and in maintenance in combination with 
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(Soignet 2001) Both drugs induce differentiation and apoptosis of leukemic cells, and have 
reduced the incidence of early fatal bleeding complications that APL is associated with. 
(Sanz, et al 2009, Stein, et al 2009) Currently, overall survival rates in children with APL are 
in the range of 80-90% (see table 8). (Creutzig, et al 2010c, Testi, et al 2005) Based on these 
results, the International-BFM Group has launched a ‘standard of care’ protocol for children 
with APL (the ICC APL study 01). The main aim of this study is to lower the cumulative dose 
of anthracyclines used in the treatment of APL, which is very high in some adult protocols that 
pediatric regimens were based upon. (Testi, et al 2005) Given the risk of severe long-term 
cardiac toxicity, the ICC APL 01 study combines a lower dose of anthracyclines with 
cytarabine and ATRA, as has been used previously by the BFM group. (Creutzig, et al 2010c) 
 
Study Group Years No of patients EFS (5yrs) OS(5yrs) References 
AML-BFM SG 1993-
2010 











53 NA 69% (Gregory, et al 
2009) 
AML-99 M3 (Japan) 1997-
2004 
58 91% 93% (Imaizumi, et al 
2011) 
* ATRA was not given to all patients 
Table 8. Outcome results in APL in children. 
Several adult studies have now also introduced arsenic trioxide in newly diagnosed patients, 
either in combination with chemotherapy, or as single-agent, or in combination with ATRA. 
(Hu, et al 2009, Mathews, et al 2010, Powell, et al 2011) Using arsenic alone, Mathews et al. 
reported durable responses with almost 70% event-free survival. (Mathews, et al 2010) This has 
also been piloted in 11 children, with similar encouraging findings. (George, et al 2004) When 
this is confirmed in larger studies treatment of APL without chemotherapy may be feasible, 
especially when no long-term toxicities from arsenic treatment emerge. 
6. Minimal Residual Disease 
In acute lymphoblastic leukemia risk group stratification is based on assessment of minimal 
residual disease (MRD) in modern treatment protocols, as this is superior to any of the 
classical prognostic factors (age, WBC, cytogenetics, immunophenotype). (Flohr, et al 2008, 
Van Dongen, et al 1998) In ALL, this can either be done using flow cytometry, or by using 
quantative polymerase chain reaction of immunoglobulin or T-cell receptor rearrangements. 
(van der Velden and van Dongen 2009) In AML, MRD assessment is more complicated. 
(Goulden, et al 2006) Flow cytometry is used by several investigators, and leukemia-specific 
aberrant immunophenotypes can be detected in the majority of patients. (van der Velden, et 
al 2010) However, flow cytometry may not always have sufficient sensitivity. For instance, 
investigators from the AML-BFM SG analysed MRD in their AML-98 study. (Langebrake, et 
al 2006) Using 4-color immunophenotyping, they could not show that MRD was superior to 
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the traditional BFM-risk group classification (based on cytogenetics at diagnosis and 
morphological assessment of bone marrow blasts at day 15 and 28) to predict clinical 
outcome. However, other groups have reported independent prognostic significance of 
MRD assessment. Van der Velden et al. have monitored MRD in the context of the MRC12 
protocol, and showed that 3-year relapse-free survival was 85% for MRD-negative patients 
(MRD<0.1%) and 64% for MRD-low-positive patients (0.1%<or=MRD<0.5%) and only 14% 
for MRD-high-positive patients (MRD>or=0.5%; P<0.001). (van der Velden, et al 2010) In the 
AML02 study from St Jude Children’s Research Hospital MRD was used for patient 
stratification. (Rubnitz, et al 2010) High MRD at the end of induction was the only 
independent risk-factor for survival, with a cut—off level for MRD-positivity of 0.1%. In 
conclusion, there is an increasing amount of evidence that flow cytometry based MRD 
stratification is superior to using more conventional parameters to risk-stratify patients. 
Molecular MRD assessment in pediatric AML has been based on the quantative assessment 
of fusion-genes using RQ-PCR. Only rising MRD values are clinically relevant, as it is 
known that for instance AML1-ETO and CBFbeta-MYH11 can still be detected with sensitive 
methods in patients in long-lasting continuous complete remission. (Leroy, et al 2005, 
Miyamoto, et al 1996, Perea, et al 2006, Viehmann, et al 2003) Using fusion genes as MRD 
targets has the limitation that only a subset of patients (approximately 40-50%) can be 
studied. However, the newly discovered molecular mutations, such as NPM1 or GATA1 
mutations, may also be suitable MRD-targets. (Pine, et al 2005, Schnittger, et al 2009) Some of 
these targets, such as FLT3 mutations, may not be stable between diagnosis and relapse, and 
this may result in false-negative results(Bachas, et al 2010), which may also occur in flow-
cytometry based MRD assessment due to immunophenotypic shifts. (Langebrake, et al 2005) 
Another important issue is the frequency of required sampling post-treatment, as leukemias 
may differ in the lag-time between molecular and overt relapse, which appears to be 
translocation/molecular marker dependent. (Ommen, et al 2010) Given this heterogeneity a 
more ubiquitously expressed MRD target would be more practical, and several investigators 
have chosen WT1-expression as a suitable MRD-target, given that WT1 is overexpressed in 
the majority of pediatric AML patients. (Cilloni, et al 2009, Lapillonne, et al 2006, Willasch, et 
al 2009) Despite all these technical advantages, MRD in pediatric AML is still mainly an area 
of research rather than a standardized approach implemented as standard of care in clinical 
treatment protocols, in contrast to pediatric ALL. The one exception in AML is acute 
promyelocytic leukemia, where MRD-follow-up is nowadays considered standard, and 
where it has been shown that pre-emptive therapy of molecular relapse may prevent the 
occurrence of overt relapse. (Grimwade, et al 2009, Testi, et al 2005)  
7. New treatment options 
7.1 Gemtuzumab ozogamicin 
Gemtuzumab ozogamicin (GO) is a conjugated antibody in which an anti-CD33 antibody is 
linked to the anti-tumor antibiotic calichemicin. (Sievers, et al 1999, Zwaan, et al 2003b) After 
binding to CD33 the complex is internalized and calicheamicin is spliced off and exterts its 
cytotoxic activity. In studies in adults, the main side-effects of GO were hematological and 
liver toxicity, referred to as sinusoidal obstruction syndrome (SOS). (Rajvanshi, et al 2002, 
Sievers, et al 2001) Although the initial development in adults concerned single-agent high-
dose GO (2 dosages of GO 9 mg/m2 IV given with a 14 day-interval), combination studies 
showed that dosages in the range of 3-5 mg/m2 could be incorporated in existing AML 
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(Soignet 2001) Both drugs induce differentiation and apoptosis of leukemic cells, and have 
reduced the incidence of early fatal bleeding complications that APL is associated with. 
(Sanz, et al 2009, Stein, et al 2009) Currently, overall survival rates in children with APL are 
in the range of 80-90% (see table 8). (Creutzig, et al 2010c, Testi, et al 2005) Based on these 
results, the International-BFM Group has launched a ‘standard of care’ protocol for children 
with APL (the ICC APL study 01). The main aim of this study is to lower the cumulative dose 
of anthracyclines used in the treatment of APL, which is very high in some adult protocols that 
pediatric regimens were based upon. (Testi, et al 2005) Given the risk of severe long-term 
cardiac toxicity, the ICC APL 01 study combines a lower dose of anthracyclines with 
cytarabine and ATRA, as has been used previously by the BFM group. (Creutzig, et al 2010c) 
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Table 8. Outcome results in APL in children. 
Several adult studies have now also introduced arsenic trioxide in newly diagnosed patients, 
either in combination with chemotherapy, or as single-agent, or in combination with ATRA. 
(Hu, et al 2009, Mathews, et al 2010, Powell, et al 2011) Using arsenic alone, Mathews et al. 
reported durable responses with almost 70% event-free survival. (Mathews, et al 2010) This has 
also been piloted in 11 children, with similar encouraging findings. (George, et al 2004) When 
this is confirmed in larger studies treatment of APL without chemotherapy may be feasible, 
especially when no long-term toxicities from arsenic treatment emerge. 
6. Minimal Residual Disease 
In acute lymphoblastic leukemia risk group stratification is based on assessment of minimal 
residual disease (MRD) in modern treatment protocols, as this is superior to any of the 
classical prognostic factors (age, WBC, cytogenetics, immunophenotype). (Flohr, et al 2008, 
Van Dongen, et al 1998) In ALL, this can either be done using flow cytometry, or by using 
quantative polymerase chain reaction of immunoglobulin or T-cell receptor rearrangements. 
(van der Velden and van Dongen 2009) In AML, MRD assessment is more complicated. 
(Goulden, et al 2006) Flow cytometry is used by several investigators, and leukemia-specific 
aberrant immunophenotypes can be detected in the majority of patients. (van der Velden, et 
al 2010) However, flow cytometry may not always have sufficient sensitivity. For instance, 
investigators from the AML-BFM SG analysed MRD in their AML-98 study. (Langebrake, et 
al 2006) Using 4-color immunophenotyping, they could not show that MRD was superior to 
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the traditional BFM-risk group classification (based on cytogenetics at diagnosis and 
morphological assessment of bone marrow blasts at day 15 and 28) to predict clinical 
outcome. However, other groups have reported independent prognostic significance of 
MRD assessment. Van der Velden et al. have monitored MRD in the context of the MRC12 
protocol, and showed that 3-year relapse-free survival was 85% for MRD-negative patients 
(MRD<0.1%) and 64% for MRD-low-positive patients (0.1%<or=MRD<0.5%) and only 14% 
for MRD-high-positive patients (MRD>or=0.5%; P<0.001). (van der Velden, et al 2010) In the 
AML02 study from St Jude Children’s Research Hospital MRD was used for patient 
stratification. (Rubnitz, et al 2010) High MRD at the end of induction was the only 
independent risk-factor for survival, with a cut—off level for MRD-positivity of 0.1%. In 
conclusion, there is an increasing amount of evidence that flow cytometry based MRD 
stratification is superior to using more conventional parameters to risk-stratify patients. 
Molecular MRD assessment in pediatric AML has been based on the quantative assessment 
of fusion-genes using RQ-PCR. Only rising MRD values are clinically relevant, as it is 
known that for instance AML1-ETO and CBFbeta-MYH11 can still be detected with sensitive 
methods in patients in long-lasting continuous complete remission. (Leroy, et al 2005, 
Miyamoto, et al 1996, Perea, et al 2006, Viehmann, et al 2003) Using fusion genes as MRD 
targets has the limitation that only a subset of patients (approximately 40-50%) can be 
studied. However, the newly discovered molecular mutations, such as NPM1 or GATA1 
mutations, may also be suitable MRD-targets. (Pine, et al 2005, Schnittger, et al 2009) Some of 
these targets, such as FLT3 mutations, may not be stable between diagnosis and relapse, and 
this may result in false-negative results(Bachas, et al 2010), which may also occur in flow-
cytometry based MRD assessment due to immunophenotypic shifts. (Langebrake, et al 2005) 
Another important issue is the frequency of required sampling post-treatment, as leukemias 
may differ in the lag-time between molecular and overt relapse, which appears to be 
translocation/molecular marker dependent. (Ommen, et al 2010) Given this heterogeneity a 
more ubiquitously expressed MRD target would be more practical, and several investigators 
have chosen WT1-expression as a suitable MRD-target, given that WT1 is overexpressed in 
the majority of pediatric AML patients. (Cilloni, et al 2009, Lapillonne, et al 2006, Willasch, et 
al 2009) Despite all these technical advantages, MRD in pediatric AML is still mainly an area 
of research rather than a standardized approach implemented as standard of care in clinical 
treatment protocols, in contrast to pediatric ALL. The one exception in AML is acute 
promyelocytic leukemia, where MRD-follow-up is nowadays considered standard, and 
where it has been shown that pre-emptive therapy of molecular relapse may prevent the 
occurrence of overt relapse. (Grimwade, et al 2009, Testi, et al 2005)  
7. New treatment options 
7.1 Gemtuzumab ozogamicin 
Gemtuzumab ozogamicin (GO) is a conjugated antibody in which an anti-CD33 antibody is 
linked to the anti-tumor antibiotic calichemicin. (Sievers, et al 1999, Zwaan, et al 2003b) After 
binding to CD33 the complex is internalized and calicheamicin is spliced off and exterts its 
cytotoxic activity. In studies in adults, the main side-effects of GO were hematological and 
liver toxicity, referred to as sinusoidal obstruction syndrome (SOS). (Rajvanshi, et al 2002, 
Sievers, et al 2001) Although the initial development in adults concerned single-agent high-
dose GO (2 dosages of GO 9 mg/m2 IV given with a 14 day-interval), combination studies 
showed that dosages in the range of 3-5 mg/m2 could be incorporated in existing AML 
 
Acute Leukemia – The Scientist's Perspective and Challenge 252 
chemotherapy regimens. (Kell, et al 2003) In AML in adults, several large randomized 
studies were performed. This includes the addition of GO in induction therapy in the MRC-
AML 15 study, which showed an improvement in survival mainly for patients with good-
risk cytogenetics. (Burnett, et al 2011) Löwenberg et al. gave 3 cycles of GO (6 mg/m2 at 4 
week intervals) as post-remission treatment in elderly AML patients, which failed to show a 
benefit in this population. (Lowenberg, et al 2010a) 
In children, phase I studies showed that 6-7.5 mg/m2 was the maximum tolerated dose. 
(Arceci, et al 2005) Several phase II studies have been performed, either as single-agent or in 
combination with cytarabine, showing response rates in the range of 30-40%. (Brethon, et al 
2008, Zwaan, et al 2010b) GO seems better tolerable in children, in that lower frequencies of 
SOD were seen. Aplenc et al. published safety data of GO in combination with either 
cytarabine and mitoxantrone or cytarabine and asparaginase in relapsed pediatric AML 
patients, and showed that the MTD for the 1st combination was 3 mg/m2 of GO, versus 2 
mg/m2 for the latter combination. (Aplenc, et al 2008) The results of a study in newly 
diagnosed AML patients as conducted by the Children’s Oncology Group are awaited. 
Rubnitz et al. gave GO in combination with induction chemotherapy to slow early 
responders (non-randomized). (Rubnitz, et al 2010) Given the results of the phase II studies 
mentioned above, the International-BFM AML group will perform a randomized study in 
relapsed/refractory AML patients in which standard chemotherapy is given with or 
without one infusion of GO.  Considering its use in pediatric AML the current phase II 
results suggest better activity and less side-effects than in adults, but no randomized studies 
have been performed as yet. The current registration status of GO is a major obstacle in its 
use, as it is only licensed for use in Japan, and hence is not commercially available in Europe 
or the US. Its prior accelerated approval in the US was withdrawn in 2010 after a follow-up 
study in adults with relapsed AML (study SWOG S0106) was interrupted as it did not show 
sufficient benefit and caused safety concerns. (FDA 2010)  
7.2 Liposomal drugs 
A major concern in children is the development of long-term cardiac toxicity following 
exposure to high dosages of anthracyclines. (Creutzig, et al 2007, Lipshultz and Adams 2010, 
van Dalen, et al 2006) It is hypothesized that liposomal daunorubicin (DNX) has less cardiac 
toxicity, as the liposomal formulation prohibits its accumulation in cardiac tissue. A cardio-
protective effect has been shown for liposomal doxorubicin in solid tumors,(van Dalen, et al 
2010) however no long-term follow-up studies are available for liposomal daunorubicin to 
show that it is indeed cardioprotective as well. In adults, a randomized trial between 80 
mg/m2 DNX compared to 45 mg/m2 of daunorubicin showed a survival advantage for the 
DNX-arm because of a reduction in late relapses, despite increased treatment related deaths 
in the DNX-arm. (Latagliata, et al 2008) In children, DNX was piloted by the BFM-group in 
the relapsed AML-98 trial, and was used in all subsequent relapse studies. (Reinhardt, et al 
2002a) Population pharmacokinetic data showed a lower volume of distribution and lower 
clearance compared to free daunorubicin. (Hempel, et al 2003) DNX is currently considered 
standard of care in relapsed pediatric AML, given the results of the I-BFM Relapsed AML 
2001/01 randomized study showing a significant benefit in terms of early treatment 
response in patients randomized to the FLAG plus DNX arm (60 mg/m2 on day 1, 3 and 5), 
versus those randomized to FLAG alone. (Kaspers, et al 2009) Moreover, in the AML-BFM 
SG upfront studies, DNX was introduced in the 2004 protocol at a dose of 80 mg/m2 and 
randomized against idarubicin. (Creutzig, et al 2010b) Patients randomized to DNX had 
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better outcome, although the results were not statistically significant. DNX appeared 
somewhat less toxic than idarubicin, which included less cases of acute cardiac toxity. 
(Creutzig, et al 2010b) Perhaps further dose-escalation of DNX is possible given the 
improved therapeutic index for acute cardiac and other toxicity(Creutzig, et al 2010b, 
Kaspers, et al 2009), as it is expected that a higher anthracycline dose will translate in better 
survival, as recently demonstrated in a randomized study in elderly patients with AML (45 
versus 90 mg/m2 for 3 days in induction). (Lowenberg, et al 2009)    
A new liposomal formulation (CPX-351) combines bot cytarabine and daunorubicin in a 5:1 
ratio. (Feldman, et al 2011) Recently, a phase I study in adults with relapsed/refractory AML 
was completed, showing responses in approximately 25% of patients. The recommended 
phase II dose was 101 U/m2, following toxicities including hypertensive crisis, congestive 
heart failure, and prolonged cytopenias at higher dosages. 
7.3 Nucleoside analogs 
2-Chlorodeoxyadenosine (2-CDA) is a synthetic nucleoside analog that inhibits 
ribonucloetide reductase and increases the activity of deoxycitidine kinase. In vitro, the drug 
was more potent than cytarabine, and especially monoblastic leukemias appeared sensitive 
to this compound. (Hubeek, et al 2006) This nucleoside analog has mainly been incorporated 
in studies from St Jude Children’s Research Hospital, showing clear anti-leukemic efficacy 
against relapsed and newly diagnosed AML. (Krance, et al 2001, Santana, et al 1991, Santana, 
et al 1992) In later studies it was combined with cytarabine to potentiate the efficacy of 
cytarabine, and enhanced cytarabine-triphosphate levels (the active metabolite of 
cytarabine) were demonstrated in patients treated with the combination. (Crews, et al 2002, 
Rubnitz, et al 2009)  The AML-BFM SG has randomized 2-CDA in consolidation in high risk 
patients in their AML-BFM 2004 study and compared activity to cytarabine, and no 
significant difference was found. (Creutzig, et al 2010b)  
Clofarabine is a new nucleoside analog, which was synthesized to improve the properties of 
its ancestors fludarabine and cladribine. The phase I study in children showed that the 
maximum tolerated dose was 52 mg/m2, once daily for 5 consecutive days. (Jeha, et al 2004) 
Liver toxicity and skin rash were the main dose-limiting toxicities. Based on its activity in 
relapsed pediatric ALL, this drug was approved for this indication in 2004. A phase II study 
in pediatric AML showed mainly partial responses, perhaps reflecting the resistant 
phenotype of the leukemias that were included. (Jeha, et al 2009) However, in adults with 
AML clofarabine appears to be an active agent. (Burnett, et al 2010) Several phase II studies 
in pediatric AML are currently ongoing which combine clofarabine with standard AML 
drugs such as cytarabine, anthracyclines and/or etopside aiming at the development of a 
new treatment block that could be randomized against other AML blocks. (Jeha, et al 2006)  
A head-to-head comparison to cytarabine or to a FLAG-course should demonstrate whether 
clofarabine has indeed superior activity, and is not available at the moment.  
Elacytarabine is a lipophilic fatty acid derivative of cytarabine, which is in phase II 
development in adults, and may retain activity in cells with deficient nucleoside membrane 
transport, and hence be able to overcome cytarabine resistance. Currently, no pediatric 
studies have been performed. (O'Brien, et al 2009)  
7.4 Signal transduction inhibitors 
7.4.1 FLT3-inhibitors 
Several activated tyrosine kinase pathways are described in pediatric AML, which have led 
to the development of targeted therapy options. Most of the attention has been focused on 
 
Acute Leukemia – The Scientist's Perspective and Challenge 252 
chemotherapy regimens. (Kell, et al 2003) In AML in adults, several large randomized 
studies were performed. This includes the addition of GO in induction therapy in the MRC-
AML 15 study, which showed an improvement in survival mainly for patients with good-
risk cytogenetics. (Burnett, et al 2011) Löwenberg et al. gave 3 cycles of GO (6 mg/m2 at 4 
week intervals) as post-remission treatment in elderly AML patients, which failed to show a 
benefit in this population. (Lowenberg, et al 2010a) 
In children, phase I studies showed that 6-7.5 mg/m2 was the maximum tolerated dose. 
(Arceci, et al 2005) Several phase II studies have been performed, either as single-agent or in 
combination with cytarabine, showing response rates in the range of 30-40%. (Brethon, et al 
2008, Zwaan, et al 2010b) GO seems better tolerable in children, in that lower frequencies of 
SOD were seen. Aplenc et al. published safety data of GO in combination with either 
cytarabine and mitoxantrone or cytarabine and asparaginase in relapsed pediatric AML 
patients, and showed that the MTD for the 1st combination was 3 mg/m2 of GO, versus 2 
mg/m2 for the latter combination. (Aplenc, et al 2008) The results of a study in newly 
diagnosed AML patients as conducted by the Children’s Oncology Group are awaited. 
Rubnitz et al. gave GO in combination with induction chemotherapy to slow early 
responders (non-randomized). (Rubnitz, et al 2010) Given the results of the phase II studies 
mentioned above, the International-BFM AML group will perform a randomized study in 
relapsed/refractory AML patients in which standard chemotherapy is given with or 
without one infusion of GO.  Considering its use in pediatric AML the current phase II 
results suggest better activity and less side-effects than in adults, but no randomized studies 
have been performed as yet. The current registration status of GO is a major obstacle in its 
use, as it is only licensed for use in Japan, and hence is not commercially available in Europe 
or the US. Its prior accelerated approval in the US was withdrawn in 2010 after a follow-up 
study in adults with relapsed AML (study SWOG S0106) was interrupted as it did not show 
sufficient benefit and caused safety concerns. (FDA 2010)  
7.2 Liposomal drugs 
A major concern in children is the development of long-term cardiac toxicity following 
exposure to high dosages of anthracyclines. (Creutzig, et al 2007, Lipshultz and Adams 2010, 
van Dalen, et al 2006) It is hypothesized that liposomal daunorubicin (DNX) has less cardiac 
toxicity, as the liposomal formulation prohibits its accumulation in cardiac tissue. A cardio-
protective effect has been shown for liposomal doxorubicin in solid tumors,(van Dalen, et al 
2010) however no long-term follow-up studies are available for liposomal daunorubicin to 
show that it is indeed cardioprotective as well. In adults, a randomized trial between 80 
mg/m2 DNX compared to 45 mg/m2 of daunorubicin showed a survival advantage for the 
DNX-arm because of a reduction in late relapses, despite increased treatment related deaths 
in the DNX-arm. (Latagliata, et al 2008) In children, DNX was piloted by the BFM-group in 
the relapsed AML-98 trial, and was used in all subsequent relapse studies. (Reinhardt, et al 
2002a) Population pharmacokinetic data showed a lower volume of distribution and lower 
clearance compared to free daunorubicin. (Hempel, et al 2003) DNX is currently considered 
standard of care in relapsed pediatric AML, given the results of the I-BFM Relapsed AML 
2001/01 randomized study showing a significant benefit in terms of early treatment 
response in patients randomized to the FLAG plus DNX arm (60 mg/m2 on day 1, 3 and 5), 
versus those randomized to FLAG alone. (Kaspers, et al 2009) Moreover, in the AML-BFM 
SG upfront studies, DNX was introduced in the 2004 protocol at a dose of 80 mg/m2 and 
randomized against idarubicin. (Creutzig, et al 2010b) Patients randomized to DNX had 
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better outcome, although the results were not statistically significant. DNX appeared 
somewhat less toxic than idarubicin, which included less cases of acute cardiac toxity. 
(Creutzig, et al 2010b) Perhaps further dose-escalation of DNX is possible given the 
improved therapeutic index for acute cardiac and other toxicity(Creutzig, et al 2010b, 
Kaspers, et al 2009), as it is expected that a higher anthracycline dose will translate in better 
survival, as recently demonstrated in a randomized study in elderly patients with AML (45 
versus 90 mg/m2 for 3 days in induction). (Lowenberg, et al 2009)    
A new liposomal formulation (CPX-351) combines bot cytarabine and daunorubicin in a 5:1 
ratio. (Feldman, et al 2011) Recently, a phase I study in adults with relapsed/refractory AML 
was completed, showing responses in approximately 25% of patients. The recommended 
phase II dose was 101 U/m2, following toxicities including hypertensive crisis, congestive 
heart failure, and prolonged cytopenias at higher dosages. 
7.3 Nucleoside analogs 
2-Chlorodeoxyadenosine (2-CDA) is a synthetic nucleoside analog that inhibits 
ribonucloetide reductase and increases the activity of deoxycitidine kinase. In vitro, the drug 
was more potent than cytarabine, and especially monoblastic leukemias appeared sensitive 
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new treatment block that could be randomized against other AML blocks. (Jeha, et al 2006)  
A head-to-head comparison to cytarabine or to a FLAG-course should demonstrate whether 
clofarabine has indeed superior activity, and is not available at the moment.  
Elacytarabine is a lipophilic fatty acid derivative of cytarabine, which is in phase II 
development in adults, and may retain activity in cells with deficient nucleoside membrane 
transport, and hence be able to overcome cytarabine resistance. Currently, no pediatric 
studies have been performed. (O'Brien, et al 2009)  
7.4 Signal transduction inhibitors 
7.4.1 FLT3-inhibitors 
Several activated tyrosine kinase pathways are described in pediatric AML, which have led 
to the development of targeted therapy options. Most of the attention has been focused on 
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FLT3 mutations and small molecule inhibitors, and pediatric development in general 
follows adult development programs. There are several FLT3-inhibitors available on the 
market, with different selectivity against FLT3. This includes for instance the relatively 
selective inhibitors AC220 and sorafenib, the intermediate selective inhibitor sunitinib, and 
the less selective inhibitors such as midostaurin and lestaurtinib. In vitro, comparing the 
properties of these compounds, Pratz et al. reported that  in newly diagnosed samples the 
less selective inhibitors appeared more effective in terms of cytotoxicity, but it is unknown 
whether this assay is a reliable predictor of clinical responses. (Pratz, et al 2010) Moreover, 
they showed that the presence of dephosphorylation not always predicted cytotoxicity, 
which may be explained by the lack of oncogenic addiction in some AML cases despite an 
activation of this pathway, or the activation of parallel pathways at the same time.  
Several of these compounds are currently being evaluated in children with leukemia. There 
is an ongoing phase I study with midostaurin in patients with relapsed pediatric AML and 
an activating FLT3-mutation (NCT00866281). This study builds on the results of studies in 
adults, which showed moderate activity as a single-agent. (Fischer, et al 2010) However, a 
randomized trial of midostaurin in combination with chemotherapy is ongoing. Sorafenib is 
evaluated in children with de novo or relapsed FLT3-mutant AML, and preliminary results 
in 15 children are reported. (Inaba, et al 2010) In this study most children are treated with 
combination therapy together with sorafenib, and hence it is difficult to draw conclusions 
regarding its activity. At 200 mg/m2 twice daily for 20 days 3/6 children had DLTs, but no 
DLTs were observed on the next lower dose-level of 150 mg/m2 twice daily. Several reports 
are available on the use of sorafenib in adults with AML. Metzelder et al. observed 
responses using single-agent sorafenib on compassionate use basis. (Metzelder, et al 2009) 
Ravandi et al performed a phase I/II study of sorafenib in conjunction with chemotherapy. 
(Ravandi, et al 2010) In the phase I portion they escalated sorafenib to 400 mg twice daily 
together with idarubicin 12 mg/m2 for 3 days and cytarabine 1.5 gram/m2 for 4 days. They 
found a 93% CR rate in the phase II part of the study for the 15 FLT3-mutated patients, 
versus 66% in FLT3-wild type patients. Serve et al. reported initial results of a placebo-
controlled trial in elderly AML patients in combination with standard chemotherapy. 
(Serve, et al 2010) No beneficial effect of sorafenib was found, also not in the small subset of 
patients with a FLT3-mutation (n=28 of the 197 patients in the total study). Lestaurtinib is 
evaluated in children and younger adults with relapsed/refractory AML (NCT00469859), 
but no results have been presented as yet. In an adult trial in FLT3-mutant AML in 1st 
relapse  patients were treated with chemotherapy alone plus or minus lestaurtinib during 
aplasia between courses and/or following chemotherapy. (Levis, et al 2011) Patients treated 
with lestaurtinib did not achieve better responses, and survival was not prolonged. Of 
interest, only 58% of patients had sufficient target inhibition in the lestaurtinib arm. This 
was considered due to the unfavorable pharmacokinetic properties of lestaurtinib, but also 
to increasingFLT3-ligand levels after intensive chemotherapy. (Sato, et al 2011) Especially the 
latter might be a problem that may cause resistance to all FLT3-small molecule inhibitors. 
Other resistance-mechanisms may consist of secondary mutations in the FLT3-gene, that 
impair with binding of the inhibitors. 
7.4.2 KIT-inhibitors 
Dasatinib may be of use for inhibition of KIT, especially as it also has activity against the 
D816V mutant, and hence is an option in core-binding factor leukemias which are 
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frequently associated with these mutations. (Goemans, et al 2005, Pollard, et al 2010) There is 
an ongoing study in adults with CBF-AML and dasatinib, and no results have been reported 
to date. In the pediatric phase I study with dasatinib no responses were observed in AML-
patients, but none of the included patients was KIT-mutated. (Zwaan, et al 2006) 
7.5 Others 
Tosedostat is a compound with a new mechanisms of action, i.e. it is an orally available 
aminopeptidase inhibitor. In a phase II study in adult relapsed/refractory AML, using the 
130 mg/m2 dose level for 28-days blocks, an overall response rate of 27% was noted. 
(Lowenberg, et al 2010b) There are, to the best of our knowledge, no pediatric studies 
ongoing at this moment. 
8. Genome-wide approaches in AML 
Genome-wide approaches proved to be a powerful tool to further dissect AML, providing 
insight in the heterogeneity of AML, and directing the development of novel treatment 
strategies. The use of high resolution array-based comparative genome hybridization (A-
CGH) and single nucleotide polymorphism arrays (SNP-A) led to the identification of 
recurrent copy number aberrations (CNAs) and regions with loss of heterozygosity. 
However, the frequency of CNAs in AML appeared to be relatively low, which suggests 
that  AML is a genomically stable disease. (Bullinger, et al 2010, Radtke, et al 2009) However, 
using such techniques, aberrations in the tumor suppressor gene TET2 were discovered in 
26% of adult MDS patients, as well as in AML. (Delhommeau, et al 2009, Langemeijer, et al 
2009) Pediatric data show that this mutation is rare in children with AML. (Langemeijer, et al 
2011) Also, the WT1 mutations and NF1-mutations described in pediatric AML were 
detected with genomic profiling. (Balgobind, et al 2008, Hollink, et al 2009a)  
The development of high-throughput sequencing methods aims at identifying new 
mutations involved in AML. The sequencing of the first AML genome led to the 
identification of repetitive IDH1-mutations, although again they appeared to be rare in 
pediatric AML. (Ho, et al 2010a, Mardis, et al 2009) Moreover, DNMT3A mutations 
(encoding DNA methyltransferase 3A) were identified in this way, which appeared highly 
recurrent and associated with poor clinical outcome. (Ley, et al 2010, Yan, et al 2011) 
Recently, Greif et al. sequenced all transcriptionally active genes in another AML genome. 
(Greif, et al 2011) Five mutations specific to the tumor sample were found.  
Novel information on the molecular pathogenesis underlying paediatric AML, can also be 
found by gene-expression profiling. For example, NPM1-mutated AML was associated with 
deregulation of homeobox genes, different from HOX gene deregulation in MLL-rearranged 
paediatric AML, thereby suggesting for the first time different routes of perturbed HOX 
gene expression in paediatric AML subclasses. (Mullighan, et al 2007) In addition novel genes 
involved in the pathogenesis of MLL-gene rearranged pediatric AML were identified, such 
as the IGSF4 and BRE genes. (Balgobind, et al 2010b, Kuipers, et al 2011) Insights into the 
function of leukemia-associated antigens were recently gained from investigating the 
expression levels of the PRAME (Preferentially Expressed Antigen of MElanoma) gene in 
paediatric AML, showing cases with PRAME-overexpression to also harbour an increased 
expression of genes encoding ABC transporters such as multidrug resistance (MDR) 
proteins, and a decreased expression of genes encoding apoptotic proteins. (Goellner, et al 
2006)  
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9. Conclusion and perspectives 
In conclusion, pediatric AML is a heterogeneous disease, which currently can be cured in 
approximately 70% of children. Despite the heterogeneity most cases of AML are treated on 
uniform treatment protocols, as a result of the historical division between lymphoblastic and 
non-lymphoblastic leukemia. Improvement in prognosis may have reached a plateau as 
further intensification of therapy is not considered feasible, due to the relatively high rate of 
treatment-related deaths. Therefore, further improvements should come from 
understanding the underlying biology of pediatric AML and the development of more 
targeted therapy options. For many of the new therapeutic developments we are dependent 
on data obtained in adults, given the small number of available patients for studies. 
Nonetheless, pediatric safety studies should always be performed, as children are not small 
adults when it comes to drug development, especially given the risk of long term toxicity on 
growth and development. (Zwaan, et al 2010a) In the end this will require large international 
collaboration, especially for smaller subgroups characterized by specific genetic 
abnormalities, such as FLT3-mutated or KIT-mutated AML. That this is feasible is shown by 
current available treatment protocols specifically for Down syndrome AML and APL. 
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1. Introduction  
Natural killer (NK) cell malignancy is a heterogeneous disorder and rare, representing <1% 
of non-Hodgkin lymphomas for most of the world, except in Asia and Latin America. In 
Asia, especially, the incidence of NK-cell lymphomas is approximately 7%–10% of 
lymphomas [Au et al., 2005]. 
The pathogenesis of NK-cell malignancies has not yet been fully elucidated. In the 2008 
World Health Organization (WHO) classification of tumors of hematopoietic and 
lymphoid tissues, there are two entities associated with NK cells: mature T-cell and NK-
cell neoplasms (including chronic lymphoproliferative disorder of NK cells, aggressive 
NK-cell leukemia, and extranodal NK/T-cell lymphoma, nasal type) and NK-cell 
lymphoblastic leukemia/lymphoma, which is included provisionally in the category of 
acute leukemias of ambiguous lineage (Table 1) [Swedlow et al., 2008]. What was 
previously described as blastic NK-cell leukemia is defined as blastic plasmacytoid 
dendritic cell neoplasm in the WHO 2008 classification [Swedlow et al., 2008]. In pediatric 
patients, the four NK cell neoplasms are rare, with blastic NK-cell lymphoma being the 
most prevalent.  
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Table 1. WHO classification of hematopoietic and lymphoid neoplasms associated with NK 
cells [Swerdlow et al., 2008] 
A rigorous review of the literature to date is required to adequately understand and manage 
the various pediatric NK-cell malignant entities. The clinical characteristics of pediatric cases 
with these NK-cell malignant entities defined according to the 2008 WHO classification are 
discussed in this paper and compared to adult cases. 
2. Pathology of NK-cell neoplasms in pediatric patients 
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The 2008 WHO classification of tumors of hematopoietic and lymphoid tissue recognizes 
four categories of NK-cell neoplasms: NK-cell lymphoblastic leukemia/lymphoma, chronic 
 
Acute Leukemia – The Scientist's Perspective and Challenge 278 
lymphoproliferative disorder of NK cells, aggressive NK-cell leukemia (ANKL), and 
extranodal NK/T-cell lymphoma, nasal type (ENKL) (Table 1). NK-cell lymphoblastic 
leukemia involves immature NK cells, while chronic lymphoblastic leukemia/lymphoma, 
chronic lymphoproliferative disorder of NK cells, and aggressive NK-cell leukemia are 
mainly neoplasms of mature NK cells. ENKL is the main neoplasm of mature NK cells. 
Among the four entities, ANKL and ENKL are associated with Epstein-Barr virus (EBV). 
2.1 NK-cell lymphoblastic leukemia/lymphoma 
NK-cell lymphoblastic leukemia/lymphoma is a very rare disease in both adults and 
children. Because of limitations in NK-cell-specific markers, it is included as acute leukemia 
of ambiguous lineage according to the WHO 2008 classification [Swerdlow et al., 2008]. This 
neoplasm has been difficult to define. CD56 is the most important and sensitive NK-cell 
marker, but CD56 is not specific for NK cells. Previously, many cases were reported as NK-
cell leukemia because of the expression of CD57 but are plasmacytoid dendritic cell 
leukemia in the WHO 2008 classification. This issue is discussed below. 
2.2 Chronic lymphoproliferative disorder of NK cells 
Chronic lymphoproliferative disorder of NK cells is rare, especially in pediatric patients. It 
occurs in adults at a median age of 60 years. This provisional entity in the WHO 2008 
classification is characterized by a persistent (>6 months) increase in peripheral blood NK 
cells (usually 2 x 109/L) without a clearly identified cause. It is very difficult to distinguish 
between neoplastic and reactive NK cells. Cells have an NK-cell phenotype: CD16+, CD56+, 
CD2–, CD7–, surface CD3 (sCD3)–, and cytoplasmic CD3 (CD3)+. Cytotoxic markers 
including T-cell-restricted intracellular antigen-1 (TIA-1), granzyme B, and granzyme M are 
positive. EBV is negative. One pediatric case has been reported from China [Kwong et al., 
1995]. CD2 was positive and CD3 was weakly positive. EBV status was not described. The 
case was a 3-year-old female who presented hepatosplenomegaly. She died 11 days after 
diagnosis because of uncontrolled disease and did not receive chemotherapy. The clinical 
course of the majority of cases with chronic lymphoproliferative disorder of NK cells shows 
a good prognosis and transformation to aggressive disease has been rarely reported [Ohno 
et al., 1998]. 
2.3 Aggressive NK-cell leukemia 
ANKL is a systemic proliferation of NK cells with primary involvement of peripheral blood 
and bone marrow, and shows a fulminant clinical course. The age distribution of ANKL 
patients has been reported to show two peaks, one at 20 years and the other at 40 years of 
age [Suzuki et al., 2004b]. The disease typically affects patients at a younger age compared to 
other NK-cell malignancies. The clinical features, and cytological and immunohistochemical 
findings of this rare pediatric NK-cell malignancy are summarized in Tables 2 and 3. EBV is 
closely associated with the pathogenesis of this disease. Latent EBV shows monoclonality 
and causes EBV-infected NK-cell lymphoproliferative disease. 
2.3.1 Diagnosis 
Patients are diagnosed with ANKL when a proliferation of large granular lymphoblasts of 
an NK-cell phenotype is found in peripheral blood and/or bone marrow exceeding 30% of 
the total nucleated cells [Suzuki et al., 2004b]. The immunophenotype of ANKL is typically 
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defined by CD2+, sCD3–, CD3ε+, and CD56+. Loss of CD7 is occasionally observed. This 
immunophenotype is almost identical to that for extranodal NK/T-cell lymphoma, except 
for CD16+. T-cell receptor (TCR) genes are in germline configuration. Some cases are CD11b+ 
and CD57–. These neoplastic cells express FAS ligand and high levels of FAS ligand can 
found in the serum of affected patients [Kato et al., 1998]. 
2.3.2 Clinical features and immunohistochemical findings in pediatric and adolescent 
patients 
To date, 19 pediatric and adolescent cases (<19 years of age) have been reported in the 
literature from 1986 to 2010. Most patients have been reported from Japan and Korea. 
Table 2 summarizes the clinical findings of these 19 pediatric cases. Median age at 
diagnosis was 14 years (range, 2–19 years). Gender distribution was equal (9 females and 
10 males), which is the same in adult patients. Acute lymphoblastic leukemia typically 
affects children at 2–6 years of age, while the median age of ANKL patients is generally 
higher. 
Pediatric ANKL patients presented acute and rapidly progressive symptomatology. The 
most common presenting symptom is fever (12/13, 92%). Hepatomegaly (10/13, 77%), 
splenomegaly (12/16, 75%), and lymphoadenopathy (6/16, 37%) are also frequently 
observed. The incidence of these symptoms is almost same as that of adult patients [Yoo et 
al., 2009]. Two patients (cases 3 and 5) presented a chronic course and spontaneous 
regression was seen and transformation to ANKL. In adult patients, transformation from 
chronic lymphoproliferative disorder of NK cells to ANKL has been rarely reported. 
Pediatric patients manifest features of chronic active EBV infection, leading to overlap with 
EBV-positive T-cell lymphoproliferative disorders [Suzuki et al., 2004a]. The clinical 
presentation of ANKL has a resemblance to EBV-associated hemophagocytic 
lymphohistiocytosis. Chronic active EBV infection occurs predominantly in children and 
young adults and the incidence of hemophagocytosis as a clinical feature is frequently 
observed in cases of pediatric ANKL. Hypersensitivity to mosquito bites is sometimes seen 
as a preceding feature of ANKL in pediatric and adolescent patients. 
This disease is typically resistant to chemotherapy and successful treatment has been 
infrequently reported. The complete response rate is below 20% and 2-year overall survival 
rate is 5% in adult patients [Suzuki, 2010; Suzuki et al., 2010]. There is insufficient data to 
interpret complete remission and overall survival rates in pediatric ANKL patients. Results 
have been unsatisfactory using combination chemotherapy regimens that are typically used 
for acute lymphoblastic leukemia or non-Hodgkin lymphoma. In adults, chemotherapy with 
L-asparaginase-containing regimens has been reported to be effective in some cases 
[Ichikawa et al., 2010]. Among pediatric ANKL cases, only two patients were reported as 
being alive and one patient died with complete remission, while 13 cases died and one (case 
15) died of graft-versus-host disease (GVHD) and infection without relapse. The median 
survival time for patients who died is 4 months. Two cases received allogeneic stem cell 
transplantation: one died due to GVHD without disease and one was alive. Chemotherapy 
with L-asparaginase-containing regimens and subsequent allogeneic stem cell 
transplantation led to prolonged survival in a few young adult patients, even when the stem 
cell transplantation was performed in patients who did not have a complete response [Ito et 
al., 2008]. Better outcome is suggested among patients who received allogeneic stem cell 
transplantation. 
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sites Treatment Prognosis Reference 
1 6 y/M + + + +  NHL-BFM 
90/Allo-SCT 
Alive Ohnuma et 
al., 1997 
2 14 y/F + + + + Skin VCR/Dox/Cy
/CA 
Aggressive, 
died 4 mo 
Koizumi et 
al., 1986 
3 13 y/M ND ND + ND  ND ND Kawa-Ha 
et al., 1989 
4 15 y/M ND ND + ND  ND ND Kawa-Ha 
et al., 1989 
5 16 y/F ND ND + ND  ND ND Kawa-Ha 
et al., 1989 
6 16 y/F + + + –  ND Aggressive, 
died 32 mo 
Imamura et 
al., 1990 
7 13 y/F + + + +  ND Aggressive, 
died 26 mo 
Imamura et 
al., 1990 
8 18 y/M + + + + Lung VDS/THP-
ADR/Cy/PSL
Aggressive, 
died 4 mo 
Furuno et 
al., 1994 
9 13 y/M + + + –  PSL Aggressive, 
died 47 d 
Kaizu et 
al., 2004 
10 19 y/F + + – – HPS DHAP Aggressive, 




11 17 y/F + + + –  COP/BLM Aggressive, 
died 1 mo 
Suzuki et 
al., 2004b 
12 12 y/M + - - + Lung DNR/Cy/VCR
/L-Asp/PSL 
Aggressive, 
died 5 mo 
Suzuki et 
al., 2004b 
13 16 y/F + + + – Kidney PSL Aggressive, 
died 1 d 
Suzuki et 
al., 2004b 
14 18 y/F + – – + Tonsil CHOP/Allo-
SCT 
Died due to 
GVHD 39 mo 
Suzuki et 
al., 2004b 
15 13 y/M – – + –  AIEOP-95 Alive, CCR 
1447 d 
Patel et al., 
2010 
16 14 y/F ND ND ND ND  ND Aggressive, 
died 1 mo 
Yoo et al., 
2009 
17 2 y/M ND ND ND ND  ND Aggressive, 
died 5 d 
Yoo et al., 
2009 
18 16 y/M ND ND ND ND  ND Aggressive, 
died 11 mo 
Yoo et al., 
2009 
19 5 y/M + + – – HPS HLH2004 Aggressive, 
died 4 mo 
Petterson 
et al., 2008 
Abbreviations: ADR, adriamycin; AIEOP-95, Associazione Italiana Ematologia Oncologia Pediatrica 95 
protocol; Allo-SCT, allogeneic stem cell transplantation; BLM, bleomycin; CA, cytarabine; CCR, clinical 
complete response; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; COP, 
cyclophosphamide, vincristine, prednisolone; Cy, cyclophosphamide; d, days; DHAP, dexamethasone, 
high-dose cytarabine, cisplatin; Dox, doxorubicin; F, female; GVHD, graft-versus-host disease; 
HLH2004, hemophagocytic lymphohistiocytosis 2004 protocol; HPS, hemophagocytosis; L-Asp, L-
asparaginase; M, male; mo, months; ND, not determined; NHL-BFM 90, non-Hodgkin lymphoma-
Berlin-Frankfurt-Munster 90 protocol; mo, month; PSL, prednisolone; THP-ADR, pirarubicin; VCR, 
vincristine; VDS, vindesine; y, year. 
Table 2. Clinical characteristics of pediatric patients with aggressive NK leukemia 
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Yoo et al. have reported that CD7 antigen loss is frequently observed among adult ANKL 
patients and the absence of CD7 may serve as a reliable marker for the diagnosis of ANKL 
in adults [Yoo et al., 2009]. However, CD7+ is shown in 13 of 16 pediatric ANKL patients 
(Table 3). Immunophenotypic analysis of CD7 expression is therefore not useful in the 




Case CD2 CD3ε sCD3 CD4 CD7 CD8 CD16 CD56 CD57 EBV DNA Reference 
1 + ND – – + – – + – + Ohnuma et al., 
1997 
2 + ND – – ND – + – – + Koizumi et al., 
1986 
3 + ND – – ND – + ND ND + Kawa-Ha et al., 
1989 
4 + + – – + – – + ND + Kawa-Ha et al., 
1989 
5 + ND – – + – + + ND + Kawa-Ha et al., 
1989 
6 + ND – – + – + ND - ND Imamura et al., 
1990 
7 + ND – – + – ND + ND ND Imamura et al., 
1990 
8 + ND – – + – + ND ND + Furuno et al., 
1994 
9 + ND – ND + ND – + – + Kaizu et al., 2004 
10 ND + – ND ND ND ND + ND ND Kohrt & Advani, 
2004 
11 + ND – – + + ND + ND + Suzuki et al., 
2004b 
12 + ND – – – – + + ND + Suzuki et al., 
2004b 
13 + ND – – + – + + ND + Suzuki et al., 
2004b 
14 + – – – + – ND + - ND Suzuki et al., 
2004b 
15 – + – – – – – + ND ND Patel et al., 2010 
16 + + – – + – + + ND ND Yoo et al., 2009 
17 + + – ND + ND + + ND ND Yoo et al., 2009 
18 + + – – + – + + ND – Yoo et al., 2009 
19 + + – – – + ND + ND + Petterson et al., 
2008 
 
Abbreviations: EBV, Epstein-Barr virus; ND, not determined. 
Table 3. Phenotypic characteristics of pediatric patients with aggressive NK leukemia. Case 
numbers correspond with those in Table 2 
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sites Treatment Prognosis Reference 
1 6 y/M + + + +  NHL-BFM 
90/Allo-SCT 
Alive Ohnuma et 
al., 1997 
2 14 y/F + + + + Skin VCR/Dox/Cy
/CA 
Aggressive, 
died 4 mo 
Koizumi et 
al., 1986 
3 13 y/M ND ND + ND  ND ND Kawa-Ha 
et al., 1989 
4 15 y/M ND ND + ND  ND ND Kawa-Ha 
et al., 1989 
5 16 y/F ND ND + ND  ND ND Kawa-Ha 
et al., 1989 
6 16 y/F + + + –  ND Aggressive, 
died 32 mo 
Imamura et 
al., 1990 
7 13 y/F + + + +  ND Aggressive, 
died 26 mo 
Imamura et 
al., 1990 
8 18 y/M + + + + Lung VDS/THP-
ADR/Cy/PSL
Aggressive, 
died 4 mo 
Furuno et 
al., 1994 
9 13 y/M + + + –  PSL Aggressive, 
died 47 d 
Kaizu et 
al., 2004 
10 19 y/F + + – – HPS DHAP Aggressive, 




11 17 y/F + + + –  COP/BLM Aggressive, 
died 1 mo 
Suzuki et 
al., 2004b 
12 12 y/M + - - + Lung DNR/Cy/VCR
/L-Asp/PSL 
Aggressive, 
died 5 mo 
Suzuki et 
al., 2004b 
13 16 y/F + + + – Kidney PSL Aggressive, 
died 1 d 
Suzuki et 
al., 2004b 
14 18 y/F + – – + Tonsil CHOP/Allo-
SCT 
Died due to 
GVHD 39 mo 
Suzuki et 
al., 2004b 
15 13 y/M – – + –  AIEOP-95 Alive, CCR 
1447 d 
Patel et al., 
2010 
16 14 y/F ND ND ND ND  ND Aggressive, 
died 1 mo 
Yoo et al., 
2009 
17 2 y/M ND ND ND ND  ND Aggressive, 
died 5 d 
Yoo et al., 
2009 
18 16 y/M ND ND ND ND  ND Aggressive, 
died 11 mo 
Yoo et al., 
2009 
19 5 y/M + + – – HPS HLH2004 Aggressive, 
died 4 mo 
Petterson 
et al., 2008 
Abbreviations: ADR, adriamycin; AIEOP-95, Associazione Italiana Ematologia Oncologia Pediatrica 95 
protocol; Allo-SCT, allogeneic stem cell transplantation; BLM, bleomycin; CA, cytarabine; CCR, clinical 
complete response; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; COP, 
cyclophosphamide, vincristine, prednisolone; Cy, cyclophosphamide; d, days; DHAP, dexamethasone, 
high-dose cytarabine, cisplatin; Dox, doxorubicin; F, female; GVHD, graft-versus-host disease; 
HLH2004, hemophagocytic lymphohistiocytosis 2004 protocol; HPS, hemophagocytosis; L-Asp, L-
asparaginase; M, male; mo, months; ND, not determined; NHL-BFM 90, non-Hodgkin lymphoma-
Berlin-Frankfurt-Munster 90 protocol; mo, month; PSL, prednisolone; THP-ADR, pirarubicin; VCR, 
vincristine; VDS, vindesine; y, year. 
Table 2. Clinical characteristics of pediatric patients with aggressive NK leukemia 
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Yoo et al. have reported that CD7 antigen loss is frequently observed among adult ANKL 
patients and the absence of CD7 may serve as a reliable marker for the diagnosis of ANKL 
in adults [Yoo et al., 2009]. However, CD7+ is shown in 13 of 16 pediatric ANKL patients 
(Table 3). Immunophenotypic analysis of CD7 expression is therefore not useful in the 




Case CD2 CD3ε sCD3 CD4 CD7 CD8 CD16 CD56 CD57 EBV DNA Reference 
1 + ND – – + – – + – + Ohnuma et al., 
1997 
2 + ND – – ND – + – – + Koizumi et al., 
1986 
3 + ND – – ND – + ND ND + Kawa-Ha et al., 
1989 
4 + + – – + – – + ND + Kawa-Ha et al., 
1989 
5 + ND – – + – + + ND + Kawa-Ha et al., 
1989 
6 + ND – – + – + ND - ND Imamura et al., 
1990 
7 + ND – – + – ND + ND ND Imamura et al., 
1990 
8 + ND – – + – + ND ND + Furuno et al., 
1994 
9 + ND – ND + ND – + – + Kaizu et al., 2004 
10 ND + – ND ND ND ND + ND ND Kohrt & Advani, 
2004 
11 + ND – – + + ND + ND + Suzuki et al., 
2004b 
12 + ND – – – – + + ND + Suzuki et al., 
2004b 
13 + ND – – + – + + ND + Suzuki et al., 
2004b 
14 + – – – + – ND + - ND Suzuki et al., 
2004b 
15 – + – – – – – + ND ND Patel et al., 2010 
16 + + – – + – + + ND ND Yoo et al., 2009 
17 + + – ND + ND + + ND ND Yoo et al., 2009 
18 + + – – + – + + ND – Yoo et al., 2009 
19 + + – – – + ND + ND + Petterson et al., 
2008 
 
Abbreviations: EBV, Epstein-Barr virus; ND, not determined. 
Table 3. Phenotypic characteristics of pediatric patients with aggressive NK leukemia. Case 
numbers correspond with those in Table 2 
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2.4 Nasal and extranodal NK-cell lymphoma 
ENKL is characterized by vascular damage and destruction, prominent necrosis, a cytotoxic 
phenotype, and an association with EBV. ENKL typically presents in the nasal cavity or 
nasopharynx, with most cases having tumors localized in the upper aerodigestive tract 
(UAT) including nasal cavity, nasopharynx, oral cavity, oropharynx, and hypopharynx. 
Primary tumors that present outside the UAT, but share identical histologic features with 
the UAT disease, have also been categorized as non-nasal-type NK/T-cell lymphoma 
(NUAT-ENKL). There is clinical heterogeneity between nasal and extranasal UAT-ENKL or 
between UAT-ENKL and NUAT-ENKL [Kohrt et al., 2009; Kim et al., 2008]. Kim et al. 
reported that NUAT-ENKL had significantly higher proportions of disseminated disease, 
aggressive biologic features, and worse prognosis than UAT-ENKL [Kim et al., 2008]. In the 
UAT-ENKL group, there are differences in clinical prognostic factors between nasal UAT 
and extranasal UAT. Patients with extranasal UAT showed a higher proportion of advanced 
disease (stages III and IV on the Ann Arbor system) and regional lympohadenopathy. 
However, there did not seem to be any difference between extranasal UAT-ENKL and nasal 
UAT-ENKL with respect to survival rate. Compared to patients with UAT-ENKL (including 
both nasal and extranasal UAT ENKL), patients with NUAT-ENKL showed significantly 
higher proportions of advanced-stage disease, two or more extranodal sites, positive 
regional lymphadenopathy, presence of B symptoms, and poor Eastern Cooperative 
Oncology Group performance status. As a result of the aggressive features of NUAT-ENKL, 
survival rates were lower than those of UAT-ENKL (5-year overall survival rate: 22% versus 
41%, P <0.001) [Kim et al., 2008]. 
ENKL is rare in Western countries, but is more frequent in East Asia, and Central and South 
America [Oshimi, 1996]. It represents 3.3% of all non-Hodgkin lymphoma in Japan, 6% in 
Hong Kong, 8% in Korea, and 5% in Taiwan [Lymphoma Study Group of Japanese 
Pathologists, 2000]. ENKL is the most common lymphoma type among primary nasal-type 
lymphomas in Asian patients. The male:female ratio in approximately 3:1 and the median 
age of presentation is middle age [Ishida & Kwong, 2010]. ENKL shows onset at an older 
age than ANKL. 
2.4.1 Diagnosis 
The immunophenotype of ENKL is typically CD2+, CD56+, CD3ε+, sCD3–, CD4–, CD20–, and 
CD30–. CD56, a highly useful marker for NK cells, is not specific for ENKL and can be 
expressed in peripheral T-cell lymphomas. Occasional cases are CD7+ or CD30+. ENKL 
shares many feature with ANKL, such as the presence of azurophilic granules in the 
cytoplasm of the neoplastic cells and identical immunophenotype except for CD16 
expression. CD16 is negative in ENKL cases, but is positive in most ANKL cases [Nava & 
Jaffe, 2005]. As with ANKL, ENKL tumor cells are usually EBV positive. Cytotoxic 
molecules are positive (granzyme B, TIA-1, and perforin). Lymphomas that demonstrate a 
CD3ε+ and CD56– immunophenotype are also classified ENKL if both cytotoxic molecules 
and EBV are positive. TCR rearrangement is in the germline configuration. CD56 is a highly 
useful marker of NK cells but is not specific for ENKL. CD56 is expressed in peripheral T-
cell lymphomas, particularly those that show the gamma delta TCR configuration. 
2.4.2 Clinical features and Immunohistochemical findings in pediatric and adolescent 
patients 
In this literature review, all journals were searched from 1996 to date for ENKL cases (Tables 
4 and 5). Twenty-one pediatric cases with ENKL were reported: seven from Asia, 11 from 
 













Treatment Prognosis Reference 
1 17 y/M IV + NUAT L/S/LN HPS mBACOD, 
2-CdA 
Aggressive, 
died 2 mo 
Kwong et al., 
1997 
2 17 y/F I – UAT 
(nasal) 
  CHOP Alive 27 mo Kwong et al., 
1997 
3 18 y/F I – UAT 
(nasal) 
  CHOP Alive 107 mo Kwong et al., 
1997 
4 16 y/F II + NUAT Cecum  CHOP Aggressive, 
died 7 mo 
Lei et al., 1997 
5 15 y/F IV + NUAT L/S/Mes
o/BM 
 – Aggressive, 
died 59 d 
Catlin et al., 
1999 
6 1 mo/M IV + NUAT L/S/BM  IFN- Aggressive, 
died 6 d 
Catlin et al., 
1999 
7 9 y/M II – NUAT Sk/LN  POG9219/
CCG1883/
HDC 
Alive, 41 mo Shaw et al., 
2001 
8 12 y/M II – NUAT M/LN  POG9219/I
CE/HDC
Alive, 15 mo Shaw et al., 
2001 
9 17 y/M IV ND NUAT Sk HPS ND Died 33 mo Ko et al., 2004 
10 17 y/M IV – NUAT L/Sk/L
N 
 GEM/IRI Aggressive, 
died 67 d 
Pol-Rodriguez 
et al., 2006 





died 3 mo 
Aydin et al., 
2007 
12 0.7 y/F I ND UAT 
(mastoid)
  POG9219 Alive Hutchinson et 
al., 2008 
13 16.3 y/M I ND UAT 
(nasal) 
  POG9219 Died Hutchinson et 
al., 2008 
14 16.3 y/F II ND UAT 
(nasal) 
Sk  POG9219 Alive Hutchinson et 
al., 2008 
15 16.6 y/M II ND UAT 
(nasal) 
  POG9219 Died Hutchinson et 
al., 2008 
16 16 y/M I – UAT 
(nasal) 
  CHOP Alive, CCR 
>24 mo 
Chang et al., 
2008 
17 12 y/F I – UAT 
(nasal) 
  CHOP/IR Alive, CCR 8 
mo 
Lee et al., 2008 
18 11 y/M IV + UAT 
(nasal) 
BM HPS – Aggressive, 
died 5 mo 
Brodkin et al., 
2008 
19 9 y/F I + UAT 
(nasophary
nx) 
 HMB CHOP ND Zhang et al., 
2009 




CHOP Died 1 mo Pellier et al., 
2009 
21 4 y/M I + UAT 
(nasal) 
  CHOP Aggressive, 
died 18 d 
Miles et al., 
2010 
Abbreviations: BM, bone marrow; CCG1883, Childhood Cancer Group 1883 protocol; CCR, clinical 
complete response; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; d, days; F, 
female; GEM, gemcitabine; HDC, high-dose chemotherapy; HMB, hypersensitivity to mosquito bites; 
HPS, hemophagocytosis; ICE, ifosfamide, carboplatin, etoposide; IFN-interferon alpha; IR, irinotecan; 
K, kidney; L, lung; Li, liver; LN, lymph node; M, mastoid; mo, months; P, pancreas; POG9219, Pediatric 
Onocology Group 9219 protocol; M, male; mBACOD; bleomycin, adriamycin, cyclophosphamide, 
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2.4 Nasal and extranodal NK-cell lymphoma 
ENKL is characterized by vascular damage and destruction, prominent necrosis, a cytotoxic 
phenotype, and an association with EBV. ENKL typically presents in the nasal cavity or 
nasopharynx, with most cases having tumors localized in the upper aerodigestive tract 
(UAT) including nasal cavity, nasopharynx, oral cavity, oropharynx, and hypopharynx. 
Primary tumors that present outside the UAT, but share identical histologic features with 
the UAT disease, have also been categorized as non-nasal-type NK/T-cell lymphoma 
(NUAT-ENKL). There is clinical heterogeneity between nasal and extranasal UAT-ENKL or 
between UAT-ENKL and NUAT-ENKL [Kohrt et al., 2009; Kim et al., 2008]. Kim et al. 
reported that NUAT-ENKL had significantly higher proportions of disseminated disease, 
aggressive biologic features, and worse prognosis than UAT-ENKL [Kim et al., 2008]. In the 
UAT-ENKL group, there are differences in clinical prognostic factors between nasal UAT 
and extranasal UAT. Patients with extranasal UAT showed a higher proportion of advanced 
disease (stages III and IV on the Ann Arbor system) and regional lympohadenopathy. 
However, there did not seem to be any difference between extranasal UAT-ENKL and nasal 
UAT-ENKL with respect to survival rate. Compared to patients with UAT-ENKL (including 
both nasal and extranasal UAT ENKL), patients with NUAT-ENKL showed significantly 
higher proportions of advanced-stage disease, two or more extranodal sites, positive 
regional lymphadenopathy, presence of B symptoms, and poor Eastern Cooperative 
Oncology Group performance status. As a result of the aggressive features of NUAT-ENKL, 
survival rates were lower than those of UAT-ENKL (5-year overall survival rate: 22% versus 
41%, P <0.001) [Kim et al., 2008]. 
ENKL is rare in Western countries, but is more frequent in East Asia, and Central and South 
America [Oshimi, 1996]. It represents 3.3% of all non-Hodgkin lymphoma in Japan, 6% in 
Hong Kong, 8% in Korea, and 5% in Taiwan [Lymphoma Study Group of Japanese 
Pathologists, 2000]. ENKL is the most common lymphoma type among primary nasal-type 
lymphomas in Asian patients. The male:female ratio in approximately 3:1 and the median 
age of presentation is middle age [Ishida & Kwong, 2010]. ENKL shows onset at an older 
age than ANKL. 
2.4.1 Diagnosis 
The immunophenotype of ENKL is typically CD2+, CD56+, CD3ε+, sCD3–, CD4–, CD20–, and 
CD30–. CD56, a highly useful marker for NK cells, is not specific for ENKL and can be 
expressed in peripheral T-cell lymphomas. Occasional cases are CD7+ or CD30+. ENKL 
shares many feature with ANKL, such as the presence of azurophilic granules in the 
cytoplasm of the neoplastic cells and identical immunophenotype except for CD16 
expression. CD16 is negative in ENKL cases, but is positive in most ANKL cases [Nava & 
Jaffe, 2005]. As with ANKL, ENKL tumor cells are usually EBV positive. Cytotoxic 
molecules are positive (granzyme B, TIA-1, and perforin). Lymphomas that demonstrate a 
CD3ε+ and CD56– immunophenotype are also classified ENKL if both cytotoxic molecules 
and EBV are positive. TCR rearrangement is in the germline configuration. CD56 is a highly 
useful marker of NK cells but is not specific for ENKL. CD56 is expressed in peripheral T-
cell lymphomas, particularly those that show the gamma delta TCR configuration. 
2.4.2 Clinical features and Immunohistochemical findings in pediatric and adolescent 
patients 
In this literature review, all journals were searched from 1996 to date for ENKL cases (Tables 
4 and 5). Twenty-one pediatric cases with ENKL were reported: seven from Asia, 11 from 
 













Treatment Prognosis Reference 
1 17 y/M IV + NUAT L/S/LN HPS mBACOD, 
2-CdA 
Aggressive, 
died 2 mo 
Kwong et al., 
1997 
2 17 y/F I – UAT 
(nasal) 
  CHOP Alive 27 mo Kwong et al., 
1997 
3 18 y/F I – UAT 
(nasal) 
  CHOP Alive 107 mo Kwong et al., 
1997 
4 16 y/F II + NUAT Cecum  CHOP Aggressive, 
died 7 mo 
Lei et al., 1997 
5 15 y/F IV + NUAT L/S/Mes
o/BM 
 – Aggressive, 
died 59 d 
Catlin et al., 
1999 
6 1 mo/M IV + NUAT L/S/BM  IFN- Aggressive, 
died 6 d 
Catlin et al., 
1999 
7 9 y/M II – NUAT Sk/LN  POG9219/
CCG1883/
HDC 
Alive, 41 mo Shaw et al., 
2001 
8 12 y/M II – NUAT M/LN  POG9219/I
CE/HDC
Alive, 15 mo Shaw et al., 
2001 
9 17 y/M IV ND NUAT Sk HPS ND Died 33 mo Ko et al., 2004 
10 17 y/M IV – NUAT L/Sk/L
N 
 GEM/IRI Aggressive, 
died 67 d 
Pol-Rodriguez 
et al., 2006 





died 3 mo 
Aydin et al., 
2007 
12 0.7 y/F I ND UAT 
(mastoid)
  POG9219 Alive Hutchinson et 
al., 2008 
13 16.3 y/M I ND UAT 
(nasal) 
  POG9219 Died Hutchinson et 
al., 2008 
14 16.3 y/F II ND UAT 
(nasal) 
Sk  POG9219 Alive Hutchinson et 
al., 2008 
15 16.6 y/M II ND UAT 
(nasal) 
  POG9219 Died Hutchinson et 
al., 2008 
16 16 y/M I – UAT 
(nasal) 
  CHOP Alive, CCR 
>24 mo 
Chang et al., 
2008 
17 12 y/F I – UAT 
(nasal) 
  CHOP/IR Alive, CCR 8 
mo 
Lee et al., 2008 
18 11 y/M IV + UAT 
(nasal) 
BM HPS – Aggressive, 
died 5 mo 
Brodkin et al., 
2008 
19 9 y/F I + UAT 
(nasophary
nx) 
 HMB CHOP ND Zhang et al., 
2009 




CHOP Died 1 mo Pellier et al., 
2009 
21 4 y/M I + UAT 
(nasal) 
  CHOP Aggressive, 
died 18 d 
Miles et al., 
2010 
Abbreviations: BM, bone marrow; CCG1883, Childhood Cancer Group 1883 protocol; CCR, clinical 
complete response; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; d, days; F, 
female; GEM, gemcitabine; HDC, high-dose chemotherapy; HMB, hypersensitivity to mosquito bites; 
HPS, hemophagocytosis; ICE, ifosfamide, carboplatin, etoposide; IFN-interferon alpha; IR, irinotecan; 
K, kidney; L, lung; Li, liver; LN, lymph node; M, mastoid; mo, months; P, pancreas; POG9219, Pediatric 
Onocology Group 9219 protocol; M, male; mBACOD; bleomycin, adriamycin, cyclophosphamide, 
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vincristine, dexamethasone, methotrexate; meso, mesosalpinx; ND, not determined; NUAT; non-upper 
aerodigestive tract; O, oral; S, spleen; Sk, skin; UAT; upper aerodigestive tract; y, years; 2-CdA, 2-
chlorodeoxyadenosine. 
Table 4. Clinical characteristics of pediatric patients with extranodal NK leukemia 
 







1 + ND – – – – – + ND ND ND Kwong et al., 
1997 
2 + ND – – – – – + ND ND ND Kwong et al., 
1997 
3 + ND – – – – – + ND ND ND Kwong et al., 
1997 
4 + – – – + –  + ND – ND Lei et al., 1997 
5 – – – – NT – – + ND NT + Catlin et al., 1999 
6 – – – + + + + + ND NT + Catlin et al., 1999 
7 + – – – – – – + ND – – Shaw et al., 2001 
8 – – – – – – – + ND ND + Shaw et al., 2001 
9 ND ND ND ND ND ND ND ND ND – + Ko et al., 2004 
10 + + + + + + + + TIA-1+ NT + Pol-Rodriguez et 
al., 2006 
11 + + ND – ND – ND – Granzym
e B+ 
– – Aydin et al., 2007 
12 ND ND ND ND ND ND ND ND ND ND ND Hutchinson et al., 
2008 
13 ND ND ND ND ND ND ND ND ND ND ND Hutchinson et al., 
2008 
14 ND ND ND ND ND ND ND ND ND ND ND Hutchinson et al., 
2008 
15 ND ND ND ND ND ND ND ND ND ND ND Hutchinson et al., 
2008 
16 + + NT + + – NT – TIA-1, 
granzyme 
B+ 
+ + Chang et al., 2008 
17 NT + + NT NT NT + + NT NT – Lee et al., 2008 
18 + + + NT NT - NT + NT NT + Brodkin et al., 
2008 
19 + NT + NT + + NT – TIA-1 + – + Zhang et al., 2009 
20 + + + + + + – + ND + + Pellier et al., 2009 
21 + + NT – + + NT – TIA-1+ + + Miles et al., 2010 
Abbreviations: EBV, Epstein Barr virus; ND, not determined; NT, not tested; TCR, T-cell antigen receptor; 
TIA-1, T-cell-restricted intracellular antigen-1. 
Table 5. Phenotypic characteristics of pediatric patients with extranodal NK leukemia. Case 
numbers correspond with those in Table 4 
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US (including one with acquired disease), and one each from Turkey, South America, and 
France. In adult patients, the International Peripheral T-cell Lymphoma Project reported a 
four-fold higher relative frequency of ENKL among lymphoma in Asian countries compared 
to Western countries [Au et al., 2009]. For peripheral T-cell lymphoma, ENKL was the most 
common histology in Asian countries (range 34%–56%) except for Japan (11%) [Au et al., 
2009]. In children and adolescents, the frequency of Asian cases is the same as in adults. 
Median age is 16 years (range, 0.7–18 years excluding the infant with acquired disease) and 
the mean age is 13 years. ENKL presents at a higher age than other forms of pediatric 
leukemia/lymphoma in a similar manner to other NK-lineage leukemias/lymphomas. 
There were 11 males and 9 females (male to female ratio, 1.22:1) and male predominance has 
been reported in adults. 
Of the 21 pediatric patients, 14 patients had local disease (stage I and II) and seven had 
disseminated disease (stage III and IV) on the Ann Arbor staging system. The ratio of 
patients with UAT-ENKL as compared to those with NUAT-ENKL is 7:2 in adults and 2:1 in 
pediatric patients (Table 4). In pediatric patients, the frequency of NUAT-ENKL patients is 
higher than in adults [Oshimi et al., 2005]. In pediatric ENKL patients, about half of them 
presented UAT-ENKL: nine patients had a nasal site and three patients had an extranasal 
site, including mastoid, tonsil, and skin. UAT patients have been regarded as having no 
dissemination to other sites [Kim & Heo, 2009]. Cases 18 and 21 are therefore exceptional 
cases. They had significant hepatomegaly and lymphadenopathy. Their condition 
deteriorated progressively and lymph node biopsy and bone marrow aspiration presented 
the invasion of ENKL cells. Case 18 died after 4 days and case 20 died after 30 days from 
onset [Brodkin et al., 2008]. In adult patients, only 16% of UAT-ENKL patients are reported 
to have involvement of an extranodal site [Kim et al., 2008]. 
The proportion of pediatric NUAT-ENKL with a primary tumor outside the UAT is higher 
than that in adults. In adults, Kim et al. reported three patients with local disease (stage II) 
and six with disseminated disease (stage IV) [Kim et al., 2008]. Patients with NUAT-ENKL 
showed higher proportions of advanced-stage disease than adult patients with NUAT- 
ENKL. In pediatric patients tumor tended to disseminate. The sites involved were lymph 
node (5 cases), spleen (5 cases), lung (4 cases), bone marrow (2 cases), and skin (2 cases). The 
predominant site of adult NUAT-ENKL group is skin (37%), liver or spleen (31%), and the 
GI tract (24%). 
Hemophagocytosis (HPS) can be a complication in ENKL (2%–8% of patients) [Kim et al., 
2008]. In pediatric patients, four (1 UAT and 3 NUAT) of 20 cases were reported with HPS 
(Table 4). The frequency of HPS in pediatric patients may be higher than that of adults. 
2.4.3 Hypersensitivity to Mosquito Bite syndrome and ENKL 
Hypersensitivity to mosquito bite (HMB) syndrome is characterized by an intense skin 
reaction and systemic symptomatology such as high fever, lymphadenopathy, and 
hepatosplenomegaly. This condition has been mostly reported in Japanese children. HMB 
syndrome occurs in association with NK-cell lymphocytosis-related chronic EBV infection. 
CD4+ T cells from patients respond markedly to mosquito salivary gland extracts, and CD4+ 
T cells stimulated by mosquito bites may play a key role in the development of HMB 
syndrome and NK-cell oncogenesis. It is unclear how stimulated CD4+ T cells are involved 
in viral reactivation of viral oncogene expression in NK cells (Fig. 1) [Asada, 2007]. In the 20 
pediatric ENKL cases in this review, two cases may have exhibited HMB syndrome before 
ENKL; one from China and the other from Turkey. 
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vincristine, dexamethasone, methotrexate; meso, mesosalpinx; ND, not determined; NUAT; non-upper 
aerodigestive tract; O, oral; S, spleen; Sk, skin; UAT; upper aerodigestive tract; y, years; 2-CdA, 2-
chlorodeoxyadenosine. 
Table 4. Clinical characteristics of pediatric patients with extranodal NK leukemia 
 







1 + ND – – – – – + ND ND ND Kwong et al., 
1997 
2 + ND – – – – – + ND ND ND Kwong et al., 
1997 
3 + ND – – – – – + ND ND ND Kwong et al., 
1997 
4 + – – – + –  + ND – ND Lei et al., 1997 
5 – – – – NT – – + ND NT + Catlin et al., 1999 
6 – – – + + + + + ND NT + Catlin et al., 1999 
7 + – – – – – – + ND – – Shaw et al., 2001 
8 – – – – – – – + ND ND + Shaw et al., 2001 
9 ND ND ND ND ND ND ND ND ND – + Ko et al., 2004 
10 + + + + + + + + TIA-1+ NT + Pol-Rodriguez et 
al., 2006 
11 + + ND – ND – ND – Granzym
e B+ 
– – Aydin et al., 2007 
12 ND ND ND ND ND ND ND ND ND ND ND Hutchinson et al., 
2008 
13 ND ND ND ND ND ND ND ND ND ND ND Hutchinson et al., 
2008 
14 ND ND ND ND ND ND ND ND ND ND ND Hutchinson et al., 
2008 
15 ND ND ND ND ND ND ND ND ND ND ND Hutchinson et al., 
2008 
16 + + NT + + – NT – TIA-1, 
granzyme 
B+ 
+ + Chang et al., 2008 
17 NT + + NT NT NT + + NT NT – Lee et al., 2008 
18 + + + NT NT - NT + NT NT + Brodkin et al., 
2008 
19 + NT + NT + + NT – TIA-1 + – + Zhang et al., 2009 
20 + + + + + + – + ND + + Pellier et al., 2009 
21 + + NT – + + NT – TIA-1+ + + Miles et al., 2010 
Abbreviations: EBV, Epstein Barr virus; ND, not determined; NT, not tested; TCR, T-cell antigen receptor; 
TIA-1, T-cell-restricted intracellular antigen-1. 
Table 5. Phenotypic characteristics of pediatric patients with extranodal NK leukemia. Case 
numbers correspond with those in Table 4 
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US (including one with acquired disease), and one each from Turkey, South America, and 
France. In adult patients, the International Peripheral T-cell Lymphoma Project reported a 
four-fold higher relative frequency of ENKL among lymphoma in Asian countries compared 
to Western countries [Au et al., 2009]. For peripheral T-cell lymphoma, ENKL was the most 
common histology in Asian countries (range 34%–56%) except for Japan (11%) [Au et al., 
2009]. In children and adolescents, the frequency of Asian cases is the same as in adults. 
Median age is 16 years (range, 0.7–18 years excluding the infant with acquired disease) and 
the mean age is 13 years. ENKL presents at a higher age than other forms of pediatric 
leukemia/lymphoma in a similar manner to other NK-lineage leukemias/lymphomas. 
There were 11 males and 9 females (male to female ratio, 1.22:1) and male predominance has 
been reported in adults. 
Of the 21 pediatric patients, 14 patients had local disease (stage I and II) and seven had 
disseminated disease (stage III and IV) on the Ann Arbor staging system. The ratio of 
patients with UAT-ENKL as compared to those with NUAT-ENKL is 7:2 in adults and 2:1 in 
pediatric patients (Table 4). In pediatric patients, the frequency of NUAT-ENKL patients is 
higher than in adults [Oshimi et al., 2005]. In pediatric ENKL patients, about half of them 
presented UAT-ENKL: nine patients had a nasal site and three patients had an extranasal 
site, including mastoid, tonsil, and skin. UAT patients have been regarded as having no 
dissemination to other sites [Kim & Heo, 2009]. Cases 18 and 21 are therefore exceptional 
cases. They had significant hepatomegaly and lymphadenopathy. Their condition 
deteriorated progressively and lymph node biopsy and bone marrow aspiration presented 
the invasion of ENKL cells. Case 18 died after 4 days and case 20 died after 30 days from 
onset [Brodkin et al., 2008]. In adult patients, only 16% of UAT-ENKL patients are reported 
to have involvement of an extranodal site [Kim et al., 2008]. 
The proportion of pediatric NUAT-ENKL with a primary tumor outside the UAT is higher 
than that in adults. In adults, Kim et al. reported three patients with local disease (stage II) 
and six with disseminated disease (stage IV) [Kim et al., 2008]. Patients with NUAT-ENKL 
showed higher proportions of advanced-stage disease than adult patients with NUAT- 
ENKL. In pediatric patients tumor tended to disseminate. The sites involved were lymph 
node (5 cases), spleen (5 cases), lung (4 cases), bone marrow (2 cases), and skin (2 cases). The 
predominant site of adult NUAT-ENKL group is skin (37%), liver or spleen (31%), and the 
GI tract (24%). 
Hemophagocytosis (HPS) can be a complication in ENKL (2%–8% of patients) [Kim et al., 
2008]. In pediatric patients, four (1 UAT and 3 NUAT) of 20 cases were reported with HPS 
(Table 4). The frequency of HPS in pediatric patients may be higher than that of adults. 
2.4.3 Hypersensitivity to Mosquito Bite syndrome and ENKL 
Hypersensitivity to mosquito bite (HMB) syndrome is characterized by an intense skin 
reaction and systemic symptomatology such as high fever, lymphadenopathy, and 
hepatosplenomegaly. This condition has been mostly reported in Japanese children. HMB 
syndrome occurs in association with NK-cell lymphocytosis-related chronic EBV infection. 
CD4+ T cells from patients respond markedly to mosquito salivary gland extracts, and CD4+ 
T cells stimulated by mosquito bites may play a key role in the development of HMB 
syndrome and NK-cell oncogenesis. It is unclear how stimulated CD4+ T cells are involved 
in viral reactivation of viral oncogene expression in NK cells (Fig. 1) [Asada, 2007]. In the 20 
pediatric ENKL cases in this review, two cases may have exhibited HMB syndrome before 
ENKL; one from China and the other from Turkey. 
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Fig. 1. CD4+ T cells stimulated by mosquito bites may play a key role in the development of 
hypersensitivity to mosquito bites (HMB) and NK-cell oncogenesis via the induction of 
Epstein-Barr virus (EBV) reactivation and EBV-oncogene latent membrane protein 1 (LMP1) 
expression, respectively [Asada 2007] 
2.4.4 Treatment and outcome 
There remains a lack of consensus on the treatment of ENKL and there is no standard 
therapy in adults or pediatric patients. ENKL shows an aggressive clinical course with 
various clinicopathologic characteristics. Due to this clinical heterogeneity of ENKL, optimal 
treatment and prognostic factors have been difficult to determine with the conventional Ann 
Arbor staging system. NUAT-ENKL has a pathologic similarity to UAT–ENKL but is a 
clinically distinct subtype. 
2.4.4.1 Radiotherapy 
For early-stage ENKL, both UAT and NUAT, experience with radiation therapy, 
chemotherapy, and combined therapy has been reported. The largest study with 
radiotherapy or radiotherapy plus chemotherapy was reported by Kim et al. [2001]. In this 
report of 143 patients, 104 received upfront radiotherapy alone with a median dose of 50.4 
Gy (range, 20–70 Gy). Of those who received radiotherapy alone, 69% of patients achieved a 
complete response (CR), while only 8% of those who received chemotherapy prior to 
radiotherapy achieved CR [Kim et al., 2001; Korht & Advani 2009]. Huang et al. reported CR 
and 5-year overall survival (OS) rates of 100% in patients who received radiotherapy alone, 
while those who received chemotherapy (CHOP) alone had rates of 25% and 90%, 
respectively [Huang et al., 2008]. Li et al. reported overall response in 85 of 87 (97.7%) 
patients with stage I UAT-ENKL who received radiotherapy with 50–56 Gy (standard is 50 
Gy). The 5-year OS, 5-year progression-free survival (PFS), and local control rates for all 
patients were 80%, 69%, and 93%, respectively [Li et al., 2011b]. 
The dose and field of radiation in stage I or II ENKL is an important factor with respect to 
outcome. A radiation dose of at least 54 Gy is seen as being associated with better outcome. 
Comparing those who received ≥54 Gy versus <54 Gy, 5-year OS and disease-free survival 
(DFS) rates were higher with the former: 75% vs 46% and 60% vs 46%, respectively [Huang 
et al., 2008]. Systemic failure is shown in 25% to 30% of patients with stage II and II disease 
treated with radiotherapy alone. This shows the role of chemotherapy in control of clinically 
occult disease. 
2.4.4.2 Chemotherapy 
There are few studies that included patients treated with chemotherapy alone. Studies of 
chemotherapy regimens including cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP) are disappointing because of high rates of refractory disease or early 
relapse: the CR rate with chemotherapy alone was <33% and 2-year DFS and OS were 23% 
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and 44%, respectively [Kim et al., 2003]. This poor prognosis with chemotherapy alone 
appears related to high P-glycoprotein (P-gp) expression in this NK-cell neoplasm. P-gp is 
associated drug efflux and treatment resistance. 
2.4.4.3 Combined modality therapy 
For the control of clinically occult early-stage disease, a combined modality therapy is 
anticipated to reduce distant failure and overall risk of relapse. In a series of 108 patients 
with early-stage ENKL receiving radiotherapy followed by chemotherapy consisting with 
cyclophosphamide, epirubicin, vincristine, prednisolone, and bleomycin [Avilés et al., 2003], 
combined therapy demonstrated high efficacy with a 92% overall response rate and 8-year 
OS of 86%. In early-stage ENKL, Guo et al. reported that patients who received CHOP 
followed by radiotherapy (45 Gy) had a CR rate of only 49% as compared to 100% for those 
who received radiotherapy prior to CHOP [Guo et al., 2008]. Li et al. reported that patients 
with early-stage UAT-ENKL (stages I and II) treated with radiotherapy or radiotherapy plus 
chemotherapy had 5-year OS and PFS rates of 72% and 65%, respectively, overall. The 
cumulative rates of 5-year systemic failure and OS, respectively, were 24% and 74% for 
combined modality therapy as compared to 28% and 70% for radiotherapy alone. There was 
no significant difference between radiotherapy alone and combined modality therapy. A 
very low incidence of cervical lymph node or CNS relapse was observed. As a result, the 
addition of chemotherapy did not significantly decrease the systemic failure rate or improve 
survival [Li et al., 2011a]. In the Japanese JCOG 0211 study [Yamaguchi et al. 2008], 27 
patients received radiotherapy (50 Gy) and reduced-dose chemotherapy (carboplatin 
etoposide, ifosfamide, and dexamethasone). The CR rate was 77% and overall response rate 
was 81%. Of the ten patients with disease recurrence, nine failed at a distant site. These 
studies demonstrate that local control using radiotherapy should precede systemic 
chemotherapy. Prospective studies are needed to clarify the role of chemotherapy. 
2.4.4.4 Advanced-stage disease 
Combined chemotherapy and radiotherapy is the most commonly used approach for 
advanced-stage disease. Due to the limited number and size of series, the efficacy of 
intensive therapy has not been demonstrated. For CHOP or m-BACOD (bleomycin, 
vincristine, dexamethasone, and methotrexate) followed by radiotherapy, the CR rate in 
patients with advanced-stage disease was 25% and median OS was 2 months as compared 
to 75% and 12 months, respectively, in those with early-stage disease [Kwong et al., 1997]. 
L-asparaginase has been reported as a novel approach for the treatment of advanced-stage 
ENKL. NK-cell tumors appear highly sensitive to L-asparaginase in vitro, as NK cells 
express low levels of asparaginase synthase. In a series of 15 patients with relapsed or 
refractory ENKL treated with L-asparaginase monotherapy, seven achieved a CR with an 
overall response rate of 87% [Jaccard et al., 2009]. Yamaguchi et al. have reported the 
efficacy of the SMILE regimen consisting with steroids, methotrexate, ifosfamide, L-
asparaginase, and etoposide. These agents are independent of the multidrug resistant 
mechanism (mediated by P-gp) in tumor cells. This phase I study included six patients with 
advanced-stage disease. The overall response rate after 2 cycles of SMILE therapy was 67%, 
with 50% achieving CR [Yamaguchi et al., 2008]. 
2.4.4.5 Stem cell transplantation 
Autologous and allogeneic stem cell transplantation (SCT) have been evaluated for 
consolidation and for relapsed or refractory disease. Suzuki et al. reported 25 CR patients 
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Fig. 1. CD4+ T cells stimulated by mosquito bites may play a key role in the development of 
hypersensitivity to mosquito bites (HMB) and NK-cell oncogenesis via the induction of 
Epstein-Barr virus (EBV) reactivation and EBV-oncogene latent membrane protein 1 (LMP1) 
expression, respectively [Asada 2007] 
2.4.4 Treatment and outcome 
There remains a lack of consensus on the treatment of ENKL and there is no standard 
therapy in adults or pediatric patients. ENKL shows an aggressive clinical course with 
various clinicopathologic characteristics. Due to this clinical heterogeneity of ENKL, optimal 
treatment and prognostic factors have been difficult to determine with the conventional Ann 
Arbor staging system. NUAT-ENKL has a pathologic similarity to UAT–ENKL but is a 
clinically distinct subtype. 
2.4.4.1 Radiotherapy 
For early-stage ENKL, both UAT and NUAT, experience with radiation therapy, 
chemotherapy, and combined therapy has been reported. The largest study with 
radiotherapy or radiotherapy plus chemotherapy was reported by Kim et al. [2001]. In this 
report of 143 patients, 104 received upfront radiotherapy alone with a median dose of 50.4 
Gy (range, 20–70 Gy). Of those who received radiotherapy alone, 69% of patients achieved a 
complete response (CR), while only 8% of those who received chemotherapy prior to 
radiotherapy achieved CR [Kim et al., 2001; Korht & Advani 2009]. Huang et al. reported CR 
and 5-year overall survival (OS) rates of 100% in patients who received radiotherapy alone, 
while those who received chemotherapy (CHOP) alone had rates of 25% and 90%, 
respectively [Huang et al., 2008]. Li et al. reported overall response in 85 of 87 (97.7%) 
patients with stage I UAT-ENKL who received radiotherapy with 50–56 Gy (standard is 50 
Gy). The 5-year OS, 5-year progression-free survival (PFS), and local control rates for all 
patients were 80%, 69%, and 93%, respectively [Li et al., 2011b]. 
The dose and field of radiation in stage I or II ENKL is an important factor with respect to 
outcome. A radiation dose of at least 54 Gy is seen as being associated with better outcome. 
Comparing those who received ≥54 Gy versus <54 Gy, 5-year OS and disease-free survival 
(DFS) rates were higher with the former: 75% vs 46% and 60% vs 46%, respectively [Huang 
et al., 2008]. Systemic failure is shown in 25% to 30% of patients with stage II and II disease 
treated with radiotherapy alone. This shows the role of chemotherapy in control of clinically 
occult disease. 
2.4.4.2 Chemotherapy 
There are few studies that included patients treated with chemotherapy alone. Studies of 
chemotherapy regimens including cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP) are disappointing because of high rates of refractory disease or early 
relapse: the CR rate with chemotherapy alone was <33% and 2-year DFS and OS were 23% 
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and 44%, respectively [Kim et al., 2003]. This poor prognosis with chemotherapy alone 
appears related to high P-glycoprotein (P-gp) expression in this NK-cell neoplasm. P-gp is 
associated drug efflux and treatment resistance. 
2.4.4.3 Combined modality therapy 
For the control of clinically occult early-stage disease, a combined modality therapy is 
anticipated to reduce distant failure and overall risk of relapse. In a series of 108 patients 
with early-stage ENKL receiving radiotherapy followed by chemotherapy consisting with 
cyclophosphamide, epirubicin, vincristine, prednisolone, and bleomycin [Avilés et al., 2003], 
combined therapy demonstrated high efficacy with a 92% overall response rate and 8-year 
OS of 86%. In early-stage ENKL, Guo et al. reported that patients who received CHOP 
followed by radiotherapy (45 Gy) had a CR rate of only 49% as compared to 100% for those 
who received radiotherapy prior to CHOP [Guo et al., 2008]. Li et al. reported that patients 
with early-stage UAT-ENKL (stages I and II) treated with radiotherapy or radiotherapy plus 
chemotherapy had 5-year OS and PFS rates of 72% and 65%, respectively, overall. The 
cumulative rates of 5-year systemic failure and OS, respectively, were 24% and 74% for 
combined modality therapy as compared to 28% and 70% for radiotherapy alone. There was 
no significant difference between radiotherapy alone and combined modality therapy. A 
very low incidence of cervical lymph node or CNS relapse was observed. As a result, the 
addition of chemotherapy did not significantly decrease the systemic failure rate or improve 
survival [Li et al., 2011a]. In the Japanese JCOG 0211 study [Yamaguchi et al. 2008], 27 
patients received radiotherapy (50 Gy) and reduced-dose chemotherapy (carboplatin 
etoposide, ifosfamide, and dexamethasone). The CR rate was 77% and overall response rate 
was 81%. Of the ten patients with disease recurrence, nine failed at a distant site. These 
studies demonstrate that local control using radiotherapy should precede systemic 
chemotherapy. Prospective studies are needed to clarify the role of chemotherapy. 
2.4.4.4 Advanced-stage disease 
Combined chemotherapy and radiotherapy is the most commonly used approach for 
advanced-stage disease. Due to the limited number and size of series, the efficacy of 
intensive therapy has not been demonstrated. For CHOP or m-BACOD (bleomycin, 
vincristine, dexamethasone, and methotrexate) followed by radiotherapy, the CR rate in 
patients with advanced-stage disease was 25% and median OS was 2 months as compared 
to 75% and 12 months, respectively, in those with early-stage disease [Kwong et al., 1997]. 
L-asparaginase has been reported as a novel approach for the treatment of advanced-stage 
ENKL. NK-cell tumors appear highly sensitive to L-asparaginase in vitro, as NK cells 
express low levels of asparaginase synthase. In a series of 15 patients with relapsed or 
refractory ENKL treated with L-asparaginase monotherapy, seven achieved a CR with an 
overall response rate of 87% [Jaccard et al., 2009]. Yamaguchi et al. have reported the 
efficacy of the SMILE regimen consisting with steroids, methotrexate, ifosfamide, L-
asparaginase, and etoposide. These agents are independent of the multidrug resistant 
mechanism (mediated by P-gp) in tumor cells. This phase I study included six patients with 
advanced-stage disease. The overall response rate after 2 cycles of SMILE therapy was 67%, 
with 50% achieving CR [Yamaguchi et al., 2008]. 
2.4.4.5 Stem cell transplantation 
Autologous and allogeneic stem cell transplantation (SCT) have been evaluated for 
consolidation and for relapsed or refractory disease. Suzuki et al. reported 25 CR patients 
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who received SCT and 4-year OS was 68% [Suzuki et al., 2006]. This demonstrated a 
significant benefit compared to 188 historical controls who had 4-year OS of 21%. As there 
have been few reports of SCT, the ability to define its role as therapy for relapsed or 
refractory disease remains limited. For refractory and relapsed ENKL patients, Yokoyama et 
al. reported a retrospective analysis of five cases treated with allogeneic SCT [Yokoyama et 
al., 2010]. All five patients received a myeloablative conditioning regimen (total body 
irradiation/cyclophosphamide with or without cytarabine) and survived without disease 
(median follow-up period of 1,911 days). This small case series suggests that allogeneic SCT 
might improve the outcome of advanced-stage ENKL. 
2.4.4.6 Pediatric study 
In the pediatric ENKL patients (excluding case 19 whose prognosis was not reported), eight 
of 12 patients with early-stage (stage I and II) disease including UAT and NUAT were alive 
(Table 4). Two cases were not described in detail and another two cases died within 1 year. 
The CR rate is 61%. Case 21 had nasal and right cervical lymphadenopathy and his tumor 
was not controlled; he died despite CHOP and more intensive chemotherapy. The outcome 
of pediatric early-stage patients was worse than in adults. The reason is that most cases did 
not receive radiotherapy and received chemotherapy alone, generally CHOP. 
In advanced-stage disease (stage IV), all cases died and average survival was 181 days (6 
days to 33 months). Both UAT and NUAT cases show very progressive disease and poor 
prognosis. Two cases with NUAT received high-dose chemotherapy, had complete 
remission, and were alive. Case 9 received cord blood SCT after a conditioning regimen 
consisting of total body irradiation (12 Gy), thiotepa, and cyclophosphamide, while case 10 
received autologous SCT after thiotepa and cyclophosphamide. 
There have been no large studies in pediatric patients. The largest is a report from China. 
Wang et al. reported the outcome of 37 pediatric and adolescent UAT-ENKL patients. 
Among the patients with stage I and II disease, 19 patients received primary radiotherapy 
with or without chemotherapy, and 14 patients received chemotherapy followed by 
radiotherapy. The CR rate after initial radiotherapy was 74%, which was significantly higher 
than the response rate after initial chemotherapy (17%). The median radiation dose for the 
primary tumor was 50 Gy (range, 15–60 Gy), with dose fractions of 1.8–2 Gy. They reported 
no late side effects, e.g. secondary malignancy [Wang et al., 2009]. 
2.5 Blastic plasmacytoid dendritic cell neoplasm and blastic NK-cell lymphoma 
Blastic plasmacytoid dendritic cell neoplasm (pDCL) defines leukemia/lymphoma with 
expression of CD4 and CD56 without any other lineage-specific markers. pDCL is rare and 
presents a <1% of acute leukemias and 0.7% of cutaneous lymphomas [Garnache-Ottou et 
al., 2007]. It primarily affects the elderly (median age 69 years) [Feuillard et al., 2002]. The 
clinical course is very aggressive and rapidly fatal [Reimer et al., 2003]. Histologically, this 
malignancy is classified as blastic NK-cell lymphoma/leukemia. The 2000 WHO 
classification considers this malignancy as blastic NK-cell lymphoma [Harris et al., 2000]. 
The ontogenic origin of this malignancy has not been clearly identified. Chaperot et al. have 
demonstrated the origin of these tumor cells as dendritic cells [Chaperot et al., 2001]. These 
malignant cells express interleukin-3 (IL-3) receptor maturation with IL-3 and produce 
interferonalpha (IFN-α) in response to influenza virus. These cells become a powerful 
inducer of naïve CD4+ T-cell proliferation and promote T-helper 2 polarization. Finally, 
these authors concluded the origin of this neoplasm is a plasmacytoid dendritic cell subset. 
Feuilliard et al. reported 23 cases with CD4+, CD56+ leukemia. The majority of patients were 
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elderly adults, but three children were included in their report. At diagnosis, most patients 
had cutaneous involvement, with disseminated purple lesions on the dermis. 
Lymphadenopathy and/or splenomegaly were frequent [Chaperot et al., 2001]. 
Morphologic and cytochemical analysis revealed a high frequency of vacuolization with 
pseudopodia-like cytoplasmic expansions. Myeloperoxidase and monocytic esterase activity 
were never detected. 
However, all cases of pDCL do not produce IFN-α and secretion levels of IFN-α have been 
lower than their normal counterparts. pDCL cells proved incapable of differentiating into 
NK cells, B cells, myeloid cells, or monocytes, and differentiation into mature pDC was only 
possible. Furthermore, a subset of pDCL demonstrated the expression of blood dendritic cell 
antigen 2 (BDCA-2), a specific dendritic cell marker. This fact supports that the origin of 
pDCL as dendritic cells [Jaye et al., 2006]. However, some other reports remain 
undetermined concerning the possible origin of pDCL. More investigation is required to 
establish the definitive nature of these CD4+/CD56+ tumor cells. 
2.5.1 Differential diagnosis 
Table 6 shows the differential diagnosis. ENKL is associated with EBV infection, while this 
has not been reported for pDCL. Although expression of CD56+, CD2+, CD7+, and 
intraplasmic granzyme B can be in common between ENKL and pDCL, ENKL never 
expresses CD4+ [Harris et al., 1997]. In about 10% to 20% of acute myelogenous leukemia 
patients, tumor cells express CD33+, CD4+, and CD56+. Very undifferentiated acute 
myelogenous leukemia weakly shows myelocytic or monoblastic markers. In these cases, 
identification of pDC-specific markers (e.g. BDCA-2) is useful [Garnache-Outtu et al., 2007] 
Mixed myeloblastic/NK-cell leukemia are defined as types of myeloid leukemia in the 
WHO 2008 classification [Swerdlow et al., 2008]. These leukemias express CD7+, CD33+, and 
CD56+. They correspond to proliferation of animmature precursor with myeloid and NK 
potential [Suzuki et al., 1997]. The leukemia phenotype is different from pDCL as they do 
not express CD4 and CD36 in reported cases [Suzuki et al., 1997]. Furthermore, in pDCL, 
there is no expression of CD34 , while its expression has always shown in mixed 
myeloblastic/NK-cell leukemia cells. 
 
Marker pDCL ENKL AML Mixed myeloblastic/NK-cell leukemia 
CD2 – + –  
CD7 – + ± + 
CD56 + + + + 
CD4 + – + – 
Granzyme B – +   
CD33 – – + + 
CD117 – – +  
CD34 – – ± + 
CD36 + – – – 
BDCA-2 + – – – 
Abbreviations: AML, acute myelogenous leukemia; BDCA-2, blood dendritic cell antigen 2; ENKL, 
extranodal NK-cell leukemia; pDCL, blastic plasmacytoid dendritic cell neoplasm. 
Table 6. Differential diagnosis of blastic plasmacytoid dendritic cell neoplasms 
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who received SCT and 4-year OS was 68% [Suzuki et al., 2006]. This demonstrated a 
significant benefit compared to 188 historical controls who had 4-year OS of 21%. As there 
have been few reports of SCT, the ability to define its role as therapy for relapsed or 
refractory disease remains limited. For refractory and relapsed ENKL patients, Yokoyama et 
al. reported a retrospective analysis of five cases treated with allogeneic SCT [Yokoyama et 
al., 2010]. All five patients received a myeloablative conditioning regimen (total body 
irradiation/cyclophosphamide with or without cytarabine) and survived without disease 
(median follow-up period of 1,911 days). This small case series suggests that allogeneic SCT 
might improve the outcome of advanced-stage ENKL. 
2.4.4.6 Pediatric study 
In the pediatric ENKL patients (excluding case 19 whose prognosis was not reported), eight 
of 12 patients with early-stage (stage I and II) disease including UAT and NUAT were alive 
(Table 4). Two cases were not described in detail and another two cases died within 1 year. 
The CR rate is 61%. Case 21 had nasal and right cervical lymphadenopathy and his tumor 
was not controlled; he died despite CHOP and more intensive chemotherapy. The outcome 
of pediatric early-stage patients was worse than in adults. The reason is that most cases did 
not receive radiotherapy and received chemotherapy alone, generally CHOP. 
In advanced-stage disease (stage IV), all cases died and average survival was 181 days (6 
days to 33 months). Both UAT and NUAT cases show very progressive disease and poor 
prognosis. Two cases with NUAT received high-dose chemotherapy, had complete 
remission, and were alive. Case 9 received cord blood SCT after a conditioning regimen 
consisting of total body irradiation (12 Gy), thiotepa, and cyclophosphamide, while case 10 
received autologous SCT after thiotepa and cyclophosphamide. 
There have been no large studies in pediatric patients. The largest is a report from China. 
Wang et al. reported the outcome of 37 pediatric and adolescent UAT-ENKL patients. 
Among the patients with stage I and II disease, 19 patients received primary radiotherapy 
with or without chemotherapy, and 14 patients received chemotherapy followed by 
radiotherapy. The CR rate after initial radiotherapy was 74%, which was significantly higher 
than the response rate after initial chemotherapy (17%). The median radiation dose for the 
primary tumor was 50 Gy (range, 15–60 Gy), with dose fractions of 1.8–2 Gy. They reported 
no late side effects, e.g. secondary malignancy [Wang et al., 2009]. 
2.5 Blastic plasmacytoid dendritic cell neoplasm and blastic NK-cell lymphoma 
Blastic plasmacytoid dendritic cell neoplasm (pDCL) defines leukemia/lymphoma with 
expression of CD4 and CD56 without any other lineage-specific markers. pDCL is rare and 
presents a <1% of acute leukemias and 0.7% of cutaneous lymphomas [Garnache-Ottou et 
al., 2007]. It primarily affects the elderly (median age 69 years) [Feuillard et al., 2002]. The 
clinical course is very aggressive and rapidly fatal [Reimer et al., 2003]. Histologically, this 
malignancy is classified as blastic NK-cell lymphoma/leukemia. The 2000 WHO 
classification considers this malignancy as blastic NK-cell lymphoma [Harris et al., 2000]. 
The ontogenic origin of this malignancy has not been clearly identified. Chaperot et al. have 
demonstrated the origin of these tumor cells as dendritic cells [Chaperot et al., 2001]. These 
malignant cells express interleukin-3 (IL-3) receptor maturation with IL-3 and produce 
interferonalpha (IFN-α) in response to influenza virus. These cells become a powerful 
inducer of naïve CD4+ T-cell proliferation and promote T-helper 2 polarization. Finally, 
these authors concluded the origin of this neoplasm is a plasmacytoid dendritic cell subset. 
Feuilliard et al. reported 23 cases with CD4+, CD56+ leukemia. The majority of patients were 
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elderly adults, but three children were included in their report. At diagnosis, most patients 
had cutaneous involvement, with disseminated purple lesions on the dermis. 
Lymphadenopathy and/or splenomegaly were frequent [Chaperot et al., 2001]. 
Morphologic and cytochemical analysis revealed a high frequency of vacuolization with 
pseudopodia-like cytoplasmic expansions. Myeloperoxidase and monocytic esterase activity 
were never detected. 
However, all cases of pDCL do not produce IFN-α and secretion levels of IFN-α have been 
lower than their normal counterparts. pDCL cells proved incapable of differentiating into 
NK cells, B cells, myeloid cells, or monocytes, and differentiation into mature pDC was only 
possible. Furthermore, a subset of pDCL demonstrated the expression of blood dendritic cell 
antigen 2 (BDCA-2), a specific dendritic cell marker. This fact supports that the origin of 
pDCL as dendritic cells [Jaye et al., 2006]. However, some other reports remain 
undetermined concerning the possible origin of pDCL. More investigation is required to 
establish the definitive nature of these CD4+/CD56+ tumor cells. 
2.5.1 Differential diagnosis 
Table 6 shows the differential diagnosis. ENKL is associated with EBV infection, while this 
has not been reported for pDCL. Although expression of CD56+, CD2+, CD7+, and 
intraplasmic granzyme B can be in common between ENKL and pDCL, ENKL never 
expresses CD4+ [Harris et al., 1997]. In about 10% to 20% of acute myelogenous leukemia 
patients, tumor cells express CD33+, CD4+, and CD56+. Very undifferentiated acute 
myelogenous leukemia weakly shows myelocytic or monoblastic markers. In these cases, 
identification of pDC-specific markers (e.g. BDCA-2) is useful [Garnache-Outtu et al., 2007] 
Mixed myeloblastic/NK-cell leukemia are defined as types of myeloid leukemia in the 
WHO 2008 classification [Swerdlow et al., 2008]. These leukemias express CD7+, CD33+, and 
CD56+. They correspond to proliferation of animmature precursor with myeloid and NK 
potential [Suzuki et al., 1997]. The leukemia phenotype is different from pDCL as they do 
not express CD4 and CD36 in reported cases [Suzuki et al., 1997]. Furthermore, in pDCL, 
there is no expression of CD34 , while its expression has always shown in mixed 
myeloblastic/NK-cell leukemia cells. 
 
Marker pDCL ENKL AML Mixed myeloblastic/NK-cell leukemia 
CD2 – + –  
CD7 – + ± + 
CD56 + + + + 
CD4 + – + – 
Granzyme B – +   
CD33 – – + + 
CD117 – – +  
CD34 – – ± + 
CD36 + – – – 
BDCA-2 + – – – 
Abbreviations: AML, acute myelogenous leukemia; BDCA-2, blood dendritic cell antigen 2; ENKL, 
extranodal NK-cell leukemia; pDCL, blastic plasmacytoid dendritic cell neoplasm. 
Table 6. Differential diagnosis of blastic plasmacytoid dendritic cell neoplasms 
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2.5.2 Pediatric cases 
Pediatric pDCL is very rare and limited to a few case reports and small case series. Jegalian 
et al. reported 25 pediatric cases (20 in the literature, 9 at their institution) with pDCL 
[Jegalian et al., 2010]. They demonstrated the clinical features and prognosis of pediatric 
patients. In pediatric patients, 24% of patients lacked cutaneous involvement, which is 
slightly higher rate than adults. In adult patients, pDCL clinical presentation at the time of 
diagnosis usually consists of a cutaneous involvement and the patients without cutaneous 
involvement are very rare. In adult patients, especially the elderly, prognosis is very poor. 
Median OS was only 13 months for all patients. Allogeneic SCT is a useful treatment in 
younger adult patients. They reported a regimen suited to acute lymphoblastic leukemia 
followed by SCT is more effective than using an acute myelogenous leukemia or non-
Hodgkin lymphoma regimen. While the OS of pediatric patients receiving SCT was 67% (4 
of 6 patients), that for patients without SCT was 74%. In pediatric patients, treatment with a 
high-risk regimen appears effective without SCT. SCT was useful for only relapsed or 
secondary remission disease. Outcome of pediatric patients was more favorable than that of 
adults [Jegalian et al., 2010]. 
3. Conclusion 
NK-cell malignancy is difficult to define and there is confusion in diagnosis. One of the 
reasons for the confusion is that CD56 is not only expressed in NK-cell malignancy but in 
various other hematopoietic malignancies, e.g. acute myelogenous leukemia non-Hodgkin 
lymphoma, pDCL. It is hoped that more specific markers for NK-cell malignancy will assist 
in defining these malignancies. NK-cell precursor tumors with lymphomatous presentation 
that expressed NK-specific CD94A1 transcripts have been described [Lin et al., 2005]. I used 
this method and clarified the origin of one case [Hashii et al., 2010]. Antibodies against killer 
immunoglobulin-like receptors (KIRs) will hopefully provide a useful tool for clarification of 
the diagnosis of the NK-cell malignancies. Currently, these antibodies are not commonly 
used. Although, BDCA-2 is useful for clarifying the difference between NK-cell malignancy 
and pDCL, it is not commonly used. The diagnosis of precursor NK-cell lymphoblastic 
leukemia/lymphoma may be considered in cases that express CD56+ along with immature 
T-cell markers (CD2+, CD7+, and CD3ε+) without B-cell or myeloid markers. 
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1. Introduction 
Constitutional trisomy 21 or Down syndrome (DS) is the most common human genetic 
aneuploidy caused by the presence of all or part of an extra 21 chromosome. The incidence 
of DS is estimated at 1 per 700 births (Malinge et al., 2009) and is the most common genetic 
factor predisposing to childhood leukemia. People with DS present several clinical 
phenotypes, including cognitive impairment, craniofacial dysmorphy, gastrointestinal tract 
abnormalities, congenital heart defects, endocrine abnormalities, neuropathology leading to 
dementia and immunological defects. Concerning the hematopoietic system, children with 
DS frequently show abnormalities in platelet counts, macrocytosis and an increased 
prevalence of leukemia (Lange, 2000; Roizen & Amarose, 1993). 
2. Manifestations of leukemia in Down Syndrome 
The high frequency of leukemia in children with DS suggests that trisomy 21 is involved 
directly and functionally to the malignant transformation of hematopoietic cells. However, 
DS is not a classic genomic instability syndrome, since the overall risk of developing cancer, 
in particular solid tumors, including neuroblastoma and Wilms tumor, is lower in these 
people (Hasle, 2001; Malinge et al., 2009). 
Newborns with DS have a risk 10 to 20 times higher of developing acute leukemia (AL) 
when compared with the incidence rates of leukemia in the general child population 
(Hitzler et al., 2003). The AL in children with DS presents an intriguing relationship between 
the age at onset of disease and the subtype of leukemia cell. DS children older than 4 years 
have predominantly acute lymphoblastic leukemia (ALL), whose incidence is approximately 
20 times higher than in the general population. However the DS patients aged under 3 years 
are more likely to develop acute megakaryoblastic leukemia (AMKL), with an incidence  500 
times higher than in children without DS (Hitzler et al., 2003; Issacs, 2003; Lange, 2000; 
Malinge et al., 2009). 
The condition of patients with DS awakens, therefore, a special interest in studies on 
leukemogenesis not only by the high prevalence of AMKL, usually rare in the general 
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pediatric population, but also by another form of clonal proliferation called transient 
myeloproliferative disorder (TMD) which affects between 5 and 10% of newborns with DS. 
The TMD is a clonal disease characterized by accumulation of immature megakaryoblasts in 
fetal liver and peripheral blood, a picture indistinguishable from AL (Hitzler et al., 2003; 
Malinge et al., 2009; Pine et al., 2007; Rainis et al., 2003; Zipursky, 2003). It is unclear whether 
all AMKLs are preceded by TMD, since several TMD cases are underdiagnosed. One study 
suggests that the prognosis for AMKLs preceded by TMD is better than de novo AMKL 
(Klusmann et al., 2008). 
In contrast to AMKL, TMD usually evolves to spontaneous remission within the first three 
months of life and therefore is considered a pre-leukemic syndrome. This spontaneous 
remission can vary from 59 to 64% (Kanezaki et al., 2010; Massey et al., 2006). However, 
approximately 20% of children diagnosed with TMD will develop AMKL after 2 to 3 years 
of TMD spontaneous remission, which does not regress without chemotherapy (Malinge et 
al., 2009). 
The biological mechanism of TMD spontaneous remission is not clear. Holt et al. (2002) 
showed that telomerase activity was decreased at the beginning of congenital leukemia and 
suggested that this deficiency could explain the spontaneous regression. Furthermore, the 
factors underlying the transformation of the TMD "benign" status for "evil" in AMKL are 
unknown (Izraeli et al., 2007; Malkin et al., 2000; Rainis et al., 2003). 
In rare cases, the TMD is fatal due to poor prognostic factors such as liver fibrosis or liver 
dysfunction, manifested by jaundice, bleeding diathesis, fetal hydrops, cardiopulmonary 
failure, high white blood cell (WBC) and failure of spontaneous remission within the first 3 
months (Malinge et al., 2009; Massey et al., 2006; Pine et al., 2007; Shimizu et al., 2008). Most 
of these variants were found in all reports. However, the risk factors for the progression to 
AMKL remain unclear (Kanezaki et al., 2010). Three studies in the United States, Japan and 
Europe reported the natural course of TMD in 264 children with DS. These studies 
confirmed the transient course of this disease that usually resolved spontaneously within 
the first 3 months of life. However, these studies revealed that the disease is not benign, 
since early deaths have been reported in 15 to 20% of the cases (Klusmann et al., 2008; 
Massey et al., 2006; Muramatsu et al., 2008). Kanezaki et al. (2010) also reported early death 
in 24.2% of the DS patients with TMD. 
3. Mutations in GATA1 gene and leukemogenesis in Down Syndrome 
The GATA1 (globin transcription factor 1) gene located on the X chromosome in the region 
Xp11.23 encodes the GATA binding protein 1 (GATA-1) belonging to the family of 
transcription factors with zinc finger structural motifs for DNA binding. GATA-1 is essential 
for survival of erythroid progenitor cells and for proper maturation of megakaryocytes, so 
in this way this protein has an essential rule in the erythrocytic and megakaryocytic 
differentiation (Wechsler et al., 2002; Yu et al., 2002). 
The GATA1 gene is 6.857 kb long with 6 exons and an open reading frame of 1,239 
nucleotides starting in exon 2. The protein GATA-1 consists of 413 amino acids and 42.75 
kDa with an N-terminal transactivation domain and two zinc finger domains. These two 
fingers are functionally distinct and cooperate to achieve specific, stable DNA binding. The 
first finger (NF) is necessary only for full specificity and stability of binding, whereas the 
second one (CF) is required for DNA binding (Martin & Orkin, 1990, Shimizu et al., 2008). 
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GATA1 mutations prevent the synthesis of heavy chain of GATA-1 (translated from the first 
ATG codon of exon 2) but not the synthesis of truncated protein, with 330 amino acids and 
34.23 kDa called GATA-1s. GATA-1s is also expressed starting at codon 84 in exon 3 in 
consequence of an alternative translation initiation site or alternative splicing that eliminates 
exon 2. This truncated protein lacks the transactivation domain, but retains both zinc finger 
domains, as shown in figure 1. The function of GATA-1s is still quite unclear. Several 
experiments suggest that GATA-1s helps the megakaryocytic and erythrocyte differentiation 
(Weiss et al., 1997). However, studies of in vivo gene rescue indicated that only the 
endogenous GATA-1s expression would not be enough to restore definitive erythropoiesis 
unless this gene is hyper expressed (Shimizu et al., 2001). Even being detected both forms of 
GATA-1 in mouse embryonic tissue, their relative proportions vary during development, 
suggesting that the transcriptional activity of GATA1 can be modulated by the relative rate 
of the two forms (Calligaris et al., 1995). 
 
 
Fig. 1. Models for the expression of GATA-1 isoforms. The GATA-1 protein is translated 
from the GATA1 mRNA, whereas the GATA-1s protein can be translated either from the 
GATA-1 mRNA or from the alternative spliced GATA1s mRNA lacking exon 2. 
The analysis of megakaryocyte-specific knockdown of GATA1 in vivo has revealed a critical 
role for this factor in megakaryocytic development. Reduced expression (or complete 
absence) of GATA-1 in megakaryocytes leads to increased proliferation and deficient 
maturation as well as a reduced number of circulating platelets (Vyas et al., 1999; Wechsler 
et al., 2002). Mice harboring a heterozygous GATA1 knockdown allele frequently develop 
erythroblastic leukemia (Shimizu et al., 2004).  
Mutations in GATA1 gene are described in TMD as well as in AMKL, and occur mainly in the 
5’ end of the gene in exon 2, and less commonly in exon 3 (Xu et al., 2003). Mutations as 
insertions, duplications, deletions and point mutations, are responsible to abrogate splicing of 
exon 2 or to generate a stop codon prior to the alternative translational start codon at position 
84. According to Rainis et al. (2003), the most frequent mutations in TMD and AMKL were 
deletions and insertions in exon 2 of GATA1 corresponding to 65, 7% followed by 25.7% of 
point mutations and the remaining 8.6% is due to failure to identify the mutation.  
Mutations in GATA1 are frequently associated with TMD and occur in utero (Taub et al., 
2004). The true frequency of TMD is unknown because it is likely that a signicant 
proportion of these patients are not routinely diagnosed (Malinge et al., 2009; Rainis et al., 
2003). Ongoing studies in Europe and North America combining screening for GATA1 
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mutations and examination of neonatal blood smears will present a more precise picture of 
the true incidence of TMD (Malinge et al., 2009). Pine et al. (2007) examined DNA from 
Guthrie cards of 585 DS infants, and reported that GATA1 mutations were detected in 3.8% 
of them. However, GATA1 mutations may have been missed in patients with minor 
preleukemic clones, subclonal mutations, low numbers of cells on Guthrie cards, or 
extramedullary TMD without circulating blasts. In addition, a significant higher frequency 
of GATA1 mutations in male newborns was observed. Malinge et al. (2009) presumed that it 
is likely that the frequency of TMD is not higher than 5% of DS newborns.  
Studies have shown that GATA1 mutations in TMD activate the proliferation of progenitor 
cells required to promote AMKL, featuring a multi-step disease. This process is likely to 
involve the participation of unidentified genes/proteins. These megakaryocytic progenitors 
quickly disappear after birth. Until now the molecular and cellular basis of this natural 
remission is unknown, but it may be related to changes in the hematopoietic 
microenvironment that occur during growth and neonatal development. Affected 
megakaryoblasts with additional genetic hits are probably subjected to clonal evolution, 
making them susceptible to malignant transformation to leukemic cells, leading to the 
development of AMKL (Shimizu et al., 2008) (figure 2). 
 
 
Fig. 2. A model for multi-step leukemogenesis in DS. The accumulation of hits (multiple 
genetic abnormalities) characterizes the evolution of TMD for AMKL.  
Somatic mutations in the N-terminus activation domain of GATA1 are found in most cases of 
TMD and AMKL, suggesting these mutations have a significant role in the process of 
leukemogenesis (Wechsler et al., 2002). GATA1 mutations with trisomy 21 may be sufficient to 
promote the expansion of transient megakaryoblasts seen in TMD (Mundschau et al., 2003).  
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The expression levels of GATA-1 isoforms are crucial for the proper development of 
erythroid and megakaryocytic cells and compromised GATA-1 expression is a causal factor 
in leukemia (Shimizu et al., 2008). These findings strongly suggest that the qualitative deficit 
of GATA-1 contributes to the genesis of TMD and AMKL (Kanezaki et al., 2010). The 
selection of mutations that retain GATA-1s may result in disruption of normal balance 
between GATA-1 and GATA-1s, which probably would be involved in regulating normal 
development of megakaryocytes (Izraeli et al., 2007), but pass to act as an oncogene directly 
in the presence of trisomy 21. Alternatively, GATA-1s may be required for survival of 
leukemic blasts and the oncogenic effect may be purchased by the loss of the heavy chain of 
GATA-1. Another possibility is that this type of mutation may reflect specific mechanisms of 
selection or generation of this mutation in the presence of trisomy 21 (Rainis et al., 2003).  
According some evidences the arising of AL is due to the cooperation between one class of 
mutations which interferes with differentiation (class II mutations) and another class which 
confers a proliferative advantage to cells (class I mutations) (Deguchi & Gilliland, 2002). It 
has been shown that high level expression of exogenous GATA-1 lacking the N-terminus 
induced differentiation rather than decreased the aberrant growth of GATA1-null 
megakaryocytes (Kuhl et al., 2005; Muntean & Crispino, 2005). This observation suggested 
that abundant GATA-1s functions like a class I mutation in TMD blasts. In contrast, 
reducing GATA-1 expression leads to differentiation arrest and aberrant growth of 
megakaryocytic cells (Vyas et al., 1999). The present data suggest that GATA-1s is expressed 
at very low levels in TMD blasts with GATA-1s low mutations. These levels may not be 
sufficient to provoke normal maturation. Together, these findings suggest that the low 
expression of GATA-1s might function like class II mutations in TMD blasts. Additional 
class I mutations or epigenetic alterations might be more effective in the development of 
leukemia in blast cells expressing GATA-1s at low levels (Kanezaki et al., 2010). 
GATA1 mutations have not been identified in normal children, in children with DS and 
other types of leukemia, or in acute myeloid leukemias (AML) of children without DS. 
Mutations restricted to leukemic clones were not detectable in samples in remission. They 
were therefore selected and acquired, probably because they granted a clonal advantage 
(Pine et al., 2007; Wechsler et al., 2002). 
Rainis et al. (2003) reported two patients with identical GATA1 mutations in TL and 
subsequently in AMKL, showing that the AMKL was originated from the clone of TMD. Thus, 
GATA1 is mutated in most patients with TMD, but that is not enough to generate leukemia 
after remission. Moreover, it has been reported that monozygotic twins that developed AMKL 
associated with acquired trisomy of chromosome 21 in blast cells have the same mutation that 
was not detected during remission. Because it was an identical mutation in the leukemic cells 
of twins, so it is likely that the mutation has occurred in one twin in utero and that his pre-
leukemic cells have migrated to the other twin by blood embryological anastomoses.  
Wechsler et al. (2002) analyzed the X chromosome inactivation in cell lysates from BM of 
women carrier from AMKL. Since the female leukemic cells showed the X chromosome 
inactivation due to monoclonality, and the mutant allele was detected only in leukemic cells, 
they predicted that the wild-type allele should be on the inactive X chromosome. As 
expected, only the truncated protein GATA-1s was observed. On the other hand Rainis et al. 
(2003) proposed that if there was no process of X chromosome inactivation, GATA1 
mutation would be involved in a higher frequency of patients with DS and TMD. Therefore, 
this inactivation of the GATA1 mutation is considered a key event for non-occurrence of the 
TMD transformation to AMKL (Rainis et al., 2003). 
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Ahmed et al. (2004) described for the first time multiple independent GATA1 mutations in 
four of 12 patients that developed AMKL, showing multiple GATA1 mutant clones in the 
same individual. In these patients, analysis of mutant clones by automated sequencing 
allowed to confirm that each clone contained a different mutation in GATA1. Interestingly, 
at the diagnosis of AMKL only one of the three mutations was present. The presence of 
these multiple GATA1 mutations suggests that mutations are a frequent event in 
hematopoietic cells of DS children. Using cell surface markers, Groet et al. (2005) showed the 
presence of several independent clonal expansions in different stages of megakaryocytic 
differentiation in a single patient with TMD. Probably this was due to independent clones 
that acquired the respective mutations in different stages of differentiation. 
GATA-1s is no different from wild type in their ability to bind to DNA and interact with its 
co-factor friend of GATA-1 (FOG-1), but shows a reduction in their ability to transcriptional 
activation since it was truncated to its activation domain N-terminal (Rainis et al., 2003; 
Wechsler et al., 2002).  
FOG-1 binds specifically to the NF zinc finger motif of GATA-1, and is expressed 
abundantly in erythroid and megakaryocytic cells (Crispino et al., 1999). FOG-1 is encoded 
by the gene ZPFM1 as a protein of 998 amino acids which contains nine zinc finger motifs, 
four of them (ZFS 1, 5, 6 and 9) mediate the interaction with GATA-1 (Fox et al., 1999; 
Muntean & Crispino, 2005). Studies using point mutations in GATA1 lead to a protein with a 
remarkable reduction of the affinity to FOG-1, but with ability of DNA binding, 
demonstrating that direct interaction FOG-1 and GATA-1 is required for normal 
erythropoiesis in vitro (Crispino et al., 1999).  
A missense mutation in the GATA1 gene was described in members without DS of a family 
affected with congenital dyserythropoietic anemia and thrombocytopenia. The 
megakaryocytes of these patients had similar changes in the megakaryocytes of mice 
deficient in expression of GATA-1 suggesting that the interaction GATA-1/FOG-1 is also 
crucial in late stages of megakaryopoiesis (Nichols et al., 2000). 
4. Other mutations associated with DS leukemia 
The occurrence of mutations in exon 2 of GATA1 in TMD suggests that there is cooperation 
between increased dosage of the gene or genes on chromosome 21 with the initiation of 
prenatal clonal proliferation of megakaryocytic precursors (Malinge et al., 2009).  
Based on numerous studies with mutations in GATA1 by several research groups, Malinge 
et al. (2009) concluded that the TMD and AMKL require both trisomy 21 and GATA1 
mutation but is not clear if only these alterations are enough to promote the TMD. 
Furthermore, the specific secondary mutations that promote the evolution of TMD to AMKL 
are still unknown. It has been identified cooperating mutations including JAK3, TP53, FLT3 
and JAK2 mutations whose frequencies are shown in table 1 (Malinge et al., 2009).  
The identification of activating mutations in tyrosine kinase genes in TMD and AMKL 
specimens has provided new insights into the evolution of AMKL. JAK3 mutations have been 
detected in a small but significant fraction of DS-leukemia samples. Among the mutations 
found, most were considered as gain of function. JAK3 was also found in the CMK cell line 
(cells that do not express GATA-1 wild type and are removed from patients with AMKL) 
inducing a lethal biphenotypic hematopoietic disorder in mice with features of AMKL 
(Walters et al., 2006). Other mutations in JAK3 have been proposed to be loss of function (De 
Vita et al., 2007). Additional experiments are necessary to determine how these different JAK3 
variants affect hematopoiesis and megakaryocyte development (Malinge et al., 2009). 
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Types of leukemia Mutated gene Localization Frequencies recorded 
 GATA1 Xp11.23 97,3% 
TMD JAK3 19p13.1 12,5% 
 TP53 17p13.1 7,7% 
 GATA1 Xp11.23 89,2% 
 JAK3 19p13.1 13,2% 
AMKL FLT3 13q12.2 5,7% 
 TP53 17p13.1 21,4% 
 JAK2 9p24.1 6,2% 
Table 1. Genetic abnormalities identified in leukemia associated SD. 
5. Trisomy 21 influence on hematopoiesis 
The functional contribution of the trisomy 21 in hematologic malignancies is supported by 
several observations such as the high incidence of leukemia in DS patients, the fact that 
TMD and AMKL blasts present trisomy 21 (even in children without DS), and that acquired 
trisomy or tetrasomy of chromosome 21 is frequently observed in blasts of different types of 
leukemia, including hyperdiploid ALL and de novo AML (Vyas & Crispino, 2007).  
It is assumed that the cells of DS complete or partial trisomy of Hsa21, approximately 33.7 
Mb, promote an overexpression of at least one of the 364 known genes, 31 antisense 
transcripts, and five different miRNAs (miR-99a, let-7c, miR-155, miR-125b-2, and miR-802), 
which could cooperate with the loss of GATA-1 in the pathogenesis of AMKL. Mutations in 
several genes on chromosome 21 have been identified in leukemia, and many of them 
recognized as encoding transcription factors acting at various stages of hematopoiesis. There 
should be contribution of genes present on chromosome 21 that cooperate with mutations of 
the GATA1 to cause leukemogenesis (Look, 2002; Malinge et al., 2009).  
The identification of the Down Syndrome Critical Region (DSCR) on the 21q22 band based 
in the genotype-phenotype correlations of partial trisomy in children suspected of having 
DS disclosed a list of genes potentially implicated in the clinical phenotype. However no 
specific genes have been certainly linked to the increased incidence of leukemia in DS. Few 
strong candidates include ERG, ETS2, and RUNX1 (Lyle et al., 2009; Malinge et al., 2009).  
Since the TMD is originated in a fetal liver progenitor and is restricted to children with DS 
(or to rare cases of acquired trisomy 21), it is presumed that trisomy 21 directly affects the 
development of hematopoietic cells during gestation. It has been shown that GATA1 
mutations can appear in 21-week-old embryos (Taub et al., 2004). To dene the cellular 
context in which GATA1 mutations occur, two groups studied hematopoiesis in trisomy 21 
human fetal livers (FLs) (Chou et al., 2008; Tunstall-Pedoe et al., 2008). They found that 
although trisomy 21 did not alter the proportion of CD34+ and CD38- cells, trisomy 21 FLs 
showed a 2 to 3 fold increase of megakaryocyte erythroid progenitors (MEPs), which 
appeared to increase over time (35% at 16 weeks to 65% at 18 weeks). 
The functional perturbations induced by trisomy 21 probably induce a highly susceptible 
cellular environment to additional transformations such as GATA1 mutagenesis in TMD. 
The FL cell-based assay is a powerful tool to determine the specic Hsa21 genes that 
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participate in TMD. Preliminary quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) studies have shown that there are no signicant differences in 
expression of ERG, ETS2, RUNX1, and SON, top-ranked candidate leukemia oncogenes, in 
trisomic versus euploid FLs (Chou et al., 2008; Tunstall-Pedoe et al., 2008). However, 
functional studies, such as knockdown of one or more of these candidates genes in FL 
progenitors followed by colony assays and transplantation experiments, are necessary to 
determine the requirements for these genes in leukemia (Malinge et al., 2009). 
6. Specific chromosome 21 genes in DS-associated leukemia 
Two microarray studies comparing AMKL versus non-DS AML have recently been reported 
(Bourquin et al., 2006; Ge et al., 2006) and 76 genes were described that discriminate 
between DS AMKL and non-DS. For example, genes encoding erythroid markers, 
glycophorin A and CD36, were found meaningly overexpressed in AMKL, as conrmed by 
immunophenotypic analysis of blasts (Langebrake et al., 2005).  
Analysis of the gene expression data also revealed that there is an overall increase in 
expression of chromosome 21 genes in AMKL, relative to non-DS AMKL. By gene set 
enrichment analysis, 47 Hsa21 genes, including BACH1, SON, C21orf66, and GABPA, 
contributed for this observed enrichment score, but the distinction between the 2 types of 
AMKL was not driven by differences in expression of chromosome 21 genes (Bourquin et 
al., 2006). By qRT-PCR and microarray analyses, Ge et al. (2006) found that 7 of 551 genes 
were up or down-regulated in AMKL relative to non-DS AMKL and not encoded by 
chromosome 21, including BST2, DUSP6, KRT18, and CD36. Differences in these two data 
might be explained by differences in the samples or different protocols and methods used to 
analyse the expression of the genes. 
6.1 Candidate leukemia oncogenes encoded by chromosome 21 
Of the genes on chromosome 21, several are compelling candidate leukemia oncogenes. Of 
these, four such candidates are RUNX1 (AML1), which encodes the heterodimeric partner of 
the complex of transcription factors denominated core-binding factor  (CBF), cooperates 
with GATA-1 during megakaryocytic differentiation, and the three ETS transcription factors, 
which are expressed and functionally involved in megakaryocytic differentiation and 
sensitivity to chemotherapy (ERG, ETS2, and GABPA) (Ge et al., 2008). It has been suggested 
that RUNX1 is involved in the AMKL, since mutations in the DNA-binding domain of RUNX1 
was identied in 5% of sporadic leukemia and in myeloid malignancies with acquired trisomy 
21 (Osato et al., 1999; Preudhomme et al., 2000). However, despite of the loss-of-function 
mutations in RUNX1 are associated with leukemia, it is not known how three copies of the 
chromosome 21 would promote tumorigenesis in DS (Izraeli, 2004). It is possible that cells with 
trisomy 21 express different levels of RUNX1 isoforms, affecting tumor development (Levanon 
& Groner, 2004). Despite of the fact that the total level of RUNX1 expression was lower in 
AMKL compared with non-DS AML, the differential expression of RUNX1 isoforms was 
indeed observed in human AMKL samples (Bourquin et al., 2006). In contrast, trisomy for 
Runx1 was found not to be required for the development of myeloproliferative disorder 
(MPD) in Ts65Dn mice (model used with partial trisomy 21) (Kirsammer et al., 2008). 
Furthermore, the Ts16 fetuses hematopoietic phenotype was not related with an increased 
ratio of Runx1 or an altered expression of its isoforms (Gjertson et al., 1999). 
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Inherited hypomorphic mutations in Runx1 cause low levels of expression in hematopoietic 
stem cells and result in the syndrome of thrombocytopenia with familial susceptibility to 
leukemia. Abnormalities in Runx1 were not detected in AMKL (Rainis et al., 2003). 
In different types of cancer, it has been shown that the ERG proto-oncogene is dysregulated, 
and its overexpression in AML samples with normal or complex karyotypes involving 
Hsa21 was observed (Baldus et al., 2004; Marcucci et al., 2005). An overexpression of ERG in 
human K562 cells that express both forms of GATA1 induced a switch in differentiation 
toward the megakaryocytic lineage and showed an increased expression of the early 
megakaryocytic markers, as CD41 and CD61 (Rainis et al., 2005). To confirm a role of ERG in 
late stages of megakaryopoiesis, Loughran et al. (2008), working with homozygous and 
heterozygous of mutant Erg mice, observed that the first one died in utero, in consequence 
of a defect in denitive hematopoiesis, and the second one showed thrombocytopenia with 
normal number of BM megakaryocytes.  
Overexpression of ETS2 has also been shown in several cancers, including AML (Baldus et 
al., 2004), and the amount of ETS2 transcripts are increased in both AMKL (DS or non-DS) 
(Ge et al., 2008). These facts and its involvement in the regulation of megakaryocytic genes 
suggest that ETS2 has an important role in TMD or AMKL. As same as for ERG, ETS2 
overexpression in K562 cells was found to promote a switch in differentiation from 
erythroid to megakaryocytic fate (Ge et al., 2008).  
The ETS family member GABPA is not considered an oncogene and its expression in the 
megakyocyte suggests that the GABPA protein has a role in early stages of megakaryocytic 
maturation (Pang et al., 2006). Recent studies have shown that GABPA directly affects the 
cell cycle by regulating the expression of genes required of DNA synthesis and degradation 
of cell-cycle inhibitors (Yang et al., 2007). Of Hsa21 genes, GABPA was one of the few whose 
expression is elevated in AMKL versus non-DS AML (Bourquin et al., 2006). 
6.2 miRNAs encoded by chromosome 21 
Hsa21 encode five miRNAs and overexpression of some of these has been observed in brain 
and heart tissues of people with DS and has been implicated in normal and pathologic 
hematopoiesis (Kuhn et al., 2008). For example, miR-99a is up-regulated during 
megakaryocytic differentiation of CD34+ cells, whereas miR-155 and let-7c are down-
regulated (Garzon et al., 2006). Notably, miR-155 has been linked to myeloproliferative and 
B-lymphoproliferative disorders (Garzon & Croce 2008; O’Connell et al., 2008). Studies have 
implicated miR-125b-2, which is overexpressed in TMD and AMKL samples compared with 
normal megakaryocytes, in the megakaryocytic leukemia of DS (Klusmann, 2007). 
Klusmann et al. (2010) showed that miR-125b-2 is an oncogene potentially involved in the 
pathogenesis of trisomy 21-associated leukemia. They demonstrated in mice and human 
that overexpression of miR-125b-2 led to specific hyperproliferation and enhanced self-
renewal capacity of megakaryocytic progenitor (MPs) and megakaryocytic/erythroid 
progenitors (MEPs), without affecting their normal differentiation. The miR-125b was highly 
expressed in AMKL blasts, whereas the identified target genes of miR-125b were down-
regulated. Thus, miR-125b-2 has a role in regulating megakaryopoiesis and in the 
pathogenesis of trisomy 21-associated TMD and AMKL, in cooperation with GATA1s. The 
miR-125b-2 exerts its oncogenic potential by at least two different mechanisms: blocking 
post-transcriptional miRNA processing through repression of DICER1 expression, and by 
inhibiting tumor suppressor genes, such as ST18. 
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7. Methods of leukemia diagnosis in DS 
The diagnosis of TMD usually occurs during the first weeks after birth and is observed as 
hydrops fetalis. The elevated blood count associated with hepatomegaly is the common 
symptom in an asymptomatic neonate. Infants with TMD can also display occasionally 
jaundice and bleeding diatheses, respiratory distress coupled with ascites, pleural effusion, 
signs of heart failure, and skin inltrates. There is megakaryocytic inltration and liver 
brosis, likely caused by excess cytokines secreted from the megakaryoblasts. The full 
clinical TMD may develop only at the second or third week of life. Laboratory tests are 
signicant for either thrombocytosis or thrombocytopenia accompanied by elevated 
leukocytes with excess of blasts. The blood smear may show nucleated red cells, giant 
platelets and megakaryocytic fragments, and, most signicantly, typical deeply basophilic 
blasts with blebs characteristic to megakaryocytic blasts. The differential diagnosis includes 
leukoerythroblastic reaction associated with prematurity, sepsis, or asphyxia. However, the 
blasts of TMD usually persist for several weeks, and GATA1 mutations are invariably found 
(Malinge et al., 2009). 
AMKL is preceded in 20 to 60% of cases by an indolent prephase of myelodysplasia (MDS), 
characterized by thrombocytopenia and dysplastic changes, BM aspiration is often dry, and 
brosis is detected in BM biopsy (Creutzig et al., 1996; Lange et al., 1998). This MDS can last 
several months or years before progressing to leukemia. In contrast to MDS in non-DS 
children, which requires stem-cell transplantation for cure, MDS in children with DS present 
a highly favorable response to chemotherapy alone (Lange et al., 1998). Therefore, Hasle et 
al. (2003) suggested that all cases of MDS and overt myeloid leukemia in DS, children 
should be classified as one disease entity, and referred to as ‘‘acute myeloid leukemia of 
Down syndrome’’ or ML DS. As this is a unique disease, it should be classified separately 
from other cases of AML in the WHO-classification. 
Immunophenotyping characterizes the hematopoietic lineage involved and their degree of 
maturation by monoclonal antibodies labeled with fluorochromes. Flow cytometry reveals 
that blasts are positive for CD34, CD33, CD41, CD61, glycophorin A, and often CD7 and 
CD36 (Langebrake et al., 2005, Massey et al., 2006). Savasan & Ravindranath (2003) observed 
that blasts of DS children with AMKL express CD36, in contrast to the low or no expression 
of CD36 in AML without DS. If 25% of blast cells are not detected, the diagnosis of AMKL 
can be given by the megakaryocytic markers CD41, CD61 and CD42a. The 
immunophenotype of the blasts in AMKL is generally similar to TMD, except that the 
percentage of CD34 cells may be lower in AMKL (Langebrake, 2005; Malinge et al., 2009).  
Pine et al. (2005) demonstrate the possibility of using specific GATA1 mutations already 
identified in the diagnosis of TMD or AMKL to monitor the size of the clone of leukemic 
cells over time with a sensitivity level (10-4 to 10-5) beyond the microscopic detection. The 
study confirmed that GATA1 mutations in TMD and AMKL can be used as clonal markers 
were suitable for measurement of minimal residual disease (MRD).  
This approach serves as a valuable tool in monitoring the spontaneous remission of TMD 
and in assessing response to treatment of AMKL subcytologic level. In addition, the MRD 
based GATA-1s mutations has been much in demand as a prognostic parameter for 
newborns with TMD. One may speculate, for example, that every group of newborns 
showing apparent remission of TMD can be divided into two subgroups: one in which the 
size of the clone of blasts in TMD after morphological remission continues to decline to 
become undetectable versus a second group, in which a clone of blasts in the TMD remains 
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detectable submicroscopic level. It is interesting to correlate these patterns of MRD kinetics 
in TMD with the probability of developing AMKL later (Hitzler & Zipursky, 2005). 
Additional copies of chromosome 8 and 21 in addition to the constitutional trisomy 21 are 
the most frequent in AMKL, and are found in approximately 10 to 15% for each 
chromosome. Cytogenetic findings associated with a high rate of relapse in non-DS AML, 
such as monosomy 7 and deletion 5/5q- also occur in DS patients but do not seem to have a 
negative impact on prognosis in the rare cases (Gamis et al., 2003, 2005; Rainis et al., 2003). 
The approach of molecular techniques including: PCR amplification of GATA1 exons 2 and 
3, followed by direct sequencing or analysis by denaturing high performance liquid 
chromatography (DHPLC), and cloning allow greater sensitivity and specificity of detection 
and have become essential for the identification of gene alterations in leukemias. The ability 
to detect mutations depends on the proportion of mutant cells in the sample. In general, for 
direct sequencing, approximately 20% of the sample has to have mutant cells. The sensitivity 
of DHPLC is higher at around 2 to 5%. Once a mutation has been identified, mutation-
specific probes and primers for mutation detection by qRT-PCR can be designed that allow 
for more sensitive detection of mutant cells, which may be used for MRD detection (Pine et 
al., 2005).  
Until recently, there were no reports on the expression levels of GATA-1s in TAM blasts, 
and the risk factors for the progression to AMKL. In 2010, Kanezaki et al. tested whether the 
spectrum of transcripts derived from the mutant GATA1 genes affects the expression levels. 
They classified the mutations according to the types of transcripts, and investigated the 
modalities of expression by in vitro transfection experiments using GATA-1 expression 
constructs harboring mutations. They have shown that the mutations altered the amount of 
mutant protein. Based on the evaluation of GATA-1s expression, the mutations were 
classified into two groups: high and low GATA-1s expression. Phenotypic analyses of 66 
TMD patients with GATA1 mutations revealed that GATA-1s low expression mutations 
were significantly associated with a high risk of progression to AMKL and lower counts of 
both WBC and blast cells. These results suggest that quantitative differences in mutant 
protein levels have significant effects on the phenotype of TMD. 
Nevertheless, neither mice nor humans with germline mutations expressing GATA-1s 
develop TMD or AMKL without trisomy 21 (Hollanda et al., 2006; Li et al., 2005). Therefore, 
the role of the trisomy 21 in the cellular transformation in AMKL seems to be fundamental 
(Klusmann et al., 2010). It remains unknown which factors on chromosome 21 cooperate 
with the oncogenic GATA-1s and which factors are involved in this transition from 
preleukemia to AMKL in only a part of these children (Kanezaki et al., 2010; Klusmann et 
al., 2007; Langebrake et al., 2006; Malinge et al., 2009).  
8. Treatment outcome  
DS children with AMKL have an excellent prognostic, with an approximately 80% cure rate, 
in relation to children without DS who develop AML (Arico et al.; 2008; Creutzig et al., 2005; 
Gamis et al., 2003; Rao et al., 2006; Taub et al., 1996). This outcome is possible on 
contemporary AML protocols which based in reducing treatment intensity regimens has 
considerably reduced the mortality rates in children with DS (Creutzig et al., 2005; Gamis et 
al., 2003; Whitlock et al., 2005; Zeller et al., 2005).  
AMKL blasts have shown hypersensitivity to varied chemotherapeutic drugs (Zwaan et al., 
2002). Probably the hypersensibility of the blasts to cytarabine (ARA-C) is due of the effect 
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of GATA1 mutations and Hsa21 on the levels of cytarabine-metabolizing enzymes (Ge et al., 
2005). ARA-C sensitivity is restricted to the leukemic population and may be caused by 
increased expression levels of the cystathionine-beta-synthase gene, which is located on 
Hsa21 (Taub et al., 2000). Despite of many patients respond favorably to a simple regimen 
including low-dose of ARA-C, this is not currently the standard of care. Since many 
problems have been occurred in treating of AMKL like toxic deaths, infections, and cardiac 
toxicity, thereby new and less-intensive protocols have been initiated in the United States 
and Europe (Creutzig et al., 2005; International Cooperative Pediatric AML Study Group 
Myeloid Leukemia DS 2006 [European Clinical Trials Database (EUDRACT) no. 2007-
006219-22]; Children’s Oncology Group: The Treatment of Down Syndrome Children with 
AML and MDS under the age of 4 Years [COG-AAML0431]; low dose cytarabine in treating 
infants with DS and TMD [COG-AAML0532]).  
Researchs in prospective clinical trials are trying to demonstrate whether treatment of TMD 
by low-dose cytarabine could prevent the arise of AMKL. Another related question to be 
clarified is whether treatment of clinically silent disease, identied by molecular detection of 
GATA1 mutations in patients who recovered from TMD, can prevent the future 
development of AMKL (Malinge et al., 2009). 
9. Conclusion 
In conclusion, many questions remain unanswered concerning the factors that contribute to 
the progression of TMD and AMKL in DS-patients. Progress in research to unravel these 
questions will improve diagnosis and treatment. Furthermore, ensuring the diagnosis of 
GATA1 mutations to the DS child to monitor the progression of the disease is essential to 
enable better clinical decision for the treatment regimen and, consequently, better quality of 
life to the patients. 
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of GATA1 mutations and Hsa21 on the levels of cytarabine-metabolizing enzymes (Ge et al., 
2005). ARA-C sensitivity is restricted to the leukemic population and may be caused by 
increased expression levels of the cystathionine-beta-synthase gene, which is located on 
Hsa21 (Taub et al., 2000). Despite of many patients respond favorably to a simple regimen 
including low-dose of ARA-C, this is not currently the standard of care. Since many 
problems have been occurred in treating of AMKL like toxic deaths, infections, and cardiac 
toxicity, thereby new and less-intensive protocols have been initiated in the United States 
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development of AMKL (Malinge et al., 2009). 
9. Conclusion 
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the progression of TMD and AMKL in DS-patients. Progress in research to unravel these 
questions will improve diagnosis and treatment. Furthermore, ensuring the diagnosis of 
GATA1 mutations to the DS child to monitor the progression of the disease is essential to 
enable better clinical decision for the treatment regimen and, consequently, better quality of 
life to the patients. 
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1. Introduction 
Allogeneic hematopoietic stem cell transplantation (HSCT) with some graft sources such as 
bone marrow (BM), mobilized peripheral blood (PB) and cord blood (CB) offers the only 
curative potential for many patients with high risk hematological malignancies, particularly 
acute leukemia. Although BM from human leukocyte antigen (HLA)–identical related 
donors within immediate families is a frontline graft source for this treatment, an alternative 
stem cell source has increasingly provided for patients lacking HLA-identical related 
donors. Recently, CB has been considered an acceptable alternative to source of stem cells in 
unrelated allogeneic HSCT for pediatric and adult patients without HLA–identical related 
or unrelated donors. This review focuses on clinical results of cord blood transplantation 
(CBT) including factors associated with transplantation outcomes and clinical comparison 
studies of CBT and other sources of allogeneic HSCT in adults with acute leukemia. Several 
strategies including a reduced intensity regimen and double CB units from different donors 
have been developed to overcome the limited cell dose in CBT for adults. Moreover, to 
reflect the current encouraging reports and potential starategies, the possibility of CB for 
immune therapy in the setting of allogeneic HSCT is also discussed. 
More than 50 years ago in 1957, Thomas et al. reported the first experience with allogeneic 
bone marrow transplantation (BMT) in patients with advanced leukemia (Thomas et al., 
1957) and since then allogeneic HSCT has been a curative treatment for patients with both 
malignant and non-malignant hematologic diseases (Appelbaum, 2007). The initial purpose 
of infusion of BM was rescue of the BM function against myeloablaitive dose of radiation 
and/or chemotherapy, which generates killing of leukemia cells. Thereafter, the evidence of 
a graft-versus-leukemia (GVL) effect, which is mediated by both host histocompatibility 
antigen-specific T cells, tumor antigen-specific T cells and Natural killer (NK) cells against 
leukemia cells, confirmed that allogeneic HSCT is also the only form of cancer immune 
therapy for leukemia refractory to chemotherapy (Jenq & van den Brink, 2010). 
Although allogeneic HSCT was initially limited to the approximately two-thirds of patients 
with a suitably HLA–identical related donor, an alternative stem cell source has increasingly 
provided for patients lacking HLA-identical related donors. After Broxmeyer et al. 
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demonstrated that CB included a number of hematopoietic stem/progenitor cells that 
would be capable of hematopoietic reconstitution in humans (Broxmeyer et al., 1989), the 
first CBT was reported by Gluckman et al. in a child with Fanconi anemia using CB from his 
HLA-matched sister in 1988 (Gluckman et al., 1989). Since the first success of CBT, 
Rubinstein et al. established the first unrelated CB bank at the New York Blood Center in 
1992 (Rubinstein et al., 1993, 1995). Since then, CB banks have been developed worldwide 
for not only related but also unrelated CBT with more than 3000 CB transplants performed 
annually around the world (Foeken et al., 2010). In 1996, Laporte et al. reported a first adult 
patient with chronic myelogenous leukemia (CML) who underwent the transplantation of 
CB from unrelated donor (Laporte et al., 1996). Earlier, most patients were pediatric 
(Kurtzberg et al., 1996; Wagner et al., 1996; Rubinstein et al., 1998) because of the relatively 
lower cell doses in CB grafts, followed by an increased number of adult CBT (Laughlin et al., 
2001; Sanz et al., 2001), showing that CB could effectively restore hematopoiesis with 
acceptable incidence of severe graft-versus-host disease (GVHD). Recently, CB has been 
considered an acceptable alternative to source of hematopoietic stem cells (HSCs) in 
unrelated allogeneic HSCT for pediatric and adult patients without HLA–identical related 
or unrelated donors. 
In comparison with other sources of allogeneic HSCT, CBT has several clinical advantages, 
including rapid and convenient availability because of the stored CB units in the CB bank, 
less stringent criteria for HLA matching for donor-recipient selection, lower incidence of 
GVHD without compromising GVL effects, low risk of viral transmitting and the absence of 
risk for donors, whereas limited cell dose remains the main disadvantage in CBT. The 
limited cell dose might contribute to higher incidence of graft failure and delayed neutrophil 
recovery, which are mostly due to higher risk of bacterial and fungal infections in the early 
phase after CBT (Narimatsu et al., 2005; Parody et al., 2006; Tomonari et al., 2007; Yazaki et 
al., 2009; Miyakoshi et al., 2007; van Burik & Brunstein, 2007; Delaney et al., 2009). Moreover, 
viral infections may be more common after CBT than after BMT/PBSCT, essentially 
attributable to delayed immune reconstitutions after CBT (Tomonari et al., 2003a, 2003b, 
2004, 2005; Parody et al., 2006; van Burik & Brunstein, 2007; Delaney et al., 2009). The 
advantages and disadvantages of CB as a source of allogeneic HSCT are shown in Table1. 
2. Clinical results in adults with acute leukemia 
2.1 Factors associated with clinical outcomes in CBT 
It is known that larger total nucleated cell (TNC) dose improve faster hematopoietic 
recovery, decrease treatment-related mortality (TRM) and survival of CBT recipients 
(Rubinstein et al., 1998; Laughlin et al., 2001; Gluckman et al., 2004; Arcese et al., 2006; 
Barker et al., 2010). Recent New York Blood Center analysis of 1061 recipients of single-unit 
myeloablative CBT for leukemia or myelodysplastic syndrome (MDS) demonstrated that 
TNC dose and HLA-match each affected survival via their effect on TRM (Barker et al., 
2010). These analysis recommended the best transplantation outcomes were in recipients of 
6 of 6 units regardless of precryopreservation TNC dose (median, 4.0×107cells/kg), 
indicating that HLA match at HLA-A and -B antigens and -DRB1 alleles, rather than high 
TNC dose, was the more favorable graft characteristic. Further, recipients of 4 of 6 units 
required a precryopreservation TNC ≥ 5.0×107cells/kg to achieve comparable TRM and 
disease-free survival (DFS) to that of recipients of 5 of 6 units with a TNC ≥ 2.5×107cells/kg. 
In contrast, the minimum cell dose is not clear for adults who have indications for CBT. In a 
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 CB BM/ mobilized PB 
Advantages   
Availability of grafts Rapid (less than one 
month) 
Prolonged (a few months) 
Requirement of HLA matching 4/6 or higher 6/6 
Risk of severe GVHD Lower risk Higher risk 
Risk of viral transmission Very low risk Low Risk 
Risk of donor No risk Low Risk 
Disadvantages   
Number of infused nucleated cells Limited cell dose Higher cell dose 
Speed of hematopoietic recovery Delay Faster than CB 
Risk of infection after HSCT Higher risk than 
BM/PB 
High risk 
Possibility of donor lymphocyte 
infusion or second HSCT from same 
donor 
Impossible Possible 
Potential of congenital disease 
transmission 
Low potential Few potential 
CB indicates cord blood; BM, bone marrow; PB, peripheral blood; HLA, human leukocyte antigen; 
GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation.  
Table 1. Advantages and disadvantages of CB as a source of hematopoietic stem cell 
compared with BM or mobilized PB 
Japanease study, patients receiving CB grafts containing 1-2×107cells/kg were observed and 
four of seven low-cell-dose recipients survived with longer follow-up (Takahashi et al., 
2006). Those results indicated that CB grafts containing fewer than 2×107cells/kg may be 
useful for cases for which no grafts with higher cell doses or other stem cell sources are 
available. On the other hands, Wagner et al. demonstrated that a correlation between higher 
CD34+ cell dose and rate of engraftment in pediatric patients (Wagner et al., 2002). 
However, CD34+ cell measurement is not standardized between CB banks.  
HLA compatibility was thought to be another key factor in CBT outcome, as with other stem 
cell sources. Several studies have shown that HLA mismatch at HLA-A, -B antigens and -
DRB1 alleles leads to delayed engraftment, increased severity of acute GVHD, increased 
TRM and decreased survival (Rubinstein et al., 1998; Gluckman et al., 2004; Barker et al., 
2010; Delaney & Ballen, 2010). Although increasing the number of HLA mismatching might 
be associated with decreased relapse risk in patients with leukemia, suggested GVL effect 
increased in HLA-mismatched CBT, HLA-mismatch does not offer any benefit in DFS 
(Barker et al., 2010). In general, recommended CB unit is ≥ 4 of 6 HLA-A, -B antigen and -
DRB1 allele matched with the patient.  
The role of anti-HLA antibodies in graft rejection of organ transplantations has been 
analyzed extensively. The majority of CBTs have HLA disparities. Takanashi et al. reported 
the impact that patients' pretransplantation anti-HLA antibodies have on the outcome of 
myeloablative CBT using single unit (Takanashi et al., 2010). Of 386 cases tested, 89 (23.1%) 
were anti-HLA antibody-positive. Of the 89 antibody-positive cases, 20 patients had 
specificity against the CB HLA. Cumulative incidence (CI) of neutrophil recovery 60 days 
after transplantation was 83% for the antibody-negative group, 73% for antibody-positive, 
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demonstrated that CB included a number of hematopoietic stem/progenitor cells that 
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including rapid and convenient availability because of the stored CB units in the CB bank, 
less stringent criteria for HLA matching for donor-recipient selection, lower incidence of 
GVHD without compromising GVL effects, low risk of viral transmitting and the absence of 
risk for donors, whereas limited cell dose remains the main disadvantage in CBT. The 
limited cell dose might contribute to higher incidence of graft failure and delayed neutrophil 
recovery, which are mostly due to higher risk of bacterial and fungal infections in the early 
phase after CBT (Narimatsu et al., 2005; Parody et al., 2006; Tomonari et al., 2007; Yazaki et 
al., 2009; Miyakoshi et al., 2007; van Burik & Brunstein, 2007; Delaney et al., 2009). Moreover, 
viral infections may be more common after CBT than after BMT/PBSCT, essentially 
attributable to delayed immune reconstitutions after CBT (Tomonari et al., 2003a, 2003b, 
2004, 2005; Parody et al., 2006; van Burik & Brunstein, 2007; Delaney et al., 2009). The 
advantages and disadvantages of CB as a source of allogeneic HSCT are shown in Table1. 
2. Clinical results in adults with acute leukemia 
2.1 Factors associated with clinical outcomes in CBT 
It is known that larger total nucleated cell (TNC) dose improve faster hematopoietic 
recovery, decrease treatment-related mortality (TRM) and survival of CBT recipients 
(Rubinstein et al., 1998; Laughlin et al., 2001; Gluckman et al., 2004; Arcese et al., 2006; 
Barker et al., 2010). Recent New York Blood Center analysis of 1061 recipients of single-unit 
myeloablative CBT for leukemia or myelodysplastic syndrome (MDS) demonstrated that 
TNC dose and HLA-match each affected survival via their effect on TRM (Barker et al., 
2010). These analysis recommended the best transplantation outcomes were in recipients of 
6 of 6 units regardless of precryopreservation TNC dose (median, 4.0×107cells/kg), 
indicating that HLA match at HLA-A and -B antigens and -DRB1 alleles, rather than high 
TNC dose, was the more favorable graft characteristic. Further, recipients of 4 of 6 units 
required a precryopreservation TNC ≥ 5.0×107cells/kg to achieve comparable TRM and 
disease-free survival (DFS) to that of recipients of 5 of 6 units with a TNC ≥ 2.5×107cells/kg. 
In contrast, the minimum cell dose is not clear for adults who have indications for CBT. In a 
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Japanease study, patients receiving CB grafts containing 1-2×107cells/kg were observed and 
four of seven low-cell-dose recipients survived with longer follow-up (Takahashi et al., 
2006). Those results indicated that CB grafts containing fewer than 2×107cells/kg may be 
useful for cases for which no grafts with higher cell doses or other stem cell sources are 
available. On the other hands, Wagner et al. demonstrated that a correlation between higher 
CD34+ cell dose and rate of engraftment in pediatric patients (Wagner et al., 2002). 
However, CD34+ cell measurement is not standardized between CB banks.  
HLA compatibility was thought to be another key factor in CBT outcome, as with other stem 
cell sources. Several studies have shown that HLA mismatch at HLA-A, -B antigens and -
DRB1 alleles leads to delayed engraftment, increased severity of acute GVHD, increased 
TRM and decreased survival (Rubinstein et al., 1998; Gluckman et al., 2004; Barker et al., 
2010; Delaney & Ballen, 2010). Although increasing the number of HLA mismatching might 
be associated with decreased relapse risk in patients with leukemia, suggested GVL effect 
increased in HLA-mismatched CBT, HLA-mismatch does not offer any benefit in DFS 
(Barker et al., 2010). In general, recommended CB unit is ≥ 4 of 6 HLA-A, -B antigen and -
DRB1 allele matched with the patient.  
The role of anti-HLA antibodies in graft rejection of organ transplantations has been 
analyzed extensively. The majority of CBTs have HLA disparities. Takanashi et al. reported 
the impact that patients' pretransplantation anti-HLA antibodies have on the outcome of 
myeloablative CBT using single unit (Takanashi et al., 2010). Of 386 cases tested, 89 (23.1%) 
were anti-HLA antibody-positive. Of the 89 antibody-positive cases, 20 patients had 
specificity against the CB HLA. Cumulative incidence (CI) of neutrophil recovery 60 days 
after transplantation was 83% for the antibody-negative group, 73% for antibody-positive, 
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but only 32% for the positive against CB (p<0.0001). These data suggested that patients' 
pretransplantation anti-HLA antibodies should be tested and considered in the selection of 
CB. 
The logistics of the selection of CB grafts, including how to select double-unit grafts, for 
transplantation are as practiced by each centers (Shaw et al., 2009; Rocha & Gluckman, 2009; 
Barker et al., 2011). 
2.2 Comparisons of unrelated donor cord blood and other stem cell sources 
After Laughlin et al. initially reported the feasibility in adult patients receiving 
myeloablative CBT (Laughlin et al., 2001), two registration-based and one single-
institution studies comparing both CBT and BMT from unrelated donor in adult patients 
with acute leukemia after myeloablative conditioning were published (Laughlin et al., 
2004; Rocha et al., 2004; Takahashi et al., 2004). Selected studies are detailed in Table 2. 
These studies demonstrated that hematological recovery after CBT was slower when 
compared to unrelated BMT and that the incidence of severe acute and chronic GVHD 
was significantly lower after CBT than after BMT. However, the DFS rate and relapse 
incidence in CB recipients were not inferior to those in BM recipients. In a two meta-
analysis using pooled comparative data from the above three reports, Hwang et al. 
reported that TRM (pooled estimate 1.04, 95% confidence interval [CI]=0.52-2.08; p=0.91) 
and DFS (pooled estimate 0.59, 95%CI=0.18-1.96; p=0.39) were not statistically different in 
adults (Hwang et al., 2007), whereas Wang et al. reported overall survival (OS) after CBT 
(hazard ratio [HR] 1.26, 95%CI=1.13-1.40) was statistically inferior in adults (Wang et al., 
2010). Recently, Eapen et al. reported a comparative analysis of CBT from unrelated donor 
with BMT or peripheral blood stem cell transplantation (PBSCT) from unrelated donors in 
1525 adult patients with acute leukemia after myeloablative conditioning (Eapen et al., 
2010). 165 received CBT, 888 received PBSCT, and 472 received BMT. Leukaemia-free 
survival (LFS) in patients after CBT was comparable with that after 8/8 and 7/8 allele-
matched PBSCT or BMT. However, TRM was higher after CBT than after 8/8 allele-
matched PBSCT (HR 1.62, 95%CI=1.18-2.23; p=0.003) or BMT (HR 1.69, 95%CI=1.19-2.39; 
p=0.003). Grades II to IV acute and chronic GVHD were lower in CBT recipients 
compared with allele-matched PBSCT (HR 0.57, 95%=0.42-0.77; p=0.002 and HR 0.38, 
95%CI=0.27-0.53; p=0.003, respectively), while the incidence of chronic, but not acute 
GVHD, was lower after CBT than after 8/8 allele-matched BMT (HR 0.63, 95%CI=0.44-
0.90; p=0.01).  
Data comparing both CBT and BMT or PBSCT from related donors in adult patients is 
equally encouraging. We studied the outcomes of 171 adults with hematological 
malignancies who received unrelated CBT as a primary unrelated stem cell source (n=100), 
or BMT or PBSCT from related donors (n=71;55 BMT and 16 PBSCT) followed by 
myeloablative regimens (Takahashi et al., 2007). Significant delays in engraftment occurred 
after CBT. The CIs of grades III to IV acute and extensive type chronic GVHD among CBT 
recipients were significantly lower than those among BMT/PBSCT recipients. Multivariate 
analysis demonstrated no apparent differences in TRM (9% in CBT and 13% in 
BMT/PBSCT), relapse (17% in CBT and 26% in BMT/PBSCT) and DFS (70% in CBT and 
60% in BMT/PBSCT). Unrelated CB could be as safe and effective a stem cell source as 
related BM or mobilized PB for adult patients when it is used as a primary unrelated stem 
cell source. 
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CB:19 19 NA 32* 34% (3) 5% (3) 61% (3) 
rBM:90 90 NA 20* 44% (3) 26% (3) 27% (3) 
uBM:15 15 NA 10* 53% (3) 20% (3) 13% (3) 
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CB:165 28 24 30 37% (2) 1.00** 1.00** 
uBM:332 39 19 39 22% (2) 0.85** 1.15** MuBM:140 46 34% (2) 0.84** 0.93** 
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CBT indicates cord blood transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic 
leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; HSC, hematopoietic 
stem cell; CB, cord blood; uBM, unrelated bone marrow; MuBM, mismatched unrelated bone marrow; 
rBM/PB, related bone marrow/ peripheral blood; uPB, unrelated peripheral blood; MuPB, mismatched 
unrelated peripheral blood; ANC, absolute neutrophil count; NA, information not available; GVHD, 
graft-versus-host disease; TRM, treatment-related mortality; DFS, disease-free survival. 
* The incidence of grade III-IV acute GVHD was shown in this study. 
**Results were expressed as hazard ratios (the relative rate of occurrence of the event with CB as 
compared with another). 
Table 2. Published comparative reports of CBT and other stem cell sources in adults with 
acute leukemia 
Another alternative option for patients lacking an HLA-matched related and unrelated donor 
is allogeneic HSCT from haploidentical related donors. Almost all patients will have available 
to them a haploidentical family member donor. However, randomized study has never been 
published the comparison of outcomes of haploidentical HSCT and CBT for adult patients 
with leukemia (Ballen & Spitzer, 2011). Clinical study comparing haploidentical HSCT to CBT 
are warranted. 
Reports of disease-specific outcomes for adult patients with acute myeloid leukemia (AML) 
or acute lymphoblastic leukemia (ALL) after CBT are still limited (Ooi et al., 2004, 2008, 
2009; Konuma et al, 2009a). Kumar et al. studied the relative impact of donor source on 
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but only 32% for the positive against CB (p<0.0001). These data suggested that patients' 
pretransplantation anti-HLA antibodies should be tested and considered in the selection of 
CB. 
The logistics of the selection of CB grafts, including how to select double-unit grafts, for 
transplantation are as practiced by each centers (Shaw et al., 2009; Rocha & Gluckman, 2009; 
Barker et al., 2011). 
2.2 Comparisons of unrelated donor cord blood and other stem cell sources 
After Laughlin et al. initially reported the feasibility in adult patients receiving 
myeloablative CBT (Laughlin et al., 2001), two registration-based and one single-
institution studies comparing both CBT and BMT from unrelated donor in adult patients 
with acute leukemia after myeloablative conditioning were published (Laughlin et al., 
2004; Rocha et al., 2004; Takahashi et al., 2004). Selected studies are detailed in Table 2. 
These studies demonstrated that hematological recovery after CBT was slower when 
compared to unrelated BMT and that the incidence of severe acute and chronic GVHD 
was significantly lower after CBT than after BMT. However, the DFS rate and relapse 
incidence in CB recipients were not inferior to those in BM recipients. In a two meta-
analysis using pooled comparative data from the above three reports, Hwang et al. 
reported that TRM (pooled estimate 1.04, 95% confidence interval [CI]=0.52-2.08; p=0.91) 
and DFS (pooled estimate 0.59, 95%CI=0.18-1.96; p=0.39) were not statistically different in 
adults (Hwang et al., 2007), whereas Wang et al. reported overall survival (OS) after CBT 
(hazard ratio [HR] 1.26, 95%CI=1.13-1.40) was statistically inferior in adults (Wang et al., 
2010). Recently, Eapen et al. reported a comparative analysis of CBT from unrelated donor 
with BMT or peripheral blood stem cell transplantation (PBSCT) from unrelated donors in 
1525 adult patients with acute leukemia after myeloablative conditioning (Eapen et al., 
2010). 165 received CBT, 888 received PBSCT, and 472 received BMT. Leukaemia-free 
survival (LFS) in patients after CBT was comparable with that after 8/8 and 7/8 allele-
matched PBSCT or BMT. However, TRM was higher after CBT than after 8/8 allele-
matched PBSCT (HR 1.62, 95%CI=1.18-2.23; p=0.003) or BMT (HR 1.69, 95%CI=1.19-2.39; 
p=0.003). Grades II to IV acute and chronic GVHD were lower in CBT recipients 
compared with allele-matched PBSCT (HR 0.57, 95%=0.42-0.77; p=0.002 and HR 0.38, 
95%CI=0.27-0.53; p=0.003, respectively), while the incidence of chronic, but not acute 
GVHD, was lower after CBT than after 8/8 allele-matched BMT (HR 0.63, 95%CI=0.44-
0.90; p=0.01).  
Data comparing both CBT and BMT or PBSCT from related donors in adult patients is 
equally encouraging. We studied the outcomes of 171 adults with hematological 
malignancies who received unrelated CBT as a primary unrelated stem cell source (n=100), 
or BMT or PBSCT from related donors (n=71;55 BMT and 16 PBSCT) followed by 
myeloablative regimens (Takahashi et al., 2007). Significant delays in engraftment occurred 
after CBT. The CIs of grades III to IV acute and extensive type chronic GVHD among CBT 
recipients were significantly lower than those among BMT/PBSCT recipients. Multivariate 
analysis demonstrated no apparent differences in TRM (9% in CBT and 13% in 
BMT/PBSCT), relapse (17% in CBT and 26% in BMT/PBSCT) and DFS (70% in CBT and 
60% in BMT/PBSCT). Unrelated CB could be as safe and effective a stem cell source as 
related BM or mobilized PB for adult patients when it is used as a primary unrelated stem 
cell source. 
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Table 2. Published comparative reports of CBT and other stem cell sources in adults with 
acute leukemia 
Another alternative option for patients lacking an HLA-matched related and unrelated donor 
is allogeneic HSCT from haploidentical related donors. Almost all patients will have available 
to them a haploidentical family member donor. However, randomized study has never been 
published the comparison of outcomes of haploidentical HSCT and CBT for adult patients 
with leukemia (Ballen & Spitzer, 2011). Clinical study comparing haploidentical HSCT to CBT 
are warranted. 
Reports of disease-specific outcomes for adult patients with acute myeloid leukemia (AML) 
or acute lymphoblastic leukemia (ALL) after CBT are still limited (Ooi et al., 2004, 2008, 
2009; Konuma et al, 2009a). Kumar et al. studied the relative impact of donor source on 
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outcomes following myeloablative HSCT for 138 adult patients with ALL (Kumar et al., 
2008). When compared with unrelated BMT, OS with CBT was better (relative risk [RR] 0.3, 
95%CI=0.1-0.7; p=0.01). Recently, Atsuta et al. reported a disease-specific comparison of CBT 
and HLA allele-matched unrelated BMT among 484 patients with AML (AML; 173 CB and 
311 BM) and 336 patients with ALL (ALL; 114 CB and 222 BM) who received myeloablative 
transplantations (Atsuta et al., 2009). In multivariate analyses, among AML cases, lower OS 
(HR 1.5, 95%CI=1.0-2.0; p=0.028) and LFS (HR 1.5, 95%CI=1.1-2.0; p=0.012) were observed in 
CB recipients. The relapse rate did not differ between the 2 groups of AML (HR 1.2, 
95%CI=0.8-1.9; p=0.38). However, the TRM rate showed higher trend in CB recipients (HR 
1.5, 95%CI=1.0-2.3; p=0.085). In ALL, there was no significant difference between the groups 
for relapse (HR 1.4, 95%CI=0.8-2.4; p=0.19) and TRM (HR 1.0, 95%CI=0.6-1.7; p=0.98), which 
contributed to similar OS (HR 1.1, 95%CI=0.7-1.6; p=0.78) and LFS (HR 1.2, 95%CI=0.9-1.8; 
p=0.28).  
Taken together, their results showed that CBT is feasible in adults when a CB unit contains a 
higher number of cells and when a transplant is needed urgently, and should be considered 
an option as an allogeneic stem cell source for patients lacking an HLA-matched unrelated 
donor. The results also showed that despite increased HLA disparity, CBT from unrelated 
donors is promising in adults with acute leukemia.  
3. Improvement methods of engraftment and delay hematopoietic recovery 
The relatively low number of HSCs and progenitors per one unit is a main limitation of CB 
instead of BM or mobilized PB as a stem cell source for HSCT, especially in adults. The low 
cell dose available for HSCT might contribute to higher incidence of graft failure, delayed 
hematopoietic recovery and delayed immune reconstitution. As a consequence, it is well 
known that transplanted cell dose is associated with TRM and survival after CBT. There 
have been several developing strategies to overcome the obstacle of low number of cell dose 
using CB as a stem cell source for transplantation, especially in adults. 
3.1 Ex vivo expansion of cord blood 
To improve limited cell dose contained in CB grafts, one attractive option is ex vivo 
expansion of CB which has been shown to have greater proliferative and self-renewal 
capacity when compared to the other sources of HSCs (Broxmeyer et al., 1992; Hows et al., 
1992). Initial CB expansion attempts have used a variety of cytokines, such as stem cell 
factor (SCF), fms-like tyrosine kinase 3 (flt-3) ligand, thrombopoietin (TPO) and G-CSF 
(granulocyte colony-stimulating factor), reagents, such as polyamine copper chelator, 
tetraethylenepentamine (TEPA), and mesenchymal stem cells (MSCs), to cell culture. Several 
clinical studies were investigated, but have not achieved clinically relevant effects (Shpall et 
al., 2002; de Lima et al., 2008, 2010; Jaroscak et al., 2003; Delaney et al., 2010; Kelly et al., 
2009) (Table 3). Delancy et al. report the development of a clinically relevant Notch-
mediated ex vivo expansion system for CB CD34+ cells and the phase I study involving 
transplantation of a non-manipulated unit along with CB progenitors from a second CB unit 
that have undergone Notch-mediated ex vivo expansion in 10 patients with acute leukemia 
(Delaney et al., 2010). After ex vivo expansion, there was an average fold expansion of 
CD34+ cells of 164 and an average fold expansion of total cell numbers of 562. The infused 
CD34+ cell dose derived from the expanded CB graft averaged 6×106 CD34+cells/kg versus 
0.24 ×106 CD34+cells/kg (p=0.0004) from the non-manipulated CB graft. Time to absolute 
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neutrophil count (ANC) ≥500/μl was shortened significantly with a median time of 16 days 
(range, 7–34 days) compared with cohort of 20 patients undergoing double CBT with a 
median time of 26 days (range, 16–48 days; p= 0.002), despite loss of contribution to 
engraftment from the expanded cell graft. This is highly suggestive of a facilitating effect of 
the cultured cells in promoting engraftment from the non-manipulated CB unit. This is the 
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ANC, absolute neutrophil count; PLT, platelet; NA, information not available; GVHD, graft-versus-host 
disease. 
Table 3. Published clinical trials of CBT using ex vivo expanded CB 
3.2 Reduced-intensity conditioning regimen 
Myeloablative conditioning (MAC) regimens for allogeneic HSCT have been restricted to 
younger patients without comorbidities, because TRM occurs more frequently among 
elderly patients and those with serious comorbidities. Reduced-intensity conditioning (RIC) 
regimens have emerged as a novel transplantation modality for those patients with the 
expectation of reducing TRM and increasing survival after allogeneic HSCT. This strategy 
was recently expanded for quick use with stem cell sources not only from BM or mobilized 
PB, but also from CB (Barker et al., 2003; Miyakoshi et al., 2004; Chao et al., 2004; Misawa et 
al., 2006; Brunstein et al., 2007; Komatsu et al., 2007; Majhail et al., 2008; Uchida et al., 2008; 
Cutler & Ballen, 2009; Horwitz & Chao, 2010). Several studies have reported on CBT using 
RIC for adult patients with leukemia, and selected studies using mainly single CB unit are 
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outcomes following myeloablative HSCT for 138 adult patients with ALL (Kumar et al., 
2008). When compared with unrelated BMT, OS with CBT was better (relative risk [RR] 0.3, 
95%CI=0.1-0.7; p=0.01). Recently, Atsuta et al. reported a disease-specific comparison of CBT 
and HLA allele-matched unrelated BMT among 484 patients with AML (AML; 173 CB and 
311 BM) and 336 patients with ALL (ALL; 114 CB and 222 BM) who received myeloablative 
transplantations (Atsuta et al., 2009). In multivariate analyses, among AML cases, lower OS 
(HR 1.5, 95%CI=1.0-2.0; p=0.028) and LFS (HR 1.5, 95%CI=1.1-2.0; p=0.012) were observed in 
CB recipients. The relapse rate did not differ between the 2 groups of AML (HR 1.2, 
95%CI=0.8-1.9; p=0.38). However, the TRM rate showed higher trend in CB recipients (HR 
1.5, 95%CI=1.0-2.3; p=0.085). In ALL, there was no significant difference between the groups 
for relapse (HR 1.4, 95%CI=0.8-2.4; p=0.19) and TRM (HR 1.0, 95%CI=0.6-1.7; p=0.98), which 
contributed to similar OS (HR 1.1, 95%CI=0.7-1.6; p=0.78) and LFS (HR 1.2, 95%CI=0.9-1.8; 
p=0.28).  
Taken together, their results showed that CBT is feasible in adults when a CB unit contains a 
higher number of cells and when a transplant is needed urgently, and should be considered 
an option as an allogeneic stem cell source for patients lacking an HLA-matched unrelated 
donor. The results also showed that despite increased HLA disparity, CBT from unrelated 
donors is promising in adults with acute leukemia.  
3. Improvement methods of engraftment and delay hematopoietic recovery 
The relatively low number of HSCs and progenitors per one unit is a main limitation of CB 
instead of BM or mobilized PB as a stem cell source for HSCT, especially in adults. The low 
cell dose available for HSCT might contribute to higher incidence of graft failure, delayed 
hematopoietic recovery and delayed immune reconstitution. As a consequence, it is well 
known that transplanted cell dose is associated with TRM and survival after CBT. There 
have been several developing strategies to overcome the obstacle of low number of cell dose 
using CB as a stem cell source for transplantation, especially in adults. 
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expansion of CB which has been shown to have greater proliferative and self-renewal 
capacity when compared to the other sources of HSCs (Broxmeyer et al., 1992; Hows et al., 
1992). Initial CB expansion attempts have used a variety of cytokines, such as stem cell 
factor (SCF), fms-like tyrosine kinase 3 (flt-3) ligand, thrombopoietin (TPO) and G-CSF 
(granulocyte colony-stimulating factor), reagents, such as polyamine copper chelator, 
tetraethylenepentamine (TEPA), and mesenchymal stem cells (MSCs), to cell culture. Several 
clinical studies were investigated, but have not achieved clinically relevant effects (Shpall et 
al., 2002; de Lima et al., 2008, 2010; Jaroscak et al., 2003; Delaney et al., 2010; Kelly et al., 
2009) (Table 3). Delancy et al. report the development of a clinically relevant Notch-
mediated ex vivo expansion system for CB CD34+ cells and the phase I study involving 
transplantation of a non-manipulated unit along with CB progenitors from a second CB unit 
that have undergone Notch-mediated ex vivo expansion in 10 patients with acute leukemia 
(Delaney et al., 2010). After ex vivo expansion, there was an average fold expansion of 
CD34+ cells of 164 and an average fold expansion of total cell numbers of 562. The infused 
CD34+ cell dose derived from the expanded CB graft averaged 6×106 CD34+cells/kg versus 
0.24 ×106 CD34+cells/kg (p=0.0004) from the non-manipulated CB graft. Time to absolute 
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neutrophil count (ANC) ≥500/μl was shortened significantly with a median time of 16 days 
(range, 7–34 days) compared with cohort of 20 patients undergoing double CBT with a 
median time of 26 days (range, 16–48 days; p= 0.002), despite loss of contribution to 
engraftment from the expanded cell graft. This is highly suggestive of a facilitating effect of 
the cultured cells in promoting engraftment from the non-manipulated CB unit. This is the 
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Myeloablative conditioning (MAC) regimens for allogeneic HSCT have been restricted to 
younger patients without comorbidities, because TRM occurs more frequently among 
elderly patients and those with serious comorbidities. Reduced-intensity conditioning (RIC) 
regimens have emerged as a novel transplantation modality for those patients with the 
expectation of reducing TRM and increasing survival after allogeneic HSCT. This strategy 
was recently expanded for quick use with stem cell sources not only from BM or mobilized 
PB, but also from CB (Barker et al., 2003; Miyakoshi et al., 2004; Chao et al., 2004; Misawa et 
al., 2006; Brunstein et al., 2007; Komatsu et al., 2007; Majhail et al., 2008; Uchida et al., 2008; 
Cutler & Ballen, 2009; Horwitz & Chao, 2010). Several studies have reported on CBT using 
RIC for adult patients with leukemia, and selected studies using mainly single CB unit are 
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detailed in Table 4. The University of Minnesota group initially reported unrelated CBT for 
adults after RIC, demonstrating that 0-2 antigen mismatched CBT was sufficient to engraft 
most adults after RIC and was associated with low incidence of severe acute GVHD (Barker 
et al., 2003). They reported the updated results of this strategy in 110 adult patients with 
hematological disease to confirm the suitability of this strategy (Brunstein et al., 2007). 
Neutrophil recovery was achieved in 92% at the median of 12 days. The incidence of grades 
III to IV acute GVHD was 22%. However, these studies included the results of 
transplantation of both single and double CB grafts, because the target cell dose for the CB 
graft was 3x107cells/kg. Recenly, same group reported the comparative efficacy of CBT after 
RIC relative to MAC in 119 adult patients with AML in CR (complete remission) (Oran et al., 
2011). The incidence of neutrophil recovery at day +42 was higher with RIC (RIC:94% vs 
MAC:82%; p<0.1). Incidence of grades II to IV acute GVHD was decreased (RIC:47% vs 
MAC:67%; p<0.01). Using RIC, 3-year LFS was decreased (RIC:31% vs MAC:55%; p=0.02) 
and 3-year relapse incidence was increased (RIC:43% vs MAC:9%; p<0.01). Two-year TRM 
was similar (RIC:19% vs MAC:27%; p=0.55). In multivariate analysis, RIC recipients and 
those in CR2 with CR1 duration <1 year had higher risk of relapse and poorer LFS with no 
independent predictors of TRM. Further studies are warranted to establish criteria for 
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Table 4. Published reports of CBT using reduced-intensity conditioning in adults 
3.3 Transplantation using multiple grafts of cord blood 
Double CBT (dCBT) was initially developed as a strategy to overcome the cell dose 
limitation preventing the number of adults transplanted with single unit CB, and has been 
widely used in United States and Europe. Several studies have reported on double CBT for 
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adult patients with acute leukemia (Barker et al., 2005; Ballen et al., 2007; Rodrigues et al., 
2009; MacMillan et al., 2009a; Gutman et al., 2009; Verneris et al., 2009; Cutler et al., 2010; 
Rocha et al., 2010a, 2010b; Brunstein et al., 2010; Delaney et al., 2009; Stanevsky et al., 2010), 
and representative studies are detailed in Table 5. Several studies showed that double CBT 
is associated with a higher incidence of acute GVHD compared with single CBT (sCBT). 
Interestingly,the risk of relapse after double CBT is significantly lower compared with single 
CBT for patients with leukemia in remission, suggesting that a greater GVL effect due to 
HLA disparity for the double CB recipient (Brunstein et al., 2007, 2010; Rodrigues et al.,  
2009; Verneris et al., 2009). On the other hand, neutrophil engraftment and LFS were similar 
for recipients of single or double CB units. Recently, Roche et al. also reported the results of 
single (n=377) and double (n=230) CBT in adult patients with AML or ALL in remission 
(Rocha et al., 2010a). In patients transplanted in CR 1, there were no statistical differences in 
CI of neutrophil recovery (dCBT 78% vs sCBT 82%; p=0.11). Acute GVHD was higher after 
dCBT compared with sCBT (45% vs 27%; p<0.001). At 3 years, relapse incidence was 15% 
after dCBT and 25% after sCBT (p=0.03). Estimated 3 years LFS was 53% after dCBT and  
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detailed in Table 4. The University of Minnesota group initially reported unrelated CBT for 
adults after RIC, demonstrating that 0-2 antigen mismatched CBT was sufficient to engraft 
most adults after RIC and was associated with low incidence of severe acute GVHD (Barker 
et al., 2003). They reported the updated results of this strategy in 110 adult patients with 
hematological disease to confirm the suitability of this strategy (Brunstein et al., 2007). 
Neutrophil recovery was achieved in 92% at the median of 12 days. The incidence of grades 
III to IV acute GVHD was 22%. However, these studies included the results of 
transplantation of both single and double CB grafts, because the target cell dose for the CB 
graft was 3x107cells/kg. Recenly, same group reported the comparative efficacy of CBT after 
RIC relative to MAC in 119 adult patients with AML in CR (complete remission) (Oran et al., 
2011). The incidence of neutrophil recovery at day +42 was higher with RIC (RIC:94% vs 
MAC:82%; p<0.1). Incidence of grades II to IV acute GVHD was decreased (RIC:47% vs 
MAC:67%; p<0.01). Using RIC, 3-year LFS was decreased (RIC:31% vs MAC:55%; p=0.02) 
and 3-year relapse incidence was increased (RIC:43% vs MAC:9%; p<0.01). Two-year TRM 
was similar (RIC:19% vs MAC:27%; p=0.55). In multivariate analysis, RIC recipients and 
those in CR2 with CR1 duration <1 year had higher risk of relapse and poorer LFS with no 
independent predictors of TRM. Further studies are warranted to establish criteria for 
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adult patients with acute leukemia (Barker et al., 2005; Ballen et al., 2007; Rodrigues et al., 
2009; MacMillan et al., 2009a; Gutman et al., 2009; Verneris et al., 2009; Cutler et al., 2010; 
Rocha et al., 2010a, 2010b; Brunstein et al., 2010; Delaney et al., 2009; Stanevsky et al., 2010), 
and representative studies are detailed in Table 5. Several studies showed that double CBT 
is associated with a higher incidence of acute GVHD compared with single CBT (sCBT). 
Interestingly,the risk of relapse after double CBT is significantly lower compared with single 
CBT for patients with leukemia in remission, suggesting that a greater GVL effect due to 
HLA disparity for the double CB recipient (Brunstein et al., 2007, 2010; Rodrigues et al.,  
2009; Verneris et al., 2009). On the other hand, neutrophil engraftment and LFS were similar 
for recipients of single or double CB units. Recently, Roche et al. also reported the results of 
single (n=377) and double (n=230) CBT in adult patients with AML or ALL in remission 
(Rocha et al., 2010a). In patients transplanted in CR 1, there were no statistical differences in 
CI of neutrophil recovery (dCBT 78% vs sCBT 82%; p=0.11). Acute GVHD was higher after 
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39% after sCBT (p=0.09). However, in patients transplanted in CR2 and CR3, estimated 3 
years LFS was 35% after dCBT and 31% after sCBT (p=0.48). These data concluded double 
CBT has extended the use of CBT for patients otherwise not eligible for single CBT and 
importantly is associated with better outcomes in adults with acute leukemia transplanted 
in early phase of the disease. Brunstein et al. reported 536 patients with leukemia who 
underwent transplantation with an HLA allele-matched related donor (MRD, n=204), HLA 
allele-matched unrelated donor (MUD, n=152) or 1-antigen-mismatched unrelated adult 
donor (MMUD, n=52) or 4-6/6 HLA matched double CB (dCB, n=128) graft after 
myeloablative conditioning (Brunstein et al., 2010). All patients received MAC with 
cyclophosphamide (CY) 120 mg/kg and total body irradiation (TBI) 12 to 13.2 Gy with the 
addition of fludarabine (Flu) 75 mg/m2 in recipients of dCBT. LFS at 5 years was similar for 
each donor type (dCB 51%, MRD 33%, MUD 48%, MMUD 38%). The risk of relapse was 
lower in recipients of dCB (15%) compared with MRD (43%), MUD (37%) and MMUD 
(35%), yet nonrelapse mortality was higher for dCB (34%), MRD (24%), and MUD (14%). 
They conclude that LFS after double CBT is comparable with that observed after MRD and 
MUD transplantation. Although clinical experience using double CBT is progressing as 
described above, 1 CB unit ultimately dominates and confers durable engraftment, but little 
is known about the mechanism of the determinants of durable engraftment by 1 CB unit 
after double CBT. More recently, Avery et al. demonstrated that indicators of CB unit 
potency including TNC dose, colony-forming unit (CFU), CD3+, and viable CD34+ cell 
content, predict the dominating unit, but HLA matching does not appear to play a role in 
unit dominance (Avery et al., 2011). 
3.4 Co-transplantation with third party donor 
Fernandez et al. have developed the strategy of single unit CBT with co-infusion of a limited 
number of mobilized HSC (MHSC) from an HLA-mismached third party donor (TPD) 
(Fernández et al., 2003; Magro et al., 2006; Bautista et al., 2009). They reported the updated 
results of this strategy in 55 adult patients with high-risk hematological malignancies 
(Bautista et al., 2009). The median CB cell dose of 2.37x107cells/kg (the median CB CD34+ 
cells of 0.11x106cells/kg) and the median TPD-MHSC CD34+ cells of 2.4x106cells/kg were 
transplanted. The median time to recovery of neutophils and CB derived neutophils as well 
as to complete CB chimerism was 10, 21 and 44 days. Finally, TPD-MHSC derived 
hematopoiesis disappeared completely. The 5 years OS and DFS were 56 % and 47%, 
respectively. This strategies suggested that transient hematopoiesis from TPD-MHSC might 
reduce the incidence of neutropenia-related serious infection, thus leading to the possibility 
of decreased TRM early after CBT in adult patients. 
3.5 Intrabone transplantation 
To improve efficient engraftment possibly due to better stem cell homing to the bone 
marrow, Frassoni et al. reported the phase I/II study of direct intrabone transplantation of 
single unit CB in 32 patients with acute leukemia (Frassoni et al., 2008). Although the 
median transplanted cell dose was 2.6x107cells/kg (range, 1.4-4.2), the median time to 
recovery of neutrophils in 28 patients and platelets in 27 patients was 23 days (range, 14-44) 
and 36 days (range 16-64), respectively. All patients with hematopoietic recovery showed 
complete donor engraftment from 30 days after CBT. No patient developed grades III to IV 
acute GVHD. This preliminary data suggest that direct intrabone CBT overcomes the 
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problem of graft failure even when low numbers of single unit unrelated HLA-mismatched 
CB are transplanted in adults and need to be confirmed in a larger number of adult patients. 
3.6 Improvement of homing capacity 
The interaction of stromal-derived factor-1 (SDF-1)/CXCL12 with CXCR4 mediates the 
homing of HSCs to the BM. CD26, a surface serine dipeptidylpeptidase IV (DPPIV), cleaves 
the amino-terminal dipeptide from some chemokines, including SDF-1. Diprotin A, which is 
inhibitor of CD26 peptidase activity, enhances engraftment of HSCs from CB into nonobese 
diabetic/severe combined immunodeficiency (NOD/SCID) mice (Campbell et al., 2007). 
Based on these data, the clinical trial to look the efficiency of CB engraftment using Diprotin 
A is now warranted. Moreover, several clinical trials should be investigated to answer the 
efficacy of co-infusion of haploidentical MSCs for the enhancement of engraftment and 
prevention of graft failure in CBT (Macmillan et al., 2009b; Gonzalo-Daganzo et al., 2009; 
Bernardo et al., 2011). 
4. Immune therapy using cord blood 
4.1 Immune reconstitution after CBT  
Infection-related mortality is the primary cause of death early after CBT, with most deaths 
occurring in the first 3-6 months after transplant. Komanduri et al. reported prolonged T 
lymphopenia, impaired T cell functional responses to superantigens and cytomegalovirus 
(CMV), thymopoietic failure were important causes of delayed immune reconstitution after 
CBT in adult (Komanduri et al., 2007). For several months, until recovery of the thymus is 
restored to support de-novo T cell generation, protective antiviral immunity depends on the 
activity of postthymic T cells infused within the CB grafts. However, almost all T cells in CB 
grafts are naïve lymphocytes that have been functionally altered by placental factors to 
provide a protective environment during pregnancy. T cells in CB grafts need to undergo in-
vivo priming, T helper (Th)1/T cytotoxic (Tc)1 maturation, and peripheral expansion before 
they can afford immunologic protection. Remarkable immunophenotypic changes are 
notable already in the first 2-3 weeks after CBT. These changes result from apparent 
’homeostatic’ peripheral T cell expansion in the lymphopenic environment (Szabolcs & 
Niedzwiecki, 2007; Szabolcs & Cairo, 2010).  
4.2 Cellular therapy for viral infection or leukemia after CBT 
One of the major limitations of CBT is the lack of donor cells available for 
posttransplantation donor leukocyte infusions (DLI) to boost immunity for severe viral 
infection or induce GVL activity for leukemia relapse, because the initial donor is 
unavailable. Although there was no obvious available source for adoptive cell therapy in the 
setting of CBT, several researches suggest that adoptive immune therapy using CB immune 
cells have the potential to improve the outcomes after CBT (Hanley et al., 2010). 
4.2.1 Cytotoxic T lymphocytes 
Ex vivo generation of T cells from CB naïve T cells has been achieved in several methods 
using CD3/CD28 costimulation, interleukin (IL)-2, and IL-7 (Mazur et al., 2008; Davis et al., 
2010). Moreover, several researchers successfully have generated antigens-specific cytotoxic 
T lymphocytes (CTLs) from CB. Park et al. developed a protocol to in-vitro-prime and 
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39% after sCBT (p=0.09). However, in patients transplanted in CR2 and CR3, estimated 3 
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problem of graft failure even when low numbers of single unit unrelated HLA-mismatched 
CB are transplanted in adults and need to be confirmed in a larger number of adult patients. 
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diabetic/severe combined immunodeficiency (NOD/SCID) mice (Campbell et al., 2007). 
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efficacy of co-infusion of haploidentical MSCs for the enhancement of engraftment and 
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occurring in the first 3-6 months after transplant. Komanduri et al. reported prolonged T 
lymphopenia, impaired T cell functional responses to superantigens and cytomegalovirus 
(CMV), thymopoietic failure were important causes of delayed immune reconstitution after 
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activity of postthymic T cells infused within the CB grafts. However, almost all T cells in CB 
grafts are naïve lymphocytes that have been functionally altered by placental factors to 
provide a protective environment during pregnancy. T cells in CB grafts need to undergo in-
vivo priming, T helper (Th)1/T cytotoxic (Tc)1 maturation, and peripheral expansion before 
they can afford immunologic protection. Remarkable immunophenotypic changes are 
notable already in the first 2-3 weeks after CBT. These changes result from apparent 
’homeostatic’ peripheral T cell expansion in the lymphopenic environment (Szabolcs & 
Niedzwiecki, 2007; Szabolcs & Cairo, 2010).  
4.2 Cellular therapy for viral infection or leukemia after CBT 
One of the major limitations of CBT is the lack of donor cells available for 
posttransplantation donor leukocyte infusions (DLI) to boost immunity for severe viral 
infection or induce GVL activity for leukemia relapse, because the initial donor is 
unavailable. Although there was no obvious available source for adoptive cell therapy in the 
setting of CBT, several researches suggest that adoptive immune therapy using CB immune 
cells have the potential to improve the outcomes after CBT (Hanley et al., 2010). 
4.2.1 Cytotoxic T lymphocytes 
Ex vivo generation of T cells from CB naïve T cells has been achieved in several methods 
using CD3/CD28 costimulation, interleukin (IL)-2, and IL-7 (Mazur et al., 2008; Davis et al., 
2010). Moreover, several researchers successfully have generated antigens-specific cytotoxic 
T lymphocytes (CTLs) from CB. Park et al. developed a protocol to in-vitro-prime and 
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expand CMV-specific CTLs from CB (Park et al., 2006). Recently, Hanley et al. reported the 
generation of single cultures of CTLs from CB that are specific for CMV, Epstein-Barr virus 
(EBV) and adenovirus (Adv) (Hanley et al., 2009). The CB CTLs recognized multiple viral 
epitopes, including CD4-restricted Adv-hexon epitopes and immunosubdominant CD4- and 
CD8-restricted CMVpp65 epitopes. A clinical trial using CB derived multivirus specific 
CTLs for prevention and treatment of these virus infection in CB transplant is now 
underway. To generate CB derived T cells recognizing B-lineage ALL because GVT effects 
are largely mediated by CTLs, several researchers developed CB derived T cells are 
expanded and genetically modified to express CD19 chimeric antigen receptors (Serrano et 
al., 2006; Micklethwaite et al., 2010). The genetically modified T-cell clones revealed an 
ability to lyse CD19+ leukemic cells specifically and repetitively.  
4.2.2 NK cell 
NK cells are a subset of lymphocytes with functions associated with innate immunity. NK 
cells also have been found to substantially contribute to GVT effects. Adoptive immune 
therapy with NK cells to treat malignancy is actively being investigated in early phase 
clinical trials. Ruggeri et al. reported the PB derived NK cell alloreactively is capable of 
preventing relapse of AML in the setting of killer immunoglobulin-like receptor (KIR) 
ligand-mismatched haploidentical HSCT (Ruggeri et al., 2002). Two retrospective studies on 
the effects of KIR ligand-mismatching in CBT for leukemia have result in conflicting results. 
Willemze et al. reported that a favourable effect of KIR ligand-mismatching on relapse rate 
and survival (Willemze et al., 2009), whereas Brunstein et al. reported no effect on relapse 
(Brunstein et al., 2009). The impact of KIR ligand-mismatching on relapse after CBT remains 
to be determined. NK cells are present at the similar percentages in both CB and PB. 
However, CB NK cells express a relatively higher percentage of inhibitory receptors, such as 
CD94/NKG2A and KIR (Verneris & Miller, 2009). The expanded CB NK cells exhibit anti 
leukemic activity in mouse model (Xing et al., 2010). Based on these data, the efficiency of 
CB NK cells to treat leukemia relapse is now underway. 
4.2.3 Regulatory T cell 
Regulatory T cells (Tregs) are a suppressive subset of the naturally occurring T cells 
characterized by their constitutive expression of CD4 and the IL-2 receptor α chain (CD25). 
Tregs are also characterized by high levels of the forkhead box protein 3 (FoxP3). Tregs can 
abrogate GVHD in murine models of major histocompatibility complex (MHC) mismatched 
allogeneic HSCT through suppression of alloreactive effector T cells.  In contrast to Tregs 
from PB, Tregs are readily purified from CB. CB Tregs have greater expansion potential 
when compared to PB Tregs (Tolar et al., 2009). Brunstein et al. reported that infusion of ex 
vivo expanded Tregs from CB reduced the incidence of grades II to IV acute GVHD in CBT 
recipients compared with historical controls without Tregs (Brunstein et al., 2011). 
4.2.4 MSCs 
MSCs were initially described as a BM-derived mononuclear cell population adhered to 
plastic with a fibroblast-like morphology, when cultured ex vivo. Thereafter, MSCs can also 
be isolated from CB (Tolar et al., 2009). These cells are capable of differentiation into 
multiple lineages, including bone, cartilage and adipocyte cells in particular. The functional 
aspects of MSCs include tissue repair, hematopoietic engraftment support, immune 
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modulation. Clinical trial studying the effects of BM derived MSCs for the treatment of 
standard therapy-resistant severe GVHD has been initiated recently with promising results 
(Le Blanc et al., 2008). However, whether CB derived MSCs have similar beneficial effects 
for the treatment of severe GVHD is unknown. 
5. Problem of donor cell leukemia 
Donor cell-derived hematological malignancy is a rare complication after allogeneic HSCT. 
Previous studies reported that 0.12-5% of patients developed donor cell leukemia (DCL) 
after allogeneic HSCT (Hertenstein et al., 2005; Flynn & Kaufman, 2007; Wiseman, 2010). 
Several reports demonstrated that donor cell-derived hematological malignancy occurred in 
patients after CBT (Matsunaga et al., 2005; Fraser et al., 2005; Ando et al., 2006; Sevilla et al., 
2006; Mitsui et al., 2007; Nagamura-Inoue et al., 2007; Hamaki et al., 2008; Konuma et al., 
2009b; Crow et al., 2010; Castleton et al., 2010; Ballen et al., 2010; Wang et al., 2011). Ballen et 
al. reported the occurrence of donor-derived hematological malignancies after double CBT 
(Ballen et al., 2010). Sixteen patients developed a second hematological malignancy (both 
cases of MDS/myeloproliferative diseases (MPD) and 14 of the lymphomas) at a median of 
134 days after double CBT. The mechanism for causing DCL after allogeneic HSCT is not 
well understood. The presence of preleukemic clones found only rarely in CB samples might 
contribute to the development of DCL after CBT (Mori et al., 2002). Moreover, various 
factors including impaired tumor surveillance, chronic antigenic stimulation by differences 
between donor and recipient cells, perturbations within the host BM microenvironment, 
premature aging of the donor cells, and the associated chromosomal instability might 
contribute to the development of DCL after allogeneic HSCT (Flynn & Kaufman, 2007; 
Wiseman, 2010). It has been hypothesized that donor cell-derived hematological malignancy 
may be substantially more frequent with a CB source of stem cells (Greaves, 2006). Further 
research and the increasing number of reports will improve understanding of the clinical 
implications of the donor cell-derived hematological malignancies after CBT. 
6. Conclusion 
Clinical results of CBT for acute leukemia have improved recently in adult patients. In 
addition to the potent HSCs in CB, multiple populations of stem cells with stem cell 
properties have been identified from CB and have led to the idea that CB can be used for 
regenerative therapies. In fact, clinical trials are now underway in type 1 diabetes, cerebral 
palsy and peripheral vascular disease. Moreover, recent studies demonstrated that it is 
possible to generate induced pluripotent stem (iPS) cells from human CB (Giorgetti et al., 
2009; Haase et al., 2009; Hu et al., 2011; Broxmeyer et al., 2011). These data offer CB derived 
iPS cells are also considered an ideal source for future regenerative therapies. 
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1. Introduction 
The development of effective therapy for children with acute lymphoblastic leukemia (ALL) 
is one of the greatest successes of clinical oncology, with long-term survival achieved in 
about  90% of children 1-10 years of age (Pui et al 2008, Pulte et al 2008). However, cure rates 
for adults with ALL remain relatively low, at only 40%-50% (Gokbuget et al 2009, Larson et 
al 2008). In the last two decades significant improvements in survival for older adolescent 
and adults (aged 15-59 years) with ALL have been observed, being especially evident in 
patients aged 15-19 yr. 
Age is a continuous prognostic variable in ALL with no single age at which prognosis 
deteriorates markedly. Within childhood ALL populations, older children have shown inferior 
outcomes (Pulte et al 2009, Smith et al 2010) while younger adults have shown superior 
outcomes among adult ALL patients (Moorman et al 2010, Juliusson et al 2010). The definition 
of the age range that encompasses the adolescent and young adults (AYA) patient is 
controversial, ranging from 15 to 21 yr in some studies, from 15-30 yr in others or even from 15 
to 40-45 yr in others. This chapter will focus on the results of treatment of AYA with ALL. 
2. Clinical and biologic characteristics in adolescents and young adults 
The incidence of ALL decreases with age, ranging from 9-10 cases/100,000 persons/year in 
childhood (representing 30% of all cancers) to 1-2 cases/100,000 persons/year in adults. In 
adolescents the incidence is 3 cases/100,000 persons/year and represents 6% of all cancers at 
that age (Bleyer et al 2006). 
Several clinical and biologic characteristics of ALL are age-dependent. In this sense, T-ALL 
is more frequent in AYA (25%) than in children (10-15%) or in older adults (Pullen et al 
1999). However, the most important differences lie in cytogenetic and molecular 
characteristics. For example, there is a lower frequency of hyperdiploidy >50 chromosomes 
or ETV6/RUNX1 (previously TEL/AML1) in AYAs (20%) compared to children 1 to 9 years 
of age (>30%) (Moorman et al 2010). In addition, the frequency of MLL (myeloid-lymphoid 
leukemia or mixed lineage leukemia gene, usually associated with 11q23) rearrangements in 
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1. Introduction 
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Age is a continuous prognostic variable in ALL with no single age at which prognosis 
deteriorates markedly. Within childhood ALL populations, older children have shown inferior 
outcomes (Pulte et al 2009, Smith et al 2010) while younger adults have shown superior 
outcomes among adult ALL patients (Moorman et al 2010, Juliusson et al 2010). The definition 
of the age range that encompasses the adolescent and young adults (AYA) patient is 
controversial, ranging from 15 to 21 yr in some studies, from 15-30 yr in others or even from 15 
to 40-45 yr in others. This chapter will focus on the results of treatment of AYA with ALL. 
2. Clinical and biologic characteristics in adolescents and young adults 
The incidence of ALL decreases with age, ranging from 9-10 cases/100,000 persons/year in 
childhood (representing 30% of all cancers) to 1-2 cases/100,000 persons/year in adults. In 
adolescents the incidence is 3 cases/100,000 persons/year and represents 6% of all cancers at 
that age (Bleyer et al 2006). 
Several clinical and biologic characteristics of ALL are age-dependent. In this sense, T-ALL 
is more frequent in AYA (25%) than in children (10-15%) or in older adults (Pullen et al 
1999). However, the most important differences lie in cytogenetic and molecular 
characteristics. For example, there is a lower frequency of hyperdiploidy >50 chromosomes 
or ETV6/RUNX1 (previously TEL/AML1) in AYAs (20%) compared to children 1 to 9 years 
of age (>30%) (Moorman et al 2010). In addition, the frequency of MLL (myeloid-lymphoid 
leukemia or mixed lineage leukemia gene, usually associated with 11q23) rearrangements in 
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non-infant ALL increases with age, being infrequent in children 1-9 yr of age and about 6% 
in adults (Moorman et al 2010). Regarding structural changes, there is a progressive increase 
in the frequency of  t(9;22)(q34;q11) or BCR-ABL rearrangements, ranging from less than 3% 
in children under 18 yr. to 6% at ages 18-25  and to 15-20% at ages 25-35 yr, and to more than 
30% over the age of 35 yr (Secker-Walker et al 1991). Finally, in recent studies, adolescents 
were more likely to have detectable minimal residual disease (MRD) during or at the end of 
remission induction (Pui et al 2011). 
In summary, with increasing age there is a progressive increase in the frequency of subsets 
of ALL patients with genetic abnormalities associated with poor prognosis and these 
changes have already become evident in AYA patients.   
As far as host factors are concerned, several features are observed in less young patients, 
being responsible for increased treatment toxicity. They include differences in the 
metabolism of chemotherapeutic agents, depleted marrow reserve and increased 
extramedullary toxicity. All these issues increase the frequency of life-threatening infections, 
organ failure, and treatment delays and dose reductions in planned chemotherapy. 
3. Which is the best treatment strategy? Pediatric-based vs. adult-based 
treatments 
3.1 Retrospective comparative studies 
A number of comparisons of the clinical outcome of adolescents enrolled in adult and 
pediatric clinical trials have resulted in interesting observations about the appropriate 
treatment strategy for prospective studies in AYA. Several retrospective reports have shown 
that adolescents (15- 20 yr.) and young adults treated by adult oncologists or hematologists 
with adult ALL protocols have poorer outcomes than similarly aged patients treated by 
pediatricians with pediatric protocols, despite having similar biologic characteristics of the 
disease (Boissel et al 2003, de Bont et al 2004, Testi et al 2004, Hallbook et al 2006, Schroeder 
et al 2006, Ramanujachar et al 2007, Lopez-Hernandez et al 2008, Stock et al 2008, Al-Khabori 
et al 2010).  
The first study in which such different outcomes were reported was performed in France 
(Boissel et al 2003).  A comparison of AYA aged 15-20 yr. treated with the pediatric-based 
protocol FRALLE-93 (n=77) with patients of the same age and comparable clinical and 
biologic characteristics of ALL who received the adult-based protocol LALA-94 (n=100) 
showed a complete remission (CR) rate of 94% vs. 83%. After a median follow-up of 3.5 yr, 
the event-free survival (EFS) probabilities were 67% vs. 41% at 5 years. Multivariate analysis 
showed an independent influence of the protocol on the outcome. The differences in the 
drugs employed and, especially in the dose-intensity, could explain the better results of the 
FRALLE-93 protocol. In this protocol the cumulated dose of prednisone was five-fold 
higher, the vinca alkaloids three-fold and the asparaginase 20-fold higher than in the LALA-
94 study. In addition, in the FRALLE-93 study the dose of prednisone in induction was 
higher and asparaginase was also given in this period, in contrast with the LALA-94 trial. 
Moreover, the time interval between CR and post-remission therapy was 2 days in FRALLE-
93 vs. 7 days in the LALA-94 study. 
The North-American Cancer and Acute Leukemia Group B (CALGB) and the Children’s 
Cancer Group (CCG) performed a retrospective comparison of presenting features, planned 
treatment, CR rate, and outcome of 321 AYA aged 16 to 20 years who were treated on 
consecutive trials in either the CCG or the CALGB from 1988 to 2001 (Stock et al 2008). Both 
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cohorts were comparable for the main clinical and biologic characteristics, although the 
median age of the patients in the CALGB studies was 19 yr. compared to 16 yr. for the CCG 
patients.  CR rates were identical (90%) for both the CALGB and CCG AYA. The CCG AYA 
had a 63% EFS and 67% overall survival (OS) probabilities at 7 years in contrast to the 
CALGB AYA, in whom the 7-year EFS was only 34% and the OS was 46%. While the 
CALGB AYA aged 16 to 17 years achieved similar outcomes to all the CCG AYA with a 7-
year EFS of 55%, the EFS for 18- to 20-year-old CALGB patients was only 29%. CALGB 
AYAs had a significant increase in CNS relapse (11%) compared to CCG AYAs (1.5%). 
Comparison of the regimens showed that the CCG AYA received earlier and more intensive 
and prolonged CNS prophylaxis and higher cumulative doses of nonmyelosuppressive 
agents (vinca alkaloid, steroids and asparaginase), as well as longer duration of maintenance 
therapy than CALGB AYAs. There were no differences in outcomes in those who reached 
maintenance therapy on time compared with those who were delayed. 
A similar Dutch study in patients aged 15-21 yr yielded similar results (de Bont et al 2004), 
with a 5-yr EFS of 69% for comparable patients treated with the more dose-intensive 
pediatric protocol  DCOG vs. 34% for those treated with adult protocols ALL-5 and ALL-18 
from the HOVON Group. Likewise, comparative retrospective studies from Italy also 
showed a poorer prognosis for patients aged 14-18 yr treated with adult-type protocols 
(Testi et al 2004). In turn, a Swedish study compared patients aged 10-40 yr treated with the 
pediatric trial NOPHO-92 (n=144) vs. a similar group of patients included in the Swedish 
Adult ALL Group (n=99) (Hallbook et al 2006). A significantly higher CR rate (99% vs. 90%) 
and EFS were observed in patients treated with the pediatric protocol, with the type of 
treatment being an independent prognostic variable on multivariate analysis. However, it is 
of note that adults aged 26-40 yr had a significantly poorer prognosis than AYA (15-25 yr.). 
Another study from Denmark yielded similar results (Schroeder et al 2006). In a 
retrospective study from the British Medical Research Council (MRC) performed only in 
adolescents (15-17 yr) included in the ALL97/revised99 (pediatric, n=61) or 
UKALLXII/E2993 (adult, n = 67) trials between 1997 and 2002 (Ramanujachar et al 2007), the 
EFS (65% vs. 49%) was higher and the rate of death in remission was lower in the former 
group of patients. In a retrospective study from the Princess Margaret Hospital from 
Toronto restricted to AYA with T-ALL 40 patients (median age 30 yr, range 17-69) were 
treated with several adult type protocols and were compared with 32 patients (median age 
32 yr, range 17-64) treated with a DFCI protocol (Al-Khabori et al 2010). Although there 
were no differences in CR attainment (93% vs. 84%), the OS and relapse-free survival (RFS) 
probabilities were significantly higher in patients treated with the DFCI trial (83% vs .56% 
and 88% vs. 23%, respectively). On multivariate analysis the treatment group (DFCI vs. non-
DFCI) was the major prognostic factor influencing both RFS and OS. Other studies from 
different countries (Lopez-Hernandez et al 2008) have shown similar results (Table 1).  
Only one population-based study from Finland showed that the outcome of AYA with ALL 
treated with pediatric or adult protocols was comparable (Usvasalo et al 2008). One hundred 
and twenty-eight patients (10-16 yr, median age 12.9 yr) were treated with the pediatric 
Nordic (NOPHO) protocols and 97 patients (17-25 yr, median age 18.9 yr) with Finnish 
Leukemia Group National protocols. All patients were centrally referred and treated in five 
academic centers. The 5-year EFS was 67% for the pediatric treatment group and 60% for the 
adult treatment group. There were no significant differences in the cumulative doses of 
corticosteroids, vincristine and asparaginase between pediatric and adult protocols, 
although pediatric protocols used a higher cumulative dose of methotrexate and lower 
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non-infant ALL increases with age, being infrequent in children 1-9 yr of age and about 6% 
in adults (Moorman et al 2010). Regarding structural changes, there is a progressive increase 
in the frequency of  t(9;22)(q34;q11) or BCR-ABL rearrangements, ranging from less than 3% 
in children under 18 yr. to 6% at ages 18-25  and to 15-20% at ages 25-35 yr, and to more than 
30% over the age of 35 yr (Secker-Walker et al 1991). Finally, in recent studies, adolescents 
were more likely to have detectable minimal residual disease (MRD) during or at the end of 
remission induction (Pui et al 2011). 
In summary, with increasing age there is a progressive increase in the frequency of subsets 
of ALL patients with genetic abnormalities associated with poor prognosis and these 
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As far as host factors are concerned, several features are observed in less young patients, 
being responsible for increased treatment toxicity. They include differences in the 
metabolism of chemotherapeutic agents, depleted marrow reserve and increased 
extramedullary toxicity. All these issues increase the frequency of life-threatening infections, 
organ failure, and treatment delays and dose reductions in planned chemotherapy. 
3. Which is the best treatment strategy? Pediatric-based vs. adult-based 
treatments 
3.1 Retrospective comparative studies 
A number of comparisons of the clinical outcome of adolescents enrolled in adult and 
pediatric clinical trials have resulted in interesting observations about the appropriate 
treatment strategy for prospective studies in AYA. Several retrospective reports have shown 
that adolescents (15- 20 yr.) and young adults treated by adult oncologists or hematologists 
with adult ALL protocols have poorer outcomes than similarly aged patients treated by 
pediatricians with pediatric protocols, despite having similar biologic characteristics of the 
disease (Boissel et al 2003, de Bont et al 2004, Testi et al 2004, Hallbook et al 2006, Schroeder 
et al 2006, Ramanujachar et al 2007, Lopez-Hernandez et al 2008, Stock et al 2008, Al-Khabori 
et al 2010).  
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(Boissel et al 2003).  A comparison of AYA aged 15-20 yr. treated with the pediatric-based 
protocol FRALLE-93 (n=77) with patients of the same age and comparable clinical and 
biologic characteristics of ALL who received the adult-based protocol LALA-94 (n=100) 
showed a complete remission (CR) rate of 94% vs. 83%. After a median follow-up of 3.5 yr, 
the event-free survival (EFS) probabilities were 67% vs. 41% at 5 years. Multivariate analysis 
showed an independent influence of the protocol on the outcome. The differences in the 
drugs employed and, especially in the dose-intensity, could explain the better results of the 
FRALLE-93 protocol. In this protocol the cumulated dose of prednisone was five-fold 
higher, the vinca alkaloids three-fold and the asparaginase 20-fold higher than in the LALA-
94 study. In addition, in the FRALLE-93 study the dose of prednisone in induction was 
higher and asparaginase was also given in this period, in contrast with the LALA-94 trial. 
Moreover, the time interval between CR and post-remission therapy was 2 days in FRALLE-
93 vs. 7 days in the LALA-94 study. 
The North-American Cancer and Acute Leukemia Group B (CALGB) and the Children’s 
Cancer Group (CCG) performed a retrospective comparison of presenting features, planned 
treatment, CR rate, and outcome of 321 AYA aged 16 to 20 years who were treated on 
consecutive trials in either the CCG or the CALGB from 1988 to 2001 (Stock et al 2008). Both 
 
Acute Lymphoblastic Leukemia in Adolescents and Young Adults 
 
341 
cohorts were comparable for the main clinical and biologic characteristics, although the 
median age of the patients in the CALGB studies was 19 yr. compared to 16 yr. for the CCG 
patients.  CR rates were identical (90%) for both the CALGB and CCG AYA. The CCG AYA 
had a 63% EFS and 67% overall survival (OS) probabilities at 7 years in contrast to the 
CALGB AYA, in whom the 7-year EFS was only 34% and the OS was 46%. While the 
CALGB AYA aged 16 to 17 years achieved similar outcomes to all the CCG AYA with a 7-
year EFS of 55%, the EFS for 18- to 20-year-old CALGB patients was only 29%. CALGB 
AYAs had a significant increase in CNS relapse (11%) compared to CCG AYAs (1.5%). 
Comparison of the regimens showed that the CCG AYA received earlier and more intensive 
and prolonged CNS prophylaxis and higher cumulative doses of nonmyelosuppressive 
agents (vinca alkaloid, steroids and asparaginase), as well as longer duration of maintenance 
therapy than CALGB AYAs. There were no differences in outcomes in those who reached 
maintenance therapy on time compared with those who were delayed. 
A similar Dutch study in patients aged 15-21 yr yielded similar results (de Bont et al 2004), 
with a 5-yr EFS of 69% for comparable patients treated with the more dose-intensive 
pediatric protocol  DCOG vs. 34% for those treated with adult protocols ALL-5 and ALL-18 
from the HOVON Group. Likewise, comparative retrospective studies from Italy also 
showed a poorer prognosis for patients aged 14-18 yr treated with adult-type protocols 
(Testi et al 2004). In turn, a Swedish study compared patients aged 10-40 yr treated with the 
pediatric trial NOPHO-92 (n=144) vs. a similar group of patients included in the Swedish 
Adult ALL Group (n=99) (Hallbook et al 2006). A significantly higher CR rate (99% vs. 90%) 
and EFS were observed in patients treated with the pediatric protocol, with the type of 
treatment being an independent prognostic variable on multivariate analysis. However, it is 
of note that adults aged 26-40 yr had a significantly poorer prognosis than AYA (15-25 yr.). 
Another study from Denmark yielded similar results (Schroeder et al 2006). In a 
retrospective study from the British Medical Research Council (MRC) performed only in 
adolescents (15-17 yr) included in the ALL97/revised99 (pediatric, n=61) or 
UKALLXII/E2993 (adult, n = 67) trials between 1997 and 2002 (Ramanujachar et al 2007), the 
EFS (65% vs. 49%) was higher and the rate of death in remission was lower in the former 
group of patients. In a retrospective study from the Princess Margaret Hospital from 
Toronto restricted to AYA with T-ALL 40 patients (median age 30 yr, range 17-69) were 
treated with several adult type protocols and were compared with 32 patients (median age 
32 yr, range 17-64) treated with a DFCI protocol (Al-Khabori et al 2010). Although there 
were no differences in CR attainment (93% vs. 84%), the OS and relapse-free survival (RFS) 
probabilities were significantly higher in patients treated with the DFCI trial (83% vs .56% 
and 88% vs. 23%, respectively). On multivariate analysis the treatment group (DFCI vs. non-
DFCI) was the major prognostic factor influencing both RFS and OS. Other studies from 
different countries (Lopez-Hernandez et al 2008) have shown similar results (Table 1).  
Only one population-based study from Finland showed that the outcome of AYA with ALL 
treated with pediatric or adult protocols was comparable (Usvasalo et al 2008). One hundred 
and twenty-eight patients (10-16 yr, median age 12.9 yr) were treated with the pediatric 
Nordic (NOPHO) protocols and 97 patients (17-25 yr, median age 18.9 yr) with Finnish 
Leukemia Group National protocols. All patients were centrally referred and treated in five 
academic centers. The 5-year EFS was 67% for the pediatric treatment group and 60% for the 
adult treatment group. There were no significant differences in the cumulative doses of 
corticosteroids, vincristine and asparaginase between pediatric and adult protocols, 
although pediatric protocols used a higher cumulative dose of methotrexate and lower 
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Country (reference) Protocol Age (yr) N CR (%) EFS (%) 
USA (32) CCG(P) 16-20 197 90 63 
 CALGB(A)  124 90 34 
France (12) FRALLE93(P) 15-20 77 94 67 
 LALA94 (A)  100 83 41 
Holland (13) DCOG (P) 15-18 47 98 69 
 HOVON (A)  44 91 34 
Italy (35) AIEOP (P) 14-18 150 94 80 
 GIMEMA (A)  95 89 71 
Sweden (11) NOPHO-92(P) 10-40 144 99 65 
 Adult (A)  99 90 48 
UK (25) ALL97 (P) 15-17 61 98 65 
 UKALLXII(A)  67 94 49 
Canada (1) DFCI (P) 17-64 32 84 83* 
 Adult (A) 17-69 40 93 56* 
Mexico (16) LALIN (P) 15-25 20 90 70 
 LALA (A)  20 80 40 
Finland (38) NOPHO (P) 10-25 128 96 67 
 ALL (A)  97 97 60 
N: number of patients; CR: complete remission. EFS: event-free survival.  
* Overall survival 
Table 1. Retrospective comparative studies in adolescents and young adults with acute 
lymphoblastic leukemia treated with pediatric-based (P) vs. adult-based (A) protocols. 
doses of  anthracyclines than adult protocols; epipodophyllotoxins and mitoxantrone were 
not included in the pediatric protocols. The authors attributed the similar results to the 
similarity of the pediatric and adult protocols and to the centralized care of the patients in 
five academic centers, ensuring good compliance and adherence to the protocols. Finally, 
the retrospective data from the MD Anderson Cancer Center using the Hyper-CVAD 
regimen (not including asparaginase) have also reported favorable results in 102 AYA 
(median age 19 yr), with  CR 97% and OS 65% (Thomas et al 2008). Preliminary reports from 
60 AYA patients aged 12-40 yr treated at the MD Anderson Cancer Center with modified 
augmented Berlin-Frankfurt-Münster (BFM) therapy showed very promising results (2-yr 
DFS and OS probabilities of 85% and 91%, respectively) in the subset of patients younger 
than 25 yr (Rytting et al 2010), stressing the importance of treating these patients in large 
referral centers.  
In summary, the 5- to 6-yr EFS rate for AYA treated with pediatric regimens ranges from 
65% to 70% vs. 35% to 50% for adult regimens in almost but not all retrospective 
comparative studies. However, it is of note that these studies have mainly focused on 
patients aged 15-21 years, but few have evaluated the results in young adults up to 30 years 
or more, in whom the frequency of adverse prognostic factors is progressively increasing. 
The reasons for the better results of pediatric protocols are multiple (Stock 2010). The first 
and probably the most important reason lay in the protocol itself. The dose-intensity and the 
dose-density of the key chemotherapeutic agents for ALL are clearly higher in pediatric 
protocols. This is especially relevant for drugs such as vincristine (usually capped to 2 mg in 
adult protocols), glucocorticoids, asparaginase and methotrexate. Conversely, pediatric-
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based protocols include lower doses of alkylating agents, high-dose cytarabine and 
antracyclines than adult trials. In addition CNS prophylaxis is more intense and prolonged 
in pediatric regimens than in adult trials. Most of the pediatric protocols include delayed 
intensifications and an extended maintenance chemotherapy phase, the former being 
omitted in many adult trials. The use of allogeneic stem cell transplantation (SCT) as part of 
first line therapy (associated with a transplant-related mortality [TRM] of 20%), is restricted 
to patients with very high-risk features in pediatric trials, whereas it is more widely used in 
adult trials, even in standard-risk patients in first CR.  
The second reason is the tolerability to essential drugs such as asparaginase, steroids and 
vincristine, which is poorer in AYA compared to children, being a reflection of changes in 
the metabolism of these drugs during late adolescence. The incidences of diabetes mellitus, 
pancreatitis, thrombosis and osteonecrosis are more frequent in the former group. The 
increased toxicity influences adherence to treatment, which is critical for the outcome of 
ALL patients.  
The third reason is the disparity in the practice patterns of the pediatric and adult 
hematologists/oncologists and patient compliance. Adherence to treatment is usually 
higher in pediatric than in adult-derived studies, probably due both to a highly skilled 
supportive staff, the better tolerability of pediatric protocols and a stricter control of time 
points of chemotherapy delivery in pediatric than in adult hematology units (Burke et al 
2007) However, in the U.S. and Canada most children and adolescents with ALL treated 
with pediatric protocols are managed in institutions and academic centers participating in 
national-sponsored clinical trials, whilst most AYA treated with adult protocols are 
managed throughout study groups by community-based medical oncologists. The fact that 
the most striking differences are observed in the 18 to 20-years-old group could be explained 
by the emancipation of some of these patients from parental control and support and the 
possible need to face significantly more challenges in access to health care due to insurance 
issues (Kantarjian et al 2009).  
3.2 Prospective trials 
3.2.1 Results of the treatment of adolescents in pediatric trials 
Barry et al reported the outcome of adolescents treated in the Dana-Farber Cancer Institute 
(DFCI) ALL Consortium Protocols conducted between 1991 and 2000 (Barry et al 2007). A total 
of 844 patients aged 1 to 18 years, with newly diagnosed ALL were enrolled into two 
consecutive DFCI-ALL Consortium Protocols. Outcomes were compared in three age groups: 
children aged 1 to 10 years (n = 685), young adolescents aged 10 to 15 years (n = 108), and 
older adolescents aged 15 to 18 years (n = 51). With a median follow-up of 6.5 years, the 5-year 
EFS for those aged 1 to 10 years was 85%, compared with 77% for those aged 10 to 15 years, 
and 78% for those aged 15 to 18 years. There was no difference in the rate of treatment-related 
complications between the 10- to 15-year and 15- to 18-year age groups.  
Nachman et al reported the results of the CCG1961 trial including AYA up to 21 yr 
(Nachman et al 2009). The EFS and overall survival (OS) rates were 71.5% and 77.5%, 
respectively. Rapid responder patients randomly assigned to augmented therapy had 5-year 
EFS 81.8% vs 66.8% for patients receiving standard  therapy, but 1 versus 2 interim 
maintenance and delayed intensification courses had no significant impact on EFS. WBC 
count over 50x109/L was an adverse prognostic factor. Given the excellent outcome with 
this chemotherapy there seems to be no role for the routine use of stem cell transplantation 
in first remission  
 
Acute Leukemia – The Scientist's Perspective and Challenge 
 
342 
Country (reference) Protocol Age (yr) N CR (%) EFS (%) 
USA (32) CCG(P) 16-20 197 90 63 
 CALGB(A)  124 90 34 
France (12) FRALLE93(P) 15-20 77 94 67 
 LALA94 (A)  100 83 41 
Holland (13) DCOG (P) 15-18 47 98 69 
 HOVON (A)  44 91 34 
Italy (35) AIEOP (P) 14-18 150 94 80 
 GIMEMA (A)  95 89 71 
Sweden (11) NOPHO-92(P) 10-40 144 99 65 
 Adult (A)  99 90 48 
UK (25) ALL97 (P) 15-17 61 98 65 
 UKALLXII(A)  67 94 49 
Canada (1) DFCI (P) 17-64 32 84 83* 
 Adult (A) 17-69 40 93 56* 
Mexico (16) LALIN (P) 15-25 20 90 70 
 LALA (A)  20 80 40 
Finland (38) NOPHO (P) 10-25 128 96 67 
 ALL (A)  97 97 60 
N: number of patients; CR: complete remission. EFS: event-free survival.  
* Overall survival 
Table 1. Retrospective comparative studies in adolescents and young adults with acute 
lymphoblastic leukemia treated with pediatric-based (P) vs. adult-based (A) protocols. 
doses of  anthracyclines than adult protocols; epipodophyllotoxins and mitoxantrone were 
not included in the pediatric protocols. The authors attributed the similar results to the 
similarity of the pediatric and adult protocols and to the centralized care of the patients in 
five academic centers, ensuring good compliance and adherence to the protocols. Finally, 
the retrospective data from the MD Anderson Cancer Center using the Hyper-CVAD 
regimen (not including asparaginase) have also reported favorable results in 102 AYA 
(median age 19 yr), with  CR 97% and OS 65% (Thomas et al 2008). Preliminary reports from 
60 AYA patients aged 12-40 yr treated at the MD Anderson Cancer Center with modified 
augmented Berlin-Frankfurt-Münster (BFM) therapy showed very promising results (2-yr 
DFS and OS probabilities of 85% and 91%, respectively) in the subset of patients younger 
than 25 yr (Rytting et al 2010), stressing the importance of treating these patients in large 
referral centers.  
In summary, the 5- to 6-yr EFS rate for AYA treated with pediatric regimens ranges from 
65% to 70% vs. 35% to 50% for adult regimens in almost but not all retrospective 
comparative studies. However, it is of note that these studies have mainly focused on 
patients aged 15-21 years, but few have evaluated the results in young adults up to 30 years 
or more, in whom the frequency of adverse prognostic factors is progressively increasing. 
The reasons for the better results of pediatric protocols are multiple (Stock 2010). The first 
and probably the most important reason lay in the protocol itself. The dose-intensity and the 
dose-density of the key chemotherapeutic agents for ALL are clearly higher in pediatric 
protocols. This is especially relevant for drugs such as vincristine (usually capped to 2 mg in 
adult protocols), glucocorticoids, asparaginase and methotrexate. Conversely, pediatric-
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based protocols include lower doses of alkylating agents, high-dose cytarabine and 
antracyclines than adult trials. In addition CNS prophylaxis is more intense and prolonged 
in pediatric regimens than in adult trials. Most of the pediatric protocols include delayed 
intensifications and an extended maintenance chemotherapy phase, the former being 
omitted in many adult trials. The use of allogeneic stem cell transplantation (SCT) as part of 
first line therapy (associated with a transplant-related mortality [TRM] of 20%), is restricted 
to patients with very high-risk features in pediatric trials, whereas it is more widely used in 
adult trials, even in standard-risk patients in first CR.  
The second reason is the tolerability to essential drugs such as asparaginase, steroids and 
vincristine, which is poorer in AYA compared to children, being a reflection of changes in 
the metabolism of these drugs during late adolescence. The incidences of diabetes mellitus, 
pancreatitis, thrombosis and osteonecrosis are more frequent in the former group. The 
increased toxicity influences adherence to treatment, which is critical for the outcome of 
ALL patients.  
The third reason is the disparity in the practice patterns of the pediatric and adult 
hematologists/oncologists and patient compliance. Adherence to treatment is usually 
higher in pediatric than in adult-derived studies, probably due both to a highly skilled 
supportive staff, the better tolerability of pediatric protocols and a stricter control of time 
points of chemotherapy delivery in pediatric than in adult hematology units (Burke et al 
2007) However, in the U.S. and Canada most children and adolescents with ALL treated 
with pediatric protocols are managed in institutions and academic centers participating in 
national-sponsored clinical trials, whilst most AYA treated with adult protocols are 
managed throughout study groups by community-based medical oncologists. The fact that 
the most striking differences are observed in the 18 to 20-years-old group could be explained 
by the emancipation of some of these patients from parental control and support and the 
possible need to face significantly more challenges in access to health care due to insurance 
issues (Kantarjian et al 2009).  
3.2 Prospective trials 
3.2.1 Results of the treatment of adolescents in pediatric trials 
Barry et al reported the outcome of adolescents treated in the Dana-Farber Cancer Institute 
(DFCI) ALL Consortium Protocols conducted between 1991 and 2000 (Barry et al 2007). A total 
of 844 patients aged 1 to 18 years, with newly diagnosed ALL were enrolled into two 
consecutive DFCI-ALL Consortium Protocols. Outcomes were compared in three age groups: 
children aged 1 to 10 years (n = 685), young adolescents aged 10 to 15 years (n = 108), and 
older adolescents aged 15 to 18 years (n = 51). With a median follow-up of 6.5 years, the 5-year 
EFS for those aged 1 to 10 years was 85%, compared with 77% for those aged 10 to 15 years, 
and 78% for those aged 15 to 18 years. There was no difference in the rate of treatment-related 
complications between the 10- to 15-year and 15- to 18-year age groups.  
Nachman et al reported the results of the CCG1961 trial including AYA up to 21 yr 
(Nachman et al 2009). The EFS and overall survival (OS) rates were 71.5% and 77.5%, 
respectively. Rapid responder patients randomly assigned to augmented therapy had 5-year 
EFS 81.8% vs 66.8% for patients receiving standard  therapy, but 1 versus 2 interim 
maintenance and delayed intensification courses had no significant impact on EFS. WBC 
count over 50x109/L was an adverse prognostic factor. Given the excellent outcome with 
this chemotherapy there seems to be no role for the routine use of stem cell transplantation 
in first remission  
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In turn, the results of the total therapy studies XIIIA, XIIIB, XIV and XV from St Jude 
Children’s Research Hospital including 963 pediatric patients, 89 of whom were older 
adolescents (aged 15 to 18 yr.), have recently been published (Pui et al 2011). In the first 
three studies the 44 older adolescents had significantly poorer EFS and OS than the 403 
younger patients. On the contrary, in study XV (incorporing the level of MRD to guide 
treatment, with featured intensive methotrexate, vincristine, glucocorticoid and 
asparaginase and early triple intrathecal chemotherapy for higher risk ALL) the EFS of 45 
older adolescents was 86.4%, similar to 87.4% for the 453 younger children. The OS was also 
comparable (87.9% vs. 94.1%, respectively). The authors concluded that most older 
adolescents with ALL can be cured with risk-adjusted intensive chemotherapy without SCT. 
In summary, with modern approaches of treatment of ALL with pediatric-based protocols 
the unfavorable prognosis of adolescents is disappearing and hopefully, this improvement 
could be translated to young adults. 
3.2.2 Results of prospective studies in adolescent and young adults 
Some studies have evaluated or are currently evaluating the feasibility and results of the 
pediatric-based protocols administered to adults up to 30 or even up to 50 or 60 years of age 
(table 2). The Spanish PETHEMA group compared the results of the pediatric protocol 
ALL96 in adolescents (15-18yr, n=35) and young adults (18-30 yr, n=46) with standard-risk 
(SR) ALL (Ribera et al 2008). Both groups were comparable for the main clinical and biologic 
characteristics of ALL. The CR rate was 98% and after a median follow-up of 4.2 yr., 6-year 
EFS and OS were 61% and 69%, with no differences between adolescents and young adults. 
No significant differences were observed in the timing of treatment delivery, although the 
hematologic toxicity in consolidation and reinforcement cycles was higher in young adults 
than in adolescents. These results suggest that pediatric protocols can be effectively and 
safely employed in adult patients with SR ALL, at least up to the age of 30 yr.  
 
Country (reference) Protocol Age (yr) N CR (%) EFS (%) 
Spain (26) PETHEMA ALL-96 15-18 35 94 60 
  19-30 46 100 63 
France (32) GRAALL-2003 15-45 172 95 58 
USA (6) DFCI 18-50 74 82 72.5** 
Canada (34) Modified DFCI 17-71 68 85 65*** 
France (10) FRALLE2000 18-55 40 90 72*** 
* Results restricted to adolescents; **Estimated at 2 years; *** Overall survival. 
N: number of patients; CR: complete remission. EFS: event-free survival. 
Table 2. Prospective studies in adolescents and young adults with acute lymphoblastic 
leukemia treated with pediatric-based or inspired protocols 
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The French GRAALL group has reported the results of the pediatric-inspired GRAALL-2003 
study including 215 patients aged 15-60 yr (Huguet et al 2009). In this study there was an 
8.6-fold, 3.7-fold and 16-fold increase in cumulative doses of prednisone, vincristine and 
asparaginase, respectively, compared with the previous adult-based LALA-94 protocol, 
although the GRAALL-2003 trial retained some adult options, such as allogeneic SCT for 
patients with high-risk ALL. The CR rate was 93.5% and at 42 months the EFS and overall 
survival (OS) rates were 55% and 60%, respectively. The CR rate, EFS and OS compared 
favorably with the previous LALA-94 experience.  It is of note, however, that in patients 
over 45 yr there was a higher cumulative incidence of chemotherapy-related deaths (23% vs. 
5%) and deaths in first CR (22% vs. 5%), although the incidence of relapse remained stable 
(30 vs. 32%). The results of this study suggest that pediatric-inspired therapy is feasible in 
young adults with ALL at least until the age of 45 yr, in whom the outcome clearly 
improves. 
Based on the promising results obtained in adolescents with ALL, the DFCI Combined 
Adult/Pediatric ALL Consortium has applied a true pediatric protocol to adults aged 18-50 
yr (DeAngelo et al 2006). Specifically, the investigators used an extended course of 
asparaginase for 30 weeks. The preliminary results in 94 patients, with a median age of 28 yr 
have shown a CR in 79 patients (84%). With a median follow-up of 45 months, the estimated 
DFS rate was 66% and the OS rate was 68%. This study proved that extended asparaginase 
treatment was feasible in adults and the drug-related toxicity was manageable, although the 
incidence of pancreatitis (13%) and thrombosis/embolism (19%) was a matter of concern. In 
turn, the Princess Margaret Hospital used a modified Dana Farber Cancer Institute pediatric 
protocol in 68 adult patients (17 to 71 yr), with a CR rate of 85% and 3-yr OS and DFS of 65% 
and 77%, respectively (Storring et al 2009). The University of South California group 
(Srivastava et al 2008) used an augmented BFM pediatric regimen with eight doses of 
pegylated asparaginase to treat adults with ALL aged 19-57 yr (median 33), with a 3-yr 
projected EFS of 65%. Toxicity attributable to asparaginase was frequent but manageable. 
However, older patients had significantly less tolerance to asparaginase, vincristine and 
steroids compared to children or adolescents. In the FRALLE group from France 28 
Philadelphia chromosome-negative adult ALL patients 16 to 57 years of age were treated in 
the FRALLE 2000 protocol consisting of a prednisone pre-phase and a four-drug induction 
including asparaginase, consolidation, delayed intensification and maintenance 
chemotherapy. The 4-yr DFS was 90% vs. 47% seen in matched historical controls (Haiat et 
al 2011). 
The largest prospective phase II trial to evaluate the feasibility of the use of a true pediatric 
regimen in AYA is currently ongoing in the US (C-10403 trial) (available at 
www.clinicaltrials.gov. NCT00558519) AYAs from 16 to 39 yr are treated by adult 
oncologists/hematologists with one treatment arm of the current AALL0232 trial from the 
pediatric COG group. More than half of the 300 planned patients have been currently 
enrolled. This study will prospectively analyze the genetic characteristics, MRD, treatment 
adherence, tolerability and psycho-social and socio-economic conditions that likely 
influence treatment outcomes.  
The results from these prospective studies demonstrate the feasibility and tolerability of 
pediatric-based regimens in AYA with SR ALL, at least until 30-50 yr. All these trials have 
the increased cumulative dosages of the most important drugs for ALL therapy, the cautious 
observance of dose-intensity and the reduction of the delays between the different phases of 
the therapy in common. If these results can be confirmed with a longer follow-up, they will 
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In turn, the results of the total therapy studies XIIIA, XIIIB, XIV and XV from St Jude 
Children’s Research Hospital including 963 pediatric patients, 89 of whom were older 
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(SR) ALL (Ribera et al 2008). Both groups were comparable for the main clinical and biologic 
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Country (reference) Protocol Age (yr) N CR (%) EFS (%) 
Spain (26) PETHEMA ALL-96 15-18 35 94 60 
  19-30 46 100 63 
France (32) GRAALL-2003 15-45 172 95 58 
USA (6) DFCI 18-50 74 82 72.5** 
Canada (34) Modified DFCI 17-71 68 85 65*** 
France (10) FRALLE2000 18-55 40 90 72*** 
* Results restricted to adolescents; **Estimated at 2 years; *** Overall survival. 
N: number of patients; CR: complete remission. EFS: event-free survival. 
Table 2. Prospective studies in adolescents and young adults with acute lymphoblastic 
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The French GRAALL group has reported the results of the pediatric-inspired GRAALL-2003 
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young adults with ALL at least until the age of 45 yr, in whom the outcome clearly 
improves. 
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asparaginase for 30 weeks. The preliminary results in 94 patients, with a median age of 28 yr 
have shown a CR in 79 patients (84%). With a median follow-up of 45 months, the estimated 
DFS rate was 66% and the OS rate was 68%. This study proved that extended asparaginase 
treatment was feasible in adults and the drug-related toxicity was manageable, although the 
incidence of pancreatitis (13%) and thrombosis/embolism (19%) was a matter of concern. In 
turn, the Princess Margaret Hospital used a modified Dana Farber Cancer Institute pediatric 
protocol in 68 adult patients (17 to 71 yr), with a CR rate of 85% and 3-yr OS and DFS of 65% 
and 77%, respectively (Storring et al 2009). The University of South California group 
(Srivastava et al 2008) used an augmented BFM pediatric regimen with eight doses of 
pegylated asparaginase to treat adults with ALL aged 19-57 yr (median 33), with a 3-yr 
projected EFS of 65%. Toxicity attributable to asparaginase was frequent but manageable. 
However, older patients had significantly less tolerance to asparaginase, vincristine and 
steroids compared to children or adolescents. In the FRALLE group from France 28 
Philadelphia chromosome-negative adult ALL patients 16 to 57 years of age were treated in 
the FRALLE 2000 protocol consisting of a prednisone pre-phase and a four-drug induction 
including asparaginase, consolidation, delayed intensification and maintenance 
chemotherapy. The 4-yr DFS was 90% vs. 47% seen in matched historical controls (Haiat et 
al 2011). 
The largest prospective phase II trial to evaluate the feasibility of the use of a true pediatric 
regimen in AYA is currently ongoing in the US (C-10403 trial) (available at 
www.clinicaltrials.gov. NCT00558519) AYAs from 16 to 39 yr are treated by adult 
oncologists/hematologists with one treatment arm of the current AALL0232 trial from the 
pediatric COG group. More than half of the 300 planned patients have been currently 
enrolled. This study will prospectively analyze the genetic characteristics, MRD, treatment 
adherence, tolerability and psycho-social and socio-economic conditions that likely 
influence treatment outcomes.  
The results from these prospective studies demonstrate the feasibility and tolerability of 
pediatric-based regimens in AYA with SR ALL, at least until 30-50 yr. All these trials have 
the increased cumulative dosages of the most important drugs for ALL therapy, the cautious 
observance of dose-intensity and the reduction of the delays between the different phases of 
the therapy in common. If these results can be confirmed with a longer follow-up, they will 
 
Acute Leukemia – The Scientist's Perspective and Challenge 
 
346 
have an impact on the clinical management of AYA patients in the future. Finally, few 
specific data are available on long-term complications of successful treatment of AYA (see 
www.survivorshipguidelines.org by the COG group) and a comprehensive approach to the 
follow-up for this significant group of patients with ALL is lacking. The next generation of 
studies, incorporating biological, pharmacological and psychosocial issues will further 
improve the cure rate and quality of life of these patients.  
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1. Introduction 
Evidence based medicine (EBM) is becoming a cornerstone in the establishment of practical 
guidelines and is nowadays part of the process of decision making in medicine (Woolf 2000). 
In evidence based medicine, decision making is based on relevant clinical trials ranked by 
their relevance and validity according to established criteria. Indeed, well designed 
randomized controlled trials (RCTs) are considered the "gold standard". However, since 
hematological disorders such as acute leukemia are rare, RCTs with a large enough sample 
size are difficult to conduct.  
Systematic reviews use a preplanned, explicit methodology to answer a predefined question 
and evaluate the benefit and harm of healthcare interventions. Meta-analyses quantitatively 
assemble results from RCTs to increase power when individual studies are too small to 
detect a statistically significant effect (Gale and Lazarus 2011). The quality of a systematic 
review reflects the quality of its included studies. Potential sources of bias are heterogeneity 
between the RCTs included, publication bias and difficulties in accessing data from the 
original clinical trials. 
In this chapter we attempted to assemble the evidence on the available meta-analyses 
analyzing the data in acute myeloid leukemia (AML) and acute lymphoblastic leukemia 
(ALL) patients. In certain domains, when no meta-analyses were identified, a literature 
search was performed and, if applicable, suggestions for future studies were made. 
2. Methods  
We searched The Cochrane and MEDLINE databases for systematic reviews. In Pubmed we 
crossed MeSH terms for 'acute myeloid leukemia' or 'acute lymphoblastic leukemia' with 
Clinical Queries to limit the search for systematic reviews.  
We included systematic reviews of RCTs (with or without meta-analyses) assessing the 
effect of different chemotherapy regimens and supportive care on overall survival of 
patients with acute leukemia. We included the use of these treatment options in the 
following clinical settings: remission induction, post remission (consolidation) including 
autologous and allogeneic stem cell transplantation and maintenance.  
We assessed the risk of bias in the systematic reviews by the following domains: use of 
explicit inclusion/exclusion criteria and a predefined protocol; comprehensive search; 
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1. Introduction 
Evidence based medicine (EBM) is becoming a cornerstone in the establishment of practical 
guidelines and is nowadays part of the process of decision making in medicine (Woolf 2000). 
In evidence based medicine, decision making is based on relevant clinical trials ranked by 
their relevance and validity according to established criteria. Indeed, well designed 
randomized controlled trials (RCTs) are considered the "gold standard". However, since 
hematological disorders such as acute leukemia are rare, RCTs with a large enough sample 
size are difficult to conduct.  
Systematic reviews use a preplanned, explicit methodology to answer a predefined question 
and evaluate the benefit and harm of healthcare interventions. Meta-analyses quantitatively 
assemble results from RCTs to increase power when individual studies are too small to 
detect a statistically significant effect (Gale and Lazarus 2011). The quality of a systematic 
review reflects the quality of its included studies. Potential sources of bias are heterogeneity 
between the RCTs included, publication bias and difficulties in accessing data from the 
original clinical trials. 
In this chapter we attempted to assemble the evidence on the available meta-analyses 
analyzing the data in acute myeloid leukemia (AML) and acute lymphoblastic leukemia 
(ALL) patients. In certain domains, when no meta-analyses were identified, a literature 
search was performed and, if applicable, suggestions for future studies were made. 
2. Methods  
We searched The Cochrane and MEDLINE databases for systematic reviews. In Pubmed we 
crossed MeSH terms for 'acute myeloid leukemia' or 'acute lymphoblastic leukemia' with 
Clinical Queries to limit the search for systematic reviews.  
We included systematic reviews of RCTs (with or without meta-analyses) assessing the 
effect of different chemotherapy regimens and supportive care on overall survival of 
patients with acute leukemia. We included the use of these treatment options in the 
following clinical settings: remission induction, post remission (consolidation) including 
autologous and allogeneic stem cell transplantation and maintenance.  
We assessed the risk of bias in the systematic reviews by the following domains: use of 
explicit inclusion/exclusion criteria and a predefined protocol; comprehensive search; 
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whether selection bias was avoided; assessment of risk of bias of original trials; correct 
statistical methods to pool the data. Assessment of risk of bias in each of the systematic 
reviews based on the AMSTAR protocol is summarized in tables 1-2 and 4 (Liberati, et al 
2009, Oxman and Guyatt 1991, Shea, et al 2007, Shea, et al 2009). 
For the evaluation of prospective comparative trials in the transplantation field, we searched 
for meta-analyses including genetically randomized trials. These trials were defined by 
patient allocation to an intervention on the basis of sibling donor availability (donor group 
versus no-donor group) and were evaluated for potential bias as previously discussed (Ram, 
et al 2011).  
3. An overview of systematic reviews in acute myeloid leukemia 
Survival of AML patients has constantly been increasing from about 5-10% in 1975 to about 
25% of diagnosed patients according to SEER data (1975-2007) in US population. This 
progress is the result of the progress in supportive care enabling treatment with intensive 
chemotherapy to induce remission and the use of allogeneic hematopoietic cell 
transplantation (HCT), as well as the use of prognostic factors in clinical decision making. 
For the majority of patients with AML this disease still has grave consequences. Our 
understanding of cytogenetic and molecular factors in the pathogenesis and the prognosis of 
patients with AML has evolved tremendously during the last decade. Still our ability to cure 
has remained unsatisfactory. 
Treatment of AML with curative intent is generally divided into remission induction and 
post remission (also referred to as consolidation) courses (Dohner, et al 2010). Management 
of patients with AML depends mainly on their age, their response to therapy and the 
cytogenetic and molecular factors of the leukemic clone, stratifying patients into favorable, 
standard and unfavorable risk groups.  
We herein reviewed the results of systematic reviews assessing chemotherapy for patients 
with AML. For each systematic review we evaluated the methodological quality using the 
AMSTAR assessment tool (Table 1). 
3.1 Induction therapy 
For more than 3 decades remission induction treatment consists of anthracyclines 
administered for 3 days and cytarabine given at a dose of 100-200 mg/m2 in continuous 
infusion for 7 days. Efforts to improve response rate and survival of patients with AML 
included the addition of other chemotherapeutic drugs to the standard induction regimen, 
using different types and doses of anthracyclines, as well as different doses of cytarabine. 
3.1.1 Does the type of anthracycline affect overall survival of adult patients with AML? 
A systematic collaborative overview of individual patient data of RCTs that compared an 
idarubicin-based induction regimen with a different anthracycline-based regimen included 
trials from 1984 to 1993 including 1898 patients (AML Collaborative Group, 1998). 
Compared to daunorubicin, idarubicin improved remission rate (53% vs. 62%, respectively, 
p = 0.002) and overall survival (14% odds reduction, p = 0.03), however disease free survival 
(DFS) did not differ significantly (15% odds reduction, p=0.07). This overview fulfilled 4 of 
11 criteria of the AMSTAR tool.  
Since the publication of this systematic review new data has accumulated (Mandelli, et al 
2009, Rowe, et al 2004).  
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3.1.2 Does the dose of anthracyclines during induction have an effect on survival? 
Historically, the conventional induction anthracycline dose was the equivalent of 
daunorubicin 45-50 mg/m2 daily given for 3 days. Large case series and observational 
studies supported a dose escalation to 60 mg/m2. It remained questionable if the dose 
response curve has reached a plateau and whether the dose amplification benefit can be 
confirmed in RCTs. A few RCTs evaluated various dosages of anthracyclines. No published 
systematic review has summarized their findings so far. 
Two RCTs evaluated dose intensification of anthracyclines (Fernandez, et al 2009, 
Lowenberg, et al 2009). Patients <60 years old treated with 90 mg/m2 of daunorubicin, as 
compared with the standard 45 mg/m2, achieved a higher rate of complete remission (CR) 
(70.6% vs. 57.3%; P<0.001) and a better overall survival (P=0.003) (Lowenberg, et al 2009). In 
another trial, >60 year-old patients treated with higher doses of daunorubicin, i.e. 90 mg/m2 
as compared to 45 mg/m2 daily, for 3 days, had higher CR rates (64% for the high dose vs. 
54% for the standard dose; P=0.002) (Pautas, et al 2010). There was no significant difference 
between the two groups in the incidence of hematological adverse events, 30-day mortality 
(11% and 12% in the 2 groups, respectively), or the incidence of adverse events (P=0.08). An 
overall survival benefit was demonstrated only in 2 subgroups: patients aged 60 to 65 years, 
and those with favorable cytogenetics. Paustas et al. compared 3-days of daunorubicin 80 
mg/m2/day with 3 or 4-days of idarubicin 12 mg/m2/day in 468 patients aged 50 to 70 
years. While a statistically significant higher rate of CR was demonstrated in patients treated 
with idarubicin (P = .04), there were no significant differences in the other outcomes.  
Thus, conventional dose for remission induction in adult patients < 60 years with AML 
should be between 60 to 90 mg/m2/day. There is no clear benefit for higher doses (90 
mg/m2/day) of daunorubicin compared to 45 mg/m2 daily in adults >65 years. 
3.1.3 Do higher doses of cytarabine during remission induction treatment improve 
survival? 
Kern and Estey reviewed the literature to examine the effect of high dose cytarabine (≥1000 
mg/m2/dose) in induction therapy compared with standard dose (100-200 mg/m2/day) 
cytarabine (Kern and Estey 2006). The search yielded 3 trials, evaluating 1691 adult AML 
patients < 60 years. There was no difference between high dose and standard dose 
cytarabine with regard to CR rate (relative risk 1.00; 95% CI 0.92 to 1.10) or early death rate 
(RR 1.53; 95% CI 0.84 to 2.78, random-effects model). However, 4-year overall survival was 
better in patients given high dose cytarabine (weighted mean difference, 6.211; 95% CI, 2.701 
to 9.721). In this meta-analysis time to event data was analyzed as continuous data, the 
assumptions made for converting median to mean and their variance to standard deviation 
were not described, and weighted mean difference was used to pool results. This review 
fulfilled 7 of 11 criteria of the AMSTAR criteria. 
3.2 Post remission therapy 
3.2.1 What is the role of transplantation in patients with AML? 
3.2.1.1 Autologous hematopoietic cell transplantation  
Four systematic reviews evaluated the effect of autologous hematopoietic cell 
transplantation (HCT) in first CR (Ashfaq, et al 2010, Levi, et al 2004, Nathan, et al 2004, 
Wang, et al 2010). 
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whether selection bias was avoided; assessment of risk of bias of original trials; correct 
statistical methods to pool the data. Assessment of risk of bias in each of the systematic 
reviews based on the AMSTAR protocol is summarized in tables 1-2 and 4 (Liberati, et al 
2009, Oxman and Guyatt 1991, Shea, et al 2007, Shea, et al 2009). 
For the evaluation of prospective comparative trials in the transplantation field, we searched 
for meta-analyses including genetically randomized trials. These trials were defined by 
patient allocation to an intervention on the basis of sibling donor availability (donor group 
versus no-donor group) and were evaluated for potential bias as previously discussed (Ram, 
et al 2011).  
3. An overview of systematic reviews in acute myeloid leukemia 
Survival of AML patients has constantly been increasing from about 5-10% in 1975 to about 
25% of diagnosed patients according to SEER data (1975-2007) in US population. This 
progress is the result of the progress in supportive care enabling treatment with intensive 
chemotherapy to induce remission and the use of allogeneic hematopoietic cell 
transplantation (HCT), as well as the use of prognostic factors in clinical decision making. 
For the majority of patients with AML this disease still has grave consequences. Our 
understanding of cytogenetic and molecular factors in the pathogenesis and the prognosis of 
patients with AML has evolved tremendously during the last decade. Still our ability to cure 
has remained unsatisfactory. 
Treatment of AML with curative intent is generally divided into remission induction and 
post remission (also referred to as consolidation) courses (Dohner, et al 2010). Management 
of patients with AML depends mainly on their age, their response to therapy and the 
cytogenetic and molecular factors of the leukemic clone, stratifying patients into favorable, 
standard and unfavorable risk groups.  
We herein reviewed the results of systematic reviews assessing chemotherapy for patients 
with AML. For each systematic review we evaluated the methodological quality using the 
AMSTAR assessment tool (Table 1). 
3.1 Induction therapy 
For more than 3 decades remission induction treatment consists of anthracyclines 
administered for 3 days and cytarabine given at a dose of 100-200 mg/m2 in continuous 
infusion for 7 days. Efforts to improve response rate and survival of patients with AML 
included the addition of other chemotherapeutic drugs to the standard induction regimen, 
using different types and doses of anthracyclines, as well as different doses of cytarabine. 
3.1.1 Does the type of anthracycline affect overall survival of adult patients with AML? 
A systematic collaborative overview of individual patient data of RCTs that compared an 
idarubicin-based induction regimen with a different anthracycline-based regimen included 
trials from 1984 to 1993 including 1898 patients (AML Collaborative Group, 1998). 
Compared to daunorubicin, idarubicin improved remission rate (53% vs. 62%, respectively, 
p = 0.002) and overall survival (14% odds reduction, p = 0.03), however disease free survival 
(DFS) did not differ significantly (15% odds reduction, p=0.07). This overview fulfilled 4 of 
11 criteria of the AMSTAR tool.  
Since the publication of this systematic review new data has accumulated (Mandelli, et al 
2009, Rowe, et al 2004).  
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3.1.2 Does the dose of anthracyclines during induction have an effect on survival? 
Historically, the conventional induction anthracycline dose was the equivalent of 
daunorubicin 45-50 mg/m2 daily given for 3 days. Large case series and observational 
studies supported a dose escalation to 60 mg/m2. It remained questionable if the dose 
response curve has reached a plateau and whether the dose amplification benefit can be 
confirmed in RCTs. A few RCTs evaluated various dosages of anthracyclines. No published 
systematic review has summarized their findings so far. 
Two RCTs evaluated dose intensification of anthracyclines (Fernandez, et al 2009, 
Lowenberg, et al 2009). Patients <60 years old treated with 90 mg/m2 of daunorubicin, as 
compared with the standard 45 mg/m2, achieved a higher rate of complete remission (CR) 
(70.6% vs. 57.3%; P<0.001) and a better overall survival (P=0.003) (Lowenberg, et al 2009). In 
another trial, >60 year-old patients treated with higher doses of daunorubicin, i.e. 90 mg/m2 
as compared to 45 mg/m2 daily, for 3 days, had higher CR rates (64% for the high dose vs. 
54% for the standard dose; P=0.002) (Pautas, et al 2010). There was no significant difference 
between the two groups in the incidence of hematological adverse events, 30-day mortality 
(11% and 12% in the 2 groups, respectively), or the incidence of adverse events (P=0.08). An 
overall survival benefit was demonstrated only in 2 subgroups: patients aged 60 to 65 years, 
and those with favorable cytogenetics. Paustas et al. compared 3-days of daunorubicin 80 
mg/m2/day with 3 or 4-days of idarubicin 12 mg/m2/day in 468 patients aged 50 to 70 
years. While a statistically significant higher rate of CR was demonstrated in patients treated 
with idarubicin (P = .04), there were no significant differences in the other outcomes.  
Thus, conventional dose for remission induction in adult patients < 60 years with AML 
should be between 60 to 90 mg/m2/day. There is no clear benefit for higher doses (90 
mg/m2/day) of daunorubicin compared to 45 mg/m2 daily in adults >65 years. 
3.1.3 Do higher doses of cytarabine during remission induction treatment improve 
survival? 
Kern and Estey reviewed the literature to examine the effect of high dose cytarabine (≥1000 
mg/m2/dose) in induction therapy compared with standard dose (100-200 mg/m2/day) 
cytarabine (Kern and Estey 2006). The search yielded 3 trials, evaluating 1691 adult AML 
patients < 60 years. There was no difference between high dose and standard dose 
cytarabine with regard to CR rate (relative risk 1.00; 95% CI 0.92 to 1.10) or early death rate 
(RR 1.53; 95% CI 0.84 to 2.78, random-effects model). However, 4-year overall survival was 
better in patients given high dose cytarabine (weighted mean difference, 6.211; 95% CI, 2.701 
to 9.721). In this meta-analysis time to event data was analyzed as continuous data, the 
assumptions made for converting median to mean and their variance to standard deviation 
were not described, and weighted mean difference was used to pool results. This review 
fulfilled 7 of 11 criteria of the AMSTAR criteria. 
3.2 Post remission therapy 
3.2.1 What is the role of transplantation in patients with AML? 
3.2.1.1 Autologous hematopoietic cell transplantation  
Four systematic reviews evaluated the effect of autologous hematopoietic cell 
transplantation (HCT) in first CR (Ashfaq, et al 2010, Levi, et al 2004, Nathan, et al 2004, 
Wang, et al 2010). 
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Nathan et al. compared the efficacy of autologous HCT with chemotherapy (or no further 
treatment) in patients aged 15 to 55 years (Nathan, et al 2004). Their search yielded 6 trials 
including 1044 patients. Patients who underwent autologous HCT had a better DFS 
(probabilities ratio of 1.24, 95% CI 1.06 to 1.44) with similar long term mortality rate (RR 
1.01, 95% CI 0.89 to 1.15). This review fulfilled 9 of 11 criteria of the AMSTAR tool. Levi et al 
performed a systematic review on the same question with similar findings (Levi, et al 2004). 
A more recent systematic review included 12 RCTs (Wang, et al 2010). Patients treated with 
autologous HCT had lower relapse rate,better DFS, but no overall survival benefit probably 
because of higher treatment related mortality. Of note, at present, transplant related 
mortality is lower than the estimated 4% reported in these systematic reviews.  
3.2.1.2 Allogeneic hematopoietic cell transplantation  
Eight reviews and meta-analyses were identified but only three of them were systematic and 
comprehensive (Ashfaq, et al 2010, Hubel, et al 2011, Koreth, et al 2009). Koreth et al. performed 
a systematic review comparing allogeneic HCT with conventional consolidation chemotherapy 
or autologous HCT (Koreth, et al 2009). Patients allocated to the allogeneic HCT arm had an 
overall survival benefit (HR 0.90 95% CI 0.82 to 0.97, 15 trials), and relapse free survival (HR 
0.80 95% CI, 0.74 to 0.86, 18 trials). In an analysis stratified according to the cytogenetic risk 
groups, only intermediate and poor risk AML patients allocated to the allogeneic HCT arm 
had improved overall survival, while favorable risk patients had similar overall survival in 
both allocated arms. This review fulfilled 10 of 11 criteria of the AMSTAR tool.  
Another comprehensive systematic review (without a quantitative summary) was done 
through the National Institute for Health Research Health Technology Assessment (HTA) 
program in UK (Ashfaq, et al 2010). The results and conclusions of this very detailed review 
were consistent with those of the previous ones. Other systematic reviews were published 
earlier and were not as comprehensive (Oliansky, et al 2008, Schlenk, et al 2004, Visani, et al 
2006, Yanada, et al 2005). 
3.3 Consolidation – dose intensity of cytarabine  
A systematic overview without a quantitative analysis of chemotherapy for patients with AML 
was conducted by The Swedish Council of Technology Assessment in Health Care (Kimby, et 
al 2001). In one trial consolidation was compared to no further treatment. This trial was closed 
early due to inferior remission duration in the latter group. In all the trials comparing high 
dose cytarabine to standard dose or maintenance therapy, high dose cytarabine was shown to 
be superior to the comparator, though overall survival advantage was not consistently shown. 
Consolidation with high dose cytarabine seemed to be of value mainly for patients with core 
binding factor AML and in younger patients, due to a high mortality rate in patients older 
than 60 years. This overview fulfilled 1 of 10 criteria of the AMSTAR tool. 
3.4 Maintenance therapy instead of consolidation chemotherapy 
This question was reviewed by Kimby et al. who found limited data to indicate that post-
remission maintenance therapy with long-term attenuated chemotherapy can prolong 
remission duration compared to no further therapy (Kimby, et al 2001). However, the data in 
support of these conclusions are sparse and effect on survival was not shown. 
3.5 Role of azacitidine  
Azacitidine was not exclusively assessed in AML patients but rather analyzed in a pooled 
myelodysplasia/AML group of patients (20%- 30% blasts, defined by the WHO as AML) 
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Nathan et al. compared the efficacy of autologous HCT with chemotherapy (or no further 
treatment) in patients aged 15 to 55 years (Nathan, et al 2004). Their search yielded 6 trials 
including 1044 patients. Patients who underwent autologous HCT had a better DFS 
(probabilities ratio of 1.24, 95% CI 1.06 to 1.44) with similar long term mortality rate (RR 
1.01, 95% CI 0.89 to 1.15). This review fulfilled 9 of 11 criteria of the AMSTAR tool. Levi et al 
performed a systematic review on the same question with similar findings (Levi, et al 2004). 
A more recent systematic review included 12 RCTs (Wang, et al 2010). Patients treated with 
autologous HCT had lower relapse rate,better DFS, but no overall survival benefit probably 
because of higher treatment related mortality. Of note, at present, transplant related 
mortality is lower than the estimated 4% reported in these systematic reviews.  
3.2.1.2 Allogeneic hematopoietic cell transplantation  
Eight reviews and meta-analyses were identified but only three of them were systematic and 
comprehensive (Ashfaq, et al 2010, Hubel, et al 2011, Koreth, et al 2009). Koreth et al. performed 
a systematic review comparing allogeneic HCT with conventional consolidation chemotherapy 
or autologous HCT (Koreth, et al 2009). Patients allocated to the allogeneic HCT arm had an 
overall survival benefit (HR 0.90 95% CI 0.82 to 0.97, 15 trials), and relapse free survival (HR 
0.80 95% CI, 0.74 to 0.86, 18 trials). In an analysis stratified according to the cytogenetic risk 
groups, only intermediate and poor risk AML patients allocated to the allogeneic HCT arm 
had improved overall survival, while favorable risk patients had similar overall survival in 
both allocated arms. This review fulfilled 10 of 11 criteria of the AMSTAR tool.  
Another comprehensive systematic review (without a quantitative summary) was done 
through the National Institute for Health Research Health Technology Assessment (HTA) 
program in UK (Ashfaq, et al 2010). The results and conclusions of this very detailed review 
were consistent with those of the previous ones. Other systematic reviews were published 
earlier and were not as comprehensive (Oliansky, et al 2008, Schlenk, et al 2004, Visani, et al 
2006, Yanada, et al 2005). 
3.3 Consolidation – dose intensity of cytarabine  
A systematic overview without a quantitative analysis of chemotherapy for patients with AML 
was conducted by The Swedish Council of Technology Assessment in Health Care (Kimby, et 
al 2001). In one trial consolidation was compared to no further treatment. This trial was closed 
early due to inferior remission duration in the latter group. In all the trials comparing high 
dose cytarabine to standard dose or maintenance therapy, high dose cytarabine was shown to 
be superior to the comparator, though overall survival advantage was not consistently shown. 
Consolidation with high dose cytarabine seemed to be of value mainly for patients with core 
binding factor AML and in younger patients, due to a high mortality rate in patients older 
than 60 years. This overview fulfilled 1 of 10 criteria of the AMSTAR tool. 
3.4 Maintenance therapy instead of consolidation chemotherapy 
This question was reviewed by Kimby et al. who found limited data to indicate that post-
remission maintenance therapy with long-term attenuated chemotherapy can prolong 
remission duration compared to no further therapy (Kimby, et al 2001). However, the data in 
support of these conclusions are sparse and effect on survival was not shown. 
3.5 Role of azacitidine  
Azacitidine was not exclusively assessed in AML patients but rather analyzed in a pooled 
myelodysplasia/AML group of patients (20%- 30% blasts, defined by the WHO as AML) 
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(Edlin, et al 2010). This RCT shows an overall survival benefit for azacytidine compared to 
best supportive care, low dose cytarabine, or intensive chemotherapy. Two RCTs that 
evaluated the effect of azacytidine in patients with high risk MDS (including patients with 
20%- 30% blasts) showed improved time to transformation or death in patients given 
azacytidine (Fenaux, et al 2009, Silverman, et al 2002). 
Azacytidine was also given as part of post remission chemotherapy: in the MRC AML 9 
trial, patients given the azacitidine-chemotherapy arm as consolidation had fewer relapses 
comparedto patients given only chemotherapy (p = 0.003), but a higher treatment related 
mortality (4.5% vs. 0%), without a statistically significant improved long term survival 
(Rees, et al 1996). 
In another trial,  patients were randomized to post remission consolidation with different 
chemotherapy regimens: standard dose cytarabine-daunorubicin vs. the same treatment 
followed by amsacrine and azacytidine vs. thioguanine and standard dose cytarabine-
daunorubicin (Volger, et al 1995). The 5-year DFS was 38%, 31%, and 27% (p<0.05), 
respectively. 
4. Acute promyelocytic leukemia  
Acute promyelocytic leukemia (APL) is usually characterized by a specific gene 
rearrangement and the generation of the PML-RARα fusion transcript which results from a 
translocation between chromosomes 15 and 17. Targeted therapy with all-trans retinoic acid 
(ATRA) and anthracycline-based chemotherapy results in cure in 70-80% of patients. 
Two systematic reviews evaluated the first line treatment of patients with APL (Xu, et al 
2009a, Xu, et al 2009b). 
The first one includes 7 RCTs (392 patients) comparing ATRA plus arsenic trioxide to other 
treatments. Compared with arsenic trioxide monotherapy, arsenic trioxide plus ATRA 
affected neither CR or DFS rates nor mortality of relapsed APL patients. Arsenic trioxide 
plus ATRA improved CR rate, DFS, mortality rate and adverse reactions compared to the 
same regimen including also chemotherapy. The review fulfilled 6 of 11 criteria of the 
AMSTAR tool. 
A systematic review and meta-analysis including 5 randomized controlled trials (328 
patients) compared ATRA plus arsenic trioxide regimen with ATRA monotherapy in 
patients with APL showed an improved 2-year DFS rate in the group treated with ATRA 
arsenic trioxide. 
5. An overview of systematic reviews in acute lymphoblastic leukemia 
Acute lymphobIastic leukemia (ALL) is the most common acute leukemia in children, while  
the incidence is much lower in adults (National Cancer Institute. SEER Cancer Statistics 
Review Available at: http://seer.cancer.gov/csr/1975_2006). The outcome of pediatric ALL 
patients has evolved from an overall survival of less than 10% in the 1960s to approximately 
80% at present (Pui, et al 2008). However, adult patients have a less optimistic prognosis. 
While the remission rate reaches 90%, the survival rate is only 40%-50% (Fielding 2008).  
ALL patients are stratified and treated according to algorithms that integrate the presenting 
features, leukemia features and early response to therapy (Faderl, et al 2003); However  the 
classification to standard and poor risk disease varies among the major studies conducted in 
adult ALL patients (Hoelzer, et al 1988, Kantarjian, et al 2004, Lazarus, et al 2006, Le, et al 
2006, Rowe, et al 2005, Ram, et al 2010). 
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Treatment of adult ALL patients usually consists of remission induction and 
consolidation/intensification phases followed by either HCT or maintenance therapy. 
As stated above, because the disease is relatively rare in adults, much of the knowledge and 
protocols have been adopted from pediatric regimens. Although we aim to focus on adult 
population, a portion of the data is based on evidence from pediatric trials.  
For each systematic review we evaluated the methodological quality using the AMSTAR 
assessment tool (table 2). 
5.1 Is there a specific induction regimen which is better? 
Different groups use various induction regimens, which have not been compared head to head 
(Gokbuget and Hoelzer 2009, Kantarjian, et al 2004, Larson, et al 1995, Linker, et al 2002, 
Thomas, et al 2004b). In adult patients, the use of growth factors such as granulocyte colony-
stimulating factor that accelerate hematopoietic recovery has greatly improved the success rate 
of ALL therapy (Kantarjian, et al 2004) and will be reviewed in a different part of this chapter.  
One individual patient data meta-analysis examined the role of incorporating different 
types of anthracycines into pediatric induction regimens (CALLCG, 2009) and identified  4 
trials recruiting 958 patients. They found that there was a borderline significant reduction in 
bone marrow leukemia relapse rate (OR 0.77, 95% CI 0.60 to 1.00; p=0.05) among patients 
treated with anthracyclines compared to those not, though there was no difference in non-
bone marrow leukemia relapse rate (OR 0.88, 95% CI 0.63 to 1.25; p=0.5). The reduction in 
relapse rate translated into improved relapse free survival (OR 0.81; 95% CI, 0.66 to 1.00; 
p=0.05). However, event free survival (EFS) and overall survival were similar between the 
two groups. No significant differences in outcomes were demonstrated when different 
anthracyclines or when different adninistration schedules were compared. As this meta-
analysis has been solely conducted in a pediatric population, results might not be applicable 
for adult patients. This systematic review fulfilled 5 of 11 criteria of the AMSTAR tool. 
5.2 What is the role of pediatric inspired regimens for adult patients, mainly for the 
group of adolescents and young adults? 
Several recent studies comparing the outcome of adolescents and young adults (AYAs) up 
to the age of 45 years, treated with pediatric versus adult protocols, demonstrated improved 
survival for AYAs who were treated by pediatric groups (Boissel, et al 2003, Ramanujachar, 
et al 2007, Stock, et al 2008). All are non-randomized trials and are therefore prone to 
significant bias. Thus, these trials are difficult to interpret because of the wide spectrum of 
patients' age, the small number of patients, the variations in the regimens utilized and the 
varying application of HCT in different studies. Recently our group completed a systematic 
review and meta analysis of all published comparative studies. We showed that up to the 
age of 20 years, pediatric inspired regimens are superior to conveintional afults 
chemotherapy ( Ram, et al 2011). Currently there are several groups conducting prospective 
trials (e.g., US AALL0232) to further elucidate which is the best treatment for AYAs. Only 
then, solid conclusions to tailor the best treatment for AYAs should be drawn.    
5.3 What is the role of thyrosine kinase inhibitors in the treatment of Philadelphia 
positive ALL? 
Philadelphia positive ALL is a disease with a historically dismal prognosis in which HCT 
provided the only chance for cure (Fielding and Goldstone 2008). Recently, the introduction of 
tyrosine kinase inhibitors (TKIs) has opened wide new perspectives of how to treat these 
patients (Thomas, et al 2004a). We were not able to identify systematic reviews assessing the 
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(Edlin, et al 2010). This RCT shows an overall survival benefit for azacytidine compared to 
best supportive care, low dose cytarabine, or intensive chemotherapy. Two RCTs that 
evaluated the effect of azacytidine in patients with high risk MDS (including patients with 
20%- 30% blasts) showed improved time to transformation or death in patients given 
azacytidine (Fenaux, et al 2009, Silverman, et al 2002). 
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comparedto patients given only chemotherapy (p = 0.003), but a higher treatment related 
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2006, Rowe, et al 2005, Ram, et al 2010). 
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Treatment of adult ALL patients usually consists of remission induction and 
consolidation/intensification phases followed by either HCT or maintenance therapy. 
As stated above, because the disease is relatively rare in adults, much of the knowledge and 
protocols have been adopted from pediatric regimens. Although we aim to focus on adult 
population, a portion of the data is based on evidence from pediatric trials.  
For each systematic review we evaluated the methodological quality using the AMSTAR 
assessment tool (table 2). 
5.1 Is there a specific induction regimen which is better? 
Different groups use various induction regimens, which have not been compared head to head 
(Gokbuget and Hoelzer 2009, Kantarjian, et al 2004, Larson, et al 1995, Linker, et al 2002, 
Thomas, et al 2004b). In adult patients, the use of growth factors such as granulocyte colony-
stimulating factor that accelerate hematopoietic recovery has greatly improved the success rate 
of ALL therapy (Kantarjian, et al 2004) and will be reviewed in a different part of this chapter.  
One individual patient data meta-analysis examined the role of incorporating different 
types of anthracycines into pediatric induction regimens (CALLCG, 2009) and identified  4 
trials recruiting 958 patients. They found that there was a borderline significant reduction in 
bone marrow leukemia relapse rate (OR 0.77, 95% CI 0.60 to 1.00; p=0.05) among patients 
treated with anthracyclines compared to those not, though there was no difference in non-
bone marrow leukemia relapse rate (OR 0.88, 95% CI 0.63 to 1.25; p=0.5). The reduction in 
relapse rate translated into improved relapse free survival (OR 0.81; 95% CI, 0.66 to 1.00; 
p=0.05). However, event free survival (EFS) and overall survival were similar between the 
two groups. No significant differences in outcomes were demonstrated when different 
anthracyclines or when different adninistration schedules were compared. As this meta-
analysis has been solely conducted in a pediatric population, results might not be applicable 
for adult patients. This systematic review fulfilled 5 of 11 criteria of the AMSTAR tool. 
5.2 What is the role of pediatric inspired regimens for adult patients, mainly for the 
group of adolescents and young adults? 
Several recent studies comparing the outcome of adolescents and young adults (AYAs) up 
to the age of 45 years, treated with pediatric versus adult protocols, demonstrated improved 
survival for AYAs who were treated by pediatric groups (Boissel, et al 2003, Ramanujachar, 
et al 2007, Stock, et al 2008). All are non-randomized trials and are therefore prone to 
significant bias. Thus, these trials are difficult to interpret because of the wide spectrum of 
patients' age, the small number of patients, the variations in the regimens utilized and the 
varying application of HCT in different studies. Recently our group completed a systematic 
review and meta analysis of all published comparative studies. We showed that up to the 
age of 20 years, pediatric inspired regimens are superior to conveintional afults 
chemotherapy ( Ram, et al 2011). Currently there are several groups conducting prospective 
trials (e.g., US AALL0232) to further elucidate which is the best treatment for AYAs. Only 
then, solid conclusions to tailor the best treatment for AYAs should be drawn.    
5.3 What is the role of thyrosine kinase inhibitors in the treatment of Philadelphia 
positive ALL? 
Philadelphia positive ALL is a disease with a historically dismal prognosis in which HCT 
provided the only chance for cure (Fielding and Goldstone 2008). Recently, the introduction of 
tyrosine kinase inhibitors (TKIs) has opened wide new perspectives of how to treat these 
patients (Thomas, et al 2004a). We were not able to identify systematic reviews assessing the 
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role of the different tyrosine kinase inhibitors. Prospective comparison, for example, by using 
genetic randomization based on donor availability along with intention-to-treat analysis, is 
necessary to draw conclusions on the clinical utility of allogeneic HCT for these patients.  
5.4 What is the role of allogeneic HCT in first CR? 
Allogeneic HCT provides a potential curative approach for patients with ALL, mainly 
through the anti-leukemic effect of the graft. Nonetheless, the relatively high non-relapse 
mortality compared to other treatment options limits the widespread use of this approach 
(Hahn, et al 2006, Ram, et al 2011). 
As stated in the Methods section, the preferred way to assess the role of allogeneic HCT is to 
use a genetic randomization design, allocating patients with a matched sibling donor and 
those lacking sibling donor to the donor/transplantation arm and the no-donor/alternative 
treatment arm, respectively (Ram, et al 2011).  
Five systematic reviews were conducted (Ashfaq, et al 2010, Hahn, et al 2006, Orsi et al 2007, 
Ram, et al 2010, Yanada et al 2006), 3 out of which included also a meta analysis (Orsi et al 
2007, Ram, et al 2010, Yanada et al 2006). All three meta-analyses showed that overall, for 
ALL patients achieving first CR, allogeneic HCT carries a survival benefit compared to the 
other options. While all 3 meta-analyses used similar search criteria, the strict intention to 
treat (ITT) inclusion criteria were different. Moreover, the two largest trials in the field 
(Cornelissen et al 2009, Goldstone et al 2008) were included only in the most recently 
published  meta-analysis only (Ram, et al 2010). This meta-analysis included 10 genetically 
trials, randomizing 2,600 patients for the main comparison of allogeneic HCT vs. other 
treatments, with only seven trials, randomizing 1,863 patients, following strict ITT criteria 
(table 2). In this meta-analysis, survival benefit was statistically significant for the standard-
risk patients (RR for all-cause mortality 0.80, 95% CI 0.68–0.94), while for the high-risk it it 
was not (RR 0.88, 95% CI 0.76–1.01) (Ram, et al 2010). As expected, there was a significant 
increase in non-relapse mortality in the allogeneic HCT arm (RR 2.99; 95% CI, 1.37-6.53) and 
a significant decrease in the relapse rate (RR 0.52; 95% CI, 0.33-0.83). This systematic review 
fulfilled 10 of 11 criteria of the AMSTAR tool. 
Although a systematic review published by Yanada et al showed a similar survival 
advantage in favor of the donor group (HR 1.29, 95% CI 1.02 to 1.63, p = 0.037), superiority 
could be demonstrated for the high-risk patients subgroup only (HR 1.42, 95% CI 1.06 to 
1.90; p = 0.019). This systematic review fulfilled 8 of 11 criteria of the AMSTAR tool.  
The difference between the two meta-analyses might stem from two main causes: The first is 
the inclusion of the two recent large trials in the last meta-analysis only (Cornelissen et al 
2009, Goldstone et al 2008) and the second from the different methodologies and inclusion 
criteria used in the various studies (with more emphasis on strict ITT methodology in the 
recently published meta-analysis).  
Orsi et al. conducted an individual patient meta-analysis of four trials (Hunault et al., 2004, 
Labar et al 2004, Ribera et al 2005, Thomas, et al 2004b). They also showed survival benefit for 
the donor group (mean EFS was 5.88 years in the donor group and 4.88 years in the no-
donor group) with survival rate of 44.2% (± 2.9%) at 7 years in the donor group and 31.6%  
(± 2.2%) in the non-donor group, log-rank test p = 0.011. Performance of allogeneic HCT in 
first CR was found to be cost effective. This systematic review fulfilled 9 of 11 criteria of the 
AMSTAR tool. 
To summarize, all meta-analyses suggest overall survival benefit for patients undergoing a 
matched donor allogeneic HCT in first CR when compared to other modalities. By drawing 
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role of the different tyrosine kinase inhibitors. Prospective comparison, for example, by using 
genetic randomization based on donor availability along with intention-to-treat analysis, is 
necessary to draw conclusions on the clinical utility of allogeneic HCT for these patients.  
5.4 What is the role of allogeneic HCT in first CR? 
Allogeneic HCT provides a potential curative approach for patients with ALL, mainly 
through the anti-leukemic effect of the graft. Nonetheless, the relatively high non-relapse 
mortality compared to other treatment options limits the widespread use of this approach 
(Hahn, et al 2006, Ram, et al 2011). 
As stated in the Methods section, the preferred way to assess the role of allogeneic HCT is to 
use a genetic randomization design, allocating patients with a matched sibling donor and 
those lacking sibling donor to the donor/transplantation arm and the no-donor/alternative 
treatment arm, respectively (Ram, et al 2011).  
Five systematic reviews were conducted (Ashfaq, et al 2010, Hahn, et al 2006, Orsi et al 2007, 
Ram, et al 2010, Yanada et al 2006), 3 out of which included also a meta analysis (Orsi et al 
2007, Ram, et al 2010, Yanada et al 2006). All three meta-analyses showed that overall, for 
ALL patients achieving first CR, allogeneic HCT carries a survival benefit compared to the 
other options. While all 3 meta-analyses used similar search criteria, the strict intention to 
treat (ITT) inclusion criteria were different. Moreover, the two largest trials in the field 
(Cornelissen et al 2009, Goldstone et al 2008) were included only in the most recently 
published  meta-analysis only (Ram, et al 2010). This meta-analysis included 10 genetically 
trials, randomizing 2,600 patients for the main comparison of allogeneic HCT vs. other 
treatments, with only seven trials, randomizing 1,863 patients, following strict ITT criteria 
(table 2). In this meta-analysis, survival benefit was statistically significant for the standard-
risk patients (RR for all-cause mortality 0.80, 95% CI 0.68–0.94), while for the high-risk it it 
was not (RR 0.88, 95% CI 0.76–1.01) (Ram, et al 2010). As expected, there was a significant 
increase in non-relapse mortality in the allogeneic HCT arm (RR 2.99; 95% CI, 1.37-6.53) and 
a significant decrease in the relapse rate (RR 0.52; 95% CI, 0.33-0.83). This systematic review 
fulfilled 10 of 11 criteria of the AMSTAR tool. 
Although a systematic review published by Yanada et al showed a similar survival 
advantage in favor of the donor group (HR 1.29, 95% CI 1.02 to 1.63, p = 0.037), superiority 
could be demonstrated for the high-risk patients subgroup only (HR 1.42, 95% CI 1.06 to 
1.90; p = 0.019). This systematic review fulfilled 8 of 11 criteria of the AMSTAR tool.  
The difference between the two meta-analyses might stem from two main causes: The first is 
the inclusion of the two recent large trials in the last meta-analysis only (Cornelissen et al 
2009, Goldstone et al 2008) and the second from the different methodologies and inclusion 
criteria used in the various studies (with more emphasis on strict ITT methodology in the 
recently published meta-analysis).  
Orsi et al. conducted an individual patient meta-analysis of four trials (Hunault et al., 2004, 
Labar et al 2004, Ribera et al 2005, Thomas, et al 2004b). They also showed survival benefit for 
the donor group (mean EFS was 5.88 years in the donor group and 4.88 years in the no-
donor group) with survival rate of 44.2% (± 2.9%) at 7 years in the donor group and 31.6%  
(± 2.2%) in the non-donor group, log-rank test p = 0.011. Performance of allogeneic HCT in 
first CR was found to be cost effective. This systematic review fulfilled 9 of 11 criteria of the 
AMSTAR tool. 
To summarize, all meta-analyses suggest overall survival benefit for patients undergoing a 
matched donor allogeneic HCT in first CR when compared to other modalities. By drawing 
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firm conclusions based on strict ITT trials it is suggested that allogeneic HCT may be more 
effective for the standard risk group.  
5.5 Is there a role for autologous HCT in first CR? 
We identified three systematic reviews that reported on the comparison between post 
remission autologous HCT and maintenance chemotherapy (Ashfaq, et al 2010, Hahn, et al 
2006, Ram, et al 2010). One of them also performed a meta-analysis of the available RCTs. 
Both Hahn et al. and Ashfaq et al. concluded that both autologous HCT and maintenance 
chemotherapy yield a similar outcome (Ashfaq, et al 2010, Hahn, et al 2006). They also 
suggested that autologous HCT might be a superior option for high risk patients. In the 
meta-analysis performed by our group (Ram, et al 2010), five conventionally randomized 
trials enrolling 963 patients were identified. Similar to previous systematic reviews, survival 
was comparable between the two arms (RR 1.02, 95%CI, 0.88 to 1.19) for both standard and 
high risk patients. However there was a significant increase in non-relapse mortality in the 
autologous HCT arm (RR 1.77; 95% CI, 1.12 to 2.8), though no statistically significant 
difference was demonstrated in the relapse risk (RR 0.92; 95% CI, 0.73-1.15).  
 
 Yanada, Cancer 2006 Orsi, BMT 2007 Ram, Cancer 2010 
Bernasconi 1992*   + 
Sebban 1994* + + + 
Attal 1995*   + 
Takeuchi 2002* +  + 
Dombret 2002,Thomas 2004* + + + 
Labar 2004# +  + 
Hunault 2004# + + + 
Ribera 2005* + + + 
Vey 2006*   + 
Cornelissen 2008#   + 
Goldstone 2008*   + 
Fielding, 2009*   + 
*True ITT trial    #Not strictly ITT trial – Reasons for the inability to perform ITT analysis: Labar,2004- 
inclusion of patients with no siblings in the non-donor arm; Hunault, 2004- inclusion of patients>50 
years in the non-donor group ; Cornelissen,2008- inclusion of patients who underwent matched 
unrelated donor transplantation in the nondonor study arm 
Table 3. Comparisons between 3 meta-analyses assessing the role of allogeneic 
hematopoietic cell transplantation in first complete remission  
5.6 Which is the best maintenance therapy? 
The post remission high relapse rate of adult ALL patients has encouraged  the exploration 
of various post-remission modalities. The optimal type and duration of maintenance 
therapy and the value of further intensification are still debated.  
We identified 3 relevant systematic reviews (CALLCG et al 1996, Eden, et al 2010, Escherich, 
et al 2011), reporting on pediatric patients.  
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The first, evaluating the impact of duration and intensity of the different maintenance 
regimens, included 16 trials, randomizing 746 patients (CALLCG et al., 1996) showed that 
maintenance treatment administered for up to 3 years was associated with a  significantly 
lower relapse rate albeit a similar  rate of death from leukemia. Of note, maintenance 
duration beyond 3 years did not yield any superiority . More intensive regimens were 
associated with significantly fewer relapse events and with prolonged survival (absolute 
difference in survival of about 3% at 5 years and of 4% at 8 years). This systematic review 
fulfilled 3 of 11 criteria of the AMSTAR tool. 
The second systematic review evaluated the addition of steroids plus vincristine pulses 
during the maintenance period (Eden, et al). In an individual patient meta-analysis 
vincristine-prednisone pulses were shown to improves EFS (70.1% vs. 62% at 5 years; OR 
0.71, 95% CI  0.61 to 0.84; p = 0.00004), while vincristine - dexamethasone pulses did not 
have this effect (80.9% vs. 79.9% at 5 year; OR 0.94; 95% CI, 0.8 to 1.11;p = 0.5) Overall 
survival was not affected by both combinations. (Bostrom, et al 2003). Results of this meta-
analysis should be taken with caution as they might be significantly biased by different pre-
maintenance induction regimens. This systematic review fulfilled 7 of 11 criteria of the 
AMSTAR tool. 
The third systematic review compared between the various thiopurines (mainly thioguanine 
and metcaptopurine) as maintenance (Escherich, et al).  In a meta-analysis of 3 trials, event-
free survival was similar for the two agents (OR 0.89, 95% CI, 0.78 to 1.03). However in a 
subgroup analysis of males aged<10 years there was a significant benefit for thiogouanine in 
terms of EFS (OR 0.70, 95% CI, 0.58 to 0.84), although this did not result in a significant 
difference in overall survival (OR 0.83, 95% CI, 0.62 to 1.10). It was concluded that 
mercaptopurine, and not thiogouanine, should be the thiopurine drug of choice for 
maintenance. Although this conclusion is valid for pediatric patients, in the absence of data 
in adults this may also be applicable for them. This systematic review fulfilled 5 of 11 
criteria of the AMSTAR tool. 
5.7 What is the role of CNS prophylaxis and is there a “gold-standard” regimen? 
CNS involvement at presentation in adult ALL patients  is estimated as 5% (Lazarus, et al 
2006). Nevertheless, without prophylaxis administration, CNS recurrence occurs in 
approximately 30% of adult patients in complete response (Omura, et al 1980). There are 
several options to administer CNS prophylaxis therapy. These include cranial radiotherapy 
and  intrathecal or intraventricular chemotherapy.  
One pediatric systematic review with individual patient meta-analysis (Clarke, et al 2003) 
reported that prophylactic radiotherapy reduced CNS relapse slightly more than long-term 
intrathecal therapy, however no survival benefit was shown. Also, higher than 21 Gy 
radiation dose did not correlate with lower relapse risk and, the addition of intravenous 
methotrexate to regimens containing either radiation and intrathecal therapy led to a better 
EFS. This systematic review fulfilled 4 of 11 criteria of the AMSTAR tool. 
6. An overview of systematic reviews in supportive care for patients with 
acute leukemia 
Supportive care in acute leukemia has improved dramatically during the last decades and 
contributed to the improved overall survival of AL patients.  
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The first, evaluating the impact of duration and intensity of the different maintenance 
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maintenance treatment administered for up to 3 years was associated with a  significantly 
lower relapse rate albeit a similar  rate of death from leukemia. Of note, maintenance 
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2006). Nevertheless, without prophylaxis administration, CNS recurrence occurs in 
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several options to administer CNS prophylaxis therapy. These include cranial radiotherapy 
and  intrathecal or intraventricular chemotherapy.  
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Supportive care in acute leukemia has improved dramatically during the last decades and 
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7. Myeloid growth factors 
The use of G-CSF and GM-CSF results in a dose dependent increase in the levels of 
circulating neutrophils, mainly as a result of shortening the transit time from stem cell to 
mature cells (Griffin 2001). During intensive chemotherapy, acute leukemia patients 
experience prolonged and profound neutropenia, which is a risk factor for bacterial and 
fungal infections, for increased mortality. Patients with acute leukemia can be treated with 
myeloid growth factors as primary or secondary prophylaxis (before or after the 
development of neutropenia, respectively) or for priming (before or concurrent with 
chemotherapy) with the aim of sensitizing blast cells and recruiting them into cell-cycle, 
thus enhancing their susceptibility to cytotxic agents like cytarabine.  
Five systematic reviews assessed the effect of myeloid growth factors in acute leukemia 
patients.  
The first one is a comprehensive systematic review and meta-analysis, published in 2007 by 
Sung et al and comprises 148 RCTs, randomizing 16,839 patients with all types of cancer. 
Patients were randomly assigned to receive chemotherapy with or without prophylaxis with 
myeloid growth factors (Sung, et al 2007). There was no difference between the two groups 
in short term all cause mortality and in infection related mortality. However, the use of 
myeloid-growth factors was associated with reduction of clinically and microbiologically 
documented infections (RR 0.75, 95% CI 0.62 to 0.92, and RR 0.86, 95% CI, 0.77-0.96, 
respectively). Subgroup analysis of  acute leukemia patients did not show any difference in 
short term all cause mortality and infection related mortality, as well (Sung, et al 2007). This 
systematic review fulfilled 9 of 11 criteria of the AMSTAR tool. 
The second systematic review and meta-analysis compared the prophylactic use of G-CSF in 
patients with AML receiving chemotherapy, to placebo/no treatment (control group) 
(Wang, et al 2009a, Wang, et al 2009b). This review included seven trials with almost 2000 
participants, and did not show difference in overall survival between the G-CSF group and 
the control group (Wang, et al 2009a) This systematic review fulfilled 5 of 11 criteria of the 
AMSTAR tool.  
In a systematic review and meta-analysis recently conducted by our group, we questioned 
the role of myeloid growth factors administrated to AML patients concurrent with or post 
chemotherapy (Gurion, et al., 2011). There was no difference in short term and long term all 
cause mortality, CR rate, DFS and relapse rate between the arm receiving growth factors and 
the control arm. Furthermore, the use of myeloid growth factors was not associated with a 
reduction in the incidence of infections. This systematic review fulfilled 10 of the 11 criteria 
of the AMSTAR tool. 
Another recently published systematic review compared the administration of myeloid 
growth factors in AML patients receiving chemotherapy to control/placebo (Heuser, et al 
2011). Among patients receiving primary prophylaxis, time to neutrophil recovery and 
hospitalization stay were shorter, yet no difference was shown in CR, event and DFS and 
overall survival, compared to no prophylaxis. Among patients receiving growth factors for 
priming, there was also no difference in CR, event free and disease free survival overall 
survival. This review fulfilled 7 of 11 criteria of the AMSTAR tool. 
In another meta-analysis, the use of myeloid growth factors for priming did not affect CR 
rate, DFS or overall survival (Sung, et al 2009). Subgroup analyses according to type of 
myeloid growth factors, the timing of administration and patients' age did not affect 
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outcomes. The main limitation of these meta-analyses is their heterogeneity in terms of 
patients’ characteristics, chemotherapy regimens and trial designs.  
To conclude, the main beneficial effects of growth factors are acceleration of neutrophil 
recovery by 2 to 5 days and a reduction in the length of hospitalization.(Griffin 2001, Inoue, 
et al 1990, Lemoli, et al 1991, Lowenberg, et al 1988, Park, et al 1989). With regard to priming 
with growth factors in AML, 2 meta-analyses did not demonstrate a statistical significant 
effect on remission rate and overall survival and therefore do not support their regular use.  
7.2 Prophylactic anti-infectious treatment 
Two systematic review and meta-analyses assessed the effect of antibacterial and antifungal 
prophylaxis in neutropenic patients receiving chemotherapy.  
Gafter-Gvili et al. evaluated the use of antibacterial prophylaxis for afebrile neuropenic 
patients (Gafter-Gvili, et al 2005). The administration of antibacterial prophylaxis reduced 
all-cause mortality by 33% (95% CI 0.55 to 0.81) in neutropenic patients who received any 
antibiotic prophylaxis and by 48% (95% CI 0.35 to 0.77) in patients who received quinolones 
for prophylaxis compared to placebo or no intervention. Also, the occurrence of febrile 
episodes and bacterial infections decreased significantly. This review fulfilled 10 of 11 
criteria of the AMSTAR tool. 
Robenshtock et al. evaluated antifungal agents for prophylaxis in neutropenic patients 
following chemotherapy or after allogeneic HCT (Robenshtok, et al 2007). All-cause 
mortality was reduced significantly in patients receiving antifungal prophylaxis compared 
with placebo, no treatment, or non-systemic antifungals (RR 0.84, 95% CI, 0.74 to 0.95). In a 
subgroup analysis of patients with acute leukemia there was a significant reduction in 
fungal-related mortality and documented invasive fungal infections, yet there was no 
difference in mortality. This review fulfilled 10 of 11 criteria of the AMSTAR tool. 
7.3 Transfusion support 
One systematic review and meta-analysis evaluated the prophylactic use of platelets in 
patients with hematological malignancies(Stanworth, et al 2004). Three studies compared 
prophylactic with therapeutic use of platelets. There was no difference in all-cause 
mortality, or mortality due to hemorrhagic cause. Of note, studies were conducted between 
1974-1982 and were small with marked heterogeneity, thus the results of this meta-analysis 
should be taken with caution. Three prospective studies compared the platelet transfusion 
thresholds of 10 vs. 20x109 /L. There were no statistically significant differences between the 
groups with regards to mortality, remission rates, number of participants with severe 
bleeding events or red cell transfusion requirements. 
The main limitation of this review is the inclusion of a limited number of small studies in 
different three meta-analyses, carrying a potential risk for bias, though no publication bias 
was reported. This review fulfilled 8 of 11 criteria of the AMSTAR tool. 
Recently, two published RCTs compared low dose to high dose prophylactic platelets 
transfusion (Heddle, et al 2009, Slichter, et al). Both showed no difference in grade 2-4 
bleeding incidence between patients allocated to low threshold of platelets administration 
and no difference between different doses of platelet transfusion. However, one of the 
studies was prematurely stopped because of 5.2% grade 4 bleeding in the lower dose 
platelets compared to none in the high dose (Heddle, et al 2009). 
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7. Myeloid growth factors 
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prophylactic with therapeutic use of platelets. There was no difference in all-cause 
mortality, or mortality due to hemorrhagic cause. Of note, studies were conducted between 
1974-1982 and were small with marked heterogeneity, thus the results of this meta-analysis 
should be taken with caution. Three prospective studies compared the platelet transfusion 
thresholds of 10 vs. 20x109 /L. There were no statistically significant differences between the 
groups with regards to mortality, remission rates, number of participants with severe 
bleeding events or red cell transfusion requirements. 
The main limitation of this review is the inclusion of a limited number of small studies in 
different three meta-analyses, carrying a potential risk for bias, though no publication bias 
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The progress made in the last 4 decades in the treatment of patients with acute leukemia is 
the consequence of a constant process of testing, data compilation and re-testing. Data 
gathering on a specific question using explicit, preplanned scientific methods to identify 
select and synthesize all relevant studies is the process of systematic review, which provides 
the clinician with the best evidence, and should form the basis for rational medical decision-
making. 
In this chapter we examined the evidence accumulated in various aspects of leukemia 
management, based on RCTs and systematic reviews and meta-analyses.  While in certain 
areas such as the role of tyrosine kinase inhibitors in Philadelphia positive ALL or allogeneic 
transplant in adult patients with ALL a consensus could be reached according to the data 
published so far, many questions are still open in the field of leukemia which warrant 
conduction of further clinical trials. 
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1. Introduction 
Cancer and especially hematological cancer during pregnancy is infrequent and its 
management is difficult for patients and their families, but also for their physicians since two 
lives with different priorities have to be considered. Treatment should adhere the standard 
treatment for the specific type and stage of cancer. Small adaptations can be considered in 
order to avoid adverse effects on fetal development. This chapter reviews the available data 
regarding the different aspects of diagnosis and – especially chemotherapeutical – treatment of 
hematological cancer during pregnancy. 
First we will discuss the general approach of a woman diagnosed with cancer during 
pregnancy. Second we will give a quick overview of chronic leukemia, Hodgkin and non-
Hodgkin disease during pregnancy and a more extended overview of acute leukemia during 
pregnancy. 
2. Diagnosis 
2.1 Physical examination and routine blood tests 
The rare occurrence and subtle presentation of these malignancies in pregnancy often results 
in a delay in diagnosis, which may worsen the prognosis. In addition, the physiological 
changes associated with pregnancy can mask certain laboratory abnormalities that are 
typically present in patients with hematological disorders (simple anemia of pregnancy, 
leukocytosis or gestational thrombocytopenia may temporarily hide a more serious 
hematological process such as leukemia) (Sadural and Smith, 1995; Doll et al., 1988).  
2.2 Histopathological examination 
The diagnosis of an hematological malignancy requires a lymph node biopsy or bone 
marrow aspirate and/or biopsy for diagnosis. Biopsies can safely be performed under local 
anesthesia during pregnancy. Overall, it appears that with modern surgical and anesthetic 
techniques, elective surgery – under general anesthesia – in a pregnant woman is safe even 
 
Acute Leukemia – The Scientist's Perspective and Challenge 
 
370 
Volger, W.R., Weiner, R.S., Moore, J.O., Omura, G.A., Bartolucci, A.A. & Stagg, M. (1995) 
Long-term follow-up of a randomized post-induction therapy trial in acute 
myelogenous leukemia (a Southeastern Cancer Study Group trial). Leukemia, 9, 
1456-1460. 
Wang, J., An, L., Chen, S., Ouyang, J., Zhou, R., Chen, B. & Yang, Y. (2009a) Prophylactic use 
of granulocyte colony-stimulating factor after chemotherapy does not affect 
survival rate in acute myeloid leukemia: a meta-analysis. Acta haematologica, 121, 
223-226. 
Wang, J., Ouyang, J., Zhou, R., Chen, B. & Yang, Y. (2010) Autologous hematopoietic stem 
cell transplantation for acute myeloid leukemia in first complete remission: a meta-
analysis of randomized trials. Acta Haematol, 124, 61-71. 
Wang, J., Zhan, P., Ouyang, J., Chen, B. & Zhou, R. (2009b) Prophylactic use of granulocyte 
colony-stimulating factor after induction chemotherapy in patients with newly 
diagnosed acute myeloid leukemia may increase the complete remission rate: a 
meta-analysis of five randomised controlled trials. Leukemia & lymphoma, 50, 457-
459. 
Woolf, S.H. (2000) Evidence-based medicine and practice guidelines: an overview. Cancer 
Control, 7, 362-367. 
Xu, S.N., Chen, J.P., Liu, J.P. & Xia, Y. (2009a) [Arsenic trioxide in combination with all-trans 
retinoic acid for acute promyelocytic leukemia: a systematic review and meta-
analysis]. Zhong Xi Yi Jie He Xue Bao, 7, 1024-1034. 
Xu, S.N., Chen, J.P., Liu, J.P. & Xia, Y. (2009b) [Efficacy of arsenic trioxide for acute 
promyelocytic leukemia: a systematic review and meta-analysis]. Zhong Xi Yi Jie He 
Xue Bao, 7, 801-808. 
Yanada M, Matsuo K, Suzuki T, Naoe T (2006) Allogeneic hematopoietic stem cell 
transplantation as part of postremission therapy improves survival for adult 
patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer, 106, 
2657-2663. 
Yanada, M., Matsuo, K., Emi, N. & Naoe, T. (2005) Efficacy of allogeneic hematopoietic stem 
cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first 
disease remission: a metaanalysis. Cancer, 103, 1652-1658. 
16 
Hematologic Malignancies in Pregnancy 
C. Vandenbriele1, A. Vassou2, G. Pentheroudakis3, 
K. Van Calsteren4 and F. Amant5 
1Internal medicine, University Hospitals Gasthuisberg, 
2Hematology Department,  
3Oncology Department, University Hospital of Ioannina, Hellas 
4Obstetrics, University Hospitals Gasthuisberg,  
5Leuven Cancer Institute, Gynecologic Oncology, University Hospitals Gasthuisberg,  
Belgium 
1. Introduction 
Cancer and especially hematological cancer during pregnancy is infrequent and its 
management is difficult for patients and their families, but also for their physicians since two 
lives with different priorities have to be considered. Treatment should adhere the standard 
treatment for the specific type and stage of cancer. Small adaptations can be considered in 
order to avoid adverse effects on fetal development. This chapter reviews the available data 
regarding the different aspects of diagnosis and – especially chemotherapeutical – treatment of 
hematological cancer during pregnancy. 
First we will discuss the general approach of a woman diagnosed with cancer during 
pregnancy. Second we will give a quick overview of chronic leukemia, Hodgkin and non-
Hodgkin disease during pregnancy and a more extended overview of acute leukemia during 
pregnancy. 
2. Diagnosis 
2.1 Physical examination and routine blood tests 
The rare occurrence and subtle presentation of these malignancies in pregnancy often results 
in a delay in diagnosis, which may worsen the prognosis. In addition, the physiological 
changes associated with pregnancy can mask certain laboratory abnormalities that are 
typically present in patients with hematological disorders (simple anemia of pregnancy, 
leukocytosis or gestational thrombocytopenia may temporarily hide a more serious 
hematological process such as leukemia) (Sadural and Smith, 1995; Doll et al., 1988).  
2.2 Histopathological examination 
The diagnosis of an hematological malignancy requires a lymph node biopsy or bone 
marrow aspirate and/or biopsy for diagnosis. Biopsies can safely be performed under local 
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during the first trimester. The risk of spontaneous abortion is comparable with that of 
normal miscarriage and there is no significant increase in the risk of maternal death, birth 
defects or late neurodevelopmental delays (Cohen-Kerem et al., 2005; Doll et al., 1988).  
2.3 Diagnostic medical imaging 
The available information on radiation-induced embryonic damage is derived from animal 
studies, follow-up of individuals exposed to atomic bomb explosions in Japan (Jablon and 
Kato, 1970; Miller and Mulvihill, 1976), and statistical analyses (Fenig et al., 2001). 
The possible embryonic or fetal damage from radiation may be classified into two principal 
types. Firstly, the deterministic radiation effects, such as mental retardation and organ 
malformations, which arise above a threshold dose of 0.1 – 0.2 Gy (Kal and Struikmans, 
2005). Teratogenic effects mainly occur after exposure to radiation in the first 12 weeks of 
pregnancy, when the embryo is in the stage of organogenesis and the CNS is especially 
sensitive to radiation (Kal and Struikmans, 2005).  
Secondly, there are stochastic effects. They generally manifest many years later (so-called 
“late” effects) and cannot definitively be associated to the radiation exposure. Examples of 
these effects include cancer induction and genetic effects (in the offspring of irradiated 
individuals). These effects do not occur in relation to a certain threshold, but it is the 
probability of the effect that increases with administered dose. 
Several studies have shown no increase in abortion, growth retardation or congenital 
malformation from diagnostic exposures below 10cGy (at any time during gestation)(Doll et 
al., 1988; Nuyttens et al., 2002). The estimated fetal dose from routine radiologic diagnostic 
procedures is less than 10 cGy. The probability of developmental damage or childhood 
cancer due to embryonic-fetal irradiation of 1cGy does not exceed one in 1000, and may be 
only one in 10 000 or even less. These figures are very low when compared to the overall 4-
6% rate of birth defects in the general population (Fenig et al., 2001). However, abdominal 
and pelvic CT are associated with high exposures  and should therefore be avoided during 
pregnancy (Doll et al., 1988; Pereg D. et al., 2008; Pereg D. et al., 2007). The more because 
ultrasonography or magnetic resonance imaging (MRI) may provide the desired diagnostic 
information without increasing the risk of fetal malformations. Iodinated contrast seems safe 
to use in pregnancy (Chen et al., 2008). Gadolinium adds to sensitivity and specificity but 
crosses the placenta resulting in high fetal concentrations. Gadolinium is associated with 
nephrogenic systemic fibrosis in adults with an impaired kidney function. Children under 1 
year are considered at low-risk to develop nephrogenic systemic fibrosis, because of their 
immature renal function. If needed, preference should be given to Gadobenate dimeglumine 
(Multihance®) and Gadoterate meglumine (Dotarem®) contrast media since no 
unconfounded cases of nephrogenic systemic fibrosis have been reported with these agents 
(Bellin et al., 2005). In contrast to previous belief, gadolinium-enhanced magnetic resonance 
imaging is thus possible during pregnancy (Webb et al., 2005). PET-CT has been 
increasingly used for both staging and treatment follow-up in patients with lymphoma. 
FDG (fluor-2-deoxy-D-glucose) can cross the placenta and reach the fetus. It may involve 
higher radiation exposure than regular CT and its use cannot be recommended during 
pregnancy. It should be performed for (re)evaluation after delivery (Doll et al., 1988). 
Positron emission tomography scan (18F-PET) is a highly sensitive technique for the 
detection of tumoral lesions. Since PET-technology is based on positron-electron 
annihilation and the detection of rather high energy photons, the biological effect of the 
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used radiopharmaceuticals is more significant. Optimization of the scanning protocol is 
therefore even more crucial, which should also include an evaluation of the protocol and 
necessity of the concurrent CT-scan in case of a combined PET/CT examination. A standard 
18F-FDG-PET examination results in a dose exposure of a 6-month old fetus of 5-6 mSv, 
which is still acceptable in many indications in view of the important information PET can 
add to the staging of e.g. lymphoma. In any case, consultation of the nuclear medicine 
physician and medical physicist before the pregnant patient presents herself to the nuclear 
department, allows to take some simple measures which can significantly limit the fetal 
exposure by limiting the dose of the radiopharmaceutical, supplementary maternal 
hydration and the use of a bladder catheter. 
3. Obstetrical and placental issues 
3.1 General follow-up 
Prenatal care in women diagnosed with cancer during pregnancy should be performed in a 
high-risk obstetric unit. As treatment options will be dependent on the gestational age, it is 
very important to have a correct dating of the pregnancy. Before oncological treatment is 
started, we advise to perform a careful fetal examination by ultrasonographic screening, to 
ensure there are no pre-existing fetal anomalies. Further ultrasound scans should be 
performed every 2-3 weeks to evaluate the fetal growth, development and well-being.  In 
case of abnormal findings, more stringent monitoring of the fetus or even preterm delivery 
might be necessary. Pregnancy-related complications should be treated according to the 
standard obstetrical care.  
3.2 Monitoring around treatment 
Before every cycle of cytotoxic treatment, an evaluation of fetal morphology, growth and 
well-being must be carried out by ultrasound screening. After treatment, it is important to 
consider fetal well-being and counsel patients to be alert when contractions occur, since an 
increased incidence in preterm contractions was reported after cytotoxic treatment during 
pregnancy (Van Calsteren et al., 2010). Furthermore, since cases have been described of 
neonatal pancytopenia, the possibility of fetal anemia has to be considered and checked 
before and after chemotherapy in pregnancy (Doppler measurement of peak systolic 
velocity of the middle cerebral artery).  
3.3 The delivery 
Delivery should take place in a hospital with a neonatal care unit. The timing of delivery 
needs to be determined according to the oncological treatment schedule and the maturation 
of the fetus. As in non cancer patients, a (near-) term delivery (> 35-37 weeks) should be 
aimed for (Van Calsteren et al., 2010). Prematurity and low birth weight associated with 
preterm delivery have been identified as negative contributing factors in the neurological 
and emotional development of children (Wood et al., 2000; Doyle, 2004; Mikkola et al., 1997; 
Ancel et al., 2006). When delivery before 34 weeks is inevitable, fetal lung maturation by 
corticosteroids should be considered and managed according to local policy (Crowley et al., 
1990). The mode of delivery is determined based on obstetrical indications. To allow the 
bone marrow to recover and to minimize the risk of maternal and fetal 
neutropenia/thrombocytopenia/anemia, delivery should be planned 3 weeks after the last 
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al., 1988; Nuyttens et al., 2002). The estimated fetal dose from routine radiologic diagnostic 
procedures is less than 10 cGy. The probability of developmental damage or childhood 
cancer due to embryonic-fetal irradiation of 1cGy does not exceed one in 1000, and may be 
only one in 10 000 or even less. These figures are very low when compared to the overall 4-
6% rate of birth defects in the general population (Fenig et al., 2001). However, abdominal 
and pelvic CT are associated with high exposures  and should therefore be avoided during 
pregnancy (Doll et al., 1988; Pereg D. et al., 2008; Pereg D. et al., 2007). The more because 
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information without increasing the risk of fetal malformations. Iodinated contrast seems safe 
to use in pregnancy (Chen et al., 2008). Gadolinium adds to sensitivity and specificity but 
crosses the placenta resulting in high fetal concentrations. Gadolinium is associated with 
nephrogenic systemic fibrosis in adults with an impaired kidney function. Children under 1 
year are considered at low-risk to develop nephrogenic systemic fibrosis, because of their 
immature renal function. If needed, preference should be given to Gadobenate dimeglumine 
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annihilation and the detection of rather high energy photons, the biological effect of the 
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used radiopharmaceuticals is more significant. Optimization of the scanning protocol is 
therefore even more crucial, which should also include an evaluation of the protocol and 
necessity of the concurrent CT-scan in case of a combined PET/CT examination. A standard 
18F-FDG-PET examination results in a dose exposure of a 6-month old fetus of 5-6 mSv, 
which is still acceptable in many indications in view of the important information PET can 
add to the staging of e.g. lymphoma. In any case, consultation of the nuclear medicine 
physician and medical physicist before the pregnant patient presents herself to the nuclear 
department, allows to take some simple measures which can significantly limit the fetal 
exposure by limiting the dose of the radiopharmaceutical, supplementary maternal 
hydration and the use of a bladder catheter. 
3. Obstetrical and placental issues 
3.1 General follow-up 
Prenatal care in women diagnosed with cancer during pregnancy should be performed in a 
high-risk obstetric unit. As treatment options will be dependent on the gestational age, it is 
very important to have a correct dating of the pregnancy. Before oncological treatment is 
started, we advise to perform a careful fetal examination by ultrasonographic screening, to 
ensure there are no pre-existing fetal anomalies. Further ultrasound scans should be 
performed every 2-3 weeks to evaluate the fetal growth, development and well-being.  In 
case of abnormal findings, more stringent monitoring of the fetus or even preterm delivery 
might be necessary. Pregnancy-related complications should be treated according to the 
standard obstetrical care.  
3.2 Monitoring around treatment 
Before every cycle of cytotoxic treatment, an evaluation of fetal morphology, growth and 
well-being must be carried out by ultrasound screening. After treatment, it is important to 
consider fetal well-being and counsel patients to be alert when contractions occur, since an 
increased incidence in preterm contractions was reported after cytotoxic treatment during 
pregnancy (Van Calsteren et al., 2010). Furthermore, since cases have been described of 
neonatal pancytopenia, the possibility of fetal anemia has to be considered and checked 
before and after chemotherapy in pregnancy (Doppler measurement of peak systolic 
velocity of the middle cerebral artery).  
3.3 The delivery 
Delivery should take place in a hospital with a neonatal care unit. The timing of delivery 
needs to be determined according to the oncological treatment schedule and the maturation 
of the fetus. As in non cancer patients, a (near-) term delivery (> 35-37 weeks) should be 
aimed for (Van Calsteren et al., 2010). Prematurity and low birth weight associated with 
preterm delivery have been identified as negative contributing factors in the neurological 
and emotional development of children (Wood et al., 2000; Doyle, 2004; Mikkola et al., 1997; 
Ancel et al., 2006). When delivery before 34 weeks is inevitable, fetal lung maturation by 
corticosteroids should be considered and managed according to local policy (Crowley et al., 
1990). The mode of delivery is determined based on obstetrical indications. To allow the 
bone marrow to recover and to minimize the risk of maternal and fetal 
neutropenia/thrombocytopenia/anemia, delivery should be planned 3 weeks after the last 
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dose of anthracycline-based chemotherapy (Loibl et al. 2006). Chemotherapy should not be 
administered after 35 weeks since spontaneous labor becomes more likely. Furthermore, 
neonates - especially preterm babies - have limited capacity to metabolize and eliminate 
drugs due to liver and renal immaturity. The delay of delivery after chemotherapy will 
allow fetal drug excretion via the placenta (Sorosky et al., 1997). Chemotherapy can be 
restarted when needed after delivery. An interval of one week after an uncomplicated 
caesarean section is required.  
3.4 Postpartum 
Although placental metastases are rare, the placenta should be analysed histopathologically 
after delivery (Alexander et al., 2003). In the absence of safety data, breastfeeding during or 
shortly after chemotherapy is contraindicated. Primary inhibition of milk production is 
needed because especially lipophylic agents can accumulate in the milk. 
 
Cancer type Cases placental M+ Cases fetal M+ Cases fetal and 
placental M+  
Total  
Melanoma 21 3 3 27 
Breast cancer 15 0 0 15 
Lung cancer 8 1 1 10 
Leukemia 6 3 0 9 
Lymphoma 3 2 1 6 
Table 1. Case reports of placental/fetal metastasis (Alexander et al., 2003) 
3.5 Transplacental transfer of chemotherapy during pregnancy 
Chemotherapy during pregnancy has been associated with congenital malformations and 
neonatal bone marrow suppression, suggesting that at least a fraction of these drugs is 
passing the placenta (Cardonick E and Iacobucci A, 2004.). Transfer mainly occurs by 
passive diffusion, but also active transporters like P-glycoprotein, Multidrug Resistance 
Proteins and Breast Cancer Resistance Protein have an important role in the regulation of 
the placental drug transfer (Syme et al., 2004.). In humans only a few case reports are 
available, however results are not conclusive (Gaillard et al., 1995; Grohard et al., 1989; 
Roboz et al., 1979, D’Incalci et al., 1983; Karp et al., 1983; Koc et al., 1994). Results in a 
baboon model showed that transplacental transfer of chemotherapeutics varies substantially 
among different drugs. Significant levels of  platinum (57.5+14.2% of maternal plasma levels 
(n=7)) after intravenous carboplatinum administration were detected in fetal plasma 
samples, but lower levels of doxorubicin (7.5+3.2%, (n=6)), epirubicin (4.0+1.6%, (n=8)), 
docetaxel (not detectable in fetal samples, (n=9)), paclitaxel (1.4+0.8%, (n=7)), vinblastine 
(18.5+15.5%, (n=9)) and 4-OH-cyclophosphamide (25.1+6.3%, (n=3)) were measured (Van 
Calsteren et al., 2010a, 2010b, 2011)  
3.6 Short and long term effect of prenatal exposure to chemotherapy on children 
The potential fetal effects depend on the gestational age at exposure. During the 
implantation period (first 10 days after conception) the number of surviving omnipotent 
 
Hematologic Malignancies in Pregnancy 375 
stem cells will determine whether a miscarriage occurs, or a normal embryo will develop. 
Between 10 days and 8 weeks after the conception organogenesis occurs and therefore, this 
period is at risk for congenital malformations. For foetal protection, the administration of 
chemotherapy is considered contraindicated until a gestational age of 10 weeks. If a ‘safety 
period’ of 4 weeks is respected, chemotherapy may start from a gestational age of 14 weeks 
(Amant et al., 2009). During the second and third trimester of pregnancy, no major 
malformations are expected to be caused by cytotoxic treatment. However, cases of growth 
restriction, prematurity, intra-uterine and neonatal death, and hematopoietic suppression 
have been reported (Cardonick and Iacobucci, 2004). 
Data on the long term of children after prenatal exposure to chemotherapy are scarce. Based 
on theoretical assumptions, potential problems of neurodevelopmental delay, sterility, 
carcinogenesis and genetic defects have to be considered, but up till now available data do 
not suggest these problems. A study that includes 84 children who were born to mothers 
who received chemotherapy during pregnancy for haematological malignancies and with a 
median follow-up of 19 years, did not show any congenital, neurological, immunological 
and psychological abnormalities including normal learning and educational behaviour 
(Aviles et al., 2001). Hahn et al. surveyed 57 parents/guardians regarding outcomes of 
children exposed to chemotherapy in utero for breast cancer treatment. At ages ranging 
from 2 to 157 months, most children had a normal development. Only 2 children required 
special attention in school: 1 had attention deficit disorder, whereas the other was the child 
with Down syndrome (Hahn et al., 2006). In a small study, 10 children were between 2 
months and 66 months of age when a full neurologic and cardiologic examination was 
performed. Whether the occurrence of a cortical malformation in a twin whose fraternal 
twin was normal, was related to cytotoxic drugs remains unclear. Otherwise, we 
encountered no development problems (Van Calsteren et al., 2006).  
The few studies that looked at the cardiac effect of chemotherapy in the foetus showed that 
acute myocardial dysfunction can appear during pregnancy with anthracyclines. (Cardonick 
and Lacobucci, 2004; Germann et al., 2004). However, follow-up with cardiac ultrasound in 
81 children who received anthracycline treatment in utero (age 9 - 29 years, mean 17 year) 
was reassuring (Aviles et al., 2006).  
4. Supportive treatment 
4.1 Antiemetics 
Up to 70% of cancer patients may suffer from nausea or emesis following chemotherapy. No 
association was found between treatment with metoclopramide, anti-histamines or 
ondansetron-based anti-emetics and fetal malformations in both animal models and humans 
(Tincello and Johnstone, 1996; Siu et al., 2002; Guikontes et al., 1992; World, 1993). 
4.2 Antibiotics 
As pregnant women with malignancy might be treated with antibiotics – especially due to 
neutropenic fever – their effects on the mother and fetus must be addressed. There is large 
data regarding fetal safety of penicillins, cephalosporins and erythromycin. 
Aminoglycosides seem to be safe in first trimester on limited data. A higher rate of 
cardiovascular malformations was found after treatment with trimethoprim-sulfamethazine 
in the second-third months of pregnancy. Quinolones that cause arthropathy and 
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dose of anthracycline-based chemotherapy (Loibl et al. 2006). Chemotherapy should not be 
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restarted when needed after delivery. An interval of one week after an uncomplicated 
caesarean section is required.  
3.4 Postpartum 
Although placental metastases are rare, the placenta should be analysed histopathologically 
after delivery (Alexander et al., 2003). In the absence of safety data, breastfeeding during or 
shortly after chemotherapy is contraindicated. Primary inhibition of milk production is 
needed because especially lipophylic agents can accumulate in the milk. 
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available, however results are not conclusive (Gaillard et al., 1995; Grohard et al., 1989; 
Roboz et al., 1979, D’Incalci et al., 1983; Karp et al., 1983; Koc et al., 1994). Results in a 
baboon model showed that transplacental transfer of chemotherapeutics varies substantially 
among different drugs. Significant levels of  platinum (57.5+14.2% of maternal plasma levels 
(n=7)) after intravenous carboplatinum administration were detected in fetal plasma 
samples, but lower levels of doxorubicin (7.5+3.2%, (n=6)), epirubicin (4.0+1.6%, (n=8)), 
docetaxel (not detectable in fetal samples, (n=9)), paclitaxel (1.4+0.8%, (n=7)), vinblastine 
(18.5+15.5%, (n=9)) and 4-OH-cyclophosphamide (25.1+6.3%, (n=3)) were measured (Van 
Calsteren et al., 2010a, 2010b, 2011)  
3.6 Short and long term effect of prenatal exposure to chemotherapy on children 
The potential fetal effects depend on the gestational age at exposure. During the 
implantation period (first 10 days after conception) the number of surviving omnipotent 
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stem cells will determine whether a miscarriage occurs, or a normal embryo will develop. 
Between 10 days and 8 weeks after the conception organogenesis occurs and therefore, this 
period is at risk for congenital malformations. For foetal protection, the administration of 
chemotherapy is considered contraindicated until a gestational age of 10 weeks. If a ‘safety 
period’ of 4 weeks is respected, chemotherapy may start from a gestational age of 14 weeks 
(Amant et al., 2009). During the second and third trimester of pregnancy, no major 
malformations are expected to be caused by cytotoxic treatment. However, cases of growth 
restriction, prematurity, intra-uterine and neonatal death, and hematopoietic suppression 
have been reported (Cardonick and Iacobucci, 2004). 
Data on the long term of children after prenatal exposure to chemotherapy are scarce. Based 
on theoretical assumptions, potential problems of neurodevelopmental delay, sterility, 
carcinogenesis and genetic defects have to be considered, but up till now available data do 
not suggest these problems. A study that includes 84 children who were born to mothers 
who received chemotherapy during pregnancy for haematological malignancies and with a 
median follow-up of 19 years, did not show any congenital, neurological, immunological 
and psychological abnormalities including normal learning and educational behaviour 
(Aviles et al., 2001). Hahn et al. surveyed 57 parents/guardians regarding outcomes of 
children exposed to chemotherapy in utero for breast cancer treatment. At ages ranging 
from 2 to 157 months, most children had a normal development. Only 2 children required 
special attention in school: 1 had attention deficit disorder, whereas the other was the child 
with Down syndrome (Hahn et al., 2006). In a small study, 10 children were between 2 
months and 66 months of age when a full neurologic and cardiologic examination was 
performed. Whether the occurrence of a cortical malformation in a twin whose fraternal 
twin was normal, was related to cytotoxic drugs remains unclear. Otherwise, we 
encountered no development problems (Van Calsteren et al., 2006).  
The few studies that looked at the cardiac effect of chemotherapy in the foetus showed that 
acute myocardial dysfunction can appear during pregnancy with anthracyclines. (Cardonick 
and Lacobucci, 2004; Germann et al., 2004). However, follow-up with cardiac ultrasound in 
81 children who received anthracycline treatment in utero (age 9 - 29 years, mean 17 year) 
was reassuring (Aviles et al., 2006).  
4. Supportive treatment 
4.1 Antiemetics 
Up to 70% of cancer patients may suffer from nausea or emesis following chemotherapy. No 
association was found between treatment with metoclopramide, anti-histamines or 
ondansetron-based anti-emetics and fetal malformations in both animal models and humans 
(Tincello and Johnstone, 1996; Siu et al., 2002; Guikontes et al., 1992; World, 1993). 
4.2 Antibiotics 
As pregnant women with malignancy might be treated with antibiotics – especially due to 
neutropenic fever – their effects on the mother and fetus must be addressed. There is large 
data regarding fetal safety of penicillins, cephalosporins and erythromycin. 
Aminoglycosides seem to be safe in first trimester on limited data. A higher rate of 
cardiovascular malformations was found after treatment with trimethoprim-sulfamethazine 
in the second-third months of pregnancy. Quinolones that cause arthropathy and 
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tetracyclines that affect bone and teeth should be avoided during pregnancy. Sulfonamides, 
similar to other folate antagonists have been associated with neural tube defects and cardiac 
malformations and should be avoided as well (Pereg et al., 2008; Werler et al.2005).  
4.3 Pain control 
Paracetamol has been reported to be used by up to 65% of pregnant women. It can be 
administered safely throughout pregnancy. NSAID’s are preferably not used during 
pregnancy, but if needed can be considered during the first and second trimester of 
pregnancy. In the third trimester (> 32 weeks) NSAID’s are contraindicated because they are 
associated with premature closure of the ductus arteriosus, oligohydramnion and prolonged 
gestation and labor (Pereg et al., 2008; Cardonick and Lacobucci, 2004). 
4.4 Growth factors 
Erythropoietin does not cross the placenta and its use is felt to be safe in pregnancy (Briggs 
and Yaffee, 2005). Granulocyte colony-stimulating factor use in pregnancy has been 
reported in a registry series of 20 patients with severe chronic neutropenia with a median 
dose of 2.7 mcg/kg/day administered daily or every other day during all three trimesters 
with an average duration of three trimesters. These data, although limited, did not reveal an 
increase in adverse congenital abnormalities or fetal death compared to pregnant patients 
that did not receive the drug (Dale et al., 2003). 
4.5 Bisphosphonates 
Animal studies with bisphosphonates have displayed maternal toxicity, foetal 
underdevelopment, embryolethality, hypocalcaemia and skeletal retardation during 
pregnancy. Bisphosphonates are therefore contra-indicated in pregnancy and have a FDA 
category C pregnancy risk. A recent literature search including 51 patients exposed to 
bisphosphonates shortly prior to conception or during pregnancy did not nd evidence of 
skeletal abnormalities or malformations in the foetuses of the exposed mothers (Djokanovic 
et al., 2008). If bisphosphonates are indicated in a pregnant patient hypocalcemia affecting 
the contractility of the uterus must be avoided. 
4.6 Leukapheresis 
Leukapheresis has been used in both acute and chronic leukemia to rapidly reduce high 
whiteblood cell counts in patients with impending vascular occlusion. Experience with 
leukapheresis during pregnancy is limited to only a handful of cases used to treat both 
chronic and acute leukemias (Ali et al., 2004a, 2004b; Bazarbashi et al, 1991; Broccia et al., 
1984; Fitzgerald et al., 1993, 1986; Nolan et al., 1988). In general, the therapy was tolerated 
well by the mother and the fetus. Although experience is limited, leukapheresis may be used 
as a short-term temporizing measure when no other options exist or in patients refusing 
other therapies during pregnancy. 
4.7 Corticoids 
Regarding the use of corticoids, methylprednisolone and hydrocortisone are extensively 
metabolized in the placenta. They are therefore preferred over dexa- or betamethasone 
(Amant et al., 2009).  
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5. Leukemia in pregnancy 
The diagnosis of leukemia in a pregnant woman is a dramatic event that generates complex 
ethical and therapeutic dilemmas. Leukemia often presents as a medical emergency and 
induction of appropriate therapy must be initiated promptly. The therapeutic decisions 
should involve a multidisciplinary team including at least an haematologist, an obstetrician, 
a neonatologist, a psychologist and a social worker. Hypothetically the treatment decision 
must be based on data from prospective clinical trials but unfortunately the available data in 
the literature derives from retrospective case reports and case series. 
Leukemia occurring during pregnancy is very rare with an estimated incidence of one per 
100.000 pregnancies annually (Pavlidis, 2002). This frequency is 3.5 times lower than the 
incidence of leukemia in the general population in Western world. This is explained by the 
fact that acute lymphoblastic leukemia occurs mainly in childhood, while acute myeloid 
leukemia occurs usually in late adulthood, thus relatively sparing the childbearing ages.  
The majority of cases of leukemia during pregnancy are acute leukemias, of which two-
thirds are acute myeloid leukemias and one-third acute lymphoblastic leukemias 
(Pentheroudakis and Pavlidis, 2006). The main chronic leukemia during pregnancy is 
chronic myeloid leukemia and accounts for about 10% of all pregnancy-associated 
leukemias, since chronic lymphocytic leukemia is extremely rare (Caliguiri and Mayer, 
1989). 
5.1 Acute leukemia in pregnancy 
Since Virchow's first description in 1856 of leukemia in pregnant woman, more than 500 
cases have been reported (Sadural and Smith, 1995). Acute leukemias are diagnosed more 
frequently during the later stages of pregnancy. It is estimated that 23% of acute leukemias 
diagnosed during pregnancy were detected in the first trimester, 37% in the second and 40% 
in the third trimester respectively (Caliguiri, 1992). 
The initial diagnosis of acute leukemia is often challenging and sometimes can be delayed 
because pregnant women frequently describe various non-specific symptoms like fatigue.  
Anemia, as already mentioned, is accompanied by marked thrombocytopenia and 
neutropenia. Recurrent infections and bleeding reflect bone marrow failure. The diagnostic 
approach is the same as in the general population. Bone marrow aspiration for morphologic 
examination and biopsy, detailed immunophenotyping, cytogenetics and molecular studies 
are essentials. 
No prospective studies comparing outcome in nonpregnant and pregnant women with 
acute leukemia are available. Case control series and historical control comparisons offer no 
evidence to suggest that pregnancy has an impact on the course and prognosis of acute 
leukemia provided that therapy is not delayed (Fey and Surbek, 2008).  
Vertical transmission of leukemia in the fetus is exceptionally rare due to placental barrier 
and fetal immune system. Nevertheless the placenta is not an absolute barrier and single 
maternal leukemic cells can pass from mother to fetus and few cases of leukemic placenta 
infiltration and leukemia dissemination to the fetus have been described (Dildy et al., 1989; 
Osada et al., 1990; Van der Velden et al., 2001). 
Cytotoxic agents have a relatively low molecular weight; most of them can cross the placenta 
and reach the fetus. When treating a pregnant woman with chemotherapy it is crucial to 
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infiltration and leukemia dissemination to the fetus have been described (Dildy et al., 1989; 
Osada et al., 1990; Van der Velden et al., 2001). 
Cytotoxic agents have a relatively low molecular weight; most of them can cross the placenta 
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consider that many physiologic changes occur in gestation, which can potentially alter the 
effectiveness of antineoplastic agents by changing their metabolism or clearance (Redmond, 
1985). Plasma volume is increased up to 50%, the amniotic fluid creates a pharmacologic third 
space and renal clearance and hepatic oxidation of drugs are enhanced (Williams and Schilsky, 
2000; Muchlow, 1986). For different drugs, among which chemotherapy, changes in 
pharmacokinetic characteristics have been shown. Recently we described a lower plasma drug 
exposure for doxorubicin, epirubicin, paclitaxel and carboplatin during pregnancy (Van 
Calsteren et al., 2010)). However these findings could not be related to different outcomes, and 
therefore it is currently advised to administer the same drug regimens/dosages to pregnant 
and nonpregnant women (Cardonick and Iacobucci, 2004). 
5.1.1 Acute Myeloid Leukemia (AML) 
Treatment protocols for AML consist of a combination of cytarabine with an anthracycline 
as an induction course in order to achieve complete remission. Afterwards various intensive 
chemotherapy combinations are administered as consolidation therapy.  
Cytarabine as an antimetabolite carries a significant risk to the fetus. A review of 93 cases of 
pregnant women exposed to cytarabine alone or in combination with other chemotherapeutic 
agents reported 4 cases of limb malformations associated with first trimester exposure. The 
administration in the second and third trimester was associated with transient neonatal 
cytopenias in 5 cases, intrauterine fetal death in 6 cases, intrauterine growth retardation in 12 
cases and 2 cases of neonatal deaths from severe infections (Cardonick and Iacobucci, 2004).  
Cytarabine use in the first trimester is not advocated and termination of pregnancy is strongly 
preferred. 
Idarubicin and daunorubicin are the anthracyclines in the treatment regimens for AML. 
Idarudicin is more lipophilic compared to other anthracyclines and so placenta transfer is 
more likely to occur. Therefore it may be associated with higher rates of  fetal complications 
and should be avoided during pregnancy (Cardonick and Iacobucci, 2004).  
The experience with the administration of anthracyclines during pregnancy is limited mostly 
to doxorubicin and daunorubicin. Of 28 pregnancies after the first trimester, exposed to 
doxorubicin and daunorubicin for the treatment of various hematologic malignancies, 21 
pregnancies were delivered without any complications (Turchi and Villasis, 1988). The results 
of daunorubicin are worrying especially the combination with cytarabine which is associated 
with serious fetal morbidity and mortality (Azim et al., 2010). A stillborn fetus was reported in 
one case after exposure to daunorubicin. Congenital anomalies including limb deformities, 
ventral septal defect and cardiomyopathy were also reported (Azim et al., 2010). 
Doxorubicin has been extensively studied in gestational breast cancer and results are rather 
reassuring (Hahn et al., 2006). 162 Pregnancies with malignancies, including 25 in the first 
trimester, were exposed to doxorubicin and reported complications were pre-eclampsia, 
midtrimester miscarriage, transient neonatal neutropenia with sepsis, intrauterine growth 
retardation and intrauterine fetal death in 18 cases (Cardonick and Iacobucci, 2004). Since 
doxorubicin seems to be as effective as the other anthracyclines for the treatment of 
leukemia, it is the preferred anthracycline during pregnancy (Shapira et al., 2008). Six 
pregnant patiens with AML were treated with a doxorubicin-based regimen with normal 
outcomes except from one premature delivery (Greenlund et al., 2001; Fassas et al., 1984).   
Doxorubicin is considered relatively safe throughout pregnancy and is not associated with 
an increased risk for severe congenital malformations (Azim et al., 2010). Whether in utero 
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exposure to anthracyclines is cardiotoxic to the developing fetus is unknown (Cardonick 
and Iacobucci, 2004; Avilés et al., 2006). 
In relapsed AML termination of pregnancy is recommended, because therapy requires high-
dose chemotherapy, stem cell transplantation or experimental drugs, which cannot be 
delivered during pregnancy (Shapira et al., 2008). 
In summary when a pregnant woman is diagnosed with AML during the 1st trimester a 
strong recommendation for pregnancy termination must be given. In 2nd and 3rd trimesters 
treatment with cytarabine and doxorubicin should be instituted promptly. Delivery should 
be planned after the 32nd week of gestation and 2-3 weeks following treatment to allow 
bone marrow recovery. 
5.1.2 Acute Promyelocytic Leukemia (APL) 
APL is a unique type of AML characterized by the reciprocal chromosomal translocation 
t(15;17) (q22;q21) and its molecular equivalent the PML/RARα fusion gene. APL has been 
reported in approximately 10% of cases of leukemia in pregnancy, similar to the percentage 
in non-pregnant women (Carradice et al., 2002). It is frequently associated with 
disseminated intravascular coagulation, which may severely complicate the management of 
pregnancy, labor and delivery. 
As in other types of leukemia, management of APL in pregnancy cannot be based on evidence 
from clinical trials and relies on data from historical cases. A novel treatment strategy of APL 
was the introduction of All-Trans-Retinoic-Acid (ATRA).  ATRA targets the fusion product of 
t(15;17). Pharmacological levels of ATRA lead to remission by differentiation of cells of the 
leukemic clone. By combining ATRA with induction and consolidation chemotherapy, APL 
has one of the more favorable outcomes (Sanz and Lo-Coco, 2011). 
As with other vitamin A derivatives, ATRA exposure during the 1st trimester carries an 85% 
risk of teratogenicity, including severe neurological and cardiovascular malformations 
(Fadilah et al., 2001). ATRA appears to be reasonably safe and well tolerated if given outside 
the first trimester (Fadilah et al., 2001). A review of 15 cases of APL in pregnancy treated 
with ATRA did not reveal any fetal malformations that could be attributed to ATRA 
(Carradice et al., 2002; Fadilah et al., 2001; Giagounidis et al., 2006). However, close 
monitoring for fetal cardiac complications is mandatory throughout pregnancy (Yang and 
Hladnik, 2009). The most important maternal adverse effect of ATRA is the potentially lethal 
retinoic acid syndrome, which may be reversed with early administation of dexamethasone. 
The combination of ATRA with an anthracycline during the 2nd and 3rd trimesters has been 
reported in several case reports (Shapira et al., 2008). This regimen appears reasonably safe 
and is not associated with increased toxicity for either the pregnant woman or the fetus. 
Among 15 women receiving this regimen, 13 were diagnosed in late pregnancy and yielded 
live newborns, whereas 2 patients in 6th and 10th week of gestation at time of APL 
diagnosis had an abortion (Breccia et al., 2002). 
The confirmation of diagnosis of APL in the 2nd and 3rd trimester should be followed by 
the initiation of ATRA with an anthracycline if the leukocyte count is less than 10,000/mm3. 
If the leukocyte count is greater than 10,000/mm3 an anthracycline alone is recommended 
to decrease the risk of ATRA syndrome. Arsenic trioxide is teratogenic and contraindicated 
in pregnancy (Rizack et al., 2009). 
5.1.3 Acute Lymphoblastic Leukemia (ALL) 
ALL is relatively rare among adults and only 21 cases of pregnant patients with ALL have 
been reported (Rizack et al., 2009). Because ALL is a highly aggressive disease, it is critical 
 
Acute Leukemia – The Scientist's Perspective and Challenge 378 
consider that many physiologic changes occur in gestation, which can potentially alter the 
effectiveness of antineoplastic agents by changing their metabolism or clearance (Redmond, 
1985). Plasma volume is increased up to 50%, the amniotic fluid creates a pharmacologic third 
space and renal clearance and hepatic oxidation of drugs are enhanced (Williams and Schilsky, 
2000; Muchlow, 1986). For different drugs, among which chemotherapy, changes in 
pharmacokinetic characteristics have been shown. Recently we described a lower plasma drug 
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pregnant women exposed to cytarabine alone or in combination with other chemotherapeutic 
agents reported 4 cases of limb malformations associated with first trimester exposure. The 
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Cytarabine use in the first trimester is not advocated and termination of pregnancy is strongly 
preferred. 
Idarubicin and daunorubicin are the anthracyclines in the treatment regimens for AML. 
Idarudicin is more lipophilic compared to other anthracyclines and so placenta transfer is 
more likely to occur. Therefore it may be associated with higher rates of  fetal complications 
and should be avoided during pregnancy (Cardonick and Iacobucci, 2004).  
The experience with the administration of anthracyclines during pregnancy is limited mostly 
to doxorubicin and daunorubicin. Of 28 pregnancies after the first trimester, exposed to 
doxorubicin and daunorubicin for the treatment of various hematologic malignancies, 21 
pregnancies were delivered without any complications (Turchi and Villasis, 1988). The results 
of daunorubicin are worrying especially the combination with cytarabine which is associated 
with serious fetal morbidity and mortality (Azim et al., 2010). A stillborn fetus was reported in 
one case after exposure to daunorubicin. Congenital anomalies including limb deformities, 
ventral septal defect and cardiomyopathy were also reported (Azim et al., 2010). 
Doxorubicin has been extensively studied in gestational breast cancer and results are rather 
reassuring (Hahn et al., 2006). 162 Pregnancies with malignancies, including 25 in the first 
trimester, were exposed to doxorubicin and reported complications were pre-eclampsia, 
midtrimester miscarriage, transient neonatal neutropenia with sepsis, intrauterine growth 
retardation and intrauterine fetal death in 18 cases (Cardonick and Iacobucci, 2004). Since 
doxorubicin seems to be as effective as the other anthracyclines for the treatment of 
leukemia, it is the preferred anthracycline during pregnancy (Shapira et al., 2008). Six 
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outcomes except from one premature delivery (Greenlund et al., 2001; Fassas et al., 1984).   
Doxorubicin is considered relatively safe throughout pregnancy and is not associated with 
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exposure to anthracyclines is cardiotoxic to the developing fetus is unknown (Cardonick 
and Iacobucci, 2004; Avilés et al., 2006). 
In relapsed AML termination of pregnancy is recommended, because therapy requires high-
dose chemotherapy, stem cell transplantation or experimental drugs, which cannot be 
delivered during pregnancy (Shapira et al., 2008). 
In summary when a pregnant woman is diagnosed with AML during the 1st trimester a 
strong recommendation for pregnancy termination must be given. In 2nd and 3rd trimesters 
treatment with cytarabine and doxorubicin should be instituted promptly. Delivery should 
be planned after the 32nd week of gestation and 2-3 weeks following treatment to allow 
bone marrow recovery. 
5.1.2 Acute Promyelocytic Leukemia (APL) 
APL is a unique type of AML characterized by the reciprocal chromosomal translocation 
t(15;17) (q22;q21) and its molecular equivalent the PML/RARα fusion gene. APL has been 
reported in approximately 10% of cases of leukemia in pregnancy, similar to the percentage 
in non-pregnant women (Carradice et al., 2002). It is frequently associated with 
disseminated intravascular coagulation, which may severely complicate the management of 
pregnancy, labor and delivery. 
As in other types of leukemia, management of APL in pregnancy cannot be based on evidence 
from clinical trials and relies on data from historical cases. A novel treatment strategy of APL 
was the introduction of All-Trans-Retinoic-Acid (ATRA).  ATRA targets the fusion product of 
t(15;17). Pharmacological levels of ATRA lead to remission by differentiation of cells of the 
leukemic clone. By combining ATRA with induction and consolidation chemotherapy, APL 
has one of the more favorable outcomes (Sanz and Lo-Coco, 2011). 
As with other vitamin A derivatives, ATRA exposure during the 1st trimester carries an 85% 
risk of teratogenicity, including severe neurological and cardiovascular malformations 
(Fadilah et al., 2001). ATRA appears to be reasonably safe and well tolerated if given outside 
the first trimester (Fadilah et al., 2001). A review of 15 cases of APL in pregnancy treated 
with ATRA did not reveal any fetal malformations that could be attributed to ATRA 
(Carradice et al., 2002; Fadilah et al., 2001; Giagounidis et al., 2006). However, close 
monitoring for fetal cardiac complications is mandatory throughout pregnancy (Yang and 
Hladnik, 2009). The most important maternal adverse effect of ATRA is the potentially lethal 
retinoic acid syndrome, which may be reversed with early administation of dexamethasone. 
The combination of ATRA with an anthracycline during the 2nd and 3rd trimesters has been 
reported in several case reports (Shapira et al., 2008). This regimen appears reasonably safe 
and is not associated with increased toxicity for either the pregnant woman or the fetus. 
Among 15 women receiving this regimen, 13 were diagnosed in late pregnancy and yielded 
live newborns, whereas 2 patients in 6th and 10th week of gestation at time of APL 
diagnosis had an abortion (Breccia et al., 2002). 
The confirmation of diagnosis of APL in the 2nd and 3rd trimester should be followed by 
the initiation of ATRA with an anthracycline if the leukocyte count is less than 10,000/mm3. 
If the leukocyte count is greater than 10,000/mm3 an anthracycline alone is recommended 
to decrease the risk of ATRA syndrome. Arsenic trioxide is teratogenic and contraindicated 
in pregnancy (Rizack et al., 2009). 
5.1.3 Acute Lymphoblastic Leukemia (ALL) 
ALL is relatively rare among adults and only 21 cases of pregnant patients with ALL have 
been reported (Rizack et al., 2009). Because ALL is a highly aggressive disease, it is critical 
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that multiagent chemotherapy is administered immediately after the diagnosis. It has been 
shown that survival is significantly longer in patients whose induction therapy is started 
before delivery, than in those treated after delivery. 
Methotrexate (a folate antagonist), a crucial component of most intensification protocols of 
ALL, is highly teratogenic and abortifacient when administered during the first trimester. 
Also the exposure to high dose methotrexate after the 1st trimester was associated with 
cranial dysostosis, delayed ossification, hypertelorism, wide nasal bridge, micrognatia, 
anomalies of external ears and cleft palate  (aminopterin syndrome)(Ebert et al., 1997). The 
risk of fetal malformations diminishes as pregnancy advances (Ebert et al., 1997). Thereafter, 
termination of pregnancy is recommended for patients prior to the 20th week of gestation 
followed by the standard intensification chemotherapeutic ALL protocol. After the 20th 
week a modified anti ALL regimen that does not include methotrexate, may be used until 
the 3rd trimester (Rizack et al., 2009). Cyclophosphamide, vinca alkaloids, L-asparaginase, 
anthracyclines, cytarabine and steroids have been used in these regimens (Ali et al., 2009). 
However, all modified ALL protocols must be considered as “ bridging treatment” until the 
3rd trimester. In the 3rd trimester treatment protocols as in non-pregnant women must be 
followed (Molkenboer et al., 2005). Close obstetric care and monitoring of the mother and 
fetus are essential to ensure the best possible outcome (Matsouka et al., 2008). Delivery after 
32 weeks is suggested, simultaneous to a non-cytopenic period. 
5.2 Chronic leukemia in pregnancy 
5.2.1 Chronic Myelogenous Leukemia (CML) 
The incidence of CML associated with pregnancy is estimated to be 1/75000 pregnancies 
(Celiloglu et al., 2000). The diagnostic approach is identical as in non-pregnant patients. The 
cytogenetic study reveals the Philadelphia chromosome and possibly additional 
chromosomal abnormalities of the clonal evolution. The disease is characterized by the 
presence of the bcr/abl fusion gene.  
The introduction of imatinib mesylate, a tyrosine kinase inhibitor, has revolutionized the 
treatment of this disease. Pre-clinical models have suggested that imatinib may be 
teratogenic and therefore the present recommendation for women treated with imatinib is to 
use contraception (Azim et al., 2010). It has been reported that the concentration of imatinib 
and its active metabolite were higher in the placenta than in the maternal blood, while they 
were low or undetected in the umbilical cord. These findings suggest limited placental 
transfer of imatinib in late pregnancy (Russell et al., 2007).  
It seems that administering imatinib during the first trimester is associated with a 
considerable risk of congenital anomalies and spontaneous abortions, while late exposure 
does not have the same impact. Nevertheless in patients diagnosed with CML during 
pregnancy, imatinib should not be the treatment of choice due to the limited experience 
(Shapira et al., 2008). Very limited data are available about the safety of second-generation 
oral tyrosine kinase inhibitors (dastinib, nilotinib) during pregnancy and it is recommended 
that patients on these drugs should avoid pregnancy (Conchon et al., 2010). 
Interferon-alpha (INFα), an immune modulator, does not cross the placenta to a great extent 
due to its high molecular weight (19kDa) and does not inhibit DNA synthesis. All reported 
cases of pregnant women with CML, treated with interferon, resulted in healthy babies and 
normal maternal outcomes. Given the available pre-clinical and clinical data, interferon can be 
safely administered throughout pregnancy and it is the treatment of choice for patients 
diagnosed with CML in pregnancy. Patients in the 2nd or 3rd trimester - who cannot tolerate 
or fail interferon therapy - may be treated with hydroxyurea or imatinib (Rizack et al., 2009). 
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Hydroxyurea is a cytotoxic drug, which inhibits DNA synthesis, and is capable of crossing 
the placenta. Several cases of hydroxyurea administration during pregnancy have been 
reported.  Hydroxyurea treatment should be avoid in 1st trimester and could be given to 
patients who cannot tolerate interferon therapy during the 2nd or 3rd trimesters (Thauvin-
Robinet et al., 2001). 
5.2.2 Chronic Lymphocytic Leukemia (CLL) 
CLL, a predominantly disease of the elderly, is very rarely associated with the reproductive 
period. Only five cases of CLL in pregnancy have been reported in literature (Chrisomalis 
and al., 1996; Baynes et al., 1996; Welsh and al., 2000; Gurman, 2002; Ali et al., 2004). In two 
of these cases placental infiltration has been described but with no impact on the fetus. 
Because CLL has an indolent clinical course, therapy of pregnant patients with CLL can 
usually be delayed until post partum. If intervention is required leukapheresis could be an 
option. Chlorambucil is contraindicated during the 1st trimester because of its teratogenicity 
and there are not enough data to recommend its use during late pregnancy.  Fludarabine 
must be avoided in pregnancy. Autoimmune complications should be managed with 
corticosteroids as in non-pregnant patients (Rizack et al., 2009). 
5.2.3 Hairy Cell Leukemia (HCL) 
HCL is a type of chronic leukemia of late age at presentation with male predominance. 
Therefore it is extremely rare during pregnancy. Six cases of pregnancy-associated HCL 
have been reported and all pregnancies came to term without complications, resulting in 
delivery of healthy neonates (Shapira et al., 2008). When therapy is indicated in HCL during 
pregnancy, interferon-alpha is the treatment of choice (Baer et al., 1992). 
5.2.4 Summary recommendations for the management of leukemia’s in pregnancy 
 
 1st  trimester 2nd trimester 3rd trimester 
AML pregnancy termination Cytarabine-doxorubicin cytarabine-doxorubicin 
APL pregnancy termination ATRA & anthracycline ATRA & anthracycline 
ALL pregnancy termination >20w modified protocols Standard protocols 
CML Interferon-alpha Interferon-alpha Interferon-alpha 
Table 2. Recommendations for the management of leukemia’s in pregnancy 
6. Hodgkin disease in pregnancy 
Hodgkin’s disease (HD) is a unique malignant disorder, usually arising in lymph nodes and 
defined by the presence of the pathognomonic Reed-Sternberggiant cell (Sadural and Smith, 
1995). HD is a neoplasia with a peak incidence between the ages of 20-30 and another peak 
incidence after the age of 55. The illness affects male patients more than female patients. 
Although it represents only 0.5% of all cancers, it is not rare to diagnose HD in pregnant 
women, due to the peak incidence among young people. In these cases the incidence varies 
between 1:1,000 and 1:6,000 deliveries (Anselmo et al., 1999). It is curable even in advanced 
stages and ABVD (doxorubicin, bleomycin, vinblastin and dacarbazine) is considered the 
standard of care chemotherapy regimen in this disease (Connors, 2005).  
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or fail interferon therapy - may be treated with hydroxyurea or imatinib (Rizack et al., 2009). 
 
Hematologic Malignancies in Pregnancy 381 
Hydroxyurea is a cytotoxic drug, which inhibits DNA synthesis, and is capable of crossing 
the placenta. Several cases of hydroxyurea administration during pregnancy have been 
reported.  Hydroxyurea treatment should be avoid in 1st trimester and could be given to 
patients who cannot tolerate interferon therapy during the 2nd or 3rd trimesters (Thauvin-
Robinet et al., 2001). 
5.2.2 Chronic Lymphocytic Leukemia (CLL) 
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of these cases placental infiltration has been described but with no impact on the fetus. 
Because CLL has an indolent clinical course, therapy of pregnant patients with CLL can 
usually be delayed until post partum. If intervention is required leukapheresis could be an 
option. Chlorambucil is contraindicated during the 1st trimester because of its teratogenicity 
and there are not enough data to recommend its use during late pregnancy.  Fludarabine 
must be avoided in pregnancy. Autoimmune complications should be managed with 
corticosteroids as in non-pregnant patients (Rizack et al., 2009). 
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defined by the presence of the pathognomonic Reed-Sternberggiant cell (Sadural and Smith, 
1995). HD is a neoplasia with a peak incidence between the ages of 20-30 and another peak 
incidence after the age of 55. The illness affects male patients more than female patients. 
Although it represents only 0.5% of all cancers, it is not rare to diagnose HD in pregnant 
women, due to the peak incidence among young people. In these cases the incidence varies 
between 1:1,000 and 1:6,000 deliveries (Anselmo et al., 1999). It is curable even in advanced 
stages and ABVD (doxorubicin, bleomycin, vinblastin and dacarbazine) is considered the 
standard of care chemotherapy regimen in this disease (Connors, 2005).  
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6.1 Chemotherapy and Hodgkin disease in pregnancy 
Based on the results of an extended literature review, we suggest that patients diagnosed 
with HD in pregnancy should be treated with the ABVD-regimen rather than with M-
/COPP-regimen. ABVD outside the first trimester seems feasible and safe. Patients with 
early stage HD diagnosed in the first trimester should be followed-up at short intervals for 
signs of disease progression without any treatment until the second trimester (Fisher et 
al.,1996; Pereg et al., 2007). Offering single agent vinblastine along with steroids is another 
option (Nisce et al., 1986), yet congenital anomalies and spontaneous abortions have been 
described with this approach. Patients diagnosed close to term could be good candidates for 
delivery anticipation to avoid any potential hazards to the fetus. 
If advanced HD is diagnosed during the rst trimester, termination of the pregnancy should 
be considered followed by appropriate staging and adequate doses of combination 
chemotherapy (Cannellos et al, 1992). 
Treatment should not be delayed during pregnancy if patient presents with symptomatic 
(i.e. B symptoms), Bulky, subdiaphragmatic, or progressive HD after the rst trimester.  
Relapsed HL during pregnancy can be treated with chemotherapy, if the patient has been 
previously treated only with radiotherapy (Cannellos et al., 1992). Data in these cases are 
very rare.  
6.2 Radiotherapy and Hodgkin Disease in pregnancy 
Patients with HD stage I and II are treated mainly with polychemotherapy followed by 
radiotherapy (RT) given only to the originally involved sites (involved-field radiotherapy). 
In these cases, the average fetal exposure should not exceed 0.1–0.2 Gy, which is the 
threshold dose at which deterministic effects (e.g. mental retardation, organ malformation) 
can be expected (Kal and Struikmans,2005). In stage III-IV disease, RT seems to be of no 
benefit if given routinely in patients who show a complete remission after chemotherapy: 
RT could benefit patients with partial responses after chemotherapy in these cases (Fenig et 
al., 2001; Kal and Struikmans,2005). 
6.3 Possible decision tree for treatment of Hodgkin Disease in pregnancy 
 
 
Fig. 1. Proposal of a possible algorithm for the treatment of pregnancy associated HD (Pereg, 
2007) 
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7. Non-Hodgkin disease in pregnancy 
Non-Hodgkin-lymphoma (NHL) forms a heterogeneous group of hematologic 
malignancies. According to the WHO-classification, we can divide them in three groups: 
indolent, aggressive and very aggressive. This disease is extremely rare in pregnancy, but 
the occurrence of NHL during pregnancy is expected to increase due not only to the 
currenttrend to postpone pregnancy, but the increasing incidence of HIV-associated 
lymphoma in developing countries (Pereg et al., 2007). NHL has an age dependent 
incidence pattern with a sharp increase in frequency starting in middle life (in contrast to 
HD). These differences in age distributions together with the higher incidence of NHL in 
young males compared to women, probably explains the scarcity of reports of NHL 
associated with pregnancy (Lishner et al., 1994). However, NHL in pregnancy is most 
commonly associated with more aggressive histology and disseminated disease. 
(Mavrommatis et al., 1998). Management of NHL varies signicantly depending on the 
pathological subtype. 
7.1 Indolent Non-Hodgkin Lymphoma 
Indolent lymphomas are diseases of the elderly and have been rarely described during 
pregnancy. The exact incidence remains unknown as a signicant proportion of the 
available reports lack a detailed pathological description. A large fraction of these tumors 
have an indolent course and thus could be safely watched during the course of pregnancy. 
In patients requiring active therapy, they could be offered regimens that have been shown to 
be safe in aggressive lymphomas (Nisce et al., 1986; Pereg et al., 2007). 
7.2 Aggressive Non-Hodgkin Lymphoma 
Treatment during the rst trimester is complex and patients with aggressive disease should 
be counselled regarding therapeutic abortion, taking into consideration the fetal risk of 
staging and chemotherapy (Koren et al., 1990). Close observation or radiation therapy 
(Spitzer et al., 1991) during the rst trimester could be considered in those patients 
presenting with early stage disease, low-volume disease, no B symptoms, and low 
international prognostic index (IPI) score. Patients with bulky disease or poorer prognostic 
indicators, such as high IPI score, B symptoms, or high Ki-67 in their biopsies should be 
treated immediately after pregnancy termination. Beyond the rst trimester, standard 
chemotherapy should be instituted due to the poor prognosis of aggressive NHL without 
therapy. 
Evidence regarding the fetal safety of CHOP during the first trimester is extremely limited. 
CHOP is considered to be safe in second and third trimester, however only seven case 
reports have been published. No reviewed data is available about the safety of M-/VACOP-
exposition during pregnancy. 
Literature suggests that anti-metabolites (such as 6-MP) in first trimester should be avoided 
(as mentioned by several previous review-rapports, although large data is lacking). 
Rituximab seems safe and without significant consequences for the foetus (Decker et 
al.,2006; Friedrichs et al., 2006; Rey et al., 2008). 
Overall it seems that offering standard regimens like CHOP or CHOP-like regimens (e.g. R-
CHOP) is safe and feasible, certainly in 2nd and 3rd trimester.  
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Literature suggests that anti-metabolites (such as 6-MP) in first trimester should be avoided 
(as mentioned by several previous review-rapports, although large data is lacking). 
Rituximab seems safe and without significant consequences for the foetus (Decker et 
al.,2006; Friedrichs et al., 2006; Rey et al., 2008). 
Overall it seems that offering standard regimens like CHOP or CHOP-like regimens (e.g. R-
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Fig. 2. Shows a possible algorithm for the treatment of first-trimester-associated NHL. 
Systemic therapy outside the first trimester (R-CHOP) seems to be safe for all forms of NHL 
(Pereg, 2007). 
8. Summary and conclusion 
Hematological malignancies are uncommon during pregnancy. Nevertheless, it includes a 
very complex medical, but also ethical and psychological problem. Delay in diagnosis and 
treatment will influence the prognosis for acute leukemia and aggressive/advanced 
lymphomas. Delay in treatment and even diagnostic delay may influence the prognosis for 
chronic leukemia and indolent non-Hodgkin lymphomas. In selected cases with limited 
disease of early stage Hodgkin’s disease, treatment may be safely postponed until after 
delivery.The decision to use chemotherapy during pregnancy must be carefully weighed 
against the effect of treatment delay on maternal survival. If possible, chemotherapy should be 
avoided during the first trimester or abortion should be taken in consideration. If the mother 
decides to continue the pregnancy and multidrug treatment in first trimester is required, 
anthracycline antibiotics, vinca alkaloids or single-agent treatment followed by multi-agent 
therapy after first trimester should be considered. Use of chemotherapy in the second and 
third trimesters seems to be relatively safe. Radiotherapy during pregnancy is possible, if the 
fetal exposure does not exceed the threshold dose of 10cGy. Seen the complexity of the 
decisions in treatment of pregnancy-associated cancer, this  should be approached 
interdisciplinary and should be individually for each patient. Every decision should be made 
together with the patient, after careful balancing of both the risks and benefits.  
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1. Introduction 
During the treatment for acute leukemia (AL) a patient may experience a wide variety of 
complications that mainly have three possible origins, namely the disease itself (leukemic 
infiltration), peripheral blood cell depression (because of hemorrhagic or infectious 
processes) and toxicity induced by chemotherapy. 
The toxicity of chemotherapy is a common cause of morbidity and mortality in cancer 
patients, as well as a frequent source of sequelae at mid-long term. These adverse effects are 
often the consequence of direct toxicity in healthy tissue, as a result of the low specificity 
displayed by these drugs. Furthermore, and regardless of their specificity, these compounds 
may also exacerbate complications derived from the tumor growth, as it is the case of 
pancytopenia or the Tumor Lysis Syndrome. Chemotherapy toxicity becomes more frequent 
as the treatment is intensified, thus challenging the clinician with both diagnostic and 
therapeutic problems. In this chapter we will discuss the major clinical signs of toxicity 
produced by chemotherapy drugs in patients with AL. Hematological and gastrointestinal 
(mucositis, nausea and vomiting) adverse effects will not be included, as their description 
suits better in an Initial Management chapter. In the last section of this chapter we will 
discuss recent data on whether pharmacogenetics may help individualize the therapy for 
AL, thus avoiding serious toxicity. 
2. Cardiotoxicity 
Cardiovascular abnormalities in patients with AL usually result from derangements in 
metabolic, electrolyte, and pulmonary function. Because leukemic infiltration of the heart is 
rare, the majority of cardiovascular problems in AL patients are chemotherapy-related 
toxicities produce by anthracyclines (Pihan, 2009). 
Anthracycline chemotherapy is associated with acute effects (occurring during and shortly 
after administration), e.g. electrocardiographic alterations including prolongation of QT 
interval, development of ventricular late potentials and various arrhythmias (Bagnes et al., 
2010); subacute effects (noted within days or weeks of administration) consisting of toxic 
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myocarditis or pericartitis and chronic effects, which occur weeks or months after 
administration and manifest as cardiomyopathy. Cardiomyopathy is a multifactorial 
process related to oxidative stress and myocyte induction of apoptosis. Our inability to 
predict and prevent anthracycline cardiotoxicity is, in part, due to the fact that the molecular 
and cellular mechanisms remain controversial and incompletely understood (Sawyer et al., 
2010). 
At a cumulative dose of 550 mg/m2 doxorubicin more than a quarter of patients develop 
congestive heart failure (CHF). This complication can take place at lower doses in 
susceptible individuals such as elderly, children, subjects with prior cardiac disease, and 
those who have had previous mediastinal irradiation (Ng et al., 2006). In the pediatric 
population , cardiomyopaty can occur at cumulative doses of 300 mg/m2 (given as 
daunorubicin equivalent) (Creutzig et al., 2007). In addition, the long-term effects of cardiac 
damage are more apparent in children. In a study of long term survivors of childhood 
cancers, cardiac mortality was shown to be the second most likely cause of death following 
malignancy (Creutzig et al., 2007). 
There are different techniques utilized to monitor for cardiotoxicity: 
1. Endomyocardial Biopsy (EB), which was traditionally viewed as the gold standard test, 
is actually an impractical means of monitoring due to the invasive nature of test. 
2. Evaluation of left ventricular ejection fraction (LVEF) with two-dimensional 
echocardiography (2D-ECHO) or radionuclide ventriculography remains the most 
pragmatic monitoring technique. Calculation of the LVEF by 2D-ECHO is slightly more 
difficult; however, the fact that radiation is not used makes it more suitable for the 
pediatric population. 
3. Other techniques have also been tested: Antimyosin antibody scintigraphy is a marker 
of cardiac damage, but its high sensitivity may produce positive results at very low 
cumulative doses of anthraciclines, thus limiting its clinical utility (Valdes Olmos et al., 
2002). Cardiac troponins and natriuretic peptides, the most commonly used biomarkers 
of myocardial destruction and ventricular dysfunction respectively, have also been 
studied for this purpose (Germanakis et al., 2008). 
Pretherapy baseline evaluation of LVEF is recommended for all patients with AL before 
starting induction therapy. However, unless the patient is known or suspected to have a 
cardiac disease, the treatment does not need to be delayed pending the results of LVEF 
(Pihan, 2009). Dose exposure should be reduced in patients with a baseline LVEF of less 
than 50% or in those with a 10% LVEF decline from baseline to final values below 50% 
(Schwartz et al., 1987). 
Different anthracyclines have different patterns of toxicity (Table 1). However, changing to a 
different anthracyclin does not substantially modify the risk for cardiotoxicity. In an attempt 
to reduce this adverse effect, liposomal doxorubicin has been developed. Most studies with 
liposomal doxorubicin have been performed in women with metastatic breast cancer. In this 
population, liposomal doxorubicin has shown equivalent efficacy to doxorubicin with a 
reduced rate of cardiotoxicity (Batist et al., 2001). 
Several meta-analysis have studied the influence of different anthracyclines or different 
dosage schedules on the risk of cardiotoxicity in adult patients with cancer. These studies 
support the administration of a 6-hour (or longer) infusion (van Dalen et al., 2009), and the 
use of liposomal-doxorubicin over doxorubicin (van Dalen et al., 2010). It is of note that both 
studies agree in that there is insufficient evidence to implement such measures in children 
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or in patients with leukemia. In this regard, a meta-analysis with data retrieved from trials 
in children with ALL that randomized anthracyclines or measures to reduce cardiotoxicity, 
found no significant differences regarding type of anthracycline, method of administration 
or use of cardioprotectants (Childhood ALL Collaborative Group, 2009). 
Because one of the proposed mechanisms of anthracyclins cardiotoxicity involves the 
generation of free iron radicals, dexazoxane, by its iron chelating effect, confers a significant 
reduction in the risk of cardiotoxicity. A meta-analysis by Van Dalen et al concluded that if 
the risk of cardiac damage is expected to be high, it might be justified the use of 
dexrazoxane in patients with cancer treated with anthracyclines (van Dalen et al., 2008). In 
children with AL, the use of dexrazoxane seems safe and provides long-term 
cardioprotection without compromising oncological efficacy. Currently, in the absence of 
more data, the use of dexrazoxane might be justified in children if the risk of cardiac 
damage is expected to be high (Lipshultz et al., 2010). 
2.1 Treatment of cardiomyopathy 
The natural history of Anthracyclines cardiomyopathy, as well as its response to modern 
CHF therapy, remains poorly defined. Hence, evidence-based recommendations for the 
management of this form of cardiomyopathy are still lacking. Progress in treatment of 
cardiac failure, in particular the availability of drugs as angiotensin converting enzyme 
(ACE) inhibitors, spironolactone and beta-blokers and the current practice of monitoring 
cardiotoxicity, may explain the improved prognosis of this complication that , in early 
retrospective studies ,  had a mortality rate of more than 40%. The prophylactic use of 
enalapril resulted in the reduction of cardiac function deterioration. A recent study has 
shown that when this therapy is initiated soon after detection of LVEF impairment, there are 
more patients who present LVEF recovery and cardiac event reduction (Cardinale et al., 
2010). These results show the importance of monitoring cardiotoxicity in all patients treated 
with anthracyclines in order to (i) identify early heart damage and (ii) begin treatment 
before the onset of CHF.  
Among the newest compounds, symptomatic or asymptomatic QT aberrations have been 
reported with tyrosine-kinase inhibitors (Bagnes et al., 2010) and arsenic trioxide (Ohnishi et 
al., 2000). 
 
Adverse effect CTX MTX ADR DNR EPI IDA NOV AMS 
         
Cardiomyopathy   +++ +++ ++ ++ ++ + 
Myo/pericarditis ++  + ++ +    
ECG changes ++ + ++ ++    + 
 
CTX, cyclophosphamide; MTX, methotrexate; ADR, doxorubicin; DNR, daunorubicin; EPI, epirubicin;  IDA, 
idarubicin; NOV, mitoxantrone; AMS, amsacrine. 
 +, rare or little clinical significance; ++, occasional or clinically relevant; +++, common or severe. 
Table 1. Main cardiac toxicity for chemotherapy drugs used in acute leukemia 
3. Hepatotoxicity 
Hepatotoxicity is defined as an injury to the liver that is associated with impaired liver 
function caused by exposure to a drug. The clinical patterns of liver injury are defined as 
hepatocellular, with a predominant initial elevation of the alanine aminotransferase level 
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Pretherapy baseline evaluation of LVEF is recommended for all patients with AL before 
starting induction therapy. However, unless the patient is known or suspected to have a 
cardiac disease, the treatment does not need to be delayed pending the results of LVEF 
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use of liposomal-doxorubicin over doxorubicin (van Dalen et al., 2010). It is of note that both 
studies agree in that there is insufficient evidence to implement such measures in children 
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or in patients with leukemia. In this regard, a meta-analysis with data retrieved from trials 
in children with ALL that randomized anthracyclines or measures to reduce cardiotoxicity, 
found no significant differences regarding type of anthracycline, method of administration 
or use of cardioprotectants (Childhood ALL Collaborative Group, 2009). 
Because one of the proposed mechanisms of anthracyclins cardiotoxicity involves the 
generation of free iron radicals, dexazoxane, by its iron chelating effect, confers a significant 
reduction in the risk of cardiotoxicity. A meta-analysis by Van Dalen et al concluded that if 
the risk of cardiac damage is expected to be high, it might be justified the use of 
dexrazoxane in patients with cancer treated with anthracyclines (van Dalen et al., 2008). In 
children with AL, the use of dexrazoxane seems safe and provides long-term 
cardioprotection without compromising oncological efficacy. Currently, in the absence of 
more data, the use of dexrazoxane might be justified in children if the risk of cardiac 
damage is expected to be high (Lipshultz et al., 2010). 
2.1 Treatment of cardiomyopathy 
The natural history of Anthracyclines cardiomyopathy, as well as its response to modern 
CHF therapy, remains poorly defined. Hence, evidence-based recommendations for the 
management of this form of cardiomyopathy are still lacking. Progress in treatment of 
cardiac failure, in particular the availability of drugs as angiotensin converting enzyme 
(ACE) inhibitors, spironolactone and beta-blokers and the current practice of monitoring 
cardiotoxicity, may explain the improved prognosis of this complication that , in early 
retrospective studies ,  had a mortality rate of more than 40%. The prophylactic use of 
enalapril resulted in the reduction of cardiac function deterioration. A recent study has 
shown that when this therapy is initiated soon after detection of LVEF impairment, there are 
more patients who present LVEF recovery and cardiac event reduction (Cardinale et al., 
2010). These results show the importance of monitoring cardiotoxicity in all patients treated 
with anthracyclines in order to (i) identify early heart damage and (ii) begin treatment 
before the onset of CHF.  
Among the newest compounds, symptomatic or asymptomatic QT aberrations have been 
reported with tyrosine-kinase inhibitors (Bagnes et al., 2010) and arsenic trioxide (Ohnishi et 
al., 2000). 
 
Adverse effect CTX MTX ADR DNR EPI IDA NOV AMS 
         
Cardiomyopathy   +++ +++ ++ ++ ++ + 
Myo/pericarditis ++  + ++ +    
ECG changes ++ + ++ ++    + 
 
CTX, cyclophosphamide; MTX, methotrexate; ADR, doxorubicin; DNR, daunorubicin; EPI, epirubicin;  IDA, 
idarubicin; NOV, mitoxantrone; AMS, amsacrine. 
 +, rare or little clinical significance; ++, occasional or clinically relevant; +++, common or severe. 
Table 1. Main cardiac toxicity for chemotherapy drugs used in acute leukemia 
3. Hepatotoxicity 
Hepatotoxicity is defined as an injury to the liver that is associated with impaired liver 
function caused by exposure to a drug. The clinical patterns of liver injury are defined as 
hepatocellular, with a predominant initial elevation of the alanine aminotransferase level 
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(ALT), cholestatic, in which the serum alkaline phosphatase concentrations are increased, or 
mixed, if both enzymes are elevated. An ALT level of more than three times the upper limit 
of normal values and a total bilirubin concentration of more than twice the upper limit are 
used to define clinically significant abnormalities on liver test. Elevation in serum enzyme 
levels is taken as indicator of liver injury, whereas increases in bilirrubin levels, albumin 
concentration and the prothrombin time are measures of overall liver function (Navarro & 
Senior, 2006). 
Chemotherapy-induced hepatotoxicity is a common cause of abnormal liver function test in 
patients with AL. It mainly occurs in an idiosyncratic manner and is generally reversible 
and nonfatal. This toxicity is manifested in a variety of patterns. In addition to those 
mentioned above, we find steatosis, ductal injury fibrosis, cirrhosis, veno-occlusion, peliosis 
hepatis, and nodular regenerative hyperplasia. The two latter lesions appear as 
pseudometastatic hepatic nodules that may indicate disease progression, especially if they 
are multiple (Brisse et al., 2000). 
Hepatotoxicity usually begins with vague clinical symptoms such as fatigue, anorexia, 
nausea, dark urine, right upper quadrant discomfort and jaundice. Suspected drug exposure 
must precede the symptoms and liver injury may improve when administration is stopped. 
However, the latent period is highly variable and enzyme levels may take weeks to increase. 
Before attributing these symptoms to a chemotherapy drug, other causes of liver injury must 
be ruled out (Navarro & Senior, 2006). Abnormal liver function may be due to multiple 
causes in patients with AL. Leukemic infiltration usually causes mild to moderate 
hepatomegaly with limited impact on serum transaminase levels. Transfusions increase the 
likelihood of viral hepatitis. Other circumstances such as sepsis, hypotension or 
malnutrition may contribute to liver damage (Pihan, 2009). 
AL patients are treated with combination chemotherapy, making it difficult to identify the 
precise agent involved in the hepatic injury. Moreover, diagnosis becomes more challenging 
by the large number of non-chemotherapeutic drugs commonly used in those patients, some 
of them holding the potential of being hepatoxic, e.g. allopurinol, ondansetron and different 
antifungal agents (Perry, 1992). 
Pre-existing liver disease can alter the metabolism and excretion of chemotherapy causing 
increased and persistent drug levels and hence systemic toxicity. On the other hand, 
chemotherapy may worsen liver disease, such as occurs with hepatitis. Severe liver 
dysfunction and fatal fulminant hepatitis through virus reactivation have been described in 
patients with viral hepatitis. Prophylactic therapy with nucleoside analogues, typically 
lamivudine, has been recommended for HBs Ag positive patients. This strategy has been 
reported to allow optimal administration of chemotherapy (Parrish et al., 2010). 
3.1 Dose modification of chemotherapy with altered hepatic function 
All patients with AL must undergo evaluation of baseline values before starting 
chemotherapy. This includes liver function test, viral hepatitis serology and, if clinically 
indicated, hepatic imaging. Liver function test should be reassessed before each course of 
therapy and known hepatotoxins should be avoided (Perry, 1992). Patients more susceptible 
to hepatotoxicity such as those with malnutrition or alcoholism, elderly, obese, or diabetic, 
should be followed up more closely. Liver response may also be abnormal in cases of 
previous liver disease or coexisting illnesses (Floyd et al., 2006). In cases of elevated liver test 
(ELT), drugs undergoing hepatic metabolism should be avoided if possible and/or dose 
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modifications should be considered if guidelines are available. In rare instances in which 
ELT is caused by leukemic infiltration it is not necessary to adjust dosing (Figure 1). 
 
 
Fig. 1. Liver biopsy of a child with relapsed ALL. Lymphoblasts (C43+) infiltrate the hepatic 
sinusoids. Despite of abnormal liver test, chemotherapy was administered without 
complications. 
3.2 Hepatotoxicity of major chemotherapy agents used in acute leukemia 
3.2.1 6-Mercaptopurine and 6-Thioguanine 
6-Mercaptopurine (6-MP) in orally daily regimen associated with weekly MTX is the 
backbone of maintenance chemotherapy acute lymphoblastic leukemia (ALL). 
Hepatotoxicity produced by this drug include both cholestatic and hepatocellular disease. 
Characteristic diagnostic profiles include prominently elevated serum bilirubin, typically 
between 3 and 7 mg/dL, accompanied by mild to moderate elevations in aminotransferases 
and alkaline phosphatase (Floyd et al., 2006). Liver function tests are transiently abnormal in 
the majority of children during maintenance of ALL, in the absence of other evidence of 
severe liver toxicity or viral hepatitis, it is generally not necessary to withhold or reduce the 
dose of continuation chemotherapy (Pui & Evans, 2006). When liver biopsies are performed 
in this population, inflammatory and fatty changes are common and not related with ALT 
levels. Early portal fibrosis is found only in patients with prolonged therapy. The risk of 
portal fibrosis is low after 2-3 years of continuing chemotherapy and most patients go back 
to normal ALT values with drug cessation. The mechanism underlying 6-MP-induced 
hepatotoxicity is related to its methylated metabolites and correlates with ALT levels. 
Indeed, ALT levels have been proposed as a surrogate marker for treatment compliance 
(Nygaard et al., 2004). A study by Schmiegelow et al. has shown that ALL pediatric patients 
with mean ALT levels above the upper normal limit (40 IU/l) who were kept on therapy 
had a significantly lower risk of hematological relapse compared to other children 
(Schmiegelow, 1991). These data support the concept of treating to toxicity for maintenance 
therapy. 
6-Thioguanine as maintenance treatment in childhood ALL has also been shown to cause 
hepatic veno-occlusive disease (VOD) usually mild and reversible on withdrawing 6-TG or 
replacing it with 6-MP (Stoneham et al., 2003). 
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MTX inhibits dihydrofolate reductase resulting in depletion of critical reduced folates. The 
net result is effective inhibition of DNA and RNA synthesis and potent cytotoxicity to 
rapidly dividing cells. MTX causes hepatotoxicity, fibrosis and cirrhosis, but usually after 
prolonged use and/or when it is used in the treatment of autoimmune diseases. 
In a high percentage of patients with ALL, MTX causes isolated elevations of ALT during 
maintenance chemotherapy, usually transient and asymptomatic. This ALT elevations are 
not predictive of subsequent hepatic disease and do not require treatment modification 
(Farrow et al., 1997). 
As in the maintenance treatment, when MTX is used in high IV doses (HD-IV MTX), the 
characteristic hepatotoxic pattern is transient, ALT levels are related to the dose of MTX and 
increase with the number of cycles received. A difference with the maintenance treatment is 
that in cases of altered hepatic function it is necessary to modify or suspend the 
administration of HD-IV MTX (Table 2). In any case, despite the usual benign character of 
MTX-induced hepatotoxicity, there are reports of hepatoma in association with hepatic 
fibrosis occurring in children following ALL treatment (Fried et al., 1987). 
3.2.3 Cytarabine 
Cytarabine (ara-C) have revealed a cumulative dose-dependent hepatotoxicity. Several case 
reports have demonstrated direct histologic evidence of a hepatotoxic role for ara-C, 
expressed as increased ALT levels or as intrahepatic cholestasis. Although the actual 
incidence of this toxicity remains to be elucidated, mild elevations of liver function in a 
cholestatic pattern represent the reversible, rarely fatal clinical picture (George et al., 1984). 
Ara-C is reported to be partially detoxified in the liver. Therefore, it is recommended that its 
dose be reduced in patients with liver impairment (Table 2). 
3.2.4 L-Asparaginase 
In addition to hypersensitivity reactions, the most common toxic effects of L-asparaginase 
are related to the depletion of proteins synthesized in the liver, such as clotting factor, 
insulin , albumin, haptoglobin and transferrin. Liver function abnormalities (including 
hyperbilirubinemia and elevated transaminase levels) and hyperlipidemia 
(hypertriglyceridemia and hypercholesterolemia) have been frequently reported in patients 
receiving the drug (Earl, 2009). As a result of these metabolic abnormalities, up to 7% of 
children with AL develop pancreatitis (Treepongkaruna et al., 2009). Another common 
metabolic complication of this drug is hyperglycemia, which occurs in up to 10% of children 
with AL during their induction therapy (Pui et al., 1981) and is associated with the 
synergistic effect of L-asparaginase and glucocorticoids (Spinola-Castro et al., 2009). It 
should be noted that the use of pegylated asparaginase does not prevent these complications 
(Silverman et al.). 
3.2.5 Other drugs 
In spite of requiring metabolic activation in the liver, cyclophosphamide, antitumor antibiotics 
and vinca alkaloids are uncommon hepatic toxins. Indeed, reports of severe hepatotoxicity 
attributed to these drugs are scarce (Floyd et al., 2006). However, dose modifications are 
necessary to prevent systemic toxicity in case of liver impairment (Table 2). 
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Agent Bilirubin (mg/dl) Aminotransferases % Dose administered 
Alkylating agents
Cyclophosphamide 3.1-5 >3 x ULN 75
>5 0
Antimetabolites
Cytarabine Any 50%; increase by 
monitoring toxicity 
6-mercaptopurine No dose reduction 
is necessary 




Doxorubicin 2-3 x ULN 75






Epirubicin 1.2-3 2-4 x ULN 75
>3 >4 xULN 50
Idarubicin 1.5-3.0 AST 2-3 x ULN 75






1.5-3.0 2-3 x ULN 50
>3.1 >3  x ULN 0
Etoposide 1.5-3.0 AST>3 x ULN 50
>3 AST>3 x ULN 0
Teniposide Evaluate if necessary 
Miscellaneous 
L-asparaginase No dose reduction 
is necessary 
*Vincristine and vinblastine: 50% reduction if alkaline phosphatase is elevated. ULN, Upper limit of normal. 
Table 2. Dosage of main chemotherapeutic agents used in AL according to liver function 
4. Peripheral neuropathy 
The most prevalent neurologic complication of cancer treatment is chemotherapy-induced 
peripheral neuropathy (CIPN). Vincristine is the main etiological agent involved in 
peripheral neuropathy in leukemia patients (Kannarkat et al., 2007). Virtually all ALL 
patients receiving vincristine have some degree of neuropathy. Neurotoxicity commonly 
pesents as peripheral neuropathy, which is predominantly sensory in nature. The clinical 
manifestations are subjective and predominantly manifest as distal and symmetrically 
distributed pure sensory symptoms such as paresthesias, hyperesthesias, hypoesthesias, and 
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dysesthesias. The most common and earliest symptoms are numbness and tingling in the 
fingertips and feet as well as constipation due to autonomic neuropathy. Symptoms of 
motor weakness are observed in patients with more persistent and severe sensory findings. 
Isolated motor weakness with the complete absence of sensory involvement has not been 
reported. If such findings were observed, consideration should be given to other conditions 
such as steroid myopathy  or diabetic neuropathy (Hausheer et al., 2006). 
Sensory findings, as diminished or absent proprioception and vibration are typically 
diminished in the stocking-glove distribution in symptomatic patients. Loss of ankle stretch 
reflexes is an early and almost universal sign, and with continued therapy all reflexes may 
diminish or disappear. The toxicity of vincristine is believed to occur through disruption of 
microtubule polymerization. Neurophysiologic studies are compatible with a primarily 
axonal neuropathy. Symptoms develop gradually and may manifest after the first dose. As 
the disease progresses, muscle weakness becomes apparent, patients lose the ability to walk 
on their heels and lose strength in wrist extensors. Motor weakness from vincristine can 
become severe enough to render the patient immobile. In addition, some patients may 
develop impotence, postural hypotension, or an atonic bladder (Quasthoff & Hartung, 
2002). When symptoms are severe, a hereditary motor and sensory neuropathy should be 
suspected (Mercuri et al., 1999). 
Because there is no effective treatment, prevention is the only useful measure for 
neurotoxicity. All patients should take prophylactic stool softeners and/or laxatives. Dose 
level and cumulative dose are the most significant risk factors. The maximum dose of 2 mg, 
and cumulative doses over 15-20 mg should not be exceeded due to the considerable 
increase in the incidence and severity of symptoms. When symptoms of neuropathy disturb 
the patient a common practice is to administer vinblastine instead and even to discontinue 
therapy if marked weakness appears. Recovery generally occurs 1 to 3 months after 
treatment cessation, withholding the drug or reducing its dose, but CIPN symptoms may 
also persist or worsen following vincristine discontinuation (Verstappen et al., 2005). 
5. Central neurotoxicity 
Chemotherapy-induced central neurotoxicity can result in multiple clinical manifestations: 
impaired consciousness, focal deficits, seizures, headaches, etc. However, before attributing 
these symptoms to chemotherapy in AL patients, other causes must be ruled out first (Table 
3). Furthermore, it is necessary to consider other factors such as drug-drug interactions. For 
instance, MTX intracellular levels may be elevated in the presence of vincristine. In addition, 
circumstances such as cranial irradiation or CNS affectation by leukemia may cause direct 
damage to the blood–brain barrier, thereby increasing MTX permeability and subsequent 
toxicity (Naing et al., 2005). 
 
Metabolic disturbances (e.g. hyponatremia) 
Intracerebral hemorrhage 






Table 3. Main causes of CNS disease in patients with AL 
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5.1 Cerebrovascular accidents 
In patients with AL, ischemic or hemorrhagic cerebrovascular accidents may be either a 
consequence of the disease or a complication of chemotherapy. Intracranial hemorrhage 
(ICH), which is the second leading cause of mortality in patients with acute myeloid 
leukemia (AML) (accounting for up to 70% in some series), occurs mostly during induction 
therapy. Brainstem, epidural and subarachnoid hemorrhage are particularly dangerous 
(Chen et al., 2009). In a risk score model for fatal intracranial hemorrhage, female gender, 
thrombocytopenia, prolonged prothrombin time, hyperleukocytosis (particularly in 
presence of symptoms of pulmonary leukostasis), and acute promyelocytic leukemia (APL), 
were significantly associated with the occurrence of this complication (Kim et al., 2006). 
Thrombotic events, particularly sino-venous thrombosis, are more frequent in ALL. Therapy 
with L-asparaginase is considered the major risk factor for this complication in these 
patients. Thrombosis develops after the administration of the first doses of the drug in 
induction therapy. The most common symptoms are headaches and seizures which resolve 
without sequelae in most cases (Kieslich et al., 2003). In a previous study with 238 patients 
treated with L-asparaginase, 4.2% of patients showed cerebral thrombosis and 2.1% cerebral 
haemorrhages (Nicholson et al., 1996). In this regard, it has been shown that increased 
triglycerides and decreases of antithrombin III, fibrinogen, protein S, protein C, 
plasminogen and alpha-2-antiplasmin are associated with the dose of L-asparaginase 
(Hongo et al., 2002; Nowak-Göttl et al., 1994). Other factors such as central venous catheters, 
obesity, use of steroids and thrombophilia may contribute to thrombotic imbalance in these 
patients.  
5.2 Aseptic meningitis 
Aseptic meningitis or chemical arachnoiditis is the most common neurotoxicity induced by 
MTX. It affects approximately 10% of patients receiving intrathecal (IT) therapy. The onset is 
generally abrupt and occurs within hours of IT administration. The patient has headache, 
meningismus, nausea, vomiting, fever, and altered consciousness. Cerebrospinal fluid (CSF) 
studies demonstrate pleocytosis and elevated protein. The symptoms are self-limited and 
usually resolve within 72 hours. Further treatment with IT MTX is not contraindicated and 
patients may receive subsequent doses of chemotherapy without incident. Co-
administration of MTX and IT hydrocortisone or premedication with oral corticosteroids 
may be useful to prevent the syndrome (Sul & Deangelis, 2006). The use of IT ara-C can also 
result in aseptic meningitis similar to that seen with IT MTX. The incidence has been 
observed to be higher with the liposomal formulation (DepoCyt®), which maintains 
cytotoxic concentrations of the drug in the CSF for up to 14 days. Side effects become so 
frequent that all patients require prophylactic corticosteroids pre and post DepoCyt® 
administration (Glantz et al., 1999). 
5.3 Transverse myelopathy 
Transverse myelopathy is an uncommon complication of IT MTX manifested by the 
development of back or leg pain followed by paraplegia, sensory loss, and sphincter 
dysfunction in the absence of a compressive lesion. The onset is usually between 30 minutes 
and 48 hours after treatment, although the reaction may also appear up to two weeks later. 
MRI may illustrate cord edema and irregular post-gadolinium enhancement. In contrast to 
myelopathies caused by other reasons, corticosteroids are not helpful. This is thought to be 
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dysesthesias. The most common and earliest symptoms are numbness and tingling in the 
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Metabolic disturbances (e.g. hyponatremia) 
Intracerebral hemorrhage 






Table 3. Main causes of CNS disease in patients with AL 
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patients may receive subsequent doses of chemotherapy without incident. Co-
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result in aseptic meningitis similar to that seen with IT MTX. The incidence has been 
observed to be higher with the liposomal formulation (DepoCyt®), which maintains 
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myelopathies caused by other reasons, corticosteroids are not helpful. This is thought to be 
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an idiosyncratic drug reaction, and therefore the identification of potentially susceptible 
patients is not possible. Unlike aseptic meningitis, transverse myelopathy is an absolute 
contraindication to further treatment with IT MTX. In addition to IT MTX, a similar 
transverse myelopathy was reported in two pediatric AML patients receiving IT and IV ara-
C (Sul & Deangelis, 2006). 
5.4 Acute encephalopathy 
High doses of Cytarabine (HD-ara-C) (≥3 g/m2 every 12 hours) may result in CNS 
dysfunction, especially impaired cerebellar function. The characteristic syndrome begins 
with somnolence and occasionally encephalopathy that develops two to five days after 
treatment. Immediately thereafter, cerebellar signs are noted on physical examination. 
Symptoms range in severity from mild ataxia to inability to sit or walk unassisted. Rarely, 
seizures may also develop. There may be MRI changes in the white matter and cerebellum, 
but the CSF is usually normal. Discontinuation of therapy generally results in partial 
recovery within several weeks, but complete resolution is achieved by only 30% of patients. 
Neurologic deficits can be permanent if treatment is continued after the onset of symptoms 
(Friedman & Shetty, 2001). 
Since the occurrence of severe cerebellar dysfunction is greatly affected by age, patients 
older than 50 years should be given a reduced schedule of HD-ara-C. Furthermore, it has 
been shown that avoidance of very high doses of the drug in patients with renal impairment 
and the administration of HD-ara-C on a once-daily rather than twice-daily schedule reduce 
the incidence of this syndrome (Smith et al., 1997). 
5.5 Subacute encephalopathy 
Subacute encephalopathy is an uncommon complication of MTX therapy that generally 
develops within 5–14 days after the administration of IT or HD-MTX, not being observed in 
maintenance therapy when low doses of oral or parenteral MTX are used. The syndrome is 
manifest by abrupt onset of focal neurological deficits, such as aphasia or hemiparesis and 
presents after a median of three courses of IV or IT MTX. Typical symptoms are headache and 
nausea followed by stroke-like hemiparesis or bilateral weakness. Hemiparesis may be 
alternating and evolving over a period of minutes to hours. In addition, aphasia or expressive 
dysphasia, emotional lability and disorientation are also common signs. Other manifestations 
such as seizure, transient ataxia, choreoathetoid movements, temporary blindness or visual 
hallucinations are less frequent. Most neurological symptoms resolve after 1-7 days and the 
majority of patients can resume HD-MTX therapy without permanent neurological sequelae. 
Recurrence may be experienced by 10-56% patients (Inaba et al., 2008).  
In the absence of histopathological data, diagnosis is based upon spinal fluid analysis and 
neuroimaging techniques. CFS analysis is usually normal and electroencephalogram (EEG) 
shows nonspecific diffuse or focal slowing. At the onset of MTX-induced encephalopathy, 
conventional CT scans, T1 or T2 weighted MR imaging and angiography typically show no 
abnormalities, whereas diffusion-weighted imaging (DWI) is able to show restricted 
diffusion of water in the brain that clears after resolution of the clinical symptoms. This 
abnormalities are consistent with cytotoxic or intramyelinic sheath edema within white 
matter tracts (Haykin et al., 2006). Follow-up MR imaging shows variable abnormal T2 and 
FLAIR signal intensity in the deep white matter, with no detectable neurological sequelae in 
most patients (Haykin et al., 2006) (Figure 2). The pathogenesis of MTX neurotoxicity is 
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poorly understood and no specific risk factors for the development of this complication have 
been identified to date. Indeed, pharmacokinetic data are normal in most patients with 
MTX-induced neurotoxicity (Rubnitz et al., 1998). In this regard, there are recent data 
indicating that pharmacogenetics could play a significant role in the development of this 
complication (Mahadeo et al., 2010; Vagace et al., 2011).  
 
 
Fig. 2. MR imaging findings six weeks after an episode of subacute encephalopathy by MTX. 
White arrows in Axial T2 (A) and coronal FLAIR (B) sequences show deep and periventricular 
white matter hyperintensity, especially in the right hemisphere (Vagace et al., 2011). 
5.6 Posterior reversible encephalopathy 
In 1996, Hinchey et al. described a reversible syndrome of headache, altered mental 
functioning, seizures, and loss of vision associated with abnormalities on neuroimaging in 
the posterior regions of the cerebral hemispheres. The syndrome occured in patients who 
had renal insufficiency or hypertension or in those who were immunosuppressed. Although 
not previously recognized as a complication of chemotherapy, Posterior Reversible 
Encephalopathy (PRE) is now considered as one the most common abnormalities leading to 
seizures in children with leukemia (Norman et al., 2007). The patient usually presents with 
headache, altered alertness, confusion, seizures (that may begin focally but usually become 
generalized), vomiting and alterations of visual perception. These visual disturbances are 
nearly always detectable with symptoms such as blurred vision, hemianopia, visual 
hallucinations or cortical blindness. Hypertension and hypomagnesemia are additional 
diagnostic criteria but are not always present (Dicuonzo et al., 2009). 
 
 
Fig. 3. Posterior Reversible Encephalopaty: MR imaging, Coronal T2 FLAIR, of a child with AL 
treated with vincristine that developed headache, hypertension and seizures. Left panel 
shows white matter hyperintensity in both hemispheres. After 18 days (right panel) these 
signs were inappreciable. 
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such as seizure, transient ataxia, choreoathetoid movements, temporary blindness or visual 
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The cardinal features of PRE are both clinical and radiologic. Abnormalities are usually 
observed in bilateral, parietal and occipital lobes. CT scans typically show posterior cerebral 
white-matter hypodensities. If PRE is suspected, MRI series should be performed, including 
T2, DWI, and FLAIR images for the most accurate diagnosis. MR abnormalities are 
characterized by increased signal on T2-weighted and FLAIR sequences. DWI may appear 
normal or show increased diffusion consistent with vasogenic edema (Shin et al., 2001) (Fig 3). 
Sudden elevations in systemic blood pressure exceeding the autoregulatory capability of the 
brain vasculature, leading to capillary leakage and subsequent vasogenic edema has been 
proposed as the underlying mechanism of PRE. The preferential involvement of the parietal 
and occipital lobes may be due to the observed relative reduction in the sympathetic 
innervation of the posterior circulation. Based on brain SPECT studies, a migraine-like 
mechanism has been proposed by other authors. Additionally, hypomagnesemia or vascular 
instability resulting from the toxicity of the chemotherapy agents on the endothelium of the 
blood-brain barrier may also be contributing factors (Sanchez-Carpintero et al., 2001). Most 
cases of PRE occur during induction chemotherapy for ALL, consequently, a variety of 
drugs routinely used during this phase have been linked to PRE, namely vincristine, IT 
MTX, HD-MTX, L-asparaginase, cyclophosphamide and ara-C (Gupta et al., 2008). 
Early and aggressive therapy for hypertension and quickly control the seizures, are the only 
defined treatment recommendations for this syndrome. In most patients chemotherapy can 
be restarted without recurrence or permanent neurological sequelae. In conclusion, 
chemotherapy for AL should be added to the growing list of causes of PRE. However, more 
information is needed before a clear association can be established between PRE and specific 
chemotherapy agents (Titos-Arcos et al., 2011). 
5.7 Chronic Leukoencephalopaty 
Chronic leukoencephalopathy is a commonly described but poorly understood phenomenon, 
which is associated with the use of HD-MTX with inadequate leucovorin rescue and that 
may be exacerbated by prior cranial irradiation. This complication presents several months 
to years after therapy and may lead to severe neuropsychological impairment (Ziereisen et 
al., 2006). 
6. Renal toxicity and electrolytes imbalance 
The kidneys, being the elimination pathway of many antitumor drugs and their metabolites, 
are quite vulnerable to injury in chemotherapy. Several factors are known to contribute to 
the nephrotoxic potential of antineoplastic drugs in patients with AL, namely the 
concomitant use of other nephrotoxic drugs (e.g., amphothericin), urinary infections, 
intravascular volume depletion, sepsis and other comorbidities such as hypertension, 
diabetes mellitus or heart failure. Suggested dosing of the main chemotherapeutic drugs 
used in AL according to renal function is shown in Table 4. 
Chemotherapy-induced nephrotoxicity may affect glomeruli, tubules, renal vasculature or 
excretory system depending on the drugs involved. Creatinine clearance is the usual measure 
to assess the glomerular filtration rate. Serum creatininine is less sensitive for this purpose and 
does not significantly change until the clearance is below 70 ml/min. Measurement of the 
tubular function is often accomplished by evaluating the fractional excretion of glucose, uric 
acid, calcium, phosphorous and magnesium (de Jonge & Verweij, 2006). 
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6.1 Hemorrhagic cystitis 
Cyclophosphamide and ifosfamide are drugs with similar chemical structures that are 
biotransformed to acrolein. Hemorrhagic cystitis occurs subsequent to urinary excretion of 
this metabolite, which is capable of binding the sulfhydryl constituent within proteins of 
bladder epithelium causing an inflammatory process. Saline-based hyperhydration and 
mesna (2-mercaptoethane sulfonate), which binds acrolein preventing direct contact with 
the uroepithelium, are concurrently administered to reduce the incidence and severity of 
hemorrhagic cystitis. Hemorrhagic cystitis is usually seen in transplant recipients who are 
treated with doses of cyclophosphamide higher than those used in AL. When the process 
lasts longer than 7 days, adenovirus and polyomavirus infection (specifically BK viruria) are 
often responsible (Korkmaz et al., 2007). 
Treatment of hemorrhagic cystitis is challenging. If blood clots form, bladder irrigation with 
isotonic saline may be required to break up an obstructive uropathy. Other measures that 
have been used include intravesical therapy with instillation of chemicals to cause mucosal 
fibrosis, hyperbaric oxygen therapy, and embolization or ligation of internal iliac arteries. 
Cystectomy is reserved for massive bladder hemorrhage, a clinical problem with a high 
mortality rate (Hu et al., 2008). 
 
Agent CrCl (ml/min) [Cr]s (mg/dl) % Dose administered 
Alkylating agents    
Cyclophosphamide 10-50  75 
<10  50 
Antimetabolites    
Cytarabine   Evaluate if necessary 
6-mercaptopurine   No formal recommendation.  
Methotrexate 30-60  50 
<30  0 
Antibiotics*    
Daunorubicin  >3.0 50 
Plant alkaloids    
Etoposide 10-50  75 
<10  50 
Miscellaneous    
L-asparaginase <60  0 
CrCl, creatinine clearance; [Cr]s, serum creatinine 
*No reduction is necessary for mitoxantrone, doxorubicin, epirubicin, idarubicin, vincristine or vinblastine 
Table 4. Dosage of main chemotherapeutic agents used in AL according to renal function 
6.2 Methotrexate-induced nephrotoxicity 
Nephrotoxicity is a potentially life-threatening complication of HD-MTX therapy (>1g/m2). 
Both the parent drug and the 7-hydroxy-MTX metabolite may precipitate in the acidic 
environment of renal tubules and collecting ducts producing acute tubular necrosis. Renal 
dysfunction results in delayed MTX excretion and sustained elevated plasma MTX 
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concentrations, which in turn may lead to a marked enhancement of other toxicities of MTX, 
especially myelosuppression, mucositis, hepatitis, and dermatitis. Uniform institution of 
aggressive hydration, alkalinization (urinary pH monitoring required), and 
pharmacokinetically guided leucovorin rescue , significantly reduce the morbidity rate in 
patients receiving this therapy. Implementation of this regimen reduces the incidence of 
nephrotoxicity to approximately 2% of patients (Widemann & Adamson, 2006). 
Delayed MTX excretion and high plasma MTX concentrations identify patients at high risk 
of toxicity. These subjects may benefit from supplemental leucovorin rescue or from the 
administration of glucarpidase (carboxypeptidase G2, CPDG2), a recombinant enzyme with 
cleaves MTX in inactive metabolites and is able to lower plasma MTX concentrations rapidly 
and efficiently. The use of CPDG2 is well-tolerated and renders a more profound, rapid, and 
consistent decrease in plasma MTX concentrations compared to dialysis-based methods, and 
should therefore be considered over dialysis in patients with HD-MTX-induced renal 
dysfunction (Patterson & Lee, 2010). 
6.3 Syndrome of inappropriate antidiuretic hormone secretion 
Hyponatremia is the most common electrolyte disorder in clinical medicine and occurs in 
approximately one of every three hospitalized patients. The syndrome of inappropriate 
Secrection of Antidiuretic Hormone (SIADH) is the most frequent cause of hyponatremia. 
Malignant diseases, pulmonary and CNS disorders and drugs are causes of SIADH. With 
regard to chemotherapy drugs used in AL, vincristine and cyclophosphamide have been 
implicated in this complication (Ellison & Berl, 2007). 
The diagnosis of SIADH requires the presence of hyponatremia (Na+<135 mmol/L) with a 
low serum osmolarity (<275 mmol/L) in the absence of other causes of hyponatremia such 
as oral or IV water excess, low effective circulating volume (heart or liver failure), use of 
thiazide diuretics, endocrine processes (hipopituitarism, adrenal insufficiency or 
hypothyroidism), renal failure or salt wasting. On the other hand Cerebral Salt Wasting is a 
syndrome due to the production of natriuretic factor and/or a disruption of neural input 
into the kidney that decreases proximal sodium reabsorption, resulting in a loss of sodium 
by the urine. The identification of this disorder is of considerable clinical importance 
because its treatment comprises vigorous sodium and volume replacement, whereas fluid 
restriction is the treatment of choice in SIADH (Hoorn & Zietse, 2008). Table 5 shows useful 
data to differentiate between these two syndromes. 
 
 CSW SIADH 
Extracellular fluid volumen* Decreased Increased 
Diuresis Normal or increased Normal or decreased 
Hematocrit Increased Normal 
Plasma BUN/Creatinine Increased Decreased 
Treatment Normal saline Fluid restriction 
*The main difference but clinical assessment of volume status is imprecise. CSW, cerebral salt wasting; 
SIADH, syndrome of inappropriate antidiuretic hormone secretion. 
Table 5. Clinical features of CSW and SIADH [Modified from (Palmer, 2003)]. 
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7. Pulmonary toxicity 
Most pulmonary complications in AL patients are due to concurrent medical problems, such 
as bacteremia, sepsis, fungal infection or CHF. These patients also show an increased risk of 
thromboembolic disorders. Therefore, the occurrence of acute respiratory insufficiency in 
AL may be suspicious of pulmonary thromboembolism, especially if treatment with L-
asparaginase was previously implemented. L-asparaginase reduces antithrombin III levels 
thereby increasing the risk for thrombosis, which may be safely prevented with the use of 
heparin (Meister et al., 2008). 
Other chemotherapy drugs such as all-trans-retinoic acid (ATRA), imatinib and ara-C can 
cause a capillary leak syndrome which manifests as pulmonary edema, pleural effusions, 
pericardial effusions or ascites. Drug withdrawal and steroid therapy is generally 
recommended in this case (Meadors et al., 2006). 
7.1 The Acute Promyelocytic Leukemia Differentiation Syndrome 
All-trans retinoic acid (ATRA) and arsenic trioxide are agents used for the treatment of the 
acute promyelocytic leukemia (APL) with a unique toxicity profile. The APL Differentiation 
Syndrome or Retinoic Acid Syndrome is mediated by endothelial inflammation and vascular leak 
that occurs when leukemic blasts suddenly differentiate into mature granulocytes and adhere 
to pulmonary endothelium. The differentiation syndrome occurs in approximately 25% of 
patients with APL treated with these agents (Luesink et al., 2009; Montesinos et al., 2009). 
Diagnosis should be suspected clinically in the presence of dyspnea, unexplained fever, 
weight gain, peripheral edema, unexplained hypotension, acute renal failure or CHF, but 
particularly by a chest radiograph demonstrating interstitial pulmonary infiltrates or pleuro-
pericardial effusion. In this situation, dexamethasone should be started promptly and ATRA 
temporarily discontinued if the patient develops respiratory distress or renal failure. 
Prophylactic treatment with corticosteroids is recommended in patients with a WBC count 
greater than 5 x 109/l to reduce mortality and morbility (Sanz et al., 2009). 
8. Cutaneous toxicity 
Cutaneous side effects related to chemotherapy (Table 6) may range from relatively 
common adverse events, such as alopecia or hyperpigmentation (which are the result of 
direct toxicity on skin in contact with the drugs through blood or sweat) to more unusual 
phenomena such as photosensitivity or hypersensitivity reactions (DeSpain, 1992). 
Most chemotherapeutic agents may cause alopecia. Hair loss usually begins 7 to 10 days 
after the initiation of treatment and is prominent within 1 to 2 months of treatment. Once 
chemotherapy is finished hair grows back in the majority of the patients, although it may 
present a different texture or color. 
Pigmentary changes involving the skin, nails, and mucous membranes are usually related to 
alkylating agents and antitumor antibiotics, but they may as well occur with other drugs 
used in AL, namely etoposide, MTX or vincristine. The latter may cause a distinctive pattern 
of hyperpigmentation called Serpentine Hyperpigmentation, which follows an underlying vein 
proximal to an infusion site (Payne, A.S. et al., 2006). 
Eccrine Squamous Syringometaplasia is characterized by self-limited, asymptomatic erythematous 
papules on trunk and extremities that may be confused with erythema nodosum. 
MTX can produce a phototoxic recall reaction (Photoreactivation) in the absence of light. It is 
characterized by an erythematous eruption in the distribution of UV-induced sunburns that 
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may have occurred months or years prior to the administration of the drug. HD-MTX is also 
associated with severe erythema in sun-exposed areas when the drug is given within two to 
five days of exposure to UV light. In contrast to Photoreactivation, retreatment with MTX 
does not usually reproduce the reaction (Payne, A.S., DMF, 2011). Patients receiving 
photosensitizing drugs should be counseled regarding the risk of adverse reactions to 
sunlight and encouraged to use UV protection with sunscreens and protective clothing. 
 
Agent AL CP ESS PS AE NEH SS HR 
Alkylating agents +        
Cyclophosphamide + + +   +  + 
Ifosfamide +        
Antimetabolites         
Cytarabine +  +  ++ ++  + 
6-mercaptopurine     +    
Methotrexate + + + + +   + 
Antibiotics         
Doxorubicin +  +  + +  + 
Plant alkaloids         
Vincristine and Vinblastine* + +  +     
Etoposide +  +  +   ++ 
Tyrosine kinase inhibitors         
Imatinib  +  +   +  
Miscellaneous         
L-asparaginase        ++ 
Tretinoin (ATRA)       +  
AL, Alopecia; CP, Cutaneous Hyper-Pigmentation; ESS, Eccrine squamous syringometaplasia; PS, 
Photosensibility; AE, Acral erythema; NEH, Neutrophilic eccrine hidradenitis ; SS, Sweet´s Syndrome; 
HR, Hypersensitivity reactions. 
Table 6. Cutaneous toxicity of the main chemotherapy agents used in AL. 
Acral Erythema or Hand-Foot Syndrome, is characterized by painful erythematous plaques on 
the palms and soles and heals with prominent desquamation that usually resolves within 
two to four weeks after discontinuation of the causative agent (Figure 4). 
 
 
Fig. 4. Hand-Foot Syndrome in a child treated with ara-C for AL 
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Neutrophilic Eccrine Hidradenitis (NEH) is a reactive disorder that may occur in association 
with malignancy (with or without chemotherapy), infections, and certain medications. NEH 
is characterized by asymptomatic and self-limited violaceus plaques on the trunk and 
extremities. In all cases of suspected NEH, a biopsy should be performed to differentiate of 
septic emboli, metastatic infiltrates or Sweet´s Syndrome (Brehler et al., 1997). 
Sweet´s Syndrome (SS), also called Acute Febrile Neutrophilic Dermatosis, is characterized by 
fever, neutrophilia, erythematous and painful skin lesions, diffuse neutrophilic infiltrate in 
the dermis, and rapid response to corticosteroids (Saavedra et al., 2006). Ten to twenty per 
cent of SS cases are related to neoplasms, especially AML, the remaining being idiopathic o 
drug related. In AL patients, therapy with cytokines such as granulocyte colony-stimulating 
factor (G-CSF) and all-trans retinoic acid (ATRA) are involved in most cases (Thompson & 
Montarella, 2007) (Figure 5). 
 
 
Fig. 5. Sweet Syndrome in an adult patient treated with ATRA for APL 
Hypersensitivity reactions (HR) typically occur within an hour of drug administration and 
are characterized by pruritus, urticaria, swelling at the injection site, rash and in more severe 
cases, bronchospasm and hypotension. L-Asparaginase shows the highest risk for such 
reactions. The overall risk approaches 30% after four doses, but it can be also observed after 
the first dose. Some risk factors for this reaction are IV administration, prior exposure to L-
Asparaginase and weekly intervals of administration (as opposed to daily). 
There is no reliable method for determining who will sustain a HR with this drug. Skin 
testing is not worthwhile for this purpose. Changing to intramuscular Erwinia L-
asparaginase instead of E.Coli L-asparaginase or use modified asparaginase with attached 
polyethylene glycol are suitable options for sensitized patients (Earl, 2009). Etopoxide is 
also capable of producing HR in 6-7% of patients from the first dose, especially when the 
drug is infused. Recommended anaphylaxis precautions for patients receiving these drugs 
include: blood pressure monitoring, premedication with IV diphenhydramine and having 
an IV access to administer epinephrine and corticosteroids in case of reaction (Shepherd, 
2003). 
Ara-C causes an acute reaction called the Cytarabine Syndrome characterized by high fever, 
rigors, diaphoresis, myalgia, arthralgia, conjunctivitis and maculopapular rash. This ara-C 
syndrome may not be a HR but a constellation of direct toxicities of the drug which is likely 
mediated by cytokines. Corticosteroids are the treatment of choice for this syndrome (Chng, 
2003). 
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9. Pharmacogenetics determinants of chemotherapy toxicity in Acute 
Leukemia 
The fact that the efficacy of chemotherapy in AL patients has significantly increased in the 
last twenty years, has rendered a growing body of pharmacogenetic studies focused on 
toxicity rather than efficiency of chemotherapy drugs. Indeed, some genetic polymorphisms 
have been identified to play an important role. 
Most notably, polymorphisms in the thiopurine methyltransferase (TPMT) gene, which 
codes for a key enzyme in the metabolism of 6-MP, have been shown to produce a 
defective enzyme. Individuals homozygous for these SNPs present extremely high levels 
of active thioguanine nucleotides and therefore may have unacceptable, life-threatening 
toxicity from normal doses of 6-MP. In consequence, AL patients scheduled to receive 6-
MP are regularly tested for polymorphisms in the TPMT gene in order to adjust therapy 
(Relling et al., 1999). 
MTX, the cornerstone for therapy of ALL, has also been the focus of many pharmacogenetic 
studies aimed to identify genetic determinants of its toxicity. The methylenetetrahydrofolate 
reductase (MTHFR) gene has been by far the most extensively studied. Two polymorphisms, 
C677T and A1298C, have been associated with increased MTX toxicity, with the first likely 
playing a more significant role (Gervasini, 2009). Accordingly, some ALL treatment 
protocols in the induction phase include MTX dose reductions for subjects homozygous for 
the 677T variant or for those carrying both heterozygous genotypes (Badell et al., 2008). 
Given the complexity of the MTX mechanism of action, there are possibly polymorphisms in 
genes other than MTHFR that could be involved in the development of MTX adverse effects. 
Particularly, the occurrence of polymorphisms in membrane transporters that are responsible 
for the intake and efflux of MTX may constitute an exciting field of research (Gervasini, 2009). 
There are other drugs included in the chemotherapy of AL whose toxicity may also be 
increased by the presence of genetic polymorphisms. In this regard, some studies have 
addressed the impact of polymorphisms in ATP binding cassette (ABC) transporters on the 
toxicity of imatinib, vincristine or mitoxantrone, albeit with contradictory results (Cotte et 
al., 2009; Gurney et al., 2007; Hartman et al., 2010; Plasschaert et al., 2004). In addition, 
polymorphisms in drug-metabolizing enzymes such cytochrome P450 (CYP) 2B6 or CYP2D6 
may also be involved in the occurrence of adverse effects in response to treatments including 
imatinib, cyclophosphamide and etoposide (Gardner et al., 2006; Kishi et al., 2004; Rocha et al., 
2009). However, these results are far from being consistently demonstrated and further 
studies are needed to elucidate whether these polymorphisms represent a clinical concern. 
10. Conclusions 
In this chapter we have aimed to describe a number of guidelines to correctly recognize and 
treat the main adverse effects induced by chemotherapy in AL patients. In order to identify 
subjects at higher risk of toxicity, a complete clinical-analytical evaluation must be performed 
in all patients before the administration of each chemotherapy cycle. Furthermore, clinicians 
should be familiar with the different metabolic pathways of each administered drug, and 
doses should be adjusted accordingly if necessary, especially in cases with decreased renal or 
liver function. However, even with these precautions, chemotherapy-induced toxicity is still 
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an important clinical concern in AL. Indeed, at the present time the cornerstone of therapy for 
AL is still formed by a reduced number of drugs with a highly toxic profile. 
The present challenge would therefore be to reduce the frequency and seriousness of 
adverse effects while maintaining efficacy and avoiding overtreatment of patients. The 
design of new drugs such as the so-called molecular target drugs, the further development 
of existing therapeutic groups, or the knowledge of genetic determinants of toxicity may 
help achieve these goals.  
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subjects at higher risk of toxicity, a complete clinical-analytical evaluation must be performed 
in all patients before the administration of each chemotherapy cycle. Furthermore, clinicians 
should be familiar with the different metabolic pathways of each administered drug, and 
doses should be adjusted accordingly if necessary, especially in cases with decreased renal or 
liver function. However, even with these precautions, chemotherapy-induced toxicity is still 
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an important clinical concern in AL. Indeed, at the present time the cornerstone of therapy for 
AL is still formed by a reduced number of drugs with a highly toxic profile. 
The present challenge would therefore be to reduce the frequency and seriousness of 
adverse effects while maintaining efficacy and avoiding overtreatment of patients. The 
design of new drugs such as the so-called molecular target drugs, the further development 
of existing therapeutic groups, or the knowledge of genetic determinants of toxicity may 
help achieve these goals.  
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1. Introduction 
The clearest role for vitamin D in human is in bone health as a regulator of serum calcium and 
skeletal homeostasis. Additional roles of vitamin D have been suggested, which include 




Chemical description Comments 
Vitamin D1 Compound of ergocalciferol with 
lumisterol (stereoisomer of 
ergosterol) 1:1 ratio 
 
Vitamin D2 Ergocalciferol  
(made from ergosterol) 
 
Vitamin D3 Cholecalciferol (made from 7-
dehydrocholesterol in the skin) 
 
Vitamin D4 22-dihydroergocalciferol  
Vitamin D5 Sitocalciferol  
(made from 7-dehydrositosterol) 
 
Vitamin D6 Calciferol  
25-(OH) 
Vitamin D 
Calcidiol or calcifediol; indicates 
no distinction between D2 and D3 
forms. When relevant, forms are 
distinguished as 25(OH)D2 and 
25(OH)D3
Vitamin D with one hydroxyl group 
added equivalent to liver activation.  
Ercalcitriol 1,25(OH)2 D2   
Calcitriol 1,25(OH)2 D3 Vitamin D with two hydroxyl groups 
added equivalent to renal activation. 
Doxercalciferol 1α(OH)D2  
Alfacalcidiol 1α(OH)D3 Vitamin D with one hydroxyl group 
added equivalent to renal activation 
Table 1. Vitamin D Analogues 
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monitoring has significantly increased as the awareness of its potential importance to health 
has increased. Also, the readily available supply of vitamin D allows for intervention.  
Vitamin D is generated in the skin from the non-enzymatic conversion of pro-vitamin D3 to 
pre-vitamin D3. Dietary intake of vitamin D is usually limited to selective foods, with the 
exception of certain kinds of fish which contain sizable amounts; supplements are 
commonly used. Vitamin D is either stored in adipose tissue or converted in the liver by the 
enzyme 25-hydoxylase to 25(OH) vitamin D3, the most stable metabolite of vitamin D that 
reflects solar and dietary exposure (Binkley, Ramamurthy et al. 2010). There are many 
different analogues of vitamin D as shown in table 1.  
Vitamin D body stores are reflected in the measurement of the serum level of the relatively 
stable (half-life approximately 3 weeks) surrogate marker 25 (OH) vitamin D3 [25(OH)D3]. 
Enzyme-linked immunosorbant assay (ELISA) is the most commonly used methodology in 
the United States (Hollis 2007); however, there are more sensitive and costly methods to 
measure vitamin D levels, e.g. mass spectroscopy (Yuan, Kosewick et al. 2011). Currently, 
the Institute of Medicine (2011) has put forth a guideline on recommended daily allowance 
and appropriate levels but this issue still remains controversial (Toner, Davis et al. 2010). In 
this paper, we will use the following definitions for vitamin D levels (Ross, Manson et al. 
2011): Vitamin D deficiency as <10ng/ml (<25nmol/L) of 25(OH)D3 in the serum. Vitamin D 
insufficiency as serum 25(OH)D3 between 10-32ng/ml (25-75 nmol/L) (Rosen 2011). 
Subnormal vitamin D levels as less than 32 ng/ml of 25(OH)D3 (Lee, HJ 2010). There are 
currently no standards of measurement or methods to measure vitamin D levels in the 
clinical setting. There have been numerous publications regarding vitamin D, but no 
consensus has yet been reached as illustrated in Table 2.  
 
Author Year Normal Insufficient Deficient 
Holick (Holick 2007) 2007 ≥ 30 mg/ml 21-29 ng/ml < 20 mg/ml 
Lee (Lee, Eisman et al. 2009) 2009 > 25 ng/ml 12-24 ng/ml < 12 ng/ml 
Vashi (Vashi, Trukova et al. 2010) 2010 ≥ 32 ng/ml < 32 ng/ml 
(suboptimal) 
N/R 
Napoli (Napoli, Vattikuti et al. 2010) 2010 ≥ 30 ng/ml 20-29 ng/ml < 20 ng/ml 
Drake (Drake, Maurer et al. 2010) 2010 ≥ 25 ng/ml < 25 ng/ml N/R 
Fedirko (Fedirko, Bostick et al. 2010) 2010 ≥ 32 ng/ml 20-31.9 ng/ml < 20 ng/ml 
Rosen (Rosen 2011) 2011 > 30 ng/ml 10-30 ng/ml < 10 ng/ml 
Choo (Choo, Mamedov et al. 2011) 2011 ≥ 30 ng/ml < 30 ng/ml N/R 
Shanafelt (Shanafelt, Drake et al. 2011) 2011 ≥25 ng/ml < 25 ng/ml N/R 
Fiscella (Fiscella, Winters et al. 2011) 2011 N/R N/R < 20 ng/ml 
Chadha (Chadha, Fakih et al. 2011) 2011 N/R N/R < 20 ng/ml 
Abbreviations: N/R, not reported  
Table 2. Various Definitions of Vitamin D Levels (25-Hydroxy Vitamin D3) 
1.1 Initial observation  
An epidemiologic study estimated that one billion people worldwide have subnormal 
vitamin D levels due to decreased exposure to sunlight or dietary inadequacy (Holick 2011). 
Many studies suggest the detrimental effect of vitamin D insufficiency on heart, kidney, 
dermatologic, endocrine, and autoimmune diseases (Gueli, Verrusio et al. 2011). The well-
established target organs of vitamin D are the intestines, kidney and bone, but several other 
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tissues also express vitamin D receptors (VDR), including normal and neoplastic 
hematopoietic cells (Haussler, Whitfield et al. 1998). In the early 1980s, in vitro data showed 
the ability of 1,25-dihydroxy vitamin D3 to differentiate acute myeloid leukemia (AML) 
[HL-60] into mature myeloid cells (Miyaura, Abe et al. 1981).  
Vitamin D is a potentially exciting therapy for AML investigators due to its promising in 
vitro data and its safety (Trump, Deeb et al. 2010). The appropriate patient population 
selection and the development of optimum dosing and delivery schedule will maximize its 
clinical effect. 
2. Epidemiologic evidence for vitamin D and leukemia 
The epidemiology of vitamin D levels have not been extensively studied in AML as it has in 
other solid tumors (Toner, Davis et al. 2010). However, a study in northern Finland, where 
colder temperatures discourage extensive outdoor activities and minimize UV exposure 
during the winter months, found that majority of acute leukemia cases were diagnosed 
during the winter months of the year, rather than during the summer months (Timonen 
1999). A possible explanation for this increase may be seasonal variation in levels of 
25(OH)D3. It is estimated that 25(OH)D3 levels can vary by 8 to 12 ng/ml from the mean 
population during different seasons. Therefore, winter months can significantly increase the 
percentage of the population with low levels of 25(OH)D3, possibly increasing the risk of 
leukemia (Bolland, Grey et al. 2007). In addition, a large epidemiological study (Boscoe and 
Schymura 2006) using data from the North American Association of Central Cancer 
Registries and the National Cancer Institute’s Surveillance, Epidemiology and End Results 
database found an inverse relationship between ultraviolet-B exposure and the incidence of 
leukemia; however, this study did not examine vitamin D levels and would make it difficult 
to conclude that vitamin D played a role in increased incidence of leukemia.  
Similarly, a study in the United Arab Emirates (UAE) found that acute leukemia was more 
common among adult females than among adult males, despite the fact that the population of 
the UAE consists of more males than females, and acute leukemia is widely known to be more 
common in males. The authors’ hypothesis was that the women’s deprived sunlight exposure, 
due to their conservative clothing, may have contributed to their higher incidence of acute 
leukemia (Hassan, Islam et al. 2009). It would be difficult to conclude that vitamin D played a 
role in the increased incidence due to lack of dietary information on the populations. 
However, these observations lend credibility to the association between AML and vitamin D. 
2.1 Vitamin D and solid tumors 
Initial observation by Garland et al. (Garland, Comstock et al. 1989) demonstrated higher 
mortality rates of colon cancer in the northeast when compared to the south and southwest 
United States, which suggested an association between sunlight exposure and cancer 
outcome. This finding led to several epidemiologic observations linking subnormal vitamin 
D levels to increased risk of breast (Garland, Garland et al. 1990), colorectal (Jenab, Bueno-
de-Mesquita et al. 2010) and prostate cancers (Barnett, Nielson et al. 2010).  
Giovannucci et al. performed a large prospective observational cohort study composed of 
51,529 U.S. male healthcare providers and illustrated that low levels 25(OH) D3 (<25nmol/L) 
were associated with increased cancer incidence and mortality in men. Strongest association 
was seen with gastrointestinal cancers (Giovannucci, Liu et al. 2006). 
On the contrary, a large randomized double blind controlled trial of 2,686 men and women 
aged 65 to 85 years of age from Oxford, England showed that supplementation of vitamin 
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On the contrary, a large randomized double blind controlled trial of 2,686 men and women 
aged 65 to 85 years of age from Oxford, England showed that supplementation of vitamin 
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D3 100,000 IU every 4 months versus placebo had a preventive benefit of reduced fracture in 
the vitamin D3 group after follow-up of five years. However, the cancer incidence was not 
statistically significant with relative risk (95% CI) 1.09 (0.86-1.36) (Trivedi, Doll et al. 2003). 
On the other hand, a study from Creighton University (Lappe, Travers-Gustafson et al. 2007) 
where they performed a population based, double blind, randomized placebo-controlled 
trial showed the opposite. Eligible subjects were >55 years and free of known cancer prior to 
entering study. Subjects were randomly assigned to take daily dosages of 1,400-1,500 mg 
supplemental calcium, 1,400-1,500 mg supplemental calcium plus 1,100 IU of vitamin D3, or 
placebo. Patients were prospectively followed for 4 years and the study showed that the 
calcium plus vitamin D group had a 60% reduction in cancer risk compared to placebo. The 
reasons for these differences are not clear but may be related to the supplementation offered 
and the subjects’ pre-treatment vitamin D levels.  
Further, the Nurses’ Health Study, consisting of 32,826 participants, showed that the odds 
ratios for colorectal cancer were inversely associated with the 25(OH) D3 serum levels 
(Feskanich, Ma et al. 2004). Similarly, Garland et al. (Garland, Garland et al. 2006) showed, in a 
meta-analysis of 980 women, that high dietary vitamin D intake was associated with 
significant reduction in developing breast cancer when compared with low vitamin D intake. 
Various VDAs have been extensively tried as cancer therapeutic agents, but so far no ideal 
agent or delivery schedule has been clearly delineated. The most promising data was 
calcitriol in combination with docetaxel in prostate cancer; however, the phase III trial was 
halted by the data safety monitoring board because the survival rate in the vitamin D group 
was lower than the placebo group (Trump, Deeb et al. 2010). Among the concerns about the 
trial were that it included two different variables between the two arms; the control arm 
used docetaxel every three weeks, while the experimental arm, which included the addition 
of vitamin D, used docetaxel weekly. Second, there was limited rationale for calcitriol dose, 
which was probably inadequate, and the dose used was well below the calcitriol human 
maximally tolerated dose. This trial further highlights the need for continued exploration to 
define the appropriate dose and schedule to study in therapeutic and preventative trials.  
2.2 Vitamin D and hematologic malignancies (NHL, CLL) 
A prospective Mayo Clinic study of 983 newly diagnosed NHL patients found that vitamin 
D insufficiency (<25 ng/ml, as determined by liquid chromatography-tandem mass 
spectrometry) was associated with inferior event free survival (EFS) and overall survival (OS) 
in diffuse large B- and T-cell lymphoma patients (Drake, Maurer et al. 2010). Similarly, the 
Mayo Clinic also examined 543 newly diagnosed CLL patients and found vitamin D 
insufficiency at diagnosis to be associated with decreased time until initiation of treatment 
(Shanafelt, Drake et al. 2011). These results lend credence to the possible correlation of adverse 
clinical effect of vitamin D insufficiency in newly diagnosed hematological malignancies. 
These studies illustrate observations that low vitamin D levels are associated with poorer 
clinical outcomes. Therefore, supplementation and corollary studies are needed to 
understand the effect of vitamin D on hematologic malignancies. 
2.3 Vitamin D and AML 
Lee et al. (Lee, HJ 2010) have recently reported 25(OH)D3 levels at the time of diagnosis of 
AML and their association with survival. A cohort of 97 newly diagnosed AML patients 
treated on similar protocols showed that patients with subnormal 25(OH)D3 (<32ng/ml) had 
significantly worse progression free survival (PFS) and OS when compared to those with 
normal 25(OH)D3 levels (≥32ng/ml) (Figure 1). 
 








Fig. 1. A: Overall Survival; B: Progression Free Survival 
Therefore, one may hypothesize the benefit of supplementing AML patients with subnormal 
25(OH)D3 levels to see if they would benefit from 25(OH)D3 normalization. There are 
several reports (Drake, Maurer et al. 2010; Lee HJ 2010; Shanafelt, Drake et al. 2011) 
indicating that low levels of vitamin D have been shown to be associated with worse clinical 
outcome; however, there are no prospective studies evaluating whether supplementation 
would improve outcome. It would be worthwhile to conduct a trial studying the effect of 
vitamin D supplementation in newly diagnosed AML patients.  
2.4 Clinical trials with VDA in myelodysplastic syndrome and AML 
Exploration of vitamin D as a possible therapeutic intervention for AML was propelled by 
the success of all-trans-retinoic acid (ATRA) treatment as a differentiating agent for AML 
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blasts (James, Williams et al. 1999). Vitamin D differentiates myeloid blasts to monocytes in 
vitro (Miyaura, Abe et al. 1981) and ex vivo (Lee, Kim et al. 1996), which prompted early 
clinical trials to investigate the anti-leukemic effects of VDAs in myelodysplastic syndromes 
(MDS) and AML (Table 3).  
 
Author Dx #N Median 
Age 
Vitamin D Chemotherapy RR CR 
Petrich (Petrich, 
Kahl et al. 2008) 
MDS 15 77 12.5 µg/d x 12 wks of 
doxercalciferol 
Single agent 0% 0% 
Siitonen (Siitonen, 
Timonen et al. 2007)
MDS 19 73 1 µg/d 1,25(OH)D3 Valproic acid 




et al. 1998) 
MDS 19 75 266 µg 3xwk 
(calcifediol) 5 pts and 
0.25-0.75 µg/d 
calcitriol 14 pts 
None 58% NA 
Ferrero (Ferrero, 
Bruno et al. 1996) 




Desforges et al. 
1992) 






Dastoli et al. 1991) 
AML 21 67.5 20 mg BID AraC x 7d 






et al. 1990) 
MDS, 
AML 
69 NR 1 µg/d of 1α(OH)D3 Low dose 
ARA-C 
26% NR 
Abbreviations: NR: Not Reported, AraC: Cytosine Arabinoside, wk: Weeks, pts: patients, cRA: cis-
retinoic acid, RR: Response Rate, CR: Complete Response 
Table 3. Vitamin D Trials in Myelodysplastic Syndrome / Acute Myeloid Leukemia 
Seven studies examined the effects of various VDAs in AML and MDS, either single agent or 
combined with other chemotherapy, including low-dose cytarabine, hydroxyurea, and 
valproic acid. All studies were small, ranging from 15 to 69 patients, and median age, when 
reported, ranged from 67.5 to 77. Overall response rates ranged from 0% to 79%, and 
complete response (CR) rates ranged from 0% to 45% when reported. Early results were 
mixed, as single agent VDA induced partial differentiation of myeloid blast cells in a few 
patients with a paucity of clinical improvements (Mellibovsky, Diez et al. 1998). 
Combination trials with VDA and chemotherapy resulted in mixed results in MDS/AML 
(Hellstrom, Robert et al. 1990; Petrini, Caracciolo et al. 1991; Petrini, Dastoli et al. 1991; 
Slapak, Desforges et al. 1992; Ferrero, Bruno et al. 1996; Siitonen, Timonen et al. 2007). 
Slapak et al. (Slapak, Desforges et al. 1992) showed promising results in a study of 29 AML 
patients, who were treated with a regimen of low-dose cytarabine, hydroxyurea, and 
calcitriol (0.25µg, oral every 12 hours) begun on day 1 of cytarabine and continued until 
relapse or the patient went off study. Three patients died within 60 days, and of the 
remainder, the overall response rate was 79%; 45% achieved CR and 34% achieved partial 
remission (PR). The median overall survival was 14 months for those who responded and 12 
months overall. Although all patients developed transient thrombocytopenia and 
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granulocytopenia and 20 patients required platelet transfusions transiently, the study 
nonetheless showed promise due to its high overall response rate and low induction death 
rate. Two patients experienced asymptomatic hypercalcemia (11.2mg/dl and 11.5mg/dl) 
but did not require treatment. The authors proposed that the favorable results might be due 
to the synergistic effects of cytarabine, hydroxyurea, and calcitriol, although they did not 
propose a specific mechanism (Slapak, Desforges et al. 1992),(Trump, Deeb et al. 2010). 
Vitamin D was studied in 19 low-risk MDS patients with a median age of 75 years 
(Mellibovsky, Diez et al. 1998). Five patients received 266 mcg of calcifediol three times per 
week, and 14 patients received 0.25-0.75 micrograms per day of calcitriol. Of the patients 
treated with calcifediol, one responded, one progressed, and the other three patients did not 
respond. Of the 14 patients treated with calcitriol, 10 responded while the other four did not. 
The authors concluded that vitamin D3 metabolites could be used to induce hematological 
responses in patients with low or intermediate risk MDS without the risk of hypercalcemia 
(Mellibovsky, Diez et al. 1998). 
Petrich et al. (Petrich, Kahl et al. 2008) conducted a phase II trial of doxercalciferol (12.5 µg 
daily for 12 weeks) in 15 MDS patients. Only 9 of the 15 patients completed the whole 12 
weeks, and no one responded. Stable disease was observed in six patients, and eight 
patients had disease progression, including two chronic myelomonocytic leukemia patients, 
who developed an increase in their monocyte count. Doxercalciferol was well tolerated; one 
patient experienced grade 3 rash, and one patient had grade 3 hypercalcemia and needed to 
be removed from the study. All toxicities resolved upon discontinuation of doxercalciferol. 
The authors therefore concluded that the study dose and scheduling of doxercalciferol 
appeared to have no efficacy in MDS patients (Petrich, Kahl et al. 2008).  
All the clinical trials were conducted with very low doses of VDA. Also, there have been no 
pharmacokinetic studies examining whether supplementation was sufficient to observe 
clinical responses. In the future, studies of pharmacokinetic and novel markers (e.g. miRNA, 
methylation pattern of vitamin D responsive elements) may be used to select and properly 
dose populations that may benefit from VDA.  
3. Molecular mechanism of vitamin D in AML 
Cardinal features of AML are the inability to differentiate and the clonal expansion of 
myeloid blasts. Intensive biological research and clinical trials to eradicate AML cells with 
cytotoxic chemotherapy have yielded minimal improvements and have rarely led to cures, 
especially in those 60 years or older (Burnett, Wetzler et al. 2011).  Vitamin D predominantly 
exerts its effects through binding to the cognate nuclear VDR; ligand bound VDR 
heterodimerizes with the retinoic X receptor (RXR) and binds to vitamin D responsive 
elements in the promoter regions of target genes, such as CYP24A1, BGLAP (osteocalcin) 
and cyclin dependent kinase inhibitor 1A (CDKN1A, p21Waf1/Cip1), several protein kinase C 
(PKC) isoforms (Shimizu, Taira et al. 2002), the p42 extracellular regulated kinase (p42 ERK), 
p38-ERK and c-Jun N-terminal kinases (JNK) families of mitogen activated protein kinases 
(MAPKs) which are important in differentiation, metabolism and cell cycle (Wang and 
Studzinski 2001; Ji, Kutner et al. 2002; Hughes and Brown 2006; Marcinkowska, Garay et al. 
2006; Studzinski, Garay et al. 2006). One of the main anti-proliferative and differentiating 
actions of vitamin D is the induction of cell cycle arrest by up-regulating anti-proliferative 
genes, such as p21, CCAAT/enhancer-binding protein α (C/EBPA) and interferon α-
inducible protein 27 (IFI27, p27). Further, non-genomic actions of vitamin D through 
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increased activation of voltage gated calcium channels can alter the actions of 
Ras/Raf/mitogen-activated protein kinase (ERK) pathway as well as phosphoinositidine-3-
kinase catalytic, alpha polypeptide (PI3K)/Akt pathway which have been shown to be 
activated in AML (Trump, Deeb et al. 2010). VDR is essential for vitamin D function. VDR is 
a highly conserved gene found in primitive organisms such as the sea squirt (Ciona 
intestinalis), a chordate invertebrate, showing that VDR was important even early in 
evolution (Reschly and Krasowski 2006). Calcium regulation is a key component to 
regulation of life itself, and vitamin D therefore is crucial to any system that relies on 
calcium for signaling. The VDR gene has been sequenced and compared among many 
different species, and now VDR polymorphism is an active area of research (Reschly and 
Krasowski 2006). VDR polymorphisms have been extensively studied in solid tumors and 
have been shown to have predictive value in cancer prognosis and recurrence (Kostner, 
Denzer et al. 2009). There are a limited number of studies of VDR polymorphisms in AML. 
In a French study (Rocha, Porcher et al. 2009), the investigators looked at VDR 
polymorphism (ApaI, TaqI and BsmI), and demonstrated worse toxicity and survival after 
allogeneic transplantation in leukemia patients with VDR TaqI polymorphism. Binding 
affinity would be greatly affected by different VDR polymorphisms, given the structural 
variations induced by the polymorphism; hence, understanding structural and functional 
variations will allow for rational therapy design. Functional activity of VDR has been shown 
to be impaired by AML associated chromosomal translocations PLZF-RAR α, PML-RAR α 
and AML-ETO1; these fusion proteins interfere with VDR nuclear localization by binding to 
VDR (Puccetti, Obradovic et al. 2002). 
3.1 Leukemia, vitamin D and the effect on apoptosis 
Programmed cell death may be aberrant in AML cells as they continue to proliferate 
uncontrollably without activating the apoptotic pathway. AML has been known to be 
deregulated in the FAS induced apoptosis as a means of avoiding death (Testa and Riccioni 
2007). VDAs have been shown to increase the expression of the FAS ligand and activate 
caspase-2,-3,-6 and -9 (Chen, Huang et al. 2008). Further, Vitamin D has been shown to 
down-regulate telomerase activity in ovarian cancers, which are known to have the highest 
level of telomerase activity in solid cancers (Jiang, Bao et al. 2004). Vitamin D was reported 
to disrupt telomerase reverse transcriptase (TERT) mRNA, therefore inducing apoptosis 
through telomere shortening and ultimately resulting in down regulation of telomerase 
activity(Jiang, Bao et al. 2004). Since AML has been reported to have high telomerase activity 
(Capraro, Zane et al. 2011), it would suggest that vitamin D may have a similar effect in this 
disease as well. Indeed, in vitro exposure of the leukemic cell line, HL-60, known to have 
high telomerase activity (Capraro, Zane et al. 2011), to vitamin D, led to down-regulation of 
the telomerase activity. This down regulation was associated with induction of p21, 
PI3K/AKT/mTOR pathways which play a key role in differentiation (Seol, Kim et al. 1998; 
Yamada, Ozaki et al. 2008). In summary, vitamin D, can modulate several pathways that 
will lead to AML apoptosis and should be exploited in AML treatment.  
3.2 Leukemia, vitamin D and the effect on proliferative signaling 
The FMS-like tyrosine kinase 3 (FLT-3) is mutated (internal tandem duplication, ITD) in cells 
of approximately 25-30% of AML patients (Burnett, Wetzler et al. 2011), providing such cells 
with a proliferative advantage. FLT-3 exerts its proliferative effect through the activation of 
many different pathways, e.g., PI3K/AKT/mTOR, RAS/RAF/ERK and signal transducer 
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and activator of transcription (STAT). Ultimately, these signaling pathways will down-
regulate pro-apoptotic signals, such as the B-cell chronic lymphocytic leukemia/lymphoma 
2 (BCL2)-family of proteins, and repress tumor suppressive genes, such as p21 and breast 
cancer 1 (BRCA1) (Stirewalt and Radich 2003). Of note, AML cells with chromosome 7 
deletion were extremely sensitive to VDA but FLT-3 positive AML cells did not differentiate 
in the presence of VDA (Gocek, Kielbinski et al. 2010). This raises the question as to whether 
a FLT-3 inhibitor would restore the ability of FLT-3-ITD positive AML cells to differentiate 
in response to VDA. The data also emphasizes potential importance of detailed molecular 
characteristics of patients’ AML cells and VDA use only in certain AML subgroups.  
3.3 Leukemia, vitamin D and the effect on tumor suppressor genes 
Leukemia cells must avoid or turn off negative regulators in order to proliferate. One 
example is the tumor suppressor transcription factor p53, whose inactivation, rather than 
mutation, is observed in many cancer types (Bohlig and Rother 2011); p53 is negatively 
regulated by murine double minute 2 (MDM2). It was recently shown that vitamin D alone 
induced monocytic differentiation of two wild-type p53 AML cell lines as well as a p53-null 
AML cells. Combination of a small molecule inhibitor (nutlin-3a) of p53-MDM2 interaction 
and vitamin D accelerated programmed cell death (Thompson, Andreeff et al. 2010). 
Interestingly, MDM2 levels dropped significantly in the presence of vitamin D3, possibly 
contributing to the apoptotic effect. Additional factors were found to contribute to the 
sensitization of the wild-type p53 cells to apoptosis when exposed to combinations such as 
BCL2, ERK and others. The authors suggested that vitamin D3 recruits its co-activators to 
enable p53 to become more effective in inducing cell death. This illustrates only a small 
amount of the complexities of cellular cross-talk seen in the vitamin D signaling pathway.  
3.4 Leukemia, vitamin D and the effect on the tumor microenvironment 
The bone marrow microenvironment is known to provide a nurturing environment for the 
hematopoietic stem cells. Leukemic stem cells also start to exploit the bone marrow 
microenvironment for survival advantage from conventional chemotherapy. Conventional 
chemotherapy induction is able to clear peripheral blood of leukemic cells, but patients 
ultimately relapse due to leukemic stem cells in the protected bone marrow 
microenvironment.  Clinical trials (Harousseau, Witz et al. 2000; von Lilienfeld-Toal, Hahn-Ast 
et al. 2007; Borthakur, Kantarjian et al. 2008) have attempted to use granulocyte colony-
stimulating factor (G-CSF) in order to bring out leukemic stem cells from the bone marrow. 
However, this method has not been shown to be widely effective. The mechanism by which G-
CSF mediates mobilization is by sympathetic nervous system suppression of osteoblasts and 
modulation of serum calcium in the endosteal proximity of the bone marrow (Metcalf 1985). A 
recent report by Kawamori et al. (Kawamori, Katayama et al. 2010) demonstrated the 
regulatory role of VDR on mobilization of hematopoietic cells by using VDR knockout mice; 
lack of VDR caused inability to mobilize hematopoietic cells. The authors demonstrated that 
VDR is important for calcium regulation in the endosteal proximity of the bone marrow. 
RANK ligand, a gene downstream of VDR, is also stimulated by the sympathetic nervous 
system and aids in the stabilization of VDR. Jeanson and Scadden (Jeanson and Scadden 2010) 
reported that VDR knockout mice had marked accumulation of hematopoietic stem cells in the 
spleen, which was reversed by dietary calcium supplementation, thus adding credence to the 
importance of calcium/VDR regulation of stem cell trafficking. These data suggest that low 
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increased activation of voltage gated calcium channels can alter the actions of 
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Krasowski 2006). VDR polymorphisms have been extensively studied in solid tumors and 
have been shown to have predictive value in cancer prognosis and recurrence (Kostner, 
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VDR (Puccetti, Obradovic et al. 2002). 
3.1 Leukemia, vitamin D and the effect on apoptosis 
Programmed cell death may be aberrant in AML cells as they continue to proliferate 
uncontrollably without activating the apoptotic pathway. AML has been known to be 
deregulated in the FAS induced apoptosis as a means of avoiding death (Testa and Riccioni 
2007). VDAs have been shown to increase the expression of the FAS ligand and activate 
caspase-2,-3,-6 and -9 (Chen, Huang et al. 2008). Further, Vitamin D has been shown to 
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and activator of transcription (STAT). Ultimately, these signaling pathways will down-
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vitamin D levels can cause leukemic stem cells to hide in the protective layers of the bone 
marrow to avoid cytotoxic chemotherapy agents. 
Further, anemia, bone marrow hypocellularity, and extramedullary hematopoiesis have been 
observed in vitamin D deficient rickets and have disappeared following vitamin D treatment. 
In two case reports, myelofibrosis and marrow dysfunction have been described secondary to 
vitamin D deficiency, and both improved following vitamin D supplementation 
(Balasubramanian, Varadharajan et al. 2005; Bhakhri and Debata 2010).  
These results suggest that the interaction between the bone marrow microenvironment and 
the leukemia cells may be mediated, at least partially, by vitamin D.  
4. Future directions 
Three studies have shown the prognostic significance of vitamin D deficiency in 
hematologic malignancies, including CLL (Shanafelt, Drake et al. 2011), NHL (Drake, 
Maurer et al. 2010) and AML (Lee HJ 2010). There have been no studies evaluating the 
clinical significance of vitamin D supplementation on raising the 25(OH)D3 levels of patients 
with hematologic malignancies to normal. It would be worthwhile to carefully design a 
pharmacokinetic study to evaluate supplementation of vitamin D in AML patients. 
Following the pharmacokinetic study, the next question of whether vitamin D 
supplementation affects outcome will need to be separately evaluated in a large phase III 
clinical trial. At least two possibilities exist, either that the mere supplementation of vitamin 
D, with its multitude effects on bone and other tissues, is causing better outcomes or that 
vitamin D has a specific differentiation effect. The support for the latter is the preclinical 
finding that AML cells with chromosome 7 deletion are extremely sensitive to the VDA 
calcitriol, while FLT3-ITD positive cells are resistant to this differentiation therapy (Gocek, 
Kielbinski et al. 2010). There are other in vitro studies showing anti-proliferative, pro-
apoptotic and differentiating properties of vitamin D on AML (Nowak, Stewart et al. 2009). 
Finally, the search for an ideal VDA that will not cause hypercalcemia is still on-going. A 
group from South Korea recently tested 11 VDAs and found that one compound had 
significant anti-leukemic activity with low proclivity toward hypercalcemia (Yoon, Kim et 
al. 2008). These new findings in the biology and improvements in VDAs will hopefully lead 
to an improved treatment option for AML patients. 
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This book provides a comprehensive overview of  he basic mechanisms underlying 
areas of acute leukemia, current advances, and future directions in management of 
this disease. The first section discusses the classification of acute leukemia, taking 
into account diagnoses  dependent on techniques that are essential, and thankfully 
readily available, in the laboratory. The second section concerns recent advances in 
molecular biology, markers, receptors, and signaling molecules responsible for disease 
progression, diagnostics based on biochips and other molecular genetic analysis. These 
advances provide clinicians with important understanding and improved decision 
making towards the most suitable therapy for acute leukemia. Biochemical, structural, 
and genetic studies may bring a new era of epigenetic based drugs along with 
additional molecular targets that will form the basis for novel treatment strategies. 
Later in the book, pediatric acute leukemia is covered, emphasizing that children are 
not small adults when it comes to drug development. The last section is a collection 
of chapters about treatment, as chemotherapy-induced toxicity is still a significant 
clinical concern. The present challenge lies in reducing the frequency and seriousness 
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